US20130203074A1 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and compositions for diagnosis and prognosis of renal injury and renal failure Download PDF

Info

Publication number
US20130203074A1
US20130203074A1 US13/806,761 US201113806761A US2013203074A1 US 20130203074 A1 US20130203074 A1 US 20130203074A1 US 201113806761 A US201113806761 A US 201113806761A US 2013203074 A1 US2013203074 A1 US 2013203074A1
Authority
US
United States
Prior art keywords
subject
measured concentration
renal
interleukin
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/806,761
Inventor
Joseph Anderberg
Jeff Gray
Paul McPherson
Kevin Nakamura
James Patrick Kampf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Priority to US13/806,761 priority Critical patent/US20130203074A1/en
Assigned to ASTUTE MEDICAL, INC. reassignment ASTUTE MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDERBERG, JOSEPH, GRAY, JEFF, KAMPF, JAMES PATRICK, MCPHERSON, PAUL, NAKAMURA, KEVIN
Publication of US20130203074A1 publication Critical patent/US20130203074A1/en
Assigned to CAPITAL ROYALTY PARTNERS II L.P., PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P., CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P. reassignment CAPITAL ROYALTY PARTNERS II L.P. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTUTE MEDICAL, INC.
Assigned to CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P., CAPITAL ROYALTY PARTNERS II L.P., PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P. reassignment CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P. CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 61831594 PREVIOUSLY RECORDED AT REEL: 032459 FRAME: 0246. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Assignors: ASTUTE MEDICAL, INC.
Assigned to ASTUTE MEDICAL, INC. reassignment ASTUTE MEDICAL, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P., CAPITAL ROYALTY PARTNERS II L.P., PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Assigned to ASTUTE MEDICAL, INC. reassignment ASTUTE MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NAKAMURA, KEVIN, ANDERBERG, JOSEPH, KAMPF, JAMES PATRICK, MCPHERSON, PAUL
Assigned to ASTUTE MEDICAL, INC. reassignment ASTUTE MEDICAL, INC. EMPLOYEE PROPRIETARY INFORMATION AND INVENTION AGREEMENT Assignors: GRAY, JEFF
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Definitions

  • the kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17 th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. Renal disease and/or injury may be acute or chronic.
  • Acute and chronic kidney disease are described as follows (from Current Medical Diagnosis & Treatment 2008, 47 1h Ed, McGraw Hill, New York, pages 785-815, which are hereby incorporated by reference in their entirety): “Acute renal failure is worsening of renal function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia.
  • Chronic renal failure results from an abnormal loss of renal function over months to years”.
  • Acute renal failure also known as acute kidney injury, or AKI
  • AKI acute kidney injury
  • Type Risk Factors Prerenal ECF volume depletion Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or burns), loss of skin and mucus membranes, renal salt- and water-wasting states
  • Low systemic vascular Septic shock, liver failure, antihypertensive drugs resistance Increased renal vascular NSAIDs, cyclosporines, tacrolimus, hypercalcemia, resistance anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome Decreased efferent ACE inhibitors or angiotensin II receptor blockers arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal
  • ischemic ARF the course of the disease may be divided into four phases.
  • an initiation phase which lasts hours to days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs.
  • Renal injury can be mediated during this phase by reperfusion of the kidney.
  • Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion.
  • the maintenance phase lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum.
  • a recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.
  • Acute kidney injury caused by radiocontrast agents also called contrast media
  • other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of days to about a week.
  • Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells.
  • CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.
  • a commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 days or within a period of hospitalization) elevation of serum creatinine.
  • serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications.
  • relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI.
  • the recent trend has been towards using smaller serum creatinine rises to define AKI.
  • “Risk” serum creatinine increased 1.5 fold from baseline OR urine production of ⁇ 0.5 ml/kg body weight/hr for 6 hours; “Injury”: serum creatinine increased 2.0 fold from baseline OR urine production ⁇ 0.5 ml/kg/hr for 12 h; “Failure”: serum creatinine increased 3.0 fold from baseline OR creatinine >355 ⁇ mol/l (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h or anuria for at least 12 hours; And included two clinical outcomes: “Loss”: persistent need for renal replacement therapy for more than four weeks. “ESRD”: end stage renal disease—the need for dialysis for more than 3 months.
  • RIFLE criteria which provide a useful clinical tool to classify renal status.
  • the RIFLE criteria provide a uniform definition of AKI which has been validated in numerous studies.
  • Stage I increase in serum creatinine of more than or equal to 0.3 mg/dL ( ⁇ 26.4 ⁇ mol/L) or increase to more than or equal to 150% (1.5-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 6 hours
  • Stage II increase in serum creatinine to more than 200% (>2-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 12 hours
  • Stage III increase in serum creatinine to more than 300% (>3-fold) from baseline OR serum creatinine ⁇ 354 ⁇ mol/L accompanied by an acute increase of at least 44 ⁇ mol/L OR urine output less than 0.3 mL/kg per hour for 24 hours or anuria
  • the CIN Consensus Working Panel uses a serum creatinine rise of 25% to define Contrast induced nephropathy (which is a type of AKI).
  • Contrast induced nephropathy which is a type of AKI.
  • various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL or 25%, are sufficient to detect AKI (worsening renal function) and that the magnitude of the serum creatinine change is an indicator of the severity of the AKI and mortality risk.
  • serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients.
  • the time period for serum creatinine to rise to values (e.g., a 0.3 mg/dL or 25% rise) considered diagnostic for AKI can be 48 hours or longer depending on the definition used. Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI.
  • serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Some patients with AKI will recover fully, some will need dialysis (either short term or long term) and some will have other detrimental outcomes including death, major adverse cardiac events and chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited, Knowing these things can be of vital importance in managing and treating patients with AKI.
  • measurement of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor,
  • kidney injury markers of the present invention may be used, individually or in panels comprising a plurality of kidney injury markers, for risk stratification (that is, to identify subjects at risk for a future injury to renal function, for future progression to reduced renal function, for future progression to ARF, for future improvement in renal function, etc.); for diagnosis of existing disease (that is, to identify subjects who have suffered an injury to renal function, who have progressed to reduced renal function, who have progressed to ARF, etc.); for monitoring for deterioration or improvement of renal function; and for predicting a future medical outcome, such as improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease,
  • the present invention relates to methods for evaluating renal status in a subject. These methods comprise performing an assay method that is configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithel
  • This correlation to renal status may include correlating the assay result(s) to one or more of risk stratification, diagnosis, prognosis, staging, classifying and monitoring of the subject as described herein.
  • the present invention utilizes one or more kidney injury markers of the present invention for the evaluation of renal injury.
  • the methods for evaluating renal status described herein are methods for risk stratification of the subject; that is, assigning a likelihood of one or more future changes in renal status to the subject.
  • the assay result(s) is/are correlated to one or more such future changes. The following are preferred risk stratification embodiments.
  • these methods comprise determining a subject's risk for a future injury to renal function, and the assay result(s) is/are correlated to a likelihood of such a future injury to renal function.
  • the measured concentration(s) may each be compared to a threshold value.
  • a threshold value For a “positive going” kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.
  • a “negative going” kidney injury marker an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • these methods comprise determining a subject's risk for future reduced renal function, and the assay result(s) is/are correlated to a likelihood of such reduced renal function.
  • the measured concentrations may each be compared to a threshold value.
  • a threshold value For a “positive going” kidney injury marker, an increased likelihood of suffering a future reduced renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.
  • a “negative going” kidney injury marker an increased likelihood of future reduced renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • these methods comprise determining a subject's likelihood for a future improvement in renal function, and the assay result(s) is/are correlated to a likelihood of such a future improvement in renal function.
  • the measured concentration(s) may each be compared to a threshold value.
  • a threshold value For a “positive going” kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • a “negative going” kidney injury marker an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.
  • these methods comprise determining a subject's risk for progression to ARF, and the result(s) is/are correlated to a likelihood of such progression to ARF.
  • the measured concentration(s) may each be compared to a threshold value.
  • a threshold value For a “positive going” kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.
  • a “negative going” kidney injury marker an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • these methods comprise determining a subject's outcome risk, and the assay result(s) is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject.
  • the measured concentration(s) may each be compared to a threshold value.
  • a “positive going” kidney injury marker an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.
  • kidney injury marker For a “negative going” kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • the likelihood or risk assigned is that an event of interest is more or less likely to occur within 180 days of the time at which the body fluid sample is obtained from the subject.
  • the likelihood or risk assigned relates to an event of interest occurring within a shorter time period such as 18 months, 120 days, 90 days, 60 days, 45 days, 30 days, 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less.
  • a risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.
  • the subject is selected for risk stratification based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.
  • a subject undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery a subject having pre-existing congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, or sepsis; or a subject exposed to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin are all preferred subjects for monitoring risks according to the methods described here
  • pre-existence in this context is meant that the risk factor exists at the time the body fluid sample is obtained from the subject.
  • a subject is chosen for risk stratification based on an existing diagnosis of injury to renal function, reduced renal function, or ARF.
  • the methods for evaluating renal status described herein are methods for diagnosing a renal injury in the subject; that is, assessing whether or not a subject has suffered from an injury to renal function, reduced renal function, or ARF.
  • the assay result(s) for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A
  • these methods comprise diagnosing the occurrence or nonoccurrence of an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of such an injury.
  • each of the measured concentration(s) may be compared to a threshold value.
  • an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold).
  • an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • these methods comprise diagnosing the occurrence or nonoccurrence of reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing reduced renal function.
  • each of the measured concentration(s) may be compared to a threshold value.
  • an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold).
  • an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • these methods comprise diagnosing the occurrence or nonoccurrence of ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing ARF.
  • each of the measured concentration(s) may be compared to a threshold value.
  • an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold).
  • an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • these methods comprise diagnosing a subject as being in need of renal replacement therapy, and the assay result(s) is/are correlated to a need for renal replacement therapy.
  • each of the measured concentration(s) may be compared to a threshold value.
  • an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold).
  • an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • these methods comprise diagnosing a subject as being in need of renal transplantation, and the assay result(s0 is/are correlated'to a need for renal transplantation.
  • each of the measured concentration(s) may be compared to a threshold value.
  • an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold).
  • an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • the methods for evaluating renal status described herein are methods for monitoring a renal injury in the subject; that is, assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF.
  • the assay result(s) for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2,
  • these methods comprise monitoring renal status in a subject suffering from an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject.
  • the measured concentration(s) may be compared to a threshold value.
  • a threshold value For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject.
  • a negative going marker when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • these methods comprise monitoring renal status in a subject suffering from reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject.
  • the measured concentration(s) may be compared to a threshold value.
  • a threshold value For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject.
  • a negative going marker when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • these methods comprise monitoring renal status in a subject suffering from acute renal failure, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject.
  • the measured concentration(s) may be compared to a threshold value.
  • a threshold value For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject.
  • a negative going marker when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • these methods comprise monitoring renal status in a subject at risk of an injury to renal function due to the pre-existence of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject.
  • the measured concentration(s) may be compared to a threshold value.
  • a threshold value For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject.
  • a negative going marker when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • the methods for evaluating renal status described herein are methods for classifying a renal injury in the subject; that is, determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage.
  • the assay result(s) for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor
  • these methods comprise determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage, and the assay result(s) is/are correlated to the injury classification for the subject. For example, the measured concentration may be compared to a threshold value, and when the measured concentration is above the threshold, a particular classification is assigned; alternatively, when the measured concentration is below the threshold, a different classification may be assigned to the subject.
  • the threshold value may be determined from a population of normal subjects by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such normal subjects.
  • the threshold value may be determined from a “diseased” population of subjects, e.g., those suffering from an injury or having a predisposition for an injury (e.g., progression to ARF or some other clinical outcome such as death, dialysis, renal transplantation, etc.), by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such subjects.
  • the threshold value may be determined from a prior measurement of a kidney injury marker in the same subject; that is, a temporal change in the level of a kidney injury marker in the subject may be used to assign risk to the subject.
  • kidney injury markers of the present invention must be compared to corresponding individual thresholds.
  • Methods for combining assay results can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, calculating ratios of markers, etc. This list is not meant to be limiting.
  • a composite result which is determined by combining individual markers may be treated as if it is itself a marker; that is, a threshold may be determined for the composite result as described herein for individual markers, and the composite result for an individual patient compared to this threshold.
  • ROC curves established from a “first” subpopulation which is predisposed to one or more future changes in renal status, and a “second” subpopulation which is not so predisposed can be used to calculate a ROC curve, and the area under the curve provides a measure of the quality of the test.
  • the tests described herein provide a ROC curve area greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.
  • the measured concentration of one or more kidney injury markers, or a composite of such markers may be treated as continuous variables.
  • any particular concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc.
  • a threshold that can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed.
  • a threshold value is selected to separate this first and second population by one or more of the following measures of test accuracy:
  • Multiple thresholds may also be used to assess renal status in a subject. For example, a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., and a “second” subpopulation which is not so predisposed can be combined into a single group. This group is then subdivided into three or more equal parts (known as tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1.
  • the second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile.
  • the third tertile is also assigned an odds ratio that is relative to that first tertile.
  • the assay method is an immunoassay.
  • Antibodies for use in such assays will specifically bind a full length kidney injury marker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. Numerous immunoassay formats are known to those of skill in the art.
  • Preferred body fluid samples are selected from the group consisting of urine, blood, serum, saliva, tears, and plasma.
  • kidney injury marker assay result(s) is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, a risk stratification, diagnostic, classification, monitoring, etc.
  • method may combine the assay result(s) with one or more variables measured for the subject selected from the group consisting of demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score
  • a glomerular filtration rate an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration.
  • NGAL neutrophil gelatinase
  • kidney injury marker assay result(s) Other measures of renal function which may be combined with one or more kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17 th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47 th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.
  • the individual markers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times.
  • the individual markers may also be measured on the same or different body fluid samples. For example, one kidney injury marker may be measured in a serum or plasma sample and another kidney injury marker may be measured in a urine sample.
  • assignment of a likelihood may combine an individual kidney injury marker assay result with temporal changes in one or more additional variables.
  • kits for performing the methods described herein comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.
  • reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit.
  • Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support.
  • such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.
  • Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).
  • a detectable reaction product e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.
  • a specific binding molecule which itself may be detectable (e.g.,
  • a signal from the signal development element can be performed using various optical, acoustical, and electrochemical methods well known in the art.
  • detection modes include fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc.
  • the solid phase antibody is coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector).
  • a transducer e.g., a diffraction grating, electrochemical sensor, etc
  • a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector).
  • Antibody-based biosensors may
  • the present invention relates to methods and compositions for diagnosis, differential diagnosis, risk stratification, monitoring, classifying and determination of treatment regimens in subjects suffering or at risk of suffering from injury to renal function, reduced renal function and/or acute renal failure through measurement of one or more kidney injury markers.
  • a measured concentration of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin
  • an “injury to renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury may be identified, for example, by a decrease in glomerular filtration rate or estimated GFR, a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy, etc.
  • “Improvement in Renal Function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.
  • reduced renal function is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL ( ⁇ 8.8 ⁇ mol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).
  • acute renal failure is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl ( ⁇ 26.4 ⁇ mol/l), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours).
  • This term is synonymous with “acute kidney injury” or “AKI.”
  • C-C motif chemokine 7 refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 7 precursor (Swiss-Prot P80098 (SEQ ID NO: 1)).
  • C-C motif chemokine 26 refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 26 precursor (Swiss-Prot Q9Y258 (SEQ ID NO: 2)).
  • Complement C4-B refers to one or more polypeptides present in a biological sample that are derived from Complement C4-B precursor (Swiss-Prot P0C0L5 (SEQ ID NO: 3)).
  • Corticotropin refers to one or more polypeptides present in a biological sample that are derived from pro-opiomelanocortin precursor (Swiss-Prot P01189 (SEQ ID NO: 4)) containing one or more epitopes of corticotropin.
  • Interferon alpha-2 refers to one or more polypeptides present in a biological sample that are derived from the Interferon alpha-2 precursor (Swiss-Prot P01563 (SEQ ID NO: 5)).
  • Interleukin-4 receptor subunit alpha refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-4 receptor subunit alpha precursor (Swiss-Prot P24394 (SEQ ID NO: 6):
  • Interleukin-4 receptor subunit alpha is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Interleukin-4 receptor subunit alpha generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form.
  • one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s).
  • the following domains have been identified in Interleukin-4 receptor subunit alpha:
  • Insulin-like growth factor-binding protein 4 refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 4 precursor (Swiss-Prot P22692 (SEQ ID NO: 7)).
  • Insulin-like growth factor-binding protein 4 The following domains have been identified in Insulin-like growth factor-binding protein 4:
  • Insulin-like growth factor-binding protein 5 refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 5 precursor (Swiss-Prot P24593 (SEQ ID NO: 8)).
  • Insulin-like growth factor-binding protein 5 The following domains have been identified in Insulin-like growth factor-binding protein 5:
  • Interleukin-21 refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-21 precursor (Swiss-Prot Q9HBE4 (SEQ ID NO: 8)).
  • Interleukin-23 subunit alpha refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-23 subunit alpha precursor (Swiss-Prot Q9NPF7 (SEQ ID NO: 9)).
  • Residues Length Domain ID 1-19 19 Signal peptide 20-189 170 Interleukin-23 subunit alpha
  • Interleukin-28A refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-28A precursor (Swiss-Prot Q81ZJ0 (SEQ ID NO: 10)).
  • Interleukin-33 refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-33 precursor (Swiss-Prot O95760 (SEQ ID NO: 11)).
  • Lutropin subunit beta refers to one or more polypeptides present in a biological sample that are derived from the Lutropin subunit beta precursor (Swiss-Prot P01229 (SEQ ID NO: 12)).
  • Interstitial collagenase also known as MMP-1 and matrix metalloproteinase 1 refers to one or more polypeptides present in a biological sample that are derived from the Interstitial collagenase precursor (Swiss-Prot P03956 (SEQ ID NO: 13)).
  • Neural cell adhesion molecule 1 refers to one or more polypeptides present in a biological sample that are derived from the Neural cell adhesion molecule 1 precursor (Swiss-Prot P13591 (SEQ ID NO: 14):
  • Neural cell adhesion molecule 1 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Neural cell adhesion molecule 1 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Neural cell adhesion molecule 1:
  • Pigment epithelium-derived factor refers to one or more polypeptides present in a biological sample that are derived from the Pigment epithelium-derived factor precursor (Swiss-Prot P36955 (SEQ ID NO: 22)).
  • Platinum-derived growth factor subunit A refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived growth factor subunit A precursor (Swiss-Prot P04085 (SEQ ID NO: 23)).
  • Vascular endothelial growth factor receptor 2 refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 2 precursor (Swiss-Prot P35968 (SEQ ID NO: 24):
  • Vascular endothelial growth factor receptor 2 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 2 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form.
  • one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 2:
  • Vascular endothelial growth factor receptor 3 refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 3 precursor (Swiss-Prot P35916 (SEQ ID NO: 25):
  • Vascular endothelial growth factor receptor 3 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 3 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form.
  • one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 3:
  • Tumor necrosis factor receptor superfamily member 8 refers to one or more polypeptides present in a biological sample that are derived from the Tumor necrosis factor receptor superfamily member 8 precursor (Swiss-Prot P28908 (SEQ ID NO: 26)):
  • Tumor necrosis factor receptor superfamily member 8 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Tumor necrosis factor receptor superfamily member 8 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Tumor necrosis factor receptor superfamily member 8:
  • Alpha-fetoprotein refers to one or more polypeptides present in a biological sample that are derived from the Alpha-fetoprotein precursor (Swiss-Prot P02771 (SEQ ID NO: 27)):
  • Thyroxine-binding globulin refers to one or more polypeptides present in a biological sample that are derived from the Thyroxine-binding globulin precursor (Swiss-Prot P05543 (SEQ ID NO: 28)).
  • Thyroxine-binding globulin The following domains have been identified in Thyroxine-binding globulin:
  • Prostate-specific antigen refers to one or more polypeptides present in a biological sample that are derived from the Prostate-specific antigen precursor (Swiss-Prot P07288 (SEQ ID NO: 29)).
  • Apolipoprotein(a) and “Apolipoprotein A” refer to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein(a) precursor (Swiss-Prot P08519 (SEQ ID NO: 30)).
  • Apolipoprotein E refers to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein E precursor (Swiss-Prot P02649 (SEQ ID NO: 31)).
  • Apolipoprotein E The following domains have been identified in Apolipoprotein E:
  • Thyrotropin subunit beta refers to one or more polypeptides present in a biological sample that are derived from the Thyrotropin subunit betaprecursor (Swiss-Prot P01222 (SEQ ID NO: 32)).
  • Thyrotropin subunit beta The following domains have been identified in Thyrotropin subunit beta:
  • Platinum-derived Growth Factor B/B dimer refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived Growth Factor V precursor and that form a homodimer (Swiss-Prot P01127 (SEQ ID NO: 33)).
  • IgG4 refers to subclass 4 of the glycoprotein immunoglobulin G (IgG), a major effector molecule of the humoral immune response in man. Antibodies of the IgG class express their predominant activity during a secondary antibody response.
  • the basic immunoglobulin G molecule has a four-chain structure, comprising two identical heavy (H) chains and two identical light (L) chains, linked together by inter-chain disulfide bonds.
  • Each heavy chain is encoded by 4 distinct types of gene segments, designated V H (variable), D (diversity), J H (joining) and C H (constant).
  • the variable region of the heavy chain is encoded by the V H , D and J H segments.
  • the light chains are encoded by the 3 gene segments, V L , J L and C L .
  • the variable region of the light chains is encoded by the V L and J L segments.
  • the length and flexibility of the hinge region varies among the IgG subclasses.
  • the hinge region of IgG1 encompasses amino acids 216-231 and since it is freely flexible, the Fab fragments can rotate about their axes of symmetry and move within a sphere centered at the first of two inter-heavy chain disulfide bridges (23).
  • IgG2 has a shorter hinge than IgG 1, with 12 amino acid residues and four disulfide bridges.
  • the hinge region of IgG2 lacks a glycine residue, it is relatively short and contains a rigid poly-proline double helix, stabilised by extra inter-heavy chain disulfide bridges. These properties restrict the flexibility of the IgG2 molecule (24).
  • IgG3 differs from the other subclasses by its unique extended hinge region (about four times as long as the IgG1 hinge), containing 62 amino acids (including 21 prolines and 11 cysteines), forming an inflexible poly-proline double helix (25,26).
  • the Fab fragments are relatively far away from the Fc fragment, giving the molecule a greater flexibility.
  • the elongated hinge in IgG3 is also responsible for its higher molecular weight compared to the other subclasses.
  • the hinge region of IgG4 is shorter than that of IgG 1 and its flexibility is intermediate between that of IgG1 and IgG2.
  • the four IgG subclasses also differ with respect to the number of inter-heavy chain disulfide bonds in the hinge region (26).
  • the structural differences between the IgG subclasses are also reflected in their susceptibility to proteolytic enzymes.
  • IgG3 is very susceptible to cleavage by these enzymes, whereas IgG2 is relatively resistant.
  • IgG1 and IgG4 exhibit an intermediary sensitivity, depending upon the enzyme used. Since these proteolytic enzymes all cleave IgG molecules near or within the hinge region, it is likely that the high sensitivity of IgG3 to enzyme digestion is related to its accessible hinge.
  • Another structural difference between the human IgG subclasses is the linkage of the heavy and light chain by a disulfide bond. This bond links the carboxy-terminal of the light chain with the cysteine residue at position 220 (in IgG) or at position 131 (in IgG2, IgG3 and IgG4) of the CH1 sequence of the heavy
  • the four IgG subclasses may be distinguished from one another, for example using antibodies that are specific for differences between the isoforms.
  • a level of IgG1 is determined using an assay which distinguishes this subclass, relative to the other subclasses.
  • the term “relating a signal to the presence or amount” of an analyte reflects the following understanding. Assay signals are typically related to the presence or amount of an analyte through the use of a standard curve calculated using known concentrations of the analyte of interest. As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte.
  • an immunoassay configured to detect a marker of interest will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay.
  • the term “related marker” as used herein with regard to a biomarker such as one of the kidney injury markers described herein refers to one or more fragments, variants, etc., of a particular marker or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers.
  • the term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.
  • the signals obtained from an immunoassay are a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., the analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample.
  • Biomarkers may also be determined by means other than immunoassays, including protein measurements (such as dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quatitation). This list is not meant to be limiting.
  • positive going marker refers to a marker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.
  • negative going marker refers to a marker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.
  • subject refers to a human or non-human organism.
  • methods and compositions described herein are applicable to both human and veterinary disease.
  • a subject is preferably a living organism, the invention described herein may be used in post-mortem analysis as well.
  • Preferred subjects are humans, and most preferably “patients,” which as used herein refers to living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology.
  • an analyte is measured in a sample.
  • a sample may be obtained from a subject, or may be obtained from biological materials intended to be provided to the subject.
  • a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, and an analyte measurement used to evaluate the kidney for preexisting damage.
  • Preferred samples are body fluid samples.
  • body fluid sample refers to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition.
  • Preferred body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions.
  • body fluid samples would be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.
  • diagnosis refers to methods by which the skilled artisan can estimate and/or determine the probability (“a likelihood”) of whether or not a patient is suffering from a given disease or condition.
  • diagnosis includes using the results of an assay, most preferably an immunoassay, for a kidney injury marker of the present invention, optionally together with other clinical characteristics, to arrive at a diagnosis (that is, the occurrence or nonoccurrence) of an acute renal injury or ARF for the subject from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Many biomarkers are indicative of multiple conditions.
  • a measured biomarker level on one side of a predetermined diagnostic threshold indicates a greater likelihood of the occurrence of disease in the subject relative to a measured level on the other side of the predetermined diagnostic threshold.
  • a prognostic risk signals a probability (“a likelihood”) that a given course or outcome will occur.
  • a level or a change in level of a prognostic indicator which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.
  • immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. See, e.g., U.S. Pat. Nos.
  • the assay devices and methods known in the art can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest.
  • Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods.
  • certain methods and devices such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims.
  • robotic instrumentation including but not limited to Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems are among the immunoassay analyzers that are capable of performing immunoassays.
  • any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.
  • Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in assays.
  • Solid phases that may be used to immobilize specific binding members include include those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates.
  • An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support.
  • Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.
  • Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied.
  • Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, metal chelates, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or by a specific binding molecule which itself may be detectable (e.g., biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).
  • a detectable reaction product e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.
  • Cross-linking reagents contain at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups.
  • kits for the analysis of the described kidney injury markers comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker.
  • the kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein.
  • Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte.
  • an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker.
  • each of the antibodies are monoclonal antibodies.
  • the instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use.
  • labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.
  • antibody refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. Fundamental Immunology, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97.
  • antibody includes antigen-binding portions, i.e., “antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR).
  • Antigen binding sites e.g., fragments, subs
  • Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention.
  • the term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s).
  • the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule.
  • Preferred antibodies bind with affinities of at least about 10 7 M ⁇ 1 , and preferably between about 10 8 M ⁇ 1 to about 10 9 M ⁇ 1 , about 10 9 M ⁇ 1 to about 10 10 M ⁇ 1 , or about 10 10 M ⁇ 1 to about 10 12 M ⁇ 1 .
  • r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot.
  • Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., J. Immunoassay 12: 425-43, 1991; Nelson and Griswold, Comput. Methods Programs Biomed. 27: 65-8, 1988.
  • epitope refers to an antigenic determinant capable of specific binding to an antibody.
  • Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
  • phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g., Cwirla et al., Proc. Natl. Acad. Sci. USA 87, 6378-82, 1990; Devlin et al., Science 249, 404-6, 1990, Scott and Smith, Science 249, 386-88, 1990; and Ladner et al., U.S. Pat. No. 5,571,698.
  • a basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide.
  • This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide.
  • the establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides.
  • Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target.
  • the identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.
  • the antibodies that are generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding.
  • the screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h.
  • microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.
  • a labeled secondary antibody for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies
  • the antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected.
  • the purified target, protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.
  • aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist. High-affinity aptamers containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions, and may include amino acid side chain functionalities.
  • correlating refers to comparing the presence or amount of the biomarker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.
  • Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, cost/benefit analysis is involved in selecting a diagnostic threshold.
  • Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction using cardiac troponin is the 97.5th percentile of the concentration seen in a normal population. Another method may be to look at serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.
  • ROC Receiver Operating Characteristic
  • the ROC graph is sometimes called the sensitivity vs (1-specificity) plot.
  • a perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5.
  • a threshold is selected to provide an acceptable level of specificity and sensitivity.
  • diseased is meant to refer to a population having one characteristic (the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” is meant to refer to a population lacking the characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.
  • other methods for correlating assay results to a patient classification include decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject belongs to one classification out of a plurality of classifications.
  • Measures of test accuracy may be obtained as described in Fischer et al., Intensive Care Med. 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas.
  • the area under the curve (“AUC”) of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one.
  • the area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.
  • suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than
  • Additional clinical indicia may be combined with the kidney injury marker assay result(s) of the present invention.
  • biomarkers related to renal status include the following, which recite the common biomarker name, followed by the Swiss-Prot entry number for that biomarker or its parent: Actin (P68133); Adenosine deaminase binding protein (DPP4, P27487); Alpha-1-acid glycoprotein 1 (P02763); Alpha-1-microglobulin (P02760); Albumin (P02768); Angiotensinogenase (Renin, P00797); Annexin A2 (P07355); Beta-glucuronidase (P08236); B-2-microglobulin (P61679); Beta-galactosidase (P16278); BMP-7 (P18075); Brain natriuretic peptide (proBNP, BNP-32, NTproBNP; P16860); Calcium-binding protein Beta (S100-beta
  • Adiponectin (Q15848); Alkaline phosphatase P05186); Aminopeptidase N(P15144); CalbindinD28k (P05937); Cystatin C(P01034); 8 subunit of FIFO ATPase (P03928); Gamma-glutamyltransferase (P19440); GSTa (alpha-glutathione-S-transferase, P08263); GSTpi (Glutathione-S-transferase P; GST class-pi; P09211); IGFBP-1 (P08833); IGFBP-2 (P18065); IGFBP-6 (P24592); Integral membrane protein 1 (Itm1, P46977); Interleukin-6 (P05231); Interleukin-8 (P10145); Interleukin-18 (Q14116); IP-10 (10 kDa interferon-gamma-induced protein, P02778); IRPR (IRPR) (IRPR
  • Other clinical indicia which may be combined with the kidney injury marker assay result(s) of the present invention includes demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score
  • kidney injury marker assay result(s) Other measures of renal function which may be combined with the kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17 th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47 th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.
  • Combining assay results/clinical indicia in this manner can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, etc. This list is not meant to be limiting.
  • the terms “acute renal (or kidney) injury” and “acute renal (or kidney) failure” as used herein are defined in part in terms of changes in serum creatinine from a baseline value.
  • Most definitions of ARF have common elements, including the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR.
  • Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of mL/min:
  • GFR glomerular filtration rate
  • eGFR glomerular filtration rate
  • Creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.
  • Creatinine clearance can be calculated if values for creatinine's urine concentration (U Cr ), urine flow rate (V), and creatinine's plasma concentration (P Cr ) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (U Cr ⁇ V) divided by its plasma concentration. This is commonly represented mathematically as:
  • the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m2. While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:
  • the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc.
  • a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc.
  • the skilled artisan is aware of appropriate treatments for numerous diseases discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N.J., 1999.
  • the markers of the present invention may be used to monitor a course of treatment. For example, improved or worsened prognostic state may indicate that a particular treatment is or
  • the objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after receiving intravascular contrast media. Approximately 250 adults undergoing radiographic/angiographic procedures involving intravascular administration of iodinated contrast media are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:
  • renal transplant recipients acutely worsening renal function prior to the contrast procedure; already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment; expected to undergo a major surgical procedure (such as involving cardiopulmonary bypass) or an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration; participation in an interventional clinical study with an experimental therapy within the previous 30 days; known infection with human immunodeficiency virus (1-HV) or a hepatitis virus.
  • a major surgical procedure such as involving cardiopulmonary bypass
  • an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration
  • participation in an interventional clinical study with an experimental therapy within the previous 30 days known infection with human immunodeficiency virus (1-HV) or a hepatitis virus.
  • an EDTA anti-coagulated blood sample (10 mL) and a urine sample (10 mL) are collected from each patient. Blood and urine samples are then collected at 4 ( ⁇ 0.5), 8 ( ⁇ 1), 24 ( ⁇ 2) 48 ( ⁇ 2), and 72 ( ⁇ 2) hrs following the last administration of contrast media during the index contrast procedure. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.
  • Serum creatinine is assessed at the site immediately prior to the first contrast administration (after any pre-procedure hydration) and at 4 ( ⁇ 0.5), 8 ( ⁇ 1), 24 ( ⁇ 2) and 48 ( ⁇ 2)), and 72 ( ⁇ 2) hours following the last administration of contrast (ideally at the same time as the study samples are obtained).
  • each patient's status is evaluated through day 30 with regard to additional serum and urine creatinine measurements, a need for dialysis, hospitalization status, and adverse clinical outcomes (including mortality).
  • the objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after undergoing cardiovascular surgery, a procedure known to be potentially damaging to kidney function. Approximately 900 adults undergoing such surgery are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:
  • an EDTA anti-coagulated blood sample (10 mL), whole blood (3 mL), and a urine sample (35 mL) are collected from each patient. Blood and urine samples are then collected at 3 ( ⁇ 0.5), 6 ( ⁇ 0.5), 12 ( ⁇ 1), 24 ( ⁇ 2) and 48 ( ⁇ 2) hrs following the procedure and then daily on days 3 through 7 if the subject remains in the hospital. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock.
  • These study blood samples are frozen and shipped to Astute Medical, Inc., San Diego, Calif.
  • the study urine samples are frozen and shipped to Astute Medical, Inc.
  • the objective of this study is to collect samples from acutely ill patients. Approximately 1900 adults expected to be in the ICU for at least 48 hours will be enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:
  • Study population 1 approximately 300 patients that have at least one of: shock (SBP ⁇ 90 mmHg and/or need for vasopressor support to maintain MAP>60 mmHg and/or documented drop in SBP of at least 40 mmHg); and sepsis;
  • Study population 2 approximately 300 patients that have at least one of: IV antibiotics ordered in computerized physician order entry (CPOE) within 24 hours of enrollment; contrast media exposure within 24 hours of enrollment; increased Intra-Abdominal Pressure with acute decompensated heart failure; and severe trauma as the primary reason for ICU admission and likely to be hospitalized in the ICU for 48 hours after enrollment;
  • Study population 3 approximately 300 patients expected to be hospitalized through acute care setting (ICU or ED) with a known risk factor for acute renal injury (e.g.
  • Study population 4 approximately 1000 patients that are 21 years of age or older, within 24 hours of being admitted into the ICU, expected to have an indwelling urinary catheter for at least 48 hours after enrollment, and have at least one of the following acute conditions within 24 hours prior to enrollment: (i) respiratory SOFA score of ⁇ 2 (PaO2/FiO2 ⁇ 300), (ii) cardiovascular SOFA score of ⁇ 1 (MAP ⁇ 70 mm Hg and/or any vasopressor required).
  • an EDTA anti-coagulated blood sample (10 mL) and a urine sample (25-50 mL) are collected from each patient. Blood and urine samples are then collected at 4 ( ⁇ 0.5) and 8 ( ⁇ 1) hours after contrast administration (if applicable); at 12 ( ⁇ 1), 24 ( ⁇ 2), 36 ( ⁇ 2), 48 ( ⁇ 2), 60 ( ⁇ 2), 72 ( ⁇ 2), and 84 ( ⁇ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.
  • Analytes are measured using standard sandwich enzyme immunoassay techniques.
  • a first antibody which binds the analyte is immobilized in wells of a 96 well polystyrene microplate.
  • Analyte standards and test samples are pipetted into the appropriate wells and any analyte present is bound by the immobilized antibody.
  • a horseradish peroxidase-conjugated second antibody which binds the analyte is added to the wells, thereby forming sandwich complexes with the analyte (if present) and the first antibody.
  • a substrate solution comprising tetramethylbenzidine and hydrogen peroxide is added to the wells. Color develops in proportion to the amount of analyte present in the sample. The color development is stopped and the intensity of the color is measured at 540 nm or 570 nm. An analyte concentration is assigned to the test sample by comparison to a standard curve determined from the analyte standards. In the case of kidney injury markers that are membrane proteins, assays are directed to soluble forms thereof as described above.
  • Tumor necrosis factor receptor superfamily member 8 pg/mL
  • Alpha-Fetoprotein ng/mL
  • Thyroxine-binding globulin pg/mL
  • Prostate-specific antigen (free form) ng/mL
  • Apolipoprotein A ng/mL
  • Apolipoprotein E ng/mL
  • Thyrotropin subunit beta pg/mL
  • Platelet-derived growth factor BB dimer pg/mL
  • C-C motif chemokine 7 pg/mL
  • C-C motif chemokine 26 pg/mL
  • Complement C4-B ng/mL
  • Corticotropin ng/mL
  • Interferon alpha-2 pg/mL
  • Interleukin-4 receptor alpha chain pg/mL
  • Insulin-like growth factor-binding protein 4 ng/mL
  • Insulin-like growth factor-binding protein 5 ng/mL
  • Chronic Disease Patients Human urine samples from donors with various chronic diseases (“Chronic Disease Patients”) including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, Va. 23454. The urine samples were shipped and stored frozen at less than ⁇ 20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking status and alcohol use, height, weight, chronic disease(s) diagnosis, current medications and previous surgeries.
  • Chronic Disease Patients including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, Va. 23454. The urine samples were shipped and stored frozen at less than ⁇ 20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking
  • ICU intensive care unit
  • O non-injury
  • R risk of injury
  • I failure
  • F failure
  • EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) were collected from each patient at enrollment, 4 ( ⁇ 0.5) and 8 ( ⁇ 1) hours after contrast administration (if applicable); at 12 ( ⁇ 1), 24 ( ⁇ 2), and 48 ( ⁇ 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Markers were each measured by standard immunoassay methods using commercially available assay reagents in the urine samples and the plasma component of the blood samples collected.
  • the time “prior max stage” represents the time at which a sample is collected, relative to the time a particular patient reaches the lowest disease stage as defined for that cohort, binned into three groups which are +/ ⁇ 12 hours.
  • 24 hr prior which uses 0 vs R, I, F as the two cohorts would mean 24 hr (+/ ⁇ 12 hours) prior to reaching stage R (or I if no sample at R, or F if no sample at R or I).
  • ROC receiver operating characteristic
  • the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of urine output; for those patients adjudicated to stage R, I, or F on the basis of urine output alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements; and for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements or urine output, the stage 0 cohort contains only patients in stage 0 for both serum creatinine measurements and urine output. Also, in the data for patients adjudicated on the basis of serum creatinine measurements or urine output, the adjudication method which yielded the most severe RIFLE stage is used.
  • FIG. 1 Comparison of marker levels in urine samples collected from Cohort I (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.
  • FIG. 2 Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.
  • FIG. 3 Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).
  • FIG. 4 Comparison of the maximum marker levels in urine samples collected from Cohort I (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.
  • FIG. 5 Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.
  • FIG. 6 Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.
  • FIG. 7 Comparison of marker levels in EDTA samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).
  • FIG. 8 Comparison of the maximum marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in EDTA samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.
  • FIG. 9 Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in urine samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.
  • FIG. 10 Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in EDTA samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.
  • FIG. 11 Comparison of marker levels in enroll urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48 hrs) and in enroll urine samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48 hrs). Enroll samples from patients already at RIFLE stage I or F were included in Cohort 2.
  • FIG. 12 Comparison of marker levels in enroll EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48 hrs) and in enroll EDTA samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48 hrs). Enroll samples from patients already at stage I or F were included in Cohort 2.

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.

Description

  • The present application claims priority to U.S. Provisional Patent Application No. 61/357,965 filed Jun. 23, 2010; U.S. Provisional Patent Application No. 61/357,956 filed Jun. 23, 2010; U.S. Provisional Patent Application No. 61/357,966 filed Jun. 23, 2010; U.S. Provisional Patent Application No. 61/364,305 filed Jul. 14, 2010; and U.S. Provisional Patent Application No. 61/364,296 filed Jul. 14, 2010, each of which is hereby incorporated in its entirety including all tables, figures, and claims.
    • BACKGROUND OF THE INVENTION
  • The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention.
  • The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. Renal disease and/or injury may be acute or chronic. Acute and chronic kidney disease are described as follows (from Current Medical Diagnosis & Treatment 2008, 471h Ed, McGraw Hill, New York, pages 785-815, which are hereby incorporated by reference in their entirety): “Acute renal failure is worsening of renal function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia. Chronic renal failure (chronic kidney disease) results from an abnormal loss of renal function over months to years”.
  • Acute renal failure (ARF, also known as acute kidney injury, or AKI) is an abrupt (typically detected within about 48 hours to 1 week) reduction in glomerular filtration. This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in the following table, which is adapted from the Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety:
  • Type Risk Factors
    Prerenal
    ECF volume depletion Excessive diuresis, hemorrhage, GI losses, loss of
    intravascular fluid into the extravascular space (due to
    ascites, peritonitis, pancreatitis, or burns), loss of skin
    and mucus membranes, renal salt- and water-wasting
    states
    Low cardiac output Cardiomyopathy, MI, cardiac tamponade, pulmonary
    embolism, pulmonary hypertension, positive-pressure
    mechanical ventilation
    Low systemic vascular Septic shock, liver failure, antihypertensive drugs
    resistance
    Increased renal vascular NSAIDs, cyclosporines, tacrolimus, hypercalcemia,
    resistance anaphylaxis, anesthetics, renal artery obstruction, renal
    vein thrombosis, sepsis, hepatorenal syndrome
    Decreased efferent ACE inhibitors or angiotensin II receptor blockers
    arteriolar tone (leading to
    decreased GFR from
    reduced glomerular
    transcapillary pressure,
    especially in patients with
    bilateral renal artery
    stenosis)
    Intrinsic Renal
    Acute tubular injury Ischemia (prolonged or severe prerenal state): surgery,
    hemorrhage, arterial or venous obstruction; Toxins:
    NSAIDs, cyclosporines, tacrolimus, aminoglycosides,
    foscarnet, ethylene glycol, hemoglobin, myoglobin,
    ifosfamide, heavy metals, methotrexate, radiopaque
    contrast agents, streptozotocin
    Acute glomerulonephritis ANCA-associated: Crescentic glomerulonephritis,
    polyarteritis nodosa, Wegener's granulomatosis; Anti-
    GBM glomerulonephritis: Goodpasture's syndrome;
    Immune-complex: Lupus glomerulonephritis,
    postinfectious glomerulonephritis, cryoglobulinemic
    glomerulonephritis
    Acute tubulointerstitial Drug reaction (eg, 13-lactams, NSAIDs, sulfonamides,
    nephritis ciprofloxacin, thiazide diuretics, furosemide, phenytoin,
    allopurinol, pyelonephritis, papillary necrosis
    Acute vascular Vasculitis, malignant hypertension, thrombotic
    nephropathy microangiopathies, scleroderma, atheroembolism
    Infiltrative diseases Lymphoma, sarcoidosis, leukemia
    Postrenal
    Tubular precipitation Uric acid (tumor lysis), sulfonamides, triamterene,
    acyclovir, indinavir, methotrexate, ethylene glycol
    ingestion, myeloma protein, myoglobin
    Ureteral obstruction Intrinsic: Calculi, clots, sloughed renal tissue, fungus
    ball, edema, malignancy, congenital defects; Extrinsic:
    Malignancy, retroperitoneal fibrosis, ureteral trauma
    during surgery or high impact injury
    Bladder obstruction Mechanical: Benign prostatic hyperplasia, prostate
    cancer, bladder cancer, urethral strictures, phimosis,
    paraphimosis, urethral valves, obstructed indwelling
    urinary catheter; Neurogenic: Anticholinergic drugs,
    upper or lower motor neuron lesion
  • In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.
  • Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.
  • A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI. The relationship between serum creatinine rise, AKI and the associated health risks are reviewed in Praught and Shlipak, Curr Opin Nephrol Hypertens 14:265-270, 2005 and Chertow et al, J Am Soc Nephrol 16: 3365-3370, 2005, which, with the references listed therein, are hereby incorporated by reference in their entirety. As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 days, 3 days, 7 days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.
  • One study (Lassnigg et all, J Am Soc Nephrol 15:1597-1605, 2004, hereby incorporated by reference in its entirety) investigated both increases and decreases in serum creatinine. Patients with a mild fall in serum creatinine of −0.1 to −0.3 mg/dL following heart surgery had the lowest mortality rate. Patients with a larger fall in serum creatinine (more than or equal to −0.4 mg/dL) or any increase in serum creatinine had a larger mortality rate. These findings caused the authors to conclude that even very subtle changes in renal function (as detected by small creatinine changes within 48 hours of surgery) seriously effect patient's outcomes. In an effort to reach consensus on a unified classification system for using serum creatinine to define AKI in clinical trials and in clinical practice, Bellomo et al., Crit. Care. 8(4):R204-12, 2004, which is hereby incorporated by reference in its entirety, proposes the following classifications for stratifying AKI patients:
  • “Risk”: serum creatinine increased 1.5 fold from baseline OR urine production of <0.5 ml/kg body weight/hr for 6 hours;
    “Injury”: serum creatinine increased 2.0 fold from baseline OR urine production <0.5 ml/kg/hr for 12 h;
    “Failure”: serum creatinine increased 3.0 fold from baseline OR creatinine >355 μmol/l (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h or anuria for at least 12 hours;
    And included two clinical outcomes:
    “Loss”: persistent need for renal replacement therapy for more than four weeks.
    “ESRD”: end stage renal disease—the need for dialysis for more than 3 months.
  • These criteria are called the RIFLE criteria, which provide a useful clinical tool to classify renal status. As discussed in Kellum, Crit. Care Med. 36: S141-45, 2008 and Ricci et al., Kidney int. 73, 538-546, 2008, each hereby incorporated by reference in its entirety, the RIFLE criteria provide a uniform definition of AKI which has been validated in numerous studies.
  • More recently, Mehta et al., Crit. Care 11:R31 (doi:10.1186.cc5713), 2007, hereby incorporated by reference in its entirety, proposes the following similar classifications for stratifying AKI patients, which have been modified from RIFLE:
    “Stage I”: increase in serum creatinine of more than or equal to 0.3 mg/dL (≧26.4 μmol/L) or increase to more than or equal to 150% (1.5-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 6 hours;
    “Stage II”: increase in serum creatinine to more than 200% (>2-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 12 hours;
    “Stage III”: increase in serum creatinine to more than 300% (>3-fold) from baseline OR serum creatinine ≧354 μmol/L accompanied by an acute increase of at least 44 μmol/L OR urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.
  • The CIN Consensus Working Panel (McCollough et al, Rev Cardiovasc Med. 2006; 7(4):177-197, hereby incorporated by reference in its entirety) uses a serum creatinine rise of 25% to define Contrast induced nephropathy (which is a type of AKI). Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL or 25%, are sufficient to detect AKI (worsening renal function) and that the magnitude of the serum creatinine change is an indicator of the severity of the AKI and mortality risk.
  • Although serial measurement of serum creatinine over a period of days is an accepted method of detecting and diagnosing AKI and is considered one of the most important tools to evaluate AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to values (e.g., a 0.3 mg/dL or 25% rise) considered diagnostic for AKI can be 48 hours or longer depending on the definition used. Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Some patients with AKI will recover fully, some will need dialysis (either short term or long term) and some will have other detrimental outcomes including death, major adverse cardiac events and chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited, Knowing these things can be of vital importance in managing and treating patients with AKI.
  • These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.
    • BRIEF SUMMARY OF THE INVENTION
  • It is an object of the invention to provide methods and compositions for evaluating renal function in a subject. As described herein, measurement of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 (each referred to herein as a “kidney injury marker”) can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).
  • The kidney injury markers of the present invention may be used, individually or in panels comprising a plurality of kidney injury markers, for risk stratification (that is, to identify subjects at risk for a future injury to renal function, for future progression to reduced renal function, for future progression to ARF, for future improvement in renal function, etc.); for diagnosis of existing disease (that is, to identify subjects who have suffered an injury to renal function, who have progressed to reduced renal function, who have progressed to ARF, etc.); for monitoring for deterioration or improvement of renal function; and for predicting a future medical outcome, such as improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc.
  • In a first aspect, the present invention relates to methods for evaluating renal status in a subject. These methods comprise performing an assay method that is configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 complex is/are then correlated to the renal status of the subject. This correlation to renal status may include correlating the assay result(s) to one or more of risk stratification, diagnosis, prognosis, staging, classifying and monitoring of the subject as described herein. Thus, the present invention utilizes one or more kidney injury markers of the present invention for the evaluation of renal injury.
  • In certain embodiments, the methods for evaluating renal status described herein are methods for risk stratification of the subject; that is, assigning a likelihood of one or more future changes in renal status to the subject. In these embodiments, the assay result(s) is/are correlated to one or more such future changes. The following are preferred risk stratification embodiments.
  • In preferred risk stratification embodiments, these methods comprise determining a subject's risk for a future injury to renal function, and the assay result(s) is/are correlated to a likelihood of such a future injury to renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a “positive going” kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a “negative going” kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • In other preferred risk stratification embodiments, these methods comprise determining a subject's risk for future reduced renal function, and the assay result(s) is/are correlated to a likelihood of such reduced renal function. For example, the measured concentrations may each be compared to a threshold value. For a “positive going” kidney injury marker, an increased likelihood of suffering a future reduced renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a “negative going” kidney injury marker, an increased likelihood of future reduced renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • In still other preferred risk stratification embodiments, these methods comprise determining a subject's likelihood for a future improvement in renal function, and the assay result(s) is/are correlated to a likelihood of such a future improvement in renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a “positive going” kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. For a “negative going” kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold.
  • In yet other preferred risk stratification embodiments, these methods comprise determining a subject's risk for progression to ARF, and the result(s) is/are correlated to a likelihood of such progression to ARF. For example, the measured concentration(s) may each be compared to a threshold value. For a “positive going” kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a “negative going” kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • And in other preferred risk stratification embodiments, these methods comprise determining a subject's outcome risk, and the assay result(s) is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject. For example, the measured concentration(s) may each be compared to a threshold value. For a “positive going” kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a “negative going” kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold.
  • In such risk stratification embodiments, preferably the likelihood or risk assigned is that an event of interest is more or less likely to occur within 180 days of the time at which the body fluid sample is obtained from the subject. In particularly preferred embodiments, the likelihood or risk assigned relates to an event of interest occurring within a shorter time period such as 18 months, 120 days, 90 days, 60 days, 45 days, 30 days, 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. A risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.
  • In preferred risk stratification embodiments, the subject is selected for risk stratification based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF. For example, a subject undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery; a subject having pre-existing congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, or sepsis; or a subject exposed to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin are all preferred subjects for monitoring risks according to the methods described herein. This list is not meant to be limiting. By “pre-existence” in this context is meant that the risk factor exists at the time the body fluid sample is obtained from the subject. In particularly preferred embodiments, a subject is chosen for risk stratification based on an existing diagnosis of injury to renal function, reduced renal function, or ARF.
  • In other embodiments, the methods for evaluating renal status described herein are methods for diagnosing a renal injury in the subject; that is, assessing whether or not a subject has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred diagnostic embodiments.
  • In preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of such an injury. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • In other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing reduced renal function. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • In yet other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing ARF. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal replacement therapy, and the assay result(s) is/are correlated to a need for renal replacement therapy. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal transplantation, and the assay result(s0 is/are correlated'to a need for renal transplantation. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold).
  • In still other embodiments, the methods for evaluating renal status described herein are methods for monitoring a renal injury in the subject; that is, assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred monitoring embodiments.
  • In preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • In other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • In yet other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from acute renal failure, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • In other additional preferred monitoring embodiments, these methods comprise monitoring renal status in a subject at risk of an injury to renal function due to the pre-existence of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject.
  • In still other embodiments, the methods for evaluating renal status described herein are methods for classifying a renal injury in the subject; that is, determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 is/are correlated to a particular class and/or subclass. The following are preferred classification embodiments.
  • In preferred classification embodiments, these methods comprise determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage, and the assay result(s) is/are correlated to the injury classification for the subject. For example, the measured concentration may be compared to a threshold value, and when the measured concentration is above the threshold, a particular classification is assigned; alternatively, when the measured concentration is below the threshold, a different classification may be assigned to the subject.
  • A variety of methods may be used by the skilled artisan to arrive at a desired, threshold value for use in these methods. For example, the threshold value may be determined from a population of normal subjects by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such normal subjects. Alternatively, the threshold value may be determined from a “diseased” population of subjects, e.g., those suffering from an injury or having a predisposition for an injury (e.g., progression to ARF or some other clinical outcome such as death, dialysis, renal transplantation, etc.), by selecting a concentration representing the 75th, 85th, 90th, 95th, or 99th percentile of a kidney injury marker measured in such subjects. In another alternative, the threshold value may be determined from a prior measurement of a kidney injury marker in the same subject; that is, a temporal change in the level of a kidney injury marker in the subject may be used to assign risk to the subject.
  • The foregoing discussion is not meant to imply, however, that the kidney injury markers of the present invention must be compared to corresponding individual thresholds. Methods for combining assay results can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, calculating ratios of markers, etc. This list is not meant to be limiting. In these methods, a composite result which is determined by combining individual markers may be treated as if it is itself a marker; that is, a threshold may be determined for the composite result as described herein for individual markers, and the composite result for an individual patient compared to this threshold.
  • The ability of a particular test to distinguish two populations can be established using ROC analysis. For example, ROC curves established from a “first” subpopulation which is predisposed to one or more future changes in renal status, and a “second” subpopulation which is not so predisposed can be used to calculate a ROC curve, and the area under the curve provides a measure of the quality of the test. Preferably, the tests described herein provide a ROC curve area greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.
  • In certain aspects, the measured concentration of one or more kidney injury markers, or a composite of such markers, may be treated as continuous variables. For example, any particular concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. In yet another alternative, a threshold that can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed. A threshold value is selected to separate this first and second population by one or more of the following measures of test accuracy:
  • an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less;
    a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;
    a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;
    at least about 75% sensitivity, combined with at least about 75% specificity;
    a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or
    a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1.
    The term “about” in the context of any of the above measurements refers to +/−5% of a given measurement.
  • Multiple thresholds may also be used to assess renal status in a subject. For example, a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., and a “second” subpopulation which is not so predisposed can be combined into a single group. This group is then subdivided into three or more equal parts (known as tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.
  • In certain embodiments, the assay method is an immunoassay. Antibodies for use in such assays will specifically bind a full length kidney injury marker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. Numerous immunoassay formats are known to those of skill in the art. Preferred body fluid samples are selected from the group consisting of urine, blood, serum, saliva, tears, and plasma.
  • The foregoing method steps should not be interpreted to mean that the kidney injury marker assay result(s) is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, a risk stratification, diagnostic, classification, monitoring, etc. method may combine the assay result(s) with one or more variables measured for the subject selected from the group consisting of demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score, risk scores of Thakar et al. (J. Am. Soc. Nephrol. 16: 162-68, 2005), Mehran et al. (J. Am. Coll. Cardiol. 44: 1393-99, 2004), Wijeysundera et al. (JAMA 297: 1801-9, 2007), Goldstein and Chawla (Clin. J. Am. Soc. Nephrol. 5: 943-49, 2010), or Chawla et al. (Kidney Intl. 68: 2274-80, 2005)), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.
  • When more than one marker is measured, the individual markers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual markers may also be measured on the same or different body fluid samples. For example, one kidney injury marker may be measured in a serum or plasma sample and another kidney injury marker may be measured in a urine sample. In addition, assignment of a likelihood may combine an individual kidney injury marker assay result with temporal changes in one or more additional variables.
  • In various related aspects, the present invention also relates to devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.
  • In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.
  • Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).
  • Generation of a signal from the signal development element can be performed using various optical, acoustical, and electrochemical methods well known in the art. Examples of detection modes include fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody is coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to methods and compositions for diagnosis, differential diagnosis, risk stratification, monitoring, classifying and determination of treatment regimens in subjects suffering or at risk of suffering from injury to renal function, reduced renal function and/or acute renal failure through measurement of one or more kidney injury markers. In various embodiments, a measured concentration of one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor BB dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 or one or more markers related thereto, are correlated to the renal status of the subject.
  • For purposes of this document, the following definitions apply:
  • As used herein, an “injury to renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury may be identified, for example, by a decrease in glomerular filtration rate or estimated GFR, a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy, etc. “Improvement in Renal Function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.
  • As used herein, “reduced renal function” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL (≧8.8 μmol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).
  • As used herein, “acute renal failure” or “ARF” is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl (≧26.4 μmol/l), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”
  • As used herein, the term “C-C motif chemokine 7” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 7 precursor (Swiss-Prot P80098 (SEQ ID NO: 1)).
  •         10         20         30         40         50         60
    MKASAALLCL LLTAAAFSPQ GLAQPVGINT STTCCYRFIN KKIPKQRLES YRRTTSSHCP
            70         80         90
    REAVIFKTKL DKEICADPTQ KWVQDFMKHL DKKTQTPKL
  • The following domains have been identified in C-C motif chemokine 7:
  • Residues Length Domain ID
     1-23 23 Signal peptide
    24-99 76 C-C motif chemokine 7
  • As used herein, the term “C-C motif chemokine 26” refers to one or more polypeptides present in a biological sample that are derived from the C-C motif chemokine 26 precursor (Swiss-Prot Q9Y258 (SEQ ID NO: 2)).
  •         10         20         30         40         50         60
    MMGLSLASAV LLASLLSLHL GTATRGSDIS KTCCFQYSHK PLPWTWVRSY EFTSNSCSQR
            70         80         90
    AVIFTTKRGK KVCTHPRKKW VQKYISLLKT PKQL
  • The following domains have been identified in C-C motif chemokine 26:
  • Residues Length Domain ID
     1-23 23 Signal peptide
    24-94 71 C-C motif chemokine 26
  • As used herein, the term “Complement C4-B” refers to one or more polypeptides present in a biological sample that are derived from Complement C4-B precursor (Swiss-Prot P0C0L5 (SEQ ID NO: 3)).
  •         10         20         30         40         50         60
    MRLLWGLIWA SSFFTLSLQK PRLLLFSPSV VHLGVPLSVG VQLQDVPRGQ VVKGSVFLRN
            70         80         90        100        110        120
    PSRNNVPCSP KVDFTLSSER DFALLSLQVP LKDAKSCGLH QLLRGPEVQL VAHSPWLKDS
           130        140        150        160        170        180
    LSRTTNIQGI NLLFSSRRGH LFLQTDQPIY NPGQRVRYRV FALDQKMRPS TDTITVMVEN
           190        200        210        220        230        240
    SHGLRVRKKE VYMPSSIFQD DFVIPDISEP GTWKISARFS DGLESNSSTQ FEVKKYVLPN
           250        260        270        280        290        300
    FEVKITPGKP YILTVPGHLD EMQLDIQARY IYGKPVQGVA YVRFGLLDED GKKTFFRGLE
           310        320        330        340        350        360
    SQTKLVNGQS HISLSKAEFQ DALEKLNMGI TDLQGLRLYV AAAIIESPGG EMEEAELTSW
           370        380        390        400        410        420
    YFVSSPFSLD LSKTKRHLVP GAPFLLQALV REMSGSPASG IPVKVSATVS SPGSVPEVQD
           430        440        450        460        470        480
    IQQNTDGSGQ VSIPIIIPQT ISELQLSVSA GSPHPAIARL TVAAPPSGGP GFLSIERPDS
           490        500        510        520        530        540
    RPPRVGDTLN LNLRAVGSGA TFSHYYYMIL SRGQIVFMNR EPKRTLTSVS VFVDHHLAPS
           550        560        570        580        590        600
    FYFVAFYYHG DHPVANSLRV DVQAGACEGK LELSVDGAKQ YRNGESVKLH LETDSLALVA
           610        620        630        640        650        660
    LGALDTALYA AGSKSHKPLN MGKVFEAMNS YDLGCGPGGG DSALQVFQAA GLAFSDGDQW
           670        680        690        700        710        720
    TLSRKRLSCP KEKTTRKKRN VNFQKAINEK LGQYASPTAK RCCQDGVTRL PMMRSCEQRA
           730        740        750        760        770        780
    ARVQQPDCRE PFLSCCQFAE SLRKKSRDKG QAGLQRALEI LQEEDLIDED DIPVRSFFPE
           790        800        810        820        830        840
    NWLWRVETVD RFQILTLWLP DSLTTWEIHG LSLSKTKGLC VATPVQLRVF REFHLHLRLP
           850        860        870        880        890        900
    MSVRRFEQLE LRPVLYNYLD KNLTVSVHVS PVEGLCLAGG GGLAQQVLVP AGSARPVAFS
           910        920        930        940        950        960
    VVPTAAAAVS LKVVARGSFE FPVGDAVSKV LQIEKEGAIH REELVYELNP LDHRGRTLEI
           970        980        990       1000       1010       1020
    PGNSDPNMIP DGDFNSYVRV TASDPLDTLG SEGALSPGGV ASLLRLPRGC GEQTMIYLAP
          1030       1040       1050       1060       1070       1080
    TLAASRYLDK TEQWSTLPPE TKDHAVDLIQ KGYMRIQQFR KADGSYAAWL SRDSSTWLTA
          1090       1100       1110       1120       1130       1140
    FVLKVLSLAQ EQVGGSPEKL QETSNWLLSQ QQADGSFQDL SPVIHRSMQG GLVGNDETVA
          1150       1160       1170       1180       1190       1200
    LTAFVTIALH HGLAVFQDEG AEPLKQRVEA SISKANSFLG EKASAGLLGA HAAAITAYAL
          1210       1220       1230       1240       1250       1260
    SLTKAPVDLL GVAHNNLMAM AQETGDNLYW GSVTGSQSNA VSPTPAPRNP SDPMPQAPAL
          1270       1280       1290       1300       1310       1320
    WIETTAYALL HLLLHEGKAE MADQASAWLT RQGSFQGGFR STQDTVIALD ALSAYWIASH
          1330       1340       1350       1360       1370       1380
    TTEERGLNVT LSSTGRNGFK SHALQLNNRQ IRGLEEELQF SLGSKINVKV GGNSKGTLKV
          1390       1400       1410       1420       1430       1440
    LRTYNVLDMK NTTCQDLQIE VTVKGHVEYT MEANEDYEDY EYDELPAKDD PDAPLQPVTP
          1450       1460       1470       1480       1490       1500
    LQLFEGRRNR RRREAPKVVE EQESRVHYTV CIWRNGKVGL SGMAIADVTL LSGFHALRAD
          1510       1520       1530       1540       1550       1560
    LEKLTSLSDR YVSHFETEGP HVLLYFDSVP TSRECVGFEA VQEVPVGLVQ PASATLYDYY
          1570       1580       1590       1600       1610       1620
    NPERRCSVFY GAPSKSRLLA TLCSAEVCQC AEGKCPRQRR ALERGLQDED GYRMKFACYY
          1630       1640       1650       1660       1670       1680
    PRVEYGFQVK VLREDSRAAF RLFETKITQV LHFTKDVKAA ANQMRNFLVR ASCRLRLEPG
          1690       1700       1710       1720       1730       1740
    KEYLIMGLDG ATYDLEGHPQ YLLDSNSWIE EMPSERLCRS TRQRAACAQL NDFLQEYGTQ
    GCQV
  • The following domains have been identified in Complement C4-B:
  • Residues Length Domain ID
       1-19 19 Signal peptide
      20-675 656 Complement C4-B beta chain
     676-679 4 Propeptide
     680-1446 767 Complement C4-B alpha chain
     680-756 77 Complement C4-a anaphylatoxin
     757-1446 690 Complement C4b-B
     957-1336 380 Complement C4d-B
    1447-1453 7 propeptide
    1454-1744 291 Complement C4-B gamma chain
  • As used herein, the term “Corticotropin” refers to one or more polypeptides present in a biological sample that are derived from pro-opiomelanocortin precursor (Swiss-Prot P01189 (SEQ ID NO: 4)) containing one or more epitopes of corticotropin.
  •         10         20         30         40         50         60
    MPRSCCSRSG ALLLALLLQA SMEVRGWCLE SSQCQDLTTE SNLLECIRAC KPDLSAETPM
            70         80         90        100        110        120
    FPGNGDEQPL TENPRKYVMG HFRWDRFGRR NSSSSGSSGA GQKREDVSAG EDCGPLPEGG
           130        140        150        160        170        180
    PEPRSDGAKP GPREGKRSYS MEHFRWGKPV GKKRRPVKVY PNGAEDESAE AFPLEFKREL
           190        200        210        220        230        240
    TGQRLREGDG PDGPADDGAG AQADLEHSLL VAAEKKDEGP YRMEHFRWGS PPKDKRYGGF
           250        260
    MTSEKSQTPL VTLFKNAIIK NAYKKGE
  • The following domains have been identified in pro-opiomelanocortin:
  • Residues Length Domain ID
      1-26 26 Signal peptide
     27-102 76 NPP
     77-87 11 Melanotropin gamma
    105-134 30 peptide
    138-176 39 Corticotropin
    138-150 13 Melanotropin alpha
    156-176 21 Corticotropin-like intermediary peptide
    179-267 89 Lipotropin beta
    179-234 56 Lipotropin gamma
    217-234 18 Melanotropin beta
    237-267 31 beta endorphin
    237-241 5 met enkephalin
  • As used herein, the term “Interferon alpha-2” refers to one or more polypeptides present in a biological sample that are derived from the Interferon alpha-2 precursor (Swiss-Prot P01563 (SEQ ID NO: 5)).
  •         10         20         30         40         50         60
    MALTFALLVA LLVLSCKSSC SVGCDLPQTH SLGSRRTLML LAQMRKISLF SCLKDRHDFG
            70         80         90        100        110        120
    FPQEEFGNQF QKAETIPVLH EMIQQIFNLF STKDSSAAWD ETLLDKFYTE LYQQLNDLEA
           130        140        150        160        170        180
    CVIQGVGVTE TPLMKEDSIL AVRKYFQRIT LYLKEKKYSP CAWEVVRAEI MRSFSLSTNL
    QESLRSKE
  • The following domains have been identified in Interferon alpha-2:
  • Residues Length Domain ID
     1-23 23 Signal peptide
    24-188 209 Interferon alpha-2
  • As used herein, the term “Interleukin-4 receptor subunit alpha” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-4 receptor subunit alpha precursor (Swiss-Prot P24394 (SEQ ID NO: 6):
  •         10         20         30         40         50         60
    MGWLCSGLLF PVSCLVLLQV ASSGNMKVLQ EPTCVSDYMS ISTCEWKMNG PTNCSTELRL
            70         80         90        100        110        120
    LYQLVFLLSE AHTCIPENNG GAGCVCHLLM DDVVSADNYT LDLWAGQQLL WKGSFKPSEH
           130        140        150        160        170        180
    VKPRAPGNLT VHTNVSDTLL LTWSNPYPPD NYLYNHLTYA VNIWSENDPA DFRIYNVTYL
           190        200        210        220        230        240
    EPSLRIAAST LKSGISYRAR VRAWAQCYNT TWSEWSPSTK WHNSYREPFE QHLLLGVSVS
           250        260        270        280        290        300
    CIVILAVCLL CYVSITKIKK EWWDQIPNPA RSRLVAIIIQ DAQGSQWEKR SRGQEPAKCP
           310        320        330        340        350        360
    HWKNCLTKLL PCFLEHNMKR DEDPHKAAKE MPFQGSGKSA WCPVEISKTV LWPESISVVR
           370        380        390        400        410        420
    CVELFEAPVE CEEEEEVEEE KGSFCASPES SRDDFQEGRE GIVARLTESL FLDLLGEENG
           430        440        450        460        470        480
    GFCQQDMGES CLLPPSGSTS AHMPWDEFPS AGPKEAPPWG KEQPLHLEPS PPASPTQSPD
           490        500        510        520        530        540
    NLTCTETPLV IAGNPAYRSF SNSLSQSPCP RELGPDPLLA RHLEEVEPEM PCVPQLSEPT
           550        560        570        580        590        600
    TVPQPEPETW EQILRRNVLQ HGAAAAPVSA PTSGYQEFVH AVEQGGTQAS AVVGLGPPGE
           610        620        630        640        650        660
    AGYKAFSSLL ASSAVSPEKC GFGASSGEEG YKPFQDLIPG CPGDPAPVPV PLFTFGLDRE
           670        680        690        700        710        720
    PPRSPQSSHL PSSSPEHLGL EPGEKVEDMP KPPLPQEQAT DPLVDSLGSG IVYSALTCHL
           730        740        750        760        770        780
    CGHLKQCHGQ EDGGQTPVMA SPCCGCCCGD RSSPPTTPLR APDPSPGGVP LEASLCPASL
           790        800        810        820
    APSGISEKSK SSSSFHPAPG NAQSSSQTPK IVNFVSVGPT YMRVS
  • Interleukin-4 receptor subunit alpha is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Interleukin-4 receptor subunit alpha generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Interleukin-4 receptor subunit alpha:
  • Residues Length Domain ID
      1-25 25 Signal peptide
     26-825 800 Interleukin-4 receptor subunit alpha
     26-232 319 Extracellular domain
    233-256 20 Transmembrane domain
    257-825 213 Cytoplasmic domain
    228-825 Missing in soluble isoform 2
    225-227 YRE → NIC in soluble isoform 2
  • As used herein, the term “Insulin-like growth factor-binding protein 4” refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 4 precursor (Swiss-Prot P22692 (SEQ ID NO: 7)).
  •         10         20         30         40         50         60
    MLPLCLVAAL LLAAGPGPSL GDEAIHCPPC SEEKLARCRP PVGCEELVRE PGCGCCATCA
            70         80         90        100        110        120
    LGLGMPCGVY TPRCGSGLRC YPPRGVEKPL HTLMHGQGVC MELAEIEAIQ ESLQPSDKDE
           130        140        150        160        170        180
    GDHPNNSFSP CSAHDRRCLQ KHFAKIRDRS TSGGKMKVNG APREDARPVP QGSCQSELHR
           190        200        210        220        230        240
    ALERLAASQS RTHEDLYIIP IPNCDRNGNF HPKQCHPALD GQRGKCWCVD RKTGVKLPGG
           250
    LEPKGELDCH QLADSFRE
  • The following domains have been identified in Insulin-like growth factor-binding protein 4:
  • Residues Length Domain ID
     1-21 21 Signal peptide
    22-258 237 Insulin-like growth factor-binding protein 4
  • As used herein, the term “Insulin-like growth factor-binding protein 5” refers to one or more polypeptides present in a biological sample that are derived from the Insulin-like growth factor-binding protein 5 precursor (Swiss-Prot P24593 (SEQ ID NO: 8)).
  •         10         20         30         40         50         60
    MVLLTAVLLL LAAYAGPAQS LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA
            70         80         90        100        110        120
    LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE
           130        140        150        160        170        180
    EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA
           190        200        210        220        230        240
    PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGFYKRKQC KPSRGRKRGI
           250        260        270
    CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE
  • The following domains have been identified in Insulin-like growth factor-binding protein 5:
  • Residues Length Domain ID
     1-20 20 Signal peptide
    21-272 252 Insulin-like growth factor-binding protein 5
  • As used herein, the term “Interleukin-21” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-21 precursor (Swiss-Prot Q9HBE4 (SEQ ID NO: 8)).
  •         10         20         30         40         50         60
    MERIVICLMV IFLGTLVHKS SSQGQDRHMI RMRQLIDIVD QLKNYVNDLV PEFLPAPEDV
            70         80         90        100        110        120
    ETNCEWSAFS CFQKAQLKSA NTGNNERIIN VSIKKLKRKP PSTNAGRRQK HRLTCPSCDS
           130        140        150
    YEKKPPKEFL ERFKSLLQKM IHQHLSSRTH GSEDS
  • The following domains have been identified in Interleukin-21:
  • Residues Length Domain ID
     1-22 22 Signal peptide
    23-155 133 Interleukin-21
  • As used herein, the term “Interleukin-23 subunit alpha” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-23 subunit alpha precursor (Swiss-Prot Q9NPF7 (SEQ ID NO: 9)).
  •         10         20         30         40         50         60
    MLGSRAVMLL LLLPWTAQGR AVPGGSSPAW TQCQQLSQKL CTLAWSAHPL VGHMDLREEG
            70         80         90        100        110        120
    DEETTNDVPH IQCGDGCDPQ GLRDNSQFCL QRIHQGLIFY EKLLGSDIFT GEPSLLPDSP
           130        140        150        160        170        180
    VGQLHASLLG LSQLLQPEGH HWETQQIPSL SPSQPWQRLL LRFKILRSLQ AFVAVAARVF
    AHGAATLSP
  • The following domains have been identified in Interleukin-23 subunit alpha:
  • Residues Length Domain ID
     1-19 19 Signal peptide
    20-189 170 Interleukin-23 subunit alpha
  • As used herein, the term “Interleukin-28A” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-28A precursor (Swiss-Prot Q81ZJ0 (SEQ ID NO: 10)).
  •         10         20         30         40         50         60
    MKLDMTGDCT PVLVLMAAVL TVTGAVPVAR LHGALPDARG CHIAQFKSLS PQELQAFKRA
            70         80         90        100        110        120
    KDALEESLLL KDCRCHSRLF PRTWDLRQLQ VRERPMALEA ELALTLKVLE ATADTDPALV
           130        140        150        160        170        180
    DVLDQPLHTL HHILSQFRAC IQPQPTAGPR TRGRLHHWLY RLQEAPKKES PGCLEASVTF
           190        200
    NLFRLLTRDL NCVASGDLCV
  • The following domains have been identified in Interleukin-28A:
  • Residues Length Domain ID
     1-25 25 Signal peptide
    26-200 175 Interleukin-28A
  • As used herein, the term “Interleukin-33” refers to one or more polypeptides present in a biological sample that are derived from the Interleukin-33 precursor (Swiss-Prot O95760 (SEQ ID NO: 11)).
  •         10         20         30         40         50         60
    MKPKMKYSTN KISTAKWKNT ASKALCFKLG KSQQKAKEVC PMYFMKLRSG LMIKKEACYF
            70         80         90        100        110        120
    RRETTKRPSL KTGRKHKRHL VLAACQQQST VECFAFGISG VQKYTRALHD SSITGISPIT
           130        140        150        160        170        180
    EYLASLSTYN DQSITFALED ESYEIYVEDL KKDEKKDKVL LSYYESQHPS NESGDGVDGK
           190        200        210        220        230        240
    MLMVTLSPTK DFWLHANNKE HSVELHKCEK PLPDQAFFVL HNMHSNCVSF ECKTDPGVFI
           250        260        270
    GVKDNHLALI KVDSSENLCT ENILFKLSET
  • The following domains have been identified in Interleukin-33:
  • Residues Length Domain ID
    1-270 270 Interleukin-33
  • As used herein, the term “Lutropin subunit beta” refers to one or more polypeptides present in a biological sample that are derived from the Lutropin subunit beta precursor (Swiss-Prot P01229 (SEQ ID NO: 12)).
  •         10         20         30         40         50         60
    MEMLQGLLLL LLLSMGGAWA SREPLRPWCH PINAILAVEK EGCPVCITVN TTICAGYCPT
            70         80         90        100        110        120
    MMRVLQAVLP PLPQVVCTYR DVRFESIRLP GCPRGVDPVV SFPVALSCRC GPCRRSTSDC
           130        140
    GGPKDHPLTC DHPQLSGLLF L
  • The following domains have been identified in Lutropin subunit beta:
  • Residues Length Domain ID
     1-20 20 Signal peptide
    21-141 121 Lutropin subunit beta
  • As used herein, the term “Interstitial collagenase” (also known as MMP-1 and matrix metalloproteinase 1) refers to one or more polypeptides present in a biological sample that are derived from the Interstitial collagenase precursor (Swiss-Prot P03956 (SEQ ID NO: 13)).
  •         10         20         30         40         50         60
    MHSFPPLLLL LFWGVVSHSF PATLETQEQD VDLVQKYLEK YYNLKNDGRQ VEKRRNSGPV
            70         80         90        100        110        120
    VEKLKQMQEF FGLKVTGKPD AETLKVMKQP RCGVPDVAQF VLTEGNPRWE QTHLTYRIEN
           130        140        150        160        170        180
    YTPDLPRADV DHAIEKAFQL WSNVTPLTFT KVSEGQADIM ISFVRGDHRD NSPFDGPGGN
           190        200        210        220        230        240
    LAHAFQPGPG IGGDAHFDED ERWTNNFREY NLHRVAAHEL GHSLGLSHST DIGALMYPSY
           250        260        270        280        290        300
    TFSGDVQLAQ DDIDGIQAIY GRSQNPVQPI GPQTPKACDS KLTFDAITTI RGEVMFFKDR
           310        320        330        340        350        360
    FYMRTNPFYP EVELNFISVF WPQLPNGLEA AYEFADRDEV RFFKGNKYWA VQGQNVLHGY
           370        380        390        400        410        420
    PKDIYSSFGF PRTVKHIDAA LSEENTGKTY FFVANKYWRY DEYKRSMDPG YPKMIAHDFP
           430        440        450        460
    GIGHKVDAVF MKDGFFYFFH GTRQYKFDPK TKRILTLQKA NSWFNCRKN
  • The following domains have been identified in Interstitial collagenase:
  • Residues Length Domain ID
     1-19 19 Signal peptide
     20-99 80 Activation peptide
    100-469 370 Interstitial collagenase
    100-269 170 22 kDa Interstitial collagenase
    270-469 200 27 kDa Interstitial collagenase
  • As used herein, the term “Neural cell adhesion molecule 1” refers to one or more polypeptides present in a biological sample that are derived from the Neural cell adhesion molecule 1 precursor (Swiss-Prot P13591 (SEQ ID NO: 14):
  •         10         20         30         40         50         60
    MLQTKDLIWT LFFLGTAVSL QVDIVPSQGE ISVGESKFFL CQVAGDAKDK DISWFSPNGE
            70         80         90        100        110        120
    KLTPNQQRIS VVWNDDSSST LTIYNANIDD AGIYKCVVTG EDGSESEATV NVKIFQKLMF
           130        140        150        160        170        180
    KNAPTPQEFR EGEDAVIVCD VVSSLPPTII WKHKGRDVIL KKDVRFIVLS NNYLQIRGIK
           190        200        210        220        230        240
    KTDEGTYRCE GRILARGEIN FKDIQVIVNV PPTIQARQNI VNATANLGQS VTLVCDAEGF
           250        260        270        280        290        300
    PEPTMSWTKD GEQIEQEEDD EKYIFSDDSS QLTIKKVDKN DEAEYICIAE NKAGEQDATI
           310        320        330        340        350        360
    HLKVFAKPKI TYVENQTAME LEEQVTLTCE ASGDPIPSIT WRTSTRNISS EEKASWTRPE
           370        380        390        400        410        420
    KQETLDGHMV VRSHARVSSL TLKSIQYTDA GEYICTASNT IGQDSQSMYL EVQYAPKLQG
           430        440        450        460        470        480
    PVAVYTWEGN QVNITCEVFA YPSATISWFR DGQLLPSSNY SNIKIYNTPS ASYLEVTPDS
           490        500        510        520        530        540
    ENDFGNYNCT AVNRIGQESL EFILVQADTP SSPSIDQVEP YSSTAQVQFD EPEATGGVPI
           550        560        570        580        590        600
    LKYKAEWRAV GEEVWHSKWY DAKEASMEGI VTIVGLKPET TYAVRLAALN GKGLGEISAA
           610        620        630        640        650        660
    SEFKTQPVQG EPSAPKLEGQ MGEDGNSIKV NLIKQDDGGS PIRHYLVRYR ALSSEWKPEI
           670        680        690        700        710        720
    RLPSGSDHVM LKSLDWNAEY EVYVVAENQQ GKSKAAHFVF RTSAQPTAIP ANGSPTSGLS
           730        740        750        760        770        780
    TGAIVGILIV IFVLLLVVVD ITCYFLNKCG LFMCIAVNLC GKAGPGAKGK DMEEGKAAFS
           790        800        810        820        830        840
    KDESKEPIVE VRTEEERTPN HDGGKHTEPN ETTPLTEPEK GPVEAKPECQ ETETKPAPAE
           850
    VKTVPNDATQ TKENESKA
  • Neural cell adhesion molecule 1 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Neural cell adhesion molecule 1 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Neural cell adhesion molecule 1:
  • Residues Length Domain ID
     1-19 19 Signal peptide
     20-858 839 Neural cell adhesion molecule 1
     20-718 699 Extracellular domain
    719-739 21 Transmembrane domain
    740-858 119 Cytoplasmic domain
    354-363 Missing in isoform 2
    354-363 Missing in isoform 3
    609 Q → HSPPPPASASSSTPVPLSPPD TTWPLP
    ALATTEPAK (SEQ ID NO: 15) in
    isoform 3
    712-736 NGSPTSGLSTGAIVGILIVIFVLLL
    (SEQ ID NO: 16) →
    TLGGNSASYTFVSLLFSAVTLLLLC
    (SEQ ID NO: 17) in isoform 3
    737-858 Missing in isoform 3
    354-363 Missing in isoform 4
    712-736 NGSPTSGLSTGAIVGILIVIFVLLL
    (SEQ ID NO: 18) →
    TLGGNSASYTFVSLLFSAVTLLLLC
    ((SEQ ID NO: 19) in isoform 4
    737-858 Missing in isoform 4
    609-665 QGEPSAPKLE . . . WKPEIRLPSG
    (SEQ ID NO: 20)→
    HSPPPPASASSSTPVPLSPPDTTWPLPALATTEPA
    KNIAQ NHCCNMFQAGLHNALMK
    (SEQ ID NO: 21) in isoform 5
    364 T → V in isoform 6
    365-858 Missing in isoform 6
  • As used herein, the term “Pigment epithelium-derived factor” refers to one or more polypeptides present in a biological sample that are derived from the Pigment epithelium-derived factor precursor (Swiss-Prot P36955 (SEQ ID NO: 22)).
  •         10         20         30         40         50         60
    MQALVLLLCI GALLGHSSCQ NPASPPEEGS PDPDSTGALV EEEDPFFKVP VNKLAAAVSN
            70         80         90        100        110        120
    FGYDLYRVRS SMSPTTNVLL SPLSVATALS ALSLGAEQRT ESIIHRALYY DLISSPDIHG
           130        140        150        160        170        180
    TYKELLDTVT APQKNLKSAS RIVFEKKLRI KSSFVAPLEK SYGTRPRVLT GNPRLDLQEI
           190        200        210        220        230        240
    NNWVQAQMKG KLARSTKEIP DEISILLLGV AHFKGQWVTK FDSRKTSLED FYLDEERTVR
           250        260        270        280        290        300
    VPMMSDPKAV LRYGLDSDLS CKIAQLPLTG SMSIIFFLPL KVTQNLTLIE ESLTSEFIHD
           310        320        330        340        350        360
    IDRELKTVQA VLTVPKLKLS YEGEVTKSLQ EMKLQSLFDS PDFSKITGKP IKLTQVEHRA
           370        380        390        400        410
    GFEWNEDGAG TTPSPGLQPA HLTFPLDYHL NQPFIFVLRD TDTGALLFIG KILDPRGP
  • The following domains have been identified in Pigment epithelium-derived factor:
  • Residues Length Domain ID
     1-19 19 Signal peptide
    20-418 399 Pigment epithelium-derived factor
  • As used herein, the term “Platelet-derived growth factor subunit A” refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived growth factor subunit A precursor (Swiss-Prot P04085 (SEQ ID NO: 23)).
  •         10         20         30         40         50         60
    MRTLACLLLL GCGYLAHVLA EEAEIPREVI ERLARSQIHS IRDLQRLLEI DSVGSEDSLD
            70         80         90        100        110        120
    TSLRAHGVHA TKHVPEKRPL PIRRKRSIEE AVPAVCKTRT VIYEIPRSQV DPTSANFLIW
           130        140        150        160        170        180
    PPCVEVKRCT GCCNTSSVKC QPSRVHHRSV KVAKVEYVRK KPKLKEVQVR LEEHLECACA
           190        200        210
    TTSLNPDYRE EDTGRPRESG KKRKRKRLKP T
  • The following domains have been identified in Platelet-derived growth factor subunit A:
  • Residues Length Domain ID
     1-20 20 Signal peptide
    21-86 66 Propeptide
    87-211 125 Platelet-derived growth factor subunit A
  • As used herein, the term “Vascular endothelial growth factor receptor 2” refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 2 precursor (Swiss-Prot P35968 (SEQ ID NO: 24):
  •         10         20         30         40         50         60
    MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD
            70         80         90        100        110        120
    WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
           130        140        150        160        170        180
    YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
           190        200        210        220        230        240
    SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
           250        260        270        280        290        300
    KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
           310        320        330        340        350        360
    DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP
           370        380        390        400        410        420
    EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP
           430        440        450        460        470        480
    PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
           490        500        510        520        530        540
    PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
           550        560        570        580        590        600
    RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT
           610        620        630        640        650        660
    PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT
           670        680        690        700        710        720
    VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR
           730        740        750        760        770        780
    NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
           790        800        810        820        830        840
    LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL
           850        860        870        880        890        900
    GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
           910        920        930        940        950        960
    LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK
           970        980        990       1000       1010       1020
    RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
          1030       1040       1050       1060       1070       1080
    SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR
          1090       1100       1110       1120       1130       1140 
    VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
          1150       1160       1170       1180       1190       1200
    DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
          1210       1220       1230       1240       1250       1260
    CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS
          1270       1280       1290       1300       1310       1320
    GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS
          1330       1340       1350
    SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV
  • Vascular endothelial growth factor receptor 2 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 2 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 2:
  • Residues Length Domain ID
      1-19 19 Signal peptide
     20-1356 1337 Vascular endothelial growth factor receptor 2
     20-764 745 Extracellular domain
    765-789 25 Transmembrane domain
    790-1356 567 Cytoplasmic domain
  • As used herein, the term “Vascular endothelial growth factor receptor 3” refers to one or more polypeptides present in a biological sample that are derived from the Vascular endothelial growth factor receptor 3 precursor (Swiss-Prot P35916 (SEQ ID NO: 25):
  •         10         20         30         40         50         60
    MQRGAALCLR LWLCLGLLDG LVSGYSMTPP TLNITEESHV IDTGDSLSIS CRGQHPLEWA
            70         80         90        100        110        120
    WPGAQEAPAT GDKDSEDTGV VRDCEGTDAR PYCKVLLLHE VHANDTGSYV CYYKYIKARI
           130        140        150        160        170        180
    EGTTAASSYV FVRDFEQPFI NKPDTLLVNR KDAMWVPCLV SIPGLNVTLR SQSSVLWPDG
           190        200        210        220        230        240
    QEVVWDDRRG MLVSTPLLHD ALYLQCETTW GDQDFLSNPF LVHITGNELY DIQLLPRKSL
           250        260        270        280        290        300
    ELLVGEKLVL NCTVWAEFNS GVTFDWDYPG KQAERGKWVP ERRSQQTHTE LSSILTIHNV
           310        320        330        340        350        360
    SQHDLGSYVC KANNGIQRFR ESTEVIVHEN PFISVEWLKG PILEATAGDE LVKLPVKLAA
           370        380        390        400        410        420
    YPPPEFQWYK DGKALSGRHS PHALVLKEVT EASTGTYTLA LWNSAAGLRR NISLELVVNV
           430        440        450        460        470        480
    PPQIHEKEAS SPSIYSRHSR QALTCTAYGV PLPLSIQWHW RPWTPCKMFA QRSLRRRQQQ
           490        500        510        520        530        540
    DLMPQCRDWR AVTTQDAVNP IESLDTWTEF VEGKNKTVSK LVIQNANVSA MYKCVVSNKV
           550        560        570        580        590        600
    GQDERLIYFY VTTIPDGFTI ESKPSEELLE GQPVLLSCQA DSYKYEHLRW YRLNLSTLHD
           610        620        630        640        650        660
    AHGNPLLLDC KNVHLFATPL AASLEEVAPG ARHATLSLSI PRVAPEHEGH YVCEVQDRRS
           670        680        690        700        710        720
    HDKHCHKKYL SVQALEAPRL TQNLTDLLVN VSDSLEMQCL VAGAHAPSIV WYKDERLLEE
           730        740        750        760        770        780
    KSGVDLADSN QKLSIQRVRE EDAGRYLCSV CNAKGCVNSS ASVAVEGSED KGSMEIVILV
           790        800        810        820        830        840
    GTGVIAVFFW VLLLLIFCNM RRPAHADIKT GYLSIIMDPG EVPLEEQCEY LSYDASQWEF
           850        860        870        880        890        900
    PRERLHLGRV LGYGAFGKVV EASAFGIHKG SSCDTVAVKM LKEGATASEH RALMSELKIL
           910        920        930        940        950        960
    IHIGNHLNVV NLLGACTKPQ GPLMVIVEFC KYGNLSNFLR AKRDAFSPCA EKSPEQRGRF
           970        980        990       1000       1010       1020
    RAMVELARLD RRRPGSSDRV LFARFSKTEG GARRASPDQE AEDLWLSPLT MEDLVCYSFQ
          1030       1040       1050       1060       1070       1080
    VARGMEFLAS RKCIHRDLAA RNILLSESDV VKICDFGLAR DIYKDPDYVR KGSARLPLKW
          1090       1100       1110       1120       1130       1140
    MAPESIFDKV YTTQSDVWSF GVLLWEIFSL GASPYPGVQI NEEFCQRLRD GTRMRAPELA
          1150       1160       1170       1180       1190       1200
    TPAIRRIMLN CWSGDPKARP AFSELVEILG DLLQGRGLQE EEEVCMAPRS SQSSEEGSFS
          1210       1220       1230       1240       1250       1260
    QVSTMALHIA QADAEDSPPS LQRHSLAARY YNWVSFPGCL ARGAETRGSS RMKTFEEFPM
          1270       1280       1290
    TPTTYKGSVD NQTDSGMVLA SEEFEQIESR HRQESGFR
  • Vascular endothelial growth factor receptor 3 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Vascular endothelial growth factor receptor 3 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Vascular endothelial growth factor receptor 3:
  • Residues Length Domain ID
      1-24 24 Signal peptide
     25-1298 1274 Vascular endothelial growth factor receptor 3
     25-775 751 Extracellular domain
    776-797 25 Transmembrane domain
    798-1298 501 Cytoplasmic domain
  • As used herein, the term “Tumor necrosis factor receptor superfamily member 8” refers to one or more polypeptides present in a biological sample that are derived from the Tumor necrosis factor receptor superfamily member 8 precursor (Swiss-Prot P28908 (SEQ ID NO: 26)):
  •         10         20         30         40         50         60
    MRVLLAALGL LFLGALRAFP QDRPFEDTCH GNPSHYYDKA VRRCCYRCPM GLFPTQQCPQ
            70         80         90        100        110        120
    RPTDCRKQCE PDYYLDEADR CTACVTCSRD DLVEKTPCAW NSSRVCECRP GMFCSTSAVN
           130        140        150        160        170        180
    SCARCFFHSV CPAGMIVKFP GTAQKNTVCE PASPGVSPAC ASPENCKEPS SGTIPQAKPT
           190        200        210        220        230        240
    PVSPATSSAS TMPVRGGTRL AQEAASKLTR APDSPSSVGR PSSDPGLSPT QPCPEGSGDC
           250        260        270        280        290        300
    RKQCEPDYYL DEAGRCTACV SCSRDDLVEK TPCAWNSSRT CECRPGMICA TSATNSCARC
           310        320        330        340        350        360
    VPYPICAAET VTKPQDMAEK DTTFEAPPLG TQPDCNPTPE NGEAPASTSP TQSLLVDSQA
           370        380        390        400        410        420
    SKTLPIPTSA PVALSSTGKP VLDAGPVLFW VILVLVVVVG SSAFLLCHRR ACRKRIRQKL
           430        440        450        460        470        480
    HLCYPVQTSQ PKLELVDSRP RRSSTQLRSG ASVTEPVAEE RGLMSQPLME TCHSVGAAYL
           490        500        510        520        530        540
    ESLPLQDASP AGGPSSPRDL PEPRVSTEHT NNKIEKIYIM KADTVIVGTV KAELPEGRGL
           550        560        570        580        590
    AGPAEPELEE ELEADHTPHY PEQETEPPLG SCSDVMLSVE EEGKEDPLPT AASGK
  • Tumor necrosis factor receptor superfamily member 8 is a single-pass type I membrane protein having a large extracellular domain, some or all of which is present in soluble forms of Tumor necrosis factor receptor superfamily member 8 generated either through alternative splicing event which deletes all or a portion of the transmembrane domain, or by proteolysis of the membrane-bound form. In the case of an immunoassay, one or more antibodies that bind to epitopes within this extracellular domain may be used to detect these soluble form(s). The following domains have been identified in Tumor necrosis factor receptor superfamily member 8:
  • Residues Length Domain ID
      1-18 18 Signal peptide
     19-595 577 Tumor necrosis factor receptor superfamily member 8
     19-379 361 Extracellular domain
    380-407 28 Transmembrane domain
      1-463 463 Missing in short isoform
  • As used herein, the term “Alpha-fetoprotein” refers to one or more polypeptides present in a biological sample that are derived from the Alpha-fetoprotein precursor (Swiss-Prot P02771 (SEQ ID NO: 27)):
  •         10         20         30         40         50         60
    MKWVESIFLI FLLNFTESRT LHRNEYGIAS ILDSYQCTAE ISLADLATIF FAQFVQEATY
            70         80         90        100        110        120
    KEVSKMVKDA LTAIEKPTGD EQSSGCLENQ LPAFLEELCH EKEILEKYGH SDCCSQSEEG
           130        140        150        160        170        180
    RHNCFLAHKK PTPASIPLFQ VPEPVTSCEA YEEDRETFMN KFIYEIARRH PFLYAPTILL
           190        200        210        220        230        240
    WAARYDKIIP SCCKAENAVE CFQTKAATVT KELRESSLLN QHACAVMKNF GTRTFQAITV
           250        260        270        280        290        300
    TKLSQKFTKV NFTEIQKLVL DVAHVHEHCC RGDVLDCLQD GEKIMSYICS QQDTLSNKIT
           310        320        330        340        350        360
    ECCKLTTLER GQCIIHAEND EKPEGLSPNL NRFLGDRDFN QFSSGEKNIF LASFVHEYSR
           370        380        390        400        410        420
    RHPQLAVSVI LRVAKGYQEL LEKCFQTENP LECQDKGEEE LQKYIQESQA LAKRSCGLFQ
           430        440        450        460        470        480
    KLGEYYLQNA FLVAYTKKAP QLTSSELMAI TRKMAATAAT CCQLSEDKLL ACGEGAADII
           490        500        510        520        530        540
    IGHLCIRHEM TPVNPGVGQC CTSSYANRRP CFSSLVVDET YVPPAFSDDK FIFHKDLCQA
           550        560        570        580        590        600
    QGVALQTMKQ EFLINLVKQK PQITEEQLEA VIADFSGLLE KCCQGQEQEV CFAEEGQKLI
    SKTRAALGV
  • The following domains have been identified in Alpha-fetoprotein:
  • Residues Length Domain ID
     1-18 18 Signal peptide
    19-609 591 Alpha-fetoprotein
  • As used herein, the term “Thyroxine-binding globulin” refers to one or more polypeptides present in a biological sample that are derived from the Thyroxine-binding globulin precursor (Swiss-Prot P05543 (SEQ ID NO: 28)).
  •         10         20         30         40         50         60
    MSPFLYLVLL VLGLHATIHC ASPEGKVTAC HSSQPNATLY KMSSINADFA FNLYRRFTVE
            70         80         90        100        110        120
    TPDKNIFFSP VSISAALVML SFGACCSTQT EIVETLGFNL TDTPMVEIQH GFQHLICSLN
           130        140        150        160        170        180
    FPKKELELQI GNALFIGKHL KPLAKFLNDV KTLYETEVFS TDFSNISAAK QEINSHVEMQ
           190        200        210        220        230        240
    TKGKVVGLIQ DLKPNTIMVL VNYIHFKAQW ANPFDPSKTE DSSSFLIDKT TTVQVPMMHQ
           250        260        270        280        290        300
    MEQYYHLVDM ELNCTVLQMD YSKNALALFV LPKEGQMESV EAAMSSKTLK KWNRLLQKGW
           310        320        330        340        350        360
    VDLFVPKFSI SATYDLGATL LKMGIQHAYS ENADFSGLTE DNGLKLSNAA HKAVLHIGEK
           370        380        390        400        410
    GTEAAAVPEV ELSDQPENTF LHPIIQIDRS FMLLILERST RSILFLGKVV NPTEA
  • The following domains have been identified in Thyroxine-binding globulin:
  • Residues Length Domain ID
     1-20 20 Signal peptide
    21-415 395 Thyroxine-binding globulin
  • As used herein, the term “Prostate-specific antigen” refers to one or more polypeptides present in a biological sample that are derived from the Prostate-specific antigen precursor (Swiss-Prot P07288 (SEQ ID NO: 29)).
  •         10         20         30         40         50         60
    MWVPVVFLTL SVTWIGAAPL ILSRIVGGWE CEKHSQPWQV LVASRGRAVC GGVLVHPQWV
            70         80         90        100        110        120
    LTAAHCIRNK SVILLGRHSL FHPEDTGQVF QVSHSFPHPL YDMSLLKNRF LRPGDDSSHD
           130        140        150        160        170        180
    LMLLRLSEPA ELTDAVKVMD LPTQEPALGT TCYASGWGSI EPEEFLTPKK LQCVDLHVIS
           190        200        210        220        230        240
    NDVCAQVHPQ KVTKFMLCAG RWTGGKSTCS GDSGGPLVCN GVLQGITSWG SEPCALPERP
           250        260
    SEYTKVVHYR KWIKDTIVAN P
  • The following domains have been identified in Prostate-specific antigen:
  • Residues Length Domain ID
     1-17 17 Signal peptide
    18-24 7 Activation peptide
    25-261 237 Prostate-specific antigen
  • As used herein, the terms “Apolipoprotein(a)” and “Apolipoprotein A” refer to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein(a) precursor (Swiss-Prot P08519 (SEQ ID NO: 30)).
  •         10         20         30         40         50         60
    MEHKEVVLLL LLFLKSAAPE QSHVVQDCYH GDGQSYRGTY STTVTGRTCQ AWSSMTPHQH
            70         80         90        100        110        120
    NRTTENYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP
           130        140        150        160        170        180
    VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY
           190        200        210        220        230        240
    YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA
           250        260        270        280        290        300
    PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL
           310        320        330        340        350        360
    IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP
           370        380        390        400        410        420
    TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR
           430        440        450        460        470        480
    NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG
           490        500        510        520        530        540
    VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA
           550        560        570        580        590        600
    APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPGVQECYH
           610        620        630        640        650        660
    GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT
           670        680        690        700        710        720
    RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY
           730        740        750        760        770        780
    RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR
           790        800        810        820        830        840
    WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST
           850        860        870        880        890        900
    TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL
           910        920        930        940        950        960
    TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT
           970        980        990       1000       1010       1020
    CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA
          1030       1040       1050       1060       1070       1080
    EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS
          1090       1100       1110       1120       1130       1140
    MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA
          1150       1160       1170       1180       1190       1200
    PPTVTPVPSL EAPSEQAPTE QRPGVQECYH GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH
          1210       1220       1230       1240       1250       1260
    SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP
          1270       1280       1290       1300       1310       1320
    VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY
          1330       1340       1350       1360       1370       1380
    YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA
          1390       1400       1410       1420       1430       1440
    PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL
          1450       1460       1470       1480       1490       1500
    IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP
          1510       1520       1530       1540       1550       1560
    TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR
          1570       1580       1590       1600       1610       1620
    NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG
          1630       1640       1650       1660       1670       1680
    VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA
          1690       1700       1710       1720       1730       1740
    APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPGVQECYH
          1750       1760       1770       1780       1790       1800
    GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT
          1810       1820       1830       1840       1850       1860
    RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY
          1870       1880       1890       1900       1910       1920
    RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR
          1930       1940       1950       1960       1970       1980
    WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST
          1990       2000       2010       2020       2030       2040
    TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL
          2050       2060       2070       2080       2090       2100
    TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT
          2110       2120       2130       2140       2150       2160
    CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA
          2170       2180       2190       2200       2210       2220
    EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS
          2230       2240       2250       2260       2270       2280
    MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA
          2290       2300       2310       2320       2330       2340
    PPTVTPVPSL EAPSEQAPTE QRPGVQECYH GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH
          2350       2360       2370       2380       2390       2400
    SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP
          2410       2420       2430       2440       2450       2460
    VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY
          2470       2480       2490       2500       2510       2520
    YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA
          2530       2540       2550       2560       2570       2580
    PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL
          2590       2600       2610       2620       2630       2640
    IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP
          2650       2660       2670       2680       2690       2700
    TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR
          2710       2720       2730       2740       2750       2760
    NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG
          2770       2780       2790       2800       2810       2820
    VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA
          2830       2840       2850       2860       2870       2880
    APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPGVQECYH
          2890       2900       2910       2920       2930       2940
    GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT
          2950       2960       2970       2980       2990       3000
    RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY
          3010       3020       3030       3040       3050       3060
    RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR
          3070       3080       3090       3100       3110       3120
    WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST
          3130       3140       3150       3160       3170       3180
    TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL
          3190       3200       3210       3220       3230       3240
    TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT
          3250       3260       3270       3280       3290       3300
    CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA
          3310       3320       3330       3340       3350       3360
    EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS
          3370       3380       3390       3400       3410       3420
    MTPHSHSRTP EYYPNAGLIM NYCRNPDPVA APYCYTRDPS VRWEYCNLTQ CSDAEGTAVA
          3430       3440       3450       3460       3470       3480
    PPTITPIPSL EAPSEQAPTE QRPGVQECYH GNGQSYQGTY FITVTGRTCQ AWSSMTPHSH
          3490       3500       3510       3520       3530       3540
    SRTPAYYPNA GLIKNYCRNP DPVAAPWCYT TDPSVRWEYC NLTRCSDAEW TAFVPPNVIL
          3550       3560       3570       3580       3590       3600
    APSLEAFFEQ ALTEETPGVQ DCYYHYGQSY RGTYSTTVTG RTCQAWSSMT PHQHSRTPEN
          3610       3620       3630       3640       3650       3660
    YPNAGLTRNY CRNPDAEIRP WCYTMDPSVR WEYCNLTQCL VTESSVLATL TVVPDPSTEA
          3670       3680       3690       3700       3710       3720
    SSEEAPTEQS PGVQDCYHGD GQSYRGSFST TVTGRTCQSW SSMTPHWHQR TTEYYPNGGL
          3730       3740       3750       3760       3770       3780
    TRNYCRNPDA EISPWCYTMD PNVRWEYCNL TQCPVTESSV LATSTAVSEQ APTEQSPTVQ
          3790       3800       3810       3820       3830       3840
    DCYHGDGQSY RGSFSTTVTG RTCQSWSSMT PHWHQRTTEY YPNGGLTRNY CRNPDAEIRP
          3850       3860       3870       3880       3890       3900
    WCYTMDPSVR WEYCNLTQCP VMESTLLTTP TVVPVPSTEL PSEEAPTENS TGVQDCYRGD
          3910       3920       3930       3940       3950       3960
    GQSYRGTLST TITGRTCQSW SSMTPHWHRR IPLYYPNAGL TRNYCRNPDA EIRPWCYTMD
          3970       3980       3990       4000       4010       4020
    PSVRWEYCNL TRCPVTESSV LTTPTVAPVP STEAPSEQAP PEKSPVVQDC YHGDGRSYRG
          4030       4040       4050       4060       4070       4080
    ISSTTVTGRT CQSWSSMIPH WHQRTPENYP NAGLTENYCR NPDSGKQPWC YTTDPCVRWE
          4090       4100       4110       4120       4130       4140
    YCNLTQCSET ESGVLETPTV VPVPSMEAHS EAAPTEQTPV VRQCYHGNGQ SYRGTFSTTV
          4150       4160       4170       4180       4190       4200
    TGRTCQSWSS MTPHRHQRTP ENYPNDGLTM NYCRNPDADT GPWCFTMDPS IRWEYCNLTR
          4210       4220       4230       4240       4250       4260
    CSDTEGTVVA PPTVIQVPSL GPPSEQDCMF GNGKGYRGKK ATTVTGTPCQ EWAAQEPHRH
          4270       4280       4290       4300       4310       4320
    STFIPGTNKW AGLEKNYCRN PDGDINGPWC YTMNPRKLFD YCDIPLCASS SFDCGKPQVE
          4330       4340       4350       4360       4370       4380
    PKKCPGSIVG GCVAHPHSWP WQVSLRTRFG KHFCGGTLIS PEWVLTAAHC LKKSSRPSSY
          4390       4400       4410       4420       4430       4440
    KVILGAHQEV NLESHVQEIE VSRLFLEPTQ ADIALLKLSR PAVITDKVMP ACLPSPDYMV
          4450       4460       4470       4480       4490       4500
    TARTECYITG WGETQGTFGT GLLKEAQLLV IENEVCNHYK YICAEHLARG TDSCQGDSGG
          4510       4520       4530       4540
    PLVCFEKDKY ILQGVTSWGL GCARPNKPGV YARVSRFVTW IEGMMRNN
  • The following domains have been identified in Apolipoprotein(a):
  • Residues Length Domain ID
     1-19 19 Signal peptide
    20-4548 4529 Apolipoprotein(a)
  • As used herein, the term “Apolipoprotein E” refers to one or more polypeptides present in a biological sample that are derived from the Apolipoprotein E precursor (Swiss-Prot P02649 (SEQ ID NO: 31)).
  •         10         20         30         40         50         60
    MKVLWAALLV TFLAGCQAKV EQAVETEPEP ELRQQTEWQS GQRWELALGR FWDYLRWVQT
            70         80         90        100        110        120
    LSEQVQEELL SSQVTQELRA LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA
           130        140        150        160        170        180
    RLGADMEDVC GRLVQYRGEV QAMLGQSTEE LRVRLASHLR KLRKRLLRDA DDLQKRLAVY
           190        200        210        220        230        240
    QAGAREGAER GLSAIRERLG PLVEQGRVRA ATVGSLAGQP LQERAQAWGE RLRARMEEMG
           250        260        270        280        290        300
    SRTRDRLDEV KEQVAEVRAK LEEQAQQIRL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
           310
    VQAAVGTSAA PVPSDNH
  • The following domains have been identified in Apolipoprotein E:
  • Residues Length Domain ID
     1-18 18 Signal peptide
    19-317 299 Apolipoprotein E
  • As used herein, the term “Thyrotropin subunit beta” refers to one or more polypeptides present in a biological sample that are derived from the Thyrotropin subunit betaprecursor (Swiss-Prot P01222 (SEQ ID NO: 32)).
  •         10         20         30         40         50         60
    MTALFLMSML FGLACGQAMS FCIPTEYTMH IERRECAYCL TINTTICAGY CMTRDINGKL
            70         80         90        100        110        120
    FLPKYALSQD VCTYRDFIYR TVEIPGCPLH VAPYFSYPVA LSCKCGKCNT DYSDCIHEAI
           130
    KTNYCTKPQK SYLVGFSV
  • The following domains have been identified in Thyrotropin subunit beta:
  • Residues Length Domain ID
      1-20 20 Signal peptide
     21-132 112 Thyrotropin subunit beta
    133-138 6 Propeptide
  • As used herein, the term “Platelet-derived Growth Factor B/B dimer” refers to one or more polypeptides present in a biological sample that are derived from the Platelet-derived Growth Factor V precursor and that form a homodimer (Swiss-Prot P01127 (SEQ ID NO: 33)).
  •         10         20         30         40         50         60
    MNRCWALFLS LCCYLRLVSA EGDPIPEELY EMLSDHSIRS FDDLQRLLHG DPGEEDGAEL
            70         80         90        100        110        120
    DLNMTRSHSG GELESLARGR RSLGSLTIAE PAMIAECKTR TEVFEISRRL IDRTNANFLV
           130        140        150        160        170        180
    WPPCVEVQRC SGCCNNRNVQ CRPTQVQLRP VQVRKIEIVR KKPIFKKATV TLEDHLACKC
           190        200        210        220        230        240
    ETVAAARPVT RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG
    • A
  • The following domains have been identified in Platelet-derived Growth Factor B:
  • Residues Length Domain ID
      1-20 20 Signal peptide
     21-81 61 Propeptide
     82-190 109 Platelet-derived Growth Factor B
    191-241 51 Propeptide
  • As used herein, the term “IgG4” refers to subclass 4 of the glycoprotein immunoglobulin G (IgG), a major effector molecule of the humoral immune response in man. Antibodies of the IgG class express their predominant activity during a secondary antibody response. The basic immunoglobulin G molecule has a four-chain structure, comprising two identical heavy (H) chains and two identical light (L) chains, linked together by inter-chain disulfide bonds. Each heavy chain is encoded by 4 distinct types of gene segments, designated VH (variable), D (diversity), JH (joining) and CH(constant). The variable region of the heavy chain is encoded by the VH, D and JH segments. The light chains are encoded by the 3 gene segments, VL, JL and CL. The variable region of the light chains is encoded by the VL and JL segments.
  • The length and flexibility of the hinge region varies among the IgG subclasses. The hinge region of IgG1 encompasses amino acids 216-231 and since it is freely flexible, the Fab fragments can rotate about their axes of symmetry and move within a sphere centered at the first of two inter-heavy chain disulfide bridges (23). IgG2 has a shorter hinge than IgG 1, with 12 amino acid residues and four disulfide bridges. The hinge region of IgG2 lacks a glycine residue, it is relatively short and contains a rigid poly-proline double helix, stabilised by extra inter-heavy chain disulfide bridges. These properties restrict the flexibility of the IgG2 molecule (24). IgG3 differs from the other subclasses by its unique extended hinge region (about four times as long as the IgG1 hinge), containing 62 amino acids (including 21 prolines and 11 cysteines), forming an inflexible poly-proline double helix (25,26). In IgG3 the Fab fragments are relatively far away from the Fc fragment, giving the molecule a greater flexibility. The elongated hinge in IgG3 is also responsible for its higher molecular weight compared to the other subclasses. The hinge region of IgG4 is shorter than that of IgG 1 and its flexibility is intermediate between that of IgG1 and IgG2.
  • The four IgG subclasses also differ with respect to the number of inter-heavy chain disulfide bonds in the hinge region (26). The structural differences between the IgG subclasses are also reflected in their susceptibility to proteolytic enzymes. IgG3 is very susceptible to cleavage by these enzymes, whereas IgG2 is relatively resistant. IgG1 and IgG4 exhibit an intermediary sensitivity, depending upon the enzyme used. Since these proteolytic enzymes all cleave IgG molecules near or within the hinge region, it is likely that the high sensitivity of IgG3 to enzyme digestion is related to its accessible hinge. Another structural difference between the human IgG subclasses is the linkage of the heavy and light chain by a disulfide bond. This bond links the carboxy-terminal of the light chain with the cysteine residue at position 220 (in IgG) or at position 131 (in IgG2, IgG3 and IgG4) of the CH1 sequence of the heavy chain.
  • As a consequence of the structural differences, the four IgG subclasses may be distinguished from one another, for example using antibodies that are specific for differences between the isoforms. In the present application, a level of IgG1 is determined using an assay which distinguishes this subclass, relative to the other subclasses.
  • As used herein, the term “relating a signal to the presence or amount” of an analyte reflects the following understanding. Assay signals are typically related to the presence or amount of an analyte through the use of a standard curve calculated using known concentrations of the analyte of interest. As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. Because an antibody epitope is on the order of 8 amino acids, an immunoassay configured to detect a marker of interest will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay. The term “related marker” as used herein with regard to a biomarker such as one of the kidney injury markers described herein refers to one or more fragments, variants, etc., of a particular marker or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.
  • In this regard, the skilled artisan will understand that the signals obtained from an immunoassay are a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., the analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (such as dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quatitation). This list is not meant to be limiting.
  • The term “positive going” marker as that term is used herein refer to a marker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition. The term “negative going” marker as that term is used herein refer to a marker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.
  • The term “subject” as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are applicable to both human and veterinary disease. Further, while a subject is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects are humans, and most preferably “patients,” which as used herein refers to living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology.
  • Preferably, an analyte is measured in a sample. Such a sample may be obtained from a subject, or may be obtained from biological materials intended to be provided to the subject. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, and an analyte measurement used to evaluate the kidney for preexisting damage. Preferred samples are body fluid samples.
  • The term “body fluid sample” as used herein refers to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition. Preferred body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions. In addition, one of skill in the art would realize that certain body fluid samples would be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.
  • The term “diagnosis” as used herein refers to methods by which the skilled artisan can estimate and/or determine the probability (“a likelihood”) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes using the results of an assay, most preferably an immunoassay, for a kidney injury marker of the present invention, optionally together with other clinical characteristics, to arrive at a diagnosis (that is, the occurrence or nonoccurrence) of an acute renal injury or ARF for the subject from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Many biomarkers are indicative of multiple conditions. The skilled clinician does not use biomarker results in an informational vacuum, but rather test results are used together with other clinical indicia to arrive at a diagnosis. Thus, a measured biomarker level on one side of a predetermined diagnostic threshold indicates a greater likelihood of the occurrence of disease in the subject relative to a measured level on the other side of the predetermined diagnostic threshold.
  • Similarly, a prognostic risk signals a probability (“a likelihood”) that a given course or outcome will occur. A level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.
  • Marker Assays
  • In general, immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and The Immunoassay Handbook, David Wild, ed. Stockton Press, New York, 1994, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims.
  • The assay devices and methods known in the art can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. One skilled in the art also recognizes that robotic instrumentation including but not limited to Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems are among the immunoassay analyzers that are capable of performing immunoassays. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.
  • Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in assays. Solid phases that may be used to immobilize specific binding members include include those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.
  • Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, metal chelates, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or by a specific binding molecule which itself may be detectable (e.g., biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).
  • Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents contain at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups. Maleimides, alkyl and aryl halides, and alpha-haloacyls react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.
  • In certain aspects, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.
  • Antibodies
  • The term “antibody” as used herein refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. Fundamental Immunology, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97. The term antibody includes antigen-binding portions, i.e., “antigen binding sites,” (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”
  • Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In preferred embodiments, Preferred antibodies bind with affinities of at least about 107 M−1, and preferably between about 108 M−1 to about 109 M−1, about 109 M−1 to about 1010 M−1, or about 1010 M−1 to about 1012 M−1.
  • Affinity is calculated as Kd=koff/kon (koff is the dissociation rate constant, Kon is the association rate constant and Kd is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: r/c=K(n−r): where r=moles of bound ligand/mole of receptor at equilibrium; c=free ligand concentration at equilibrium; K=equilibrium association constant; and n=number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., J. Immunoassay 12: 425-43, 1991; Nelson and Griswold, Comput. Methods Programs Biomed. 27: 65-8, 1988.
  • The term “epitope” refers to an antigenic determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
  • Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g., Cwirla et al., Proc. Natl. Acad. Sci. USA 87, 6378-82, 1990; Devlin et al., Science 249, 404-6, 1990, Scott and Smith, Science 249, 386-88, 1990; and Ladner et al., U.S. Pat. No. 5,571,698. A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.
  • The antibodies that are generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.
  • The antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target, protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.
  • While the present application describes antibody-based binding assays in detail, alternatives to antibodies as binding species in assays are well known in the art. These include receptors for a particular target, aptamers, etc. Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist. High-affinity aptamers containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions, and may include amino acid side chain functionalities.
  • Assay Correlations
  • The term “correlating” as used herein in reference to the use of biomarkers refers to comparing the presence or amount of the biomarker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.
  • Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, cost/benefit analysis is involved in selecting a diagnostic threshold.
  • Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction using cardiac troponin is the 97.5th percentile of the concentration seen in a normal population. Another method may be to look at serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.
  • Population studies may also be used to select a decision threshold. Receiver Operating Characteristic (“ROC”) arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a “diseased” subpopulation from a “nondiseased” subpopulation. A false positive in this case occurs when the person tests positive, but actually does not have the disease. A false negative, on the other hand, occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease. To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to 1-specificity, the ROC graph is sometimes called the sensitivity vs (1-specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold is selected to provide an acceptable level of specificity and sensitivity.
  • In this context, “diseased” is meant to refer to a population having one characteristic (the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” is meant to refer to a population lacking the characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.
  • In addition to threshold comparisons, other methods for correlating assay results to a patient classification (occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject belongs to one classification out of a plurality of classifications.
  • Measures of test accuracy may be obtained as described in Fischer et al., Intensive Care Med. 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas. The area under the curve (“AUC”) of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. The area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.
  • As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1
  • Additional clinical indicia may be combined with the kidney injury marker assay result(s) of the present invention. These include other biomarkers related to renal status. Examples include the following, which recite the common biomarker name, followed by the Swiss-Prot entry number for that biomarker or its parent: Actin (P68133); Adenosine deaminase binding protein (DPP4, P27487); Alpha-1-acid glycoprotein 1 (P02763); Alpha-1-microglobulin (P02760); Albumin (P02768); Angiotensinogenase (Renin, P00797); Annexin A2 (P07355); Beta-glucuronidase (P08236); B-2-microglobulin (P61679); Beta-galactosidase (P16278); BMP-7 (P18075); Brain natriuretic peptide (proBNP, BNP-32, NTproBNP; P16860); Calcium-binding protein Beta (S100-beta, P04271); Carbonic anhydrase (Q 16790); Casein Kinase 2 (P68400); Ceruloplasmin (P00450); Clusterin (P10909); Complement C3 (P01024); Cysteine-rich protein (CYR61, 000622); Cytochrome C(P99999); Epidermal growth factor (EGF, P01133); Endothelin-1 (P05305); Exosomal Fetuin-A (P02765); Fatty acid-binding protein, heart (FABP3, P05413); Fatty acid-binding protein, liver (P07148); Ferritin (light chain, P02793; heavy chain P02794); Fructose-1,6-biphosphatase (P09467); GRO-alpha (CXCL1, (P09341); Growth Hormone (P01241); Hepatocyte growth factor (P14210); Insulin-like growth factor I (P01343); Immunoglobulin G; Immunoglobulin Light Chains (Kappa and Lambda); Interferon gamma (P01308); Lysozyme (P61626); Interleukin-1alpha (P01583); Interleukin-2 (P60568); Interleukin-4 (P60568); Interleukin-9 (P15248); Interleukin-12p40 (P29460); Interleukin-13 (P35225); Interleukin-16 (Q14005); L1 cell adhesion molecule (P32004); Lactate dehydrogenase (P00338); Leucine Aminopeptidase (P28838); Meprin A-alpha subunit (Q16819); Meprin A-beta subunit (Q16820); Midkine (P21741); MIP2-alpha (CXCL2, P19875); MMP-2 (P08253); MMP-9 (P14780); Netrin-1 (O95631); Neutral endopeptidase (P08473); Osteopontin (P10451); Renal papillary antigen 1 (RPA1); Renal papillary antigen 2 (RPA2); Retinol binding protein (P09455); Ribonuclease; S100 calcium-binding protein A6 (P06703); Serum Amyloid P Component (P02743); Sodium/Hydrogen exchanger isoform (NHE3, P48764); Spermidine/spermine N1-acetyltransferase (P21673); TGF-Beta1 (P01137); Transferrin (P02787); Trefoil factor 3 (TFF3, Q07654); Toll-Like protein 4 (000206); Total protein; Tubulointerstitial nephritis antigen (Q9UJW2); Uromodulin (Tamm-Horsfall protein, P07911).
  • For purposes of risk stratification, Adiponectin (Q15848); Alkaline phosphatase P05186); Aminopeptidase N(P15144); CalbindinD28k (P05937); Cystatin C(P01034); 8 subunit of FIFO ATPase (P03928); Gamma-glutamyltransferase (P19440); GSTa (alpha-glutathione-S-transferase, P08263); GSTpi (Glutathione-S-transferase P; GST class-pi; P09211); IGFBP-1 (P08833); IGFBP-2 (P18065); IGFBP-6 (P24592); Integral membrane protein 1 (Itm1, P46977); Interleukin-6 (P05231); Interleukin-8 (P10145); Interleukin-18 (Q14116); IP-10 (10 kDa interferon-gamma-induced protein, P02778); IRPR (IFRD1, O00458); Isovaleryl-CoA dehydrogenase (IVD, P26440); I-TAC/CXCL11 (O14625); Keratin 19 (P08727); Kim-1 (Hepatitis A virus cellular receptor 1, O43656); L-arginine:glycine amidinotransferase (P50440); Leptin (P41159); Lipocalin2 (NGAL, P80188); MCP-1 (P13500); MIG (Gamma-interferon-induced monokine Q07325); MIP-1a (P10147); MIP-3a (P78556); MIP-1beta (P13236); MIP-1d (Q16663); NAG (N-acetyl-beta-D-glucosaminidase, P54802); Organic ion transporter (OCT2, O15244); Osteoprotegerin (O14788); P8 protein (O60356); Plasminogen activator inhibitor 1 (PM-1, P05121); ProANP(1-98) (P01160); Protein phosphatase 1-beta (PPI-beta, P62140); Rab GDI-beta (P50395); Renal kallikrein (Q86U61); RT1.B-1 (alpha) chain of the integral membrane protein (Q5Y7A8); Soluble tumor necrosis factor receptor superfamily member IA (sTNFR-I, P19438); Soluble tumor necrosis factor receptor superfamily member 1B (sTNFR-II, P20333); Tissue inhibitor of metalloproteinases 3 (TIMP-3, P35625); uPAR (Q03405) may be combined with the kidney injury marker assay result(s) of the present invention.
  • Other clinical indicia which may be combined with the kidney injury marker assay result(s) of the present invention includes demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a urine total protein measurement, a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a renal papillary antigen 1 (RPA1) measurement; a renal papillary antigen 2 (RPA2) measurement; a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, and/or a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine). Other measures of renal function which may be combined with the kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety.
  • Combining assay results/clinical indicia in this manner can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, etc. This list is not meant to be limiting.
  • Diagnosis of Acute Renal Failure
  • As noted above, the terms “acute renal (or kidney) injury” and “acute renal (or kidney) failure” as used herein are defined in part in terms of changes in serum creatinine from a baseline value. Most definitions of ARF have common elements, including the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of mL/min:
  • G F R = Urine Concentration × Urine Flow Plasma Concentration
  • By normalizing the GFR to the body surface area, a GFR of approximately 75-100 mL/min per 1.73 m2 can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.
  • There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.
  • Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (UCr), urine flow rate (V), and creatinine's plasma concentration (PCr) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (UCr×V) divided by its plasma concentration. This is commonly represented mathematically as:
  • C Cr = U Cr × V P Cr
  • Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:
  • C Cr = U Cr × 24 - hour volume P Cr × 24 × 60 mins
  • To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m2. While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:
  • C Cr - corrected = C Cr × 1.73 B S A
  • The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.
  • For purposes of determining urine output on a Urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, Bagshaw et al., Nephrol. Dial. Transplant. 23: 1203-1210, 2008, assumes an average patient weight of 70 kg, and patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure).
  • Selecting a Treatment Regimen
  • Once a diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. The skilled artisan is aware of appropriate treatments for numerous diseases discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N.J., 1999. In addition, since the methods and compositions described herein provide prognostic information, the markers of the present invention may be used to monitor a course of treatment. For example, improved or worsened prognostic state may indicate that a particular treatment is or is not efficacious.
  • One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention.
    • Example 1 Contrast-Induced Nephropathy Sample Collection
  • The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after receiving intravascular contrast media. Approximately 250 adults undergoing radiographic/angiographic procedures involving intravascular administration of iodinated contrast media are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:
    • Inclusion Criteria
  • males and females 18 years of age or older;
    undergoing a radiographic/angiographic procedure (such as a CT scan or coronary intervention) involving the intravascular administration of contrast media;
    expected to be hospitalized for at least 48 hours after contrast administration.
    able and willing to provide written informed consent for study participation and to comply with all study procedures.
    • Exclusion Criteria
  • renal transplant recipients;
    acutely worsening renal function prior to the contrast procedure;
    already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;
    expected to undergo a major surgical procedure (such as involving cardiopulmonary bypass) or an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration;
    participation in an interventional clinical study with an experimental therapy within the previous 30 days;
    known infection with human immunodeficiency virus (1-HV) or a hepatitis virus.
  • Immediately prior to the first contrast administration (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL) and a urine sample (10 mL) are collected from each patient. Blood and urine samples are then collected at 4 (±0.5), 8 (±1), 24 (±2) 48 (±2), and 72 (±2) hrs following the last administration of contrast media during the index contrast procedure. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.
  • Serum creatinine is assessed at the site immediately prior to the first contrast administration (after any pre-procedure hydration) and at 4 (±0.5), 8 (±1), 24 (±2) and 48 (±2)), and 72 (±2) hours following the last administration of contrast (ideally at the same time as the study samples are obtained). In addition, each patient's status is evaluated through day 30 with regard to additional serum and urine creatinine measurements, a need for dialysis, hospitalization status, and adverse clinical outcomes (including mortality).
  • Prior to contrast administration, each patient is assigned a risk based on the following assessment: systolic blood pressure <80 mm Hg=5 points; intra-arterial balloon pump=5 points; congestive heart failure (Class or history of pulmonary edema)=5 points; age >75 yrs=4 points; hematocrit level <39% for men, <35% for women=3 points; diabetes=3 points; contrast media volume=1 point for each 100 mL; serum creatinine level >1.5 g/dL=4 points OR estimated GFR 40-60 mL/min/1.73 m2=2 points, 20-40 mL/min/1.73 m2=4 points, <20 mL/min/1.73 m2=6 points. The risks assigned are as follows: risk for CIN and dialysis: 5 or less total points=risk of CIN—7.5%, risk of dialysis—0.04%; 6-10 total points=risk of CIN—14%, risk of dialysis—0.12%; 11-16 total points=risk of CIN—26.1%, risk of dialysis—1.09%; >16 total points=risk of CIN—57.3%, risk of dialysis—12.8%.
    • Example 2 Cardiac Surgery Sample Collection
  • The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after undergoing cardiovascular surgery, a procedure known to be potentially damaging to kidney function. Approximately 900 adults undergoing such surgery are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:
    • Inclusion Criteria
  • males and females 18 years of age or older;
    undergoing cardiovascular surgery;
    Toronto/Ottawa Predictive Risk Index for Renal Replacement risk score of at least 2 (Wijeysundera et al., JAMA 297: 1801-9, 2007); and
    able and willing to provide written informed consent for study participation and to comply with all study procedures.
    • Exclusion Criteria
  • known pregnancy;
    previous renal transplantation;
    acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria);
    already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment;
    currently enrolled in another clinical study or expected to be enrolled in another clinical study within 7 days of cardiac surgery that involves drug infusion or a therapeutic intervention for AKI;
    known infection with human immunodeficiency virus (HIV) or a hepatitis virus.
  • Within 3 hours prior to the first incision (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL), whole blood (3 mL), and a urine sample (35 mL) are collected from each patient. Blood and urine samples are then collected at 3 (±0.5), 6 (±0.5), 12 (±1), 24 (±2) and 48 (±2) hrs following the procedure and then daily on days 3 through 7 if the subject remains in the hospital. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.
    • Example 3 Acutely Ill Subject Sample Collection
  • The objective of this study is to collect samples from acutely ill patients. Approximately 1900 adults expected to be in the ICU for at least 48 hours will be enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria:
    • Inclusion Criteria
  • males and females 18 years of age or older;
    Study population 1: approximately 300 patients that have at least one of:
    shock (SBP<90 mmHg and/or need for vasopressor support to maintain MAP>60 mmHg and/or documented drop in SBP of at least 40 mmHg); and
    sepsis;
    Study population 2: approximately 300 patients that have at least one of:
    IV antibiotics ordered in computerized physician order entry (CPOE) within 24 hours of enrollment;
    contrast media exposure within 24 hours of enrollment;
    increased Intra-Abdominal Pressure with acute decompensated heart failure; and
    severe trauma as the primary reason for ICU admission and likely to be hospitalized in the ICU for 48 hours after enrollment;
    Study population 3: approximately 300 patients expected to be hospitalized through acute care setting (ICU or ED) with a known risk factor for acute renal injury (e.g. sepsis, hypotension/shock (Shock=systolic BP<90 mmHg and/or the need for vasopressor support to maintain a MAP>60 mmHg and/or a documented drop in SBP>40 mmHg), major trauma, hemorrhage, or major surgery); and/or expected to be hospitalized to the ICU for at least 24 hours after enrollment;
    Study population 4: approximately 1000 patients that are 21 years of age or older, within 24 hours of being admitted into the ICU, expected to have an indwelling urinary catheter for at least 48 hours after enrollment, and have at least one of the following acute conditions within 24 hours prior to enrollment:
    (i) respiratory SOFA score of ≧2 (PaO2/FiO2<300), (ii) cardiovascular SOFA score of ≧1 (MAP<70 mm Hg and/or any vasopressor required).
    • Exclusion Criteria
  • known pregnancy;
    institutionalized individuals;
    previous renal transplantation;
    known acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria);
    received dialysis (either acute or chronic) within 5 days prior to enrollment or in imminent need of dialysis at the time of enrollment;
    known infection with human immunodeficiency virus (HIV) or a hepatitis virus;
    meets any of the following:
    (i) active bleeding with an anticipated need for >4 units PRBC in a day;
    (ii) hemoglobin <7 g/dL;
    (iii) any other condition that in the physician's opinion would contraindicate drawing serial blood samples for clinical study purposes;
    meets only the SBP<90 mmHg inclusion criterion set forth above, and does not have shock in the attending physician's or principal investigator's opinion;
  • After obtaining informed consent, an EDTA anti-coagulated blood sample (10 mL) and a urine sample (25-50 mL) are collected from each patient. Blood and urine samples are then collected at 4 (±0.5) and 8 (±1) hours after contrast administration (if applicable); at 12 (±1), 24 (±2), 36 (±2), 48 (±2), 60 (±2), 72 (±2), and 84 (±2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, Calif. The study urine samples are frozen and shipped to Astute Medical, Inc.
    • Example 4 Immunoassay Format
  • Analytes are measured using standard sandwich enzyme immunoassay techniques. A first antibody which binds the analyte is immobilized in wells of a 96 well polystyrene microplate. Analyte standards and test samples are pipetted into the appropriate wells and any analyte present is bound by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidase-conjugated second antibody which binds the analyte is added to the wells, thereby forming sandwich complexes with the analyte (if present) and the first antibody. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution comprising tetramethylbenzidine and hydrogen peroxide is added to the wells. Color develops in proportion to the amount of analyte present in the sample. The color development is stopped and the intensity of the color is measured at 540 nm or 570 nm. An analyte concentration is assigned to the test sample by comparison to a standard curve determined from the analyte standards. In the case of kidney injury markers that are membrane proteins, assays are directed to soluble forms thereof as described above.
  • Commercially-available reagents were sourced from the following vendors:
  • Analyte Assay Source Catalog number
    Platelet-derived Millipore Cat. # HNDG3-36K
    growth factor
    (AB/BB)
    Platelet-derived Millipore Cat. # HNDG3-36K
    growth factor
    subunit A (AA-
    dimer)
    Immunoglobulin Millipore Cat. # HGAM-301
    G, subclass 4
    Interleukin-4 Millipore Cat. # HSCR-32K
    receptor alpha
    chain
    Alpha-Fetoprotein EMD Chemicals Cat. # BPHCP001-6
    Apolipoprotein E EMD Chemicals Cat. # BPHCVD01-7
    Apolipoprotein(a) EMD Chemicals Cat. # BPHCVD05-8
    C-C motif Millipore Cat. # MPXHCYP2-
    chemokine 26 62K
    C-C motif Millipore Cat. # MPXHCYTO-
    chemokine 7 60K
    Complement C4-B Millipore Cat. # HNDG2-36K
    Corticotropin Millipore Cat. # HPT-66K
    Insulin-like Millipore Cat. # HIGFBP-53K
    growth factor-
    binding protein 4
    Insulin-like Millipore Cat. # HIGFBP-53K
    growth factor-
    binding protein 5
    Interferon alpha-2 Millipore Cat. # MPXHCYTO-60K
    Interleukin 23, Millipore Cat. # MPXHCYP2-
    alpha subunit 62K
    Interleukin-21 Millipore Cat. # MPXHCYP2-62K
    Interleukin-28A Millipore Cat. # MPXHCYP2-
    (interferon, lambda 2) 62K
    Interleukin-33 (IL-33) Millipore Cat. # MPXHCYP2-62K
    Lutropin subunit beta Millipore Cat # HBDP-33K
    Matrix R&D Systems Cat. # LMP000
    Metalloproteinase-1
    Neural cell Millipore Cat. # HNDG3-36K
    adhesion molecule 1
    Pigment epithelium- Millipore Cat. # HNDG2-36K
    derived factor
    Platelet-derived Bio-Rad Cat. # 171-A4011M
    growth factor
    (BB-dimer)
    Prostate-specific Millipore Cat # HCCBPIMAG-
    antigen, free 58K
    Thyrotropin Millipore Cat # HPT-66K
    subunit beta
    Thyroxine- Rules-Based Medicine No catalog number
    binding globulin
    Tumor necrosis Millipore Cat. # HSCR-32K
    factor receptor
    superfamily
    member 8
    Vascular Millipore Cat. # HSCR-32K
    endothelial growth
    factor receptor 2
    Vascular Millipore Cat. # HSCR-32K
    endothelial growth
    factor receptor 3
  • Units for the concentrations reported in the following data tables are as follows: Tumor necrosis factor receptor superfamily member 8—pg/mL, Alpha-Fetoprotein—ng/mL, Thyroxine-binding globulin—pg/mL, Prostate-specific antigen (free form)—ng/mL, Apolipoprotein A—ng/mL, Apolipoprotein E—ng/mL, Thyrotropin subunit beta—pg/mL, Platelet-derived growth factor BB dimer—pg/mL, C-C motif chemokine 7—pg/mL, C-C motif chemokine 26—pg/mL, Complement C4-B—ng/mL, Corticotropin—ng/mL, Interferon alpha-2—pg/mL, Interleukin-4 receptor alpha chain—pg/mL, Insulin-like growth factor-binding protein 4—ng/mL, Insulin-like growth factor-binding protein 5—ng/mL, Interleukin 21—pg/mL, Interleukin 23 alpha subunit—pg/mL, Interleukin-28A—pg/mL, Interleukin-33—pg/mL, Lutropin subunit beta—mIU/mL, Matrix Metalloproteinase-1—pg/mL, Neural cell adhesion molecule 1—pg/mL, Pigment epithelium-derived factor—ng/mL, Vascular Vascular endothelial growth factor receptor 2—pg/mL, Vascular endothelial growth factor receptor 3—pg/mL, IgG4—ng/mL.
    • Example 5 Apparently Healthy Donor and Chronic Disease Patient Samples
  • Human urine samples from donors with no known chronic or acute disease (“Apparently Healthy Donors”) were purchased from two vendors (Golden West Biologicals, Inc., 27625 Commerce Center Dr., Temecula, Calif. 92590 and Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, Va. 23454). The urine samples were shipped and stored frozen at less than −20° C. The vendors supplied demographic information for the individual donors including gender, race (Black/White), smoking status and age.
  • Human urine samples from donors with various chronic diseases (“Chronic Disease Patients”) including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, Va. 23454. The urine samples were shipped and stored frozen at less than −20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking status and alcohol use, height, weight, chronic disease(s) diagnosis, current medications and previous surgeries.
    • Example 6 Use of Kidney Injury Markers for Evaluating Renal Status in Patients
  • Patients from the intensive care unit (ICU) were enrolled in the following study. Each patient was classified by kidney status as non-injury (O), risk of injury (R), injury (I), and failure (F) according to the maximum stage reached within 7 days of enrollment as determined by the RIFLE criteria. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) were collected from each patient at enrollment, 4 (±0.5) and 8 (±1) hours after contrast administration (if applicable); at 12 (±1), 24 (±2), and 48 (±2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Markers were each measured by standard immunoassay methods using commercially available assay reagents in the urine samples and the plasma component of the blood samples collected.
  • Two cohorts were defined to represent a “diseased” and a “normal” population. While these terms are used for convenience, “diseased” and “normal” simply represent two cohorts for comparison (say RIFLE 0 vs RIFLE R, I and F; RIFLE 0 vs RIFLE R; RIFLE 0 and R vs RIFLE I and F; etc.). The time “prior max stage” represents the time at which a sample is collected, relative to the time a particular patient reaches the lowest disease stage as defined for that cohort, binned into three groups which are +/−12 hours. For example, “24 hr prior” which uses 0 vs R, I, F as the two cohorts would mean 24 hr (+/−12 hours) prior to reaching stage R (or I if no sample at R, or F if no sample at R or I).
  • A receiver operating characteristic (ROC) curve was generated for each biomarker measured and the area under each ROC curve (AUC) is determined. Patients in Cohort 2 were also separated according to the reason for adjudication to cohort 2 as being based on serum creatinine measurements (sCr), being based on urine output (UO), or being based on either serum creatinine measurements or urine output. Using the same example discussed above (0 vs R, I, F), for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of urine output; for those patients adjudicated to stage R, I, or F on the basis of urine output alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements; and for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements or urine output, the stage 0 cohort contains only patients in stage 0 for both serum creatinine measurements and urine output. Also, in the data for patients adjudicated on the basis of serum creatinine measurements or urine output, the adjudication method which yielded the most severe RIFLE stage is used.
  • The ability to distinguish cohort 1 from Cohort 2 was determined using ROC analysis. SE is the standard error of the AUC, n is the number of sample or individual patients (“pts,” as indicated). Standard errors are calculated as described in Hanley, J. A., and McNeil, B. J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 143: 29-36; p values are calculated with a two-tailed Z-test. An AUC<0.5 is indicative of a negative going marker for the comparison, and an AUC>0.5 is indicative of a positive going marker for the comparison.
  • Various threshold (or “cutoff”) concentrations were selected, and the associated sensitivity and specificity for distinguishing cohort 1 from cohort 2 are determined. OR is the odds ratio calculated for the particular cutoff concentration, and 95% CI is the confidence interval for the odds ratio.
  • FIG. 1: Comparison of marker levels in urine samples collected from Cohort I (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.
  •
    Complement C4-B
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 14.6 18.7 14.6 18.9 14.6 22.3
    Average 52.6 70.9 52.6 51.2 52.6 47.9
    Stdev 134 196 134 98.2 134 92.5
    p (t-test) 0.23 0.91 0.81
    Min 0.00607 0.383 0.00607 0.211 0.00607 0.448
    Max 1950 2000 1950 625 1950 562
    n (Samp) 463 119 463 128 463 47
    n (Patient) 223 119 223 128 223 47
    sCr only
    Median 17.3 14.0 17.3 22.3 17.3 21.1
    Average 59.1 23.1 59.1 43.1 59.1 48.7
    Stdev 139 29.6 139 84.8 139 65.3
    p (t-test) 0.10 0.44 0.70
    Min 0.00607 0.754 0.00607 0.211 0.00607 0.448
    Max 2000 130 2000 556 2000 252
    n (Samp) 1015 40 1015 46 1015 26
    n (Patient) 374 40 374 46 374 26
    UO only
    Median 17.7 27.6 17.7 19.8 17.7 23.2
    Average 53.8 80.7 53.8 53.9 53.8 44.1
    Stdev 128 206 128 95.8 128 89.5
    p (t-test) 0.090 0.99 0.62
    Min 0.00329 0.383 0.00329 0.259 0.00329 0.544
    Max 1950 2000 1950 625 1950 562
    n (Samp) 436 107 436 117 436 44
    n (Patient) 173 107 173 117 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.44 0.56 0.52 0.51 0.50 0.55 0.52 0.51
    SE 0.030 0.048 0.032 0.029 0.044 0.030 0.045 0.058 0.046
    p 0.041 0.23 0.042 0.51 0.77 0.89 0.25 0.69 0.81
    nCohort 1 463 1015 436 463 1015 436 463 1015 436
    nCohort 2 119 40 107 128 46 117 47 26 44
    Cutoff 1 8.26 4.22 10.2 4.60 5.88 5.01 10.5 6.04 6.59
    Sens 1 71% 70% 70% 70% 72% 70% 70% 73% 70%
    Spec 1 40% 26% 39% 30% 31% 26% 45% 31% 30%
    Cutoff 2 3.27 2.69 4.12 1.77 4.60 2.22 4.27 2.22 3.99
    Sens 2 81% 80% 80% 80% 80% 80% 81% 81% 82%
    Spec 2 23% 19% 21% 15% 28% 13% 28% 17% 21%
    Cutoff 3 1.35 1.88 1.30 0.895 1.66 1.09 3.00 0.995 2.76
    Sens 3 91% 90% 91% 91% 91% 91% 91% 92% 91%
    Spec 3 12% 15%  9%  8% 14%  7% 22%  9% 15%
    Cutoff 4 36.1 41.3 40.6 36.1 41.3 40.6 36.1 41.3 40.6
    Sens 4 42% 18% 44% 34% 33% 35% 26% 31% 27%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 60.0 68.7 60.5 60.0 68.7 60.5 60.0 68.7 60.5
    Sens 5 28%  8% 34% 23% 13% 26% 21% 23% 18%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 133 144 133 133 144 133 133 144 133
    Sens 6 12%  0% 16%  9%  4% 10%  6% 12%  5%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.99 4.1 0.90 0.77 1.3 0.58 1.6 0.83 0.71
    p Value 0.98 0.029 0.73 0.36 0.51 0.074 0.34 0.76 0.47
    95% CI of 0.54 1.2 0.48 0.43 0.56 0.32 0.60 0.25 0.27
    OR Quart 2 1.8 15 1.7 1.4 3.3 1.1 4.3 2.8 1.8
    OR Quart 3 1.1 4.9 0.85 1.0 1.8 0.68 2.8 1.2 1.4
    p Value 0.65 0.014 0.61 0.91 0.16 0.19 0.025 0.78 0.41
    95% CI of 0.64 1.4 0.45 0.59 0.79 0.38 1.1 0.39 0.62
    OR Quart 3 2.1 17 1.6 1.8 4.2 1.2 7.0 3.5 3.2
    OR Quart 4 1.6 3.8 1.6 1.2 1.00 1.1 1.6 1.3 0.90
    p Value 0.097 0.042 0.090 0.51 0.99 0.81 0.34 0.59 0.82
    95% CI of 0.92 1.0 0.92 0.70 0.39 0.62 0.60 0.46 0.37
    OR Quart 4 2.8 14 2.9 2.1 2.6 1.8 4.3 3.9 2.2
    C-C motif chemokine 26
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0320 0.0240 0.0320 0.0311 0.0320 0.0254
    Average 0.0543 0.155 0.0543 0.391 0.0543 0.0836
    Stdev 0.424 1.33 0.424 3.72 0.424 0.251
    p (t-test) 0.17 0.057 0.64
    Min 0.00872 0.00872 0.00872 0.00872 0.00872 0.00872
    Max 9.14 14.6 9.14 42.3 9.14 1.25
    n (Samp) 463 120 463 130 463 46
    n (Patient) 223 120 223 130 223 46
    sCr only
    Median 0.0368 0.0240 0.0368 0.0311 0.0368 0.0240
    Average 0.243 0.0346 0.243 0.0675 0.243 0.0794
    Stdev 2.46 0.0171 2.46 0.239 2.46 0.244
    p (t-test) 0.59 0.63 0.74
    Min 0.00872 0.00872 0.00872 0.00872 0.00872 0.00872
    Max 42.3 0.0633 42.3 1.65 42.3 1.25
    n (Samp) 1019 40 1019 46 1019 25
    n (Patient) 375 40 375 46 375 25
    UO only
    Median 0.0383 0.0276 0.0383 0.0247 0.0383 0.0240
    Average 0.0390 0.387 0.0390 0.473 0.0390 0.0572
    Stdev 0.0608 2.15 0.0608 3.94 0.0608 0.184
    p (t-test) 7.5E−4 0.022 0.15
    Min 0.00872 0.00872 0.00872 0.00872 0.00872 0.00872
    Max 1.25 14.6 1.25 42.3 1.25 1.25
    n (Samp) 435 108 435 119 435 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.49 0.50 0.47 0.47 0.46 0.43 0.47 0.45 0.40
    SE 0.030 0.047 0.031 0.029 0.044 0.030 0.045 0.060 0.047
    p 0.78 0.98 0.36 0.29 0.32 0.025 0.46 0.45 0.028
    nCohort 1 463 1019 435 463 1019 435 463 1019 435
    nCohort 2 120 40 108 130 46 119 46 25 44
    Cutoff 1 0.0195 0.0226 0.0195 0.0204 0.0232 0.0204 0.0218 0.0218 0.0204
    Sens 1 78% 72% 79% 72% 72% 71% 72% 72% 70%
    Spec 1 19% 26% 16% 23% 31% 21% 29% 26% 21%
    Cutoff 2 0.0192 0.0195 0.0192 0.0192 0.0195 0.0143 0.0195 0.0204 0.0173
    Sens 2 80% 85% 81% 82% 80% 86% 80% 84% 82%
    Spec 2 13% 16% 11% 13% 16%  7% 19% 21% 11%
    Cutoff 3 0.0143 0.0143 0.00872 0.00872 0.00872 0.00872 0.00872 0.00872 0.00872
    Sens 3 90% 90% 95% 95% 96% 93% 98% 92% 95%
    Spec 3  9%  8%  4%  6%  4%  4%  6%  4%  4%
    Cutoff 4 0.0443 0.0443 0.0486 0.0443 0.0443 0.0486 0.0443 0.0443 0.0486
    Sens 4 35% 35% 26% 20% 20% 16% 17% 24%  9%
    Spec 4 74% 73% 75% 74% 73% 75% 74% 73% 75%
    Cutoff 5 0.0504 0.0504 0.0504 0.0504 0.0504 0.0504 0.0504 0.0504 0.0504
    Sens 5 22% 28% 22% 14%  9% 15% 13% 16%  9%
    Spec 5 84% 83% 81% 84% 83% 81% 84% 83% 81%
    Cutoff 6 0.0526 0.0526 0.0526 0.0526 0.0526 0.0526 0.0526 0.0526 0.0526
    Sens 6  8%  8% 10%  8%  7%  8% 11% 12%  5%
    Spec 6 92% 90% 91% 92% 90% 91% 92% 90% 91%
    OR Quart 2 0.54 0.45 0.83 1.6 2.1 1.8 1.7 0.60 3.8
    p Value 0.042 0.1 1 0.54 0.11 0.12 0.049 0.25 0.48 0.021
    95% CI of 0.30 0.17 0.45 0.90 0.82 1.0 0.68 0.14 1.2
    OR Quart 2 0.98 1.2 1.5 2.8 5.2 3.4 4.3 2.5 12
    OR Quart 3 0.60 0.76 0.74 1.2 2.1 1.4 1.9 2.3 3.2
    p Value 0.084 0.52 0.35 0.53 0.12 0.34 0.18 0.14 0.048
    95% CI of 0.34 0.33 0.40 0.67 0.82 0.72 0.75 0.77 1.0
    OR Quart 3 1.1 1.8 1.4 2.2 5.2 2.5 4.6 6.6 10
    OR Quart 4 1.1 0.84 1.3 1.6 1.6 2.1 1.4 1.2 3.9
    p Value 0.76 0.68 0.37 0.11 0.34 0.018 0.47 0.76 0.020
    95% CI of 0.64 0.37 0.74 0.90 0.61 1.1 0.55 0.36 1.2
    OR Quart 4 1.8 1.9 2.3 2.8 4.2 3.7 3.7 4.0 12
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.515 0.812 0.515 0.584 0.515 0.584
    Average 1.72 3.44 1.72 3.13 1.72 1.59
    Stdev 7.00 16.1 7.00 15.0 7.00 3.45
    p (t-test) 0.082 0.13 0.90
    Min 0.146 0.146 0.146 0.146 0.146 0.146
    Max 125 161 125 163 125 13.6
    n (Samp) 462 120 462 130 462 47
    n (Patient) 223 120 223 130 223 47
    sCr only
    Median 0.584 0.604 0.584 0.737 0.584 0.625
    Average 2.20 2.18 2.20 3.16 2.20 2.44
    Stdev 13.0 6.16 13.0 8.29 13.0 4.49
    p (t-test) 0.99 0.62 0.93
    Min 0.146 0.146 0.146 0.146 0.146 0.146
    Max 291 29.9 291 43.8 291 13.6
    n (Samp) 1019 40 1019 46 1019 26
    n (Patient) 375 40 375 46 375 26
    UO only
    Median 0.584 0.812 0.584 0.584 0.584 0.484
    Average 1.83 5.88 1.83 4.24 1.83 1.66
    Stdev 7.17 23.3 7.17 18.7 7.17 5.26
    p (t-test) 0.0021 0.030 0.88
    Min 0.146 0.146 0.146 0.146 0.146 0.146
    Max 125 166 125 163 125 33.0
    n (Samp) 436 108 436 119 436 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.60 0.50 0.60 0.56 0.59 0.51 0.51 0.53 0.46
    SE 0.030 0.047 0.031 0.029 0.045 0.030 0.044 0.058 0.047
    p 5.6E−4 0.99 9.7E−4 0.054 0.046 0.65 0.81 0.65 0.37
    nCohort 1 462 1019 436 462 1019 436 462 1019 436
    nCohort 2 120 40 108 130 46 119 47 26 44
    Cutoff 1 0.551 0.320 0.584 0.336 0.512 0.320 0.336 0.320 0.336
    Sens 1 70% 78% 71% 72% 74% 76% 77% 73% 73%
    Spec 1 52% 30% 50% 39% 44% 31% 39% 30% 36%
    Cutoff 2 0.320 0.319 0.483 0.319 0.336 0.319 0.282 0.319 0.319
    Sens 2 81% 82% 81% 82% 80% 82% 85% 81% 82%
    Spec 2 35% 26% 44% 29% 34% 27% 18% 26% 23%
    Cutoff 3 0.282 0.254 0.282 0.301 0.254 0.301 0.254 0.301 0.264
    Sens 3 92% 92% 93% 91% 93% 91% 91% 92% 91%
    Spec 3 18%  8% 18% 18%  8% 18%  9% 17% 14%
    Cutoff 4 0.816 1.04 1.04 0.816 1.04 1.04 0.816 1.04 1.04
    Sens 4 38% 20% 31% 35% 39% 23% 26% 27% 14%
    Spec 4 71% 72% 72% 71% 72% 72% 71% 72% 72%
    Cutoff 5 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12
    Sens 5 27% 20% 31% 22% 33% 20% 17% 23% 14%
    Spec 5 83% 81% 80% 83% 81% 80% 83% 81% 80%
    Cutoff 6 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59
    Sens 6  7%  8% 11%  8% 11%  9%  9% 15%  7%
    Spec 6 94% 94% 94% 94% 94% 94% 94% 94% 94%
    OR Quart 2 1.7 1.7 2.6 1.8 1.0 2.2 1.1 1.0 1.9
    p Value 0.14 0.27 0.0087 0.057 1.0 0.010 0.82 1.0 0.21
    95% CI of 0.85 0.68 1.3 0.98 0.37 1.2 0.45 0.29 0.69
    OR Quart 2 3.3 4.1 5.2 3.2 2.7 3.9 2.7 3.5 5.4
    OR Quart 3 3.7 1.5 2.9 2.0 1.8 1.7 1.8 1.8 3.4
    p Value 3.6E−5 0.37 0.0026 0.016 0.20 0.075 0.16 0.29 0.014
    95% CI of 2.0 0.61 1.5 1.1 0.74 0.95 0.79 0.60 1.3
    OR Quart 3 7.0 3.8 5.8 3.7 4.3 3.2 4.1 5.5 8.8
    OR Quart 4 2.4 0.88 3.2 1.7 2.1 1.3 0.88 1.4 1.5
    p Value 0.0096 0.80 0.0011 0.077 0.10 0.44 0.80 0.57 0.43
    95% CI of 1.2 0.31 1.6 0.94 0.86 0.68 0.35 0.44 0.53
    OR Quart 4 4.5 2.4 6.3 3.1 4.9 2.4 2.3 4.5 4.5
    Thyrotropin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.1000 0.118 0.1000 0.106 0.1000 0.124
    Average 0.296 0.126 0.296 0.195 0.296 0.214
    Stdev 1.96 0.0588 1.96 0.250 1.96 0.408
    p (t-test) 0.55 0.71 0.83
    Min 0.0321 0.0383 0.0321 0.0574 0.0321 0.0189
    Max 21.8 0.303 21.8 1.58 21.8 2.18
    n (Samp) 122 47 122 51 122 26
    n (Patient) 99 47 99 51 99 26
    sCr only
    Median 0.106 0.132 0.106 0.123 0.106 0.123
    Average 0.232 0.129 0.232 0.152 0.232 0.130
    Stdev 1.35 0.0472 1.35 0.0958 1.35 0.0635
    p (t-test) 0.78 0.80 0.79
    Min 0.0321 0.0383 0.0321 0.0698 0.0321 0.0189
    Max 21.8 0.198 21.8 0.430 21.8 0.248
    n (Samp) 262 14 262 19 262 13
    n (Patient) 160 14 160 19 160 13
    UO only
    Median 0.109 0.118 0.109 0.105 0.109 0.130
    Average 0.322 0.126 0.322 0.202 0.322 0.234
    Stdev 2.05 0.0582 2.05 0.257 2.05 0.431
    p (t-test) 0.53 0.69 0.84
    Min 0.0230 0.0403 0.0230 0.0574 0.0230 0.0383
    Max 21.8 0.303 21.8 1.58 21.8 2.18
    n (Samp) 111 44 111 47 111 23
    n (Patient) 86 44 86 47 86 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.56 0.52 0.60 0.59 0.57 0.58 0.55 0.59
    SE 0.050 0.082 0.052 0.048 0.071 0.051 0.064 0.084 0.068
    p 0.22 0.43 0.71 0.036 0.22 0.15 0.19 0.56 0.17
    nCohort 1 122 262 111 122 262 111 122 262 111
    nCohort 2 47 14 44 51 19 47 26 13 23
    Cutoff 1 0.0862 0.114 0.0862 0.0930 0.105 0.0930 0.0862 0.104 0.0950
    Sens 1 70% 71% 70% 71% 74% 72% 73% 77% 74%
    Spec 1 41% 55% 36% 45% 50% 41% 41% 49% 42%
    Cutoff 2 0.0698 0.0808 0.0780 0.0854 0.0918 0.0854 0.0666 0.0877 0.0666
    Sens 2 81% 86% 82% 80% 84% 81% 81% 85% 83%
    Spec 2 28% 31% 32% 40% 41% 35% 25% 37% 19%
    Cutoff 3 0.0617 0.0715 0.0627 0.0717 0.0717 0.0717 0.0509 0.0360 0.0608
    Sens 3 91% 93% 91% 92% 95% 91% 92% 92% 91%
    Spec 3 21% 23% 18% 29% 23% 24% 11%  2% 17%
    Cutoff 4 0.146 0.154 0.151 0.146 0.154 0.151 0.146 0.154 0.151
    Sens 4 32% 43% 27% 33% 32% 34% 38% 31% 48%
    Spec 4 71% 71% 70% 71% 71% 70% 71% 71% 70%
    Cutoff 5 0.161 0.186 0.170 0.161 0.186 0.170 0.161 0.186 0.170
    Sens 5 21%  7% 18% 27% 21% 30% 31% 23% 35%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 0.212 0.248 0.215 0.212 0.248 0.215 0.212 0.248 0.215
    Sens 6  6%  0%  7% 22% 11% 23% 15%  0% 17%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.2 1.0 1.7 2.8 2.6 5.0 0.46 1.5 0.97
    p Value 0.79 1.0 0.33 0.052 0.26 0.0032 0.29 0.66 0.96
    95% CI of 0.40 0.14 0.59 0.99 0.49 1.7 0.10 0.24 0.25
    OR Quart 2 3.4 7.3 4.7 7.7 14 14 2.0 9.3 3.7
    OR Quart 3 2.9 2.6 2.1 2.5 4.4 1.4 1.4 2.6 0.56
    p Value 0.035 0.26 0.15 0.084 0.068 0.56 0.55 0.27 0.46
    95% CI of 1.1 0.49 0.76 0.89 0.90 0.44 0.44 0.48 0.12
    OR Quart 3 7.7 14 5.8 7.0 21 4.6 4.6 14 2.6
    OR Quart 4 1.8 2.6 1.3 2.7 2.0 3.0 1.7 1.5 2.3
    p Value 0.24 0.26 0.63 0.061 0.42 0.050 0.39 0.66 0.17
    95% CI of 0.67 0.49 0.45 0.96 0.36 1.00 0.52 0.24 0.70
    OR Quart 4 5.0 14 3.7 7.4 11 8.8 5.3 9.3 7.8
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 277 318 277 351 277 366
    Average 300 374 300 365 300 374
    Stdev 237 217 237 181 237 229
    p (t-test) 0.011 0.018 0.096
    Min 1.37 1.37 1.37 1.37 1.37 1.37
    Max 2070 1280 2070 901 2070 942
    n (Samp) 217 90 217 94 217 32
    n (Patient) 128 90 128 94 128 32
    sCr only
    Median 318 359 318 375 318 307
    Average 339 387 339 398 339 372
    Stdev 246 241 246 213 246 295
    p (t-test) 0.32 0.19 0.59
    Min 1.37 2.36 1.37 3.28 1.37 1.37
    Max 2750 901 2750 913 2750 942
    n (Samp) 513 28 513 32 513 18
    n (Patient) 240 28 240 32 240 18
    UO only
    Median 282 346 282 351 282 354
    Average 310 378 310 356 310 375
    Stdev 240 213 240 167 240 200
    p (t-test) 0.026 0.11 0.15
    Min 1.37 1.37 1.37 1.37 1.37 2.01
    Max 2070 1280 2070 901 2070 854
    n (Samp) 227 80 227 84 227 31
    n (Patient) 122 80 122 84 122 31
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.61 0.55 0.62 0.62 0.59 0.61 0.62 0.51 0.62
    SE 0.036 0.057 0.038 0.036 0.054 0.037 0.056 0.070 0.057
    p 0.0022 0.34 0.0022 7.9E−4 0.100 0.0038 0.039 0.91 0.034
    nCohort 1 217 513 227 217 513 227 217 513 227
    nCohort 2 90 28 80 94 32 84 32 18 31
    Cutoff 1 249 230 249 251 251 277 249 166 282
    Sens 1 71% 71% 74% 71% 72% 71% 72% 72% 71%
    Spec 1 44% 32% 42% 46% 38% 48% 44% 20% 52%
    Cutoff 2 208 179 208 208 208 219 166 130 247
    Sens 2 80% 82% 81% 81% 81% 81% 81% 83% 81%
    Spec 2 37% 24% 36% 37% 28% 38% 29% 14% 41%
    Cutoff 3 136 127 136 161 160 163 39.3 0 130
    Sens 3 90% 93% 90% 90% 91% 90% 91% 100%  90%
    Spec 3 22% 13% 19% 26% 16% 23% 10%  0% 18%
    Cutoff 4 386 414 386 386 414 386 386 414 386
    Sens 4 42% 32% 46% 43% 41% 42% 41% 39% 39%
    Spec 4 71% 70% 71% 71% 70% 71% 71% 70% 71%
    Cutoff 5 440 468 440 440 468 440 440 468 440
    Sens 5 33% 32% 38% 30% 34% 26% 38% 33% 35%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 496 572 509 496 572 509 496 572 509
    Sens 6 26% 21% 24% 24% 25% 17% 25% 28% 23%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.3 1.6 1.7 2.3 1.2 2.0 1.2 0.27 0.98
    p Value 0.030 0.40 0.18 0.030 0.78 0.088 0.75 0.11 0.98
    95% CI of 1.1 0.52 0.78 1.1 0.38 0.90 0.35 0.056 0.27
    OR Quart 2 5.0 5.1 3.7 5.0 3.6 4.4 4.2 1.3 3.6
    OR Quart 3 1.9 1.2 1.4 2.8 1.2 2.6 1.9 0.27 1.9
    p Value 0.094 0.76 0.44 0.0084 0.78 0.018 0.26 0.11 0.26
    95% CI of 0.89 0.36 0.61 1.3 0.38 1.2 0.61 0.056 0.61
    OR Quart 3 4.2 4.1 3.1 5.9 3.6 5.6 6.1 1.3 6.1
    OR Quart 4 3.1 1.8 3.1 2.8 2.1 2.7 2.7 0.99 2.7
    p Value 0.0033 0.28 0.0033 0.0084 0.16 0.012 0.081 0.99 0.082
    95% CI of 1.5 0.60 1.5 1.3 0.76 1.2 0.88 0.34 0.88
    OR Quart 4 6.6 5.6 6.6 5.9 5.7 5.9 8.1 2.9 8.1
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0967 0.0974 0.0967 0.0974 0.0967 5.72
    Average 7.58 12.0 7.58 9.69 7.58 15.2
    Stdev 17.4 24.3 17.4 19.9 17.4 18.2
    p (t-test) 0.023 0.24 0.0045
    Min 0.0238 0.0348 0.0238 0.0238 0.0238 0.0369
    Max 126 125 126 108 126 67.1
    n (Samp) 462 120 462 130 462 47
    n (Patient) 223 120 223 130 223 47
    sCr only
    Median 0.0967 0.0974 0.0967 0.0967 0.0967 0.113
    Average 7.94 7.91 7.94 9.73 7.94 14.4
    Stdev 18.2 16.7 18.2 19.4 18.2 19.7
    p (t-test) 0.99 0.52 0.075
    Min 0.0238 0.0348 0.0238 0.0348 0.0238 0.0369
    Max 126 60.4 126 77.3 126 67.1
    n (Samp) 1019 40 1019 46 1019 26
    n (Patient) 375 40 375 46 375 26
    UO only
    Median 0.0974 0.0974 0.0974 0.0974 0.0974 2.50
    Average 7.12 13.5 7.12 8.00 7.12 10.7
    Stdev 16.4 26.2 16.4 18.0 16.4 14.9
    p (t-test) 0.0015 0.61 0.16
    Min 0.0238 0.0348 0.0238 0.0238 0.0238 0.0348
    Max 126 125 126 108 126 57.3
    n (Samp) 436 108 436 119 436 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 0.50 0.56 0.52 0.53 0.51 0.65 0.61 0.59
    SE 0.030 0.047 0.032 0.029 0.044 0.030 0.045 0.059 0.047
    p 0.093 0.92 0.066 0.41 0.45 0.68 6.6E−4 0.061 0.044
    nCohort 1 462 1019 436 462 1019 436 462 1019 436
    nCohort 2 120 40 108 130 46 119 47 26 44
    Cutoff 1 0.0724 0.0656 0.0724 0.0709 0.0709 0.0709 0.0815 0.0724 0.0724
    Sens 1 73% 75% 74% 70% 72% 71% 70% 77% 70%
    Spec 1 39% 29% 36% 36% 37% 33% 47% 41% 36%
    Cutoff 2 0.0656 0.0398 0.0709 0.0435 0.0606 0.0435 0.0709 0.0672 0.0656
    Sens 2 83% 80% 81% 81% 80% 81% 81% 81% 82%
    Spec 2 29% 14% 33% 19% 26% 17% 36% 33% 26%
    Cutoff 3 0.0369 0.0348 0.0398 0.0369 0.0369 0.0348 0.0398 0.0398 0.0369
    Sens 3 90% 92% 91% 90% 93% 92% 91% 92% 95%
    Spec 3  8%  7% 12%  8% 11%  6% 14% 14%  9%
    Cutoff 4 0.311 0.311 0.311 0.311 0.311 0.311 0.311 0.311 0.311
    Sens 4 26% 22% 30% 29% 30% 28% 60% 46% 50%
    Spec 4 71% 73% 72% 71% 73% 72% 71% 73% 72%
    Cutoff 5 10.9 12.7 9.75 10.9 12.7 9.75 10.9 12.7 9.75
    Sens 5 24% 20% 28% 25% 24% 23% 47% 42% 36%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 28.7 30.2 27.4 28.7 30.2 27.4 28.7 30.2 27.4
    Sens 6 20% 15% 21% 15% 15% 11% 21% 19% 14%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.0 0.89 2.9 0.96 1.8 0.95 1.3 1.0 1.0
    p Value 0.020 0.81 0.0015 0.89 0.16 0.86 0.61 1.0 1.0
    95% CI of 1.1 0.36 1.5 0.55 0.79 0.52 0.47 0.29 0.36
    OR Quart 2 3.7 2.2 5.6 1.7 4.2 1.7 3.6 3.5 2.8
    OR Quart 3 1.8 1.2 1.9 1.1 1.0 1.2 1.3 0.80 1.0
    p Value 0.050 0.67 0.065 0.78 1.0 0.58 0.61 0.74 1.0
    95% CI of 1.00 0.51 0.96 0.62 0.39 0.66 0.47 0.21 0.36
    OR Quart 3 3.4 2.8 3.8 1.9 2.6 2.1 3.6 3.0 2.8
    OR Quart 4 1.7 0.89 2.4 1.2 1.3 1.2 3.6 2.5 2.8
    p Value 0.097 0.81 0.011 0.49 0.51 0.58 0.0052 0.096 0.019
    95% CI of 0.91 0.36 1.2 0.70 0.56 0.66 1.5 0.85 1.2
    OR Quart 4 3.1 2.2 4.7 2.1 3.2 2.1 8.7 7.1 6.6
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.733 0.670 0.733 0.896 0.733 0.957
    Average 1.33 1.05 1.33 2.36 1.33 4.27
    Stdev 4.52 1.46 4.52 5.77 4.52 17.0
    p (t-test) 0.63 0.17 0.072
    Min 0.0319 0.0319 0.0319 0.0319 0.0319 0.0558
    Max 53.9 7.51 53.9 42.8 53.9 85.6
    n (Samp) 155 61 155 60 155 25
    n (Patient) 109 61 109 60 109 25
    sCr only
    Median 0.733 0.733 0.733 0.398 0.733 0.660
    Average 1.92 1.67 1.92 1.63 1.92 0.908
    Stdev 6.94 2.39 6.94 2.27 6.94 1.12
    p (t-test) 0.88 0.84 0.59
    Min 0.0319 0.0319 0.0319 0.0558 0.0319 0.0319
    Max 85.6 9.68 85.6 7.59 85.6 3.90
    n (Samp) 338 20 338 23 338 14
    n (Patient) 184 20 184 23 184 14
    UO only
    Median 0.733 0.733 0.733 0.923 0.733 0.957
    Average 1.20 1.20 1.20 2.56 1.20 4.79
    Stdev 4.49 1.52 4.49 6.01 4.49 17.6
    p (t-test) 1.00 0.079 0.034
    Min 0.0319 0.0319 0.0319 0.0319 0.0319 0.0319
    Max 53.9 7.51 53.9 42.8 53.9 85.6
    n (Samp) 155 54 155 56 155 23
    n (Patient) 99 54 99 56 99 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.47 0.51 0.55 0.55 0.51 0.61 0.55 0.48 0.63
    SE 0.044 0.067 0.046 0.044 0.063 0.045 0.064 0.080 0.066
    p 0.44 0.86 0.29 0.23 0.85 0.019 0.39 0.84 0.052
    nCohort 1 155 338 155 155 338 155 155 338 155
    nCohort 2 61 20 54 60 23 56 25 14 23
    Cutoff 1 0.184 0.141 0.141 0.141 0.0585 0.341 0.382 0.141 0.382
    Sens 1 72% 70% 76% 72% 78% 71% 72% 71% 74%
    Spec 1 25% 28% 30% 25% 16% 39% 32% 28% 39%
    Cutoff 2 0.0558 0.0558 0.0558 0.0558 0.0558 0.0558 0.0439 0.0439 0.0439
    Sens 2 90% 80% 91% 82% 83% 82% 100%  93% 96%
    Spec 2 14% 16% 15% 14% 16% 15% 10% 10% 13%
    Cutoff 3 0.0558 0 0.0558 0.0439 0.0439 0 0.0439 0.0439 0.0439
    Sens 3 90% 100%  91% 92% 100%  100%  100%  93% 96%
    Spec 3 14%  0% 15% 10% 10%  0% 10% 10% 13%
    Cutoff 4 0.923 0.957 0.923 0.923 0.957 0.923 0.923 0.957 0.923
    Sens 4 25% 40% 31% 43% 35% 43% 52% 21% 57%
    Spec 4 72% 76% 74% 72% 76% 74% 72% 76% 74%
    Cutoff 5 1.05 1.37 0.957 1.05 1.37 0.957 1.05 1.37 0.957
    Sens 5 21% 35% 30% 37% 30% 36% 20% 14% 30%
    Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 2.07 3.12 1.88 2.07 3.12 1.88 2.07 3.12 1.88
    Sens 6 20% 20% 28% 27% 17% 29% 12%  7% 22%
    Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 0.91 0.81 1.4 0.59 0.48 0.59 0.81 1.3 0.56
    p Value 0.82 0.74 0.50 0.24 0.24 0.30 0.75 0.70 0.44
    95% CI of 0.38 0.24 0.56 0.24 0.14 0.22 0.23 0.29 0.12
    OR Quart 2 2.2 2.8 3.3 1.4 1.6 1.6 2.9 6.2 2.5
    OR Quart 3 1.4 0.16 0.79 0.59 0.35 1.4 1.4 1.0 1.7
    p Value 0.40 0.090 0.63 0.24 0.13 0.41 0.56 1.0 0.37
    95% CI of 0.62 0.019 0.31 0.24 0.091 0.60 0.44 0.20 0.52
    OR Quart 3 3.3 1.3 2.0 1.4 1.4 3.4 4.4 5.1 5.8
    OR Quart 4 1.2 1.3 1.6 1.6 0.99 2.0 1.0 1.3 1.4
    p Value 0.67 0.59 0.30 0.26 0.98 0.11 1.0 0.70 0.56
    95% CI of 0.52 0.45 0.66 0.71 0.35 0.86 0.30 0.29 0.42
    OR Quart 4 2.8 4.1 3.7 3.5 2.8 4.7 3.4 6.2 4.9
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0407 0.0682 0.0407 0.0682 0.0407 0.397
    Average 0.473 0.722 0.473 0.778 0.473 0.991
    Stdev 1.04 1.54 1.04 1.57 1.04 1.96
    p (t-test) 0.17 0.099 0.048
    Min 0.0116 0.0116 0.0116 0.0116 0.0116 0.0393
    Max 5.79 8.53 5.79 8.07 5.79 9.43
    n (Samp) 155 61 155 60 155 25
    n (Patient) 109 61 109 60 109 25
    sCr only
    Median 0.0682 0.0682 0.0682 0.0682 0.0682 0.403
    Average 0.598 1.28 0.598 0.648 0.598 1.32
    Stdev 1.31 2.31 1.31 1.19 1.31 1.56
    p (t-test) 0.034 0.86 0.047
    Min 0.0116 0.0116 0.0116 0.0210 0.0116 0.0116
    Max 9.43 10.0 9.43 4.35 9.43 4.63
    n (Samp) 338 20 338 23 338 14
    n (Patient) 184 20 184 23 184 14
    UO only
    Median 0.0407 0.0682 0.0407 0.0400 0.0407 0.397
    Average 0.402 0.853 0.402 0.737 0.402 0.930
    Stdev 0.925 1.66 0.925 1.54 0.925 2.00
    p (t-test) 0.014 0.056 0.035
    Min 0.0116 0.0116 0.0116 0.0116 0.0116 0.0116
    Max 5.79 8.53 5.79 8.07 5.79 9.43
    n (Samp) 156 54 156 56 156 23
    n (Patient) 100 54 100 56 100 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 0.55 0.60 0.54 0.56 0.51 0.74 0.71 0.67
    SE 0.044 0.068 0.046 0.044 0.064 0.045 0.060 0.079 0.065
    p 0.22 0.45 0.027 0.37 0.35 0.74 7.0E−5 0.0068 0.010
    nCohort 1 155 338 156 155 338 156 155 338 156
    nCohort 2 61 20 54 60 23 56 25 14 23
    Cutoff 1 0.0358 0.0400 0.0400 0.0255 0.0358 0.0116 0.0682 0.0838 0.0400
    Sens 1 70% 70% 72% 78% 83% 88% 80% 79% 74%
    Spec 1 38% 37% 40% 26% 33% 13% 64% 60% 40%
    Cutoff 2 0.0255 0.0116 0.0262 0.0116 0.0358 0.0116 0.0682 0.0544 0.0358
    Sens 2 87% 80% 91% 92% 83% 88% 80% 86% 87%
    Spec 2 26% 10% 26%  9% 33% 13% 64% 46% 38%
    Cutoff 3 0.0116 0 0.0262 0.0116 0.0255 0 0.0358 0.0358 0.0116
    Sens 3 92% 100%  91% 92% 91% 100%  100%  93% 96%
    Spec 3  9%  0% 26%  9% 21%  0% 38% 33% 13%
    Cutoff 4 0.0994 0.397 0.0994 0.0994 0.397 0.0994 0.0994 0.397 0.0994
    Sens 4 31% 45% 37% 37% 22% 38% 68% 50% 61%
    Spec 4 72% 79% 75% 72% 79% 75% 72% 79% 75%
    Cutoff 5 0.397 0.465 0.397 0.397 0.465 0.397 0.397 0.465 0.397
    Sens 5 26% 45% 30% 23% 22% 23% 32% 43% 26%
    Spec 5 82% 80% 85% 82% 80% 85% 82% 80% 85%
    Cutoff 6 1.75 1.99 1.58 1.75 1.99 1.58 1.75 1.99 1.58
    Sens 6 13% 15% 19% 17% 13% 14% 16% 36% 17%
    Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 2.2 0.99 2.0 1.2 2.8 0.62 >4.4 1.0 1.3
    p Value 0.082 0.99 0.17 0.70 0.13 0.28 <0.19 1.0 0.72
    95% CI of 0.90 0.28 0.75 0.50 0.73 0.26 >0.47 0.062 0.28
    OR Quart 2 5.4 3.5 5.2 2.8 11 1.5 na 16 6.3
    OR Quart 3 2.0 0.19 2.4 1.4 2.1 0.27 >15 5.2 0.98
    p Value 0.12 0.13 0.067 0.42 0.31 0.013 <0.012 0.13 0.98
    95% CI of 0.83 0.022 0.94 0.60 0.50 0.097 >1.8 0.60 0.19
    OR Quart 3 4.9 1.7 6.4 3.3 8.6 0.75 na 46 5.1
    OR Quart 4 1.9 1.9 2.4 1.2 2.0 1.4 >13 7.5 5.6
    p Value 0.18 0.28 0.075 0.70 0.32 0.42 <0.017 0.062 0.012
    95% CI of 0.75 0.60 0.92 0.50 0.50 0.63 >1.6 0.91 1.5
    OR Quart 4 4.6 5.8 6.2 2.8 8.5 3.1 na 62 21
    Immunoglogulin G4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 163 269 163 282 163 167
    Average 430 558 430 525 430 487
    Stdev 667 726 667 697 667 702
    p (t-test) 0.069 0.16 0.58
    Min 0.619 1.73 0.619 2.63 0.619 4.92
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 461 119 461 126 461 47
    n (Patient) 222 119 222 126 222 47
    sCr only
    Median 210 293 210 358 210 291
    Average 479 521 479 589 479 542
    Stdev 689 736 689 742 689 675
    p (t-test) 0.71 0.29 0.65
    Min 0.00642 28.3 0.00642 5.21 0.00642 8.44
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 1011 40 1011 46 1011 26
    n (Patient) 373 40 373 46 373 26
    UO only
    Median 203 309 203 307 203 172
    Average 482 603 482 552 482 497
    Stdev 702 741 702 708 702 707
    p (t-test) 0.12 0.35 0.89
    Min 0.619 1.73 0.619 2.63 0.619 4.92
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 433 107 433 115 433 44
    n (Patient) 171 107 171 115 171 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.60 0.56 0.58 0.58 0.56 0.56 0.53 0.55 0.50
    SE 0.030 0.048 0.032 0.029 0.045 0.031 0.045 0.059 0.046
    p 0.0012 0.25 0.0089 0.0055 0.20 0.040 0.49 0.37 0.94
    nCohort 1 461 1011 433 461 1011 433 461 1011 433
    nCohort 2 119 40 107 126 46 115 47 26 44
    Cutoff 1 146 146 181 113 107 129 80.8 120 78.5
    Sens 1 71% 70% 70% 71% 72% 70% 70% 73% 70%
    Spec 1 47% 40% 49% 42% 33% 38% 34% 36% 30%
    Cutoff 2 75.7 108 93.8 80.8 55.4 98.1 55.4 53.9 55.4
    Sens 2 81% 80% 80% 80% 80% 80% 81% 81% 82%
    Spec 2 34% 33% 32% 34% 23% 32% 29% 23% 25%
    Cutoff 3 28.9 48.3 27.6 21.5 27.6 21.3 20.5 11.3 26.1
    Sens 3 91% 90% 91% 90% 91% 90% 91% 92% 91%
    Spec 3 15% 21% 12% 12% 14%  9% 11%  7% 11%
    Cutoff 4 356 402 402 356 402 402 356 402 402
    Sens 4 34% 22% 38% 41% 46% 37% 30% 42% 30%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 523 597 587 523 597 587 523 597 587
    Sens 5 26% 18% 26% 27% 28% 26% 26% 27% 23%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1470 1640 1910 1470 1640 1910 1470 1640 1910
    Sens 6 13% 12% 11% 12% 13% 10% 13%  8%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.2 0.62 1.5 1.4 0.72 1.6 1.5 0.66 1.6
    p Value 0.61 0.40 0.24 0.35 0.49 0.15 0.37 0.53 0.28
    95% CI of 0.61 0.20 0.77 0.72 0.28 0.84 0.62 0.18 0.68
    OR Quart 2 2.4 1.9 2.9 2.6 1.8 3.0 3.6 2.4 3.9
    OR Quart 3 3.3 2.3 2.4 2.4 0.91 2.1 1.4 1.0 1.1
    p Value 1.2E−4 0.051 0.0064 0.0033 0.82 0.023 0.50 1.0 0.81
    95% CI of 1.8 1.00 1.3 1.3 0.38 1.1 0.56 0.32 0.44
    OR Quart 3 6.0 5.5 4.6 4.4 2.2 3.8 3.4 3.1 2.9
    OR Quart 4 2.2 1.1 2.1 2.3 1.6 2.1 1.5 1.7 1.2
    p Value 0.016 0.81 0.028 0.0070 0.25 0.023 0.37 0.32 0.65
    95% CI of 1.2 0.43 1.1 1.3 0.72 1.1 0.62 0.60 0.49
    OR Quart 4 4.0 3.0 4.0 4.1 3.4 3.8 3.6 4.7 3.1
    Interleukin-21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 9.57 4.21 9.57 4.50 9.57 5.09
    Average 11.9 7.35 11.9 8.30 11.9 8.54
    Stdev 11.4 8.68 11.4 10.1 11.4 10.4
    p (t-test) 4.2E−5 9.9E−4 0.049
    Min 0.00404 0.00411 0.00404 0.0122 0.00404 0.0210
    Max 87.9 56.2 87.9 59.4 87.9 49.5
    n (Samp) 463 120 463 130 463 47
    n (Patient) 223 120 223 130 223 47
    sCr only
    Median 7.83 7.12 7.83 5.28 7.83 3.77
    Average 10.7 10.9 10.7 8.66 10.7 5.91
    Stdev 11.1 12.0 11.1 8.54 11.1 6.18
    p (t-test) 0.89 0.23 0.030
    Min 0.00404 0.0177 0.00404 0.0122 0.00404 0.0210
    Max 87.9 56.2 87.9 41.5 87.9 20.6
    n (Samp) 1019 40 1019 46 1019 26
    n (Patient) 375 40 375 46 375 26
    UO only
    Median 9.33 3.57 9.33 4.53 9.33 5.20
    Average 11.6 6.81 11.6 8.06 11.6 8.62
    Stdev 11.1 7.25 11.1 9.91 11.1 10.6
    p (t-test) 2.0E−5 0.0016 0.085
    Min 0.00404 0.00404 0.00404 0.0122 0.00404 0.0177
    Max 87.9 30.5 87.9 59.4 87.9 49.5
    n (Samp) 435 108 435 119 435 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.36 0.50 0.36 0.38 0.47 0.39 0.38 0.37 0.39
    SE 0.030 0.047 0.031 0.029 0.044 0.030 0.045 0.059 0.047
    p 2.4E−6 0.95 5.5E−6 6.4E−5 0.47 1.4E−4 0.010 0.027 0.024
    nCohort 1 463 1019 435 463 1019 435 463 1019 435
    nCohort 2 120 40 108 130 46 119 47 26 44
    Cutoff 1 1.82 3.10 1.62 1.99 3.10 1.76 1.29 0.728 1.57
    Sens 1 71% 70% 70% 70% 72% 71% 70% 73% 70%
    Spec 1 17% 32% 17% 18% 32% 17% 13% 14% 17%
    Cutoff 2 1.05 2.19 1.03 1.37 2.16 1.13 0.689 0.418 0.362
    Sens 2 80% 80% 81% 80% 80% 81% 81% 81% 82%
    Spec 2 11% 24% 13% 13% 24% 13%  9% 12%  9%
    Cutoff 3 0.0528 0.313 0.0528 0.296 0.968 0.227 0.136 0.0350 0.136
    Sens 3 90% 90% 91% 90% 91% 91% 91% 92% 91%
    Spec 3  4% 11%  6%  7% 15%  9%  6%  5%  8%
    Cutoff 4 15.8 13.5 14.9 15.8 13.5 14.9 15.8 13.5 14.9
    Sens 4 12% 28% 13% 14% 26% 14% 17% 15% 18%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 19.2 17.9 19.2 19.2 17.9 19.2 19.2 17.9 19.2
    Sens 5 11% 22%  9% 10% 17%  9% 13%  4% 14%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 26.2 25.1 25.4 26.2 25.1 25.4 26.2 25.1 25.4
    Sens 6  3% 12%  2%  5%  4%  5%  6%  0%  7%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.8 0.79 2.1 1.6 0.72 2.0 1.5 3.1 0.87
    p Value 0.12 0.63 0.050 0.14 0.49 0.044 0.44 0.17 0.79
    95% CI of 0.87 0.31 1.0 0.85 0.29 1.0 0.54 0.61 0.30
    OR Quart 2 3.6 2.0 4.4 3.1 1.8 4.0 4.0 15 2.5
    OR Quart 3 3.2 1.3 2.9 2.7 1.6 2.6 1.8 3.1 1.6
    p Value 6.1E−4 0.52 0.0034 0.0015 0.24 0.0052 0.24 0.17 0.35
    95% CI of 1.6 0.57 1.4 1.5 0.73 1.3 0.68 0.61 0.61
    OR Quart 3 6.2 3.1 6.0 5.0 3.5 5.0 4.7 15 4.0
    OR Quart 4 4.4 0.90 4.8 3.2 0.91 3.9 2.9 6.3 2.3
    p Value 9.1E−6 0.82 8.8E−6 1.8E−4 0.83 3.9E−5 0.024 0.017 0.060
    95% CI of 2.3 0.36 2.4 1.7 0.38 2.0 1.1 1.4 0.97
    OR Quart 4 8.4 2.3 9.7 5.8 2.2 7.4 7.1 28 5.6
    Interleukin-23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 392 156 392 186 392 127
    Average 625 311 625 330 625 376
    Stdev 802 435 802 412 802 537
    p (t-test) 4.1E−5 5.8E−5 0.038
    Min 0.491 0.564 0.491 0.491 0.491 0.552
    Max 8520 2340 8520 1760 8520 2000
    n (Samp) 463 120 463 130 463 47
    n (Patient) 223 120 223 130 223 47
    sCr only
    Median 272 185 272 167 272 145
    Average 518 343 518 307 518 333
    Stdev 706 468 706 375 706 454
    p (t-test) 0.12 0.044 0.18
    Min 0.491 0.785 0.491 0.552 0.491 0.491
    Max 8520 2000 8520 1370 8520 1820
    n (Samp) 1019 40 1019 46 1019 26
    n (Patient) 375 40 375 46 375 26
    UO only
    Median 385 138 385 150 385 135
    Average 634 287 634 314 634 358
    Stdev 804 401 804 419 804 500
    p (t-test) 1.6E−5 3.3E−5 0.026
    Min 0.491 0.564 0.491 0.491 0.491 0.552
    Max 8520 2340 8520 1760 8520 2000
    n (Samp) 435 108 435 119 435 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.38 0.47 0.35 0.39 0.43 0.36 0.39 0.43 0.37
    SE 0.030 0.047 0.031 0.029 0.045 0.030 0.045 0.059 0.047
    p 9.5E−5 0.50 2.2E−6 1.3E−4 0.14 6.6E−6 0.013 0.21 0.0044
    nCohort 1 463 1019 435 463 1019 435 463 1019 435
    nCohort 2 120 40 108 130 46 119 47 26 44
    Cutoff 1 38.3 66.6 1.31 3.48 1.41 3.02 1.41 1.41 1.11
    Sens 1 70% 70% 72% 70% 74% 71% 72% 73% 70%
    Spec 1 25% 32% 19% 21% 25% 20% 20% 25% 17%
    Cutoff 2 1.09 21.4 1.05 1.05 1.08 1.01 0.754 1.01 0.723
    Sens 2 81% 80% 81% 81% 83% 81% 85% 81% 82%
    Spec 2 17% 28% 14% 15% 20% 12%  9% 18%  7%
    Cutoff 3 0.844 1.09 0.723 0.723 0.754 0.720 0.720 0.682 0.643
    Sens 3 91% 90% 92% 90% 93% 92% 91% 92% 91%
    Spec 3 11% 21%  7%  9% 11%  7%  8%  6%  3%
    Cutoff 4 735 608 756 735 608 756 735 608 756
    Sens 4 11% 20%  9% 14% 17% 13% 19% 23% 16%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 1120 894 1020 1120 894 1020 1120 894 1020
    Sens 5  6% 10%  6%  5% 11%  9% 11%  8%  9%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1580 1400 1630 1580 1400 1630 1580 1400 1630
    Sens 6  2%  5%  1%  2%  0%  3%  6%  4%  5%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.2 2.0 2.3 1.8 1.8 1.5 1.4 0.66 2.3
    p Value 0.036 0.20 0.040 0.079 0.25 0.28 0.47 0.53 0.10
    95% CI of 1.1 0.69 1.0 0.94 0.68 0.73 0.55 0.19 0.85
    OR Quart 2 4.6 6.0 5.1 3.4 4.5 3.0 3.7 2.4 6.3
    OR Quart 3 5.6 4.0 5.1 2.8 2.2 3.7 1.3 1.5 1.0
    p Value 6.9E−7 0.0065 1.9E−5 9.9E−4 0.087 7.0E−5 0.63 0.43 1.0
    95% CI of 2.8 1.5 2.4 1.5 0.89 1.9 0.48 0.53 0.31
    OR Quart 3 11 11 11 5.1 5.5 7.1 3.3 4.3 3.2
    OR Quart 4 3.6 1.2 4.9 2.9 1.8 3.4 2.5 1.2 3.6
    p Value 4.0E−4 0.76 2.7E−5 6.5E−4 0.25 2.4E−4 0.042 0.77 0.0085
    95% CI of 1.8 0.36 2.3 1.6 0.68 1.8 1.0 0.39 1.4
    OR Quart 4 7.2 4.0 10 5.3 4.5 6.5 5.9 3.5 9.4
    Interleukin-28A
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 20.8 11.8 20.8 10.4 20.8 12.4
    Average 36.5 24.4 36.5 24.9 36.5 26.3
    Stdev 43.7 31.6 43.7 34.6 43.7 39.8
    p (t-test) 0.0048 0.0055 0.12
    Min 0.0254 0.0254 0.0254 0.0254 0.0254 0.0254
    Max 228 168 228 172 228 186
    n (Samp) 463 120 463 130 463 47
    n (Patient) 223 120 223 130 223 47
    sCr only
    Median 16.1 10.1 16.1 10.4 16.1 7.94
    Average 33.0 26.8 33.0 21.8 33.0 20.9
    Stdev 41.3 37.0 41.3 30.9 41.3 29.6
    p (t-test) 0.35 0.071 0.14
    Min 0.0254 0.0777 0.0254 0.0254 0.0254 0.0495
    Max 235 168 235 131 235 89.5
    n (Samp) 1019 40 1019 46 1019 26
    n (Patient) 375 40 375 46 375 26
    UO only
    Median 23.1 11.8 23.1 12.0 23.1 12.3
    Average 37.9 24.0 37.9 25.3 37.9 25.9
    Stdev 44.6 29.8 44.6 34.5 44.6 40.1
    p (t-test) 0.0022 0.0046 0.089
    Min 0.0254 0.0254 0.0254 0.0254 0.0254 0.0254
    Max 228 127 228 172 228 186
    n (Samp) 435 108 435 119 435 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 0.49 0.43 0.44 0.45 0.43 0.43 0.42 0.42
    SE 0.030 0.047 0.032 0.029 0.045 0.030 0.045 0.059 0.047
    p 0.074 0.87 0.025 0.036 0.28 0.018 0.10 0.18 0.087
    nCohort 1 463 1019 435 463 1019 435 463 1019 435
    nCohort 2 120 40 108 130 46 119 47 26 44
    Cutoff 1 0.246 0.246 0.243 0.198 0.216 0.198 0.189 0.176 0.198
    Sens 1 72% 70% 73% 72% 72% 71% 70% 73% 70%
    Spec 1 29% 32% 25% 25% 30% 23% 24% 23% 23%
    Cutoff 2 0.182 0.194 0.176 0.176 0.184 0.155 0.134 0.0996 0.142
    Sens 2 81% 80% 82% 80% 80% 81% 81% 81% 82%
    Spec 2 22% 26% 19% 21% 24% 19% 18% 17% 17%
    Cutoff 3 0.0996 0.149 0.0775 0.0854 0.0854 0.0854 0.0775 0.0775 0.0784
    Sens 3 91% 95% 91% 93% 93% 91% 91% 92% 93%
    Spec 3 16% 20%  7% 12% 12% 11%  7%  6% 10%
    Cutoff 4 51.6 45.8 53.1 51.6 45.8 53.1 51.6 45.8 53.1
    Sens 4 18% 20% 16% 17% 17% 16% 17% 15% 16%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 68.1 62.2 68.3 68.1 62.2 68.3 68.1 62.2 68.3
    Sens 5 11% 15% 10% 11%  9% 11% 15% 15% 14%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 98.2 90.1 96.2 98.2 90.1 96.2 98.2 90.1 96.2
    Sens 6  3%  8%  4%  5%  7%  5%  4%  0%  7%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.6 1.6 1.9 1.7 2.7 2.1 1.6 1.5 1.2
    p Value 0.12 0.34 0.070 0.092 0.063 0.026 0.32 0.52 0.79
    95% CI of 0.88 0.61 0.95 0.92 0.95 1.1 0.61 0.42 0.40
    OR Quart 2 3.0 4.2 3.6 3.1 7.7 4.0 4.4 5.4 3.3
    OR Quart 3 2.6 2.1 2.8 2.6 3.6 2.5 2.0 1.5 2.1
    p Value 0.0013 0.13 0.0017 0.0014 0.014 0.0044 0.17 0.52 0.12
    95% CI of 1.5 0.82 1.5 1.4 1.3 1.3 0.75 0.42 0.83
    OR Quart 3 4.7 5.2 5.3 4.6 9.8 4.7 5.1 5.4 5.5
    OR Quart 4 1.4 1.2 2.0 1.7 2.3 2.4 2.5 2.6 2.3
    p Value 0.26 0.79 0.048 0.069 0.14 0.0060 0.053 0.11 0.077
    95% CI of 0.77 0.41 1.0 0.96 0.77 1.3 0.99 0.80 0.91
    OR Quart 4 2.7 3.2 3.8 3.2 6.6 4.6 6.3 8.3 5.9
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 51.7 28.7 51.7 30.6 51.7 28.5
    Average 66.3 36.4 66.3 41.3 66.3 35.3
    Stdev 72.8 34.8 72.8 37.4 72.8 38.8
    p (t-test) 1.4E−5 1.7E−4 0.0041
    Min 0.0232 0.0372 0.0232 0.0232 0.0232 0.0232
    Max 958 148 958 162 958 155
    n (Samp) 463 120 463 130 463 47
    n (Patient) 223 120 223 130 223 47
    sCr only
    Median 42.7 32.7 42.7 31.8 42.7 18.8
    Average 58.1 38.1 58.1 38.9 58.1 33.3
    Stdev 62.9 30.5 62.9 34.0 62.9 33.5
    p (t-test) 0.046 0.040 0.046
    Min 0.0232 0.0743 0.0232 0.0232 0.0232 0.0591
    Max 958 138 958 133 958 122
    n (Samp) 1019 40 1019 46 1019 26
    n (Patient) 375 40 375 46 375 26
    UO only
    Median 50.4 23.2 50.4 28.8 50.4 33.1
    Average 67.0 35.9 67.0 39.9 67.0 35.2
    Stdev 74.1 38.6 74.1 38.5 74.1 37.5
    p (t-test) 2.9E−5 1.3E−4 0.0051
    Min 0.0232 0.0372 0.0232 0.0232 0.0232 0.0232
    Max 958 203 958 162 958 155
    n (Samp) 435 108 435 119 435 44
    n (Patient) 173 108 173 119 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.36 0.43 0.35 0.39 0.42 0.38 0.35 0.38 0.35
    SE 0.030 0.048 0.031 0.029 0.045 0.030 0.045 0.059 0.047
    p 4.7E−6 0.13 8.1E−7 2.2E−4 0.087 4.4E−5 7.1E−4 0.044 9.5E−4
    nCohort 1 463 1019 435 463 1019 435 463 1019 435
    nCohort 2 120 40 108 130 46 119 47 26 44
    Cutoff 1 12.9 16.3 9.92 16.8 17.0 15.3 4.46 6.25 6.20
    Sens 1 70% 70% 71% 70% 74% 71% 70% 73% 70%
    Spec 1 21% 27% 18% 24% 28% 21% 14% 18% 15%
    Cutoff 2 7.93 12.1 2.92 10.7 6.57 6.58 0.172 2.84 0.172
    Sens 2 80% 80% 81% 80% 80% 81% 81% 81% 82%
    Spec 2 17% 23% 14% 20% 18% 16% 13% 14% 12%
    Cutoff 3 0.0837 7.09 0.0731 0.0768 0.0768 0.0749 0.0591 0.0631 0.0686
    Sens 3 90% 90% 91% 90% 91% 92% 91% 96% 91%
    Spec 3 11% 19%  6%  9% 10%  8%  5%  6%  5%
    Cutoff 4 84.4 74.8 85.3 84.4 74.8 85.3 84.4 74.8 85.3
    Sens 4 10% 15% 11% 14% 20% 12% 11% 12%  9%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 109 96.1 109 109 96.1 109 109 96.1 109
    Sens 5  4%  2%  5%  8%  7%  9%  6%  8%  7%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 145 130 148 145 130 148 145 130 148
    Sens 6  1%  2%  1%  1%  2%  1%  2%  0%  2%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.5 4.1 2.3 1.7 1.1 2.0 1.7 2.4 1.5
    p Value 0.012 0.029 0.031 0.11 0.80 0.057 0.39 0.21 0.52
    95% CI of 1.2 1.2 1.1 0.89 0.43 0.98 0.53 0.61 0.42
    OR Quart 2 5.2 15 5.0 3.2 3.0 4.0 5.2 9.3 5.6
    OR Quart 3 3.9 4.9 3.2 3.2 2.2 3.6 2.8 2.4 4.1
    p Value 1.2E−4 0.014 0.0019 1.8E−4 0.070 1.5E−4 0.059 0.21 0.014
    95% CI of 2.0 1.4 1.5 1.7 0.94 1.9 0.96 0.61 1.3
    OR Quart 3 7.9 17 6.7 5.8 5.2 7.0 8.0 9.3 13
    OR Quart 4 4.7 3.8 5.5 2.6 1.5 3.6 4.9 3.1 5.5
    p Value 1.1E−5 0.042 2.9E−6 0.0022 0.36 1.3E−4 0.0021 0.094 0.0026
    95% CI of 2.4 1.0 2.7 1.4 0.61 1.9 1.8 0.83 1.8
    OR Quart 4 9.4 14 11 4.8 3.8 7.1 13 12 17
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 393 825 393 599 393 370
    Average 584 1020 584 794 584 576
    Stdev 622 838 622 701 622 601
    p (t-test) 1.3E−6 0.0092 0.95
    Min 0.218 0.218 0.218 0.386 0.218 1.13
    Max 4170 3930 4170 4210 4170 2260
    n (Samp) 212 87 212 93 212 31
    n (Patient) 124 87 124 93 124 31
    sCr only
    Median 647 617 647 587 647 448
    Average 807 876 807 747 807 884
    Stdev 796 985 796 809 796 970
    p (t-test) 0.66 0.68 0.69
    Min 0.218 0.218 0.218 0.386 0.218 1.13
    Max 5940 3930 5940 4210 5940 2720
    n (Samp) 504 28 504 32 504 18
    n (Patient) 236 28 236 32 236 18
    UO only
    Median 407 916 407 665 407 455
    Average 612 1160 612 897 612 639
    Stdev 669 1080 669 987 669 684
    p (t-test) 3.3E−7 0.0042 0.84
    Min 0.218 0.218 0.218 0.616 0.218 0.218
    Max 4210 7140 4210 7060 4210 2820
    n (Samp) 224 77 224 83 224 30
    n (Patient) 120 77 120 83 120 30
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.67 0.49 0.70 0.61 0.48 0.62 0.50 0.48 0.51
    SE 0.036 0.056 0.037 0.036 0.053 0.037 0.056 0.070 0.057
    p 2.3E−6 0.89 6.1E−8 0.0018 0.65 0.0018 0.99 0.78 0.83
    nCohort 1 212 504 224 212 504 224 212 504 224
    nCohort 2 87 28 77 93 32 83 31 18 30
    Cutoff 1 524 291 606 346 288 346 140 92.0 196
    Sens 1 70% 71% 70% 71% 72% 72% 71% 72% 73%
    Spec 1 58% 30% 62% 46% 30% 46% 27% 15% 31%
    Cutoff 2 252 54.3 495 262 182 234 11.6 22.6 7.42
    Sens 2 80% 82% 81% 81% 81% 81% 81% 83% 80%
    Spec 2 39% 14% 57% 39% 22% 35% 14% 11% 12%
    Cutoff 3 27.3 1.40 140 113 64.5 119 1.40 1.48 1.40
    Sens 3 91% 93% 91% 90% 91% 90% 94% 94% 93%
    Spec 3 16%  8% 25% 25% 14% 23% 12%  8% 10%
    Cutoff 4 708 1010 710 708 1010 710 708 1010 710
    Sens 4 61% 29% 66% 43% 28% 47% 35% 39% 37%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 975 1360 1070 975 1360 1070 975 1360 1070
    Sens 5 43% 18% 42% 34% 12% 30% 19% 28% 17%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1410 1740 1450 1410 1740 1450 1410 1740 1450
    Sens 6 29% 14% 32% 15%  6% 16% 10% 22% 10%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.68 1.4 0.89 1.8 1.6 1.6 0.63 0 0.58
    p Value 0.37 0.58 0.81 0.13 0.40 0.25 0.41 na 0.37
    95% CI of 0.29 0.46 0.34 0.84 0.52 0.72 0.21 na 0.18
    OR Quart 2 1.6 4.0 2.3 3.9 5.1 3.5 1.9 na 1.9
    OR Quart 3 2.1 1.0 3.4 2.2 2.5 1.9 0.75 0.56 1.3
    p Value 0.051 1.0 0.0030 0.043 0.089 0.094 0.59 0.36 0.61
    95% CI of 1.00 0.31 1.5 1.0 0.87 0.89 0.26 0.16 0.48
    OR Quart 3 4.4 3.2 7.8 4.6 7.4 4.2 2.2 2.0 3.5
    OR Quart 4 3.4 1.4 4.7 3.1 1.4 2.9 1.0 1.0 0.84
    p Value 8.5E−4 0.58 1.6E−4 0.0023 0.56 0.0052 0.97 0.99 0.76
    95% CI of 1.7 0.46 2.1 1.5 0.44 1.4 0.37 0.34 0.29
    OR Quart 4 7.1 4.0 11 6.6 4.6 6.2 2.8 3.0 2.5
    Prostate-specific antigen
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0131 0.0123 0.0131 0.126 nd nd
    Average 4.19 4.25 4.19 7.92 nd nd
    Stdev 7.89 8.36 7.89 9.60 nd nd
    p (t-test) 0.98 0.10 nd nd
    Min 0.00354 0.00392 0.00354 0.00462 nd nd
    Max 20.0 20.0 20.0 20.0 nd nd
    n (Samp) 52 19 52 19 nd nd
    n (Patient) 41 19 41 19 nd nd
    UO only
    Median 0.0140 0.0349 0.0140 0.0849 nd nd
    Average 3.70 4.05 3.70 6.79 nd nd
    Stdev 7.37 8.26 7.37 9.06 nd nd
    p (t-test) 0.88 0.15 nd nd
    Min 0.00354 0.00392 0.00354 0.00462 nd nd
    Max 20.0 20.0 20.0 20.0 nd nd
    n (Samp) 44 15 44 20 nd nd
    n (Patient) 34 15 34 20 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 nd 0.53 0.65 nd 0.63 nd nd nd
    SE 0.079 nd 0.088 0.077 nd 0.078 nd nd nd
    p 0.54 nd 0.71 0.046 nd 0.11 nd nd nd
    nCohort 1 52 nd 44 52 nd 44 nd nd nd
    nCohort 2 19 nd 15 19 nd 20 nd nd nd
    Cutoff 1 0.0105 nd 0.00959 0.0127 nd 0.0135 nd nd nd
    Sens 1 74% nd 73% 74% nd 70% nd nd nd
    Spec 1 44% nd 36% 50% nd 50% nd nd nd
    Cutoff 2 0.00897 nd 0.00870 0.00938 nd 0.0127 nd nd nd
    Sens 2 84% nd 87% 84% nd 80% nd nd nd
    Spec 2 33% nd 25% 37% nd 45% nd nd nd
    Cutoff 3 0.00606 nd 0.00776 0.00776 nd 0.00781 nd nd nd
    Sens 3 95% nd 93% 95% nd 90% nd nd nd
    Spec 3  8% nd 18% 21% nd 18% nd nd nd
    Cutoff 4 0.105 nd 0.127 0.105 nd 0.127 nd nd nd
    Sens 4 26% nd 27% 53% nd 45% nd nd nd
    Spec 4 71% nd 70% 71% nd 70% nd nd nd
    Cutoff 5 11.9 nd 4.24 11.9 nd 4.24 nd nd nd
    Sens 5 21% nd 20% 37% nd 40% nd nd nd
    Spec 5 81% nd 82% 81% nd 82% nd nd nd
    Cutoff 6 20.0 nd 20.0 20.0 nd 20.0 nd nd nd
    Sens 6  0% nd  0%  0% nd  0% nd nd nd
    Spec 6 100%  nd 100%  100%  nd 100%  nd nd nd
    OR Quart 2 3.0 nd 3.0 2.9 nd 2.0 nd nd nd
    p Value 0.17 nd 0.24 0.25 nd 0.42 nd nd nd
    95% CI of 0.62 nd 0.48 0.48 nd 0.38 nd nd nd
    OR Quart 2 14 nd 19 17 nd 10 nd nd nd
    OR Quart 3 1.8 nd 3.0 2.9 nd 1.4 nd nd nd
    p Value 0.48 nd 0.24 0.25 nd 0.67 nd nd nd
    95% CI of 0.36 nd 0.48 0.48 nd 0.27 nd nd nd
    OR Quart 3 9.1 nd 19 17 nd 7.8 nd nd nd
    OR Quart 4 1.3 nd 1.5 4.8 nd 4.3 nd nd nd
    p Value 0.74 nd 0.69 0.081 nd 0.071 nd nd nd
    95% CI of 0.25 nd 0.21 0.83 nd 0.88 nd nd nd
    OR Quart 4 7.1 nd 11 28 nd 21 nd nd nd
    Lutropin subunit beta
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 19.2 16.5 19.2 25.6 nd nd
    Average 60.1 41.4 60.1 69.5 nd nd
    Stdev 101 64.5 101 92.5 nd nd
    p (t-test) 0.20 0.58 nd nd
    Min 0.0297 0.130 0.0297 0.0746 nd nd
    Max 400 277 400 325 nd nd
    n (Samp) 127 59 127 46 nd nd
    n (Patient) 68 59 68 46 nd nd
    sCr only
    Median 21.0 5.20 21.0 23.1 21.0 9.45
    Average 60.1 36.1 60.1 77.8 60.1 12.5
    Stdev 92.4 55.8 92.4 91.5 92.4 13.5
    p (t-test) 0.29 0.45 0.21
    Min 0.0297 0.211 0.0297 0.146 0.0297 0.505
    Max 400 179 400 256 400 36.9
    n (Samp) 267 17 267 16 267 6
    n (Patient) 128 17 128 16 128 6
    UO only
    Median 19.4 21.0 19.4 23.6 19.4 16.2
    Average 63.9 48.5 63.9 68.9 63.9 86.8
    Stdev 99.3 74.9 99.3 100 99.3 119
    p (t-test) 0.31 0.76 0.51
    Min 0.0297 0.130 0.0297 0.0746 0.0297 0.463
    Max 400 325 400 393 400 332
    n (Samp) 148 51 148 47 148 9
    n (Patient) 72 51 72 47 72 9
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.48 0.39 0.51 0.57 0.54 0.55 nd 0.33 0.57
    SE 0.046 0.075 0.047 0.050 0.076 0.049 nd 0.12 0.10
    p 0.74 0.16 0.89 0.19 0.63 0.28 nd 0.17 0.51
    nCohort 1 127 267 148 127 267 148 nd 267 148
    nCohort 2 59 17 51 46 16 47 nd 6 9
    Cutoff 1 4.35 3.23 7.60 10.6 5.10 10.6 nd 3.00 11.6
    Sens 1 71% 71% 71% 72% 75% 70% nd 83% 78%
    Spec 1 28% 19% 35% 41% 24% 39% nd 18% 40%
    Cutoff 2 2.03 1.98 4.33 6.10 4.35 6.19 nd 3.00 6.57
    Sens 2 81% 82% 80% 80% 81% 81% nd 83% 89%
    Spec 2 16% 15% 26% 37% 22% 34% nd 18% 34%
    Cutoff 3 0.393 0.339 0.986 0.933 0.408 3.86 nd 0.448 0.422
    Sens 3 92% 94% 90% 91% 94% 91% nd 100%  100% 
    Spec 3  9%  8% 11% 13%  9% 26% nd 10%  9%
    Cutoff 4 38.7 46.3 43.9 38.7 46.3 43.9 nd 46.3 43.9
    Sens 4 29% 24% 29% 37% 38% 32% nd  0% 33%
    Spec 4 70% 70% 70% 70% 70% 70% nd 70% 70%
    Cutoff 5 80.9 89.1 134 80.9 89.1 134 nd 89.1 134
    Sens 5 14% 18% 10% 28% 38% 19% nd  0% 33%
    Spec 5 80% 80% 80% 80% 80% 80% nd 80% 80%
    Cutoff 6 232 225 217 232 225 217 nd 225 217
    Sens 6  5%  0%  8% 11%  6% 13% nd  0% 22%
    Spec 6 91% 90% 91% 91% 90% 91% nd 90% 91%
    OR Quart 2 0.84 0.49 1.7 3.0 0.57 1.8 nd >1.0 4.3
    p Value 0.70 0.41 0.27 0.046 0.46 0.24 nd <0.98 0.20
    95% CI of 0.35 0.086 0.67 1.0 0.13 0.67 nd >0.063 0.46
    OR Quart 2 2.0 2.7 4.2 8.7 2.5 4.9 nd na 41
    OR Quart 3 1.2 0.74 1.7 2.4 0.38 2.0 nd >2.1 1.0
    p Value 0.66 0.70 0.27 0.12 0.25 0.17 nd <0.55 1.0
    95% CI of 0.51 0.16 0.67 0.80 0.071 0.75 nd >0.19 0.060
    OR Quart 3 2.8 3.4 4.2 7.1 2.0 5.3 nd na 17
    OR Quart 4 0.93 2.1 1.1 2.9 1.2 1.6 nd >3.2 3.1
    p Value 0.88 0.24 0.85 0.053 0.77 0.34 nd <0.32 0.34
    95% CI of 0.39 0.61 0.42 0.99 0.35 0.60 nd >0.32 0.31
    OR Quart 4 2.2 7.4 2.9 8.4 4.1 4.4 nd na 31
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2250 3580 2250 2690 2250 2950
    Average 2910 3890 2910 4150 2910 3090
    Stdev 2240 4020 2240 6560 2240 1780
    p (t-test) 3.9E−4 6.5E−4 0.59
    Min 6.83 221 6.83 216 6.83 293
    Max 22000 40700 22000 55700 22000 6560
    n (Samp) 463 119 463 128 463 47
    n (Patient) 223 119 223 128 223 47
    sCr only
    Median 2830 2300 2830 2420 2830 1930
    Average 3460 2540 3460 3220 3460 2360
    Stdev 3360 1640 3360 2380 3360 1600
    p (t-test) 0.085 0.63 0.097
    Min 6.83 221 6.83 216 6.83 387
    Max 55700 6210 55700 10800 55700 6110
    n (Samp) 1014 40 1014 46 1014 26
    n (Patient) 373 40 373 46 373 26
    UO only
    Median 2400 3900 2400 2850 2400 2920
    Average 2980 4670 2980 4590 2980 3220
    Stdev 2070 4820 2070 7080 2070 1960
    p (t-test) 4.3E−8 4.0E−5 0.45
    Min 173 506 173 224 173 293
    Max 11700 40700 11700 55700 11700 9700
    n (Samp) 436 107 436 117 436 44
    n (Patient) 173 107 173 117 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.62 0.40 0.66 0.56 0.48 0.58 0.56 0.37 0.56
    SE 0.030 0.048 0.031 0.029 0.044 0.031 0.045 0.059 0.047
    p 1.2E−4 0.043 2.3E−7 0.026 0.61 0.0086 0.20 0.025 0.21
    nCohort 1 463 1014 436 463 1014 436 463 1014 436
    nCohort 2 119 40 107 128 46 117 47 26 44
    Cutoff 1 2270 1150 2690 1950 1680 2080 2150 1190 2250
    Sens 1 71% 70% 70% 70% 72% 70% 70% 73% 70%
    Spec 1 51% 14% 56% 42% 25% 43% 48% 14% 46%
    Cutoff 2 1550 994 2000 1250 1110 1560 1500 1110 1650
    Sens 2 81% 80% 80% 80% 80% 80% 81% 81% 82%
    Spec 2 30% 11% 41% 20% 13% 30% 29% 13% 32%
    Cutoff 3 919 830 1450 898 883 1030 485 491 881
    Sens 3 91% 90% 91% 91% 91% 91% 91% 92% 91%
    Spec 3 11%  7% 27% 11%  8% 14%  3%  2% 10%
    Cutoff 4 3530 4050 3620 3530 4050 3620 3530 4050 3620
    Sens 4 51% 18% 56% 37% 33% 38% 38% 15% 36%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 4180 4930 4360 4180 4930 4360 4180 4930 4360
    Sens 5 32%  8% 34% 30% 22% 32% 28%  8% 25%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 5630 6450 6000 5630 6450 6000 5630 6450 6000
    Sens 6 17%  0% 23% 20%  9% 20%  9%  0%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.2 1.5 1.3 0.99 0.74 1.4 1.1 1.0 1.3
    p Value 0.63 0.43 0.47 0.98 0.51 0.27 0.83 1.0 0.61
    95% CI of 0.61 0.53 0.63 0.55 0.31 0.76 0.44 0.25 0.47
    OR Quart 2 2.3 4.3 2.8 1.8 1.8 2.6 2.8 4.0 3.6
    OR Quart 3 2.0 1.7 2.8 1.1 1.0 1.4 1.6 2.0 2.5
    p Value 0.034 0.31 0.0032 0.79 1.0 0.27 0.28 0.25 0.055
    95% CI of 1.1 0.61 1.4 0.61 0.44 0.76 0.68 0.60 0.98
    OR Quart 3 3.6 4.7 5.5 1.9 2.3 2.6 3.9 6.8 6.3
    OR Quart 4 3.0 2.6 3.9 1.9 1.1 2.3 1.6 2.6 1.8
    p Value 3.7E−4 0.052 6.4E−5 0.017 0.84 0.0072 0.29 0.12 0.24
    95% CI of 1.6 0.99 2.0 1.1 0.49 1.2 0.67 0.79 0.68
    OR Quart 4 5.4 6.8 7.5 3.3 2.4 4.1 3.9 8.3 4.7
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.961 1.70 0.961 1.70 0.961 1.75
    Average 3.43 3.67 3.43 14.0 3.43 4.02
    Stdev 15.8 10.6 15.8 102 15.8 7.14
    p (t-test) 0.90 0.060 0.81
    Min 0.00246 0.00313 0.00246 0.00408 0.00246 0.00683
    Max 270 86.2 270 935 270 34.8
    n (Samp) 365 70 365 84 365 41
    n (Patient) 191 70 191 84 191 41
    sCr only
    Median 1.06 2.21 1.06 2.31 1.06 2.18
    Average 4.26 6.20 4.26 3.16 4.26 4.35
    Stdev 35.9 16.9 35.9 3.24 35.9 7.82
    p (t-test) 0.79 0.86 0.99
    Min 0.00246 0.0144 0.00246 0.0140 0.00246 0.00408
    Max 935 86.2 935 16.9 935 34.8
    n (Samp) 754 25 754 32 754 21
    n (Patient) 295 25 295 32 295 21
    UO only
    Median 1.14 1.82 1.14 1.77 1.14 1.63
    Average 3.66 3.62 3.66 15.7 3.66 3.35
    Stdev 16.6 7.97 16.6 106 16.6 5.16
    p (t-test) 0.99 0.054 0.91
    Min 0.00246 0.00313 0.00246 0.00408 0.00246 0.00683
    Max 270 59.1 270 935 270 22.1
    n (Samp) 317 65 317 77 317 36
    n (Patient) 136 65 136 77 136 36
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.60 0.66 0.60 0.60 0.67 0.58 0.59 0.64 0.56
    SE 0.038 0.060 0.040 0.036 0.053 0.037 0.049 0.066 0.052
    p 0.0078 0.0097 0.010 0.0046 0.0015 0.027 0.057 0.030 0.25
    nCohort 1 365 754 317 365 754 317 365 754 317
    nCohort 2 70 25 65 84 32 77 41 21 36
    Cutoff 1 0.718 1.09 1.14 0.901 1.39 0.965 0.392 1.24 0.353
    Sens 1 70% 72% 71% 70% 72% 70% 71% 71% 72%
    Spec 1 40% 51% 50% 48% 57% 46% 30% 54% 27%
    Cutoff 2 0.483 0.737 0.536 0.273 0.465 0.162 0.286 0.869 0.232
    Sens 2 80% 80% 80% 81% 81% 81% 80% 81% 81%
    Spec 2 32% 39% 32% 25% 31% 21% 26% 44% 22%
    Cutoff 3 0.0238 0.477 0.0238 0.0238 0.278 0.0238 0.0244 0.0244 0.0140
    Sens 3 94% 92% 95% 93% 91% 91% 90% 90% 92%
    Spec 3 17% 31% 15% 17% 25% 15% 20% 19% 11%
    Cutoff 4 1.79 1.99 1.99 1.79 1.99 1.99 1.79 1.99 1.99
    Sens 4 47% 64% 49% 48% 62% 45% 46% 62% 42%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 2.54 3.02 3.08 2.54 3.02 3.08 2.54 3.02 3.08
    Sens 5 34% 32% 31% 31% 44% 25% 39% 38% 31%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 4.63 4.73 5.05 4.63 4.73 5.05 4.63 4.73 5.05
    Sens 6 13% 20% 14% 15% 19% 13% 15% 10% 17%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.99 2.5 1.6 0.57 0.74 0.66 0.99 0.99 0.47
    p Value 0.98 0.27 0.30 0.17 0.70 0.30 0.98 0.99 0.19
    95% CI of 0.42 0.48 0.67 0.26 0.16 0.30 0.36 0.20 0.15
    OR Quart 2 2.3 13 3.7 1.3 3.4 1.5 2.7 5.0 1.4
    OR Quart 3 1.9 3.0 1.9 1.6 2.9 1.4 1.0 1.7 0.78
    p Value 0.098 0.18 0.15 0.18 0.077 0.37 1.0 0.48 0.62
    95% CI of 0.89 0.61 0.80 0.81 0.89 0.68 0.36 0.39 0.29
    OR Quart 3 4.1 15 4.3 3.1 9.1 2.8 2.8 7.1 2.1
    OR Quart 4 2.4 6.3 2.7 1.8 3.7 1.7 2.3 3.4 1.3
    p Value 0.023 0.017 0.017 0.079 0.024 0.13 0.063 0.064 0.52
    95% CI of 1.1 1.4 1.2 0.93 1.2 0.85 0.95 0.93 0.55
    OR Quart 4 5.0 29 6.0 3.5 11 3.4 5.7 13 3.2
    Thyroxine-binding globulin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0694 0.0901 0.0694 0.106 0.0694 0.148
    Average 0.182 0.240 0.182 0.238 0.182 0.169
    Stdev 0.262 0.381 0.262 0.515 0.262 0.173
    p (t-test) 0.20 0.24 0.80
    Min 0.000191 8.30E−5 0.000191 0.000156 0.000191 0.00190
    Max 1.59 1.86 1.59 3.60 1.59 0.775
    n (Samp) 255 48 255 56 255 27
    n (Patient) 103 48 103 56 103 27
    sCr only
    Median 0.0777 0.0623 0.0777 0.0721 0.0777 0.0390
    Average 0.189 0.0799 0.189 0.162 0.189 0.0671
    Stdev 0.308 0.0770 0.308 0.219 0.308 0.0674
    p (t-test) 0.16 0.70 0.15
    Min 0.000191 8.30E−5 0.000191 0.000156 0.000191 0.00190
    Max 3.60 0.250 3.60 0.792 3.60 0.218
    n (Samp) 447 16 447 20 447 13
    n (Patient) 170 16 170 20 170 13
    UO only
    Median 0.0675 0.0555 0.0675 0.114 0.0675 0.149
    Average 0.172 0.241 0.172 0.249 0.172 0.178
    Stdev 0.259 0.391 0.259 0.537 0.259 0.177
    p (t-test) 0.14 0.14 0.91
    Min 0.000191 0.00106 0.000191 0.00324 0.000191 0.00366
    Max 1.59 1.86 1.59 3.60 1.59 0.775
    n (Samp) 218 46 218 51 218 25
    n (Patient) 87 46 87 51 87 25
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.52 0.41 0.51 0.52 0.47 0.53 0.57 0.37 0.60
    SE 0.046 0.076 0.047 0.043 0.067 0.045 0.060 0.084 0.063
    p 0.66 0.24 0.83 0.69 0.68 0.47 0.28 0.12 0.098
    nCohort 1 255 447 218 255 447 218 255 447 218
    nCohort 2 48 16 46 56 20 51 27 13 25
    Cutoff 1 0.0279 0.0196 0.0169 0.0293 0.0357 0.0287 0.0617 0.0196 0.0694
    Sens 1 71% 75% 72% 71% 70% 71% 70% 77% 72%
    Spec 1 30% 23% 22% 31% 33% 32% 47% 23% 52%
    Cutoff 2 0.0150 0.0157 0.0138 0.0194 0.0187 0.0164 0.0471 0.00877 0.0547
    Sens 2 81% 81% 80% 80% 80% 80% 81% 85% 80%
    Spec 2 20% 20% 20% 22% 22% 22% 41% 15% 46%
    Cutoff 3 0.00405 0.00990 0.00446 0.00715 0.00325 0.0100 0.00715 0.00319 0.0138
    Sens 3 92% 94% 91% 91% 90% 90% 93% 92% 92%
    Spec 3  7% 16%  8% 14%  6% 16% 14%  6% 20%
    Cutoff 4 0.193 0.198 0.174 0.193 0.198 0.174 0.193 0.198 0.174
    Sens 4 35% 12% 39% 30% 25% 37% 33%  8% 44%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 0.274 0.290 0.248 0.274 0.290 0.248 0.274 0.290 0.248
    Sens 5 23%  0% 28% 21% 15% 25% 11%  0% 16%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 0.448 0.466 0.418 0.448 0.466 0.418 0.448 0.466 0.418
    Sens 6 19%  0% 20% 12% 10% 12%  7%  0%  8%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.64 5.2 0.54 0.74 1.5 0.59 2.1 >5.2 1.7
    p Value 0.34 0.14 0.18 0.49 0.52 0.26 0.32 <0.13 0.48
    95% CI of 0.26 0.60 0.22 0.31 0.42 0.23 0.49 >0.60 0.39
    OR Quart 2 1.6 45 1.3 1.7 5.6 1.5 8.6 na 7.4
    OR Quart 3 0.89 5.2 0.40 1.3 1.3 1.0 4.6 >4.1 3.3
    p Value 0.80 0.14 0.067 0.45 0.73 1.0 0.022 <0.21 0.086
    95% CI of 0.38 0.60 0.15 0.62 0.33 0.43 1.2 >0.46 0.84
    OR Quart 3 2.1 45 1.1 3.0 4.8 2.3 17 na 13
    OR Quart 4 1.1 5.2 1.0 0.90 1.3 0.98 2.1 >4.1 2.9
    p Value 0.86 0.13 1.0 0.80 0.72 0.96 0.32 <0.21 0.13
    95% CI of 0.47 0.60 0.44 0.39 0.33 0.43 0.49 >0.46 0.72
    OR Quart 4 2.5 45 2.3 2.1 4.9 2.3 8.6 na 11
    Pigment epithelium-derived factor
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 3.04 4.18 3.04 2.78 3.04 3.54
    Average 20.4 23.7 20.4 22.4 20.4 17.8
    Stdev 49.4 52.1 49.4 51.0 49.4 34.6
    p (t-test) 0.52 0.68 0.72
    Min 0.000563 0.0167 0.000563 0.00102 0.000563 0.159
    Max 400 302 400 400 400 171
    n (Samp) 463 119 463 128 463 47
    n (Patient) 223 119 223 128 223 47
    sCr only
    Median 3.10 3.91 3.10 3.28 3.10 2.70
    Average 18.7 25.3 18.7 27.7 18.7 25.4
    Stdev 45.5 64.6 45.5 53.3 45.5 50.3
    p (t-test) 0.38 0.19 0.46
    Min 0.000401 0.115 0.000401 0.0102 0.000401 0.00102
    Max 400 361 400 302 400 218
    n (Samp) 1015 40 1015 46 1015 26
    n (Patient) 374 40 374 46 374 26
    UO only
    Median 3.33 4.99 3.33 3.59 3.33 6.11
    Average 24.7 27.8 24.7 29.2 24.7 22.5
    Stdev 54.1 56.4 54.1 65.5 54.1 41.4
    p (t-test) 0.60 0.44 0.80
    Min 0.000563 0.0167 0.000563 0.00102 0.000563 0.189
    Max 400 302 400 400 400 171
    n (Samp) 436 107 436 117 436 44
    n (Patient) 173 107 173 117 173 44
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 0.52 0.56 0.51 0.54 0.52 0.54 0.50 0.55
    SE 0.030 0.047 0.032 0.029 0.044 0.030 0.045 0.058 0.047
    p 0.081 0.73 0.055 0.70 0.43 0.61 0.39 0.94 0.29
    nCohort 1 463 1015 436 463 1015 436 463 1015 436
    nCohort 2 119 40 107 128 46 117 47 26 44
    Cutoff 1 1.88 1.94 2.14 1.13 0.884 1.45 1.56 0.913 2.03
    Sens 1 71% 70% 70% 70% 72% 70% 70% 73% 70%
    Spec 1 41% 40% 41% 31% 25% 33% 38% 26% 40%
    Cutoff 2 0.861 0.565 1.30 0.602 0.596 0.751 0.863 0.514 0.874
    Sens 2 81% 80% 80% 80% 80% 81% 81% 81% 82%
    Spec 2 26% 17% 30% 21% 18% 20% 26% 15% 22%
    Cutoff 3 0.329 0.169 0.596 0.283 0.132 0.320 0.361 0.185 0.681
    Sens 3 91% 90% 91% 91% 91% 91% 91% 92% 91%
    Spec 3 11%  5% 16% 10%  4%  8% 13%  6% 19%
    Cutoff 4 9.21 8.99 11.3 9.21 8.99 11.3 9.21 8.99 11.3
    Sens 4 36% 30% 40% 32% 41% 34% 30% 31% 36%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 19.2 18.7 27.1 19.2 18.7 27.1 19.2 18.7 27.1
    Sens 5 27% 18% 23% 26% 37% 24% 23% 23% 18%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 52.9 45.1 83.6 52.9 45.1 83.6 52.9 45.1 83.6
    Sens 6 11% 15%  8% 12% 20%  9%  9% 19%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.3 0.79 1.6 0.99 0.76 1.2 1.5 1.2 0.89
    p Value 0.37 0.63 0.16 0.98 0.52 0.55 0.36 0.77 0.81
    95% CI of 0.72 0.31 0.84 0.57 0.33 0.67 0.61 0.39 0.35
    OR Quart 2 2.4 2.0 3.0 1.7 1.8 2.1 3.9 3.5 2.3
    OR Quart 3 1.4 1.1 1.4 0.67 0.30 0.95 1.8 1.0 1.2
    p Value 0.29 0.83 0.27 0.18 0.036 0.88 0.19 0.99 0.65
    95% CI of 0.76 0.46 0.76 0.37 0.096 0.52 0.74 0.32 0.51
    OR Quart 3 2.5 2.6 2.8 1.2 0.92 1.7 4.6 3.2 2.9
    OR Quart 4 1.8 1.1 2.0 1.2 1.5 1.3 1.7 1.2 1.3
    p Value 0.047 0.83 0.025 0.52 0.28 0.40 0.27 0.77 0.51
    95% CI of 1.0 0.46 1.1 0.70 0.72 0.72 0.67 0.39 0.56
    OR Quart 4 3.2 2.6 3.8 2.0 3.1 2.3 4.2 3.5 3.2
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 15.0 24.9 15.0 19.7 15.0 30.0
    Average 25.2 35.9 25.2 27.2 25.2 32.8
    Stdev 36.7 35.9 36.7 24.9 36.7 25.6
    p (t-test) 0.020 0.63 0.26
    Min 0.0493 0.0493 0.0493 0.121 0.0493 0.196
    Max 277 176 277 111 277 110
    n (Samp) 217 91 217 96 217 32
    n (Patient) 128 91 128 96 128 32
    sCr only
    Median 19.5 19.8 19.5 30.5 19.5 33.4
    Average 31.1 29.5 31.1 43.0 31.1 38.0
    Stdev 48.0 28.0 48.0 60.6 48.0 31.6
    p (t-test) 0.86 0.18 0.55
    Min 0.0493 0.121 0.0493 0.121 0.0493 0.0561
    Max 554 126 554 353 554 110
    n (Samp) 517 28 517 33 517 18
    n (Patient) 242 28 242 33 242 18
    UO only
    Median 13.2 26.6 13.2 19.0 13.2 18.8
    Average 23.7 37.3 23.7 26.7 23.7 27.7
    Stdev 36.2 36.1 36.2 25.8 36.2 24.0
    p (t-test) 0.0040 0.47 0.55
    Min 0.0493 0.0493 0.0493 0.196 0.0493 0.196
    Max 277 176 277 126 277 111
    n (Samp) 227 81 227 86 227 31
    n (Patient) 122 81 122 86 122 31
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.63 0.54 0.66 0.57 0.62 0.58 0.65 0.61 0.62
    SE 0.036 0.057 0.037 0.036 0.054 0.037 0.056 0.072 0.057
    p 4.6E−4 0.46 1.4E−5 0.047 0.025 0.022 0.0079 0.14 0.037
    nCohort 1 217 517 227 217 517 227 217 517 227
    nCohort 2 91 28 81 96 33 86 32 18 31
    Cutoff 1 12.5 12.5 12.5 9.84 19.8 8.69 18.3 18.3 12.4
    Sens 1 71% 71% 70% 71% 73% 71% 72% 72% 71%
    Spec 1 47% 39% 49% 36% 52% 39% 53% 46% 48%
    Cutoff 2 8.52 5.14 7.30 5.14 12.3 5.14 12.1 5.76 7.30
    Sens 2 80% 89% 80% 81% 82% 81% 81% 83% 81%
    Spec 2 35% 21% 39% 27% 37% 30% 43% 23% 39%
    Cutoff 3 4.86 0.811 4.86 2.45 5.09 2.45 6.53 0.196 5.14
    Sens 3 90% 96% 90% 91% 94% 91% 91% 94% 90%
    Spec 3 23% 11% 24% 20% 20% 22% 30%  8% 30%
    Cutoff 4 27.0 32.9 25.8 27.0 32.9 25.8 27.0 32.9 25.8
    Sens 4 45% 36% 53% 39% 39% 41% 53% 50% 45%
    Spec 4 70% 71% 70% 70% 71% 70% 70% 71% 70%
    Cutoff 5 35.9 42.2 34.0 35.9 42.2 34.0 35.9 42.2 34.0
    Sens 5 38% 29% 43% 33% 30% 31% 41% 33% 29%
    Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 53.5 62.7 50.8 53.5 62.7 50.8 53.5 62.7 50.8
    Sens 6 20% 14% 21% 15% 12% 13% 12% 22% 10%
    Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91%
    OR Quart 2 1.3 1.2 2.3 1.5 1.2 2.2 3.8 0.49 3.3
    p Value 0.56 0.78 0.061 0.29 0.74 0.044 0.10 0.41 0.087
    95% CI of 0.58 0.38 0.96 0.73 0.33 1.0 0.76 0.088 0.84
    OR Quart 2 2.7 3.6 5.5 3.0 4.8 4.6 19 2.7 13
    OR Quart 3 1.8 1.2 2.7 1.1 3.2 1.3 5.1 1.2 2.5
    p Value 0.14 0.78 0.027 0.85 0.049 0.55 0.043 0.74 0.20
    95% CI of 0.84 0.38 1.1 0.52 1.0 0.58 1.1 0.33 0.62
    OR Quart 3 3.7 3.6 6.3 2.2 10 2.8 25 4.8 10
    OR Quart 4 3.4 1.3 6.0 2.1 3.2 2.8 8.6 1.8 4.6
    p Value 7.7E−4 0.59 2.3E−5 0.032 0.051 0.0061 0.0059 0.37 0.023
    95% CI of 1.7 0.45 2.6 1.1 1.00 1.3 1.9 0.51 1.2
    OR Quart 4 7.1 4.0 14 4.1 10 5.8 40 6.1 17
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00520 0.00428 0.00520 0.00587 0.00520 0.00587
    Average 0.0545 0.0877 0.0545 0.0927 0.0545 0.0161
    Stdev 0.124 0.239 0.124 0.347 0.124 0.0327
    p (t-test) 0.13 0.18 0.12
    Min 0.000463 0.000463 0.000463 0.000463 0.000463 0.000523
    Max 0.803 1.74 0.803 2.85 0.803 0.118
    n (Samp) 194 86 194 76 194 26
    n (Patient) 123 86 123 76 123 26
    sCr only
    Median 0.00520 0.00508 0.00520 0.00428 0.00520 0.00546
    Average 0.0560 0.170 0.0560 0.0759 0.0560 0.0270
    Stdev 0.186 0.369 0.186 0.199 0.186 0.0391
    p (t-test) 0.0052 0.58 0.53
    Min 0.000463 0.000463 0.000463 0.000463 0.000463 0.000523
    Max 2.85 1.74 2.85 0.889 2.85 0.109
    n (Samp) 428 26 428 28 428 16
    n (Patient) 210 26 210 28 210 16
    UO only
    Median 0.00505 0.00428 0.00505 0.00624 0.00505 0.00587
    Average 0.0557 0.0575 0.0557 0.0924 0.0557 0.107
    Stdev 0.132 0.144 0.132 0.343 0.132 0.346
    p (t-test) 0.92 0.19 0.14
    Min 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463
    Max 0.803 0.840 0.803 2.85 0.803 1.74
    n (Samp) 210 78 210 72 210 27
    n (Patient) 119 78 119 72 119 27
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 0.52 0.46 0.50 0.41 0.57 0.46 0.51 0.52
    SE 0.038 0.059 0.039 0.039 0.058 0.040 0.061 0.074 0.060
    p 0.25 0.79 0.28 0.99 0.11 0.074 0.47 0.86 0.77
    nCohort 1 194 428 210 194 428 210 194 428 210
    nCohort 2 86 26 78 76 28 72 26 16 27
    Cutoff 1 0.00296 0.00296 0.00296 0.00367 0.00132 0.00428 0.00367 0.00367 0.00423
    Sens 1 74% 73% 72% 71% 86% 71% 73% 75% 70%
    Spec 1 19% 21% 21% 30% 13% 42% 30% 32% 32%
    Cutoff 2 0.00132 0.00132 0.00132 0.000523 0.00132 0.00296 0.000523 0.00132 0.000523
    Sens 2 81% 85% 81% 87% 86% 81% 96% 94% 93%
    Spec 2 12% 13% 17% 12% 13% 21% 12% 13% 17%
    Cutoff 3 0.000463 0 0.000463 0 0 0.000463 0.000523 0.00132 0.000523
    Sens 3 91% 100%  92% 100%  100%  92% 96% 94% 93%
    Spec 3  5%  0% 10%  0%  0% 10% 12% 13% 17%
    Cutoff 4 0.0385 0.00660 0.0128 0.0385 0.00660 0.0128 0.0385 0.00660 0.0128
    Sens 4 29% 35% 27% 30% 18% 43% 12% 31% 22%
    Spec 4 71% 71% 70% 71% 71% 70% 71% 71% 70%
    Cutoff 5 0.0728 0.0499 0.0641 0.0728 0.0499 0.0641 0.0728 0.0499 0.0641
    Sens 5 20% 31% 18% 20% 18% 28% 12% 25% 22%
    Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80%
    Cutoff 6 0.176 0.162 0.176 0.176 0.162 0.176 0.176 0.162 0.176
    Sens 6 14% 31% 10%  8% 14%  8%  0%  0%  7%
    Spec 6 90% 91% 90% 90% 91% 90% 90% 91% 90%
    OR Quart 2 0.56 0.84 0.57 1.1 1.0 0.98 4.8 1.0 0.22
    p Value 0.13 0.76 0.17 0.88 1.0 0.97 0.020 1.0 0.066
    95% CI of 0.26 0.27 0.26 0.49 0.28 0.43 1.3 0.24 0.045
    OR Quart 2 1.2 2.6 1.3 2.3 3.6 2.2 18 4.1 1.1
    OR Quart 3 1.0 0.70 1.2 1.3 1.6 1.8 1.4 1.0 1.5
    p Value 1.0 0.55 0.59 0.44 0.40 0.12 0.70 1.0 0.45
    95% CI of 0.49 0.22 0.60 0.63 0.52 0.85 0.29 0.24 0.54
    OR Quart 3 2.0 2.3 2.5 2.9 5.2 4.0 6.4 4.1 3.9
    OR Quart 4 1.1 1.1 1.1 1.2 2.1 1.8 2.5 1.0 0.71
    p Value 0.72 0.80 0.71 0.60 0.19 0.14 0.20 1.0 0.55
    95% CI of 0.56 0.40 0.56 0.57 0.69 0.83 0.62 0.24 0.23
    OR Quart 4 2.3 3.3 2.3 2.6 6.3 3.9 10 4.1 2.2
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 3.26 2.40 3.26 2.03 3.26 2.72
    Average 27.3 21.6 27.3 25.4 27.3 7.72
    Stdev 162 164 162 183 162 12.5
    p (t-test) 0.71 0.90 0.40
    Min 0.000147 0.00122 0.000147 0.000147 0.000147 0.000147
    Max 2160 1960 2160 2140 2160 63.1
    n (Samp) 499 143 499 143 499 48
    n (Patient) 235 143 235 143 235 48
    sCr only
    Median 2.68 1.25 2.68 1.18 2.68 2.72
    Average 22.5 3.42 22.5 5.41 22.5 8.50
    Stdev 142 6.10 142 9.08 142 16.4
    p (t-test) 0.36 0.39 0.60
    Min 0.000147 0.000147 0.000147 0.000147 0.000147 0.000147
    Max 2160 33.8 2160 37.9 2160 82.5
    n (Samp) 1100 46 1100 51 1100 28
    n (Patient) 397 46 397 51 397 28
    UO only
    Median 2.97 3.06 2.97 2.03 2.97 2.24
    Average 21.4 25.0 22.4 26.8 22.4 7.59
    Stdev 131 173 131 190 131 13.1
    p (t-test) 0.85 0.75 0.44
    Min 0.000147 0.00122 0.000147 0.000147 0.000147 0.00122
    Max 2140 1960 2140 2140 2140 63.1
    n (Samp) 487 130 487 133 487 47
    n (Patient) 190 130 190 133 190 47
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 0.37 0.49 0.45 0.41 0.45 0.48 0.48 0.46
    SE 0.028 0.045 0.029 0.028 0.043 0.029 0.044 0.056 0.045
    p 0.20 0.0027 0.80 0.073 0.042 0.082 0.62 0.75 0.34
    nCohort 1 499 1100 487 499 1100 487 499 1100 487
    nCohort 2 143 46 130 143 51 133 48 28 47
    Cutoff 1 0.858 0.393 0.882 0.737 0.628 0.737 0.942 1.06 0.711
    Sens 1 71% 72% 70% 71% 71% 71% 71% 71% 70%
    Spec 1 26% 17% 27% 24% 23% 23% 30% 32% 22%
    Cutoff 2 0.467 0.103 0.554 0.411 0.404 0.393 0.211 0.103 0.211
    Sens 2 80% 80% 80% 80% 80% 80% 81% 82% 81%
    Spec 2 19%  8% 19% 18% 17% 15% 12%  8% 11%
    Cutoff 3 0.0862 0.0258 0.130 0.0999 0.0258 0.103 0.0520 0.00238 0.0263
    Sens 3 91% 91% 90% 90% 90% 90% 92% 93% 91%
    Spec 3  8%  6% 10%  9%  6% 10%  8%  4%  8%
    Cutoff 4 7.57 7.31 6.96 7.57 7.31 6.96 7.57 7.31 6.96
    Sens 4 27% 13% 33% 22% 20% 23% 31% 29% 30%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 13.3 12.7 11.4 13.3 12.7 11.4 13.3 12.7 11.4
    Sens 5 17%  4% 22% 17% 16% 18% 17% 14% 19%
    Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80%
    Cutoff 6 30.2 27.2 28.8 30.2 27.2 28.8 30.2 27.2 28.8
    Sens 6  8%  2% 10%  6%  6%  6%  6%  7%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.2 2.6 0.74 1.2 1.4 1.1 0.59 1.3 0.83
    p Value 0.56 0.12 0.28 0.55 0.49 0.66 0.26 0.59 0.67
    95% CI of 0.68 0.79 0.43 0.68 0.55 0.64 0.24 0.46 0.34
    OR Quart 2 2.0 8.3 1.3 2.1 3.5 2.0 1.5 3.9 2.0
    OR Quart 3 1.3 3.6 0.68 1.6 1.8 1.4 1.1 1.2 0.73
    p Value 0.34 0.025 0.17 0.079 0.20 0.26 0.84 0.78 0.50
    95% CI of 0.76 1.2 0.39 0.95 0.74 0.79 0.49 0.39 0.30
    OR Quart 3 2.2 11 1.2 2.8 4.3 2.4 2.4 3.5 1.8
    OR Quart 4 1.4 4.8 1.0 1.7 2.3 1.7 1.0 1.2 1.4
    p Value 0.27 0.0053 0.97 0.056 0.050 0.056 0.98 0.78 0.41
    95% CI of 0.79 1.6 0.60 0.99 1.0 0.99 0.45 0.39 0.63
    OR Quart 4 2.3 14 1.7 2.9 5.5 2.9 2.3 3.5 3.1
    Apolipoprotein(a)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1.92 2.90 1.92 2.91 1.92 2.09
    Average 26.2 147 26.2 48.0 26.2 32.2
    Stdev 128 1540 128 402 128 151
    p (t-test) 0.092 0.31 0.77
    Min 0.00770 0.00479 0.00770 0.00241 0.00770 0.00838
    Max 1510 17500 1510 4580 1510 1000
    n (Samp) 471 129 471 133 471 45
    n (Patient) 230 129 230 133 230 45
    sCr only
    Median 2.04 1.80 2.04 2.90 2.04 3.02
    Average 45.0 4.31 45.0 9.65 45.0 11.7
    Stdev 578 9.90 578 30.9 578 31.2
    p (t-test) 0.64 0.67 0.77
    Min 0.00241 0.00770 0.00241 0.00241 0.00241 0.00838
    Max 17500 60.7 17500 215 17500 161
    n (Samp) 1040 43 1040 49 1040 26
    n (Patient) 391 43 391 49 391 26
    UO only
    Median 2.11 3.31 2.11 2.86 2.11 2.04
    Average 20.0 172 20.0 50.6 20.0 30.5
    Stdev 111 1630 111 420 111 153
    p (t-test) 0.049 0.16 0.57
    Min 0.00770 0.00479 0.00770 0.00241 0.00770 0.00790
    Max 1510 17500 1510 4580 1510 1000
    n (Samp) 457 115 457 122 457 43
    n (Patient) 185 115 185 122 185 43
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.58 0.46 0.61 0.58 0.53 0.58 0.53 0.59 0.51
    SE 0.029 0.046 0.031 0.029 0.043 0.030 0.046 0.059 0.046
    p 0.0097 0.40 4.2E−4 0.0068 0.48 0.0099 0.50 0.13 0.84
    nCohort 1 471 1040 457 471 1040 457 471 1040 457
    nCohort 2 129 43 115 133 49 122 45 26 43
    Cutoff 1 1.51 0.917 1.95 1.67 0.863 1.65 1.16 1.67 1.19
    Sens 1 71% 72% 70% 71% 71% 72% 71% 73% 72%
    Spec 1 42% 29% 49% 46% 27% 44% 34% 45% 33%
    Cutoff 2 0.977 0.556 1.23 1.16 0.108 1.24 0.766 1.65 0.766
    Sens 2 81% 81% 80% 80% 82% 80% 80% 81% 81%
    Spec 2 31% 22% 33% 34% 12% 33% 27% 45% 26%
    Cutoff 3 0.108 0.108 0.496 0.108 0.0112 0.430 0.479 0.369 0.479
    Sens 3 92% 91% 90% 90% 92% 90% 93% 92% 93%
    Spec 3 14% 12% 22% 14%  4% 17% 19% 15% 18%
    Cutoff 4 3.77 3.78 3.85 3.77 3.78 3.85 3.77 3.78 3.85
    Sens 4 39% 23% 43% 37% 37% 36% 31% 42% 23%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 5.63 5.65 5.30 5.63 5.65 5.30 5.63 5.65 5.30
    Sens 5 22% 12% 30% 28% 33% 26% 20% 23% 19%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 16.0 18.3 12.9 16.0 18.3 12.9 16.0 18.3 12.9
    Sens 6 12%  7% 17% 11%  8% 11% 13% 15% 14%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.4 1.9 1.8 1.1 0.28 1.6 1.2 1.2 2.0
    p Value 0.28 0.18 0.098 0.76 0.024 0.17 0.64 0.74 0.13
    95% CI of 0.76 0.75 0.90 0.60 0.089 0.83 0.50 0.33 0.81
    OR Quart 2 2.6 4.8 3.5 2.0 0.85 2.9 3.1 4.7 4.9
    OR Quart 3 2.2 1.9 2.4 2.1 1.0 2.0 1.5 1.8 1.4
    p Value 0.0072 0.18 0.0088 0.0093 1.0 0.020 0.38 0.37 0.48
    95% CI of 1.2 0.75 1.2 1.2 0.47 1.1 0.62 0.51 0.55
    OR Quart 3 4.0 4.8 4.6 3.7 2.1 3.7 3.6 6.1 3.6
    OR Quart 4 2.2 1.5 3.1 1.9 1.2 2.1 1.4 2.5 1.1
    p Value 0.0072 0.46 5.2E−4 0.026 0.59 0.014 0.50 0.12 0.80
    95% CI of 1.2 0.54 1.6 1.1 0.59 1.2 0.56 0.79 0.42
    OR Quart 4 4.0 3.9 5.8 3.4 2.5 3.9 3.4 8.2 3.0
  • FIG. 2: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.
  •
    Complement C4-B
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 16.8 30.7 16.8 30.3 16.8 11.2
    Average 54.2 59.9 54.2 69.1 54.2 35.1
    Stdev 132 84.9 132 155 132 61.6
    p(t-test) 0.74 0.37 0.37
    Min 0.00329 0.161 0.00329 0.211 0.00329 0.00263
    Max 2000 417 2000 1150 2000 341
    n (Samp) 927 62 927 70 927 39
    n (Patient) 360 62 360 70 360 39
    sCr only
    Median 17.8 6.31 17.8 5.52 17.8 17.8
    Average 59.9 13.8 59.9 29.0 59.9 40.1
    Stdev 146 17.1 146 47.7 146 51.7
    p(t-test) 0.22 0.37 0.58
    Min 0.00329 0.161 0.00329 0.211 0.00329 0.448
    Max 2000 47.7 2000 173 2000 146
    n (Samp) 1230 15 1230 18 1230 17
    n (Patient) 440 15 440 18 440 17
    UO only
    Median 17.8 30.6 17.8 33.3 17.8 15.3
    Average 55.4 63.6 55.4 72.3 55.4 39.5
    Stdev 134 87.3 134 162 134 63.7
    p(t-test) 0.65 0.34 0.49
    Min 0.00329 0.754 0.00329 0.383 0.00329 0.00263
    Max 2000 417 2000 1150 2000 341
    n (Samp) 815 57 815 63 815 34
    n (Patient) 282 57 282 63 282 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.57 0.33 0.59 0.55 0.41 0.56 0.45 0.47 0.48
    SE 0.039 0.077 0.041 0.037 0.071 0.039 0.048 0.072 0.051
    p 0.071 0.027 0.031 0.13 0.20 0.10 0.29 0.71 0.69
    nCohort 1 927 1230 815 927 1230 815 927 1230 815
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 10.5 2.00 13.2 6.41 4.28 7.34 3.33 6.89 4.30
    Sens 1 71% 73% 70% 70% 72% 71% 72% 71% 71%
    Spec 1 41% 15% 43% 32% 25% 33% 22% 31% 25%
    Cutoff 2 4.21 0.968 8.26 4.21 3.21 3.60 1.74 1.49 2.00
    Sens 2 81% 80% 81% 80% 83% 81% 82% 82% 82%
    Spec 2 26%  8% 35% 26% 20% 21% 13% 11% 14%
    Cutoff 3 0.990 0.587 2.46 1.70 1.66 1.74 0.752 0.544 1.66
    Sens 3 90% 93% 91% 90% 94% 90% 92% 94% 91%
    Spec 3  8%  4% 16% 13% 12% 13%  6%  4% 12%
    Cutoff 4 38.7 42.6 41.5 38.7 42.6 41.5 38.7 42.6 41.5
    Sens 4 44% 13% 40% 40% 22% 43% 26% 35% 32%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 61.6 68.8 65.8 61.6 68.8 65.8 61.6 68.8 65.8
    Sens 5 29%  0% 30% 29% 17% 24% 21% 18% 21%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 130 141 130 130 141 130 130 141 130
    Sens 6 11%  0% 12% 14%  6% 14%  8%  6%  6%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.1 >4.1 1.4 1.0 1.0 0.91 0.59 1.3 0.77
    p Value 0.84 <0.21 0.50 1.0 1.0 0.83 0.32 0.74 0.62
    95% CI of 0.49 >0.45 0.56 0.47 0.20 0.41 0.21 0.33 0.28
    OR Quart 2 2.4 na 3.3 2.1 5.0 2.1 1.7 4.7 2.1
    OR Quart 3 1.4 >5.1 1.7 1.3 2.4 1.2 1.1 0.75 1.0
    p Value 0.44 <0.14 0.21 0.47 0.22 0.70 0.82 0.70 0.99
    95% CI of 0.63 >0.59 0.73 0.64 0.61 0.54 0.46 0.17 0.39
    OR Quart 3 2.9 na 4.0 2.7 9.2 2.5 2.7 3.4 2.6
    OR Quart 4 1.8 >6.1 2.5 1.8 1.7 1.9 1.2 1.3 1.0
    p Value 0.11 <0.094 0.027 0.098 0.48 0.088 0.66 0.73 0.99
    95% CI of 0.87 >0.73 1.1 0.90 0.40 0.91 0.52 0.33 0.39
    OR Quart 4 3.8 na 5.5 3.5 7.1 3.8 2.9 4.7 2.6
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.584 0.662 0.584 0.643 0.584 0.584
    Average 1.89 5.43 1.89 2.29 1.89 3.19
    Stdev 9.38 13.3 9.38 6.39 9.38 7.98
    p(t-test) 0.0054 0.73 0.39
    Min 0.146 0.146 0.146 0.146 0.146 0.264
    Max 163 61.7 163 45.7 163 33.9
    n (Samp) 930 62 930 70 930 39
    n (Patient) 361 62 361 70 361 39
    sCr only
    Median 0.584 0.812 0.584 0.637 0.584 0.816
    Average 2.24 8.59 2.24 5.64 2.24 3.49
    Stdev 12.2 18.9 12.2 14.5 12.2 8.42
    p(t-test) 0.046 0.24 0.67
    Min 0.146 0.264 0.146 0.282 0.146 0.264
    Max 291 69.7 291 61.7 291 33.9
    n (Samp) 1234 15 1234 18 1234 17
    n (Patient) 441 15 441 18 441 17
    UO only
    Median 0.625 0.662 0.625 0.662 0.625 0.584
    Average 2.01 8.67 2.01 4.29 2.01 2.87
    Stdev 9.92 25.3 9.92 15.7 9.92 7.34
    p(t-test) 2.7E−5 0.095 0.62
    Min 0.146 0.146 0.146 0.146 0.146 0.264
    Max 163 166 163 114 163 33.0
    n (Samp) 819 57 819 63 819 34
    n (Patient) 283 57 283 63 283 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.63 0.65 0.61 0.56 0.59 0.54 0.56 0.64 0.52
    SE 0.039 0.078 0.041 0.037 0.071 0.038 0.048 0.073 0.051
    p 0.0012 0.059 0.0085 0.12 0.18 0.31 0.22 0.063 0.74
    nCohort 1 930 1234 819 930 1234 819 930 1234 819
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 0.551 0.512 0.515 0.320 0.336 0.320 0.385 0.584 0.385
    Sens 1 77% 73% 77% 73% 78% 73% 72% 82% 71%
    Spec 1 50% 44% 46% 32% 34% 29% 41% 52% 37%
    Cutoff 2 0.336 0.424 0.336 0.319 0.320 0.319 0.336 0.584 0.336
    Sens 2 81% 80% 81% 86% 83% 87% 85% 82% 85%
    Spec 2 36% 39% 34% 28% 30% 26% 36% 52% 34%
    Cutoff 3 0.319 0.320 0.319 0.301 0.301 0.301 0.319 0.301 0.320
    Sens 3 92% 93% 93% 96% 94% 95% 92% 94% 91%
    Spec 3 23% 30% 21% 17% 17% 17% 23% 17% 29%
    Cutoff 4 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04
    Sens 4 37% 47% 35% 27% 39% 25% 21% 29% 18%
    Spec 4 74% 72% 72% 74% 72% 72% 74% 72% 72%
    Cutoff 5 1.12 1.12 1.15 1.12 1.12 1.15 1.12 1.12 1.15
    Sens 5 37% 47% 32% 26% 39% 22% 21% 24% 18%
    Spec 5 82% 81% 84% 82% 81% 84% 82% 81% 84%
    Cutoff 6 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59
    Sens 6 16% 20% 19% 10% 22% 11% 13% 12% 12%
    Spec 6 94% 94% 94% 94% 94% 94% 94% 94% 94%
    OR Quart 2 2.6 4.0 3.0 2.2 1.7 2.8 5.6 0 6.1
    p Value 0.052 0.21 0.024 0.046 0.48 0.017 0.0065 na 0.0044
    95% CI of 0.99 0.45 1.2 1.0 0.40 1.2 1.6 na 1.8
    OR Quart 2 6.8 36 7.7 4.8 7.1 6.4 20 na 21
    OR Quart 3 3.2 3.0 2.4 2.2 1.0 2.5 4.2 5.1 2.7
    p Value 0.017 0.34 0.075 0.046 1.0 0.034 0.029 0.036 0.14
    95% CI of 1.2 0.31 0.91 1.0 0.20 1.1 1.2 1.1 0.71
    OR Quart 3 8.1 29 6.4 4.8 5.0 5.9 15 24 10
    OR Quart 4 4.1 7.1 3.6 1.9 2.4 1.9 2.7 2.5 2.0
    p Value 0.0025 0.067 0.0075 0.12 0.22 0.14 0.14 0.27 0.32
    95% CI of 1.6 0.87 1.4 0.84 0.61 0.80 0.71 0.48 0.50
    OR Quart 4 10 58 9.1 4.1 9.2 4.6 10 13 8.2
    Vascular endothelial growth factor receptor 3
    0 hr 24 hr 48 hr
    prior to AKI stage prior to AKI stage prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 304 364 304 318 304 316
    Average 314 398 314 379 314 354
    Stdev 214 273 214 378 214 221
    p(t-test) 0.013 0.056 0.34
    Min 1.37 81.1 1.37 1.37 1.37 3.04
    Max 2070 1700 2070 2750 2070 913
    n (Samp) 470 47 470 53 470 28
    n (Patient) 239 47 239 53 239 28
    sCr only
    Median 318 354 318 351 318 512
    Average 340 395 340 335 340 495
    Stdev 248 284 248 113 248 264
    p(t-test) 0.51 0.95 0.040
    Min 1.37 76.2 1.37 145 1.37 161
    Max 2750 901 2750 512 2750 913
    n (Samp) 630 9 630 10 630 11
    n (Patient) 293 9 293 10 293 11
    UO only
    Median 308 364 308 315 308 318
    Average 322 394 322 384 322 367
    Stdev 217 274 217 402 217 225
    p(t-test) 0.042 0.091 0.31
    Min 1.37 81.1 1.37 1.37 1.37 3.04
    Max 2070 1700 2070 2750 2070 901
    n (Samp) 438 43 438 47 438 25
    n (Patient) 209 43 209 47 209 25
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.59 0.54 0.58 0.55 0.54 0.54 0.54 0.68 0.55
    SE 0.045 0.099 0.047 0.043 0.094 0.045 0.057 0.090 0.061
    p 0.039 0.66 0.083 0.22 0.69 0.38 0.45 0.043 0.41
    nCohort 1 470 630 438 470 630 438 470 630 438
    nCohort 2 47 9 43 53 10 47 28 11 25
    Cutoff 1 249 247 242 249 305 249 249 264 277
    Sens 1 70% 78% 72% 72% 70% 70% 71% 73% 72%
    Spec 1 39% 35% 36% 39% 47% 37% 39% 40% 44%
    Cutoff 2 178 76.8 178 174 230 171 166 249 242
    Sens 2 83% 89% 81% 81% 80% 81% 82% 82% 80%
    Spec 2 25% 11% 23% 24% 33% 22% 24% 37% 36%
    Cutoff 3 163 74.3 163 74.3 208 61.2 120 166 120
    Sens 3 91% 100%  91% 91% 90% 94% 93% 91% 92%
    Spec 3 22%  9% 20% 11% 29%  9% 15% 20% 13%
    Cutoff 4 397 414 397 397 414 397 397 414 397
    Sens 4 38% 22% 42% 38% 30% 38% 29% 64% 28%
    Spec 4 71% 71% 70% 71% 71% 70% 71% 71% 70%
    Cutoff 5 445 469 445 445 469 445 445 469 445
    Sens 5 28% 22% 30% 26% 10% 32% 25% 55% 24%
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81%
    Cutoff 6 534 574 537 534 574 537 534 574 537
    Sens 6 19% 22% 19% 11%  0% 13% 14% 36% 16%
    Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91%
    OR Quart 2 1.3 0.49 0.68 1.1 3.0 0.91 1.2 1.0 1.2
    p Value 0.63 0.57 0.45 0.84 0.34 0.83 0.79 1.0 0.77
    95% CI of 0.48 0.044 0.25 0.46 0.31 0.38 0.38 0.14 0.36
    OR Quart 2 3.3 5.5 1.9 2.6 30 2.1 3.6 7.2 4.0
    OR Quart 3 2.0 2.0 1.2 1.3 5.1 0.64 1.4 0 1.6
    p Value 0.13 0.42 0.65 0.54 0.14 0.35 0.58 na 0.40
    95% CI of 0.81 0.36 0.51 0.56 0.59 0.25 0.46 na 0.52
    OR Quart 3 4.9 11 2.9 3.0 44 1.6 4.0 na 5.1
    OR Quart 4 1.8 0.99 1.4 1.5 1.0 1.4 1.2 3.6 1.2
    p Value 0.19 0.99 0.40 0.32 1.0 0.44 0.79 0.11 0.77
    95% CI of 0.74 0.14 0.61 0.67 0.062 0.62 0.38 0.73 0.36
    OR Quart 4 4.5 7.1 3.4 3.4 16 3.0 3.6 18 4.0
    Interferon alpha-2
    0 hr 24 hr 48 hr
    prior to AKI stage prior to AKI stage prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0967 0.104 0.0967 0.0974 0.0967 0.122
    Average 7.76 13.4 7.76 8.07 7.76 11.1
    Stdev 17.7 23.4 17.7 17.5 17.7 16.9
    p(t-test) 0.018 0.89 0.24
    Min 0.0238 0.0348 0.0238 0.0348 0.0238 0.0348
    Max 126 99.7 126 77.3 126 74.5
    n (Samp) 930 62 930 70 930 39
    n (Patient) 361 62 361 70 361 39
    sCr only
    Median 0.0967 0.0724 0.0967 0.0864 0.0967 0.0967
    Average 7.73 4.18 7.73 9.65 7.73 7.16
    Stdev 18.1 13.1 18.1 22.9 18.1 12.2
    p(t-test) 0.45 0.66 0.90
    Min 0.0238 0.0238 0.0238 0.0348 0.0238 0.0369
    Max 126 50.5 126 77.3 126 39.0
    n (Samp) 1234 15 1234 18 1234 17
    n (Patient) 441 15 441 18 441 17
    UO only
    Median 0.0967 0.104 0.0967 0.0974 0.0967 1.02
    Average 7.47 15.1 7.47 6.62 7.47 12.4
    Stdev 17.2 24.8 17.2 14.3 17.2 18.2
    p(t-test) 0.0019 0.70 0.10
    Min 0.0238 0.0348 0.0238 0.0348 0.0238 0.0348
    Max 126 99.7 126 66.2 126 74.5
    n (Samp) 819 57 819 63 819 34
    n (Patient) 283 57 283 63 283 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.57 0.40 0.59 0.55 0.48 0.55 0.60 0.57 0.61
    SE 0.039 0.078 0.041 0.037 0.069 0.039 0.049 0.073 0.052
    p 0.062 0.19 0.036 0.19 0.83 0.16 0.041 0.31 0.039
    nCohort 1 930 1234 819 930 1234 819 930 1234 819
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 0.0724 0.0606 0.0724 0.0754 0.0435 0.0754 0.0754 0.0754 0.0815
    Sens 1 71% 73% 72% 70% 78% 75% 72% 76% 71%
    Spec 1 40% 26% 38% 44% 19% 42% 44% 45% 47%
    Cutoff 2 0.0656 0.0369 0.0656 0.0709 0.0398 0.0709 0.0435 0.0724 0.0435
    Sens 2 84% 80% 82% 81% 83% 83% 82% 82% 82%
    Spec 2 29% 11% 27% 36% 15% 34% 19% 41% 17%
    Cutoff 3 0.0398 0.0238 0.0398 0.0398 0.0369 0.0398 0.0369 0.0398 0.0369
    Sens 3 92% 93% 91% 93% 94% 94% 92% 94% 91%
    Spec 3 14% 3% 12% 14% 11% 12% 10% 15% 10%
    Cutoff 4 0.311 0.311 0.311 0.311 0.311 0.311 0.311 0.311 0.311
    Sens 4 34% 13% 39% 24% 17% 25% 49% 35% 50%
    Spec 4 73% 74% 73% 73% 74% 73% 73% 74% 73%
    Cutoff 5 10.9 10.8 9.93 10.9 10.8 9.93 10.9 10.8 9.93
    Sens 5 32% 13% 37% 20% 17% 21% 38% 29% 44%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 30.2 29.7 30.0 30.2 29.7 30.0 30.2 29.7 30.0
    Sens 6 19%  7% 21% 11% 17%  8% 13%  6% 15%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.0 1.0 1.5 1.4 2.0 1.6 0.62 3.0 0.56
    p Value 0.090 1.00 0.31 0.44 0.32 0.29 0.40 0.18 0.37
    95% CI of 0.90 0.14 0.67 0.63 0.50 0.67 0.20 0.61 0.16
    OR Quart 2 4.3 7.2 3.5 2.9 8.1 3.7 1.9 15 2.0
    OR Quart 3 1.2 3.6 1.1 2.2 1.0 2.9 1.3 2.0 1.1
    p Value 0.66 0.11 0.82 0.030 1.0 0.0089 0.63 0.42 0.79
    95% CI of 0.51 0.74 0.46 1.1 0.20 1.3 0.49 0.36 0.41
    OR Quart 3 2.9 17 2.7 4.5 5.0 6.3 3.3 11 3.2
    OR Quart 4 2.2 2.0 2.2 1.4 2.0 1.8 2.1 2.5 2.2
    p Value 0.046 0.42 0.045 0.34 0.32 0.16 0.10 0.27 0.089
    95% CI of 1.0 0.37 1.0 0.68 0.50 0.79 0.87 0.48 0.89
    OR Quart 4 4.8 11 4.8 3.1 8.1 4.2 4.9 13 5.6
    Insulin-like growth factor-binding protein 4
    0 hr prior to 24 hr prior to 48 hr prior to
    AKI stage AKI stage AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.733 0.441 0.733 0.923 0.733 0.660
    Average 1.83 1.47 1.83 2.61 1.83 0.852
    Stdev 6.92 2.61 6.92 4.90 6.92 0.999
    p(t-test) 0.77 0.49 0.53
    Min 0.0319 0.0319 0.0319 0.0319 0.0319 0.0319
    Max 85.6 13.8 85.6 28.0 85.6 3.77
    n (Samp) 322 31 322 40 322 20
    n (Patient) 185 31 185 40 185 20
    sCr only
    Median nd nd 0.733 0.733 0.733 1.80
    Average nd nd 1.77 2.04 1.77 2.08
    Stdev nd nd 6.31 3.45 6.31 2.18
    p(t-test) nd nd 0.91 0.89
    Min nd nd 0.0319 0.0319 0.0319 0.0612
    Max nd nd 85.6 9.68 85.6 6.53
    n (Samp) nd nd 416 7 416 8
    n (Patient) nd nd 221 7 221 8
    UO only
    Median 0.733 0.419 0.733 0.923 0.733 0.733
    Average 1.91 1.67 1.91 2.55 1.91 0.946
    Stdev 7.28 3.20 7.28 4.93 7.28 1.21
    p(t-test) 0.86 0.60 0.57
    Min 0.0319 0.0319 0.0319 0.0319 0.0319 0.0319
    Max 85.6 13.8 85.6 28.0 85.6 4.20
    n (Samp) 290 30 290 37 290 19
    n (Patient) 158 30 158 37 158 19
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.52 nd 0.52 0.58 0.54 0.59 0.48 0.66 0.48
    SE 0.055 nd 0.056 0.050 0.11 0.052 0.067 0.11 0.069
    p 0.69 nd 0.78 0.10 0.75 0.081 0.72 0.13 0.74
    nCohort 1 322 nd 290 322 416 290 322 416 290
    nCohort 2 31 nd 30 40 7 37 20 8 19
    Cutoff 1 0.184 nd 0.141 0.390 0.390 0.390 0.0439 0.390 0.0439
    Sens 1 71% nd 70% 72% 71% 73% 85% 75% 84%
    Spec 1 29% nd 30% 37% 38% 38% 11% 38% 12%
    Cutoff 2 0.0585 nd 0.0585 0.184 0.184 0.0585 0.0439 0.141 0.0439
    Sens 2 81% nd 80% 80% 86% 86% 85% 88% 84%
    Spec 2 15% nd 15% 29% 30% 15% 11% 30% 12%
    Cutoff 3 0 nd 0 0.0439 0 0.0439 0 0.0585 0
    Sens 3 100%  nd 100%  92% 100%  92% 100%  100%  100% 
    Spec 3  0% nd  0% 11%  0% 12%  0% 18%  0%
    Cutoff 4 0.957 nd 0.957 0.957 0.957 0.957 0.957 0.957 0.957
    Sens 4 32% nd 30% 35% 29% 35% 25% 50% 26%
    Spec 4 76% nd 76% 76% 75% 76% 76% 75% 76%
    Cutoff 5 1.37 nd 1.27 1.37 1.46 1.27 1.37 1.46 1.27
    Sens 5 26% nd 23% 35% 29% 35% 20% 50% 21%
    Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 3.09 nd 3.12 3.09 3.30 3.12 3.09 3.30 3.12
    Sens 6 10% nd 10% 22% 14% 22%  5% 12% 11%
    Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.0 nd 1.8 1.6 3.0 0.85 1.0 2.0 0.80
    p Value 1.0 nd 0.30 0.34 0.34 0.77 0.98 0.57 0.75
    95% CI of 0.36 nd 0.61 0.60 0.31 0.29 0.28 0.18 0.21
    OR Quart 2 2.8 nd 5.1 4.4 30 2.5 3.6 23 3.1
    OR Quart 3 0.60 nd 0.82 1.2 0.99 1.1 0.59 1.0 0.59
    p Value 0.39 nd 0.76 0.79 0.99 0.82 0.47 1.0 0.48
    95% CI of 0.19 nd 0.24 0.40 0.061 0.41 0.14 0.062 0.14
    OR Quart 3 1.9 nd 2.8 3.3 16 3.1 2.5 16 2.6
    OR Quart 4 1.3 nd 1.6 2.2 2.0 1.7 1.5 4.1 1.5
    p Value 0.64 nd 0.42 0.12 0.57 0.26 0.54 0.21 0.53
    95% CI of 0.47 nd 0.53 0.83 0.18 0.67 0.44 0.45 0.44
    OR Quart 4 3.4 nd 4.6 5.6 22 4.4 4.8 37 4.8
    Insulin-like growth factor-binding protein 5
    0 hr prior to 24 hr prior to 48 hr prior to
    AKI stage AKI stage AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0682 0.397 0.0682 0.0682 0.0682 0.248
    Average 0.587 1.22 0.587 0.858 0.587 0.859
    Stdev 1.27 2.10 1.27 1.63 1.27 1.19
    p(t-test) 0.014 0.22 0.35
    Min 0.0116 0.0116 0.0116 0.0116 0.0116 0.0116
    Max 9.43 10.0 9.43 8.53 9.43 3.48
    n (Samp) 323 31 323 40 323 20
    n (Patient) 186 31 186 40 186 20
    sCr only
    Median nd nd 0.0682 0.0407 0.0682 0.811
    Average nd nd 0.624 0.664 0.624 1.23
    Stdev nd nd 1.30 1.15 1.30 1.34
    p(t-test) nd nd 0.94 0.19
    Min nd nd 0.0116 0.0116 0.0116 0.0393
    Max nd nd 9.43 2.99 9.43 3.48
    n (Samp) nd nd 417 7 417 8
    n (Patient) nd nd 222 7 222 8
    UO only
    Median 0.0682 0.397 0.0682 0.0682 0.0682 0.0938
    Average 0.598 0.937 0.598 0.815 0.598 1.22
    Stdev 1.39 1.50 1.39 1.64 1.39 2.37
    p(t-test) 0.21 0.38 0.073
    Min 0.0116 0.0116 0.0116 0.0116 0.0116 0.0116
    Max 10.3 5.59 10.3 8.53 10.3 10.0
    n (Samp) 291 30 291 37 291 19
    n (Patient) 159 30 159 37 159 19
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.64 nd 0.64 0.52 0.48 0.51 0.61 0.73 0.59
    SE 0.056 nd 0.057 0.049 0.11 0.051 0.069 0.10 0.071
    p 0.0099 nd 0.012 0.66 0.84 0.83 0.12 0.026 0.22
    nCohort 1 323 nd 291 323 417 291 323 417 291
    nCohort 2 31 nd 30 40 7 37 20 8 19
    Cutoff 1 0.0544 nd 0.0544 0.0262 0.0262 0.0262 0.0400 0.0838 0.0358
    Sens 1 81% nd 80% 75% 71% 73% 75% 75% 79%
    Spec 1 48% nd 48% 23% 23% 22% 38% 59% 35%
    Cutoff 2 0.0544 nd 0.0544 0.0116 0.0116 0.0116 0.0358 0.0544 0.0262
    Sens 2 81% nd 80% 90% 86% 89% 85% 88% 84%
    Spec 2 48% nd 48% 11% 12% 12% 36% 46% 22%
    Cutoff 3 0 nd 0 0.0116 0 0 0.0116 0.0358 0
    Sens 3 100%  nd 100%  90% 100%  100%  90% 100%  100% 
    Spec 3  0% nd  0% 11%  0%  0% 11% 34%  0%
    Cutoff 4 0.397 nd 0.232 0.397 0.397 0.232 0.397 0.397 0.232
    Sens 4 39% nd 57% 32% 29% 35% 30% 50% 47%
    Spec 4 79% nd 70% 79% 77% 70% 79% 77% 70%
    Cutoff 5 0.518 nd 0.397 0.518 0.689 0.397 0.518 0.689 0.397
    Sens 5 35% nd 40% 32% 29% 30% 30% 50% 32%
    Spec 5 80% nd 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 1.99 nd 1.99 1.99 2.04 1.99 1.99 2.04 1.99
    Sens 6 16% nd 13% 12% 14% 11% 25% 25% 26%
    Spec 6 91% nd 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 0.78 nd 0.19 0.69 0.50 0.78 1.3 >1.0 1.7
    p Value 0.72 nd 0.13 0.45 0.57 0.62 0.71 <0.99 0.48
    95% CI of 0.20 nd 0.022 0.26 0.044 0.29 0.29 >0.062 0.39
    OR Quart 2 3.0 nd 1.7 1.8 5.5 2.1 6.1 na 7.3
    OR Quart 3 2.1 nd 2.6 0.69 1.0 0.78 1.3 >3.1 1.0
    p Value 0.19 nd 0.081 0.45 1.0 0.62 0.71 <0.33 1.0
    95% CI of 0.70 nd 0.89 0.26 0.14 0.29 0.29 >0.32 0.20
    OR Quart 3 6.5 nd 7.9 1.8 7.2 2.1 6.1 na 5.1
    OR Quart 4 2.6 nd 2.6 1.2 1.0 1.1 3.2 >4.1 2.8
    p Value 0.087 nd 0.086 0.68 1.0 0.82 0.090 <0.21 0.14
    95% CI of 0.87 nd 0.87 0.51 0.14 0.45 0.83 >0.45 0.72
    OR Quart 4 7.7 nd 7.8 2.8 7.2 2.8 12 na 11
    Immunoglogulin G4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 209 304 209 353 209 170
    Average 471 576 471 661 471 294
    Stdev 682 766 682 753 682 441
    p (t-test) 0.24 0.025 0.11
    Min 0.00862 5.90 0.00862 2.63 0.00862 0.203
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 922 62 922 70 922 39
    n (Patient) 358 62 358 70 358 39
    sCr only
    Median 219 288 219 330 219 354
    Average 499 473 499 635 499 492
    Stdev 704 698 704 799 704 600
    p (t-test) 0.89 0.42 0.97
    Min 0.00642 27.3 0.00642 11.5 0.00642 8.44
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 1225 15 1225 18 1225 17
    n (Patient) 438 15 438 18 438 17
    UO only
    Median 227 336 227 384 227 201
    Average 487 639 487 743 487 364
    Stdev 688 802 688 797 688 519
    p (t-test) 0.11 0.0050 0.30
    Min 0.00962 5.90 0.00962 2.63 0.00962 0.203
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 810 57 810 63 810 34
    n (Patient) 280 57 280 63 280 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.51 0.58 0.60 0.54 0.62 0.45 0.54 0.47
    SE 0.039 0.076 0.041 0.037 0.070 0.039 0.048 0.072 0.051
    p 0.11 0.88 0.055 0.0084 0.52 0.0019 0.28 0.55 0.60
    nCohort 1 922 1225 810 922 1225 810 922 1225 810
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 174 143 189 146 103 182 75.7 118 78.5
    Sens 1 71% 73% 70% 70% 72% 71% 72% 71% 71%
    Spec 1 46% 38% 46% 41% 31% 46% 28% 34% 27%
    Cutoff 2 45.1 108 57.6 103 34.8 112 53.9 53.9 67.5
    Sens 2 81% 80% 81% 80% 83% 81% 82% 82% 82%
    Spec 2 20% 32% 23% 32% 15% 33% 22% 21% 25%
    Cutoff 3 28.9 36.0 28.0 27.6 21.7 81.1 10.6 11.0 26.3
    Sens 3 90% 93% 91% 90% 94% 90% 92% 94% 91%
    Spec 3 13% 15% 12% 13% 10% 27%  6%  6% 11%
    Cutoff 4 389 416 409 389 416 409 389 416 409
    Sens 4 37% 20% 42% 46% 39% 48% 23% 41% 26%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 581 622 609 581 622 609 581 622 609
    Sens 5 21% 13% 25% 33% 28% 38% 8% 29% 12%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1540 2060 1570 1540 2060 1570 1540 2060 1570
    Sens 6 15%  7% 16% 16% 11% 17%  3%  6%  6%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.70 1.0 0.65 2.0 0.75 2.8 1.9 0.75 2.0
    p Value 0.40 1.0 0.36 0.11 0.70 0.035 0.22 0.70 0.20
    95% CI of 0.31 0.20 0.26 0.85 0.17 1.1 0.68 0.17 0.69
    OR Quart 2 1.6 5.0 1.6 4.5 3.4 7.3 5.2 3.4 6.1
    OR Quart 3 1.5 2.4 1.6 2.0 1.00 2.4 2.2 1.3 2.5
    p Value 0.29 0.22 0.20 0.11 1.00 0.075 0.11 0.74 0.093
    95% CI of 0.72 0.61 0.77 0.85 0.25 0.91 0.84 0.33 0.86
    OR Quart 3 3.0 9.2 3.4 4.5 4.0 6.4 6.0 4.7 7.2
    OR Quart 4 1.3 0.66 1.5 3.2 1.8 5.0 1.5 1.2 1.4
    p Value 0.47 0.66 0.26 0.0030 0.37 5.2E−4 0.43 0.74 0.56
    95% CI of 0.64 0.11 0.72 1.5 0.51 2.0 0.53 0.33 0.44
    OR Quart 4 2.7 4.0 3.3 7.1 6.1 12 4.4 4.7 4.5
    Interleukin-21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 8.31 3.89 8.31 5.21 8.31 4.89
    Average 11.3 7.73 11.3 7.98 11.3 7.18
    Stdev 11.5 9.96 11.5 8.29 11.5 6.85
    p (t-test) 0.018 0.019 0.028
    Min 0.00404 0.00761 0.00404 0.00404 0.00404 0.0177
    Max 87.9 56.2 87.9 33.5 87.9 27.6
    n (Samp) 928 62 928 70 928 39
    n (Patient) 361 62 361 70 361 39
    sCr only
    Median 7.64 8.82 7.64 7.31 7.64 5.50
    Average 10.7 15.1 10.7 9.85 10.7 10.5
    Stdev 11.4 15.6 11.4 8.89 11.4 9.11
    p (t-test) 0.14 0.76 0.96
    Min 0.00404 0.418 0.00404 0.0537 0.00404 1.29
    Max 105 56.2 105 29.9 105 27.6
    n (Samp) 1232 15 1232 18 1232 17
    n (Patient) 441 15 441 18 441 17
    UO only
    Median 8.23 3.57 8.23 4.60 8.23 3.75
    Average 11.0 6.36 11.0 7.33 11.0 6.34
    Stdev 11.1 6.83 11.1 7.99 11.1 6.02
    p (t-test) 0.0020 0.011 0.016
    Min 0.00404 0.00761 0.00404 0.00404 0.00404 0.0177
    Max 87.9 26.7 87.9 33.5 87.9 19.3
    n (Samp) 817 57 817 63 817 34
    n (Patient) 283 57 283 63 283 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.40 0.58 0.38 0.42 0.50 0.41 0.41 0.53 0.39
    SE 0.039 0.078 0.041 0.037 0.069 0.039 0.049 0.072 0.052
    p 0.0075 0.29 0.0030 0.031 0.95 0.015 0.058 0.68 0.031
    nCohort 1 928 1232 817 928 1232 817 928 1232 817
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 1.78 3.73 1.78 2.09 3.24 1.37 2.16 3.10 2.55
    Sens 1 71% 73% 70% 70% 72% 71% 72% 71% 71%
    Spec 1 20% 34% 21% 23% 32% 18% 24% 31% 27%
    Cutoff 2 1.26 3.01 1.04 1.13 2.34 1.04 0.728 2.18 0.386
    Sens 2 81% 80% 81% 80% 83% 81% 82% 82% 82%
    Spec 2 16% 31% 16% 16% 26% 16% 13% 25% 12%
    Cutoff 3 0.161 1.29 0.161 0.527 0.0537 0.527 0.0528 1.58 0.0528
    Sens 3 92% 93% 91% 90% 94% 90% 92% 94% 91%
    Spec 3  9% 18% 10% 12%  7% 13%  6% 21%  7%
    Cutoff 4 14.4 13.5 14.2 14.4 13.5 14.2 14.4 13.5 14.2
    Sens 4 18% 47% 14% 21% 33% 19% 15% 35% 15%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 18.6 17.9 18.6 18.6 17.9 18.6 18.6 17.9 18.6
    Sens 5 16% 47% 11% 13% 17% 11%  8% 24%  6%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 25.8 24.7 25.4 25.8 24.7 25.4 25.8 24.7 25.4
    Sens 6  5% 20%  2%  4% 11%  5%  3% 12%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.90 2.5 2.1 1.8 2.0 1.9 4.2 0.80 3.1
    p Value 0.82 0.27 0.15 0.15 0.33 0.18 0.029 0.74 0.094
    95% CI of 0.36 0.48 0.76 0.80 0.50 0.75 1.2 0.21 0.82
    OR Quart 2 2.3 13 5.6 4.2 8.1 4.9 15 3.0 12
    OR Quart 3 2.4 0.50 3.6 2.7 1.7 3.2 4.2 0.60 4.2
    p Value 0.023 0.57 0.0075 0.013 0.48 0.0091 0.029 0.48 0.029
    95% CI of 1.1 0.045 1.4 1.2 0.40 1.3 1.2 0.14 1.2
    OR Quart 3 5.2 5.5 9.1 6.0 7.1 7.7 15 2.5 15
    OR Quart 4 2.1 3.5 3.4 2.6 1.3 3.4 4.2 1.00 3.5
    p Value 0.063 0.12 0.011 0.019 0.71 0.0062 0.028 1.00 0.062
    95% CI of 0.96 0.73 1.3 1.2 0.30 1.4 1.2 0.29 0.94
    OR Quart 4 4.6 17 8.7 5.8 6.0 8.1 15 3.5 13
    Interleukin-23
    0 hr prior to 24 hr prior 48 hr prior to
    AKI stage to AKI stage AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 304 141 304 222 304 79.6
    Average 548 252 548 379 548 292
    Stdev 730 346 730 415 730 518
    p (t-test) 0.0016 0.056 0.030
    Min 0.491 0.491 0.491 0.564 0.491 0.491
    Max 8520 1350 8520 1540 8520 2340
    n (Samp) 928 62 928 70 928 39
    n (Patient) 361 62 361 70 361 39
    sCr only
    Median 246 105 246 293 246 190
    Average 499 379 499 399 499 407
    Stdev 691 583 691 423 691 494
    p (t-test) 0.50 0.54 0.58
    Min 0.491 0.491 0.491 0.564 0.491 0.651
    Max 8520 2120 8520 1370 8520 1820
    n (Samp) 1232 15 1232 18 1232 17
    n (Patient) 441 15 441 18 441 17
    UO only
    Median 311 141 311 173 311 75.4
    Average 552 248 552 335 552 232
    Stdev 733 341 733 398 733 466
    p (t-test) 0.0020 0.020 0.012
    Min 0.491 0.491 0.491 0.564 0.491 0.491
    Max 8520 1350 8520 1540 8520 2340
    n (Samp) 817 57 817 63 817 34
    n (Patient) 283 57 283 63 283 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.37 0.43 0.36 0.47 0.49 0.44 0.36 0.50 0.32
    SE 0.039 0.077 0.041 0.036 0.069 0.039 0.049 0.071 0.052
    p 8.8E−4 0.35 6.3E−4 0.36 0.87 0.097 0.0040 0.97 6.3E−4
    nCohort 1 928 1232 817 928 1232 817 928 1232 817
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 1.06 1.05 1.06 48.7 1.21 16.8 1.06 79.3 1.06
    Sens 1 71% 73% 70% 70% 72% 71% 72% 71% 71%
    Spec 1 18% 19% 18% 29% 24% 25% 18% 35% 18%
    Cutoff 2 0.754 0.754 0.754 1.21 1.08 1.08 0.754 1.41 0.754
    Sens 2 87% 87% 84% 80% 83% 81% 82% 82% 82%
    Spec 2 10% 11% 10% 21% 20% 18% 10% 26% 10%
    Cutoff 3 0.682 0.682 0.643 0.844 0.682 0.844 0.552 0.844 0.552
    Sens 3 92% 93% 91% 91% 94% 90% 92% 94% 91%
    Spec 3  6%  6%  4% 13%  6% 13%  1% 14%  1%
    Cutoff 4 640 583 647 640 583 647 640 583 647
    Sens 4 13% 27% 11% 26% 39% 19% 13% 29%  6%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 923 857 935 923 857 935 923 857 935
    Sens 5 10% 13%  9% 11% 11% 10% 10% 18%  6%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1520 1380 1460 1520 1380 1460 1520 1380 1460
    Sens 6  0%  7%  0%  3%  0%  3%  5%  6%  3%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.2 0.66 1.4 1.9 0.80 2.2 2.0 0.60 3.1
    p Value 0.79 0.66 0.58 0.098 0.74 0.070 0.25 0.48 0.17
    95% CI of 0.41 0.11 0.46 0.89 0.21 0.94 0.60 0.14 0.61
    OR Quart 2 3.2 4.0 4.0 4.0 3.0 5.3 6.8 2.5 15
    OR Quart 3 3.7 1.7 3.8 2.1 0.60 2.8 2.8 1.2 5.7
    p Value 0.0030 0.48 0.0051 0.052 0.48 0.016 0.078 0.76 0.024
    95% CI of 1.6 0.40 1.5 0.99 0.14 1.2 0.89 0.36 1.3
    OR Quart 3 8.7 7.1 9.5 4.4 2.5 6.5 9.0 4.0 26
    OR Quart 4 3.5 1.7 4.0 1.6 1.2 2.2 4.2 0.60 8.0
    p Value 0.0042 0.48 0.0033 0.24 0.76 0.070 0.011 0.48 0.0061
    95% CI of 1.5 0.40 1.6 0.73 0.36 0.94 1.4 0.14 1.8
    OR Quart 4 8.4 7.1 10 3.5 4.0 5.3 13 2.5 36
    Interleukin-28A
    0 hr prior to 24 hr prior 48 hr prior
    AKI stage to AKI stage to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 16.3 11.6 16.3 22.4 16.3 6.62
    Average 34.6 24.2 34.6 32.9 34.6 18.5
    Stdev 45.7 33.4 45.7 37.2 45.7 24.7
    p (t-test) 0.080 0.76 0.029
    Min 0.0254 0.0517 0.0254 0.0495 0.0254 0.0517
    Max 587 164 587 156 587 82.9
    n (Samp) 928 62 928 70 928 39
    n (Patient) 361 62 361 70 361 39
    sCr only
    Median 14.7 20.2 14.7 26.1 14.7 22.5
    Average 32.5 29.6 32.5 36.7 32.5 27.9
    Stdev 43.6 31.8 43.6 38.1 43.6 28.4
    p (t-test) 0.80 0.68 0.67
    Min 0.0254 0.0777 0.0254 0.0517 0.0254 0.155
    Max 587 105 587 131 587 82.9
    n (Samp) 1232 15 1232 18 1232 17
    n (Patient) 441 15 441 18 441 17
    UO only
    Median 18.7 8.37 18.7 14.6 18.7 3.36
    Average 35.5 22.9 35.5 28.2 35.5 14.5
    Stdev 46.4 33.0 46.4 34.9 46.4 19.7
    p (t-test) 0.044 0.22 0.0088
    Min 0.0254 0.0517 0.0254 0.0495 0.0254 0.0517
    Max 587 164 587 156 587 70.2
    n (Samp) 817 57 817 63 817 34
    n (Patient) 283 57 283 63 283 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 0.53 0.43 0.52 0.57 0.48 0.41 0.54 0.38
    SE 0.039 0.076 0.041 0.036 0.071 0.038 0.049 0.072 0.052
    p 0.20 0.70 0.097 0.59 0.34 0.54 0.081 0.62 0.018
    nCohort 1 928 1232 817 928 1232 817 928 1232 817
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 0.194 4.33 0.194 8.60 16.3 0.243 0.194 4.11 0.194
    Sens 1 74% 73% 74% 70% 72% 71% 72% 71% 71%
    Spec 1 24% 39% 24% 41% 52% 28% 24% 38% 24%
    Cutoff 2 0.176 3.53 0.176 0.194 7.98 0.184 0.142 0.184 0.0896
    Sens 2 84% 80% 84% 80% 83% 81% 82% 82% 88%
    Spec 2 22% 38% 21% 24% 41% 22% 18% 25% 14%
    Cutoff 3 0.0896 0.0896 0.0896 0.142 0.0854 0.0854 0.0854 0.176 0.0854
    Sens 3 90% 93% 91% 90% 94% 90% 97% 94% 97%
    Spec 3 14% 15% 14% 18% 12% 12% 12% 23% 12%
    Cutoff 4 47.5 44.0 50.6 47.5 44.0 50.6 47.5 44.0 50.6
    Sens 4 16% 33% 14% 24% 22% 19% 15% 29%  9%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 65.2 61.1 66.6 65.2 61.1 66.6 65.2 61.1 66.6
    Sens 5 10% 20% 11% 19% 22% 14%  8% 12%  3%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 90.8 88.8 91.5 90.8 88.8 91.5 90.8 88.8 91.5
    Sens 6  5%  7%  4%  9% 11%  6%  0%  0%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.8 2.0 2.4 1.1 0.66 1.9 1.8 1.3 5.2
    p Value 0.17 0.42 0.059 0.72 0.65 0.098 0.28 0.70 0.035
    95% CI of 0.79 0.36 0.97 0.56 0.11 0.89 0.60 0.30 1.1
    OR Quart 2 3.9 11 6.0 2.3 4.0 4.1 5.5 6.0 24
    OR Quart 3 1.6 2.5 2.4 1.6 3.1 1.5 2.9 2.0 4.1
    p Value 0.23 0.27 0.061 0.18 0.096 0.32 0.044 0.32 0.076
    95% CI of 0.73 0.48 0.96 0.81 0.82 0.68 1.0 0.50 0.86
    OR Quart 3 3.7 13 5.9 3.1 11 3.3 8.2 8.1 20
    OR Quart 4 2.0 2.0 2.7 1.00 1.3 1.5 2.3 1.3 7.5
    p Value 0.088 0.42 0.028 0.99 0.71 0.32 0.13 0.71 0.0084
    95% CI of 0.90 0.36 1.1 0.48 0.30 0.68 0.78 0.30 1.7
    OR Quart 4 4.4 11 6.7 2.1 6.0 3.3 6.6 6.0 33
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 43.8 20.7 43.8 37.6 43.8 25.0
    Average 60.0 31.0 60.0 44.0 60.0 34.4
    Stdev 64.2 30.3 64.2 41.1 64.2 39.8
    p (t-test) 4.5E−4 0.041 0.014
    Min 0.0232 0.0360 0.0232 0.0232 0.0232 0.0554
    Max 958 112 958 235 958 148
    n (Samp) 928 62 928 70 928 39
    n (Patient) 361 62 361 70 361 39
    sCr only
    Median 41.0 33.6 41.0 43.0 41.0 26.5
    Average 56.3 42.0 56.3 44.8 56.3 50.6
    Stdev 61.2 34.0 61.2 34.6 61.2 47.5
    p (t-test) 0.37 0.43 0.70
    Min 0.0232 3.22 0.0232 0.0591 0.0232 0.111
    Max 958 109 958 117 958 146
    n (Samp) 1232 15 1232 18 1232 17
    n (Patient) 441 15 441 18 441 17
    UO only
    Median 43.9 17.8 43.9 32.9 43.9 19.2
    Average 60.2 29.1 60.2 41.1 60.2 32.0
    Stdev 65.3 29.7 65.3 41.1 65.3 38.0
    p (t-test) 3.8E−4 0.023 0.013
    Min 0.0232 0.0360 0.0232 0.0232 0.0232 0.0554
    Max 958 112 958 235 958 148
    n (Samp) 817 57 817 63 817 34
    n (Patient) 283 57 283 63 283 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.36 0.46 0.34 0.44 0.48 0.41 0.36 0.49 0.34
    SE 0.039 0.076 0.040 0.037 0.069 0.039 0.049 0.071 0.052
    p 2.1E−4 0.64 5.1E−5 0.091 0.77 0.028 0.0046 0.89 0.0028
    nCohort 1 928 1232 817 928 1232 817 928 1232 817
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 10.4 14.5 7.17 16.2 23.2 14.5 7.06 17.0 7.06
    Sens 1 71% 73% 70% 70% 72% 71% 72% 71% 71%
    Spec 1 21% 26% 18% 26% 34% 24% 18% 29% 18%
    Cutoff 2 4.04 14.2 2.67 12.4 13.6 8.99 2.98 10.4 0.0768
    Sens 2 81% 80% 81% 80% 83% 81% 82% 82% 82%
    Spec 2 15% 26% 14% 23% 25% 19% 15% 22%  9%
    Cutoff 3 0.0837 10.4 0.0558 0.106 0.0749 0.106 0.0686 5.13 0.0686
    Sens 3 90% 93% 91% 91% 94% 90% 95% 94% 94%
    Spec 3 11% 22%  4% 11%  9% 11%  6% 17%  6%
    Cutoff 4 78.3 73.3 77.4 78.3 73.3 77.4 78.3 73.3 77.4
    Sens 4  8% 20%  7% 16% 22% 13% 13% 24% 12%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 99.1 93.9 98.2 99.1 93.9 98.2 99.1 93.9 98.2
    Sens 5  5% 13%  4%  9% 11%  6% 10% 24%  9%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 135 127 135 135 127 135 135 127 135
    Sens 6  0%  0%  0%  1%  0%  2%  5%  6%  6%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 3.9 2.0 4.9 3.2 2.0 2.8 1.8 1.0 2.0
    p Value 0.016 0.42 0.013 0.0092 0.32 0.035 0.37 1.00 0.32
    95% CI of 1.3 0.37 1.4 1.3 0.50 1.1 0.51 0.25 0.50
    OR Quart 2 12 11 17 7.7 8.2 7.3 6.1 4.0 8.2
    OR Quart 3 4.8 3.0 5.7 3.2 2.0 3.6 2.8 1.3 2.7
    p Value 0.0053 0.18 0.0064 0.0094 0.32 0.0075 0.078 0.73 0.14
    95% CI of 1.6 0.61 1.6 1.3 0.50 1.4 0.89 0.33 0.71
    OR Quart 3 14 15 20 7.6 8.1 9.1 9.0 4.7 10
    OR Quart 4 6.9 1.5 8.9 3.2 1.0 3.8 4.5 1.0 6.1
    p Value 4.2E−4 0.65 4.2E−4 0.0092 1.00 0.0051 0.0075 1.00 0.0043
    95% CI of 2.4 0.25 2.6 1.3 0.20 1.5 1.5 0.25 1.8
    OR Quart 4 20 9.1 30 7.7 5.0 9.5 14 4.0 21
    Interleukin-4 receptor alpha chain
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 46.5 47.2 46.5 69.4 46.5 48.6
    Average 56.0 57.0 56.0 76.7 56.0 50.1
    Stdev 49.4 56.5 49.4 60.5 49.4 32.8
    p (t-test) 0.89 0.0057 0.54
    Min 0.839 2.31 0.839 2.31 0.839 4.67
    Max 297 293 297 239 297 112
    n (Samp) 460 46 460 51 460 28
    n (Patient) 234 46 234 51 234 28
    sCr only
    Median 47.8 24.4 47.8 76.6 47.8 85.3
    Average 58.1 40.6 58.1 68.4 58.1 82.2
    Stdev 53.5 34.4 53.5 58.4 53.5 46.3
    p (t-test) 0.33 0.53 0.14
    Min 0.839 10.3 0.839 4.67 0.839 10.3
    Max 299 97.7 299 200 299 154
    n (Samp) 617 9 617 11 617 11
    n (Patient) 287 9 287 11 287 11
    UO only
    Median 46.2 49.3 46.2 68.0 46.2 49.3
    Average 56.2 60.7 56.2 75.6 56.2 50.8
    Stdev 50.8 57.8 50.8 60.5 50.8 32.2
    p (t-test) 0.59 0.017 0.60
    Min 0.839 2.31 0.839 2.31 0.839 4.67
    Max 297 293 297 239 297 122
    n (Samp) 431 42 431 45 431 25
    n (Patient) 206 42 206 45 206 25
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.50 0.45 0.51 0.61 0.56 0.60 0.50 0.67 0.51
    SE 0.045 0.100 0.047 0.044 0.090 0.047 0.056 0.090 0.060
    p 0.97 0.60 0.75 0.012 0.53 0.025 0.94 0.057 0.81
    nCohort 1 460 617 431 460 617 431 460 617 431
    nCohort 2 46 9 42 51 11 45 28 11 25
    Cutoff 1 11.8 11.8 19.1 35.1 24.0 35.1 38.0 67.2 38.0
    Sens 1 80% 89% 71% 71% 73% 71% 71% 73% 72%
    Spec 1 25% 24% 33% 42% 34% 42% 42% 64% 43%
    Cutoff 2 11.8 11.8 11.3 11.8 11.8 11.8 11.8 41.5 19.1
    Sens 2 80% 89% 81% 86% 82% 84% 86% 82% 80%
    Spec 2 25% 24% 21% 25% 24% 25% 25% 46% 33%
    Cutoff 3 7.93 9.16 6.56 11.3 6.56 9.16 9.16 11.8 10.3
    Sens 3 91% 100%  93% 90% 91% 91% 93% 91% 92%
    Spec 3 13% 12%  6% 20%  6% 13% 13% 24% 20%
    Cutoff 4 75.2 75.2 75.2 75.2 75.2 75.2 75.2 75.2 75.2
    Sens 4 24% 22% 26% 45% 55% 40% 18% 64% 16%
    Spec 4 71% 71% 71% 71% 71% 71% 71% 71% 71%
    Cutoff 5 93.9 95.7 93.9 93.9 95.7 93.9 93.9 95.7 93.9
    Sens 5 22% 11% 24% 31% 18% 33% 14% 45% 12%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 116 126 122 116 126 122 116 126 122
    Sens 6 17%  0% 17% 20%  9% 18%  7% 18%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.3 1.0 1.2 1.5 1.0 1.0 2.3 2.0 2.8
    p Value 0.50 0.99 0.64 0.46 1.0 1.0 0.16 0.57 0.14
    95% CI of 0.57 0.14 0.50 0.54 0.14 0.34 0.70 0.18 0.72
    OR Quart 2 3.2 7.2 3.1 3.9 7.2 2.9 7.8 22 11
    OR Quart 3 1.4 2.0 1.4 2.3 1.5 2.3 2.9 3.0 3.6
    p Value 0.39 0.42 0.49 0.084 0.65 0.080 0.073 0.34 0.059
    95% CI of 0.62 0.37 0.55 0.89 0.25 0.91 0.90 0.31 0.95
    OR Quart 3 3.4 11 3.4 5.8 9.2 5.9 9.5 30 13
    OR Quart 4 0.90 0.50 1.1 3.0 2.0 2.5 1.0 5.1 1.3
    p Value 0.83 0.57 0.83 0.018 0.42 0.054 1.0 0.14 0.70
    95% CI of 0.35 0.045 0.43 1.2 0.37 0.98 0.24 0.59 0.29
    OR Quart 4 2.3 5.6 2.8 7.4 11 6.3 4.1 44 6.2
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 545 857 545 746 545 455
    Average 735 1230 735 997 735 642
    Stdev 803 1210 803 952 803 706
    p (t-test) 1.7E−4 0.030 0.56
    Min 0.218 1.48 0.218 0.218 0.218 1.48
    Max 7140 5940 7140 4750 7140 2820
    n (Samp) 462 46 462 51 462 27
    n (Patient) 235 46 235 51 235 27
    sCr only
    Median 651 806 651 658 651 609
    Average 863 1060 863 954 863 522
    Stdev 917 1180 917 975 917 406
    p (t-test) 0.53 0.76 0.22
    Min 0.218 1.48 0.218 1.48 0.218 1.48
    Max 7140 3710 7140 2870 7140 1350
    n (Samp) 618 9 618 10 618 11
    n (Patient) 288 9 288 10 288 11
    UO only
    Median 539 932 539 825 539 495
    Average 732 1240 732 1040 732 714
    Stdev 805 1170 805 967 805 722
    p (t-test) 2.4E−4 0.018 0.91
    Min 0.218 10.8 0.218 0.218 0.218 1.48
    Max 7140 5940 7140 4750 7140 2820
    n (Samp) 433 42 433 45 433 24
    n (Patient) 207 42 207 45 207 24
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.64 0.54 0.66 0.60 0.53 0.61 0.46 0.41 0.50
    SE 0.046 0.099 0.048 0.044 0.093 0.046 0.058 0.091 0.061
    p 0.0017 0.72 8.4E−4 0.028 0.78 0.017 0.53 0.30 1.00
    nCohort 1 462 618 433 462 618 433 462 618 433
    nCohort 2 46 9 42 51 10 45 27 11 24
    Cutoff 1 566 189 581 421 421 577 159 164 237
    Sens 1 72% 78% 71% 71% 70% 71% 70% 73% 71%
    Spec 1 51% 22% 53% 43% 38% 52% 23% 20% 29%
    Cutoff 2 292 152 333 304 354 228 106 134 106
    Sens 2 80% 89% 81% 80% 80% 80% 81% 82% 83%
    Spec 2 34% 20% 37% 35% 35% 27% 20% 18% 18%
    Cutoff 3 113 1.48 185 129 321 123 1.48 35.7 1.48
    Sens 3 91% 100%  90% 90% 90% 91% 100%  91% 100% 
    Spec 3 20%  8% 24% 21% 32% 19% 10% 12%  9%
    Cutoff 4 907 1070 903 907 1070 903 907 1070 903
    Sens 4 48% 33% 50% 39% 20% 44% 26%  9% 29%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 1190 1410 1180 1190 1410 1180 1190 1410 1180
    Sens 5 33% 33% 36% 29% 20% 33% 22%  0% 25%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1660 1850 1650 1660 1850 1650 1660 1850 1650
    Sens 6 26% 11% 24% 12% 20% 11%  7%  0%  8%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.87 0.33 1.4 1.3 4.1 0.60 0.83 2.0 0.83
    p Value 0.79 0.34 0.57 0.63 0.21 0.39 0.77 0.57 0.77
    95% CI of 0.30 0.034 0.44 0.48 0.45 0.19 0.25 0.18 0.25
    OR Quart 2 2.5 3.2 4.6 3.3 37 1.9 2.8 23 2.8
    OR Quart 3 1.7 0.66 2.8 2.1 3.0 2.0 1.2 4.1 1.2
    p Value 0.26 0.65 0.061 0.092 0.34 0.13 0.76 0.21 0.76
    95% CI of 0.68 0.11 0.96 0.88 0.31 0.81 0.39 0.45 0.39
    OR Quart 3 4.2 4.0 8.0 5.2 30 4.9 3.6 37 3.7
    OR Quart 4 2.5 0.99 3.8 2.3 2.0 2.3 1.6 4.1 1.0
    p Value 0.043 0.99 0.012 0.067 0.57 0.066 0.42 0.21 0.99
    95% CI of 1.0 0.20 1.3 0.95 0.18 0.95 0.54 0.45 0.32
    OR Quart 4 5.9 5.0 11 5.5 22 5.5 4.5 37 3.2
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2640 3420 2640 2770 2640 2260
    Average 3270 3890 3270 4280 3270 2770
    Stdev 2970 2700 2970 6730 2970 2190
    p (t-test) 0.11 0.015 0.30
    Min 6.83 85.5 6.83 375 6.83 138
    Max 48400 15000 48400 55700 48400 9700
    n (Samp) 926 62 926 70 926 39
    n (Patient) 359 62 359 70 359 39
    sCr only
    Median 2800 2420 2800 2590 2800 2370
    Average 3450 2380 3450 3790 3450 3200
    Stdev 3250 1460 3250 2950 3250 2300
    p (t-test) 0.20 0.66 0.75
    Min 6.83 301 6.83 921 6.83 932
    Max 55700 4670 55700 10800 55700 8410
    n (Samp) 1229 15 1229 18 1229 17
    n (Patient) 439 15 439 18 439 17
    UO only
    Median 2730 4020 2730 3060 2730 2460
    Average 3320 4690 3320 4760 3320 2920
    Stdev 2980 4040 2980 7510 2980 2190
    p (t-test) 0.0011 0.0016 0.44
    Min 0.234 85.5 0.234 375 0.234 138
    Max 48400 26600 48400 55700 48400 9700
    n (Samp) 814 57 814 63 814 34
    n (Patient) 281 57 281 63 281 34
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.58 0.39 0.63 0.54 0.53 0.55 0.43 0.47 0.45
    SE 0.039 0.078 0.041 0.036 0.070 0.039 0.049 0.072 0.052
    p 0.040 0.16 0.0016 0.30 0.70 0.24 0.16 0.71 0.34
    nCohort 1 926 1229 814 926 1229 814 926 1229 814
    nCohort 2 62 15 57 70 18 63 39 17 34
    Cutoff 1 2290 1120 2720 2030 2080 2030 1250 1670 1650
    Sens 1 71% 73% 70% 70% 72% 71% 72% 71% 71%
    Spec 1 44% 14% 50% 37% 35% 34% 17% 26% 26%
    Cutoff 2 1570 849 1960 1210 1700 1210 962 965 1180
    Sens 2 81% 80% 81% 80% 83% 81% 82% 82% 82%
    Spec 2 26%  8% 32% 17% 27% 16% 11% 10% 15%
    Cutoff 3 863 615 1210 1040 1080 986 402 950 402
    Sens 3 90% 93% 91% 90% 94% 90% 92% 94% 91%
    Spec 3  9%  4% 16% 13% 13% 11%  2% 10%  2%
    Cutoff 4 3860 4020 3910 3860 4020 3910 3860 4020 3910
    Sens 4 44%  7% 51% 37% 39% 40% 21% 35% 21%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 4660 4940 4740 4660 4940 4740 4660 4940 4740
    Sens 5 34%  0% 42% 29% 28% 32% 18% 24% 18%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 6190 6480 6230 6190 6480 6230 6190 6480 6230
    Sens 6 21%  0% 25% 17% 17% 17%  8%  6%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.83 6.1 1.5 1.1 2.0 1.3 0.88 0.16 1.1
    p Value 0.66 0.095 0.37 0.71 0.33 0.45 0.80 0.096 0.79
    95% CI of 0.35 0.73 0.61 0.56 0.50 0.63 0.31 0.020 0.41
    OR Quart 2 1.9 51 3.8 2.3 8.1 2.8 2.5 1.4 3.2
    OR Quart 3 1.4 2.0 1.5 1.1 1.3 0.92 1.5 0.83 1.4
    p Value 0.34 0.57 0.37 0.85 0.71 0.84 0.36 0.76 0.46
    95% CI of 0.68 0.18 0.61 0.52 0.30 0.41 0.62 0.25 0.54
    OR Quart 3 3.1 22 3.8 2.2 6.0 2.1 3.8 2.8 3.9
    OR Quart 4 2.0 6.1 3.4 1.5 1.7 1.7 1.5 0.83 1.3
    p Value 0.058 0.095 0.0036 0.23 0.48 0.16 0.36 0.77 0.61
    95% CI of 0.98 0.73 1.5 0.77 0.40 0.82 0.62 0.25 0.47
    OR Quart 4 4.1 51 7.7 3.0 7.1 3.4 3.8 2.8 3.6
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to 24 hr prior to 48 hr prior to
    AKI stage AKI stage AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1.16 2.27 1.16 1.69 1.16 2.14
    Average 3.31 3.21 3.31 22.5 3.31 2.17
    Stdev 12.7 4.27 12.7 137 12.7 1.82
    p (t-test) 0.96 5.2E−4 0.64
    Min 0.00246 0.00313 0.00246 0.00408 0.00246 0.00313
    Max 270 24.9 270 935 270 8.46
    n (Samp) 691 36 691 46 691 28
    n (Patient) 280 36 280 46 280 28
    sCr only
    Median 1.17 2.02 1.17 2.53 1.17 2.18
    Average 4.08 2.61 4.08 5.64 4.08 2.38
    Stdev 33.0 1.80 33.0 8.01 33.0 2.33
    p (t-test) 0.90 0.87 0.85
    Min 0.00246 0.709 0.00246 0.00741 0.00246 0.166
    Max 935 5.92 935 26.6 935 8.93
    n (Samp) 899 8 899 12 899 13
    n (Patient) 335 8 335 12 335 13
    UO only
    Median 1.24 2.75 1.24 1.69 1.24 2.10
    Average 3.34 4.89 3.34 25.0 3.34 2.26
    Stdev 13.1 10.4 13.1 142 13.1 1.83
    p (t-test) 0.49 4.8E−4 0.68
    Min 0.00246 0.00313 0.00246 0.00408 0.00246 0.00313
    Max 270 59.1 270 935 270 8.46
    n (Samp) 581 35 581 43 581 25
    n (Patient) 208 35 208 43 208 25
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.64 0.67 0.63 0.57 0.68 0.55 0.59 0.60 0.60
    SE 0.051 0.11 0.052 0.045 0.086 0.047 0.058 0.084 0.061
    p 0.0079 0.10 0.011 0.12 0.036 0.30 0.12 0.24 0.11
    nCohort 1 691 899 581 691 899 581 691 899 581
    nCohort 2 36 8 35 46 12 43 28 13 25
    Cutoff 1 1.39 1.39 1.66 0.943 1.26 0.536 0.884 0.505 1.04
    Sens 1 72% 75% 71% 72% 75% 72% 71% 77% 72%
    Spec 1 56% 55% 58% 45% 53% 30% 43% 31% 45%
    Cutoff 2 0.621 1.14 0.506 0.447 1.18 0.0558 0.393 0.365 0.742
    Sens 2 81% 88% 80% 80% 83% 81% 82% 85% 80%
    Spec 2 34% 49% 30% 29% 50% 18% 28% 27% 36%
    Cutoff 3 0.0183 0.708 0.0183 0.0140 1.09 0.0140 0.361 0.361 0.392
    Sens 3 92% 100%  91% 98% 92% 98% 93% 92% 92%
    Spec 3 13% 36% 13% 10% 48% 10% 27% 27% 27%
    Cutoff 4 2.13 2.17 2.22 2.13 2.17 2.22 2.13 2.17 2.22
    Sens 4 53% 38% 57% 39% 58% 35% 50% 54% 44%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 3.13 3.13 3.15 3.13 3.13 3.15 3.13 3.13 3.15
    Sens 5 36% 38% 40% 28% 42% 28% 21% 23% 24%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 5.18 5.05 5.21 5.18 5.05 5.21 5.18 5.05 5.21
    Sens 6 14% 12% 17%  9% 25% 12%  4%  8%  4%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.99 >2.0 0.66 0.88 1.00 0.79 4.7 4.1 3.1
    p Value 0.99 <0.57 0.52 0.80 1.00 0.63 0.051 0.21 0.17
    95% CI of 0.28 >0.18 0.18 0.33 0.062 0.30 0.99 0.45 0.61
    OR Quart 2 3.5 na 2.4 2.3 16 2.1 22 37 15
    OR Quart 3 1.8 >3.0 1.9 1.6 4.0 1.1 3.1 2.0 4.7
    p Value 0.29 <0.34 0.22 0.29 0.21 0.82 0.18 0.57 0.050
    95% CI of 0.60 >0.31 0.68 0.68 0.45 0.46 0.61 0.18 1.0
    OR Quart 3 5.6 na 5.3 3.8 36 2.7 15 22 22
    OR Quart 4 3.6 >3.0 2.5 1.7 6.1 1.4 5.8 6.1 4.1
    p Value 0.013 <0.34 0.072 0.21 0.095 0.40 0.024 0.094 0.076
    95% CI of 1.3 >0.31 0.92 0.73 0.73 0.62 1.3 0.73 0.86
    OR Quart 4 10 na 6.6 4.0 51 3.3 26 51 20
    Corticotropin
    0 hr prior to 24 hr prior to 48 hr prior to
    AKI stage AKI stage AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00163 0.00162 0.00163 0.00208 0.00163 0.00175
    Average 0.00229 0.00185 0.00229 0.00430 0.00229 0.00180
    Stdev 0.00404 0.00124 0.00404 0.00727 0.00404 0.000819
    p (t-test) 0.61 0.018 0.63
    Min 3.92E−6 0.000273 3.92E−6 0.000388 3.92E−6 0.000570
    Max 0.0489 0.00666 0.0489 0.0377 0.0489 0.00318
    n (Samp) 249 22 249 32 249 16
    n (Patient) 162 22 162 32 162 16
    sCr only
    Median nd nd 0.00163 0.00293 0.00163 0.00274
    Average nd nd 0.00223 0.00603 0.00223 0.00742
    Stdev nd nd 0.00365 0.00820 0.00365 0.0134
    p(t-test) nd nd 0.015 9.1E−4
    Min nd nd 3.92E−6 0.00134 3.92E−6 0.00109
    Max nd nd 0.0489 0.0224 0.0489 0.0377
    n (Samp) nd nd 315 6 315 7
    n (Patient) nd nd 189 6 189 7
    UO only
    Median 0.00163 0.00162 0.00163 0.00204 0.00163 0.00160
    Average 0.00239 0.00186 0.00239 0.00374 0.00239 0.00300
    Stdev 0.00430 0.00126 0.00430 0.00680 0.00430 0.00542
    p (t-test) 0.57 0.14 0.60
    Min 0.000355 0.000273 0.000355 0.000388 0.000355 0.000570
    Max 0.0489 0.00666 0.0489 0.0377 0.0489 0.0224
    n (Samp) 217 22 217 29 217 15
    n (Patient) 135 22 135 29 135 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.48 nd 0.47 0.62 0.66 0.60 0.50 0.73 0.47
    SE 0.065 nd 0.066 0.056 0.12 0.059 0.075 0.11 0.078
    p 0.79 nd 0.66 0.025 0.18 0.085 0.97 0.038 0.69
    nCohort 1 249 nd 217 249 315 217 249 315 217
    nCohort 2 22 nd 22 32 6 29 16 7 15
    Cutoff 1 0.00134 nd 0.00134 0.00149 0.00134 0.00149 0.00111 0.00212 0.00111
    Sens 1 77% nd 73% 72% 83% 72% 75% 71% 73%
    Spec 1 33% nd 32% 42% 32% 41% 22% 69% 23%
    Cutoff 2 0.00106 nd 0.00106 0.00124 0.00134 0.00111 0.00109 0.00201 0.00109
    Sens 2 86% nd 86% 81% 83% 83% 81% 86% 80%
    Spec 2 20% nd 21% 32% 32% 23% 21% 65% 12%
    Cutoff 3 0.000794 nd 0.000794 0.00109 0.00124 0.000888 0.000523 0.00106 0.000523
    Sens 3 91% nd 91% 91% 100%  93% 100%  100%  100% 
    Spec 3 10% nd  9% 21% 31% 15%  7% 19%  6%
    Cutoff 4 0.00222 nd 0.00227 0.00222 0.00222 0.00227 0.00222 0.00222 0.00227
    Sens 4 23% nd 27% 47% 50% 41% 31% 57% 20%
    Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 0.00282 nd 0.00282 0.00282 0.00274 0.00282 0.00282 0.00274 0.00282
    Sens 5  9% nd  9% 34% 50% 28% 12% 43% 13%
    Spec 5 80% nd 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 0.00362 nd 0.00380 0.00362 0.00352 0.00380 0.00362 0.00352 0.00380
    Sens 6  5% nd  5% 28% 50% 14%  0% 14%  7%
    Spec 6 91% nd 91% 91% 90% 91% 91% 90% 91%
    OR Quart 2 2.5 nd 4.5 1.0 >3.1 0.39 1.0 0 1.0
    p Value 0.20 nd 0.066 1.0 <0.33 0.19 0.98 na 1.0
    95% CI of 0.62 nd 0.91 0.31 >0.32 0.097 0.24 na 0.19
    OR Quart 2 10 nd 22 3.3 na 1.6 4.2 na 5.2
    OR Quart 3 2.5 nd 3.2 1.4 >0 1.3 0.75 2.0 1.4
    p Value 0.20 nd 0.16 0.57 <na 0.59 0.71 0.57 0.70
    95% CI of 0.62 nd 0.62 0.45 >na 0.46 0.16 0.18 0.29
    OR Quart 3 10 nd 17 4.2 na 3.8 3.5 23 6.4
    OR Quart 4 1.7 nd 3.3 2.2 >3.1 1.5 1.3 4.1 1.7
    p Value 0.46 nd 0.16 0.15 <0.33 0.46 0.71 0.21 0.47
    95% CI of 0.40 nd 0.63 0.77 >0.31 0.53 0.33 0.45 0.39
    OR Quart 4 7.6 nd 17 6.1 na 4.2 5.0 38 7.6
    Thyroxine-binding globulin
    0 hr prior to 24 hr prior to 48 hr prior to
    AKI stage AKI stage AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0709 0.0370 0.0709 0.0576 0.0709 0.136
    Average 0.176 0.107 0.176 0.246 0.176 0.165
    Stdev 0.265 0.203 0.265 0.631 0.265 0.173
    p (t-test) 0.20 0.21 0.86
    Min 8.30E−5 0.000476 8.30E−5 0.00330 8.30E−5 0.00324
    Max 1.86 0.885 1.86 3.60 1.86 0.602
    n (Samp) 421 25 421 32 421 17
    n (Patient) 165 25 165 32 165 17
    sCr only
    Median nd nd 0.0749 0.0237 0.0749 0.0201
    Average nd nd 0.178 0.130 0.178 0.0811
    Stdev nd nd 0.294 0.177 0.294 0.107
    p (t-test) nd nd 0.67 0.38
    Min nd nd 8.30E−5 0.00330 8.30E−5 0.00324
    Max nd nd 3.60 0.466 3.60 0.250
    n (Samp) nd nd 511 7 511 7
    n (Patient) nd nd 198 7 198 7
    UO only
    Median 0.0686 0.0423 0.0686 0.0428 0.0686 0.142
    Average 0.178 0.119 0.178 0.251 0.178 0.173
    Stdev 0.272 0.204 0.272 0.661 0.272 0.168
    p(t-test) 0.28 0.24 0.94
    Min 0.000191 0.000476 0.000191 0.00343 0.000191 0.00768
    Max 1.86 0.885 1.86 3.60 1.86 0.602
    n (Samp) 357 25 357 29 357 17
    n (Patient) 135 25 135 29 135 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.38 nd 0.41 0.49 0.42 0.49 0.56 0.38 0.60
    SE 0.061 nd 0.062 0.053 0.11 0.056 0.073 0.11 0.074
    p 0.058 nd 0.15 0.88 0.47 0.85 0.41 0.28 0.19
    nCohort 1 421 nd 357 421 511 357 421 511 357
    nCohort 2 25 nd 25 32 7 29 17 7 17
    Cutoff 1 0.0145 nd 0.0131 0.0184 0.00990 0.0184 0.0617 0.0187 0.109
    Sens 1 72% nd 72% 72% 71% 72% 71% 71% 71%
    Spec 1 20% nd 18% 23% 16% 23% 47% 23% 59%
    Cutoff 2 0.0112 nd 0.00915 0.00971 0.00423 0.0158 0.0353 0.0145 0.0497
    Sens 2 80% nd 80% 81% 86% 83% 82% 86% 82%
    Spec 2 17% nd 16% 16%  8% 21% 33% 20% 43%
    Cutoff 3 0.00446 nd 0.00423 0.00556 0.00325 0.00556 0.00767 0.00319 0.0196
    Sens 3 92% nd 92% 91% 100%  93% 94% 100%  94%
    Spec 3  9% nd  8% 11%  6% 11% 14%  6% 24%
    Cutoff 4 0.179 nd 0.179 0.179 0.179 0.179 0.179 0.179 0.179
    Sens 4 16% nd 20% 34% 29% 34% 24% 29% 24%
    Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 0.251 nd 0.249 0.251 0.259 0.249 0.251 0.259 0.249
    Sens 5  8% nd  8% 28% 29% 28% 18%  0% 18%
    Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 0.434 nd 0.466 0.434 0.422 0.466 0.434 0.422 0.466
    Sens 6  8% nd  8%  9% 14%  7% 12%  0% 12%
    Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 3.1 nd 2.5 0.43 0.50 0.38 0.99 0 1.5
    p Value 0.17 nd 0.20 0.13 0.57 0.11 0.99 na 0.66
    95% CI of 0.62 nd 0.62 0.15 0.045 0.11 0.20 na 0.24
    OR Quart 2 16 nd 9.8 1.3 5.6 1.3 5.0 na 9.2
    OR Quart 3 3.1 nd 1.7 0.43 0.50 0.47 2.8 0.50 4.9
    p Value 0.17 nd 0.47 0.13 0.57 0.19 0.14 0.57 0.047
    95% CI of 0.61 nd 0.40 0.15 0.044 0.16 0.72 0.044 1.0
    OR Quart 3 16 nd 7.3 1.3 5.5 1.4 11 5.5 23
    OR Quart 4 6.0 nd 3.6 1.0 1.5 1.0 0.99 2.0 1.5
    p Value 0.021 nd 0.055 0.98 0.65 0.98 0.99 0.41 0.66
    95% CI of 1.3 nd 0.97 0.42 0.25 0.40 0.20 0.37 0.24
    OR Quart 4 28 nd 14 2.4 9.3 2.6 5.0 11 9.2
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 18.5 33.8 18.5 26.4 18.5 18.6
    Average 24.9 46.9 24.9 36.4 24.9 27.1
    Stdev 30.5 60.4 30.5 36.8 30.5 27.6
    p (t-test) 3.0E−5 0.010 0.70
    Min 0.0493 0.121 0.0493 0.0561 0.0493 0.0688
    Max 277 350 277 158 277 111
    n (Samp) 473 47 473 54 473 28
    n (Patient) 240 47 240 54 240 28
    sCr only
    Median 19.8 12.5 19.8 32.3 19.8 38.9
    Average 31.0 23.4 31.0 59.4 31.0 32.8
    Stdev 46.2 25.8 46.2 98.6 46.2 21.4
    p (t-test) 0.62 0.050 0.90
    Min 0.0493 0.196 0.0493 12.1 0.0493 0.0688
    Max 554 63.3 554 353 554 59.7
    n (Samp) 634 9 634 11 634 11
    n (Patient) 295 9 295 11 295 11
    UO only
    Median 16.9 35.1 16.9 26.4 16.9 18.8
    Average 24.3 49.2 24.3 37.3 24.3 27.5
    Stdev 31.1 62.2 31.1 38.9 31.1 28.0
    p (t-test) 9.9E−6 0.0075 0.62
    Min 0.0493 0.121 0.0493 0.0561 0.0493 0.196
    Max 277 350 277 158 277 111
    n (Samp) 441 43 441 48 441 25
    n (Patient) 210 43 210 48 210 25
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.64 0.45 0.67 0.60 0.65 0.60 0.53 0.61 0.55
    SE 0.045 0.100 0.047 0.043 0.091 0.045 0.057 0.091 0.061
    p 0.0018 0.59 2.9E−4 0.021 0.098 0.028 0.59 0.24 0.37
    nCohort 1 473 634 441 473 634 441 473 634 441
    nCohort 2 47 9 43 54 11 48 28 11 25
    Cutoff 1 15.4 5.09 15.4 12.3 23.1 9.75 8.69 18.3 10.4
    Sens 1 70% 78% 72% 70% 73% 71% 71% 73% 72%
    Spec 1 48% 19% 49% 40% 56% 35% 31% 46% 36%
    Cutoff 2 6.53 1.18 12.1 5.14 18.5 5.09 5.76 9.75 6.53
    Sens 2 81% 89% 81% 83% 82% 81% 82% 82% 84%
    Spec 2 27% 12% 41% 23% 47% 23% 25% 30% 29%
    Cutoff 3 1.18 0.121 5.14 1.80 13.6 1.18 0.196 5.76 0.196
    Sens 3 94% 100%  91% 91% 91% 94% 93% 91% 96%
    Spec 3 14%  6% 25% 16% 43% 15%  9% 23% 11%
    Cutoff 4 29.5 32.9 27.0 29.5 32.9 27.0 29.5 32.9 27.0
    Sens 4 55% 33% 60% 48% 27% 48% 39% 55% 40%
    Spec 4 70% 71% 70% 70% 71% 70% 70% 71% 70%
    Cutoff 5 38.9 42.2 37.4 38.9 42.2 37.4 38.9 42.2 37.4
    Sens 5 43% 33% 49% 35% 27% 42% 25% 45% 24%
    Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80%
    Cutoff 6 53.5 63.6 53.5 53.5 63.6 53.5 53.5 63.6 53.5
    Sens 6 26%  0% 26% 20%  9% 21%  7%  0%  8%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.8 0 2.3 0.89 >3.1 0.89 1.4 1.0 1.8
    p Value 0.24 na 0.13 0.81 <0.34 0.81 0.56 1.0 0.37
    95% CI of 0.68 na 0.78 0.37 >0.31 0.35 0.44 0.14 0.51
    OR Quart 2 4.7 na 6.9 2.2 na 2.3 4.6 7.2 6.3
    OR Quart 3 0.70 0.66 1.0 1.1 >5.2 0.79 1.6 0.50 1.3
    p Value 0.56 0.65 1.0 0.84 <0.14 0.62 0.40 0.57 0.73
    95% CI of 0.22 0.11 0.28 0.46 >0.60 0.30 0.52 0.045 0.33
    OR Quart 3 2.3 4.0 3.5 2.6 na 2.1 5.2 5.5 4.8
    OR Quart 4 3.8 1.4 5.2 2.1 >3.0 2.3 1.6 3.1 2.3
    p Value 0.0032 0.70 0.0014 0.066 <0.34 0.041 0.41 0.18 0.17
    95% CI of 1.6 0.30 1.9 0.95 >0.31 1.0 0.52 0.61 0.70
    OR Quart 4 9.2 6.1 14 4.5 na 5.1 5.1 15 7.8
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00508 0.00505 0.00508 0.00587 0.00508 0.00428
    Average 0.0492 0.0230 0.0492 0.109 0.0492 0.0706
    Stdev 0.117 0.0651 0.117 0.406 0.117 0.242
    p (t-test) 0.17 0.021 0.40
    Min 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463
    Max 0.889 0.280 0.889 2.85 0.889 1.25
    n (Samp) 407 39 407 50 407 27
    n (Patient) 214 39 214 50 214 27
    sCr only
    Median nd nd 0.00505 0.00624 0.00505 0.00286
    Average nd nd 0.0563 0.0846 0.0563 0.0277
    Stdev nd nd 0.178 0.126 0.178 0.0583
    p (t-test) nd nd 0.62 0.60
    Min nd nd 0.000463 0.000463 0.000463 0.000463
    Max nd nd 2.85 0.317 2.85 0.185
    n (Samp) nd nd 535 10 535 11
    n (Patient) nd nd 256 10 256 11
    UO only
    Median 0.00505 0.00505 0.00505 0.00587 0.00505 0.00428
    Average 0.0537 0.0230 0.0537 0.111 0.0537 0.0739
    Stdev 0.148 0.0651 0.148 0.418 0.148 0.251
    p (t-test) 0.20 0.058 0.53
    Min 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463
    Max 1.74 0.280 1.74 2.85 1.74 1.25
    n (Samp) 380 39 380 47 380 25
    n (Patient) 189 39 189 47 189 25
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.42 nd 0.42 0.52 0.57 0.53 0.43 0.38 0.44
    SE 0.050 nd 0.050 0.044 0.095 0.045 0.059 0.091 0.061
    p 0.100 nd 0.13 0.57 0.43 0.53 0.22 0.19 0.31
    nCohort 1 407 nd 380 407 535 380 407 535 380
    nCohort 2 39 nd 39 50 10 47 27 11 25
    Cutoff 1 0.00132 nd 0.00132 0.00296 0.00483 0.00296 0.00132 0.00132 0.00132
    Sens 1 87% nd 87% 78% 70% 77% 81% 91% 80%
    Spec 1 14% nd 15% 19% 44% 20% 14% 15% 15%
    Cutoff 2 0.00132 nd 0.00132 0.00132 0.00296 0.00132 0.00132 0.00132 0.00132
    Sens 2 87% nd 87% 84% 80% 83% 81% 91% 80%
    Spec 2 14% nd 15% 14% 22% 15% 14% 15% 15%
    Cutoff 3 0 nd 0 0.000463 0.000463 0.000463 0.000463 0.00132 0.000463
    Sens 3 100%  nd 100%  92% 90% 91% 93% 91% 92%
    Spec 3  0% nd  0%  8%  9%  9%  8% 15%  9%
    Cutoff 4 0.0128 nd 0.00660 0.0128 0.00660 0.00660 0.0128 0.00660 0.00660
    Sens 4 10% nd 10% 40% 40% 40% 22% 18% 24%
    Spec 4 70% nd 71% 70% 72% 71% 70% 72% 71%
    Cutoff 5 0.0613 nd 0.0613 0.0613 0.0499 0.0613 0.0613 0.0499 0.0613
    Sens 5  8% nd  8% 24% 30% 23% 19% 18% 16%
    Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 0.141 nd 0.131 0.141 0.154 0.131 0.141 0.154 0.131
    Sens 6  8% nd  8% 16% 30% 15% 11%  9% 12%
    Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 5.2 nd 5.2 1.2 1.0 0.99 1.4 0.50 1.4
    p Value 0.011 nd 0.011 0.67 1.0 0.98 0.54 0.57 0.54
    95% CI of 1.5 nd 1.5 0.52 0.14 0.41 0.44 0.045 0.44
    OR Quart 2 19 nd 19 2.8 7.2 2.4 4.7 5.6 4.7
    OR Quart 3 3.6 nd 3.6 1.2 1.0 0.99 0.59 1.0 0.80
    p Value 0.059 nd 0.058 0.67 1.0 0.98 0.48 1.0 0.74
    95% CI of 0.95 nd 0.96 0.52 0.14 0.41 0.14 0.14 0.21
    OR Quart 3 13 nd 13 2.8 7.2 2.4 2.5 7.2 3.1
    OR Quart 4 4.4 nd 4.4 1.2 2.0 1.3 2.6 3.1 1.9
    p Value 0.025 nd 0.024 0.68 0.42 0.54 0.083 0.17 0.27
    95% CI of 1.2 nd 1.2 0.51 0.36 0.56 0.88 0.62 0.61
    OR Quart 4 16 nd 16 2.8 11 3.0 7.7 16 5.9
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.68 1.90 2.68 1.73 2.68 1.37
    Average 21.4 9.42 21.4 34.9 21.4 4.56
    Stdev 132 20.1 132 239 132 12.4
    p (t-test) 0.45 0.41 0.39
    Min 0.000147 0.00122 0.000147 0.000147 0.000147 0.000147
    Max 2160 135 2160 2140 2160 83.4
    n (Samp) 1008 70 1008 80 1008 46
    n (Patient) 386 70 386 80 386 46
    sCr only
    Median 2.56 0.695 2.56 1.07 2.56 1.79
    Average 20.2 1.91 20.2 3.33 20.2 3.52
    Stdev 129 3.03 129 6.71 129 4.87
    p (t-test) 0.57 0.55 0.56
    Min 0.000147 0.00154 0.000147 0.000147 0.000147 0.000147
    Max 2160 10.5 2160 28.7 2160 19.7
    n (Samp) 1344 16 1344 21 1344 20
    n (Patient) 472 16 472 21 472 20
    UO only
    Median 2.57 3.56 2.57 1.85 2.57 1.41
    Average 19.5 11.2 19.5 38.5 19.5 4.94
    Stdev 120 22.0 120 250 120 13.3
    p (t-test) 0.58 0.24 0.44
    Min 0.000147 0.00122 0.000147 0.000147 0.000147 0.00328
    Max 2140 135 2140 2140 2140 83.4
    n (Samp) 900 65 900 73 900 40
    n (Patient) 310 65 310 73 310 40
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.47 0.29 0.50 0.45 0.34 0.47 0.37 0.40 0.39
    SE 0.036 0.074 0.037 0.034 0.066 0.036 0.045 0.067 0.048
    p 0.36 0.0050 0.94 0.13 0.016 0.37 0.0052 0.15 0.027
    nCohort 1 1008 1344 900 1008 1344 900 1008 1344 900
    nCohort 2 70 16 65 80 21 73 46 20 40
    Cutoff 1 0.809 0.201 0.825 0.551 0.423 0.422 0.505 0.757 0.515
    Sens 1 70% 75% 71% 70% 71% 71% 72% 70% 70%
    Spec 1 26% 12% 26% 20% 18% 16% 19% 26% 19%
    Cutoff 2 0.393 0.130 0.393 0.153 0.260 0.153 0.172 0.178 0.177
    Sens 2 80% 81% 80% 80% 81% 81% 83% 80% 80%
    Spec 2 16% 10% 16% 10% 13% 10% 11% 12% 10%
    Cutoff 3 0.103 0.00323 0.103 0.00463 0.00129 0.0258 0.0258 0.0258 0.0994
    Sens 3 90% 94% 91% 90% 90% 90% 93% 95% 90%
    Spec 3  9%  5%  9%  6%  2%  7%  6%  6%  9%
    Cutoff 4 7.24 6.96 6.93 7.24 6.96 6.93 7.24 6.96 6.93
    Sens 4 33% 12% 37% 26% 14% 29% 15% 20% 15%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 12.6 12.4 11.5 12.6 12.4 11.5 12.6 12.4 11.5
    Sens 5 17%  0% 28% 22% 10% 26%  7%  5% 10%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 28.1 26.8 27.0 28.1 26.8 27.0 28.1 26.8 27.0
    Sens 6  6%  0% 11%  9%  5% 10%  2%  0%  2%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.63 3.0 0.87 0.94 2.0 0.79 1.5 2.5 1.5
    p Value 0.22 0.34 0.71 0.86 0.42 0.50 0.43 0.27 0.43
    95% CI of 0.31 0.31 0.43 0.48 0.37 0.40 0.53 0.49 0.53
    OR Quart 2 1.3 29 1.8 1.8 11 1.6 4.3 13 4.3
    OR Quart 3 0.84 3.0 0.63 0.78 3.0 0.53 2.4 3.6 1.7
    p Value 0.61 0.34 0.25 0.48 0.17 0.10 0.076 0.12 0.31
    95% CI of 0.43 0.31 0.29 0.39 0.61 0.25 0.91 0.73 0.61
    OR Quart 3 1.6 29 1.4 1.6 15 1.1 6.4 17 4.7
    OR Quart 4 1.0 9.2 1.3 1.5 4.6 1.3 3.0 3.0 2.6
    p Value 0.99 0.036 0.41 0.17 0.052 0.35 0.024 0.18 0.052
    95% CI of 0.53 1.2 0.68 0.83 0.99 0.73 1.2 0.61 0.99
    OR Quart 4 1.9 73 2.5 2.8 21 2.5 7.7 15 6.8
    Apolipoprotein(a)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.16 2.88 2.16 3.39 2.16 2.04
    Average 46.7 10.1 46.7 23.9 46.7 5.40
    Stdev 602 22.6 602 97.8 602 13.0
    p(t-test) 0.62 0.74 0.66
    Min 0.00241 0.00241 0.00241 0.00838 0.00241 0.00838
    Max 17500 118 17500 802 17500 75.7
    n (Samp) 953 65 953 75 953 41
    n (Patient) 381 65 381 75 381 41
    sCr only
    Median 2.09 1.68 2.09 3.09 2.09 2.25
    Average 39.7 3.70 39.7 5.16 39.7 11.5
    Stdev 523 6.91 523 8.41 523 21.6
    p(t-test) 0.80 0.77 0.81
    Min 0.00241 0.0122 0.00241 0.00479 0.00241 0.00838
    Max 17500 27.0 17500 37.7 17500 91.1
    n (Samp) 1273 14 1273 20 1273 19
    n (Patient) 466 14 466 20 466 19
    UO only
    Median 2.19 2.95 2.19 3.88 2.19 2.13
    Average 46.2 20.7 46.2 26.4 46.2 6.18
    Stdev 637 81.1 637 102 637 14.0
    p(t-test) 0.76 0.80 0.71
    Min 0.00241 0.00241 0.00241 0.00838 0.00241 0.0122
    Max 17500 618 17500 802 17500 75.7
    n (Samp) 845 61 845 68 845 35
    n (Patient) 305 61 305 68 305 35
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.45 0.59 0.60 0.54 0.64 0.49 0.53 0.54
    SE 0.038 0.080 0.039 0.036 0.066 0.037 0.046 0.068 0.051
    p 0.10 0.49 0.020 0.0058 0.58 2.2E−4 0.89 0.64 0.44
    nCohort 1 953 1273 845 953 1273 845 953 1273 845
    nCohort 2 65 14 61 75 20 68 41 19 35
    Cutoff 1 1.40 0.892 1.82 1.65 1.65 1.82 1.18 0.971 1.38
    Sens 1 71% 71% 70% 71% 70% 71% 71% 74% 71%
    Spec 1 39% 28% 46% 44% 44% 46% 33% 30% 38%
    Cutoff 2 0.917 0.108 0.977 1.20 0.751 1.26 0.826 0.0122 0.977
    Sens 2 80% 86% 80% 80% 80% 81% 80% 84% 80%
    Spec 2 28% 11% 31% 34% 25% 35% 26%  6% 31%
    Cutoff 3 0.108 0.0847 0.108 0.0847 0.0140 0.509 0.182 0.00790 0.699
    Sens 3 91% 93% 92% 91% 90% 91% 90% 100%  91%
    Spec 3 13% 11% 12% 12%  7% 22% 14%  1% 25%
    Cutoff 4 3.89 3.89 3.74 3.89 3.89 3.74 3.89 3.89 3.74
    Sens 4 37% 14% 43% 44% 40% 53% 24% 42% 31%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 5.71 5.71 5.25 5.71 5.71 5.25 5.71 5.71 5.25
    Sens 5 25%  7% 28% 31% 15% 40% 12% 37% 20%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 17.0 18.8 13.7 17.0 18.8 13.7 17.0 18.8 13.7
    Sens 6 15%  7% 18% 15%  5% 19%  5% 16%  6%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.1 2.0 1.1 1.4 1.0 1.8 1.0 0.80 4.0
    p Value 0.85 0.42 0.83 0.42 1.0 0.20 0.99 0.74 0.016
    95% CI of 0.48 0.37 0.46 0.62 0.25 0.74 0.39 0.21 1.3
    OR Quart 2 2.4 11 2.6 3.1 4.0 4.4 2.6 3.0 12
    OR Quart 3 1.7 2.0 2.0 2.1 1.5 2.1 1.8 0.40 1.5
    p Value 0.15 0.42 0.089 0.052 0.53 0.100 0.16 0.27 0.53
    95% CI of 0.82 0.37 0.90 0.99 0.42 0.87 0.79 0.076 0.42
    OR Quart 3 3.6 11 4.4 4.4 5.4 5.0 4.2 2.1 5.4
    OR Quart 4 1.7 2.0 2.2 2.6 1.5 4.1 0.77 1.6 2.6
    p Value 0.15 0.42 0.046 0.0090 0.53 5.2E−4 0.62 0.40 0.12
    95% CI of 0.82 0.37 1.0 1.3 0.42 1.9 0.28 0.52 0.79
    OR Quart 4 3.6 11 4.8 5.4 5.4 9.3 2.1 5.0 8.3
  • FIG. 3: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).
  •
    C-C motif chemokine 7
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.737 0.625 0.515 0.428 0.816 0.625
    Average 3.18 2.02 2.28 1.04 3.91 1.08
    Stdev 15.8 5.30 6.57 1.96 17.8 1.64
    p (t-test) 0.63 0.49 0.38
    Min 0.146 0.146 0.146 0.146 0.146 0.264
    Max 161 33.0 33.0 7.75 161 7.33
    n (Samp) 124 45 49 14 97 31
    n (Patient) 124 45 49 14 97 31
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.45 0.44 0.40
    SE 0.051 0.089 0.060
    p 0.37 0.48 0.086
    nCohort 1 124 49 97
    nCohort 2 45 14 31
    Cutoff 1 0.341 0.319 0.515
    Sens 1 71% 79% 71%
    Spec 1 25% 20% 27%
    Cutoff 2 0.320 0.146 0.336
    Sens 2 80% 93% 81%
    Spec 2 19%  6% 20%
    Cutoff 3 0.264 0.146 0.319
    Sens 3 91% 93% 90%
    Spec 3  6% 6% 11%
    Cutoff 4 1.04 0.812 1.15
    Sens 4 22% 21% 13%
    Spec 4 73% 73% 77%
    Cutoff 5 1.15 1.04 1.29
    Sens 5 20% 14% 10%
    Spec 5 81% 84% 82%
    Cutoff 6 1.59 1.59 6.92
    Sens 6 11%  7%  3%
    Spec 6 92% 92% 91%
    OR Quart 2 0.78 1.4 2.3
    p Value 0.64 0.67 0.21
    95% CI of 0.27 0.27 0.62
    OR Quart 2 2.2 7.8 8.7
    OR Quart 3 2.0 1.0 3.2
    p Value 0.14 1.0 0.078
    95% CI of 0.79 0.17 0.88
    OR Quart 3 5.2 5.9 12
    OR Quart 4 1.2 1.6 2.7
    p Value 0.75 0.60 0.13
    95% CI of 0.44 0.29 0.75
    OR Quart 4 3.1 8.6 10
    Interleukin-33
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 22.3 38.9 18.4 33.3 23.5 39.6
    Average 34.5 48.9 32.2 42.7 36.8 54.2
    Stdev 34.0 41.1 33.2 33.6 37.8 42.3
    p (t-test) 0.023 0.30 0.032
    Min 0.0232 0.0591 0.0232 0.0591 0.0232 0.0645
    Max 138 148 138 136 203 148
    n (Samp) 124 45 49 14 97 31
    n (Patient) 124 45 49 14 97 31
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.61 0.62 0.64
    SE 0.051 0.089 0.060
    p 0.028 0.16 0.020
    nCohort 1 124 49 97
    nCohort 2 45 14 31
    Cutoff 1 23.5 22.7 26.3
    Sens 1 71% 71% 71%
    Spec 1 52% 55% 54%
    Cutoff 2 14.6 18.6 19.4
    Sens 2 80% 86% 81%
    Spec 2 40% 53% 46%
    Cutoff 3 0.0879 12.9 13.7
    Sens 3 91% 93% 90%
    Spec 3 14% 39% 37%
    Cutoff 4 48.0 46.3 53.0
    Sens 4 33% 36% 39%
    Spec 4 70% 71% 70%
    Cutoff 5 65.3 59.3 70.3
    Sens 5 29% 14% 29%
    Spec 5 81% 82% 80%
    Cutoff 6 82.3 80.5 88.8
    Sens 6 18%  7% 19%
    Spec 6 90% 92% 91%
    OR Quart 2 1.4 3.2 3.2
    p Value 0.58 0.34 0.11
    95% CI of 0.46 0.30 0.77
    OR Quart 2 4.1 35 14
    OR Quart 3 3.1 8.4 3.8
    p Value 0.031 0.066 0.066
    95% CI of 1.1 0.87 0.92
    OR Quart 3 8.6 81 16
    OR Quart 4 2.2 4.7 5.1
    p Value 0.15 0.19 0.023
    95% CI of 0.77 0.46 1.3
    OR Quart 4 6.1 48 20
    Interleukin-4 receptor alpha chain
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 46.2 69.6 47.1 80.3 46.2 69.6
    Average 56.0 74.5 53.5 62.1 60.2 80.6
    Stdev 50.9 55.4 37.9 40.8 56.9 62.8
    p (t-test) 0.081 0.54 0.15
    Min 2.31 7.12 2.31 4.67 2.31 10.3
    Max 256 239 122 119 256 239
    n (Samp) 90 34 34 10 71 12
    n (Patient) 90 34 34 10 71 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.63 0.57 0.63
    SE 0.058 0.11 0.071
    p 0.027 0.50 0.066
    nCohort 1 90 34 71
    nCohort 2 34 10 22
    Cutoff 1 40.7 49.3 25.4
    Sens 1 71% 70% 73%
    Spec 1 39% 56% 37%
    Cutoff 2 12.4 11.7 20.5
    Sens 2 82% 80% 82%
    Spec 2 33% 26% 35%
    Cutoff 3 11.8 4.67 11.8
    Sens 3 91% 90% 91%
    Spec 3 28%  6% 25%
    Cutoff 4 69.4 79.9 68.1
    Sens 4 50% 50% 55%
    Spec 4 70% 71% 70%
    Cutoff 5 93.9 94.4 105
    Sens 5 35% 10% 27%
    Spec 5 80% 82% 80%
    Cutoff 6 115 104 137
    Sens 6 15% 10% 14%
    Spec 6 90% 91% 90%
    OR Quart 2 2.3 0.45 3.7
    p Value 0.21 0.54 0.14
    95% CI of 0.63 0.035 0.66
    OR Quart 2 8.8 5.8 21
    OR Quart 3 3.2 2.6 3.7
    p Value 0.077 0.35 0.14
    95% CI of 0.88 0.36 0.66
    OR Quart 3 12 18 21
    OR Quart 4 4.3 1.7 5.2
    p Value 0.026 0.61 0.053
    95% CI of 1.2 0.22 0.98
    OR Quart 4 15 13 28
    Lutropin subunit beta
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 16.9 10.4 nd nd 20.2 27.2
    Average 45.9 40.9 nd nd 41.3 64.1
    Stdev 67.7 70.4 nd nd 61.1 97.6
    p (t-test) 0.75 nd nd 0.27
    Min 0.211 0.0858 nd nd 0.311 0.0858
    Max 268 277 nd nd 268 325
    n (Samp) 54 28 nd nd 40 20
    n (Patient) 54 28 nd nd 40 20
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.45 nd 0.52
    SE 0.068 nd 0.080
    p 0.42 nd 0.77
    nCohort 1 54 nd 40
    nCohort 2 28 nd 20
    Cutoff 1 4.22 nd 8.91
    Sens 1 71% nd 70%
    Spec 1 24% nd 40%
    Cutoff 2 2.03 nd 4.22
    Sens 2 82% nd 80%
    Spec 2 19% nd 20%
    Cutoff 3 0.388 nd 0.388
    Sens 3 93% nd 90%
    Spec 3  7% nd  8%
    Cutoff 4 42.8 nd 43.5
    Sens 4 25% nd 35%
    Spec 4 70% nd 70%
    Cutoff 5 68.4 nd 59.7
    Sens 5 14% nd 25%
    Spec 5 81% nd 80%
    Cutoff 6 162 nd 76.4
    Sens 6  7% nd 20%
    Spec 6 91% nd 90%
    OR Quart 2 1.3 nd 0.38
    p Value 0.66 nd 0.24
    95% CI of 0.36 nd 0.073
    OR Quart 2 5.0 nd 1.9
    OR Quart 3 1.2 nd 1.0
    p Value 0.74 nd 1.0
    95% CI of 0.34 nd 0.23
    OR Quart 3 4.6 nd 4.3
    OR Quart 4 1.7 nd 0.75
    p Value 0.44 nd 0.71
    95% CI of 0.45 nd 0.17
    OR Quart 4 6.1 nd 3.3
    Platelet-derived growth factor subunit B (dimer)
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 1.82 2.07 2.78 1.24 1.71 1.76
    Average 3.46 2.36 5.94 1.92 2.45 2.25
    Stdev 9.80 2.42 15.1 2.62 2.77 2.39
    p (t-test) 0.53 0.41 0.76
    Min 0.00313 0.00369 0.0244 0.0144 0.00313 0.00369
    Max 86.2 10.8 86.2 8.93 17.1 10.8
    n (Samp) 77 33 31 10 61 24
    n (Patient) 77 33 31 10 61 24
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.48 0.25 0.49
    SE 0.061 0.097 0.070
    p 0.73 0.0084 0.84
    nCohort 1 77 31 61
    nCohort 2 33 10 24
    Cutoff 1 0.484 0.463 0.545
    Sens 1 73% 70% 71%
    Spec 1 18%  3% 21%
    Cutoff 2 0.365 0.0244 0.365
    Sens 2 82% 80% 83%
    Spec 2 17%  3% 20%
    Cutoff 3 0.0144 0 0.0244
    Sens 3 91% 100%  92%
    Spec 3  3%  0% 11%
    Cutoff 4 3.07 3.71 3.00
    Sens 4 27% 10% 29%
    Spec 4 70% 71% 70%
    Cutoff 5 3.71 4.20 3.42
    Sens 5 21% 10% 25%
    Spec 5 81% 81% 80%
    Cutoff 6 6.35 8.43 5.18
    Sens 6  6% 10%  4%
    Spec 6 91% 90% 90%
    OR Quart 2 0.89 1.1 1.1
    p Value 0.84 0.94 0.92
    95% CI of 0.28 0.060 0.28
    OR Quart 2 2.8 20 4.0
    OR Quart 3 0.46 4.3 0.63
    p Value 0.22 0.25 0.53
    95% CI of 0.13 0.37 0.15
    OR Quart 3 1.6 50 2.6
    OR Quart 4 1.5 10 1.6
    p Value 0.51 0.060 0.45
    95% CI of 0.48 0.91 0.45
    OR Quart 4 4.4 110 5.9
    Corticotropin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.00163 0.00194 nd nd 0.00163 0.00171
    Average 0.00250 0.00276 nd nd 0.00260 0.00164
    Stdev 0.00498 0.00438 nd nd 0.00550 0.000678
    p (t-test) 0.82 nd nd 0.49
    Min 3.92E−6 0.000355 nd nd 0.000355 0.000355
    Max 0.0373 0.0224 nd nd 0.0373 0.00282
    n (Samp) 53 23 nd nd 43 16
    n (Patient) 53 23 nd nd 43 16
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.53 nd 0.47
    SE 0.073 nd 0.086
    p 0.66 nd 0.73
    nCohort 1 53 nd 43
    nCohort 2 23 nd 16
    Cutoff 1 0.00119 nd 0.00134
    Sens 1 74% nd 75%
    Spec 1 30% nd 35%
    Cutoff 2 0.00111 nd 0.00111
    Sens 2 87% nd 81%
    Spec 2 23% nd 21%
    Cutoff 3 0.000909 nd 0.000355
    Sens 3 91% nd 94%
    Spec 3 23% nd  5%
    Cutoff 4 0.00222 nd 0.00222
    Sens 4 26% nd 12%
    Spec 4 72% nd 72%
    Cutoff 5 0.00291 nd 0.00256
    Sens 5 13% nd 12%
    Spec 5 85% nd 81%
    Cutoff 6 0.00362 nd 0.00304
    Sens 6 13% nd  0%
    Spec 6 91% nd 91%
    OR Quart 2 1.0 nd 4.3
    p Value 1.0 nd 0.11
    95% CI of 0.24 nd 0.71
    OR Quart 2 4.2 nd 27
    OR Quart 3 1.6 nd 2.4
    p Value 0.49 nd 0.37
    95% CI of 0.41 nd 0.36
    OR Quart 3 6.5 nd 15
    OR Quart 4 1.3 nd 2.6
    p Value 0.72 nd 0.32
    95% CI of 0.32 nd 0.39
    OR Quart 4 5.3 nd 17
    Thyroxine-binding globulin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.0750 0.136 nd nd 0.0894 0.150
    Average 0.225 0.184 nd nd 0.263 0.191
    Stdev 0.373 0.205 nd nd 0.411 0.184
    p (t-test) 0.62 nd nd 0.50
    Min 8.30E−5 0.00330 nd nd 0.00106 0.00330
    Max 1.86 0.748 nd nd 1.86 0.564
    n (Samp) 52 23 nd nd 43 16
    n (Patient) 52 23 nd nd 43 16
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.52 nd 0.51
    SE 0.073 nd 0.085
    p 0.83 nd 0.93
    nCohort 1 52 nd 43
    nCohort 2 23 nd 16
    Cutoff 1 0.0183 nd 0.0179
    Sens 1 74% nd 75%
    Spec 1 27% nd 28%
    Cutoff 2 0.0138 nd 0.0119
    Sens 2 83% nd 81%
    Spec 2 19% nd 21%
    Cutoff 3 0.00575 nd 0.00330
    Sens 3 91% nd 94%
    Spec 3 12% nd  5%
    Cutoff 4 0.212 nd 0.296
    Sens 4 35% nd 31%
    Spec 4 71% nd 72%
    Cutoff 5 0.369 nd 0.468
    Sens 5 13% nd 12%
    Spec 5 83% nd 81%
    Cutoff 6 0.486 nd 0.792
    Sens 6  9% nd  0%
    Spec 6 90% nd 91%
    OR Quart 2 0.93 nd 0.62
    p Value 0.92 nd 0.59
    95% CI of 0.22 nd 0.11
    OR Quart 2 4.0 nd 3.5
    OR Quart 3 1.5 nd 1.7
    p Value 0.56 nd 0.52
    95% CI of 0.38 nd 0.35
    OR Quart 3 6.1 nd 7.9
    OR Quart 4 1.2 nd 0.62
    p Value 0.80 nd 0.59
    95% CI of 0.29 nd 0.11
    OR Quart 4 4.9 nd 3.5
    Alpha-fetoprotein
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.00505 0.00587 0.00428 0.0385 0.00486 0.00587
    Average 0.0525 0.122 0.0656 0.297 0.0435 0.0801
    Stdev 0.106 0.321 0.126 0.568 0.0900 0.196
    p (t-test) 0.083 0.037 0.22
    Min 0.000463 0.000463 0.000463 0.000523 0.000463 0.000463
    Max 0.585 1.74 0.585 1.74 0.507 0.840
    n (Samp) 79 40 31 9 62 31
    n (Patient) 79 40 31 9 62 31
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.50 0.67 0.50
    SE 0.056 0.11 0.064
    p 0.99 0.12 0.96
    nCohort 1 79 31 62
    nCohort 2 40 9 31
    Cutoff 1 0.00286 0.00483 0.00132
    Sens 1 70% 78% 74%
    Spec 1 18% 55% 15%
    Cutoff 2 0.000463 0.000523 0.000463
    Sens 2 85% 89% 90%
    Spec 2  8% 19%  6%
    Cutoff 3 0 0.000463 0.000463
    Sens 3 100%  100%  90%
    Spec 3  0% 19%  6%
    Cutoff 4 0.0499 0.0671 0.00660
    Sens 4 25% 44% 32%
    Spec 4 72% 71% 71%
    Cutoff 5 0.0728 0.107 0.0613
    Sens 5 22% 44% 19%
    Spec 5 81% 81% 81%
    Cutoff 6 0.198 0.236 0.130
    Sens 6 10% 22% 16%
    Spec 6 91% 90% 90%
    OR Quart 2 0.43 0 2.2
    p Value 0.14 na 0.19
    95% CI of 0.14 na 0.67
    OR Quart 2 1.3 na 7.4
    OR Quart 3 0.82 1.7 0.36
    p Value 0.71 0.61 0.19
    95% CI of 0.29 0.22 0.081
    OR Quart 3 2.3 13 1.6
    OR Quart 4 0.71 2.7 1.9
    p Value 0.52 0.34 0.31
    95% CI of 0.25 0.36 0.56
    OR Quart 4 2.0 20 6.2
    Apolipoprotein E
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 3.11 1.74 1.37 1.13 4.13 1.77
    Average 24.3 6.24 8.39 3.15 27.8 6.55
    Stdev 169 12.6 34.1 6.55 190 13.7
    p (t-test) 0.41 0.55 0.46
    Min 0.00102 0.000147 0.000147 0.000147 0.00122 0.00129
    Max 1960 83.4 254 26.8 1960 83.4
    n (Samp) 137 59 56 16 107 43
    n (Patient) 137 59 56 16 107 43
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.45 0.44 0.42
    SE 0.045 0.083 0.053
    p 0.24 0.46 0.15
    nCohort 1 137 56 107
    nCohort 2 59 16 43
    Cutoff 1 0.957 0.177 1.00
    Sens 1 71% 75% 72%
    Spec 1 34% 23% 31%
    Cutoff 2 0.551 0.0954 0.551
    Sens 2 81% 81% 81%
    Spec 2 20% 16% 17%
    Cutoff 3 0.0862 0.00122 0.0954
    Sens 3 92% 94% 91%
    Spec 3  9%  5%  7%
    Cutoff 4 7.35 3.25 9.11
    Sens 4 19% 25% 19%
    Spec 4 70% 71% 71%
    Cutoff 5 14.2 4.55 17.3
    Sens 5 12% 12% 12%
    Spec 5 80% 80% 80%
    Cutoff 6 25.4 14.2 30.5
    Sens 6  7%  6%  2%
    Spec 6 91% 91% 91%
    OR Quart 2 1.9 1.4 1.2
    p Value 0.17 0.67 0.74
    95% CI of 0.76 0.27 0.41
    OR Quart 2 4.7 7.5 3.6
    OR Quart 3 2.3 1.4 2.4
    p Value 0.077 0.67 0.084
    95% CI of 0.92 0.27 0.89
    OR Quart 3 5.6 7.5 6.8
    OR Quart 4 1.7 1.9 1.6
    p Value 0.25 0.43 0.39
    95% CI of 0.68 0.38 0.55
    OR Quart 4 4.3 9.6 4.5
  • FIG. 4: Comparison of the maximum marker levels in urine samples collected from Cohort I (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.
  •
    Complement C4-B
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 24.7 74.8 24.7 63.2 24.7 53.0
    Average 80.6 110 80.6 103 80.6 92.3
    Stdev 182 165 182 163 182 110
    p (t-test) 0.41 0.52 0.80
    Min 0.00607 0.499 0.00607 0.499 0.00607 3.05
    Max 1950 827 1950 827 1950 425
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 35.2 71.6 35.2 71.6 35.2 71.6
    Average 106 101 106 101 106 115
    Stdev 206 118 206 118 206 142
    p (t-test) 0.94 0.94 0.90
    Min 0.00607 0.499 0.00607 0.499 0.00607 17.0
    Max 2000 425 2000 425 2000 425
    n (Samp) 374 13 374 13 374 7
    n (Patient) 374 13 374 13 374 7
    UO only
    Median 28.0 78.0 28.0 71.6 28.0 63.2
    Average 88.7 111 88.7 103 88.7 84.8
    Stdev 187 169 187 168 187 72.8
    p (t-test) 0.59 0.73 0.94
    Min 0.00329 0.904 0.00329 0.672 0.00329 3.05
    Max 1950 827 1950 827 1950 236
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.60 0.55 0.60 0.59 0.55 0.58 0.63 0.64 0.61
    SE 0.058 0.084 0.066 0.058 0.084 0.066 0.077 0.11 0.083
    p 0.080 0.54 0.12 0.14 0.54 0.20 0.085 0.22 0.18
    nCohort 1 223 374 173 223 374 173 223 374 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 16.9 17.0 16.9 16.9 17.0 16.9 17.8 47.7 30.8
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 44% 34% 38% 44% 34% 38% 45% 56% 51%
    Cutoff 2 8.71 5.52 8.98 5.52 5.52 8.71 17.0 32.9 16.9
    Sens 2 80% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 35% 19% 27% 26% 19% 27% 44% 48% 38%
    Cutoff 3 2.76 0.923 4.28 2.22 0.923 2.76 4.27 17.0 4.27
    Sens 3 90% 92% 91% 90% 92% 91% 94% 100%  93%
    Spec 3 16%  4% 17% 13%  4% 10% 22% 34% 16%
    Cutoff 4 57.6 87.6 63.7 57.6 87.6 63.7 57.6 87.6 63.7
    Sens 4 53% 38% 57% 50% 38% 52% 44% 29% 50%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 106 150 128 106 150 128 106 150 128
    Sens 5 37% 23% 35% 33% 23% 30% 31% 14% 36%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 213 260 229 213 260 229 213 260 229
    Sens 6 10%  8%  9%  7%  8%  4% 12% 14%  7%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.4 0.65 1.7 1.0 0.65 1.0 1.5 >2.0 0.98
    p Value 0.55 0.64 0.47 1.0 0.64 1.0 0.66 <0.56 0.98
    95% CI of 0.43 0.11 0.39 0.30 0.11 0.24 0.24 >0.18 0.13
    OR Quart 2 4.8 4.0 7.7 3.3 4.0 4.2 9.3 na 7.3
    OR Quart 3 0.79 1.3 2.1 0.82 1.3 1.9 2.0 >3.1 2.0
    p Value 0.73 0.71 0.30 0.75 0.71 0.34 0.42 <0.33 0.42
    95% CI of 0.20 0.29 0.50 0.24 0.29 0.51 0.36 >0.32 0.36
    OR Quart 3 3.1 6.1 9.1 2.8 6.1 6.9 12 na 12
    OR Quart 4 3.2 1.3 3.4 2.4 1.3 2.2 3.8 >2.0 3.2
    p Value 0.034 0.71 0.077 0.095 0.71 0.23 0.11 <0.57 0.17
    95% CI of 1.1 0.29 0.87 0.86 0.29 0.61 0.75 >0.18 0.61
    OR Quart 4 9.7 6.1 14 6.8 6.1 7.8 19 na 17
    C-C motif chemokine 26
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0402 0.0421 0.0402 0.0405 0.0402 0.0379
    Average 0.0784 1.93 0.0784 1.93 0.0784 0.0347
    Stdev 0.610 8.08 0.610 8.08 0.610 0.0128
    p (t-test) 7.9E−4 8.0E−4 0.78
    Min 0.00872 0.00872 0.00872 0.00872 0.00872 0.0195
    Max 9.14 42.3 9.14 42.3 9.14 0.0526
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 0.0438 0.0402 0.0438 0.0402 0.0438 0.0443
    Average 0.408 0.0374 0.408 0.0359 0.408 0.0393
    Stdev 3.41 0.0150 3.41 0.0152 3.41 0.0124
    p (t-test) 0.70 0.69 0.78
    Min 0.00872 0.00872 0.00872 0.00872 0.00872 0.0195
    Max 42.3 0.0633 42.3 0.0633 42.3 0.0526
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 0.0443 0.0433 0.0443 0.0433 0.0443 0.0363
    Average 0.0482 2.91 0.0482 2.83 0.0482 0.0340
    Stdev 0.0942 9.28 0.0942 9.23 0.0942 0.0117
    p (t-test) 5.6E−5 7.9E−5 0.57
    Min 0.00872 0.0196 0.00872 0.0196 0.00872 0.0196
    Max 1.25 42.3 1.25 42.3 1.25 0.0525
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 0.44 0.53 0.51 0.42 0.48 0.47 0.47 0.38
    SE 0.057 0.084 0.065 0.057 0.084 0.065 0.076 0.11 0.083
    p 0.37 0.48 0.62 0.85 0.37 0.81 0.66 0.79 0.15
    nCohort 1 223 375 173 223 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 0.0311 0.0240 0.0386 0.0235 0.0235 0.0232 0.0232 0.0433 0.0232
    Sens 1 70% 77% 74% 73% 77% 78% 75% 71% 79%
    Spec 1 47% 30% 41% 39% 27% 28% 39% 47% 28%
    Cutoff 2 0.0232 0.0232 0.0232 0.0231 0.0232 0.0231 0.0196 0.0232 0.0196
    Sens 2 83% 85% 87% 80% 85% 83% 81% 86% 86%
    Spec 2 39% 27% 28% 32% 27% 23% 15% 27% 13%
    Cutoff 3 0.0196 0.0188 0.0231 0.0195 0.0188 0.0196 0.0195 0.0188 0.0195
    Sens 3 90% 92% 91% 93% 92% 91% 94% 100%  100% 
    Spec 3 15%  8% 23% 15%  8% 13% 15%  8% 13%
    Cutoff 4 0.0504 0.0525 0.0525 0.0504 0.0525 0.0525 0.0504 0.0525 0.0525
    Sens 4 23% 15% 22% 20% 15% 17% 12% 14%  0%
    Spec 4 78% 76% 77% 78% 76% 77% 78% 76% 77%
    Cutoff 5 0.0525 0.0526 0.0526 0.0525 0.0526 0.0526 0.0525 0.0526 0.0526
    Sens 5 20%  8% 22% 17%  8% 17%  6%  0%  0%
    Spec 5 85% 82% 86% 85% 82% 86% 85% 82% 86%
    Cutoff 6 0.0628 0.0628 0.0628 0.0628 0.0628 0.0628 0.0628 0.0628 0.0628
    Sens 6 17%  8% 22% 13%  8% 17%  0%  0%  0%
    Spec 6 95% 90% 92% 95% 90% 92% 95% 90% 92%
    OR Quart 2 2.5 1.5 4.4 1.4 1.5 0.78 3.2 3.1 3.1
    p Value 0.15 0.65 0.030 0.57 0.65 0.73 0.16 0.33 0.33
    95% CI of 0.72 0.25 1.2 0.45 0.25 0.20 0.62 0.32 0.31
    OR Quart 2 8.4 9.3 17 4.2 9.3 3.1 17 30 31
    OR Quart 3 2.8 3.1 1.0 1.8 3.1 2.3 2.1 2.0 8.0
    p Value 0.099 0.17 1.0 0.29 0.17 0.17 0.41 0.57 0.056
    95% CI of 0.82 0.62 0.19 0.61 0.62 0.71 0.36 0.18 0.95
    OR Quart 3 9.4 16 5.2 5.3 16 7.2 12 13 68
    OR Quart 4 1.8 1.0 2.1 0.98 1.0 0.78 2.1 1.0 3.2
    p Value 0.36 1.0 0.30 0.98 1.0 0.73 0.40 0.99 0.32
    95% CI of 0.50 0.14 0.50 0.30 0.14 0.20 0.37 0.062 0.32
    OR Quart 4 6.5 7.2 9.1 3.2 7.2 3.1 12 16 32
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.662 1.22 0.662 0.812 0.662 0.625
    Average 2.62 17.1 2.62 9.44 2.62 11.0
    Stdev 9.67 24.1 9.67 18.5 9.67 22.3
    p (t-test) 4.3E−9 0.0017 0.0035
    Min 0.146 0.188 0.146 0.188 0.146 0.319
    Max 125 82.4 125 82.4 125 82.4
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 0.816 1.29 0.816 1.15 0.816 0.625
    Average 3.99 34.0 3.99 12.4 3.99 7.89
    Stdev 19.3 80.2 19.3 20.1 19.3 13.3
    p (t-test) 8.9E−6 0.12 0.59
    Min 0.146 0.188 0.146 0.188 0.146 0.319
    Max 291 293 291 67.6 291 33.9
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 0.816 1.15 0.816 0.812 0.816 0.625
    Average 3.35 26.1 3.35 14.4 3.35 8.82
    Stdev 10.9 40.2 10.9 29.5 10.9 22.9
    p (t-test) 7.5E−9 5.7E−4 0.11
    Min 0.146 0.341 0.146 0.319 0.146 0.341
    Max 125 166 125 114 125 82.4
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.72 0.64 0.67 0.62 0.60 0.54 0.59 0.50 0.46
    SE 0.055 0.084 0.065 0.058 0.084 0.065 0.077 0.11 0.082
    p 9.6E−5 0.088 0.0087 0.038 0.26 0.50 0.22 1.00 0.62
    nCohort 1 223 375 173 223 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 0.584 0.380 0.584 0.515 0.380 0.515 0.483 0.336 0.515
    Sens 1 73% 77% 78% 70% 77% 74% 75% 86% 71%
    Spec 1 46% 29% 31% 43% 29% 29% 43% 22% 29%
    Cutoff 2 0.483 0.336 0.515 0.406 0.336 0.499 0.380 0.336 0.380
    Sens 2 83% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 43% 22% 29% 41% 22% 28% 41% 22% 25%
    Cutoff 3 0.380 0.319 0.499 0.320 0.319 0.320 0.320 0.319 0.320
    Sens 3 90% 92% 91% 90% 92% 96% 94% 100%  100% 
    Spec 3 41% 12% 28% 31% 12% 20% 31% 12% 20%
    Cutoff 4 1.04 1.15 1.29 1.04 1.15 1.29 1.04 1.15 1.29
    Sens 4 60% 54% 43% 40% 46% 26% 31% 29% 14%
    Spec 4 74% 74% 77% 74% 74% 77% 74% 74% 77%
    Cutoff 5 1.29 1.29 1.59 1.29 1.29 1.59 1.29 1.29 1.59
    Sens 5 43% 46% 43% 27% 38% 26% 25% 29% 14%
    Spec 5 84% 81% 87% 84% 81% 87% 84% 81% 87%
    Cutoff 6 1.59 7.96 13.6 1.59 7.96 13.6 1.59 7.96 13.6
    Sens 6 43% 46% 43% 27% 38% 26% 25% 29% 14%
    Spec 6 90% 90% 97% 90% 90% 97% 90% 90% 97%
    OR Quart 2 5.1 1.5 3.9 4.2 2.0 2.5 8.9 0.32 1.0
    p Value 0.043 0.65 0.100 0.033 0.42 0.15 0.042 0.33 1.0
    95% CI of 1.1 0.25 0.77 1.1 0.37 0.72 1.1 0.033 0.13
    OR Quart 2 25 9.3 20 16 11 8.9 74 3.2 7.4
    OR Quart 3 1.0 0.49 2.1 1.4 0.49 1.0 2.0 0.33 3.9
    p Value 1.0 0.57 0.41 0.70 0.57 1.0 0.58 0.34 0.099
    95% CI of 0.14 0.044 0.36 0.29 0.044 0.24 0.18 0.033 0.77
    OR Quart 3 7.3 5.5 12 6.3 5.5 4.2 23 3.2 20
    OR Quart 4 11 3.7 6.0 4.6 3.1 1.6 5.3 0.65 1.6
    p Value 0.0019 0.11 0.026 0.023 0.17 0.51 0.13 0.64 0.63
    95% CI of 2.4 0.75 1.2 1.2 0.62 0.41 0.60 0.11 0.25
    OR Quart 4 50 18 29 17 16 5.9 47 4.0 9.9
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 343 467 343 414 343 414
    Average 340 507 340 494 340 470
    Stdev 278 193 278 207 278 270
    p (t-test) 0.0076 0.017 0.11
    Min 1.37 166 1.37 166 1.37 3.04
    Max 2070 913 2070 913 2070 913
    n (Samp) 128 22 128 21 128 13
    n (Patient) 128 22 128 21 128 13
    sCr only
    Median 397 414 397 401 nd nd
    Average 405 524 405 494 nd nd
    Stdev 292 206 292 232 nd nd
    p (t-test) 0.26 0.40 nd nd
    Min 1.37 362 1.37 249 nd nd
    Max 2750 913 2750 913 nd nd
    n (Samp) 240 8 240 8 nd nd
    n (Patient) 240 8 240 8 nd nd
    UO only
    Median 356 509 356 511 356 406
    Average 362 511 362 508 362 437
    Stdev 286 188 286 193 286 245
    p (t-test) 0.039 0.049 0.38
    Min 1.37 166 1.37 166 1.37 3.04
    Max 2070 835 2070 835 2070 835
    n (Samp) 122 17 122 16 122 12
    n (Patient) 122 17 122 16 122 12
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.74 0.66 0.73 0.71 0.60 0.72 0.65 nd 0.60
    SE 0.064 0.11 0.073 0.067 0.11 0.075 0.086 nd 0.090
    p 1.5E−4 0.15 0.0014 0.0017 0.37 0.0031 0.083 nd 0.24
    nCohort 1 128 240 122 128 240 122 128 nd 122
    nCohort 2 22 8 17 21 8 16 13 nd 12
    Cutoff 1 397 397 407 364 358 397 354 nd 354
    Sens 1 73% 75% 71% 71% 75% 75% 77% nd 75%
    Spec 1 65% 51% 63% 58% 43% 61% 53% nd 50%
    Cutoff 2 364 366 364 337 295 364 242 nd 236
    Sens 2 82% 88% 82% 81% 88% 81% 85% nd 83%
    Spec 2 58% 47% 53% 49% 31% 53% 36% nd 30%
    Cutoff 3 337 358 236 247 247 236 145 nd 145
    Sens 3 91% 100%  94% 90% 100%  94% 92% nd 92%
    Spec 3 49% 43% 30% 36% 25% 30% 24% nd 20%
    Cutoff 4 425 486 441 425 486 441 425 nd 441
    Sens 4 50% 38% 59% 48% 38% 56% 38% nd 33%
    Spec 4 70% 72% 70% 70% 72% 70% 70% nd 70%
    Cutoff 5 475 534 475 475 534 475 475 nd 475
    Sens 5 50% 38% 59% 48% 38% 56% 38% nd 33%
    Spec 5 81% 82% 80% 81% 82% 80% 81% nd 80%
    Cutoff 6 534 651 574 534 651 574 534 nd 574
    Sens 6 36% 25% 29% 33% 25% 31% 38% nd 33%
    Spec 6 91% 90% 90% 91% 90% 90% 91% nd 90%
    OR Quart 2 3.1 >2.1 3.1 4.4 9.0 3.1 0.49 nd 0.97
    p Value 0.34 <0.56 0.34 0.20 0.57 0.34 0.56 nd 0.98
    95% CI of 0.31 >0.18 0.31 0.46 0.18 0.31 0.042 nd 0.13
    OR Quart 2 31 na 31 41 23 31 5.6 nd 7.3
    OR Quart 3 8.4 >3.2 3.1 7.0 2.0 3.2 2.8 nd 2.1
    p Value 0.052 <0.33 0.34 0.080 0.57 0.33 0.25 nd 0.40
    95% CI of 0.98 >0.32 0.31 0.79 0.18 0.32 0.50 nd 0.36
    OR Quart 3 72 na 31 61 23 32 15 nd 13
    OR Quart 4 15 >3.2 13 13 3.1 11 2.7 nd 2.1
    p Value 0.012 <0.33 0.017 0.018 0.33 0.025 0.26 nd 0.42
    95% CI of 1.8 >0.32 1.6 1.6 0.31 1.4 0.48 nd 0.35
    OR Quart 4 120 na 110 110 31 96 15 nd 12
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.122 3.93 0.122 2.03 0.122 9.04
    Average 13.0 10.4 13.0 9.15 13.0 13.7
    Stdev 22.3 12.8 22.3 12.4 22.3 13.6
    p (t-test) 0.53 0.36 0.90
    Min 0.0369 0.0450 0.0369 0.0398 0.0369 0.0450
    Max 126 34.7 126 34.7 126 34.7
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 0.122 5.88 0.122 2.21 0.122 0.122
    Average 14.5 10.5 14.5 8.16 14.5 9.54
    Stdev 24.0 12.9 24.0 11.6 24.0 13.9
    p (t-test) 0.55 0.34 0.59
    Min 0.0238 0.0450 0.0238 0.0450 0.0238 0.0398
    Max 126 34.7 126 34.7 126 34.7
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 0.311 5.47 0.311 2.39 0.311 10.8
    Average 14.4 11.0 14.4 10.7 14.4 15.1
    Stdev 22.4 12.9 22.4 13.0 22.4 13.8
    p (t-test) 0.48 0.45 0.91
    Min 0.0348 0.0672 0.0348 0.0398 0.0348 0.104
    Max 126 34.7 126 34.7 126 34.7
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.58 0.57 0.53 0.54 0.52 0.51 0.65 0.46 0.64
    SE 0.058 0.084 0.065 0.057 0.083 0.064 0.077 0.11 0.083
    p 0.19 0.43 0.67 0.48 0.77 0.93 0.055 0.76 0.095
    nCohort 1 223 375 173 223 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 0.0974 0.0974 0.0974 0.0974 0.0967 0.0974 1.45 0.0802 2.24
    Sens 1 77% 77% 78% 70% 77% 74% 75% 71% 71%
    Spec 1 42% 39% 30% 42% 34% 30% 59% 33% 57%
    Cutoff 2 0.0967 0.0967 0.0967 0.0802 0.0724 0.0802 0.112 0.0418 1.45
    Sens 2 83% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 34% 34% 25% 33% 24% 24% 48% 13% 54%
    Cutoff 3 0.0606 0.0754 0.0606 0.0606 0.0656 0.0606 0.0974 0.0369 0.0974
    Sens 3 97% 92% 100%  90% 92% 91% 94% 100%  100% 
    Spec 3 22% 27% 14% 22% 18% 14% 42%  5% 30%
    Cutoff 4 16.0 17.0 20.3 16.0 17.0 20.3 16.0 17.0 20.3
    Sens 4 30% 31% 30% 27% 23% 30% 38% 29% 43%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 25.6 30.0 29.7 25.6 30.0 29.7 25.6 30.0 29.7
    Sens 5 20% 15% 13% 17%  8% 13% 31% 14% 21%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 40.0 47.3 41.7 40.0 47.3 41.7 40.0 47.3 41.7
    Sens 6  0%  0%  0%  0%  0%  0%  0%  0%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.4 3.1 1.0 1.4 1.0 0.78 3.1 3.1 >2.0
    p Value 0.55 0.34 1.0 0.55 1.0 0.73 0.34 0.33 <0.56
    95% CI of 0.43 0.31 0.24 0.43 0.14 0.20 0.31 0.32 >0.18
    OR Quart 2 4.8 30 4.2 4.8 7.2 3.1 30 30 na
    OR Quart 3 1.9 6.3 2.5 2.2 3.7 1.7 6.4 1.0 >8.0
    p Value 0.26 0.090 0.15 0.18 0.11 0.38 0.089 1.0 <0.056
    95% CI of 0.61 0.75 0.72 0.70 0.75 0.52 0.75 0.062 >0.95
    OR Quart 3 6.1 54 8.9 6.8 18 5.7 55 16 na
    OR Quart 4 1.9 3.1 1.6 1.7 1.0 1.2 6.4 2.0 >5.5
    p Value 0.28 0.34 0.51 0.40 1.0 0.75 0.089 0.56 <0.13
    95% CI of 0.60 0.31 0.41 0.51 0.14 0.35 0.75 0.18 >0.61
    OR Quart 4 6.0 30 5.9 5.4 7.2 4.3 55 23 na
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.923 2.85 0.923 2.84 0.923 2.33
    Average 1.70 4.02 1.70 3.86 1.70 2.23
    Stdev 5.34 3.59 5.34 3.69 5.34 1.89
    p (t-test) 0.13 0.16 0.78
    Min 0.0439 0.0558 0.0439 0.0558 0.0439 0.0558
    Max 53.9 11.4 53.9 11.4 53.9 5.52
    n (Samp) 109 13 109 13 109 8
    n (Patient) 109 13 109 13 109 8
    sCr only
    Median 0.923 2.85 0.923 0.923 nd nd
    Average 2.46 3.66 2.46 3.36 nd nd
    Stdev 8.16 3.70 8.16 3.86 nd nd
    p (t-test) 0.70 0.77 nd nd
    Min 0.0319 0.0558 0.0319 0.0558 nd nd
    Max 85.6 9.68 85.6 9.68 nd nd
    n (Samp) 184 7 184 7 nd nd
    n (Patient) 184 7 184 7 nd nd
    UO only
    Median 0.923 4.65 0.923 4.65 0.923 2.43
    Average 1.65 4.84 1.65 4.84 1.65 2.53
    Stdev 5.56 3.27 5.56 3.27 5.56 1.97
    p (t-test) 0.11 0.11 0.70
    Min 0.0439 0.957 0.0439 0.957 0.0439 0.0558
    Max 53.9 11.4 53.9 11.4 53.9 5.52
    n (Samp) 99 8 99 8 99 6
    n (Patient) 99 8 99 8 99 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.75 0.62 0.92 0.71 0.55 0.92 0.67 nd 0.74
    SE 0.081 0.12 0.068 0.084 0.11 0.068 0.11 nd 0.12
    p 0.0016 0.30 8.9E−10 0.010 0.65 8.9E−10 0.11 nd 0.046
    nCohort 1 109 184 99 109 184 99 109 nd 99
    nCohort 2 13 7 8 13 7 8 8 nd 6
    Cutoff 1 0.923 0.733 2.44 0.733 0.670 2.44 0.923 nd 0.923
    Sens 1 77% 71% 75% 77% 71% 75% 75% nd 83%
    Spec 1 64% 41% 91% 43% 34% 91% 64% nd 65%
    Cutoff 2 0.733 0.0558 1.94 0.670 0.0558 1.94 0.0558 nd 0.923
    Sens 2 85% 86% 88% 85% 86% 88% 88% nd 83%
    Spec 2 43%  6% 89% 36%  6% 89%  6% nd 65%
    Cutoff 3 0.0558 0.0439 0.923 0.0558 0.0439 0.923 0.0439 nd 0.0439
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3  6%  1% 65%  6%  1% 65%  1% nd  1%
    Cutoff 4 0.957 1.17 0.957 0.957 1.17 0.957 0.957 nd 0.957
    Sens 4 69% 57% 88% 62% 43% 88% 62% nd 67%
    Spec 4 73% 71% 74% 73% 71% 74% 73% nd 74%
    Cutoff 5 1.46 2.33 1.46 1.46 2.33 1.46 1.46 nd 1.46
    Sens 5 69% 57% 88% 62% 43% 88% 62% nd 67%
    Spec 5 81% 80% 82% 81% 80% 82% 81% nd 82%
    Cutoff 6 2.50 3.90 2.44 2.50 3.90 2.44 2.50 nd 2.44
    Sens 6 62% 43% 75% 54% 43% 75% 50% nd 50%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 0.47 0.48 >0 0.97 0.98 >0 0 nd 0
    p Value 0.54 0.55 <na 0.97 0.98 <na na nd na
    95% CI of 0.040 0.042 >na 0.13 0.13 >na na nd na
    OR Quart 2 5.4 5.5 na 7.3 7.2 na na nd na
    OR Quart 3 0.48 0 >1.0 0.48 0 >1.0 0.48 nd 1.0
    p Value 0.56 na <1.0 0.56 na <1.0 0.56 nd 1.0
    95% CI of 0.041 na >0.059 0.041 na >0.059 0.041 nd 0.059
    OR Quart 3 5.6 na na 5.6 na na 5.6 nd 17
    OR Quart 4 5.7 2.0 >9.1 4.9 1.5 >9.1 2.7 nd 4.3
    p Value 0.036 0.42 <0.047 0.059 0.67 <0.047 0.26 nd 0.20
    95% CI of 1.1 0.36 >1.0 0.94 0.24 >1.0 0.48 nd 0.45
    OR Quart 4 29 12 na 25 9.4 na 15 nd 42
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0682 1.58 0.0682 1.22 0.0682 2.34
    Average 0.622 1.87 0.622 1.55 0.622 2.16
    Stdev 1.19 1.87 1.19 1.80 1.19 2.03
    p (t-test) 0.0012 0.014 0.0011
    Min 0.0210 0.0210 0.0210 0.0210 0.0210 0.0393
    Max 5.79 5.59 5.79 5.59 5.79 5.59
    n (Samp) 109 13 109 13 109 8
    n (Patient) 109 13 109 13 109 8
    sCr only
    Median 0.0994 1.22 0.0994 0.0938 nd nd
    Average 0.941 1.76 0.941 1.18 nd nd
    Stdev 1.65 1.83 1.65 1.60 nd nd
    p (t-test) 0.20 0.70 nd nd
    Min 0.0116 0.0210 0.0116 0.0210 nd nd
    Max 9.43 4.11 9.43 3.48 nd nd
    n (Samp) 184 7 184 7 nd nd
    n (Patient) 184 7 184 7 nd nd
    UO only
    Median 0.0682 1.68 0.0682 1.68 0.0682 2.34
    Average 0.567 1.92 0.567 1.92 0.567 2.29
    Stdev 1.10 1.98 1.10 1.98 1.10 2.14
    p (t-test) 0.0024 0.0024 7.0E−4
    Min 0.0210 0.0210 0.0210 0.0210 0.0210 0.0393
    Max 5.79 5.59 5.79 5.59 5.79 5.59
    n (Samp) 100 8 100 8 100 6
    n (Patient) 100 8 100 8 100 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.67 0.61 0.65 0.61 0.50 0.65 0.74 nd 0.73
    SE 0.086 0.12 0.11 0.087 0.11 0.11 0.10 nd 0.12
    p 0.055 0.33 0.16 0.21 0.97 0.16 0.022 nd 0.054
    nCohort 1 109 184 100 109 184 100 109 nd 100
    nCohort 2 13 7 8 13 7 8 8 nd 6
    Cutoff 1 0.0358 0.0682 0.0358 0.0358 0.0358 0.0358 0.0682 nd 0.0400
    Sens 1 85% 71% 88% 77% 71% 88% 75% nd 83%
    Spec 1 29% 46% 26% 29% 22% 26% 54% nd 28%
    Cutoff 2 0.0358 0.0358 0.0358 0.0255 0.0255 0.0358 0.0400 nd 0.0400
    Sens 2 85% 86% 88% 85% 86% 88% 88% nd 83%
    Spec 2 29% 22% 26% 19% 14% 26% 32% nd 28%
    Cutoff 3 0 0.0116 0 0 0.0116 0 0.0358 nd 0.0358
    Sens 3 100%  100%  100%  100%  100%  100%  100%  nd 100% 
    Spec 3  0%  1%  0%  0%  1%  0% 29% nd 26%
    Cutoff 4 0.397 0.558 0.397 0.397 0.558 0.397 0.397 nd 0.397
    Sens 4 62% 57% 62% 54% 43% 62% 62% nd 67%
    Spec 4 76% 70% 78% 76% 70% 78% 76% nd 78%
    Cutoff 5 0.593 1.58 0.465 0.593 1.58 0.465 0.593 nd 0.465
    Sens 5 62% 43% 62% 54% 29% 62% 62% nd 67%
    Spec 5 81% 80% 80% 81% 80% 80% 81% nd 80%
    Cutoff 6 2.38 3.03 1.76 2.38 3.03 1.76 2.38 nd 1.76
    Sens 6 38% 43% 50% 31% 29% 50% 50% nd 67%
    Spec 6 91% 90% 90% 91% 90% 90% 91% nd 90%
    OR Quart 2 0.97 0.48 2.1 0.62 0.31 2.1 >2.1 nd >2.1
    p Value 0.97 0.55 0.56 0.62 0.32 0.56 <0.54 nd <0.56
    95% CI of 0.13 0.042 0.18 0.096 0.031 0.18 >0.18 nd >0.18
    OR Quart 2 7.3 5.5 24 4.0 3.1 24 na nd na
    OR Quart 30 0.48 0 0 0.31 0 0 >1.0 nd >0
    p Value 0.56 na na 0.32 na na <0.98 nd <na
    95% CI of 0.041 na na 0.030 na na >0.062 nd >na
    OR Quart 3 5.6 na na 3.2 na na na nd na
    OR Quart 4 4.9 2.0 5.9 2.6 0.98 5.9 >5.8 nd >4.5
    p Value 0.059 0.42 0.12 0.20 0.98 0.12 <0.12 nd <0.19
    95% CI of 0.94 0.36 0.64 0.61 0.19 0.64 >0.63 nd >0.47
    OR Quart 4 25 12 54 11 5.1 54 na nd na
    Interleukin-21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 13.0 9.95 13.0 7.46 13.0 9.22
    Average 15.4 11.4 15.4 9.90 15.4 10.5
    Stdev 13.1 9.82 13.1 9.70 13.1 12.0
    p (t-test) 0.11 0.027 0.14
    Min 0.0191 0.0219 0.0191 0.0219 0.0191 0.0177
    Max 87.9 49.5 87.9 49.5 87.9 49.5
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 13.0 8.34 13.0 8.34 13.0 6.02
    Average 15.9 12.5 15.9 12.2 15.9 13.7
    Stdev 13.8 12.3 13.8 12.5 13.8 16.7
    p (t-test) 0.37 0.33 0.68
    Min 0.0122 2.66 0.0122 2.65 0.0122 2.35
    Max 87.9 49.5 87.9 49.5 87.9 49.5
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 12.6 8.82 12.6 6.02 12.6 8.02
    Average 15.2 10.3 15.2 8.31 15.2 7.93
    Stdev 12.9 6.93 12.9 6.17 12.9 6.07
    p (t-test) 0.071 0.012 0.037
    Min 0.0160 0.0219 0.0160 0.0219 0.0160 0.0177
    Max 87.9 24.2 87.9 20.6 87.9 17.2
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.41 0.42 0.39 0.36 0.41 0.33 0.36 0.42 0.32
    SE 0.058 0.084 0.066 0.057 0.084 0.065 0.077 0.11 0.081
    p 0.12 0.34 0.10 0.015 0.26 0.0091 0.059 0.46 0.025
    nCohort 1 223 375 173 223 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 5.82 5.90 5.32 3.89 5.44 3.50 2.73 5.44 2.95
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 26% 27% 25% 20% 26% 16% 15% 26% 14%
    Cutoff 2 3.89 5.44 3.50 2.73 4.24 2.35 2.61 2.61 0.0975
    Sens 2 80% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 20% 26% 16% 15% 21% 12% 14% 13%  3%
    Cutoff 3 2.73 4.24 2.22 2.22 2.65 0.689 0.0191 2.34 0.0191
    Sens 3 90% 92% 91% 90% 92% 91% 94% 100%  93%
    Spec 3 15% 21% 12% 13% 13%  5%  0% 12%  1%
    Cutoff 4 19.2 19.3 19.6 19.2 19.3 19.6 19.2 19.3 19.6
    Sens 4 20% 15% 17% 13% 15%  9%  6% 14%  0%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 24.9 25.4 24.9 24.9 25.4 24.9 24.9 25.4 24.9
    Sens 5  3%  8%  0%  3%  8%  0%  6% 14%  0%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 31.3 33.5 31.2 31.3 33.5 31.2 31.3 33.5 31.2
    Sens 6  3%  8%  0%  3%  8%  0%  6% 14%  0%
    Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 0.66 3.1 6.7 1.0 3.1 6.7 4.2 2.0 >3.2
    p Value 0.53 0.34 0.084 0.98 0.34 0.084 0.20 0.56 <0.32
    95% CI of 0.18 0.31 0.77 0.24 0.31 0.77 0.46 0.18 >0.32
    OR Quart 2 2.4 30 58 4.3 30 58 39 23 na
    OR Quart 3 2.3 7.5 12 3.2 6.3 9.4 5.4 2.0 >6.9
    p Value 0.12 0.062 0.019 0.060 0.090 0.039 0.13 0.57 <0.080
    95% CI of 0.80 0.90 1.5 0.95 0.75 1.1 0.61 0.18 >0.79
    OR Quart 3 6.5 62 100 11 54 78 47 23 na
    OR Quart 4 1.4 2.0 6.7 3.2 3.1 9.4 6.7 2.0 >5.7
    p Value 0.55 0.57 0.084 0.060 0.34 0.039 0.083 0.56 <0.12
    95% CI of 0.46 0.18 0.77 0.95 0.31 1.1 0.78 0.18 >0.64
    OR Quart 4 4.3 23 58 11 30 78 57 23 na
    Interleukin-23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 583 447 583 304 583 562
    Average 800 615 800 483 800 666
    Stdev 942 593 942 512 942 597
    p (t-test) 0.30 0.072 0.58
    Min 0.643 0.552 0.643 0.552 0.643 0.564
    Max 8520 2120 8520 2000 8520 2000
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 588 389 588 229 588 279
    Average 798 520 798 475 798 633
    Stdev 890 559 890 579 890 747
    p (t-test) 0.26 0.20 0.63
    Min 0.552 0.552 0.552 0.552 0.552 1.09
    Max 8520 2000 8520 2000 8520 2000
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 652 420 652 329 652 562
    Average 870 608 870 457 870 587
    Stdev 990 598 990 474 990 521
    p (t-test) 0.22 0.050 0.29
    Min 0.564 0.552 0.564 0.552 0.564 0.552
    Max 8520 2120 8520 1450 8520 1450
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 0.41 0.41 0.39 0.38 0.34 0.48 0.45 0.41
    SE 0.057 0.084 0.066 0.058 0.084 0.065 0.076 0.11 0.083
    p 0.39 0.28 0.19 0.059 0.17 0.015 0.80 0.65 0.30
    nCohort 1 223 375 173 223 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 233 152 129 135 136 1.61 233 152 214
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 32% 26% 17% 24% 24% 10% 32% 26% 28%
    Cutoff 2 129 84.5 0.967 1.61 1.61 0.967 152 1.61 0.967
    Sens 2 80% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 24% 19%  5% 14% 14%  5% 26% 14%  5%
    Cutoff 3 0.967 1.09 0.682 0.967 1.09 0.682 0.967 1.06 0.552
    Sens 3 90% 92% 91% 90% 92% 91% 94% 100%  93%
    Spec 3  9% 11%  2%  9% 11%  2%  9% 10%  0%
    Cutoff 4 952 977 983 952 977 983 952 977 983
    Sens 4 27% 15% 26% 17% 15% 17% 31% 29% 29%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 1390 1360 1390 1390 1360 1390 1390 1360 1390
    Sens 5 10%  8%  9%  7%  8%  4% 12% 14%  7%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 1830 1900 1960 1830 1900 1960 1830 1900 1960
    Sens 6  7%  8%  4%  3%  8%  0%  6% 14%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.86 1.0 0.47 1.2 1.0 0.73 1.0 0.50 0.48
    p Value 0.79 1.0 9.30 0.73 1.0 0.70 1.0 0.57 0.41
    95% CI of 0.27 0.14 0.11 0.36 0.14 0.16 0.24 0.045 0.083
    OR Quart 2 2.7 7.2 2.0 4.3 7.2 3.5 4.2 5.6 2.7
    OR Quart 3 1.5 3.1 1.2 2.0 2.6 1.6 1.3 1.0 1.0
    p Value 0.42 0.17 0.77 0.25 0.26 0.51 0.73 1.0 1.0
    95% CI of 0.55 0.62 0.37 0.62 0.49 0.41 0.32 0.14 0.23
    OR Quart 3 4.3 16 3.9 6.2 14 5.9 5.0 7.2 4.3
    OR Quart 4 1.0 1.5 1.2 2.2 2.0 2.9 0.75 1.0 1.0
    p Value 0.98 0.65 0.77 0.17 0.42 0.093 0.71 0.99 0.97
    95% CI of 0.34 0.25 0.37 0.72 0.37 0.84 0.16 0.14 0.24
    OR Quart 4 3.1 9.3 3.9 6.9 11 9.9 3.5 1.3 4.4
    Interleukin-28A
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 34.2 30.9 34.2 26.9 34.2 25.5
    Average 48.6 42.1 48.6 34.5 48.6 42.0
    Stdev 50.2 41.0 50.2 38.4 50.2 46.6
    p (t-test) 0.50 0.14 0.61
    Min 0.0495 0.0996 0.0495 0.0854 0.0495 0.155
    Max 228 186 228 186 228 186
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 38.8 28.9 38.8 27.7 38.8 26.1
    Average 51.6 43.5 51.6 40.0 51.6 50.8
    Stdev 50.3 50.2 50.3 50.9 50.3 67.4
    p (t-test) 0.57 0.41 0.96
    Min 0.0254 0.0996 0.0254 0.0996 0.0254 0.0860
    Max 235 186 235 186 235 186
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 40.0 29.2 40.0 24.2 40.0 24.5
    Average 54.0 38.1 54.0 29.4 54.0 32.2
    Stdev 52.2 33.0 52.2 27.4 52.2 28.1
    p (t-test) 0.16 0.028 0.12
    Min 0.0517 0.204 0.0517 0.0777 0.0517 0.155
    Max 228 127 228 91.0 228 91.0
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.49 0.45 0.44 0.43 0.43 0.37 0.48 0.46 0.41
    SE 0.057 0.083 0.066 0.057 0.084 0.066 0.075 0.11 0.083
    p 0.86 0.57 0.37 0.25 0.39 0.045 0.84 0.76 0.25
    nCohort 1 223 375 173 223 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 21.6 14.7 18.7 14.1 10.1 0.932 18.7 10.1 18.7
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 40% 33% 32% 35% 30% 22% 38% 30% 32%
    Cutoff 2 10.1 10.1 1.80 0.198 1.55 0.198 10.1 1.55 2.62
    Sens 2 80% 85% 83% 83% 85% 83% 81% 86% 86%
    Spec 2 33% 30% 22% 16% 23% 11% 33% 23% 23%
    Cutoff 3 0.198 0.131 0.198 0.131 0.131 0.0854 0.198 0.0854 0.198
    Sens 3 93% 92% 100%  90% 92% 91% 94% 100%  93%
    Spec 3 16% 11% 11% 14% 11%  8% 16%  7% 11%
    Cutoff 4 65.2 70.9 78.3 65.2 70.9 78.3 65.2 70.9 78.3
    Sens 4 23% 15%  9% 17% 15%  4% 25% 29%  7%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 92.2 94.0 96.2 92.2 94.0 96.2 92.2 94.0 96.2
    Sens 5  7%  8%  4%  3%  8%  0%  6% 14%  0%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 120 123 120 120 123 120 120 123 120
    Sens 6  7%  8%  4%  3%  8%  0%  6% 14%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 3.8 1.0 3.3 5.2 0.49 6.7 2.1 0 3.1
    p Value 0.050 1.0 0.16 0.041 0.57 0.084 0.41 na 0.33
    95% CI of 1.0 0.14 0.63 1.1 0.044 0.77 0.36 na 0.31
    OR Quart 2 15 7.2 17 25 5.5 58 12 na 31
    OR Quart 3 4.3 3.7 6.0 6.6 3.7 11 4.5 1.5 8.0
    p Value 0.031 0.11 0.026 0.017 0.11 0.027 0.066 0.65 0.056
    95% CI of 1.1 0.75 1.2 1.4 0.75 1.3 0.91 0.25 0.95
    OR Quart 3 16 18 29 31 18 89 22 9.3 68
    OR Quart 4 2.1 1.0 2.7 4.5 1.5 8.0 1.0 1.0 3.2
    p Value 0.30 1.0 0.25 0.064 0.65 0.056 0.99 0.99 0.32
    95% CI of 0.51 0.14 0.49 0.92 0.25 0.95 0.14 0.14 0.32
    OR Quart 4 9.0 7.2 14 22 9.3 68 7.5 7.3 32
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 69.0 48.4 69.0 43.9 69.0 54.0
    Average 83.7 58.2 83.7 52.1 83.7 61.6
    Stdev 88.6 45.1 88.6 44.4 88.6 44.2
    p (t-test) 0.12 0.056 0.32
    Min 0.0360 0.0523 0.0360 0.0232 0.0360 0.0523
    Max 958 170 958 170 958 136
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 68.9 45.5 68.9 38.8 68.9 57.9
    Average 82.6 57.8 82.6 55.5 82.6 58.4
    Stdev 79.9 46.6 79.9 47.9 79.9 39.9
    p (t-test) 0.27 0.22 0.42
    Min 0.0232 1.78 0.0232 1.78 0.0232 14.4
    Max 958 170 958 170 958 135
    n (Samp) 375 13 375 13 375 7
    n (Patient) 375 13 375 13 375 7
    UO only
    Median 71.8 50.0 71.8 43.5 71.8 48.0
    Average 91.0 53.0 91.0 45.9 91.0 55.6
    Stdev 95.6 42.0 95.6 39.6 95.6 43.3
    p (t-test) 0.061 0.027 0.17
    Min 0.0447 0.0436 0.0447 0.0232 0.0447 0.0523
    Max 958 136 958 136 958 136
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.41 0.40 0.36 0.37 0.38 0.31 0.44 0.41 0.37
    SE 0.058 0.084 0.065 0.057 0.084 0.064 0.077 0.11 0.083
    p 0.14 0.24 0.029 0.027 0.17 0.0032 0.41 0.45 0.11
    nCohort 1 223 375 173 2/3 375 173 223 375 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 33.2 33.2 14.4 24.0 23.7 14.4 43.4 38.4 43.4
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 27% 26% 12% 20% 19% 12% 35% 31% 31%
    Cutoff 2 14.9 23.7 12.3 14.9 22.0 2.92 38.4 23.7 0.0743
    Sens 2 80% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 15% 19% 12% 15% 18%  6% 32% 19%  3%
    Cutoff 3 2.92 20.9 0.0743 0.172 12.9 0.0447 0.0558 12.9 0.0558
    Sens 3 90% 92% 91% 90% 92% 91% 94% 100%  93%
    Spec 3  9% 17%  3%  8% 13%  1%  4% 13%  1%
    Cutoff 4 103 103 115 103 103 115 103 103 115
    Sens 4 23% 15%  9% 17% 15%  9% 25% 14% 14%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 127 127 130 127 127 130 127 127 130
    Sens 5 10% 15%  4% 10% 15%  4% 12% 14%  7%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 159 157 176 159 157 176 159 157 176
    Sens 6  3%  8%  0%  3%  8%  0%  0%  0%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.2 1.0 3.3 1.6 1.0 2.7 1.4 2.0 1.0
    p Value 0.22 1.0 0.16 0.50 1.0 0.25 0.70 0.56 1.0
    95% CI of 0.62 0.14 0.63 0.42 0.14 0.49 0.29 0.18 0.13
    OR Quart 2 7.7 7.2 17 5.9 7.2 14 6.3 23 7.4
    OR Quart 3 2.5 3.1 3.3 2.5 2.6 2.7 2.1 2.0 3.3
    p Value 0.15 0.17 0.16 0.15 0.26 0.25 0.31 0.57 0.16
    95% CI of 0.73 0.62 0.63 0.73 0.49 0.49 0.50 0.18 0.63
    OR Quart 3 8.6 16 17 8.6 14 14 8.9 23 17
    OR Quart 4 2.5 1.5 5.3 3.2 2.0 6.8 1.0 2.0 2.1
    p Value 0.15 0.65 0.040 0.060 0.42 0.016 0.98 0.56 0.39
    95% CI of 0.73 0.25 1.1 0.95 0.37 1.4 0.20 0.18 0.37
    OR Quart 4 8.6 9.3 26 11 11 33 5.3 23 12
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 412 1060 412 830 412 752
    Average 634 1330 634 1160 634 1150
    Stdev 691 962 691 784 691 885
    p (t-test) 7.5E−5 0.0019 0.018
    Min 0.218 106 0.218 106 0.218 27.3
    Max 4170 4230 4170 2820 4170 2820
    n (Samp) 124 22 124 21 124 12
    n (Patient) 124 22 124 21 124 12
    sCr only
    Median 692 1320 692 939 nd nd
    Average 955 1350 955 1200 nd nd
    Stdev 940 841 940 817 nd nd
    p (t-test) 0.24 0.47 nd nd
    Min 0.218 122 0.218 122 nd nd
    Max 5940 2630 5940 2630 nd nd
    n (Samp) 236 8 236 8 nd nd
    n (Patient) 236 8 236 8 nd nd
    UO only
    Median 488 1050 488 939 488 757
    Average 706 1350 706 1200 706 1120
    Stdev 774 1010 774 811 774 878
    p (t-test) 0.0025 0.017 0.097
    Min 0.218 106 0.218 106 0.218 27.3
    Max 4210 4230 4210 2820 4210 2820
    n (Samp) 120 17 120 16 120 11
    n (Patient) 120 17 120 16 120 11
    0 hr prior to AKI stage 24 hr prior to AKI stage 148 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.76 0.67 0.75 0.74 0.63 0.73 0.72 nd 0.69
    SE 0.062 0.11 0.071 0.065 0.11 0.075 0.086 nd 0.092
    p 2.8E−5 0.11 5.4E−4 3.0E−4 0.23 0.0025 0.012 nd 0.040
    nCohort 1 124 236 120 124 236 120 124 nd 120
    nCohort 2 22 8 17 21 8 16 12 nd 11
    Cutoff 1 734 825 747 734 741 734 623 nd 626
    Sens 1 73% 75% 71% 71% 75% 75% 75% nd 73%
    Spec 1 72% 59% 69% 72% 53% 69% 62% nd 61%
    Cutoff 2 623 606 626 623 606 626 606 nd 623
    Sens 2 82% 88% 82% 81% 88% 81% 83% nd 82%
    Spec 2 62% 44% 61% 62% 44% 61% 61% nd 60%
    Cutoff 3 508 113 508 508 113 508 508 nd 508
    Sens 3 91% 100%  94% 90% 100%  94% 92% nd 91%
    Spec 3 57% 15% 53% 57% 15% 53% 57% nd 53%
    Cutoff 4 708 1220 757 708 1220 757 708 nd 757
    Sens 4 73% 50% 65% 71% 38% 62% 58% nd 45%
    Spec 4 70% 70% 70% 70% 70% 70% 70% nd 70%
    Cutoff 5 1130 1600 1220 1130 1600 1220 1130 nd 1220
    Sens 5 45% 38% 41% 33% 38% 31% 33% nd 27%
    Spec 5 81% 81% 80% 81% 81% 80% 81% nd 80%
    Cutoff 6 1630 2040 1660 1630 2040 1660 1630 nd 1660
    Sens 6 27% 25% 24% 24% 12% 19% 25% nd 18%
    Spec 6 90% 90% 90% 90% 90% 90% 90% nd 90%
    OR Quart 2 0 1.0 1.0 0 1.0 1.0 0 nd 0
    p Value na 1.0 1.0 na 1.0 1.0 na nd na
    95% CI of na 0.061 0.060 na 0.061 0.060 na nd na
    OR Quart 2 na 16 17 na 16 17 na nd na
    OR Quart 3 6.5 2.0 10 5.7 3.1 12 7.1 nd 8.3
    p Value 0.022 0.57 0.034 0.035 0.33 0.023 0.078 nd 0.054
    95% CI of 1.3 0.18 1.2 1.1 0.31 1.4 0.80 nd 0.96
    OR Quart 3 32 23 86 28 31 100 62 nd 72
    OR Quart 4 6.3 4.2 8.2 6.3 3.1 5.7 5.7 nd 3.1
    p Value 0.024 0.20 0.055 0.024 0.33 0.12 0.12 nd 0.34
    95% CI of 1.3 0.46 0.96 1.3 0.31 0.63 0.63 nd 0.31
    OR Quart 4 31 39 71 31 31 52 52 nd 31
    Lutropin subunit beta
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 23.7 9.51 23.7 9.51 23.7 8.03
    Average 76.3 57.0 76.3 57.0 76.3 79.4
    Stdev 120 111 120 111 120 135
    p (t-test) 0.58 0.58 0.94
    Min 0.0297 0.341 0.0297 0.341 0.0297 0.505
    Max 400 393 400 393 400 393
    n (Samp) 68 14 68 14 68 9
    n (Patient) 68 14 68 14 68 9
    sCr only
    Median 29.6 37.1 29.6 37.1 29.6 46.2
    Average 78.0 86.3 78.0 86.3 78.0 118
    Stdev 110 132 110 132 110 154
    p (t-test) 0.83 0.83 0.40
    Min 0.0297 0.341 0.0297 0.341 0.0297 4.62
    Max 400 393 400 393 400 393
    n (Samp) 128 9 128 9 128 6
    n (Patient) 128 9 128 9 128 6
    UO only
    Median 26.4 4.44 26.4 4.44 nd nd
    Average 85.1 9.51 85.1 9.51 nd nd
    Stdev 120 12.7 120 12.7 nd nd
    p (t-test) 0.10 0.10 nd nd
    Min 0.0297 0.505 0.0297 0.505 nd nd
    Max 400 37.1 400 37.1 nd nd
    n (Samp) 72 7 72 7 nd nd
    n (Patient) 72 7 72 7 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.42 0.52 0.25 0.42 0.52 0.25 0.46 0.59 nd
    SE 0.087 0.10 0.11 0.087 0.10 0.11 0.10 0.12 nd
    p 0.36 0.84 0.021 0.36 0.84 0.021 0.73 0.46 nd
    nCohort 1 68 128 72 68 128 72 68 128 nd
    nCohort 2 14 9 7 14 9 7 9 6 nd
    Cutoff 1 4.35 7.97 3.37 4.35 7.97 3.37 4.35 7.97 nd
    Sens 1 71% 78% 71% 71% 78% 71% 78% 83% nd
    Spec 1 21% 30% 19% 21% 30% 19% 21% 30% nd
    Cutoff 2 0.933 4.00 0.840 0.933 4.00 0.840 4.00 7.97 nd
    Sens 2 86% 89% 86% 86% 89% 86% 89% 83% nd
    Spec 2 12% 19% 12% 12% 19% 12% 21% 30% nd
    Cutoff 3 0.341 0.311 0.422 0.341 0.311 0.422 0.234 4.00 nd
    Sens 3 93% 100%  100%  93% 100%  100%  100%  100%  nd
    Spec 3  6%  6%  8%  6%  6%  8%  6% 19% nd
    Cutoff 4 43.9 63.3 68.2 43.9 63.3 68.2 43.9 63.3 nd
    Sens 4 29% 22%  0% 29% 22%  0% 33% 33% nd
    Spec 4 71% 70% 71% 71% 70% 71% 71% 70% nd
    Cutoff 5 134 139 151 134 139 151 134 139 nd
    Sens 5 14% 22%  0% 14% 12%  0% 22% 33% nd
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% nd
    Cutoff 6 315 275 311 315 275 311 315 275 nd
    Sens 6  7% 11%  0%  7% 11%  0% 11% 17% nd
    Spec 6 91% 91% 90% 91% 91% 90% 91% 91% nd
    OR Quart 2 0.67 1.0 >1.1 0.67 1.0 >1.1 1.1 0.97 nd
    p Value 0.68 1.0 <0.97 0.68 1.0 <0.97 0.96 0.98 nd
    95% CI of 0.099 0.13 >0.061 0.099 0.13 >0.061 0.13 0.058 nd
    OR Quart 2 4.5 7.5 na 4.5 7.5 na 8.4 16 nd
    OR Quart 3 1.0 1.5 >2.2 1.0 1.5 >2.2 0.50 2.1 nd
    p Value 1.0 0.64 <0.53 1.0 0.64 <0.53 0.59 0.56 nd
    95% CI of 0.18 0.24 >0.19 0.18 0.24 >0.19 0.042 0.18 nd
    OR Quart 3 5.6 9.9 na 5.6 9.9 na 6.0 24 nd
    OR Quart 4 2.6 0.97 >5.3 2.6 0.97 >5.3 2.4 2.0 nd
    p Value 0.23 0.98 <0.15 0.23 0.98 <0.15 0.35 0.58 nd
    95% CI of 0.54 0.13 >0.54 0.54 0.13 >0.54 0.38 0.17 nd
    OR Quart 4 12 7.3 na 12 7.3 na 15 23 nd
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2810 4940 2810 4490 2810 3900
    Average 3350 6880 3350 6380 3350 4540
    Stdev 2580 9710 2580 9720 2580 2430
    p (t-test) 1.4E−5 1.8E−4 0.076
    Min 6.83 161 6.83 142 6.83 1650
    Max 22000 55700 22000 55700 22000 9700
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 3740 4080 3740 4080 3740 5050
    Average 4460 4520 4460 4470 4460 5230
    Stdev 4470 2200 4470 2240 4470 1940
    p (t-test) 0.96 0.99 0.65
    Min 6.83 161 6.83 142 6.83 2880
    Max 55700 7860 55700 7860 55700 7860
    n (Samp) 373 13 373 13 373 7
    n (Patient) 373 13 373 13 373 7
    UO only
    Median 3210 5230 3210 5050 3210 4490
    Average 3630 8840 3630 8180 3630 4640
    Stdev 2320 11500 2320 11600 2320 2470
    p (t-test) 3.6E−7 8.1E−6 0.12
    Min 485 1700 485 1120 485 1650
    Max 11700 55700 11700 55700 11700 9700
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.72 0.58 0.74 0.67 0.57 0.68 0.67 0.66 0.63
    SE 0.055 0.084 0.062 0.057 0.084 0.065 0.076 0.11 0.083
    p 5.5E−5 0.37 8.9E−5 0.0033 0.42 0.0065 0.030 0.16 0.12
    nCohort 1 223 373 173 223 373 173 223 373 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 3720 3410 3940 2810 2870 2690 2870 3970 2990
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 65% 46% 65% 51% 37% 44% 53% 56% 49%
    Cutoff 2 2870 2870 2990 2210 2810 2160 2690 3720 1720
    Sens 2 80% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 53% 37% 49% 41% 36% 36% 49% 50% 22%
    Cutoff 3 2170 2200 2160 1720 2200 1720 1700 2870 1700
    Sens 3 90% 92% 91% 90% 92% 91% 94% 100%  93%
    Spec 3 41% 27% 36% 27% 27% 22% 26% 37% 21%
    Cutoff 4 3930 5290 4360 3930 5290 4360 3930 5290 4360
    Sens 4 63% 31% 65% 57% 31% 61% 50% 29% 50%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 4960 6450 5580 4960 6450 5580 4960 6450 5580
    Sens 5 50% 23% 48% 47% 23% 43% 38% 29% 36%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 6160 7690 6670 6160 7690 6670 6160 7690 6670
    Sens 6 33% 15% 35% 30% 15% 35% 25% 29% 21%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.4 4.1 1.5 2.5 4.1 1.0 3.1 >2.0 0.64
    p Value 0.70 0.21 0.65 0.20 0.21 1.0 0.34 <0.56 0.63
    95% CI of 0.29 0.45 0.24 0.62 0.45 0.24 0.31 >0.18 0.10
    OR Quart 2 6.3 37 9.6 10 37 4.2 30 na 4.0
    OR Quart 3 2.5 5.2 3.9 1.7 5.2 1.3 5.3 >3.1 1.3
    p Value 0.20 0.13 0.100 0.47 0.13 0.73 0.13 <0.33 0.72
    95% CI of 0.62 0.60 0.77 0.39 0.60 0.32 0.60 >0.32 0.28
    OR Quart 3 10 46 20 7.5 46 5.1 47 na 6.3
    OR Quart 4 6.7 3.0 6.8 6.1 3.0 2.9 7.7 >2.0 1.7
    p Value 0.0040 0.34 0.016 0.0061 0.34 0.093 0.061 <0.56 0.48
    95% CI of 1.8 0.31 1.4 1.7 0.31 0.84 0.91 >0.18 0.38
    OR Quart 4 24 30 33 22 30 9.9 64 na 7.6
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1.35 3.57 1.35 3.33 1.35 3.23
    Average 5.15 52.4 5.15 52.1 5.15 4.20
    Stdev 21.4 208 21.4 208 21.4 3.82
    p (t-test) 0.0026 0.0028 0.88
    Min 0.00246 0.283 0.00246 0.166 0.00246 0.283
    Max 270 935 270 935 270 12.9
    n (Samp) 191 20 191 20 191 11
    n (Patient) 191 20 191 20 191 11
    sCr only
    Median 1.68 4.25 1.68 3.52 1.68 2.23
    Average 8.22 7.08 8.22 5.72 8.22 4.46
    Stdev 57.1 6.03 57.1 5.43 57.1 5.26
    p (t-test) 0.95 0.89 0.87
    Min 0.00246 0.283 0.00246 0.283 0.00246 0.166
    Max 935 16.9 935 16.9 935 12.9
    n (Samp) 295 10 295 10 295 6
    n (Patient) 295 10 295 10 295 6
    UO only
    Median 1.81 4.34 1.81 3.71 1.81 3.71
    Average 6.27 71.8 6.27 69.4 6.27 4.77
    Stdev 24.9 239 24.9 240 24.9 3.98
    p (t-test) 0.0021 0.0031 0.86
    Min 0.00246 0.401 0.00246 0.166 0.00246 0.401
    Max 270 935 270 935 270 12.9
    n (Samp) 136 15 136 15 136 9
    n (Patient) 136 15 136 15 136 9
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.75 0.75 0.76 0.71 0.71 0.69 0.68 0.55 0.69
    SE 0.065 0.091 0.075 0.068 0.093 0.079 0.091 0.12 0.10
    p 1.3E−4 0.0059 6.1E−4 0.0024 0.023 0.014 0.050 0.69 0.060
    nCohort 1 191 295 136 191 295 136 191 295 136
    nCohort 2 20 10 15 20 10 15 11 6 9
    Cutoff 1 2.84 3.05 3.16 2.40 2.50 2.37 2.40 0.279 2.37
    Sens 1 70% 70% 73% 70% 70% 73% 73% 83% 78%
    Spec 1 75% 71% 74% 71% 65% 65% 71% 15% 65%
    Cutoff 2 2.13 2.50 2.84 1.39 2.13 1.39 0.903 0.279 0.903
    Sens 2 80% 80% 80% 80% 80% 80% 82% 83% 89%
    Spec 2 67% 65% 69% 51% 60% 44% 37% 15% 29%
    Cutoff 3 0.903 2.13 0.903 0.392 2.01 0.392 0.392 0.132 0.392
    Sens 3 90% 90% 93% 90% 90% 93% 91% 100%  100% 
    Spec 3 37% 60% 29% 20% 58% 16% 20% 13% 16%
    Cutoff 4 2.30 3.00 2.99 2.30 3.00 2.99 2.30 3.00 2.99
    Sens 4 75% 70% 73% 70% 60% 67% 73% 50% 67%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 3.30 3.77 3.85 3.30 3.77 3.85 3.30 3.77 3.85
    Sens 5 55% 60% 53% 50% 50% 47% 45% 33% 44%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 5.81 7.01 6.04 5.81 7.01 6.04 5.81 7.01 6.04
    Sens 6 25% 40% 33% 25% 30% 33% 18% 33% 22%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.48 0 0.97 0.64 0 0.97 0.48 0.49 1.0
    p Value 0.55 na 0.98 0.63 na 0.98 0.55 0.57 1.0
    95% CI of 0.042 na 0.059 0.10 na 0.13 0.042 0.044 0.060
    OR Quart 2 5.5 na 16 4.0 na 7.3 5.5 5.6 17
    OR Quart 3 2.6 3.1 5.5 1.3 4.2 1.5 1.0 0.49 2.1
    p Value 0.27 0.33 0.13 0.72 0.21 0.67 1.0 0.57 0.56
    95% CI of 0.48 0.31 0.61 0.28 0.45 0.24 0.14 0.044 0.18
    OR Quart 3 14 30 49 6.3 38 9.5 7.4 5.6 24
    OR Quart 4 7.3 6.3 9.6 4.3 5.2 4.7 3.2 0.99 5.5
    p Value 0.012 0.091 0.038 0.034 0.14 0.063 0.17 0.99 0.13
    95% CI of 1.5 0.74 1.1 1.1 0.59 0.92 0.61 0.14 0.61
    OR Quart 4 35 54 81 16 46 24 17 7.2 49
    Corticotropin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00187 0.00448 0.00187 0.00448 0.00187 0.00227
    Average 0.00264 0.00863 0.00264 0.00863 0.00264 0.00340
    Stdev 0.00485 0.0109 0.00485 0.0109 0.00485 0.00271
    p (t-test) 9.1E−4 9.1E−4 0.68
    Min 0.000316 0.00109 0.000316 0.00109 0.000316 0.00111
    Max 0.0489 0.0377 0.0489 0.0377 0.0489 0.00909
    n (Samp) 99 12 99 12 99 7
    n (Patient) 99 12 99 12 99 7
    sCr only
    Median 0.00205 0.00713 0.00205 0.00713 nd nd
    Average 0.00292 0.0133 0.00292 0.0133 nd nd
    Stdev 0.00497 0.0141 0.00497 0.0141 nd nd
    p (t-test) 1.0E−5 1.0E−5 nd nd
    Min 0.000316 0.00109 0.000316 0.00109 nd nd
    Max 0.0489 0.0377 0.0489 0.0377 nd nd
    n (Samp) 160 6 160 6 nd nd
    n (Patient) 160 6 160 6 nd nd
    UO only
    Median 0.00182 0.00425 0.00182 0.00425 0.00182 0.00219
    Average 0.00266 0.00883 0.00266 0.00883 0.00266 0.00333
    Stdev 0.00519 0.0121 0.00519 0.0121 0.00519 0.00296
    p (t-test) 0.0066 0.0066 0.76
    Min 0.000388 0.00136 0.000388 0.00136 0.000388 0.00111
    Max 0.0489 0.0377 0.0489 0.0377 0.0489 0.00909
    n (Samp) 86 8 86 8 86 6
    n (Patient) 86 8 86 8 86 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.78 0.82 0.79 0.78 0.82 0.79 0.65 nd 0.62
    SE 0.081 0.11 0.097 0.081 0.11 0.097 0.12 nd 0.13
    p 5.8E−4 0.0026 0.0027 5.8E−4 0.0026 0.0027 0.19 nd 0.33
    nCohort 1 99 160 86 99 160 86 99 nd 86
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 0.00217 0.00415 0.00217 0.00217 0.00415 0.00217 0.00210 nd 0.00159
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 61% 91% 62% 61% 91% 62% 60% nd 44%
    Cutoff 2 0.00210 0.00415 0.00206 0.00210 0.00415 0.00206 0.00159 nd 0.00159
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 60% 91% 60% 60% 91% 60% 38% nd 44%
    Cutoff 3 0.00124 0.00106 0.00124 0.00124 0.00106 0.00124 0.00109 nd 0.00109
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 30% 11% 31% 30% 11% 31% 15% nd 19%
    Cutoff 4 0.00275 0.00275 0.00274 0.00275 0.00275 0.00274 0.00275 nd 0.00274
    Sens 4 67% 83% 62% 67% 83% 62% 43% nd 33%
    Spec 4 72% 71% 71% 72% 71% 71% 72% nd 71%
    Cutoff 5 0.00307 0.00306 0.00285 0.00307 0.00306 0.00285 0.00307 nd 0.00285
    Sens 5 67% 83% 62% 67% 83% 62% 43% nd 33%
    Spec 5 81% 80% 80% 81% 80% 80% 81% nd 80%
    Cutoff 6 0.00380 0.00404 0.00412 0.00380 0.00404 0.00412 0.00380 nd 0.00412
    Sens 6 58% 83% 50% 58% 83% 50% 29% nd 17%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 0.96 0 >1.0 0.96 0 >1.0 0.96 nd 1.0
    p Value 0.98 na <1.0 0.98 na <1.0 0.98 nd 1.0
    95% CI of 0.057 na >0.059 0.057 na >0.059 0.057 nd 0.059
    OR Quart 2 16 na na 16 na na 16 nd 17
    OR Quart 3 2.0 0 >2.2 2.0 0 >2.2 2.1 nd 2.1
    p Value 0.58 na <0.53 0.58 na <0.53 0.56 nd 0.56
    95% CI of 0.17 na >0.18 0.17 na >0.18 0.18 nd 0.18
    OR Quart 3 23 na na 23 na na 25 nd 25
    OR Quart 4 10 5.4 >6.1 10 5.4 >6.1 3.1 nd 2.1
    p Value 0.034 0.13 <0.11 0.034 0.13 <0.11 0.34 nd 0.56
    95% CI of 1.2 0.60 >0.65 1.2 0.60 >0.65 0.30 nd 0.18
    OR Quart 4 90 48 na 90 48 na 32 nd 25
    Thyroxine-binding globulin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.155 0.225 0.155 0.197 0.155 0.159
    Average 0.268 0.589 0.268 0.610 0.268 0.451
    Stdev 0.327 0.955 0.327 0.988 0.327 0.621
    p (t-test) 0.011 0.0091 0.16
    Min 0.000191 0.00635 0.000191 0.00635 0.000191 0.0485
    Max 1.59 3.60 1.59 3.60 1.59 1.88
    n (Samp) 103 15 103 14 103 8
    n (Patient) 103 15 103 14 103 8
    sCr only
    Median 0.182 0.225 0.182 0.225 nd nd
    Average 0.313 0.470 0.313 0.470 nd nd
    Stdev 0.425 0.648 0.425 0.648 nd nd
    p (t-test) 0.35 0.35 nd nd
    Min 0.000191 0.00635 0.000191 0.00635 nd nd
    Max 3.60 1.88 3.60 1.88 nd nd
    n (Samp) 170 7 170 7 nd nd
    n (Patient) 170 7 170 7 nd nd
    UO only
    Median 0.155 0.234 0.155 0.225 0.155 0.128
    Average 0.252 0.637 0.252 0.676 0.252 0.260
    Stdev 0.323 1.07 0.323 1.13 0.323 0.269
    p (t-test) 0.012 0.0088 0.95
    Min 0.000191 0.0485 0.000191 0.0485 0.000191 0.0485
    Max 1.59 3.60 1.59 3.60 1.59 0.607
    n (Samp) 87 10 87 9 87 6
    n (Patient) 87 10 87 9 87 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.61 0.57 0.66 0.60 0.57 0.65 0.59 nd 0.54
    SE 0.082 0.11 0.098 0.085 0.11 0.10 0.11 nd 0.12
    p 0.19 0.57 0.10 0.25 0.57 0.16 0.43 nd 0.74
    nCohort 1 103 170 87 103 170 87 103 nd 87
    nCohort 2 15 7 10 14 7 9 8 nd 6
    Cutoff 1 0.135 0.163 0.135 0.135 0.163 0.104 0.103 nd 0.0496
    Sens 1 73% 71% 70% 71% 71% 78% 75% nd 83%
    Spec 1 46% 46% 48% 46% 46% 43% 41% nd 30%
    Cutoff 2 0.103 0.136 0.104 0.0496 0.136 0.0496 0.0496 nd 0.0496
    Sens 2 80% 86% 80% 86% 86% 89% 88% nd 83%
    Spec 2 41% 42% 43% 29% 42% 30% 29% nd 30%
    Cutoff 3 0.0462 0.00446 0.0927 0.0462 0.00446 0.0462 0.0462 nd 0.0462
    Sens 3 93% 100%  90% 93% 100%  100%  100%  nd 100% 
    Spec 3 27%  5% 40% 27%  5% 29% 27% nd 29%
    Cutoff 4 0.313 0.356 0.249 0.313 0.356 0.249 0.313 nd 0.249
    Sens 4 33% 29% 40% 36% 29% 44% 38% nd 33%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 0.407 0.448 0.368 0.407 0.448 0.368 0.407 nd 0.368
    Sens 5 33% 29% 40% 36% 29% 44% 38% nd 33%
    Spec 5 81% 80% 80% 81% 80% 80% 81% nd 80%
    Cutoff 6 0.693 0.750 0.693 0.693 0.750 0.693 0.693 nd 0.693
    Sens 6 13% 14% 10% 14% 14% 11% 12% nd  0%
    Spec 6 90% 90% 91% 90% 90% 91% 90% nd 91%
    OR Quart 2 7.0 2.0 >4.8 5.8 2.0 >4.8 >4.5 nd >4.8
    p Value 0.081 0.56 <0.18 0.12 0.56 <0.18 <0.19 nd <0.17
    95% CI of 0.79 0.18 >0.50 0.64 0.18 >0.50 >0.47 nd >0.50
    OR Quart 2 62 23 na 53 23 na na nd na
    OR Quart 3 3.2 2.0 >2.2 3.2 2.0 >1.0 >1.0 nd >0
    p Value 0.32 0.56 <0.54 0.32 0.56 <0.98 <1.0 nd <na
    95% CI of 0.32 0.18 >0.18 0.32 0.18 >0.062 >0.059 nd >na
    OR Quart 3 33 23 na 33 23 na na nd na
    OR Quart 4 5.6 2.0 >4.6 5.6 2.0 >4.8 >3.2 nd >2.1
    p Value 0.13 0.58 <0.19 0.13 0.58 <0.18 <0.32 nd <0.56
    95% CI of 0.61 0.17 >0.47 0.61 0.17 >0.50 >0.32 nd >0.18
    OR Quart 4 51 23 na 51 23 na na nd na
    Pigment epithelium-derived factor
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 3.77 40.6 3.77 34.8 3.77 14.1
    Average 25.0 61.2 25.0 54.2 25.0 42.7
    Stdev 52.8 66.7 52.8 60.6 52.8 58.4
    p (t-test) 7.5E−4 0.0056 0.20
    Min 0.00100 0.121 0.00100 0.0312 0.00100 0.683
    Max 400 218 400 218 400 218
    n (Samp) 223 30 223 30 223 16
    n (Patient) 223 30 223 30 223 16
    sCr only
    Median 5.82 58.3 5.82 47.1 5.82 70.8
    Average 28.4 66.5 28.4 62.7 28.4 79.6
    Stdev 55.5 66.4 55.5 68.0 55.5 71.7
    p (t-test) 0.016 0.030 0.017
    Min 0.00100 0.121 0.00100 0.0312 0.00100 2.29
    Max 400 218 400 218 400 218
    n (Samp) 374 13 374 13 374 7
    n (Patient) 374 13 374 13 374 7
    UO only
    Median 5.79 44.2 5.79 44.2 5.79 10.0
    Average 30.8 73.7 30.8 66.7 30.8 42.8
    Stdev 60.5 79.4 60.5 73.2 60.5 61.7
    p (t-test) 0.0024 0.0099 0.48
    Min 0.00106 2.09 0.00106 2.00 0.00106 0.683
    Max 400 250 400 250 400 218
    n (Samp) 173 23 173 23 173 14
    n (Patient) 173 23 173 23 173 14
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.74 0.73 0.74 0.71 0.70 0.71 0.67 0.79 0.62
    SE 0.054 0.081 0.062 0.055 0.082 0.063 0.076 0.10 0.083
    p 8.8E−6 0.0053 1.2E−4 1.1E−4 0.014 7.3E−4 0.028 0.0041 0.15
    nCohort 1 223 374 173 223 374 173 223 374 173
    nCohort 2 30 13 23 30 13 23 16 7 14
    Cutoff 1 8.99 7.75 8.99 7.24 6.55 7.24 3.22 56.9 6.44
    Sens 1 70% 77% 74% 70% 77% 74% 75% 71% 71%
    Spec 1 62% 55% 59% 59% 52% 55% 47% 87% 53%
    Cutoff 2 6.55 6.55 6.44 3.77 4.09 3.77 3.11 18.0 3.11
    Sens 2 80% 85% 83% 80% 85% 83% 81% 86% 86%
    Spec 2 57% 52% 53% 50% 45% 47% 46% 67% 40%
    Cutoff 3 2.56 2.25 3.11 2.19 2.25 2.14 1.56 2.25 1.56
    Sens 3 90% 92% 91% 90% 92% 91% 94% 100%  93%
    Spec 3 42% 32% 40% 39% 32% 31% 33% 32% 24%
    Cutoff 4 17.4 21.1 20.5 17.4 21.1 20.5 17.4 21.1 20.5
    Sens 4 63% 69% 65% 60% 62% 61% 50% 71% 43%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 27.6 32.9 37.5 27.6 32.9 37.5 27.6 32.9 37.5
    Sens 5 57% 62% 52% 53% 54% 52% 38% 71% 36%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 70.1 81.7 105 70.1 81.7 105 70.1 81.7 105
    Sens 6 33% 23% 30% 33% 23% 30% 31% 29% 14%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 5.3 0.99 >5.6 7.8 2.0 >6.8 4.1 >1.0 0.98
    p Value 0.13 0.99 <0.12 0.059 0.57 <0.081 0.21 <0.99 0.98
    95% CI of 0.61 0.061 >0.63 0.92 0.18 >0.79 0.45 >0.062 0.13
    OR Quart 2 47 16 na 65 22 na 38 na 7.3
    OR Quart 3 7.8 2.0 >5.6 6.5 2.0 >4.4 4.1 >1.0 2.6
    p Value 0.059 0.57 <0.12 0.087 0.57 <0.20 0.21 <0.99 0.27
    95% CI of 0.92 0.18 >0.63 0.76 0.18 >0.47 0.45 >0.062 0.48
    OR Quart 3 65 22 na 56 22 na 38 na 14
    OR Quart 4 22 9.7 >18 21 8.5 >18 7.7 >5.2 2.6
    p Value 0.0030 0.033 <0.0068 0.0039 0.045 <0.0068 0.061 <0.13 0.27
    95% CI of 2.9 1.2 >2.2 2.6 1.0 >2.2 0.91 >0.60 0.48
    OR Quart 4 170 78 na 160 70 na 64 na 14
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 21.7 39.4 21.7 38.9 21.7 38.9
    Average 30.9 55.9 30.9 54.7 30.9 34.7
    Stdev 38.1 68.3 38.1 69.1 38.1 22.0
    p (t-test) 0.012 0.018 0.72
    Min 0.0561 4.17 0.0561 4.17 0.0561 0.196
    Max 277 353 277 353 277 68.6
    n (Samp) 128 24 128 23 128 13
    n (Patient) 128 24 128 23 128 13
    sCr only
    Median 27.0 43.9 27.0 43.9 nd nd
    Average 43.4 75.5 43.4 75.5 nd nd
    Stdev 61.9 105 61.9 105 nd nd
    p (t-test) 0.14 0.14 nd nd
    Min 0.0561 25.7 0.0561 25.7 nd nd
    Max 554 353 554 353 nd nd
    n (Samp) 242 9 242 9 nd nd
    n (Patient) 242 9 242 9 nd nd
    UO only
    Median 19.9 39.4 19.9 38.9 19.9 33.1
    Average 30.3 44.9 30.3 42.6 30.3 33.8
    Stdev 39.0 29.0 39.0 26.7 39.0 22.8
    p (t-test) 0.13 0.21 0.76
    Min 0.0561 4.17 0.0561 4.17 0.0561 0.196
    Max 277 117 277 102 277 68.6
    n (Samp) 122 18 122 17 122 12
    n (Patient) 122 18 122 17 122 12
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.71 0.69 0.71 0.70 0.69 0.69 0.61 nd 0.61
    SE 0.063 0.100 0.072 0.065 0.100 0.075 0.087 nd 0.090
    p 8.7E−4 0.062 0.0028 0.0025 0.062 0.0096 0.20 nd 0.22
    nCohort 1 128 242 122 128 242 122 128 nd 122
    nCohort 2 24 9 18 23 9 17 13 nd 12
    Cutoff 1 30.9 31.1 30.2 27.2 31.1 27.2 15.0 nd 15.0
    Sens 1 71% 78% 72% 74% 78% 71% 77% nd 75%
    Spec 1 66% 57% 67% 61% 57% 64% 38% nd 39%
    Cutoff 2 26.3 26.3 24.9 24.9 26.3 24.5 12.7 nd 12.7
    Sens 2 83% 89% 83% 83% 89% 82% 85% nd 83%
    Spec 2 58% 49% 57% 55% 49% 55% 34% nd 35%
    Cutoff 3 24.5 25.6 5.76 19.5 25.6 5.76 6.53 nd 6.53
    Sens 3 92% 100%  94% 91% 100%  94% 92% nd 92%
    Spec 3 54% 45% 16% 46% 45% 16% 14% nd 17%
    Cutoff 4 34.0 42.3 32.9 34.0 42.3 32.9 34.0 nd 32.9
    Sens 4 62% 56% 67% 57% 56% 59% 54% nd 50%
    Spec 4 70% 70% 71% 70% 70% 71% 70% nd 71%
    Cutoff 5 47.1 53.5 41.1 47.1 53.5 41.1 47.1 nd 41.1
    Sens 5 29% 22% 39% 30% 22% 41% 31% nd 42%
    Spec 5 80% 80% 80% 80% 80% 80% 80% nd 80%
    Cutoff 6 58.1 90.9 56.7 58.1 90.9 56.7 58.1 nd 56.7
    Sens 6 21% 11% 22% 22% 11% 24% 15% nd 17%
    Spec 6 91% 90% 90% 91% 90% 90% 91% nd 90%
    OR Quart 2 1.0 >2.0 0.49 1.5 >2.0 0.47 1.0 nd 0.97
    p Value 1.0 <0.57 0.56 0.67 <0.57 0.55 1.0 nd 0.98
    95% CI of 0.13 >0.18 0.042 0.24 >0.18 0.041 0.13 nd 0.13
    OR Quart 2 7.5 na 5.6 9.5 na 5.4 7.5 nd 7.3
    OR Quart 3 6.4 >4.2 3.4 4.7 >4.2 3.3 1.5 nd 1.0
    p Value 0.022 <0.20 0.15 0.063 <0.20 0.16 0.64 nd 1.0
    95% CI of 1.3 >0.46 0.64 0.92 >0.46 0.62 0.24 nd 0.13
    OR Quart 3 32 na 18 24 na 18 9.9 nd 7.6
    OR Quart 4 6.4 >3.1 5.7 6.2 >3.1 4.7 3.3 nd 3.3
    p Value 0.022 <0.33 0.035 0.025 <0.33 0.062 0.16 nd 0.16
    95% CI of 1.3 >0.31 1.1 1.3 >0.31 0.93 0.62 nd 0.62
    OR Quart 4 32 na 29 31 na 24 18 nd 18
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00587 0.142 0.00587 0.142 0.00587 0.0837
    Average 0.0687 0.323 0.0687 0.323 0.0687 0.116
    Stdev 0.133 0.650 0.133 0.650 0.133 0.157
    p (t-test) 1.6E−4 1.6E−4 0.23
    Min 0.000523 0.000523 0.000523 0.000523 0.000523 0.000463
    Max 0.803 2.85 0.803 2.85 0.803 0.537
    n (Samp) 123 18 123 18 123 13
    n (Patient) 123 18 123 18 123 13
    sCr only
    Median 0.00660 0.189 0.00660 0.189 0.00660 0.107
    Average 0.0908 0.188 0.0908 0.188 0.0908 0.158
    Stdev 0.246 0.162 0.246 0.162 0.246 0.189
    p (t-test) 0.20 0.20 0.45
    Min 0.000523 0.000523 0.000523 0.000523 0.000523 0.000523
    Max 2.85 0.537 2.85 0.537 2.85 0.537
    n (Samp) 210 11 210 11 210 8
    n (Patient) 210 11 210 11 210 8
    UO only
    Median 0.00587 0.123 0.00587 0.123 0.00587 0.0604
    Average 0.0775 0.406 0.0775 0.406 0.0775 0.0703
    Stdev 0.151 0.870 0.151 0.870 0.151 0.0706
    p (t-test) 3.8E−4 3.8E−4 0.89
    Min 0.000463 0.00286 0.000463 0.00286 0.000463 0.000463
    Max 0.803 2.85 0.803 2.85 0.803 0.189
    n (Samp) 119 10 119 10 119 8
    n (Patient) 119 10 119 10 119 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.73 0.71 0.70 0.73 0.71 0.70 0.55 0.58 0.52
    SE 0.071 0.090 0.096 0.071 0.090 0.096 0.086 0.11 0.11
    p 0.0011 0.021 0.040 0.0011 0.021 0.040 0.59 0.48 0.84
    nCohort 1 123 210 119 123 210 119 123 210 119
    nCohort 2 18 11 10 18 11 10 13 8 8
    Cutoff 1 0.0728 0.0880 0.0728 0.0728 0.0880 0.0728 0.00296 0.00296 0.00296
    Sens 1 72% 73% 70% 72% 73% 70% 77% 75% 75%
    Spec 1 76% 78% 76% 76% 78% 76% 11% 10% 10%
    Cutoff 2 0.0309 0.0309 0.0309 0.0309 0.0309 0.0309 0.000523 0.00132 0.000523
    Sens 2 83% 82% 80% 83% 82% 80% 85% 88% 88%
    Spec 2 59% 57% 61% 59% 57% 61%  2%  3%  5%
    Cutoff 3 0.000523 0.00132 0.00296 0.000523 0.00132 0.00296 0.000463 0 0
    Sens 3 94% 91% 90% 94% 91% 90% 92% 100%  100% 
    Spec 3  2%  3% 10%  2%  3% 10%  0%  0%  0%
    Cutoff 4 0.0499 0.0728 0.0613 0.0499 0.0728 0.0613 0.0499 0.0728 0.0613
    Sens 4 72% 73% 70% 72% 73% 70% 54% 62% 50%
    Spec 4 71% 73% 71% 71% 73% 71% 71% 73% 71%
    Cutoff 5 0.0842 0.112 0.0880 0.0842 0.112 0.0880 0.0842 0.112 0.0880
    Sens 5 67% 64% 60% 67% 64% 60% 46% 50% 38%
    Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 0.198 0.213 0.259 0.198 0.213 0.259 0.198 0.213 0.259
    Sens 6 33% 36% 20% 33% 36% 20% 15% 25%  0%
    Spec 6 91% 90% 91% 91% 90% 91% 91% 90% 91%
    OR Quart 2 0 0 0 0 0 0 0 0 0
    p Value na na na na na na na na na
    95% CI of na na na na na na na na na
    OR Quart 2 na na na na na na na na na
    OR Quart 3 1.0 0.49 0.48 1.0 0.49 0.48 0.18 0 0.30
    p Value 1.0 0.57 0.56 1.0 0.57 0.56 0.12 na 0.31
    95% CI of 0.19 0.043 0.042 0.19 0.043 0.042 0.019 na 0.030
    OR Quart 3 5.3 5.6 5.6 5.3 5.6 5.6 1.6 na 3.1
    OR Quart 4 5.3 4.4 4.0 5.3 4.4 4.0 1.5 1.7 1.3
    p Value 0.017 0.068 0.099 0.017 0.068 0.099 0.53 0.48 0.72
    95% CI of 1.4 0.89 0.77 1.4 0.89 0.77 0.43 0.39 0.27
    OR Quart 4 21 22 21 21 22 21 5.3 7.5 6.5
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 5.23 5.48 5.23 4.43 5.23 4.43
    Average 43.6 94.8 43.6 90.7 43.6 10.3
    Stdev 222 370 222 371 222 18.1
    p (t-test) 0.25 0.29 0.49
    Min 0.000147 0.00247 0.000147 0.00247 0.000147 0.211
    Max 2160 2140 2160 2140 2160 82.5
    n (Samp) 235 35 235 35 235 21
    n (Patient) 235 35 235 35 235 21
    sCr only
    Median 5.95 3.82 5.95 3.60 5.95 3.60
    Average 46.5 39.7 46.5 39.0 46.5 4.20
    Stdev 226 143 226 143 226 3.93
    p (t-test) 0.90 0.89 0.54
    Min 0.000147 0.500 0.000147 0.290 0.000147 0.556
    Max 2160 594 2160 594 2160 12.3
    n (Samp) 397 17 397 17 397 11
    n (Patient) 397 17 397 17 397 11
    UO only
    Median 5.32 6.96 5.32 5.48 5.32 4.87
    Average 38.7 110 38.7 104 38.7 12.2
    Stdev 192 425 192 425 192 20.5
    p (t-test) 0.15 0.19 0.58
    Min 0.000147 0.00247 0.000147 0.00247 0.000147 0.211
    Max 2140 2140 2140 2140 2140 82.5
    n (Samp) 190 25 190 25 190 16
    n (Patient) 190 25 190 25 190 16
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.52 0.40 0.54 0.48 0.37 0.51 0.47 0.34 0.47
    SE 0.053 0.074 0.063 0.053 0.074 0.062 0.067 0.091 0.076
    p 0.78 0.16 0.54 0.75 0.088 0.87 0.63 0.077 0.72
    nCohort 1 235 397 190 235 397 190 235 397 190
    nCohort 2 35 17 25 35 17 25 21 11 16
    Cutoff 1 1.82 1.06 3.39 1.82 1.06 3.25 3.25 0.890 3.25
    Sens 1 71% 71% 72% 71% 71% 72% 71% 73% 75%
    Spec 1 26% 17% 37% 26% 17% 34% 35% 14% 34%
    Cutoff 2 0.882 0.692 1.06 0.626 0.609 0.626 1.76 0.626 2.00
    Sens 2 80% 82% 80% 80% 82% 80% 81% 82% 81%
    Spec 2 17% 12% 15% 14% 11%  9% 25% 11% 23%
    Cutoff 3 0.460 0.554 0.380 0.380 0.380 0.380 0.882 0.609 0.500
    Sens 3 91% 94% 92% 91% 94% 92% 90% 91% 94%
    Spec 3 11% 10%  7% 10%  8%  7% 17% 11%  8%
    Cutoff 4 11.3 14.7 11.3 11.3 14.7 11.3 11.3 14.7 11.3
    Sens 4 34%  6% 40% 29%  6% 36% 19%  0% 25%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 19.4 24.7 22.9 19.4 24.7 22.9 19.4 24.7 22.9
    Sens 5 23%  6% 32% 20%  6% 28% 14%  0% 19%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 59.6 64.4 57.8 59.6 64.4 57.8 59.6 64.4 57.8
    Sens 6 14%  6% 20% 11%  6% 12%  5%  0%  6%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.86 6.4 0.53 0.76 5.3 0.67 2.5 >4.2 1.4
    p Value 0.77 0.089 0.33 0.62 0.13 0.52 0.20 <0.21 0.68
    95% CI of 0.31 0.75 0.14 0.27 0.60 0.20 0.62 >0.46 0.30
    OR Quart 2 2.4 54 1.9 2.2 46 2.3 10 na 6.5
    OR Quart 3 0.87 3.1 0.67 1.1 4.1 0.67 2.1 >2.0 1.7
    p Value 0.80 0.34 0.52 0.80 0.21 0.52 0.31 <0.56 0.47
    95% CI of 0.32 0.31 0.20 0.43 0.45 0.20 0.50 >0.18 0.39
    OR Quart 3 2.4 30 2.3 3.0 38 2.3 8.8 na 7.7
    OR Quart 4 1.1 7.5 1.3 1.0 7.5 1.1 1.7 >5.3 1.4
    p Value 0.83 0.062 0.62 0.97 0.062 0.81 0.47 <0.13 0.68
    95% CI of 0.42 0.91 0.45 0.38 0.91 0.38 0.39 >0.60 0.30
    OR Quart 4 2.9 62 3.8 2.7 62 3.4 7.5 na 6.5
    Apolipoprotein(a)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.89 5.31 2.89 5.01 2.89 5.01
    Average 45.1 70.6 45.1 67.4 45.1 18.3
    Stdev 176 234 176 234 176 34.3
    p (t-test) 0.45 0.51 0.49
    Min 0.00770 0.123 0.00770 0.0122 0.00770 0.0122
    Max 1510 1170 1510 1170 1510 118
    n (Samp) 230 35 230 35 230 21
    n (Patient) 230 35 230 35 230 21
    sCr only
    Median 3.62 7.43 3.62 5.47 3.62 7.43
    Average 93.7 10.7 93.7 9.98 93.7 11.5
    Stdev 910 12.9 910 13.1 910 15.4
    p (t-test) 0.71 0.70 0.76
    Min 0.00479 1.16 0.00479 0.0122 0.00479 1.16
    Max 17500 54.1 17500 54.1 17500 54.1
    n (Samp) 391 17 391 17 391 11
    n (Patient) 391 17 391 17 391 11
    UO only
    Median 3.46 5.31 3.46 5.31 3.46 5.16
    Average 39.4 119 39.4 91.2 39.4 20.4
    Stdev 166 293 166 275 166 37.7
    p (t-test) 0.045 0.18 0.65
    Min 0.00790 0.123 0.00790 0.0122 0.00790 0.0122
    Max 1510 1170 1510 1170 1510 118
    n (Samp) 185 25 185 25 185 16
    n (Patient) 185 25 185 25 185 16
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.62 0.60 0.60 0.59 0.55 0.58 0.59 0.58 0.56
    SE 0.054 0.074 0.063 0.054 0.073 0.063 0.068 0.091 0.077
    p 0.024 0.20 0.11 0.10 0.49 0.21 0.20 0.39 0.46
    nCohort 1 230 391 185 230 391 185 230 391 185
    nCohort 2 35 17 25 35 17 25 21 11 16
    Cutoff 1 2.20 4.09 1.80 1.80 3.14 1.80 1.95 3.14 1.24
    Sens 1 71% 71% 72% 71% 71% 72% 71% 73% 75%
    Spec 1 43% 55% 33% 39% 43% 33% 40% 43% 19%
    Cutoff 2 1.25 1.61 1.24 1.25 1.25 1.24 1.25 1.61 1.16
    Sens 2 83% 82% 80% 80% 82% 80% 81% 82% 81%
    Spec 2 26% 28% 19% 26% 20% 19% 26% 28% 19%
    Cutoff 3 1.07 1.16 0.751 0.123 0.893 0.123 1.07 1.25 0.123
    Sens 3 91% 94% 92% 91% 94% 92% 90% 91% 94%
    Spec 3 23% 19% 15% 12% 16%  8% 23% 20%  8%
    Cutoff 4 5.04 7.01 5.73 5.04 7.01 5.73 5.04 7.01 5.73
    Sens 4 51% 53% 48% 49% 47% 44% 48% 55% 38%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 9.17 16.0 9.17 9.17 16.0 9.17 9.17 16.0 9.17
    Sens 5 37% 24% 40% 31% 24% 36% 29% 27% 31%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 61.4 61.4 52.0 61.4 61.4 52.0 61.4 61.4 52.0
    Sens 6 11%  0% 20%  9%  0% 12% 10%  0% 12%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.0 0.66 0.63 0.69 0.49 0.63 0.72 0.99 0.18
    p Value 1.0 0.65 0.49 0.55 0.42 0.49 0.68 0.99 0.13
    95% CI of 0.31 0.11 0.17 0.21 0.088 0.17 0.16 0.14 0.021
    OR Quart 2 3.3 4.0 2.4 2.3 2.7 2.4 3.4 7.2 1.6
    OR Quart 3 1.4 2.1 0.64 1.5 1.5 0.82 1.5 1.5 0.78
    p Value 0.57 0.32 0.51 0.44 0.52 0.75 0.53 0.65 0.73
    95% CI of 0.45 0.50 0.17 0.54 0.42 0.23 0.41 0.25 0.20
    OR Quart 3 4.2 8.5 2.4 4.2 5.6 2.9 5.7 9.3 3.1
    OR Quart 4 2.9 2.1 2.0 2.0 1.3 1.8 2.1 2.0 1.2
    p Value 0.041 0.32 0.21 0.16 0.73 0.30 0.24 0.42 0.78
    95% CI of 1.0 0.50 0.68 0.75 0.33 0.60 0.60 0.36 0.34
    OR Quart 4 8.0 8.5 5.9 5.5 4.8 5.3 7.4 11 4.2
  • FIG. 5: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2.
  •
    Complement C4-B
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 65500 78300 65500 83200 65500 65900
    Average 72500 79400 72500 78500 72500 73500
    Stdev 40600 45100 40600 38300 40600 36100
    p (t-test) 0.32 0.37 0.91
    Min 305 1250 305 10700 305 21500
    Max 203000 223000 203000 188000 203000 140000
    n (Samp) 121 53 121 53 121 26
    n (Patient) 87 53 87 53 87 26
    sCr only
    Median 70800 87600 70800 93700 70800 90200
    Average 77800 83300 77800 91300 77800 84300
    Stdev 42600 39300 42600 43900 42600 46200
    p (t-test) 0.61 0.23 0.64
    Min 305 7620 305 5510 305 10700
    Max 223000 144000 223000 161000 223000 140000
    n (Samp) 288 16 288 15 288 10
    n (Patient) 161 16 161 15 161 10
    UO only
    Median 65500 64200 65500 77100 65500 62800
    Average 71100 78000 71100 75500 71100 67500
    Stdev 36500 48100 36500 38900 36500 32700
    p (t-test) 0.33 0.46 0.67
    Min 305 1250 305 10700 305 21500
    Max 160000 223000 160000 188000 160000 136000
    n (Samp) 125 43 125 54 125 23
    n (Patient) 80 43 80 54 80 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 0.56 0.53 0.56 0.62 0.53 0.51 0.56 0.47
    SE 0.048 0.076 0.052 0.048 0.079 0.047 0.063 0.096 0.066
    p 0.34 0.43 0.57 0.23 0.13 0.55 0.83 0.53 0.66
    nCohort 1 121 288 125 121 288 125 121 288 125
    nCohort 2 53 16 43 53 15 54 26 10 23
    Cutoff 1 47600 68900 46200 51400 79100 49100 49100 66700 40700
    Sens 1 72% 75% 72% 72% 73% 70% 73% 70% 74%
    Spec 1 31% 49% 29% 36% 57% 32% 33% 49% 21%
    Cutoff 2 39400 46200 36700 43600 77900 41700 39400 42000 38300
    Sens 2 81% 81% 81% 81% 80% 81% 81% 80% 83%
    Spec 2 21% 26% 18% 27% 55% 22% 21% 23% 19%
    Cutoff 3 29600 20400 21400 25500 5890 25500 29100 25600 29100
    Sens 3 91% 94% 91% 91% 93% 91% 92% 90% 91%
    Spec 3 10%  4%  6%  7%  2%  6%  8%  7%  7%
    Cutoff 4 86800 99700 87900 86800 99700 87900 86800 99700 87900
    Sens 4 42% 38% 40% 43% 40% 35% 35% 40% 26%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 105000 113000 100000 105000 113000 100000 105000 113000 100000
    Sens 5 23% 19% 33% 23% 33% 26% 27% 40% 22%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 132000 133000 129000 132000 133000 129000 132000 133000 129000
    Sens 6 13% 12% 14%  6% 13%  6%  8% 10%  4%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.97 0.66 1.0 1.2 0.49 1.1 1.2 0.32 0.81
    p Value 0.95 0.65 1.0 0.67 0.56 0.87 0.80 0.33 0.74
    95% CI of 0.38 0.11 0.38 0.47 0.043 0.43 0.35 0.033 0.22
    OR Quart 2 2.5 4.1 2.6 3.3 5.5 2.7 3.9 3.1 2.9
    OR Quart 3 1.0 2.5 0.47 1.8 3.7 1.1 0.78 0.66 0.81
    p Value 1.0 0.20 0.18 0.24 0.11 0.87 0.71 0.65 0.74
    95% CI of 0.39 0.61 0.16 0.69 0.74 0.43 0.22 0.11 0.22
    OR Quart 3 2.6 9.9 1.4 4.6 18 2.7 2.8 4.1 2.9
    OR Quart 4 1.6 1.4 1.6 1.9 2.6 1.5 1.4 1.3 1.2
    p Value 0.29 0.70 0.35 0.18 0.27 0.40 0.59 0.71 0.76
    95% CI of 0.66 0.29 0.62 0.74 0.48 0.60 0.43 0.29 0.36
    OR Quart 4 4.0 6.3 4.0 4.8 14 3.6 4.5 6.2 4.0
    C-C motif chemokine 26
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.725 1.25 0.725 1.62 0.725 5.42
    Average 12.8 5.27 12.8 8.50 12.8 11.0
    Stdev 65.9 10.1 65.9 14.0 65.9 15.6
    p (t-test) 0.45 0.68 0.91
    Min 0.0121 0.0232 0.0121 0.0121 0.0121 0.0339
    Max 468 55.4 468 51.1 468 53.5
    n (Samp) 93 45 93 42 93 18
    n (Patient) 64 45 64 42 64 18
    sCr only
    Median 0.785 3.74 0.785 3.16 0.785 4.75
    Average 8.23 7.35 8.23 11.6 8.23 12.3
    Stdev 43.2 9.45 43.2 16.6 43.2 18.3
    p (t-test) 0.94 0.74 0.78
    Min 0.0121 0.0121 0.0121 0.0232 0.0121 0.0121
    Max 468 29.4 468 51.1 468 50.9
    n (Samp) 224 14 224 18 224 9
    n (Patient) 131 14 131 18 131 9
    UO only
    Median 0.0587 0.725 0.0587 1.48 0.0587 5.00
    Average 12.3 3.90 12.3 6.69 12.3 8.29
    Stdev 63.1 9.51 63.1 11.4 63.1 13.5
    p (t-test) 0.42 0.57 0.81
    Min 0.0121 0.0232 0.0121 0.0121 0.0121 0.0325
    Max 468 55.4 468 46.1 468 53.5
    n (Samp) 102 37 102 41 102 15
    n (Patient) 63 37 63 41 63 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.60 0.55 0.60 0.68 0.58 0.76 0.64 0.68
    SE 0.053 0.082 0.056 0.054 0.072 0.054 0.070 0.10 0.080
    p 0.23 0.25 0.41 0.068 0.015 0.14 2.3E−4 0.17 0.029
    nCohort 1 93 224 102 93 224 102 93 224 102
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 0.0339 0.0503 0.0339 0.0339 1.25 0.0339 4.62 0.0503 0.0587
    Sens 1 82% 71% 81% 81% 72% 73% 72% 78% 73%
    Spec 1 25% 41% 27% 25% 56% 27% 80% 41% 51%
    Cutoff 2 0.0339 0.0232 0.0339 0.0339 0.652 0.0325 1.84 0.0339 0.0339
    Sens 2 82% 93% 81% 81% 83% 85% 83% 89% 80%
    Spec 2 25%  4% 27% 25% 47% 25% 67% 25% 27%
    Cutoff 3 0.0232 0.0232 0.0232 0.0232 0.0339 0.0232 0.0325 0 0.0325
    Sens 3 98% 93% 97% 93% 94% 93% 100%  100%  93%
    Spec 3  5%  4%  5%  5% 25%  5% 22%  0% 25%
    Cutoff 4 2.43 3.90 2.43 2.43 3.90 2.43 2.43 3.90 2.43
    Sens 4 36% 50% 27% 43% 44% 44% 78% 56% 67%
    Spec 4 71% 70% 72% 71% 70% 72% 71% 70% 72%
    Cutoff 5 5.00 6.86 5.00 5.00 6.86 5.00 5.00 6.86 5.00
    Sens 5 29% 43% 19% 31% 33% 32% 50% 33% 40%
    Spec 5 83% 81% 82% 83% 81% 82% 83% 81% 82%
    Cutoff 6 10.6 10.7 13.4 10.6 10.7 13.4 10.6 10.7 13.4
    Sens 6 13% 21%  5% 24% 28% 15% 28% 33% 13%
    Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 1.4 0.64 1.1 1.1 0.98 1.5 0.46 2.0 1.6
    p Value 0.48 0.64 0.82 0.83 0.99 0.44 0.54 0.57 0.64
    95% CI of 0.52 0.10 0.36 0.37 0.13 0.51 0.039 0.18 0.24
    OR Quart 2 4.1 4.0 3.6 3.4 7.2 4.6 5.4 23 10
    OR Quart 3 1.0 0.65 2.3 1.5 3.2 1.3 2.7 2.0 0.48
    p Value 1.0 0.65 0.13 0.46 0.16 0.61 0.26 0.57 0.56
    95% CI of 0.34 0.1 1 0.78 0.51 0.62 0.43 0.48 0.18 0.041
    OR Quart 3 2.9 4.1 6.7 4.4 17 4.1 15 23 5.6
    OR Quart 4 2.1 2.5 1.3 2.2 4.4 2.9 6.9 4.1 5.8
    p Value 0.16 0.21 0.61 0.14 0.069 0.052 0.020 0.21 0.035
    95% CI of 0.76 0.61 0.43 0.77 0.89 0.99 1.4 0.45 1.1
    OR Quart 4 5.7 10 4.1 6.2 22 8.3 36 38 30
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.620 0.512 0.620 0.804 0.620 0.512
    Average 8.13 7.46 8.13 10.4 8.13 12.7
    Stdev 22.1 14.3 22.1 15.1 22.1 21.1
    p (t-test) 0.85 0.55 0.42
    Min 0.193 0.193 0.193 0.193 0.193 0.193
    Max 128 79.4 128 60.8 128 75.6
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 0.620 0.712 0.620 0.620 0.620 0.512
    Average 9.35 5.26 9.35 23.9 9.35 11.1
    Stdev 24.0 8.50 24.0 54.7 24.0 25.1
    p (t-test) 0.53 0.031 0.83
    Min 0.193 0.193 0.193 0.193 0.193 0.193
    Max 181 26.1 181 219 181 75.6
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 0.620 0.512 0.620 0.804 0.620 0.512
    Average 6.86 7.17 6.86 11.9 6.86 8.74
    Stdev 20.9 15.2 20.9 17.6 20.9 15.0
    p (t-test) 0.93 0.18 0.74
    Min 0.193 0.193 0.193 0.193 0.193 0.193
    Max 128 79.4 128 67.3 128 48.7
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.49 0.50 0.50 0.58 0.52 0.64 0.57 0.49 0.57
    SE 0.053 0.080 0.056 0.054 0.072 0.053 0.076 0.099 0.082
    p 0.87 0.95 0.95 0.16 0.73 0.010 0.34 0.90 0.40
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 0.193 0.308 0.193 0.193 0.193 0.308 0.308 0.308 0.308
    Sens 1 76% 71% 76% 88% 78% 80% 94% 78% 87%
    Spec 1 18% 30% 20% 18% 19% 38% 34% 30% 38%
    Cutoff 2 0 0.193 0 0.193 0 0.308 0.308 0.193 0.308
    Sens 2 100%  86% 100%  88% 100%  80% 94% 89% 87%
    Spec 2  0% 19%  0% 18%  0% 38% 34% 19% 38%
    Cutoff 3 0 0 0 0 0 0.193 0.308 0 0.193
    Sens 3 100%  100%  100%  100%  100%  93% 94% 100%  93%
    Spec 3  0%  0%  0%  0%  0% 20% 34%  0% 20%
    Cutoff 4 0.804 2.71 0.804 0.804 2.71 0.804 0.804 2.71 0.804
    Sens 4 36% 29% 32% 45% 44% 46% 39% 22% 33%
    Spec 4 70% 70% 75% 70% 70% 75% 70% 70% 75%
    Cutoff 5 8.42 9.52 5.10 8.42 9.52 5.10 8.42 9.52 5.10
    Sens 5 31% 29% 27% 38% 39% 41% 33% 22% 33%
    Spec 5 84% 80% 81% 84% 80% 81% 84% 80% 81%
    Cutoff 6 19.2 28.8 14.4 19.2 28.8 14.4 19.2 28.8 14.4
    Sens 6 13%  0% 16% 21% 17% 29% 28% 11% 20%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.38 0.72 0.45 0.86 1.5 1.2 15 1.0 8.5
    p Value 0.072 0.68 0.17 0.79 0.53 0.78 0.013 0.99 0.053
    95% CI of 0.13 0.15 0.15 0.30 0.41 0.39 1.8 0.14 0.98
    OR Quart 2 1.1 3.4 1.4 2.5 5.7 3.5 130 7.5 74
    OR Quart 3 0.69 0.72 0.55 0.62 0.23 1.0 0 1.5 2.1
    p Value 0.46 0.68 0.28 0.40 0.20 1.0 na 0.65 0.56
    95% CI of 0.26 0.15 0.18 0.20 0.025 0.33 na 0.25 0.18
    OR Quart 3 1.8 3.4 1.6 1.9 2.2 3.0 na 9.5 24
    OR Quart 4 0.93 0.98 1.3 2.1 1.8 2.8 9.0 1.0 5.6
    p Value 0.88 0.98 0.61 0.14 0.36 0.049 0.047 0.99 0.13
    95% CI of 0.35 0.23 0.48 0.79 0.50 1.0 1.0 0.14 0.61
    OR Quart 4 2.4 4.1 3.5 5.8 6.6 7.8 79 7.5 51
    Thyrotropin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1.37 1.65 1.37 1.55 1.37 1.52
    Average 2.10 3.14 2.10 2.51 2.10 2.57
    Stdev 2.10 4.63 2.10 2.75 2.10 3.77
    p (t-test) 0.092 0.35 0.42
    Min 0.0304 0.0228 0.0304 0.174 0.0304 0.101
    Max 9.94 20.0 9.94 12.1 9.94 14.7
    n (Samp) 85 35 85 42 85 25
    n (Patient) 75 35 75 42 75 25
    sCr only
    Median 1.55 2.14 1.55 1.82 1.55 1.36
    Average 3.21 3.62 3.21 2.43 3.21 1.69
    Stdev 5.66 5.87 5.66 2.33 5.66 1.27
    p (t-test) 0.82 0.65 0.45
    Min 0.0304 0.0228 0.0304 0.244 0.0304 0.101
    Max 60.1 20.0 60.1 8.20 60.1 3.88
    n (Samp) 201 10 201 11 201 8
    n (Patient) 132 10 132 11 132 8
    UO only
    Median 1.37 1.65 1.37 1.40 1.37 1.16
    Average 2.63 2.84 2.63 2.61 2.63 2.64
    Stdev 3.37 3.87 3.37 2.99 3.37 4.07
    p (t-test) 0.79 0.97 0.99
    Min 0.0304 0.0956 0.0304 0.174 0.0304 0.106
    Max 20.0 19.8 20.0 12.1 20.0 14.7
    n (Samp) 77 29 77 43 77 21
    n (Patient) 64 29 64 43 64 21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.53 0.52 0.52 0.53 0.52 0.51 0.49 0.47 0.47
    SE 0.059 0.095 0.063 0.055 0.091 0.055 0.066 0.11 0.072
    p 0.57 0.80 0.78 0.57 0.80 0.84 0.91 0.75 0.64
    nCohort 1 85 201 77 85 201 77 85 201 77
    nCohort 2 35 10 29 42 11 43 25 8 21
    Cutoff 1 0.568 1.25 0.568 0.785 1.25 0.785 0.714 1.13 0.714
    Sens 1 71% 70% 72% 71% 73% 72% 72% 75% 71%
    Spec 1 26% 45% 26% 33% 45% 35% 29% 43% 30%
    Cutoff 2 0.395 1.00 0.383 0.463 0.645 0.463 0.463 0.787 0.463
    Sens 2 80% 80% 83% 81% 82% 81% 80% 88% 81%
    Spec 2 20% 39% 18% 22% 28% 23% 22% 34% 23%
    Cutoff 3 0.268 0.380 0.268 0.395 0.418 0.341 0.106 0.0956 0.216
    Sens 3 91% 90% 93% 90% 91% 91% 92% 100%  90%
    Spec 3 13% 16% 12% 20% 18% 16%  6%  3% 10%
    Cutoff 4 2.84 3.09 3.18 2.84 3.09 3.18 2.84 3.09 3.18
    Sens 4 34% 20% 24% 29% 27% 28% 24% 25% 19%
    Spec 4 71% 70% 70% 71% 70% 70% 71% 70% 70%
    Cutoff 5 3.68 4.30 3.82 3.68 4.30 3.82 3.68 4.30 3.82
    Sens 5 26% 10% 24% 21% 18% 23% 20%  0% 19%
    Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 4.63 7.46 6.31 4.63 7.46 6.31 4.63 7.46 6.31
    Sens 6 14% 10% 10% 17%  9% 14%  8%  0% 10%
    Spec 6 91% 90% 91% 91% 90% 91% 91% 90% 91%
    OR Quart 2 0.71 0.98 0.78 1.3 1.5 1.2 1.3 3.2 1.8
    p Value 0.56 0.98 0.69 0.65 0.65 0.79 0.70 0.32 0.44
    95% CI of 0.22 0.13 0.22 0.44 0.25 0.40 0.37 0.32 0.43
    OR Quart 2 2.2 7.2 2.7 3.7 9.5 3.3 4.5 32 7.2
    OR Quart 3 1.2 2.0 1.4 1.3 2.1 1.3 1.0 3.2 1.7
    p Value 0.78 0.42 0.55 0.65 0.41 0.59 1.0 0.32 0.48
    95% CI of 0.39 0.36 0.44 0.44 0.36 0.46 0.28 0.32 0.41
    OR Quart 3 3.5 12 4.7 3.7 12 3.8 3.6 32 6.8
    OR Quart 4 1.0 0.98 0.95 1.3 1.0 1.0 1.0 1.0 1.4
    p Value 1.0 0.98 0.93 0.65 1.0 1.0 0.94 0.99 0.66
    95% CI of 0.33 0.13 0.28 0.44 0.14 0.34 0.29 0.062 0.32
    OR Quart 4 3.0 7.2 3.2 3.7 7.4 2.9 3.8 17 5.9
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 5470 5330 5470 5760 5470 6250
    Average 6870 8430 6870 7300 6870 6400
    Stdev 5340 7900 5340 5490 5340 2520
    p (t-test) 0.17 0.66 0.72
    Min 219 1360 219 1000 219 2840
    Max 29400 43200 29400 26900 29400 12100
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 6210 5870 6210 5070 6210 3710
    Average 7000 8490 7000 7680 7000 4330
    Stdev 5110 7420 5110 6800 5110 2310
    p (t-test) 0.30 0.60 0.12
    Min 219 4080 219 1280 219 1030
    Max 43200 32800 43200 26900 43200 8610
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 5640 5240 5640 5950 5640 6330
    Average 7340 7870 7340 6590 7340 6900
    Stdev 6250 7620 6250 4150 6250 2300
    p (t-test) 0.68 0.48 0.78
    Min 219 1360 219 924 219 2840
    Max 32800 43200 32800 16600 32800 12100
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.56 0.51 0.52 0.48 0.49 0.54 0.32 0.58
    SE 0.053 0.082 0.056 0.054 0.072 0.054 0.076 0.10 0.082
    p 0.24 0.47 0.83 0.74 0.80 0.85 0.57 0.074 0.32
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 4260 5140 4160 3490 4050 3400 4580 3020 5450
    Sens 1 71% 71% 70% 71% 72% 71% 72% 78% 73%
    Spec 1 35% 40% 29% 27% 31% 22% 38% 17% 49%
    Cutoff 2 3620 4120 3440 2930 3440 2580 3700 3010 5360
    Sens 2 80% 86% 81% 81% 83% 80% 83% 89% 80%
    Spec 2 30% 31% 22% 18% 23% 12% 32% 17% 49%
    Cutoff 3 2930 4080 2580 2070 1720 1720 2930 1010 4530
    Sens 3 91% 93% 92% 90% 94% 90% 94% 100%  93%
    Spec 3 18% 31% 12% 11%  7%  7% 18%  4% 31%
    Cutoff 4 7770 8350 7770 7770 8350 7770 7770 8350 7770
    Sens 4 40% 29% 35% 38% 22% 37% 28% 11% 33%
    Spec 4 70% 71% 71% 70% 71% 71% 70% 71% 71%
    Cutoff 5 9000 9630 8980 9000 9630 8980 9000 9630 8980
    Sens 5 27% 21% 24% 31% 22% 32% 11%  0% 13%
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81%
    Cutoff 6 13200 11800 13800 13200 11800 13800 13200 11800 13800
    Sens 6 11%  7% 11% 10% 17%  5%  0%  0%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 2.4 >7.8 1.3 1.1 0.74 0.51 1.8 >2.1 4.3
    p Value 0.092 <0.059 0.60 0.79 0.70 0.20 0.45 <0.55 0.20
    95% CI of 0.86 >0.93 0.47 0.41 0.16 0.18 0.39 >0.19 0.45
    OR Quart 2 6.9 na 3.8 3.2 3.4 1.4 8.4 na 41
    OR Quart 3 0.81 >4.2 0.48 0.74 1.8 0.43 2.3 >3.2 8.9
    p Value 0.72 <0.20 0.24 0.58 0.35 0.12 0.28 <0.33 0.048
    95% CI of 0.26 >0.46 0.14 0.25 0.51 0.15 0.51 >0.32 1.0
    OR Quar 3 2.6 na 1.6 2.2 6.7 1.2 10 na 78
    OR Quart 4 2.4 >3.1 1.5 1.5 1.0 1.0 1.4 >4.4 3.1
    p Value 0.092 <0.33 0.44 0.44 0.98 1.0 0.69 <0.19 0.34
    95% CI of 0.86 >0.31 0.54 0.54 0.24 0.38 0.28 >0.47 0.30
    OR Quart 4 6.9 na 4.2 4.1 4.3 2.6 6.9 na 32
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 9.44 17.2 9.44 13.4 9.44 23.0
    Average 17.1 19.3 17.1 16.9 17.1 22.5
    Stdev 29.3 19.4 29.3 16.2 29.3 10.6
    p (t-test) 0.64 0.97 0.44
    Min 0.0320 0.0627 0.0320 0.0320 0.0320 0.0627
    Max 223 108 223 67.7 223 44.7
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 13.5 10.2 13.5 11.2 13.5 11.8
    Average 18.1 17.0 18.1 23.4 18.1 15.4
    Stdev 24.6 27.7 24.6 39.4 24.6 10.2
    p (t-test) 0.87 0.40 0.74
    Min 0.0320 0.0627 0.0320 0.0320 0.0320 5.14
    Max 223 108 223 163 223 35.3
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 7.03 17.2 7.03 13.5 7.03 24.2
    Average 15.4 18.8 15.4 17.0 15.4 22.0
    Stdev 29.5 14.7 29.5 14.9 29.5 12.8
    p (t-test) 0.50 0.74 0.39
    Min 0.0320 0.0627 0.0320 0.0320 0.0320 0.0627
    Max 223 49.9 223 52.4 223 44.7
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.58 0.46 0.64 0.54 0.46 0.61 0.71 0.54 0.73
    SE 0.053 0.081 0.055 0.054 0.072 0.054 0.073 0.10 0.078
    p 0.13 0.60 0.013 0.43 0.59 0.041 0.0036 0.71 0.0035
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 5.80 4.47 6.46 3.73 0.0324 7.03 19.0 7.76 19.0
    Sens 1 71% 71% 70% 71% 89% 71% 72% 78% 73%
    Spec 1 40% 33% 49% 33%  2% 50% 70% 40% 77%
    Cutoff 2 3.73 0.0764 3.73 0.0627 0.0324 0.0997 13.5 5.98 13.5
    Sens 2 80% 93% 81% 86% 89% 80% 83% 89% 80%
    Spec 2 33% 17% 38% 16%  2% 27% 60% 37% 65%
    Cutoff 3 0.0324 0.0764 0.0324 0.0324 0.0320 0.0627 5.80 4.65 0.0627
    Sens 3 100%  93% 100%  95% 94% 93% 94% 100%  93%
    Spec 3  2% 17%  2%  2%  1% 17% 40% 34% 17%
    Cutoff 4 19.0 23.2 14.8 19.0 23.2 14.8 19.0 23.2 14.8
    Sens 4 42% 14% 62% 38% 28% 49% 72% 22% 73%
    Spec 4 70% 71% 71% 70% 71% 71% 70% 71% 71%
    Cutoff 5 26.9 29.0 20.8 26.9 29.0 20.8 26.9 29.0 20.8
    Sens 5 27% 14% 41% 26% 28% 37% 28% 11% 67%
    Spec 5 81% 80% 82% 81% 80% 82% 81% 80% 82%
    Cutoff 6 36.4 39.9 29.4 36.4 39.9 29.4 36.4 39.9 29.4
    Sens 6 18%  7% 24% 10% 11% 20%  6%  0% 33%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.96 2.1 0.83 0.74 0.58 1.0 2.1 >5.4 0.47
    p Value 0.94 0.41 0.76 0.58 0.47 1.0 0.56 <0.13 0.54
    95% CI of 0.33 0.36 0.25 0.25 0.13 0.33 0.18 >0.61 0.040
    OR Quart 2 2.8 12 2.8 2.2 2.5 3.0 24 na 5.4
    OR Quart 3 1.6 2.1 1.4 1.3 0.79 1.2 9.0 >3.2 1.0
    p Value 0.34 0.41 0.57 0.60 0.73 0.78 0.047 <0.32 1.0
    95% CI of 0.59 0.36 0.45 0.47 0.20 0.39 1.0 >0.32 0.13
    OR Quart 3 4.6 12 4.3 3.6 3.1 3.5 79 na 7.6
    OR Quart 4 1.9 2.1 3.0 1.3 1.2 2.8 11 >1.0 6.8
    p Value 0.24 0.40 0.043 0.60 0.73 0.049 0.031 <1.0 0.021
    95% CI of 0.67 0.37 1.0 0.47 0.36 1.0 1.2 >0.061 1.3
    OR Quart 4 5.1 12 8.7 3.6 4.3 7.8 93 na 34
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.93 3.18 2.93 2.93 2.93 2.93
    Average 14.5 13.6 14.5 10.9 14.5 6.68
    Stdev 26.1 14.8 26.1 12.5 26.1 7.82
    p (t-test) 0.82 0.35 0.14
    Min 0.0862 0.572 0.0862 0.572 0.0862 0.572
    Max 158 57.3 158 52.0 158 24.1
    n (Samp) 119 52 119 53 119 26
    n (Patient) 87 52 87 53 87 26
    sCr only
    Median 2.93 8.11 2.93 2.93 2.93 2.93
    Average 12.8 13.3 12.8 13.1 12.8 10.2
    Stdev 19.6 13.6 19.6 15.9 19.6 11.9
    p (t-test) 0.92 0.95 0.68
    Min 0.0862 0.572 0.0862 0.572 0.0862 0.572
    Max 158 46.7 158 52.0 158 30.5
    n (Samp) 283 16 283 14 283 10
    n (Patient) 161 16 161 14 161 10
    UO only
    Median 3.29 3.18 3.29 2.93 3.29 2.93
    Average 15.0 13.6 15.0 9.49 15.0 6.86
    Stdev 25.6 14.9 25.6 10.6 25.6 7.85
    p (t-test) 0.74 0.13 0.13
    Min 0.0728 0.572 0.0728 0.572 0.0728 0.572
    Max 158 57.3 158 33.5 158 21.7
    n (Samp) 123 42 123 54 123 23
    n (Patient) 80 42 80 54 80 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.57 0.55 0.55 0.52 0.54 0.48 0.50 0.53 0.45
    SE 0.048 0.076 0.052 0.048 0.081 0.047 0.063 0.095 0.067
    p 0.16 0.52 0.30 0.68 0.66 0.69 0.95 0.76 0.42
    nCohort 1 119 283 123 119 283 123 119 283 123
    nCohort 2 52 16 42 53 14 54 26 10 23
    Cutoff 1 0.971 0.971 0.971 0.971 0.971 0.971 0.971 2.43 0.572
    Sens 1 79% 81% 81% 72% 86% 72% 77% 70% 87%
    Spec 1 36% 29% 33% 36% 29% 33% 36% 41% 15%
    Cutoff 2 0.572 0.971 0.971 0.572 0.971 0.572 0.572 0.971 0.572
    Sens 2 88% 81% 81% 83% 86% 83% 92% 90% 87%
    Spec 2 16% 29% 33% 16% 29% 15% 16% 29% 15%
    Cutoff 3 0.0862 0.0862 0.572 0.0862 0.0862 0.0862 0.572 0.971 0.0862
    Sens 3 100%  100%  90% 100%  100%  100%  92% 90% 100% 
    Spec 3  1%  0% 15%  1%  0%  2% 16% 29%  2%
    Cutoff 4 14.4 17.1 16.6 14.4 17.1 16.6 14.4 17.1 16.6
    Sens 4 40% 38% 43% 28% 29% 22% 23% 30% 17%
    Spec 4 71% 70% 72% 71% 70% 72% 71% 70% 72%
    Cutoff 5 23.1 23.1 23.1 23.1 23.1 23.1 23.1 23.1 23.1
    Sens 5 25% 31% 24% 21% 29% 17%  4% 30%  0%
    Spec 5 81% 81% 80% 81% 81% 80% 81% 81% 80%
    Cutoff 6 36.9 31.3 34.8 36.9 31.3 34.8 36.9 31.3 34.8
    Sens 6  8%  6% 10%  2% 14%  0%  0%  0%  0%
    Spec 6 92% 90% 90% 92% 90% 90% 92% 90% 90%
    OR Quart 2 2.8 3.1 1.9 0.79 2.1 1.4 2.8 4.2 1.0
    p Value 0.042 0.17 0.21 0.63 0.41 0.44 0.12 0.21 0.97
    95% CI of 1.0 0.61 0.69 0.31 0.37 0.57 0.76 0.46 0.24
    OR Quart 2 7.4 16 5.3 2.0 12 3.7 9.9 38 4.5
    OR Quart 3 1.6 0.99 1.3 1.5 2.1 1.8 2.8 2.0 2.7
    p Value 0.34 0.99 0.59 0.37 0.41 0.22 0.12 0.57 0.14
    95% CI of 0.59 0.14 0.47 0.62 0.37 0.71 0.76 0.18 0.74
    OR Quart 3 4.6 7.2 3.8 3.7 12 4.4 9.9 23 9.5
    OR Quart 4 2.3 3.1 1.5 0.89 2.0 1.3 1.0 3.0 1.6
    p Value 0.10 0.17 0.47 0.81 0.42 0.59 0.97 0.34 0.47
    95% CI of 0.84 0.61 0.52 0.35 0.36 0.51 0.24 0.31 0.42
    OR Quart 4 6.1 16 4.1 2.3 11 3.3 4.5 30 6.4
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 21.0 5.45 21.0 9.99 21.0 24.0
    Average 37.8 33.6 37.8 36.6 37.8 41.1
    Stdev 49.2 53.3 49.2 55.6 49.2 48.4
    p (t-test) 0.62 0.89 0.75
    Min 0.204 0.204 0.204 0.204 0.204 0.204
    Max 257 189 257 228 257 149
    n (Samp) 119 52 119 53 119 26
    n (Patient) 87 52 87 53 87 26
    sCr only
    Median 14.7 0.763 14.7 0.763 14.7 6.07
    Average 34.2 29.8 34.2 44.9 34.2 45.5
    Stdev 47.7 51.3 47.7 66.8 47.7 62.9
    p (t-test) 0.72 0.42 0.47
    Min 0.204 0.222 0.204 0.316 0.204 0.222
    Max 257 151 257 177 257 149
    n (Samp) 283 16 283 14 283 10
    n (Patient) 161 16 161 14 161 10
    UO only
    Median 8.50 5.45 8.50 11.4 8.50 8.58
    Average 30.2 34.4 30.2 34.0 30.2 33.3
    Stdev 47.5 53.1 47.5 50.4 47.5 44.1
    p (t-test) 0.64 0.63 0.78
    Min 0.204 0.204 0.204 0.204 0.204 0.204
    Max 257 189 257 228 257 149
    n (Samp) 123 42 123 54 123 23
    n (Patient) 80 42 80 54 80 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.44 0.44 0.51 0.46 0.52 0.51 0.54 0.53 0.55
    SE 0.048 0.076 0.052 0.048 0.080 0.047 0.063 0.094 0.067
    p 0.25 0.47 0.89 0.40 0.80 0.79 0.57 0.77 0.43
    nCohort 1 119 283 123 119 283 123 119 283 123
    nCohort 2 52 16 42 53 14 54 26 10 23
    Cutoff 1 0.357 0.316 0.357 0.316 0.357 0.316 0.696 0.357 0.488
    Sens 1 73% 75% 71% 75% 71% 70% 73% 70% 74%
    Spec 1 22% 22% 28% 18% 26% 24% 32% 26% 41%
    Cutoff 2 0.222 0.222 0.222 0.222 0.316 0.222 0.357 0.316 0.222
    Sens 2 87% 81% 86% 87% 93% 83% 81% 90% 91%
    Spec 2 16% 16% 20% 16% 22% 20% 22% 22% 20%
    Cutoff 3 0.204 0.204 0.204 0.204 0.316 0.204 0.222 0.316 0.222
    Sens 3 94% 100%  93% 96% 93% 96% 96% 90% 91%
    Spec 3  4%  5%  5%  4% 22%  5% 16% 22% 20%
    Cutoff 4 47.6 41.5 36.4 47.6 41.5 36.4 47.6 41.5 36.4
    Sens 4 19% 31% 29% 26% 36% 28% 35% 30% 30%
    Spec 4 71% 70% 71% 71% 70% 71% 71% 70% 71%
    Cutoff 5 64.4 61.4 49.7 64.4 61.4 49.7 64.4 61.4 49.7
    Sens 5 15% 19% 21% 19% 29% 26% 27% 30% 30%
    Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80%
    Cutoff 6 97.6 97.6 80.9 97.6 97.6 80.9 97.6 97.6 80.9
    Sens 6 13% 12% 17% 15% 21% 13% 19% 30% 13%
    Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 1.3 0.66 1.0 0.89 1.0 0.57 1.5 1.0 1.2
    p Value 0.62 0.65 1.0 0.81 1.0 0.24 0.53 1.0 0.78
    95% CI of 0.48 0.11 0.38 0.34 0.24 0.22 0.43 0.20 0.33
    OR Quart 2 3.4 4.1 2.7 2.3 4.2 1.5 5.2 5.1 4.3
    OR Quart 3 2.0 2.5 0.88 1.2 0.24 1.0 1.2 0.32 1.0
    p Value 0.16 0.20 0.80 0.64 0.21 1.0 0.74 0.33 1.0
    95% CI of 0.76 0.61 0.33 0.50 0.026 0.41 0.34 0.033 0.26
    OR Quart 3 5.0 9.9 2.4 3.1 2.2 2.4 4.5 3.2 3.8
    OR Quart 4 1.6 1.4 0.85 1.5 1.2 0.87 1.7 0.99 1.4
    p Value 0.30 0.69 0.75 0.36 0.75 0.76 0.39 0.99 0.56
    95% CI of 0.63 0.30 0.32 0.62 0.32 0.36 0.50 0.19 0.41
    OR Quart 4 4.3 6.4 2.3 3.8 4.9 2.1 5.8 5.1 5.1
    Immunoglogulin G4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 416000 348000 416000 364000 416000 325000
    Average 815000 435000 815000 451000 815000 395000
    Stdev 1020000 366000 1020000 338000 1020000 384000
    p (t-test) 0.033 0.035 0.20
    Min 15300 2000 15300 14400 15300 18500
    Max 5190000 1690000 5190000 1480000 5190000 1070000
    n (Samp) 94 35 94 37 94 10
    n (Patient) 67 35 67 37 67 10
    sCr only
    Median 364000 506000 364000 357000 nd nd
    Average 626000 585000 626000 454000 nd nd
    Stdev 765000 449000 765000 347000 nd nd
    p (t-test) 0.87 0.53 nd nd
    Min 2000 61100 2000 58300 nd nd
    Max 5190000 1690000 5190000 939000 nd nd
    n (Samp) 205 10 205 8 nd nd
    n (Patient) 126 10 126 8 nd nd
    UO only
    Median 417000 328000 417000 409000 417000 385000
    Average 719000 486000 719000 585000 719000 434000
    Stdev 858000 677000 858000 651000 858000 371000
    p (t-test) 0.19 0.40 0.26
    Min 15300 2000 15300 14400 15300 18500
    Max 5140000 3560000 5140000 3700000 5140000 1070000
    n (Samp) 101 28 101 36 101 12
    n (Patient) 65 28 65 36 65 12
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.42 0.57 0.40 0.44 0.48 0.48 0.37 nd 0.41
    SE 0.058 0.096 0.063 0.057 0.11 0.056 0.099 nd 0.091
    p 0.15 0.49 0.11 0.32 0.82 0.77 0.18 nd 0.30
    nCohort 1 94 205 101 94 205 101 94 nd 101
    nCohort 2 35 10 28 37 8 36 10 nd 12
    Cutoff 1 191000 402000 186000 277000 250000 299000 71200 nd 71200
    Sens 1 71% 70% 71% 70% 75% 72% 70% nd 75%
    Spec 1 30% 53% 28% 40% 34% 40% 13% nd 11%
    Cutoff 2 83300 347000 56300 164000 90700 245000 37500 nd 37500
    Sens 2 80% 80% 82% 81% 88% 81% 80% nd 83%
    Spec 2 16% 49%  7% 26% 18% 34%  5% nd  4%
    Cutoff 3 33600 191000 15300 38600 58100 38600 18500 nd 18500
    Sens 3 91% 90% 93% 92% 100%  92% 90% nd 92%
    Spec 3  4% 29%  1%  5% 12%  4%  1% nd  1%
    Cutoff 4 977000 705000 884000 977000 705000 884000 977000 nd 884000
    Sens 4  3% 20% 14%  5% 25% 19% 10% nd  8%
    Spec 4 70% 70% 70% 70% 70% 70% 70% nd 70%
    Cutoff 5 1370000 977000 1080000 1370000 977000 1080000 1370000 nd 1080000
    Sens 5  3% 10%  4%  3%  0%  8%  0% nd  0%
    Spec 5 81% 80% 80% 81% 80% 80% 81% nd 80%
    Cutoff 6 2130000 1380000 1590000 2130000 1380000 1590000 2130000 nd 1590000
    Sens 6  0% 10%  4%  0%  0%  3%  0% nd  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% nd 90%
    OR Quart 2 6.8 2.0 2.0 4.7 1.0 1.9 3.3 nd 4.7
    p Value 0.0063 0.58 0.30 0.016 0.98 0.25 0.32 nd 0.18
    95% CI of 1.7 0.18 0.53 1.3 0.14 0.64 0.32 nd 0.49
    OR Quart 2 27 23 7.8 17 7.5 5.7 34 nd 45
    OR Quart 3 5.2 6.5 2.8 4.1 1.0 1.9 2.1 nd 3.4
    p Value 0.020 0.088 0.12 0.027 0.98 0.25 0.56 nd 0.31
    95% CI of 1.3 0.75 0.77 1.2 0.14 0.64 0.18 nd 0.33
    OR Quart 3 21 56 10 15 7.5 5.7 25 nd 34
    OR Quart 4 3.3 0.98 2.4 2.4 1.0 1.0 4.5 nd 4.7
    p Value 0.099 0.99 0.19 0.19 0.98 0.95 0.19 nd 0.18
    95% CI of 0.80 0.060 0.65 0.65 0.14 0.32 0.47 nd 0.49
    OR Quart 4 14 16 9.0 9.0 7.5 3.4 44 nd 45
    Interleukin-21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.694 0.220 0.694 0.631 0.694 1.76
    Average 62.7 2.10 62.7 2.18 62.7 2.97
    Stdev 560 4.20 560 3.76 560 4.00
    p (t-test) 0.47 0.49 0.65
    Min 0.0102 0.0102 0.0102 0.0102 0.0102 0.0102
    Max 5430 18.3 5430 15.6 5430 14.3
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 0.430 1.62 0.430 1.56 0.430 1.36
    Average 27.5 4.80 27.5 4.77 27.5 3.68
    Stdev 362 6.58 362 7.34 362 5.30
    p (t-test) 0.82 0.79 0.84
    Min 0.0102 0.0102 0.0102 0.0257 0.0102 0.0102
    Max 5430 18.3 5430 26.6 5430 14.3
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 0.829 0.174 0.829 0.630 0.829 0.829
    Average 57.9 1.06 57.9 1.90 57.9 2.24
    Stdev 535 2.03 535 3.33 535 3.16
    p (t-test) 0.52 0.50 0.69
    Min 0.0102 0.0102 0.0102 0.0102 0.0102 0.0102
    Max 5430 8.97 5430 16.0 5430 11.5
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 0.58 0.37 0.52 0.68 0.47 0.62 0.63 0.54
    SE 0.053 0.082 0.055 0.054 0.072 0.054 0.076 0.10 0.081
    p 0.37 0.33 0.020 0.70 0.011 0.56 0.099 0.20 0.63
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 0.0154 0.0154 0.0154 0.0257 0.231 0.0257 0.605 0.783 0.430
    Sens 1 76% 79% 70% 74% 72% 71% 78% 78% 73%
    Spec 1 19% 22% 14% 33% 48% 32% 50% 59% 46%
    Cutoff 2 0.0142 0.0142 0.0102 0.0182 0.174 0.0154 0.430 0.0182 0.174
    Sens 2 82% 86% 89% 83% 89% 85% 83% 89% 80%
    Spec 2 15% 14%  5% 24% 43% 14% 49% 29% 36%
    Cutoff 3 0.0102 0.0102 0 0.0142 0.0257 0.0142 0.0142 0 0.0142
    Sens 3 91% 93% 100%  93% 94% 93% 94% 100%  93%
    Spec 3 10%  9%  0% 15% 39% 11% 15%  0% 11%
    Cutoff 4 1.77 1.61 2.03 1.77 1.61 2.03 1.77 1.61 2.03
    Sens 4 29% 50% 19% 31% 39% 24% 50% 44% 20%
    Spec 4 70% 71% 72% 70% 71% 72% 70% 71% 72%
    Cutoff 5 2.93 2.46 3.18 2.93 2.46 3.18 2.93 2.46 3.18
    Sens 5 16% 43%  8% 24% 39% 17% 22% 22% 20%
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81%
    Cutoff 6 10.6 5.00 14.5 10.6 5.00 14.5 10.6 5.00 14.5
    Sens 6  7% 29%  0%  7% 28%  2% 11% 22%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.57 0.47 1.4 1.5 >6.5 1.0 2.2 0.98 3.4
    p Value 0.29 0.40 0.55 0.43 <0.087 1.0 0.40 0.99 0.16
    95% CI of 0.20 0.083 0.44 0.54 >0.76 0.34 0.36 0.060 0.62
    OR Quart 2 1.6 2.7 4.7 4.3 na 2.9 13 16 18
    OR Quart 3 1.1 0.23 2.2 1.0 >5.4 1.5 4.3 4.2 2.2
    p Value 0.80 0.20 0.17 1.0 <0.13 0.44 0.086 0.20 0.40
    95% CI of 0.43 0.025 0.71 0.34 >0.61 0.54 0.81 0.46 0.36
    OR Quart 3 3.0 2.1 6.9 2.9 na 4.2 23 39 13
    OR Quart 4 1.0 1.8 2.5 1.5 >7.8 1.3 2.8 3.1 1.5
    p Value 0.93 0.36 0.11 0.43 <0.059 0.60 0.24 0.34 0.67
    95% CI of 0.39 0.50 0.82 0.54 >0.93 0.47 0.50 0.31 0.23
    OR Quart 4 2.8 6.6 7.7 4.3 na 3.7 16 30 9.7
    Interleukin-23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.886 1.10 0.886 1.10 0.886 6.06
    Average 1780 3580 1780 4170 1780 1560
    Stdev 10800 15400 10800 15900 10800 4960
    p (t-test) 0.43 0.31 0.93
    Min 0.257 0.257 0.257 0.257 0.257 0.603
    Max 100000 100000 100000 100000 100000 20500
    n (Samp) 93 45 93 42 93 18
    n (Patient) 64 45 64 42 64 18
    sCr only
    Median 1.10 0.886 1.10 1.10 1.10 0.603
    Average 2750 3820 2750 8680 2750 2270
    Stdev 14900 7430 14900 23800 14900 6820
    p (t-test) 0.79 0.12 0.92
    Min 0.257 0.257 0.257 0.257 0.257 0.257
    Max 100000 20000 100000 100000 100000 20500
    n (Samp) 224 14 224 18 224 9
    n (Patient) 131 14 131 18 131 9
    UO only
    Median 0.995 1.10 0.995 1.10 0.995 44.5
    Average 2480 2920 2480 3160 2480 511
    Stdev 11000 16400 11000 15600 11000 1650
    p (t-test) 0.86 0.77 0.49
    Min 0.257 0.257 0.257 0.257 0.257 0.603
    Max 100000 100000 100000 100000 100000 6480
    n (Samp) 102 37 102 41 102 15
    n (Patient) 63 37 63 41 63 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.52 0.50 0.49 0.55 0.60 0.53 0.55 0.34 0.60
    SE 0.053 0.080 0.056 0.054 0.073 0.054 0.076 0.10 0.082
    p 0.74 0.98 0.79 0.32 0.17 0.56 0.51 0.11 0.24
    nCohort 1 93 224 102 93 224 102 93 224 102
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 0.603 0.603 0.603 0.603 0.770 0.603 0.257 0.257 0.653
    Sens 1 78% 79% 76% 79% 78% 80% 100%  89% 80%
    Spec 1 25% 22% 24% 25% 38% 24% 18% 13% 41%
    Cutoff 2 0.257 0.257 0.257 0.257 0.257 0.603 0.257 0.257 0.653
    Sens 2 84% 86% 84% 81% 83% 80% 100%  89% 80%
    Spec 2 18% 13% 19% 18% 13% 24% 18% 13% 41%
    Cutoff 3 0 0 0 0 0 0 0.257 0 0.257
    Sens 3 100%  100%  100%  100%  100%  100%  100%  100%  100% 
    Spec 3  0%  0%  0%  0%  0%  0% 18%  0% 19%
    Cutoff 4 11.0 44.5 55.0 11.0 44.5 55.0 11.0 44.5 55.0
    Sens 4 31% 29% 27% 43% 44% 34% 44% 11% 47%
    Spec 4 71% 71% 71% 71% 71% 71% 71% 71% 71%
    Cutoff 5 501 267 530 501 267 530 501 267 530
    Sens 5 16% 29%  8% 29% 39% 24% 11% 11%  7%
    Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80%
    Cutoff 6 1500 1040 2000 1500 1040 2000 1500 1040 2000
    Sens 6 11% 29%  5% 14% 33% 12% 11% 11%  7%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.1 1.7 2.9 1.1 0.72 1.7 0.34 1.0 1.6
    p Value 0.86 0.48 0.065 0.85 0.68 0.33 0.22 0.99 0.64
    95% CI of 0.39 0.39 0.94 0.38 0.16 0.59 0.060 0.062 0.24
    OR Quart 2 3.1 7.4 8.7 3.2 3.4 4.8 1.9 17 10
    OR Quart 3 1.9 0.65 1.7 1.3 0.74 1.5 1.5 2.1 4.3
    p Value 0.21 0.65 0.38 0.65 0.70 0.47 0.56 0.56 0.087
    95% CI of 0.70 0.11 0.52 0.45 0.16 0.51 0.40 0.18 0.81
    OR Quart 3 5.2 4.1 5.3 3.6 3.4 4.3 5.3 23 23
    OR Quart 4 0.83 1.3 1.7 1.5 2.1 1.3 0.73 5.5 1.5
    p Value 0.73 0.71 0.35 0.48 0.24 0.63 0.67 0.13 0.67
    95% CI of 0.29 0.29 0.54 0.51 0.60 0.44 0.17 0.62 0.23
    OR Quart 4 2.4 6.2 5.6 4.1 7.4 3.8 3.1 48 9.7
    Interleukin-28A
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.168 0.265 0.168 0.265 0.168 12.7
    Average 60.1 15.3 60.1 13.9 60.1 26.7
    Stdev 387 47.2 387 41.9 387 54.8
    p (t-test) 0.44 0.44 0.72
    Min 0.0727 0.0727 0.0727 0.0727 0.0727 0.148
    Max 3150 246 3150 243 3150 235
    n (Samp) 93 45 93 42 93 18
    n (Patient) 64 45 64 42 64 18
    sCr only
    Median 0.195 0.230 0.195 0.265 0.195 0.265
    Average 28.7 36.9 28.7 136 28.7 31.0
    Stdev 250 80.9 250 470 250 77.2
    p (t-test) 0.90 0.11 0.98
    Min 0.0727 0.0727 0.0727 0.148 0.0727 0.0727
    Max 3150 246 3150 2000 3150 235
    n (Samp) 224 14 224 18 224 9
    n (Patient) 131 14 131 18 131 9
    UO only
    Median 0.168 0.265 0.168 0.265 0.168 0.265
    Average 57.5 4.69 57.5 7.99 57.5 13.5
    Stdev 370 10.1 370 16.8 370 18.3
    p (t-test) 0.39 0.39 0.65
    Min 0.0727 0.0727 0.0727 0.0727 0.0727 0.0727
    Max 3150 49.8 3150 92.3 3150 62.9
    n (Samp) 102 37 102 41 102 15
    n (Patient) 63 37 63 41 63 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.59 0.55 0.61 0.62 0.65 0.62 0.76 0.60 0.69
    SE 0.053 0.082 0.056 0.054 0.073 0.053 0.069 0.10 0.080
    p 0.072 0.53 0.051 0.026 0.036 0.028 2.1E−4 0.31 0.015
    nCohort 1 93 224 102 93 224 102 93 224 102
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 0.120 0.120 0.120 0.168 0.168 0.148 0.168 0.158 0.168
    Sens 1 91% 79% 92% 71% 72% 73% 89% 78% 80%
    Spec 1 19% 17% 24% 54% 48% 46% 54% 38% 56%
    Cutoff 2 0.120 0 0.120 0.120 0.158 0.120 0.168 0.120 0.168
    Sens 2 91% 100%  92% 88% 83% 83% 89% 89% 80%
    Spec 2 19%  0% 24% 19% 38% 24% 54% 17% 56%
    Cutoff 3 0.120 0 0.120 0 0.120 0 0.148 0 0.120
    Sens 3 91% 100%  92% 100%  100%  100%  94% 100%  93%
    Spec 3 19%  0% 24%  0% 17%  0% 41%  0% 24%
    Cutoff 4 0.265 0.265 0.265 0.265 0.265 0.265 0.265 0.265 0.265
    Sens 4 42% 36% 41% 36% 39% 39% 61% 44% 47%
    Spec 4 80% 71% 82% 80% 71% 82% 80% 71% 82%
    Cutoff 5 3.03 10.2 0.265 3.03 10.2 0.265 3.03 10.2 0.265
    Sens 5 33% 36% 41% 33% 28% 39% 56% 33% 47%
    Spec 5 81% 80% 82% 81% 80% 82% 81% 80% 82%
    Cutoff 6 16.5 19.3 16.5 16.5 19.3 16.5 16.5 19.3 16.5
    Sens 6 16% 29%  8% 12% 28% 10% 39% 22% 33%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 5.0 1.3 3.4 0.81 >6.5 0.47 >3.2 1.0 1.0
    p Value 0.011 0.71 0.056 0.72 <0.087 0.22 <0.32 0.57 1.0
    95% CI of 1.4 0.29 0.97 0.26 >0.76 0.14 >0.32 0.18 0.060
    OR Quart 2 17 6.2 12 2.6 na 1.6 na 23 17
    OR Quart 3 3.6 0.65 1.9 1.7 >6.7 1.3 >5.9 3.1 7.3
    p Value 0.048 0.65 0.36 0.33 <0.084 0.65 <0.12 0.33 0.075
    95% CI of 1.0 0.11 0.49 0.59 >0.78 0.45 >0.64 0.31 0.82
    OR Quart 3 13 4.1 7.1 4.9 na 3.6 na 31 65
    OR Quart 4 6.3 1.7 5.6 2.5 >6.5 2.3 >15 3.1 8.5
    p Value 0.0035 0.48 0.0063 0.090 <0.087 0.10 <0.013 0.34 0.053
    95% CI of 1.8 0.39 1.6 0.87 >0.76 0.85 >1.8 0.31 0.98
    OR Quart 4 22 7.4 19 7.0 na 6.3 na 30 74
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0981 0.0981 0.0981 0.101 0.0981 0.101
    Average 481 183 481 184 481 63.4
    Stdev 4130 710 4130 626 4130 210
    p (t-test) 0.63 0.64 0.67
    Min 0.0445 0.0445 0.0445 0.0445 0.0445 0.0445
    Max 40000 4440 40000 3770 40000 892
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 0.0981 0.0762 0.0981 0.0993 0.0981 0.101
    Average 327 240 327 844 327 99.4
    Stdev 2850 485 2850 2870 2850 297
    p (t-test) 0.91 0.46 0.81
    Min 0.0445 0.0445 0.0445 0.0445 0.0445 0.0455
    Max 40000 1270 40000 12300 40000 892
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 0.0981 0.0981 0.0981 0.101 0.0981 0.101
    Average 503 132 503 131 503 16.7
    Stdev 3950 730 3950 595 3950 38.5
    p (t-test) 0.57 0.55 0.64
    Min 0.0445 0.0445 0.0445 0.0445 0.0445 0.0445
    Max 40000 4440 40000 3770 40000 149
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 0.46 0.45 0.55 0.54 0.56 0.62 0.55 0.59
    SE 0.053 0.081 0.056 0.054 0.072 0.054 0.076 0.10 0.082
    p 0.49 0.63 0.39 0.38 0.59 0.27 0.13 0.61 0.28
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 0.0455 0.0494 0.0455 0.0494 0.0445 0.0494 0.0996 0.0846 0.0996
    Sens 1 73% 71% 73% 76% 83% 83% 83% 78% 73%
    Spec 1 24% 21% 23% 24% 10% 23% 55% 36% 60%
    Cutoff 2 0.0445 0.0445 0.0445 0.0445 0.0445 0.0494 0.0996 0.0494 0.0543
    Sens 2 89% 86% 89% 95% 83% 83% 83% 89% 80%
    Spec 2 11% 10%  8% 11% 10% 23% 55% 21% 41%
    Cutoff 3 0 0 0 0.0445 0 0.0445 0 0.0445 0
    Sens 3 100%  100%  100%  95% 100%  98% 100%  100%  100% 
    Spec 3  0%  0%  0% 11%  0%  8%  0% 10%  0%
    Cutoff 4 2.20 3.29 3.29 2.20 3.29 3.29 2.20 3.29 3.29
    Sens 4 24% 29% 19% 43% 44% 39% 39% 11% 40%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 27.4 14.4 33.8 27.4 14.4 33.8 27.4 14.4 33.8
    Sens 5 13% 29%  8% 19% 28% 20% 17% 11% 13%
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81%
    Cutoff 6 79.4 76.8 99.5 79.4 76.8 99.5 79.4 76.8 99.5
    Sens 6 11% 21%  5% 17% 28% 15% 11% 11%  7%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.0 0.24 1.4 0.54 0.47 1.8 1.0 2.0 0.47
    p Value 1.0 0.20 0.57 0.27 0.30 0.28 1.0 0.58 0.54
    95% CI of 0.36 0.026 0.45 0.18 0.11 0.61 0.13 0.18 0.040
    OR Quart 2 2.7 2.2 4.3 1.6 2.0 5.4 7.6 23 5.4
    OR Quart 3 1.1 1.0 1.8 1.0 0.31 2.1 5.2 5.4 4.3
    p Value 0.80 1.0 0.28 1.0 0.16 0.19 0.051 0.13 0.087
    95% CI of 0.42 0.24 0.61 0.36 0.059 0.71 0.99 0.61 0.81
    OR Quart 3 3.1 4.2 5.5 2.8 1.6 6.1 27 48 23
    OR Quart 4 1.0 1.3 1.6 1.3 1.2 1.8 3.5 0.98 2.7
    p Value 0.93 0.71 0.41 0.61 0.79 0.28 0.14 0.99 0.26
    95% CI of 0.38 0.33 0.53 0.48 0.37 0.61 0.65 0.060 0.48
    OR Quart 4 2.9 5.1 4.8 3.5 3.7 5.4 19 16 15
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 8090 7910 8090 7810 8090 6760
    Average 11100 9090 11100 9460 11100 7180
    Stdev 15800 5160 15800 4940 15800 2560
    p (t-test) 0.41 0.52 0.30
    Min 3720 3140 3720 4110 3720 3790
    Max 153000 32000 153000 26100 153000 14300
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 7990 8380 7990 7560 7990 6380
    Average 10200 10500 10200 21300 10200 7330
    Stdev 14900 7740 14900 49000 14900 2720
    p (t-test) 0.94 0.020 0.56
    Min 3640 3020 3640 3140 3640 5310
    Max 166000 32000 166000 216000 166000 14300
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 8040 7390 8040 7820 8040 6900
    Average 11500 8180 11500 8500 11500 6830
    Stdev 15500 3310 15500 3670 15500 2010
    p (t-test) 0.20 0.23 0.25
    Min 3900 3140 3900 4110 3900 3790
    Max 153000 19800 153000 26100 153000 11800
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 0.51 0.43 0.47 0.51 0.45 0.31 0.34 0.30
    SE 0.053 0.080 0.056 0.054 0.071 0.054 0.074 0.10 0.079
    p 0.33 0.93 0.19 0.60 0.87 0.33 0.0082 0.11 0.013
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 6200 6200 6340 6710 6110 6690 5920 6010 5440
    Sens 1 71% 71% 70% 71% 72% 71% 72% 78% 73%
    Spec 1 19% 24% 23% 28% 22% 30% 13% 20% 11%
    Cutoff 2 5620 5310 5570 6250 5560 6210 5050 5920 5140
    Sens 2 80% 86% 81% 81% 83% 80% 83% 89% 80%
    Spec 2 10% 12% 11% 19% 14% 21%  6% 19%  8%
    Cutoff 3 5230 4920 5230 5070 4780 5620 3900 5300 4330
    Sens 3 91% 93% 92% 90% 94% 90% 94% 100%  93%
    Spec 3  7%  7%  9%  6%  6% 12%  2% 11%  2%
    Cutoff 4 9710 9520 10000 9710 9520 10000 9710 9520 10000
    Sens 4 29% 29% 19% 26% 33% 17% 11% 11%  7%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 11000 10600 11300 11000 10600 11300 11000 10600 11300
    Sens 5 16% 21% 11% 21% 33% 12% 11% 11%  7%
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81%
    Cutoff 6 15300 14200 18800 15300 14200 18800 15300 14200 18800
    Sens 6  9% 21%  3% 12% 28%  2%  0% 11%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.1 0.72 1.6 0.74 0.63 1.8 0.48 0 1.0
    p Value 0.79 0.68 0.41 0.58 0.49 0.28 0.56 na 0.98
    95% CI of 0.41 0.15 0.53 0.25 0.17 0.61 0.041 na 0.062
    OR Quart 2 3.2 3.4 4.8 2.2 2.4 5.4 5.6 na 17
    OR Quart 3 1.0 0.72 1.4 1.7 0.31 2.3 4.3 4.2 8.8
    p Value 1.0 0.68 0.57 0.31 0.16 0.12 0.086 0.20 0.049
    95% CI of 0.35 0.15 0.45 0.61 0.059 0.80 0.81 0.46 1.0
    OR Quart 3 2.8 3.4 4.3 4.6 1.6 6.8 23 39 77
    OR Quart 4 1.8 0.98 1.8 1.0 0.98 1.6 5.2 4.3 7.6
    p Value 0.27 0.98 0.28 1.0 0.98 0.41 0.051 0.20 0.070
    95% CI of 0.64 0.23 0.61 0.35 0.30 0.53 0.99 0.47 0.85
    OR Quart 4 4.8 4.1 5.5 2.8 3.2 4.8 27 40 67
    Lutropin subunit beta
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 4.52 3.87 4.52 4.46 4.52 1.63
    Average 7.77 7.10 7.77 5.30 7.77 2.03
    Stdev 10.8 10.6 10.8 4.52 10.8 2.17
    p (t-test) 0.79 0.25 0.14
    Min 0.00783 0.0399 0.00783 0.00467 0.00783 4.11E−5
    Max 66.0 50.0 66.0 16.5 66.0 6.33
    n (Samp) 68 25 68 27 68 8
    n (Patient) 43 25 43 27 43 8
    sCr only
    Median 3.65 5.59 3.65 4.50 nd nd
    Average 7.37 6.27 7.37 5.90 nd nd
    Stdev 11.4 4.33 11.4 4.44 nd nd
    p (t-test) 0.80 0.74 nd nd
    Min 4.11E−5 1.36 4.11E−5 1.58 nd nd
    Max 66.0 15.3 66.0 14.5 nd nd
    n (Samp) 153 7 153 7 nd nd
    n (Patient) 89 7 89 7 nd nd
    UO only
    Median 4.52 3.40 4.52 4.46 4.52 1.22
    Average 7.66 7.21 7.66 5.08 7.66 1.87
    Stdev 10.3 11.7 10.3 4.52 10.3 2.19
    p (t-test) 0.87 0.21 0.12
    Min 0.0621 0.0399 0.0621 0.00467 0.0621 4.11E−5
    Max 66.0 50.0 66.0 16.5 66.0 6.33
    n (Samp) 76 20 76 27 76 8
    n (Patient) 43 20 43 27 43 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 0.63 0.42 0.48 0.59 0.45 0.26 nd 0.23
    SE 0.068 0.12 0.074 0.066 0.12 0.066 0.10 nd 0.10
    p 0.58 0.26 0.30 0.78 0.42 0.46 0.024 nd 0.0062
    nCohort 1 68 153 76 68 153 76 68 nd 76
    nCohort 2 25 7 20 27 7 27 8 nd 8
    Cutoff 1 1.85 5.10 1.85 2.38 3.52 1.54 0.471 nd 0.471
    Sens 1 72% 71% 70% 70% 71% 70% 75% nd 75%
    Spec 1 34% 64% 29% 35% 50% 20%  9% nd  7%
    Cutoff 2 1.17 4.12 0.544 1.40 2.38 1.32 4.11E−5 nd 4.11E−5
    Sens 2 80% 86% 80% 81% 86% 81% 88% nd 88%
    Spec 2 25% 55%  9% 25% 41% 20%  0% nd  0%
    Cutoff 3 0.218 1.17 0.134 0.218 1.54 0.158 0 nd 0
    Sens 3 92% 100%  90% 93% 100%  93% 100%  nd 100% 
    Spec 3  6% 29%  4%  6% 33%  4%  0% nd  0%
    Cutoff 4 6.94 6.28 6.94 6.94 6.28 6.94 6.94 nd 6.94
    Sens 4 20% 29% 20% 26% 29% 22%  0% nd  0%
    Spec 4 71% 71% 71% 71% 71% 71% 71% nd 71%
    Cutoff 5 11.6 9.89 9.89 11.6 9.89 9.89 11.6 nd 9.89
    Sens 5 20% 14% 20% 15% 14% 15%  0% nd  0%
    Spec 5 81% 80% 80% 81% 80% 80% 81% nd 80%
    Cutoff 6 22.6 18.0 20.6 22.6 18.0 20.6 22.6 nd 20.6
    Sens 6  4%  0% 10%  0%  0%  0%  0% nd  0%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 1.3 >1.0 1.0 1.2 >3.2 1.2 >1.1 nd >1.0
    p Value 0.67 <0.99 1.0 0.75 <0.32 0.75 <0.97 nd <0.97
    95% CI of 0.35 >0.062 0.22 0.34 >0.32 0.35 >0.061 nd >0.061
    OR Quart 2 5.2 na 4.6 4.4 na 4.3 na nd na
    OR Quart 3 2.0 >5.7 1.7 1.5 >2.1 0.79 >5.1 nd >2.2
    p Value 0.29 <0.12 0.48 0.53 <0.55 0.73 <0.17 nd <0.53
    95% CI of 0.55 >0.64 0.40 0.43 >0.18 0.21 >0.51 nd >0.19
    OR Quart 3 7.5 na 6.9 5.3 na 3.0 na nd na
    OR Quart 4 1.3 >1.0 1.7 1.1 >2.1 1.9 >3.6 nd >6.6
    p Value 0.67 <0.99 0.48 0.93 <0.55 0.31 <0.29 nd <0.10
    95% CI of 0.35 >0.062 0.40 0.29 >0.18 0.55 >0.34 nd >0.70
    OR Quart 4 5.2 na 6.9 3.9 na 6.4 na nd na
    Interstitial collagenase
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 54.1 65.2 54.1 46.2 54.1 92.4
    Average 136 206 136 149 136 174
    Stdev 174 477 174 202 174 294
    p (t-test) 0.16 0.68 0.39
    Min 0.0125 0.0125 0.0125 0.0125 0.0125 0.0125
    Max 764 3260 764 760 764 1230
    n (Samp) 121 53 121 52 121 26
    n (Patient) 87 53 87 52 87 26
    sCr only
    Median 53.7 73.9 53.7 65.2 53.7 56.4
    Average 146 98.2 146 145 146 121
    Stdev 271 103 271 213 271 156
    p (t-test) 0.49 0.99 0.77
    Min 0.0125 0.0125 0.0125 0.0131 0.0125 0.0125
    Max 3260 332 3260 760 3260 488
    n (Samp) 287 16 287 15 287 10
    n (Patient) 161 16 161 15 161 10
    UO only
    Median 47.3 82.2 47.3 54.7 47.3 110
    Average 113 236 113 149 113 195
    Stdev 157 524 157 189 157 309
    p (t-test) 0.020 0.19 0.056
    Min 0.0125 0.0131 0.0125 0.0125 0.0125 4.10
    Max 711 3260 711 741 711 1230
    n (Samp) 125 43 125 53 125 23
    n (Patient) 80 43 80 53 80 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.51 0.49 0.59 0.48 0.48 0.54 0.51 0.47 0.61
    SE 0.048 0.075 0.052 0.048 0.077 0.048 0.063 0.095 0.067
    p 0.84 0.86 0.080 0.62 0.78 0.39 0.87 0.73 0.12
    nCohort 1 121 287 125 121 287 125 121 287 125
    nCohort 2 53 16 43 52 15 53 26 10 23
    Cutoff 1 18.5 2.35 31.6 18.2 2.08 20.2 24.3 12.0 38.7
    Sens 1 72% 75% 72% 71% 73% 72% 73% 70% 74%
    Spec 1 24% 15% 39% 23% 15% 33% 31% 23% 43%
    Cutoff 2 5.04 2.08 17.3 1.65 1.45 8.43 10.4 0.0270 24.3
    Sens 2 81% 81% 81% 81% 80% 81% 81% 80% 83%
    Spec 2 13% 15% 30% 12% 14% 23% 18% 10% 37%
    Cutoff 3 0.0281 0.0243 1.65 0.0131 0.0131 0.0270 4.08 0.0125 8.08
    Sens 3 91% 94% 91% 92% 93% 91% 92% 90% 91%
    Spec 3 10%  7% 18%  5%  6% 13% 12%  1% 22%
    Cutoff 4 167 129 105 167 129 105 167 129 105
    Sens 4 34% 31% 47% 29% 33% 34% 27% 40% 52%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 232 218 198 232 218 198 232 218 198
    Sens 5 21% 12% 30% 25% 20% 26% 12% 20% 17%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 354 406 333 354 406 333 354 406 333
    Sens 6 11%  0% 14% 19% 13% 21% 12% 10% 13%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.48 4.4 1.3 0.92 1.0 1.1 0.97 0.24 2.6
    p Value 0.14 0.069 0.60 0.87 0.98 0.87 0.96 0.21 0.19
    95% CI of 0.18 0.89 0.47 0.36 0.24 0.43 0.28 0.027 0.63
    OR Quart 2 1.3 21 3.8 2.3 4.2 2.7 3.3 2.2 11
    OR Quart 3 1.1 0.49 1.5 0.92 0.49 1.0 1.9 0.24 2.6
    p Value 0.82 0.57 0.44 0.87 0.41 1.0 0.29 0.21 0.19
    95% CI of 0.46 0.044 0.54 0.36 0.086 0.39 0.59 0.027 0.63
    OR Quart 3 2.7 5.6 4.2 2.3 2.7 2.6 5.8 2.2 11
    OR Quart 4 0.78 2.6 2.1 1.3 1.3 1.5 0.61 1.0 2.2
    p Value 0.59 0.25 0.14 0.59 0.72 0.40 0.47 0.98 0.29
    95% CI of 0.32 0.50 0.78 0.52 0.33 0.60 0.16 0.24 0.50
    OR Quart 4 1.9 14 5.8 3.1 5.0 3.6 2.4 4.2 9.5
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 186000 192000 186000 182000 186000 174000
    Average 194000 192000 194000 191000 194000 182000
    Stdev 76100 67500 76100 71400 76100 61100
    p (t-test) 0.86 0.86 0.46
    Min 73000 63300 73000 93300 73000 49200
    Max 520000 371000 520000 506000 520000 297000
    n (Samp) 120 53 120 53 120 26
    n (Patient) 86 53 86 53 86 26
    sCr only
    Median 181000 199000 181000 206000 181000 183000
    Average 186000 200000 186000 219000 186000 189000
    Stdev 67200 62800 67200 99400 67200 58600
    p (t-test) 0.44 0.080 0.92
    Min 49200 118000 49200 105000 49200 108000
    Max 520000 316000 520000 506000 520000 280000
    n (Samp) 287 16 287 15 287 10
    n (Patient) 160 16 160 15 160 10
    UO only
    Median 180000 182000 180000 182000 180000 172000
    Average 191000 187000 191000 184000 191000 178000
    Stdev 77000 69700 77000 54300 77000 59400
    p (t-test) 0.72 0.52 0.44
    Min 73000 63300 73000 93300 73000 49200
    Max 520000 371000 520000 337000 520000 297000
    n (Samp) 124 43 124 54 124 23
    n (Patient) 79 43 79 54 79 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.51 0.57 0.49 0.49 0.59 0.50 0.48 0.52 0.48
    SE 0.048 0.076 0.051 0.048 0.079 0.047 0.063 0.094 0.066
    p 0.84 0.33 0.91 0.88 0.23 0.98 0.80 0.80 0.80
    nCohort 1 120 287 124 120 287 124 120 287 124
    nCohort 2 53 16 43 53 15 54 26 10 23
    Cutoff 1 151000 160000 141000 161000 166000 161000 147000 169000 147000
    Sens 1 72% 75% 72% 72% 73% 70% 73% 70% 74%
    Spec 1 31% 36% 23% 36% 40% 37% 26% 40% 28%
    Cutoff 2 133000 125000 119000 135000 164000 133000 125000 144000 125000
    Sens 2 81% 81% 81% 81% 80% 81% 81% 80% 83%
    Spec 2 18% 16% 11% 18% 38% 21% 12% 25% 15%
    Cutoff 3 105000 118000 105000 111000 129000 111000 115000 115000 119000
    Sens 3 91% 94% 91% 91% 93% 91% 92% 90% 91%
    Spec 3  8% 13%  6%  8% 18%  7% 10% 13% 11%
    Cutoff 4 212000 207000 209000 212000 207000 209000 212000 207000 209000
    Sens 4 30% 44% 33% 30% 47% 26% 35% 30% 35%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 227000 227000 228000 227000 227000 228000 227000 227000 228000
    Sens 5 25% 38% 21% 26% 40% 24% 35% 30% 35%
    Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81%
    Cutoff 6 262000 263000 257000 262000 263000 257000 262000 263000 257000
    Sens 6 13% 12% 14%  8% 13%  9% 12% 20%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.80 0.48 1.0 0.66 1.3 1.0 0.18 1.5 0.21
    p Value 0.64 0.40 1.0 0.39 0.71 0.94 0.039 0.65 0.058
    95% CI of 0.32 0.085 0.38 0.26 0.29 0.42 0.037 0.25 0.041
    OR Quart 2 2.0 2.7 2.6 1.7 6.2 2.5 0.92 9.4 1.1
    OR Quart 3 0.80 0.99 0.77 0.84 0.66 0.81 0.86 1.0 0.85
    p Value 0.64 0.98 0.61 0.70 0.65 0.64 0.78 1.0 0.77
    95% CI of 0.32 0.24 0.28 0.34 0.11 0.32 0.29 0.14 0.27
    OR Quart 3 2.0 4.1 2.1 2.1 4.1 2.0 2.5 7.3 2.6
    OR Quart 4 1.1 1.5 1.2 0.93 2.1 1.0 0.75 1.5 0.72
    p Value 0.88 0.53 0.75 0.88 0.32 0.94 0.61 0.66 0.59
    95% CI of 0.44 0.41 0.45 0.38 0.50 0.42 0.25 0.24 0.22
    OR Quart 4 2.6 5.6 3.1 2.3 8.5 2.5 2.3 9.2 2.3
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 358 321 358 367 358 468
    Average 426 373 426 433 426 470
    Stdev 264 206 264 405 264 204
    p (t-test) 0.19 0.89 0.45
    Min 39.4 33.7 39.4 0.189 39.4 91.4
    Max 1540 854 1540 2690 1540 836
    n (Samp) 119 52 119 49 119 24
    n (Patient) 85 52 85 49 85 24
    sCr only
    Median 348 260 348 283 348 425
    Average 399 346 399 503 399 454
    Stdev 245 218 245 670 245 238
    p (t-test) 0.40 0.17 0.49
    Min 0.189 43.4 0.189 33.7 0.189 129
    Max 1540 807 1540 2690 1540 836
    n (Samp) 278 16 278 14 278 10
    n (Patient) 157 16 157 14 157 10
    UO only
    Median 321 321 321 363 321 463
    Average 378 377 378 399 378 444
    Stdev 249 208 249 249 249 209
    p (t-test) 0.99 0.61 0.25
    Min 28.1 33.7 28.1 0.189 28.1 48.9
    Max 1540 854 1540 1260 1540 813
    n (Samp) 123 42 123 50 123 21
    n (Patient) 78 42 78 50 78 21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 0.44 0.52 0.47 0.45 0.53 0.58 0.58 0.61
    SE 0.048 0.076 0.052 0.049 0.081 0.049 0.066 0.096 0.070
    p 0.31 0.43 0.72 0.54 0.54 0.56 0.21 0.42 0.11
    nCohort 1 119 278 123 119 278 123 119 278 123
    nCohort 2 52 16 42 49 14 50 24 10 21
    Cutoff 1 238 194 238 250 220 250 301 277 300
    Sens 1 71% 75% 71% 71% 71% 70% 71% 70% 71%
    Spec 1 24% 21% 32% 27% 25% 35% 35% 37% 45%
    Cutoff 2 218 192 220 202 150 218 259 247 259
    Sens 2 81% 81% 81% 82% 86% 80% 83% 80% 81%
    Spec 2 22% 21% 29% 19% 15% 29% 32% 29% 41%
    Cutoff 3 135 117 135 122 145 122 229 242 211
    Sens 3 90% 94% 90% 92% 93% 90% 92% 90% 90%
    Spec 3 10% 11% 15%  8% 14% 12% 24% 28% 27%
    Cutoff 4 539 497 475 539 497 475 539 497 475
    Sens 4 21% 31% 24% 18% 21% 34% 38% 50% 43%
    Spec 4 71% 70% 71% 71% 70% 71% 71% 70% 71%
    Cutoff 5 618 599 544 618 599 544 618 599 544
    Sens 5 13% 19% 21% 16% 14% 18% 21% 40% 33%
    Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80%
    Cutoff 6 741 721 673 741 721 673 741 721 673
    Sens 6 10%  6% 14%  8% 14% 14%  8% 10% 14%
    Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90%
    OR Quart 2 1.3 0.75 2.5 2.9 0.66 1.1 1.2 4.2 1.4
    p Value 0.63 0.71 0.081 0.035 0.65 0.80 0.76 0.21 0.69
    95% CI of 0.49 0.16 0.89 1.1 0.11 0.42 0.31 0.46 0.28
    OR Quart 2 3.2 3.5 7.1 7.7 4.1 3.0 5.1 38 6.6
    OR Quart 3 1.4 1.0 2.0 1.5 1.7 2.2 1.6 1.0 2.7
    p Value 0.48 1.0 0.19 0.44 0.47 0.11 0.53 1.0 0.18
    95% CI of 0.55 0.24 0.70 0.54 0.39 0.85 0.40 0.061 0.63
    OR Quart 3 3.6 4.2 5.8 4.2 7.5 5.5 6.0 16 11
    OR Quart 4 1.5 1.3 1.3 1.9 1.4 1.2 2.6 4.2 2.7
    p Value 0.43 0.72 0.62 0.21 0.70 0.67 0.15 0.21 0.18
    95% CI of 0.57 0.33 0.44 0.69 0.29 0.47 0.71 0.46 0.63
    OR Quart 4 3.7 5.0 4.0 5.2 6.3 3.3 9.3 38 11
    Thyroxine-binding globulin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 38.2 37.2 38.2 33.1 38.2 32.2
    Average 39.2 36.8 39.2 34.5 39.2 34.4
    Stdev 11.0 10.3 11.0 9.68 11.0 9.33
    p (t-test) 0.15 0.0040 0.034
    Min 13.4 12.8 13.4 13.9 13.4 16.3
    Max 75.8 56.7 75.8 56.1 75.8 51.1
    n (Samp) 262 51 262 55 262 26
    n (Patient) 110 51 110 55 110 26
    sCr only
    Median 36.0 33.2 36.0 33.2 36.0 33.2
    Average 37.2 36.1 37.2 35.1 37.2 35.6
    Stdev 11.3 10.9 11.3 9.71 11.3 7.59
    p (t-test) 0.69 0.42 0.63
    Min 12.8 23.2 12.8 22.7 12.8 26.8
    Max 75.8 63.7 75.8 62.0 75.8 51.1
    n (Samp) 466 18 466 20 466 13
    n (Patient) 180 18 180 20 180 13
    UO only
    Median 36.8 34.2 36.8 33.2 36.8 32.1
    Average 38.0 35.7 38.0 34.3 38.0 34.2
    Stdev 10.4 10.8 10.4 9.95 10.4 10.2
    p (t-test) 0.17 0.023 0.099
    Min 13.4 12.8 13.4 13.9 13.4 16.3
    Max 75.8 56.7 75.8 56.1 75.8 51.1
    n (Samp) 221 50 221 52 221 23
    n (Patient) 91 50 91 52 91 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.44 0.45 0.44 0.38 0.43 0.40 0.37 0.46 0.40
    SE 0.045 0.071 0.046 0.043 0.068 0.045 0.061 0.083 0.065
    p 0.22 0.52 0.23 0.0041 0.30 0.030 0.037 0.61 0.14
    nCohort 1 262 466 221 262 466 221 262 466 221
    nCohort 2 51 18 50 55 20 52 26 13 23
    Cutoff 1 29.1 28.0 29.1 28.7 28.5 27.9 28.1 29.8 28.0
    Sens 1 71% 72% 70% 71% 70% 71% 73% 77% 74%
    Spec 1 19% 22% 22% 18% 24% 16% 15% 28% 16%
    Cutoff 2 26.5 26.7 26.5 26.5 28.3 25.0 27.8 29.4 27.4
    Sens 2 80% 83% 80% 80% 80% 81% 81% 85% 87%
    Spec 2 11% 18% 12% 11% 23% 10% 14% 27% 14%
    Cutoff 3 24.2 24.4 23.7 22.5 25.7 21.4 26.5 27.8 17.9
    Sens 3 90% 94% 90% 91% 90% 90% 92% 92% 91%
    Spec 3  7% 12%  6%  5% 15%  4% 11% 21%  2%
    Cutoff 4 44.9 43.4 43.6 44.9 43.4 43.6 44.9 43.4 43.6
    Sens 4 25% 22% 28% 18% 20% 19% 19% 15% 22%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 47.3 46.4 46.3 47.3 46.4 46.3 47.3 46.4 46.3
    Sens 5 14% 17% 20% 11% 10% 15%  8% 15% 22%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 52.5 50.3 49.9 52.5 50.3 49.9 52.5 50.3 49.9
    Sens 6  6% 11% 10%  4%  5%  6%  0%  8%  9%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.1 1.7 0.65 1.6 0.75 1.1 0.79 1.5 0.58
    p Value 0.80 0.48 0.35 0.33 0.71 0.78 0.73 0.65 0.47
    95% CI of 0.47 0.40 0.26 0.62 0.16 0.45 0.20 0.25 0.13
    OR Quart 2 2.6 7.3 1.6 4.2 3.4 2.9 3.1 9.2 2.5
    OR Quart 3 0.73 1.0 0.91 1.9 1.5 1.3 1.4 3.1 1.5
    p Value 0.50 1.0 0.82 0.16 0.52 0.62 0.55 0.17 0.54
    95% CI of 0.29 0.20 0.38 0.76 0.42 0.51 0.44 0.61 0.43
    OR Quart 3 1.8 5.1 2.2 4.9 5.5 3.2 4.8 16 4.9
    OR Quart 4 1.6 2.4 1.3 3.3 1.8 2.3 2.2 1.0 1.7
    p Value 0.29 0.21 0.50 0.0089 0.35 0.058 0.18 0.99 0.38
    95% CI of 0.69 0.61 0.58 1.3 0.52 0.97 0.70 0.14 0.52
    OR Quart 4 3.5 9.6 3.0 7.9 6.4 5.4 6.7 7.3 5.5
    Pigment epithelium-derived factor
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1630 1820 1630 1420 1630 1640
    Average 1720 2180 1720 1690 1720 1580
    Stdev 753 1290 753 987 753 695
    p (t-test) 0.0042 0.78 0.36
    Min 445 317 445 339 445 347
    Max 4240 5620 4240 4750 4240 3400
    n (Samp) 121 53 121 53 121 26
    n (Patient) 87 53 87 53 87 26
    sCr only
    Median 1660 1950 1660 1670 1660 1960
    Average 1920 2130 1920 1820 1920 2000
    Stdev 1150 1270 1150 1050 1150 998
    p (t-test) 0.47 0.77 0.82
    Min 84.2 328 84.2 629 84.2 813
    Max 7450 4300 7450 4910 7450 4360
    n (Samp) 288 16 288 15 288 10
    n (Patient) 161 16 161 15 161 10
    UO only
    Median 1560 1740 1560 1400 1560 1510
    Average 1720 2200 1720 1690 1720 1480
    Stdev 787 1320 787 1020 787 701
    p (t-test) 0.0046 0.87 0.19
    Min 328 317 328 339 328 347
    Max 4510 5620 4510 4750 4510 3400
    n (Samp) 125 43 125 54 125 23
    n (Patient) 80 43 80 54 80 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.58 0.55 0.59 0.44 0.49 0.45 0.47 0.57 0.43
    SE 0.048 0.076 0.052 0.048 0.077 0.047 0.063 0.096 0.067
    p 0.082 0.52 0.067 0.24 0.88 0.28 0.63 0.49 0.30
    nCohort 1 121 288 125 121 288 125 121 288 125
    nCohort 2 53 16 43 53 15 54 26 10 23
    Cutoff 1 1310 1170 1340 1150 1280 1150 1190 1770 1040
    Sens 1 72% 75% 72% 72% 73% 70% 73% 70% 74%
    Spec 1 32% 26% 35% 22% 32% 22% 27% 58% 18%
    Cutoff 2 1060 1080 1060 813 1220 812 1030 1450 760
    Sens 2 81% 81% 81% 81% 80% 81% 81% 80% 83%
    Spec 2 19% 22% 20%  8% 29%  7% 17% 41%  7%
    Cutoff 3 974 529 999 733 760 677 591 852 529
    Sens 3 91% 94% 91% 91% 93% 91% 92% 90% 91%
    Spec 3 13%  4% 15%  7%  9%  6%  3% 10%  2%
    Cutoff 4 1970 2080 1970 1970 2080 1970 1970 2080 1970
    Sens 4 45% 44% 44% 25% 33% 28% 27% 30% 17%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 2210 2510 2160 2210 2510 2160 2210 2510 2160
    Sens 5 38% 31% 40% 21% 13% 26% 12% 10%  9%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 2820 3520 2830 2820 3520 2830 2820 3520 2830
    Sens 6 25% 31% 23% 11%  7% 13%  4% 10%  4%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.68 0.74 0.64 0.72 1.7 0.43 2.7 0.49 1.9
    p Value 0.43 0.70 0.42 0.51 0.47 0.095 0.14 0.56 0.33
    95% CI of 0.26 0.16 0.22 0.28 0.39 0.16 0.74 0.043 0.51
    OR Quart 2 1.8 3.4 1.9 1.9 7.4 1.2 9.5 5.5 7.2
    OR Quart 3 0.70 1.0 0.87 1.1 1.4 0.90 1.6 2.1 1.3
    p Value 0.47 1.0 0.79 0.82 0.70 0.82 0.50 0.41 0.72
    95% CI of 0.27 0.24 0.31 0.45 0.29 0.37 0.41 0.37 0.32
    OR Quart 3 1.8 4.2 2.4 2.8 6.3 2.2 6.2 12 5.2
    OR Quart 4 1.9 1.3 2.2 1.4 1.0 1.3 2.0 1.5 1.9
    p Value 0.15 0.73 0.11 0.45 0.99 0.60 0.31 0.66 0.33
    95% CI of 0.80 0.33 0.85 0.58 0.20 0.53 0.53 0.24 0.51
    OR Quart 4 4.6 4.9 5.6 3.5 5.2 3.0 7.5 9.2 7.2
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 96.5 104 96.5 122 96.5 123
    Average 184 201 184 187 184 122
    Stdev 461 420 461 202 461 70.9
    p (t-test) 0.83 0.97 0.57
    Min 12.8 19.4 12.8 12.8 12.8 4.06
    Max 3360 2810 3360 1040 3360 288
    n (Samp) 94 45 94 42 94 18
    n (Patient) 65 45 65 42 65 18
    sCr only
    Median 101 97.7 101 163 101 103
    Average 199 192 199 343 199 115
    Stdev 425 225 425 395 425 71.5
    p (t-test) 0.95 0.17 0.55
    Min 4.06 39.7 4.06 33.2 4.06 56.2
    Max 3360 726 3360 1460 3360 288
    n (Samp) 225 14 225 18 225 9
    n (Patient) 132 14 132 18 132 9
    UO only
    Median 100 96.4 100 101 100 116
    Average 211 184 211 129 211 110
    Stdev 468 447 468 102 468 66.6
    p (t-test) 0.76 0.27 0.41
    Min 12.8 19.4 12.8 12.8 12.8 4.06
    Max 3360 2810 3360 595 3360 208
    n (Samp) 103 37 103 41 103 15
    n (Patient) 64 37 64 41 64 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 0.51 0.50 0.62 0.66 0.51 0.54 0.46 0.47
    SE 0.053 0.080 0.056 0.054 0.072 0.054 0.076 0.10 0.081
    p 0.32 0.94 0.93 0.031 0.025 0.85 0.56 0.67 0.74
    nCohort 1 94 225 103 94 225 103 94 225 103
    nCohort 2 45 14 37 42 18 41 18 9 15
    Cutoff 1 76.5 76.5 75.6 96.4 104 83.2 84.9 65.4 56.2
    Sens 1 71% 71% 70% 71% 72% 71% 72% 78% 73%
    Spec 1 36% 33% 33% 50% 51% 40% 44% 23% 18%
    Cutoff 2 74.6 62.3 73.4 83.2 82.7 68.4 56.2 56.6 54.3
    Sens 2 80% 86% 81% 81% 83% 80% 83% 89% 80%
    Spec 2 34% 20% 31% 41% 36% 28% 19% 16% 17%
    Cutoff 3 62.3 53.7 62.3 68.4 50.8 47.2 34.2 54.3 36.7
    Sens 3 91% 93% 92% 90% 94% 90% 94% 100%  93%
    Spec 3 24% 13% 23% 31% 12% 15% 10% 14% 11%
    Cutoff 4 145 151 149 145 151 149 145 151 149
    Sens 4 29% 21% 19% 33% 56% 20% 33% 11% 40%
    Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71%
    Cutoff 5 178 205 192 178 205 192 178 205 192
    Sens 5 16% 21% 11% 24% 33% 15% 22% 11% 13%
    Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81%
    Cutoff 6 258 285 318 258 285 318 258 285 318
    Sens 6 11% 21%  3% 17% 33%  5%  6% 11%  0%
    Spec 6 90% 91% 90% 90% 91% 90% 90% 91% 90%
    OR Quart 2 5.5 0.72 3.2 4.1 1.5 1.8 0.17 4.3 1.0
    p Value 0.0040 0.68 0.039 0.028 0.66 0.30 0.12 0.20 0.96
    95% CI of 1.7 0.15 1.1 1.2 0.24 0.61 0.019 0.47 0.23
    OR Quart 2 17 3.4 9.8 14 9.3 5.0 1.6 40 4.6
    OR Quart 3 3.4 0.98 1.9 5.2 2.6 2.2 1.5 1.0 0.22
    p Value 0.039 0.98 0.26 0.0091 0.27 0.13 0.52 1.0 0.19
    95% CI of 1.1 0.23 0.62 1.5 0.48 0.79 0.42 0.061 0.024
    OR Quart 3 11 4.1 6.1 18 14 6.3 5.6 16 2.1
    OR Quart 4 2.3 0.72 1.2 4.1 4.4 0.84 1.0 3.2 1.7
    p Value 0.17 0.68 0.76 0.028 0.069 0.77 1.0 0.32 0.45
    95% CI of 0.70 0.15 0.36 1.2 0.89 0.27 0.25 0.32 0.42
    OR Quart 4 7.7 3.4 4.0 14 22 2.6 3.9 31 6.8
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.324 0.333 0.324 0.394 0.324 0.477
    Average 0.366 0.334 0.366 0.418 0.366 0.480
    Stdev 0.364 0.323 0.364 0.325 0.364 0.292
    p (t-test) 0.58 0.37 0.14
    Min 0.00580 0.00580 0.00580 0.00580 0.00580 0.00580
    Max 1.81 1.31 1.81 1.53 1.81 1.42
    n (Samp) 121 53 121 53 121 26
    n (Patient) 87 53 87 53 87 26
    sCr only
    Median 0.329 0.438 0.329 0.547 0.329 0.484
    Average 0.355 0.401 0.355 0.502 0.355 0.488
    Stdev 0.344 0.363 0.344 0.401 0.344 0.316
    p (t-test) 0.61 0.11 0.23
    Min 0.00580 0.00580 0.00580 0.00580 0.00580 0.00580
    Max 1.81 1.11 1.81 1.40 1.81 0.979
    n (Samp) 288 16 288 15 288 10
    n (Patient) 161 16 161 15 161 10
    UO only
    Median 0.309 0.289 0.309 0.400 0.309 0.445
    Average 0.341 0.311 0.341 0.444 0.341 0.437
    Stdev 0.366 0.308 0.366 0.352 0.366 0.303
    p (t-test) 0.63 0.082 0.24
    Min 0.00580 0.00580 0.00580 0.00580 0.00580 0.00580
    Max 1.81 1.31 1.81 1.53 1.81 1.42
    n (Samp) 125 43 125 54 125 23
    n (Patient) 80 43 80 54 80 23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.48 0.56 0.49 0.57 0.61 0.60 0.64 0.65 0.62
    SE 0.048 0.076 0.051 0.048 0.079 0.047 0.063 0.096 0.067
    p 0.70 0.47 0.81 0.16 0.18 0.028 0.029 0.12 0.073
    nCohort 1 121 288 125 121 288 125 121 288 125
    nCohort 2 53 16 43 53 15 54 26 10 23
    Cutoff 1 0.00580 0.00580 0.00580 0.272 0.207 0.272 0.347 0.392 0.272
    Sens 1 79% 88% 79% 72% 73% 72% 73% 70% 74%
    Spec 1 16% 16% 19% 42% 39% 46% 55% 62% 46%
    Cutoff 2 0 0.00580 0 0.00580 0 0.00580 0.272 0.387 0.173
    Sens 2 100%  88% 100%  89% 100%  93% 81% 80% 83%
    Spec 2  0% 16%  0% 16%  0% 19% 42% 61% 42%
    Cutoff 3 0 0 0 0 0 0.00580 0.0850 0.00580 0.0687
    Sens 3 100%  100%  100%  100%  100%  93% 92% 90% 91%
    Spec 3  0%  0%  0%  0%  0% 19% 31% 16% 38%
    Cutoff 4 0.446 0.485 0.446 0.446 0.485 0.446 0.446 0.485 0.446
    Sens 4 32% 50% 28% 38% 60% 39% 50% 50% 48%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 0.607 0.585 0.588 0.607 0.585 0.588 0.607 0.585 0.588
    Sens 5 17% 31% 14% 21% 40% 26% 27% 40% 22%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 0.836 0.767 0.836 0.836 0.767 0.836 0.836 0.767 0.836
    Sens 6  8% 12%  7%  8% 20% 11%  8% 20%  4%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.3 2.1 1.5 1.8 0.24 1.6 6.8 0 8.4
    p Value 0.59 0.41 0.45 0.24 0.20 0.34 0.084 na 0.052
    95% CI of 0.52 0.37 0.54 0.67 0.026 0.60 0.77 na 0.98
    OR Quart 2 3.1 12 4.0 5.0 2.2 4.5 59 na 72
    OR Quart 3 0.79 2.6 1.6 2.6 0.73 2.7 13 2.1 8.4
    p Value 0.63 0.26 0.32 0.058 0.69 0.043 0.018 0.41 0.052
    95% CI of 0.31 0.49 0.61 0.97 0.16 1.0 1.6 0.37 0.98
    OR Quart 3 2.0 14 4.4 6.9 3.4 7.2 110 12 72
    OR Quart 4 1.2 2.6 1.0 2.5 1.8 2.7 11 2.0 9.9
    p Value 0.76 0.26 1.0 0.068 0.36 0.043 0.026 0.42 0.035
    95% CI of 0.46 0.49 0.35 0.94 0.50 1.0 1.3 0.36 1.2
    OR Quart 4 2.9 14 2.8 6.7 6.4 7.2 94 11 84
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 53900 51900 53900 41500 53900 28700
    Average 66800 69000 66800 53100 66800 33700
    Stdev 47000 50500 47000 43200 47000 20200
    p (t-test) 0.76 0.051 4.4E−4
    Min 8630 13000 8630 10300 8630 4980
    Max 260000 244000 260000 232000 260000 73300
    n (Samp) 145 64 145 62 145 27
    n (Patient) 111 64 111 62 111 27
    sCr only
    Median 49300 50300 49300 51700 49300 49300
    Average 61100 60300 61100 70300 61100 47800
    Stdev 44800 37100 44800 61900 44800 22100
    p (t-test) 0.94 0.38 0.29
    Min 1940 20700 1940 13500 1940 4980
    Max 260000 147000 260000 232000 260000 75700
    n (Samp) 341 19 341 20 341 13
    n (Patient) 193 19 193 20 193 13
    UO only
    Median 53200 49900 53200 41200 53200 26000
    Average 64500 69900 64500 45600 64500 28600
    Stdev 43200 52200 43200 26400 43200 15400
    p (t-test) 0.46 0.0024 8.5E−5
    Min 4980 13000 4980 10300 4980 5170
    Max 218000 244000 218000 132000 218000 68300
    n (Samp) 151 54 151 56 151 24
    n (Patient) 103 54 103 56 103 24
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.50 0.51 0.51 0.39 0.50 0.37 0.23 0.46 0.18
    SE 0.043 0.068 0.046 0.044 0.067 0.045 0.056 0.083 0.055
    p 0.99 0.91 0.81 0.0095 0.95 0.0039 2.0E−6 0.65 8.4E−9
    nCohort 1 145 341 151 145 341 151 145 341 151
    nCohort 2 64 19 54 62 20 56 27 13 24
    Cutoff 1 39600 29600 39600 25800 33900 27000 23900 34000 19800
    Sens 1 70% 74% 70% 71% 70% 71% 70% 77% 75%
    Spec 1 31% 22% 33%  8% 29% 14%  7% 30%  9%
    Cutoff 2 27200 25600 29100 19600 20200 23500 16400 28600 16500
    Sens 2 81% 84% 81% 81% 80% 80% 81% 85% 83%
    Spec 2 10% 16% 17%  6% 11% 10%  5% 20%  7%
    Cutoff 3 20700 23900 20200 14300 19100 13800 8630 15100 13800
    Sens 3 91% 95% 91% 90% 90% 91% 93% 92% 92%
    Spec 3  6% 14%  9%  3% 10%  3%  1%  7%  3%
    Cutoff 4 76000 67600 76000 76000 67600 76000 76000 67600 76000
    Sens 4 34% 32% 35% 19% 35% 14%  0% 23%  0%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 90100 86400 92000 90100 86400 92000 90100 86400 92000
    Sens 5 27% 26% 26% 11% 30%  4%  0%  0%  0%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 131000 113000 120000 131000 113000 120000 131000 113000 120000
    Sens 6 12% 11% 13%  6% 20%  2%  0%  0%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.70 0.48 1.2 1.2 0.65 2.0 >7.0 >7.7 >2.1
    p Value 0.40 0.31 0.66 0.65 0.52 0.15 <0.078 <0.059 <0.55
    95% CI of 0.30 0.12 0.51 0.50 0.18 0.77 >0.80 >0.93 >0.18
    OR Quart 2 1.6 2.0 2.9 3.0 2.4 5.4 na na na
    OR Quart 3 0.63 0.65 0.80 1.1 0.65 2.0 >5.7 >3.1 >6.9
    p Value 0.29 0.52 0.64 0.82 0.52 0.15 <0.12 <0.33 <0.079
    95% CI of 0.27 0.18 0.32 0.45 0.18 0.77 >0.63 >0.32 >0.80
    OR Quart 3 1.5 2.4 2.0 2.7 2.4 5.4 na na na
    OR Quart 4 1.1 1.0 1.2 2.7 0.99 3.5 >25 >3.1 >26
    p Value 0.89 1.0 0.70 0.020 0.98 0.0083 <0.0022 <0.33 <0.0021
    95% CI of 0.47 0.31 0.50 1.2 0.31 1.4 >3.2 >0.32 >3.3
    OR Quart 4 2.4 3.2 2.8 6.4 3.2 9.1 na na na
    Apolipoprotein(a)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 47000 38500 47000 29800 47000 41500
    Average 76700 78000 76700 72900 76700 82500
    Stdev 99200 105000 99200 123000 99200 106000
    p (t-test) 0.93 0.82 0.78
    Min 7.99 1060 7.99 20.1 7.99 341
    Max 631000 560000 631000 722000 631000 382000
    n (Samp) 145 64 145 62 145 27
    n (Patient) 111 64 111 62 111 27
    sCr only
    Median 41400 53200 41400 46900 41400 49600
    Average 80100 84900 80100 109000 80100 94500
    Stdev 102000 88500 102000 167000 102000 129000
    p (t-test) 0.84 0.24 0.62
    Min 7.99 2390 7.99 20.1 7.99 341
    Max 631000 309000 631000 722000 631000 382000
    n (Samp) 341 19 341 20 341 13
    n (Patient) 193 19 193 20 193 13
    UO only
    Median 51100 29500 51100 22200 51100 29300
    Average 75400 68600 75400 61700 75400 55600
    Stdev 94800 104000 94800 92400 94800 68400
    p (t-test) 0.66 0.35 0.33
    Min 7.99 1060 7.99 977 7.99 1300
    Max 631000 560000 631000 512000 631000 290000
    n (Samp) 151 54 151 56 151 24
    n (Patient) 103 54 103 56 103 24
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.49 0.55 0.43 0.44 0.53 0.41 0.49 0.49 0.43
    SE 0.044 0.070 0.046 0.044 0.068 0.046 0.061 0.082 0.065
    p 0.75 0.48 0.12 0.20 0.63 0.052 0.88 0.89 0.27
    nCohort 1 145 341 151 145 341 151 145 341 151
    nCohort 2 64 19 54 62 20 56 27 13 24
    Cutoff 1 14100 32400 11100 10500 25900 8730 16800 4700 15300
    Sens 1 70% 74% 70% 71% 70% 71% 70% 77% 71%
    Spec 1 29% 45% 19% 21% 40% 15% 32% 11% 28%
    Cutoff 2 8730 15600 6840 5630 15300 5630 5630 4300 5630
    Sens 2 81% 84% 81% 81% 80% 80% 81% 85% 83%
    Spec 2 18% 31% 11% 12% 31%  9% 12%  9%  9%
    Cutoff 3 4980 2640 4320 2640 4700 2640 1810 1680 3010
    Sens 3 91% 95% 91% 90% 90% 91% 93% 92% 92%
    Spec 3  8%  6%  5%  6% 11%  4%  6%  4%  5%
    Cutoff 4 80900 89900 81800 80900 89900 81800 80900 89900 81800
    Sens 4 27% 32% 22% 23% 30% 23% 33% 31% 25%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 122000 125000 112000 122000 125000 112000 122000 125000 112000
    Sens 5 19% 21% 19% 16% 30% 18% 22% 23% 17%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 209000 214000 180000 209000 214000 180000 209000 214000 180000
    Sens 6 11% 11% 11% 10% 15%  7% 11% 15%  4%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.85 1.7 0.91 0.90 1.3 0.55 0.58 0.75 0.46
    p Value 0.71 0.47 0.85 0.82 0.73 0.23 0.37 0.71 0.30
    95% CI of 0.36 0.40 0.35 0.38 0.33 0.20 0.17 0.16 0.11
    OR Quart 2 2.0 7.4 2.4 2.2 4.9 1.5 1.9 3.5 2.0
    OR Quart 3 1.0 2.1 1.6 1.2 1.3 1.5 0.71 0.49 1.4
    p Value 0.95 0.31 0.34 0.67 0.73 0.39 0.56 0.42 0.56
    95% CI of 0.45 0.50 0.63 0.52 0.33 0.62 0.22 0.087 0.44
    OR Quart 3 2.4 8.6 3.8 2.8 4.9 3.4 2.3 2.7 4.5
    OR Quart 4 1.2 1.7 2.0 1.6 1.5 1.6 1.0 1.0 1.2
    p Value 0.63 0.47 0.11 0.26 0.53 0.26 1.0 0.99 0.73
    95% CI of 0.54 0.40 0.84 0.70 0.41 0.70 0.34 0.24 0.38
    OR Quart 4 2.8 7.4 4.9 3.7 5.6 3.8 3.0 4.2 4.0
  • FIG. 6: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2.
  •
    Complement C4-B
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 70800 86100 70800 78800 70800 59900
    Average 76600 85000 76600 83100 76600 71500
    Stdev 39900 53500 39900 52600 39900 39100
    p (t-test) 0.42 0.43 0.58
    Min 305 7620 305 5510 305 10700
    Max 223000 172000 223000 214000 223000 140000
    n (Samp) 282 16 282 28 282 20
    n (Patient) 160 16 160 28 160 20
    sCr only
    Median nd nd nd nd 72400 112000
    Average nd nd nd nd 77600 104000
    Stdev nd nd nd nd 41600 51900
    p (t-test) nd nd nd nd 0.13
    Min nd nd nd nd 305 15300
    Max nd nd nd nd 223000 161000
    n (Samp) nd nd nd nd 353 6
    n (Patient) nd nd nd nd 193 6
    UO only
    Median 66200 84700 66200 67900 66200 59300
    Average 73700 80900 73700 81800 73700 69000
    Stdev 38600 57100 38600 54200 38600 35600
    p (t-test) 0.53 0.33 0.62
    Min 305 7620 305 5510 305 10700
    Max 223000 172000 223000 214000 223000 126000
    n (Samp) 258 13 258 26 258 17
    n (Patient) 140 13 140 26 140 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.54 nd 0.52 0.52 nd 0.52 0.47 0.68 0.47
    SE 0.076 nd 0.083 0.058 nd 0.060 0.068 0.12 0.073
    p 0.57 nd 0.83 0.74 nd 0.75 0.67 0.14 0.73
    nCohort 1 282 nd 258 282 nd 258 282 353 258
    nCohort 2 16 nd 13 28 nd 26 20 6 17
    Cutoff 1 39400 nd 32200 46200 nd 45900 50900 81100 50900
    Sens 1 75% nd 77% 71% nd 73% 70% 83% 71%
    Spec 1 19% nd 13% 24% nd 26% 30% 57% 33%
    Cutoff 2 32200 nd 29600 34900 nd 34900 39400 81100 39400
    Sens 2 81% nd 85% 82% nd 81% 80% 83% 82%
    Spec 2 12% nd 10% 15% nd 16% 19% 57% 20%
    Cutoff 3 7620 nd 7620 23300 nd 23300 21400 13500 21400
    Sens 3 94% nd 92% 93% nd 92% 90% 100%  94%
    Spec 3  2% nd  3%  6% nd  6%  5%  4%  5%
    Cutoff 4 96100 nd 90900 96100 nd 90900 96100 100000 90900
    Sens 4 38% nd 38% 36% nd 42% 35% 50% 29%
    Spec 4 70% nd 70% 70% nd 70% 70% 70% 70%
    Cutoff 5 111000 nd 108000 111000 nd 108000 111000 113000 108000
    Sens 5 31% nd 38% 32% nd 35% 25% 50% 24%
    Spec 5 80% nd 80% 80% nd 80% 80% 80% 80%
    Cutoff 6 132000 nd 131000 132000 nd 131000 132000 132000 131000
    Sens 6 25% nd 23% 14% nd 12%  5% 33%  0%
    Spec 6 90% nd 90% 90% nd 90% 90% 90% 90%
    OR Quart 2 0.19 nd 0.19 0.59 nd 0.84 0.80 0 0.74
    p Value 0.13 nd 0.13 0.38 nd 0.77 0.75 na 0.70
    95% CI of 0.021 nd 0.021 0.18 nd 0.27 0.21 na 0.16
    OR Quart 2 1.6 nd 1.6 1.9 nd 2.6 3.1 na 3.4
    OR Quart 3 0.79 nd 0.38 0.73 nd 0.40 1.0 2.0 1.5
    p Value 0.73 nd 0.25 0.58 nd 0.20 1.0 0.57 0.51
    95% CI of 0.20 nd 0.070 0.24 nd 0.100 0.28 0.18 0.42
    OR Quart 3 3.1 nd 2.0 2.2 nd 1.6 3.6 22 5.7
    OR Quart 4 1.2 nd 0.98 1.1 nd 1.5 1.2 3.0 1.0
    p Value 0.77 nd 0.98 0.82 nd 0.44 0.74 0.34 0.98
    95% CI of 0.35 nd 0.27 0.41 nd 0.54 0.36 0.31 0.24
    OR Quart 4 4.1 nd 3.6 3.1 nd 4.2 4.2 30 4.2
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.620 0.804 0.620 0.712 0.620 0.620
    Average 7.83 22.1 7.83 11.9 7.83 10.9
    Stdev 19.8 46.2 19.8 21.0 19.8 18.8
    p (t-test) 0.015 0.31 0.54
    Min 0.193 0.193 0.193 0.193 0.193 0.193
    Max 166 181 166 79.4 166 60.8
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 0.620 0.804 0.620 0.512 0.620 0.620
    Average 8.13 24.1 8.13 10.6 8.13 10.8
    Stdev 21.4 51.2 21.4 20.6 21.4 19.8
    p (t-test) 0.022 0.56 0.65
    Min 0.193 0.193 0.193 0.193 0.193 0.193
    Max 166 181 166 79.4 166 60.8
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.58 nd 0.56 0.52 nd 0.51 0.57 nd 0.55
    SE 0.077 nd 0.085 0.059 nd 0.058 0.075 nd 0.079
    p 0.30 nd 0.48 0.69 nd 0.93 0.37 nd 0.57
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 0.308 nd 0 0.193 nd 0.193 0.308 nd 0.308
    Sens 1 75% nd 100%  86% nd 86% 88% nd 87%
    Spec 1 30% nd  0% 18% nd 20% 30% nd 32%
    Cutoff 2 0 nd 0 0.193 nd 0.193 0.308 nd 0.308
    Sens 2 100%  nd 100%  86% nd 86% 88% nd 87%
    Spec 2  0% nd  0% 18% nd 20% 30% nd 32%
    Cutoff 3 0 nd 0 0 nd 0 0.193 nd 0.193
    Sens 3 100%  nd 100%  100%  nd 100%  94% nd 93%
    Spec 3  0% nd  0%  0% nd  0% 18% nd 20%
    Cutoff 4 2.71 nd 2.32 2.71 nd 2.32 2.71 nd 2.32
    Sens 4 44% nd 38% 32% nd 34% 29% nd 27%
    Spec 4 71% nd 71% 71% nd 71% 71% nd 71%
    Cutoff 5 11.7 nd 9.52 11.7 nd 9.52 11.7 nd 9.52
    Sens 5 38% nd 31% 29% nd 24% 29% nd 27%
    Spec 5 80% nd 81% 80% nd 81% 80% nd 81%
    Cutoff 6 19.2 nd 18.9 19.2 nd 18.9 19.2 nd 18.9
    Sens 6 31% nd 31% 25% nd 21% 24% nd 20%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.48 nd 0.24 0.72 nd 1.3 8.9 nd 3.2
    p Value 0.41 nd 0.20 0.57 nd 0.59 0.042 nd 0.17
    95% CI of 0.085 nd 0.025 0.23 nd 0.46 1.1 nd 0.61
    OR Quart 2 2.7 nd 2.2 2.2 nd 3.9 74 nd 17
    OR Quart 3 1.0 nd 1.0 0.72 nd 0.69 3.1 nd 1.5
    p Value 1.0 nd 1.0 0.57 nd 0.54 0.33 nd 0.65
    95% CI of 0.24 nd 0.24 0.23 nd 0.20 0.31 nd 0.25
    OR Quart 3 4.2 nd 4.2 2.2 nd 2.3 31 nd 9.5
    OR Quart 4 1.5 nd 1.0 0.98 nd 1.2 5.3 nd 2.0
    p Value 0.53 nd 1.0 0.97 nd 0.78 0.13 nd 0.42
    95% CI of 0.41 nd 0.24 0.34 nd 0.39 0.60 nd 0.36
    OR Quart 4 5.7 nd 4.2 2.8 nd 3.5 47 nd 12
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 6100 5150 6100 5290 6100 5450
    Average 7380 6360 7380 6050 7380 6270
    Stdev 5900 3290 5900 3460 5900 3330
    p (t-test) 0.49 0.24 0.44
    Min 219 1190 219 1360 219 1500
    Max 43200 12400 43200 16600 43200 12900
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 6100 5110 6100 5810 6100 5450
    Average 7350 6420 7350 6480 7350 6490
    Stdev 5870 3590 5870 3710 5870 3400
    p (t-test) 0.58 0.44 0.58
    Min 219 1190 219 1360 219 1500
    Max 43200 12400 43200 16600 43200 12900
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.49 nd 0.49 0.45 nd 0.48 0.47 nd 0.49
    SE 0.075 nd 0.083 0.059 nd 0.058 0.074 nd 0.078
    p 0.90 nd 0.89 0.38 nd 0.71 0.70 nd 0.93
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 4400 nd 4400 3920 nd 3920 3700 nd 4610
    Sens 1 75% nd 77% 71% nd 72% 71% nd 73%
    Spec 1 32% nd 31% 28% nd 28% 27% nd 34%
    Cutoff 2 4100 nd 4050 3400 nd 3400 3140 nd 3230
    Sens 2 81% nd 85% 82% nd 83% 82% nd 80%
    Spec 2 29% nd 29% 21% nd 21% 17% nd 18%
    Cutoff 3 1630 nd 1630 1810 nd 1810 2780 nd 2780
    Sens 3 94% nd 92% 93% nd 93% 94% nd 93%
    Spec 3  6% nd  6%  6% nd  7% 12% nd 13%
    Cutoff 4 8170 nd 8170 8170 nd 8170 8170 nd 8170
    Sens 4 31% nd 38% 21% nd 24% 29% nd 33%
    Spec 4 70% nd 70% 70% nd 70% 70% nd 70%
    Cutoff 5 9670 nd 9630 9670 nd 9630 9670 nd 9630
    Sens 5 25% nd 31% 14% nd 17% 18% nd 27%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 12600 nd 12600 12600 nd 12600 12600 nd 12600
    Sens 6  0% nd  0%  4% nd  7%  6% nd  7%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.39 nd 0 0.83 nd 1.0 0.59 nd 0.38
    p Value 0.27 nd na 0.77 nd 1.0 0.48 nd 0.27
    95% CI of 0.072 nd na 0.24 nd 0.33 0.13 nd 0.071
    OR Quart 2 2.1 nd na 2.9 nd 3.1 2.6 nd 2.1
    OR Quart 3 1.5 nd 1.2 1.8 nd 1.2 0.79 nd 0.78
    p Value 0.52 nd 0.75 0.27 nd 0.78 0.73 nd 0.73
    95% CI of 0.44 nd 0.35 0.62 nd 0.39 0.20 nd 0.20
    OR Quart 3 5.0 nd 4.3 5.4 nd 3.5 3.1 nd 3.1
    OR Quart 4 0.39 nd 0.38 1.2 nd 1.0 1.0 nd 0.80
    p Value 0.27 nd 0.26 0.75 nd 1.0 0.98 nd 0.75
    95% CI of 0.072 nd 0.070 0.38 nd 0.33 0.28 nd 0.20
    OR Quart 4 2.1 nd 2.0 3.8 nd 3.1 3.7 nd 3.2
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 13.4 13.5 13.4 8.40 13.4 16.4
    Average 17.6 19.9 17.6 14.8 17.6 16.6
    Stdev 24.2 25.8 24.2 23.0 24.2 10.9
    p (t-test) 0.72 0.56 0.86
    Min 0.0320 0.0627 0.0320 0.0627 0.0320 0.0627
    Max 223 95.9 223 121 223 35.3
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 12.2 8.40 12.2 8.40 12.2 17.2
    Average 16.8 19.1 16.8 16.5 16.8 17.7
    Stdev 24.8 28.6 24.8 23.8 24.8 11.7
    p (t-test) 0.75 0.95 0.89
    Min 0.0320 0.0627 0.0320 0.0627 0.0320 0.0627
    Max 223 95.9 223 121 223 35.3
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.51 nd 0.49 0.46 nd 0.50 0.56 nd 0.60
    SE 0.075 nd 0.083 0.059 nd 0.058 0.075 nd 0.080
    p 0.89 nd 0.87 0.45 nd 0.97 0.45 nd 0.21
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 4.47 nd 0.0764 4.03 nd 4.03 9.68 nd 9.68
    Sens 1 75% nd 85% 71% nd 72% 71% nd 73%
    Spec 1 34% nd 18% 31% nd 34% 45% nd 48%
    Cutoff 2 0.0627 nd 0.0764 0.0627 nd 0.0764 5.98 nd 8.88
    Sens 2 88% nd 85% 86% nd 86% 82% nd 80%
    Spec 2 16% nd 18% 16% nd 18% 38% nd 46%
    Cutoff 3 0.0324 nd 0.0324 0.0324 nd 0.0324 0.0627 nd 0.0764
    Sens 3 100%  nd 100%  100%  nd 100%  94% nd 93%
    Spec 3  3% nd  3%  3% nd  3% 16% nd 18%
    Cutoff 4 23.2 nd 20.8 23.2 nd 20.8 23.2 nd 20.8
    Sens 4 19% nd 31% 14% nd 28% 18% nd 47%
    Spec 4 71% nd 71% 71% nd 71% 71% nd 71%
    Cutoff 5 28.1 nd 27.4 28.1 nd 27.4 28.1 nd 27.4
    Sens 5 19% nd 15% 11% nd 14% 18% nd 27%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 38.0 nd 36.7 38.0 nd 36.7 38.0 nd 36.7
    Sens 6 12% nd 15%  4% nd  7%  0% nd  0%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 1.0 nd 1.5 1.9 nd 1.8 2.0 nd 1.5
    p Value 1.0 nd 0.65 0.34 nd 0.29 0.42 nd 0.66
    95% CI of 0.24 nd 0.25 0.52 nd 0.61 0.36 nd 0.24
    OR Quart 2 4.2 nd 9.5 6.8 nd 5.4 12 nd 9.4
    OR Quart 3 1.3 nd 2.7 2.8 nd 1.4 4.5 nd 3.3
    p Value 0.73 nd 0.26 0.093 nd 0.57 0.065 nd 0.16
    95% CI of 0.32 nd 0.49 0.84 nd 0.45 0.91 nd 0.63
    OR Quart 3 5.0 nd 14 9.6 nd 4.3 22 nd 17
    OR Quart 4 0.72 nd 1.5 1.9 nd 0.82 1.5 nd 2.0
    p Value 0.68 nd 0.65 0.34 nd 0.75 0.66 nd 0.42
    95% CI of 0.15 nd 0.25 0.52 nd 0.23 0.24 nd 0.36
    OR Quart 4 3.4 nd 9.5 6.8 nd 2.8 9.3 nd 12
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.93 20.4 2.93 8.48 2.93 2.93
    Average 12.2 19.6 12.2 15.8 12.2 10.9
    Stdev 19.3 15.9 19.3 17.1 19.3 11.5
    p (t-test) 0.15 0.34 0.75
    Min 0.0728 2.43 0.0728 0.572 0.0728 0.572
    Max 158 47.3 158 57.3 158 33.5
    n (Samp) 278 15 278 28 278 20
    n (Patient) 160 15 160 28 160 20
    sCr only
    Median nd nd nd nd 2.93 13.3
    Average nd nd nd nd 12.7 13.9
    Stdev nd nd nd nd 18.5 13.3
    p (t-test) nd nd nd nd 0.87
    Min nd nd nd nd 0.0728 0.572
    Max nd nd nd nd 158 26.9
    n (Samp) nd nd nd nd 347 6
    n (Patient) nd nd nd nd 193 6
    UO only
    Median 2.93 21.7 2.93 8.48 2.93 2.93
    Average 12.2 20.2 12.2 15.2 12.2 9.66
    Stdev 19.5 14.3 19.5 16.1 19.5 11.1
    p (t-test) 0.16 0.45 0.60
    Min 0.0728 2.43 0.0728 0.572 0.0728 0.572
    Max 158 47.3 158 57.3 158 33.5
    n (Samp) 254 12 254 26 254 17
    n (Patient) 140 12 140 26 140 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.68 nd 0.71 0.58 nd 0.57 0.54 0.54 0.51
    SE 0.078 nd 0.086 0.059 nd 0.061 0.068 0.12 0.073
    p 0.018 nd 0.015 0.19 nd 0.23 0.60 0.76 0.84
    nCohort 1 278 nd 254 278 nd 254 278 347 254
    nCohort 2 15 nd 12 28 nd 26 20 6 17
    Cutoff 1 2.43 nd 10.7 0.971 nd 0.971 0.971 0.971 2.43
    Sens 1 73% nd 75% 79% nd 77% 85% 83% 71%
    Spec 1 41% nd 61% 30% nd 29% 30% 27% 39%
    Cutoff 2 0.971 nd 0.971 0.572 nd 0.572 0.971 0.971 0.971
    Sens 2 100%  nd 100%  89% nd 88% 85% 83% 82%
    Spec 2 30% nd 29% 15% nd 15% 30% 27% 29%
    Cutoff 3 0.971 nd 0.971 0.0862 nd 0.0862 0.572 0.0862 0.0862
    Sens 3 100%  nd 100%  100%  nd 100%  90% 100%  100% 
    Spec 3 30% nd 29%  1% nd  1% 15%  1%  1%
    Cutoff 4 14.4 nd 14.4 14.4 nd 14.4 14.4 16.6 14.4
    Sens 4 53% nd 58% 46% nd 46% 40% 50% 35%
    Spec 4 71% nd 71% 71% nd 71% 71% 71% 71%
    Cutoff 5 21.4 nd 20.4 21.4 nd 20.4 21.4 23.1 20.4
    Sens 5 47% nd 50% 32% nd 38% 25% 50% 24%
    Spec 5 81% nd 80% 81% nd 80% 81% 81% 80%
    Cutoff 6 30.3 nd 28.1 30.3 nd 28.1 30.3 31.3 28.1
    Sens 6 27% nd 25% 18% nd 23% 10%  0% 12%
    Spec 6 90% nd 91% 90% nd 91% 90% 90% 91%
    OR Quart 2 >5.4 nd >3.1 1.2 nd 1.4 3.7 2.0 2.8
    p Value <0.13 nd <0.33 0.77 nd 0.55 0.11 0.57 0.14
    95% CI of >0.61 nd >0.31 0.35 nd 0.44 0.74 0.18 0.72
    OR Quart 2 na nd na 4.1 nd 4.8 18 23 11
    OR Quart 3 >2.1 nd >2.1 1.2 nd 0.79 2.6 0 0.65
    p Value <0.56 nd <0.56 0.75 nd 0.73 0.26 na 0.64
    95% CI of >0.18 nd >0.18 0.36 nd 0.20 0.49 na 0.10
    OR Quart 3 na nd na 4.2 nd 3.1 14 na 4.0
    OR Quart 4 >8.8 nd >7.7 2.4 nd 2.2 3.1 3.0 1.3
    p Value <0.042 nd <0.060 0.13 nd 0.18 0.17 0.34 0.71
    95% CI of >1.1 nd >0.92 0.78 nd 0.70 0.61 0.31 0.29
    OR Quart 4 na nd na 7.2 nd 6.7 16 30 6.2
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 14.4 0.488 14.4 0.488 14.4 10.7
    Average 37.5 22.2 37.5 30.1 37.5 27.4
    Stdev 52.0 40.5 52.0 49.6 52.0 39.9
    p (t-test) 0.26 0.47 0.40
    Min 0.204 0.222 0.204 0.204 0.204 0.222
    Max 257 151 257 177 257 149
    n (Samp) 278 15 278 28 278 20
    n (Patient) 160 15 160 28 160 20
    sCr only
    Median nd nd nd nd 12.8 20.6
    Average nd nd nd nd 34.3 50.2
    Stdev nd nd nd nd 48.7 64.5
    p (t-test) nd nd nd nd 0.43
    Min nd nd nd nd 0.204 0.357
    Max nd nd nd nd 257 149
    n (Samp) nd nd nd nd 347 6
    n (Patient) nd nd nd nd 193 6
    UO only
    Median 8.54 1.20 8.54 0.488 8.54 0.488
    Average 32.1 15.1 32.1 24.5 32.1 14.6
    Stdev 49.2 21.2 49.2 38.7 49.2 19.0
    p (t-test) 0.24 0.44 0.15
    Min 0.204 0.222 0.204 0.204 0.204 0.222
    Max 257 66.0 257 126 257 51.0
    n (Samp) 254 12 254 26 254 17
    n (Patient) 140 12 140 26 140 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.41 nd 0.44 0.43 nd 0.44 0.46 0.59 0.42
    SE 0.079 nd 0.088 0.059 nd 0.061 0.068 0.12 0.075
    p 0.27 nd 0.47 0.23 nd 0.35 0.51 0.46 0.29
    nCohort 1 278 nd 254 278 nd 254 278 347 254
    nCohort 2 15 nd 12 28 nd 26 20 6 17
    Cutoff 1 0.316 nd 0.316 0.316 nd 0.222 0.316 0.357 0.222
    Sens 1 80% nd 83% 71% nd 77% 75% 83% 82%
    Spec 1 22% nd 25% 22% nd 18% 22% 28% 18%
    Cutoff 2 0.316 nd 0.316 0.204 nd 0.204 0.222 0.357 0.222
    Sens 2 80% nd 83% 93% nd 92% 85% 83% 82%
    Spec 2 22% nd 25%  5% nd  6% 17% 28% 18%
    Cutoff 3 0.204 nd 0.204 0.204 nd 0.204 0.204 0.316 0.204
    Sens 3 100%  nd 100%  93% nd 92% 100%  100%  100% 
    Spec 3  5% nd  6%  5% nd  6%  5% 23%  6%
    Cutoff 4 43.8 nd 35.0 43.8 nd 35.0 43.8 40.2 35.0
    Sens 4 13% nd  8% 25% nd 31% 20% 33% 24%
    Spec 4 71% nd 70% 71% nd 70% 71% 70% 70%
    Cutoff 5 64.4 nd 55.8 64.4 nd 55.8 64.4 61.6 55.8
    Sens 5 13% nd  8% 18% nd 19% 10% 33%  0%
    Spec 5 80% nd 80% 80% nd 80% 80% 80% 80%
    Cutoff 6 125 nd 105 125 nd 105 125 105 105
    Sens 6  7% nd  0% 11% nd  8%  5% 33%  0%
    Spec 6 90% nd 91% 90% nd 91% 90% 90% 91%
    OR Quart 2 2.1 nd 4.3 0.83 nd 0.65 2.1 >3.1 3.2
    p Value 0.40 nd 0.20 0.77 nd 0.51 0.30 <0.33 0.16
    95% CI of 0.37 nd 0.46 0.24 nd 0.17 0.51 >0.32 0.62
    OR Quart 2 12 nd 39 2.9 nd 2.4 8.8 na 16
    OR Quart 3 1.0 nd 5.3 1.0 nd 1.4 1.7 >1.0 1.5
    p Value 0.99 nd 0.13 1.0 nd 0.57 0.47 <0.99 0.65
    95% CI of 0.14 nd 0.60 0.31 nd 0.45 0.39 >0.062 0.25
    OR Quart 3 7.4 nd 47 3.2 nd 4.2 7.4 na 9.4
    OR Quart 4 3.8 nd 2.1 2.0 nd 1.4 2.1 >2.0 3.2
    p Value 0.10 nd 0.56 0.19 nd 0.57 0.30 <0.57 0.16
    95% CI of 0.77 nd 0.18 0.70 nd 0.45 0.51 >0.18 0.63
    OR Quart 4 19 nd 23 5.7 nd 4.2 8.8 na 17
    Immunoglogulin G4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 414000 444000 414000 250000 414000 70300
    Average 667000 519000 667000 415000 667000 205000
    Stdev 807000 481000 807000 406000 807000 245000
    p (t-test) 0.59 0.17 0.11
    Min 2000 30100 2000 4650 2000 18500
    Max 5190000 1210000 5190000 1350000 5190000 681000
    n (Samp) 205 9 205 20 205 8
    n (Patient) 127 9 127 20 127 8
    UO only
    Median 412000 444000 412000 250000 412000 90700
    Average 642000 519000 642000 442000 642000 227000
    Stdev 750000 481000 750000 418000 750000 255000
    p (t-test) 0.63 0.27 0.15
    Min 2000 30100 2000 4650 2000 18500
    Max 5140000 1210000 5140000 1350000 5140000 681000
    n (Samp) 191 9 191 18 191 7
    n (Patient) 113 9 113 18 113 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 nd 0.47 0.39 nd 0.42 0.24 nd 0.27
    SE 0.10 nd 0.10 0.070 nd 0.073 0.10 nd 0.11
    p 0.71 nd 0.73 0.12 nd 0.26 0.0093 nd 0.034
    nCohort 1 205 nd 191 205 nd 191 205 nd 191
    nCohort 2 9 nd 9 20 nd 18 8 nd 7
    Cutoff 1 83300 nd 83300 206000 nd 206000 37500 nd 37500
    Sens 1 78% nd 78% 70% nd 72% 75% nd 71%
    Spec 1 14% nd 14% 25% nd 27%  6% nd  6%
    Cutoff 2 51700 nd 51700 59500 nd 59500 33600 nd 33600
    Sens 2 89% nd 89% 80% nd 83% 88% nd 86%
    Spec 2  7% nd  7% 10% nd 10%  5% nd  5%
    Cutoff 3 29400 nd 29400 52400 nd 8490 17900 nd 17900
    Sens 3 100%  nd 100%  90% nd 94% 100%  nd 100% 
    Spec 3  4% nd  5%  7% nd  2%  3% nd  3%
    Cutoff 4 731000 nd 731000 731000 nd 731000 731000 nd 731000
    Sens 4 33% nd 33% 15% nd 17%  0% nd  0%
    Spec 4 70% nd 70% 70% nd 70% 70% nd 70%
    Cutoff 5 935000 nd 935000 935000 nd 935000 935000 nd 935000
    Sens 5 33% nd 33% 15% nd 17%  0% nd  0%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 1490000 nd 1380000 1490000 nd 1380000 1490000 nd 1380000
    Sens 6  0% nd  0%  0% nd  0%  0% nd  0%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.67 nd 0.65 1.4 nd 1.4 >2.1 nd >2.1
    p Value 0.66 nd 0.65 0.68 nd 0.68 <0.55 nd <0.54
    95% CI of 0.11 nd 0.10 0.30 nd 0.30 >0.19 nd >0.19
    OR Quart 2 4.2 nd 4.1 6.5 nd 6.5 na nd na
    OR Quart 3 0 nd 0 2.6 nd 2.2 >1.0 nd >1.0
    p Value na nd na 0.19 nd 0.29 <0.98 nd <0.99
    95% CI of na nd na 0.63 nd 0.51 >0.063 nd >0.062
    OR Quart 3 na nd na 10 nd 9.2 na nd na
    OR Quart 4 1.4 nd 1.4 2.2 nd 1.8 >5.6 nd >4.4
    p Value 0.68 nd 0.70 0.29 nd 0.45 <0.12 nd <0.19
    95% CI of 0.30 nd 0.29 0.51 nd 0.40 >0.63 nd >0.48
    OR Quart 4 6.5 nd 6.4 9.1 nd 7.8 na nd na
    Interleukin-21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.430 0.784 0.430 0.630 0.430 1.63
    Average 28.3 2.46 28.3 2.05 28.3 11.1
    Stdev 369 3.78 369 3.54 369 31.5
    p (t-test) 0.78 0.71 0.85
    Min 0.0102 0.0102 0.0102 0.0102 0.0102 0.0102
    Max 5430 12.6 5430 15.6 5430 132
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 0.430 0.605 0.430 0.630 0.430 0.964
    Average 30.7 1.70 30.7 1.61 30.7 11.4
    Stdev 385 2.93 385 2.31 385 33.6
    p (t-test) 0.79 0.68 0.85
    Min 0.0102 0.0102 0.0102 0.0102 0.0102 0.0102
    Max 5430 9.84 5430 8.04 5430 132
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.53 nd 0.46 0.50 nd 0.50 0.62 nd 0.58
    SE 0.076 nd 0.084 0.058 nd 0.058 0.075 nd 0.080
    p 0.67 nd 0.67 0.97 nd 0.94 0.11 nd 0.33
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 0.0182 nd 0.0154 0.0257 nd 0.0257 0.783 nd 0.174
    Sens 1 75% nd 85% 71% nd 72% 71% nd 80%
    Spec 1 26% nd 18% 35% nd 36% 55% nd 40%
    Cutoff 2 0.0154 nd 0.0154 0.0154 nd 0.0154 0.174 nd 0.174
    Sens 2 88% nd 85% 82% nd 83% 82% nd 80%
    Spec 2 18% nd 18% 18% nd 18% 40% nd 40%
    Cutoff 3 0 nd 0 0.0102 nd 0.0102 0 nd 0
    Sens 3 100%  nd 100%  93% nd 93% 100%  nd 100% 
    Spec 3  0% nd  0%  7% nd  6%  0% nd  0%
    Cutoff 4 1.89 nd 1.89 1.89 nd 1.89 1.89 nd 1.89
    Sens 4 38% nd 23% 29% nd 31% 29% nd 27%
    Spec 4 72% nd 72% 72% nd 72% 72% nd 72%
    Cutoff 5 2.75 nd 2.81 2.75 nd 2.81 2.75 nd 2.81
    Sens 5 19% nd 15% 21% nd 17% 29% nd 27%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 6.18 nd 7.58 6.18 nd 7.58 6.18 nd 7.58
    Sens 6 12% nd  8% 11% nd  7% 29% nd 27%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.48 nd 1.4 1.2 nd 0.69 0.32 nd 0.64
    p Value 0.41 nd 0.70 0.77 nd 0.54 0.32 nd 0.63
    95% CI of 0.085 nd 0.29 0.38 nd 0.20 0.032 nd 0.10
    OR Quart 2 2.7 nd 6.4 3.8 nd 2.3 3.1 nd 4.0
    OR Quart 3 1.3 nd 0.65 1.4 nd 1.7 2.9 nd 2.1
    p Value 0.73 nd 0.65 0.57 nd 0.31 0.13 nd 0.30
    95% CI of 0.32 nd 0.10 0.45 nd 0.61 0.74 nd 0.50
    OR Quart 3 5.0 nd 4.1 4.3 nd 4.8 12 nd 9.0
    OR Quart 4 1.2 nd 1.4 1.2 nd 0.84 1.7 nd 1.3
    p Value 0.75 nd 0.70 0.79 nd 0.77 0.48 nd 0.72
    95% CI of 0.32 nd 0.29 0.37 nd 0.26 0.39 nd 0.28
    OR Quart 4 4.9 nd 6.4 3.7 nd 2.7 7.5 nd 6.3
    Interleukin-23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.886 1.10 0.886 1.10 0.886 1.10
    Average 1270 8060 1270 5040 1270 13400
    Stdev 7660 25000 7660 19200 7660 33000
    p (t-test) 0.0080 0.053 3.5E−5
    Min 0.257 0.653 0.257 0.257 0.257 0.603
    Max 100000 100000 100000 100000 100000 100000
    n (Samp) 216 16 216 28 216 17
    n (Patient) 132 16 132 28 132 17
    UO only
    Median 0.886 1.10 0.886 1.10 0.886 72.6
    Average 1350 8370 1350 4290 1350 13800
    Stdev 7990 27600 7990 18500 7990 35000
    p (t-test) 0.017 0.14 1.2E−4
    Min 0.257 0.653 0.257 0.257 0.257 0.603
    Max 100000 100000 100000 100000 100000 100000
    n (Samp) 198 13 198 29 198 15
    n (Patient) 117 13 117 29 117 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.63 nd 0.60 0.54 nd 0.52 0.62 nd 0.63
    SE 0.077 nd 0.085 0.059 nd 0.058 0.075 nd 0.080
    p 0.082 nd 0.24 0.51 nd 0.77 0.12 nd 0.097
    nCohort 1 216 nd 198 216 nd 198 216 nd 198
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 0.770 nd 0.603 0.603 nd 0.603 0.770 nd 0.770
    Sens 1 75% nd 100%  75% nd 72% 71% nd 73%
    Spec 1 41% nd 23% 25% nd 23% 41% nd 41%
    Cutoff 2 0.603 nd 0.603 0 nd 0 0.603 nd 0.603
    Sens 2 100%  nd 100%  100%  nd 100%  88% nd 93%
    Spec 2 25% nd 23%  0% nd  0% 25% nd 23%
    Cutoff 3 0.603 nd 0.603 0 nd 0 0.257 nd 0.603
    Sens 3 100%  nd 100%  100%  nd 100%  100%  nd 93%
    Spec 3 25% nd 23%  0% nd  0% 15% nd 23%
    Cutoff 4 1.10 nd 1.10 1.10 nd 1.10 1.10 nd 1.10
    Sens 4 38% nd 31% 43% nd 41% 47% nd 53%
    Spec 4 71% nd 70% 71% nd 70% 71% nd 70%
    Cutoff 5 179 nd 267 179 nd 267 179 nd 267
    Sens 5 25% nd 23% 32% nd 24% 35% nd 20%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 1040 nd 1040 1040 nd 1040 1040 nd 1040
    Sens 6 25% nd 23% 14% nd 14% 24% nd 20%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 >6.7 nd >5.4 0.84 nd 0.71 1.5 nd 2.1
    p Value <0.083 nd <0.13 0.77 nd 0.55 0.65 nd 0.41
    95% CI of >0.78 nd >0.61 0.27 nd 0.23 0.25 nd 0.36
    OR Quart 2 na nd na 2.7 nd 2.2 9.5 nd 12
    OR Quart 3 >5.5 nd >5.4 0.69 nd 0.58 2.6 nd 1.5
    p Value <0.13 nd <0.13 0.54 nd 0.36 0.26 nd 0.65
    95% CI of >0.62 nd >0.61 0.21 nd 0.18 0.49 nd 0.25
    OR Quart 3 na nd na 2.3 nd 1.9 14 nd 9.5
    OR Quart 4 >5.5 nd >3.1 1.5 nd 1.3 3.8 nd 3.2
    p Value <0.13 nd <0.33 0.43 nd 0.64 0.11 nd 0.17
    95% CI of >0.62 nd >0.31 0.54 nd 0.46 0.75 nd 0.61
    OR Quart 4 na nd na 4.3 nd 3.5 19 nd 17
    Interleukin-28A
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.195 0.148 0.195 0.265 0.195 2.92
    Average 31.1 18.2 31.1 12.7 31.1 26.0
    Stdev 255 61.1 255 45.7 255 58.2
    p (t-test) 0.84 0.70 0.93
    Min 0.0727 0.0727 0.0727 0.0727 0.0727 0.0727
    Max 3150 246 3150 243 3150 235
    n (Samp) 216 16 216 28 216 17
    n (Patient) 132 16 132 28 132 17
    UO only
    Median 0.195 0.148 0.195 0.265 0.195 0.195
    Average 32.4 2.50 32.4 4.50 32.4 12.9
    Stdev 266 5.90 266 8.06 266 23.4
    p (t-test) 0.69 0.57 0.78
    Min 0.0727 0.0727 0.0727 0.0727 0.0727 0.0727
    Max 3150 20.8 3150 35.6 3150 71.6
    n (Samp) 198 13 198 29 198 15
    n (Patient) 117 13 117 29 117 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.43 nd 0.35 0.54 nd 0.58 0.60 nd 0.57
    SE 0.077 nd 0.085 0.059 nd 0.059 0.075 nd 0.080
    p 0.34 nd 0.081 0.45 nd 0.17 0.16 nd 0.35
    nCohort 1 216 nd 198 216 nd 198 216 nd 198
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 0 nd 0 0.158 nd 0.158 0.158 nd 0.158
    Sens 1 100%  nd 100%  71% nd 72% 76% nd 73%
    Spec 1  0% nd  0% 38% nd 41% 38% nd 41%
    Cutoff 2 0 nd 0 0.120 nd 0.120 0.120 nd 0.120
    Sens 2 100%  nd 100%  86% nd 86% 82% nd 80%
    Spec 2  0% nd  0% 17% nd 19% 17% nd 19%
    Cutoff 3 0 nd 0 0 nd 0 0 nd 0
    Sens 3 100%  nd 100%  100%  nd 100%  100%  nd 100% 
    Spec 3  0% nd  0%  0% nd  0%  0% nd  0%
    Cutoff 4 0.265 nd 0.265 0.265 nd 0.265 0.265 nd 0.265
    Sens 4 38% nd 23% 32% nd 34% 53% nd 40%
    Spec 4 71% nd 75% 71% nd 75% 71% nd 75%
    Cutoff 5 10.2 nd 5.01 10.2 nd 5.01 10.2 nd 5.01
    Sens 5 19% nd 15% 21% nd 31% 41% nd 33%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 21.9 nd 20.8 21.9 nd 20.8 21.9 nd 20.8
    Sens 6  6% nd  0%  7% nd  3% 24% nd 20%
    Spec 6 91% nd 90% 91% nd 90% 91% nd 90%
    OR Quart 2 0.48 nd 0 2.2 nd 1.8 0.74 nd 1.7
    p Value 0.41 nd na 0.23 nd 0.36 0.70 nd 0.47
    95% CI of 0.085 nd na 0.61 nd 0.50 0.16 nd 0.39
    OR Quart 2 2.7 nd na 7.6 nd 6.6 3.4 nd 7.7
    OR Quart 3 1.3 nd 1.7 1.8 nd 2.4 0.74 nd 0.32
    p Value 0.73 nd 0.47 0.35 nd 0.16 0.70 nd 0.33
    95% CI of 0.32 nd 0.39 0.51 nd 0.70 0.16 nd 0.032
    OR Quart 3 5.0 nd 7.7 6.7 nd 8.4 3.4 nd 3.2
    OR Quart 4 1.3 nd 1.8 2.5 nd 2.4 1.8 nd 2.1
    p Value 0.73 nd 0.45 0.15 nd 0.16 0.36 nd 0.32
    95% CI of 0.32 nd 0.40 0.72 nd 0.70 0.50 nd 0.49
    OR Quart 4 5.0 nd 7.8 8.5 nd 8.4 6.6 nd 8.8
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0981 0.0981 0.0981 0.0981 0.0981 2.20
    Average 244 336 244 222 244 1080
    Stdev 2720 1030 2720 849 2720 3330
    p (t-test) 0.89 0.97 0.23
    Min 0.0445 0.0445 0.0445 0.0445 0.0445 0.0445
    Max 40000 4130 40000 4440 40000 13500
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 0.0981 0.0981 0.0981 0.0981 0.0981 2.20
    Average 264 351 264 196 264 1160
    Stdev 2850 1140 2850 828 2850 3540
    p (t-test) 0.91 0.90 0.25
    Min 0.0445 0.0445 0.0445 0.0445 0.0445 0.0445
    Max 40000 4130 40000 4440 40000 13500
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.53 nd 0.52 0.51 nd 0.52 0.64 nd 0.66
    SE 0.076 nd 0.084 0.058 nd 0.058 0.075 nd 0.079
    p 0.72 nd 0.81 0.82 nd 0.79 0.053 nd 0.042
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 0.0494 nd 0.0494 0.0494 nd 0.0494 0.0996 nd 0.0996
    Sens 1 88% nd 92% 71% nd 72% 71% nd 73%
    Spec 1 23% nd 21% 23% nd 21% 57% nd 58%
    Cutoff 2 0.0494 nd 0.0494 0.0445 nd 0.0445 0.0494 nd 0.0846
    Sens 2 88% nd 92% 93% nd 93% 88% nd 80%
    Spec 2 23% nd 21% 10% nd  9% 23% nd 39%
    Cutoff 3 0 nd 0.0494 0.0445 nd 0.0445 0 nd 0.0494
    Sens 3 100%  nd 92% 93% nd 93% 100%  nd 93%
    Spec 3  0% nd 21% 10% nd  9%  0% nd 21%
    Cutoff 4 0.821 nd 0.101 0.821 nd 0.101 0.821 nd 0.101
    Sens 4 31% nd 31% 39% nd 41% 59% nd 60%
    Spec 4 71% nd 70% 71% nd 70% 71% nd 70%
    Cutoff 5 10.4 nd 13.1 10.4 nd 13.1 10.4 nd 13.1
    Sens 5 25% nd 23% 25% nd 24% 35% nd 33%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 58.1 nd 58.1 58.1 nd 58.1 58.1 nd 58.1
    Sens 6 25% nd 23% 14% nd 14% 24% nd 20%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 4.5 nd 7.9 0.86 nd 0.86 1.5 nd 0.48
    p Value 0.065 nd 0.057 0.78 nd 0.78 0.66 nd 0.56
    95% CI of 0.91 nd 0.94 0.29 nd 0.29 0.24 nd 0.042
    OR Quart 2 22 nd 67 2.5 nd 2.5 9.3 nd 5.5
    OR Quart 3 0.49 nd 2.0 0.59 nd 0.72 2.6 nd 3.9
    p Value 0.57 nd 0.57 0.38 nd 0.57 0.26 nd 0.10
    95% CI of 0.043 nd 0.18 0.18 nd 0.23 0.49 nd 0.77
    OR Quart 3 5.6 nd 23 1.9 nd 2.2 14 nd 20
    OR Quart 4 2.6 nd 3.1 0.98 nd 1.0 3.8 nd 2.6
    p Value 0.27 nd 0.33 0.97 nd 1.0 0.11 nd 0.27
    95% CI of 0.48 nd 0.31 0.34 nd 0.35 0.75 nd 0.48
    OR Quart 4 14 nd 31 2.8 nd 2.9 19 nd 14
    Interleukin-4 receptor alpha chain
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 218 269 218 218 218 228
    Average 288 396 288 297 288 332
    Stdev 210 321 210 271 210 233
    p (t-test) 0.057 0.83 0.40
    Min 49.7 111 49.7 3.27 49.7 103
    Max 1200 1090 1200 1210 1200 997
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 229 298 229 191 229 228
    Average 297 442 297 286 297 341
    Stdev 215 336 215 268 215 247
    p (t-test) 0.024 0.82 0.45
    Min 49.7 138 49.7 3.27 49.7 84.5
    Max 1200 1090 1200 1210 1200 997
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.59 nd 0.64 0.48 nd 0.44 0.56 nd 0.54
    SE 0.077 nd 0.085 0.059 nd 0.059 0.075 nd 0.079
    p 0.26 nd 0.11 0.72 nd 0.32 0.44 nd 0.58
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 195 nd 204 148 nd 142 178 nd 170
    Sens 1 75% nd 77% 71% nd 72% 71% nd 73%
    Spec 1 43% nd 42% 23% nd 19% 35% nd 30%
    Cutoff 2 153 nd 195 104 nd 104 165 nd 165
    Sens 2 81% nd 85% 89% nd 93% 82% nd 80%
    Spec 2 25% nd 40%  6% nd  6% 30% nd 29%
    Cutoff 3 111 nd 153 83.5 nd 104 121 nd 121
    Sens 3 94% nd 92% 93% nd 93% 94% nd 93%
    Spec 3  6% nd 24%  3% nd  6%  9% nd  8%
    Cutoff 4 299 nd 317 299 nd 317 299 nd 317
    Sens 4 44% nd 46% 39% nd 28% 47% nd 47%
    Spec 4 70% nd 70% 70% nd 70% 70% nd 70%
    Cutoff 5 380 nd 400 380 nd 400 380 nd 400
    Sens 5 31% nd 38% 18% nd 17% 35% nd 33%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 529 nd 560 529 nd 560 529 nd 560
    Sens 6 25% nd 23% 11% nd 10% 18% nd 20%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 1.4 nd 1.5 0.74 nd 0.54 1.7 nd 1.7
    p Value 0.70 nd 0.65 0.59 nd 0.35 0.48 nd 0.48
    95% CI of 0.29 nd 0.25 0.24 nd 0.15 0.39 nd 0.39
    OR Quart 2 6.4 nd 9.5 2.3 nd 2.0 7.5 nd 7.5
    OR Quart 3 1.0 nd 1.5 0.60 nd 1.2 1.0 nd 0.32
    p Value 1.0 nd 0.65 0.40 nd 0.78 1.0 nd 0.33
    95% CI of 0.19 nd 0.25 0.19 nd 0.39 0.19 nd 0.032
    OR Quart 3 5.2 nd 9.5 2.0 nd 3.5 5.2 nd 3.2
    OR Quart 4 2.1 nd 2.7 1.2 nd 1.5 2.1 nd 2.1
    p Value 0.32 nd 0.26 0.77 nd 0.43 0.32 nd 0.32
    95% CI of 0.49 nd 0.49 0.42 nd 0.53 0.49 nd 0.49
    OR Quart 4 8.7 nd 14 3.3 nd 4.3 8.7 nd 8.8
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 7910 9090 7910 7270 7910 7250
    Average 9670 9560 9670 8430 9670 17800
    Stdev 11000 4770 11000 3820 11000 38600
    p (t-test) 0.97 0.55 0.028
    Min 3640 3140 3640 4110 3640 3340
    Max 153000 18000 153000 19800 153000 166000
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 7930 9140 7930 7590 7930 7250
    Average 9820 9510 9820 8350 9820 19000
    Stdev 11400 4780 11400 3590 11400 41100
    p (t-test) 0.92 0.49 0.025
    Min 3640 3140 3640 4110 3640 4480
    Max 153000 18000 153000 19800 153000 166000
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.53 nd 0.54 0.45 nd 0.45 0.45 nd 0.44
    SE 0.076 nd 0.084 0.059 nd 0.059 0.075 nd 0.079
    p 0.71 nd 0.67 0.38 nd 0.41 0.47 nd 0.46
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 5760 nd 5620 5720 nd 5720 6010 nd 6010
    Sens 1 75% nd 77% 71% nd 72% 71% nd 73%
    Spec 1 15% nd 14% 15% nd 15% 18% nd 18%
    Cutoff 2 5620 nd 5310 5610 nd 5610 5140 nd 5880
    Sens 2 81% nd 85% 82% nd 83% 82% nd 80%
    Spec 2 14% nd  9% 14% nd 14%  8% nd 16%
    Cutoff 3 4780 nd 4730 5140 nd 5140 4330 nd 5030
    Sens 3 94% nd 92% 93% nd 93% 94% nd 93%
    Spec 3  6% nd  5%  8% nd  7%  4% nd  6%
    Cutoff 4 9260 nd 9260 9260 nd 9260 9260 nd 9260
    Sens 4 44% nd 46% 25% nd 24% 29% nd 27%
    Spec 4 70% nd 70% 70% nd 70% 70% nd 70%
    Cutoff 5 10300 nd 10500 10300 nd 10500 10300 nd 10500
    Sens 5 25% nd 23% 21% nd 21% 29% nd 27%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 14000 nd 14400 14000 nd 14400 14000 nd 14400
    Sens 6 25% nd 23% 14% nd  7% 18% nd 13%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.15 nd 0 1.2 nd 1.2 0.19 nd 0.24
    p Value 0.086 nd na 0.75 nd 0.77 0.13 nd 0.21
    95% CI of 0.018 nd na 0.38 nd 0.37 0.021 nd 0.026
    OR Quart 2 1.3 nd na 3.8 nd 3.8 1.7 nd 2.2
    OR Quart 3 0.64 nd 0.78 0.48 nd 0.82 0.79 nd 1.0
    p Value 0.51 nd 0.73 0.32 nd 0.75 0.73 nd 1.0
    95% CI of 0.17 nd 0.20 0.12 nd 0.23 0.20 nd 0.24
    OR Quart 3 2.4 nd 3.1 2.0 nd 2.8 3.1 nd 4.2
    OR Quart 4 0.80 nd 0.78 2.3 nd 2.0 1.5 nd 1.6
    p Value 0.73 nd 0.73 0.12 nd 0.19 0.52 nd 0.49
    95% CI of 0.23 nd 0.20 0.80 nd 0.70 0.44 nd 0.42
    OR Quart 4 2.8 nd 3.1 6.5 nd 5.9 5.0 nd 6.0
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 185000 178000 185000 185000 185000 165000
    Average 192000 187000 192000 195000 192000 164000
    Stdev 67100 63200 67100 86900 67100 55500
    p (t-test) 0.77 0.84 0.067
    Min 63300 93200 63300 81100 63300 49200
    Max 520000 316000 520000 506000 520000 280000
    n (Samp) 281 16 281 28 281 20
    n (Patient) 159 16 159 28 159 20
    sCr only
    Median nd nd nd nd 181000 181000
    Average nd nd nd nd 187000 203000
    Stdev nd nd nd nd 65700 57300
    p (t-test) nd nd nd nd 0.55
    Min nd nd nd nd 49200 140000
    Max nd nd nd nd 520000 280000
    n (Samp) nd nd nd nd 352 6
    n (Patient) nd nd nd nd 192 6
    UO only
    Median 184000 172000 184000 177000 184000 156000
    Average 191000 168000 191000 173000 191000 155000
    Stdev 69000 51800 69000 56900 69000 47600
    p (t-test) 0.24 0.20 0.032
    Min 63300 93200 63300 81100 63300 49200
    Max 520000 282000 520000 331000 520000 230000
    n (Samp) 257 13 257 26 257 17
    n (Patient) 139 13 139 26 139 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.48 nd 0.40 0.48 nd 0.42 0.37 0.58 0.35
    SE 0.075 nd 0.085 0.058 nd 0.061 0.069 0.12 0.074
    p 0.84 nd 0.24 0.73 nd 0.21 0.069 0.54 0.037
    nCohort 1 281 nd 257 281 nd 257 281 352 257
    nCohort 2 16 nd 13 28 nd 26 20 6 17
    Cutoff 1 152000 nd 133000 158000 nd 130000 144000 166000 144000
    Sens 1 75% nd 77% 71% nd 73% 70% 83% 71%
    Spec 1 29% nd 19% 31% nd 18% 23% 40% 25%
    Cutoff 2 133000 nd 121000 125000 nd 121000 121000 166000 107000
    Sens 2 81% nd 85% 82% nd 81% 80% 83% 82%
    Spec 2 18% nd 13% 12% nd 13% 11% 40%  8%
    Cutoff 3 95600 nd 95600 105000 nd 105000 106000 140000 91800
    Sens 3 94% nd 92% 93% nd 92% 90% 100%  94%
    Spec 3  4% nd  4%  6% nd  7%  7% 23%  3%
    Cutoff 4 214000 nd 215000 214000 nd 215000 214000 207000 215000
    Sens 4 25% nd  8% 29% nd 19% 15% 33% 12%
    Spec 4 70% nd 70% 70% nd 70% 70% 70% 70%
    Cutoff 5 233000 nd 234000 233000 nd 234000 233000 228000 234000
    Sens 5 19% nd  8% 14% nd 12% 10% 33%  0%
    Spec 5 80% nd 80% 80% nd 80% 80% 80% 80%
    Cutoff 6 266000 nd 266000 266000 nd 266000 266000 262000 266000
    Sens 6 12% nd  8% 11% nd  4% 10% 33%  0%
    Spec 6 90% nd 90% 90% nd 90% 90% 90% 90%
    OR Quart 2 0.75 nd 3.1 1.0 nd 1.8 1.0 2.0 1.5
    p Value 0.71 nd 0.33 0.98 nd 0.35 0.99 0.57 0.64
    95% CI of 0.16 nd 0.32 0.34 nd 0.51 0.20 0.18 0.25
    OR Quart 2 3.5 nd 31 3.0 nd 6.6 5.2 22 9.6
    OR Quart 3 1.3 nd 5.3 0.86 nd 1.5 2.5 1.0 3.8
    p Value 0.72 nd 0.13 0.79 nd 0.51 0.20 1.0 0.11
    95% CI of 0.33 nd 0.60 0.27 nd 0.42 0.62 0.062 0.76
    OR Quart 3 5.0 nd 47 2.7 nd 5.7 10 16 19
    OR Quart 4 1.0 nd 4.3 1.2 nd 2.5 2.5 2.0 2.7
    p Value 0.98 nd 0.20 0.77 nd 0.15 0.20 0.57 0.25
    95% CI of 0.24 nd 0.46 0.40 nd 0.72 0.62 0.18 0.50
    OR Quart 4 4.2 nd 39 3.4 nd 8.4 10 22 14
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 357 228 357 346 357 448
    Average 410 280 410 523 410 398
    Stdev 246 155 246 668 246 234
    p (t-test) 0.039 0.067 0.84
    Min 28.1 33.7 28.1 74.0 28.1 45.0
    Max 1540 601 1540 2720 1540 750
    n (Samp) 274 16 274 27 274 19
    n (Patient) 158 16 158 27 158 19
    sCr only
    Median nd nd nd nd 342 357
    Average nd nd nd nd 391 385
    Stdev nd nd nd nd 245 160
    p (t-test) nd nd nd nd 0.95
    Min nd nd nd nd 0.189 220
    Max nd nd nd nd 1540 609
    n (Samp) nd nd nd nd 341 6
    n (Patient) nd nd nd nd 188 6
    UO only
    Median 334 224 334 346 334 352
    Average 389 283 389 456 389 385
    Stdev 238 171 238 532 238 247
    p (t-test) 0.12 0.25 0.95
    Min 28.1 33.7 28.1 74.0 28.1 45.0
    Max 1540 601 1540 2720 1540 750
    n (Samp) 250 13 250 25 250 16
    n (Patient) 138 13 138 25 138 16
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.34 nd 0.36 0.46 nd 0.47 0.50 0.52 0.49
    SE 0.076 nd 0.085 0.059 nd 0.061 0.069 0.12 0.075
    p 0.030 nd 0.11 0.50 nd 0.67 0.95 0.86 0.94
    nCohort 1 274 nd 250 274 nd 250 274 341 250
    nCohort 2 16 nd 13 27 nd 25 19 6 16
    Cutoff 1 192 nd 171 220 nd 220 242 247 229
    Sens 1 75% nd 77% 70% nd 72% 74% 83% 75%
    Spec 1 19% nd 18% 23% nd 26% 26% 31% 27%
    Cutoff 2 171 nd 165 155 nd 155 122 247 122
    Sens 2 81% nd 85% 81% nd 80% 84% 83% 81%
    Spec 2 16% nd 18% 15% nd 16% 10% 31% 11%
    Cutoff 3 138 nd 138 88.8 nd 88.8 88.8 220 88.8
    Sens 3 94% nd 92% 93% nd 92% 95% 100%  94%
    Spec 3 12% nd 13%  5% nd  5%  5% 27%  5%
    Cutoff 4 504 nd 478 504 nd 478 504 496 478
    Sens 4 12% nd 23% 22% nd 24% 42% 33% 44%
    Spec 4 70% nd 70% 70% nd 70% 70% 70% 70%
    Cutoff 5 613 nd 569 613 nd 569 613 583 569
    Sens 5  0% nd  8% 22% nd 24% 16% 17% 25%
    Spec 5 80% nd 80% 80% nd 80% 80% 80% 80%
    Cutoff 6 728 nd 697 728 nd 697 728 704 697
    Sens 6  0% nd  0% 19% nd 20% 11%  0% 19%
    Spec 6 90% nd 90% 90% nd 90% 90% 90% 90%
    OR Quart 2 4.2 nd 1.0 1.2 nd 1.2 1.0 >3.1 0.59
    p Value 0.20 nd 1.0 0.75 nd 0.77 0.98 <0.34 0.48
    95% CI of 0.46 nd 0.14 0.38 nd 0.38 0.28 >0.31 0.14
    OR Quart 2 39 nd 7.3 3.8 nd 3.7 3.7 na 2.6
    OR Quart 3 3.1 nd 1.5 0.83 nd 0.82 0.80 >2.0 0.79
    p Value 0.33 nd 0.65 0.77 nd 0.75 0.75 <0.57 0.73
    95% CI of 0.31 nd 0.25 0.24 nd 0.24 0.21 >0.18 0.20
    OR Quart 3 30 nd 9.4 2.9 nd 2.8 3.1 na 3.1
    OR Quart 4 9.0 nd 3.3 1.6 nd 1.2 1.0 >1.0 0.80
    p Value 0.041 nd 0.16 0.40 nd 0.75 0.98 <1.0 0.75
    95% CI of 1.1 nd 0.63 0.54 nd 0.38 0.28 >0.062 0.21
    OR Quart 4 74 nd 17 4.7 nd 3.8 3.7 na 3.1
    Corticotropin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.000668 0.00344 0.000668 0.00402 0.000668 0.00254
    Average 0.00568 0.00650 0.00568 0.00599 0.00568 0.00960
    Stdev 0.0263 0.00561 0.0263 0.00669 0.0263 0.0224
    p (t-test) 0.93 0.96 0.56
    Min 3.38E−6 6.17E−6 3.38E−6 3.38E−6 3.38E−6 3.38E−6
    Max 0.292 0.0140 0.292 0.0251 0.292 0.0908
    n (Samp) 197 7 197 20 197 16
    n (Patient) 131 7 131 20 131 16
    UO only
    Median nd nd 0.000881 0.00389 0.000881 0.00297
    Average nd nd 0.00636 0.00721 0.00636 0.0115
    Stdev nd nd 0.0280 0.00813 0.0280 0.0246
    p (t-test) nd nd 0.90 0.52
    Min nd nd 3.38E−6 3.38E−6 3.38E−6 3.38E−6
    Max nd nd 0.292 0.0251 0.292 0.0908
    n (Samp) nd nd 173 18 173 13
    n (Patient) nd nd 111 18 111 13
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.74 nd nd 0.67 nd 0.67 0.56 nd 0.63
    SE 0.11 nd nd 0.069 nd 0.072 0.077 nd 0.086
    p 0.026 nd nd 0.016 nd 0.016 0.46 nd 0.12
    nCohort 1 197 nd nd 197 nd 173 197 nd 173
    nCohort 2 7 nd nd 20 nd 18 16 nd 13
    Cutoff 1 0.00317 nd nd 0.000466 nd 0.000293 4.31E−6 nd 0.00192
    Sens 1 71% nd nd 70% nd 72% 75% nd 77%
    Spec 1 76% nd nd 45% nd 42% 16% nd 64%
    Cutoff 2 0.00183 nd nd 0.000278 nd 0.000278 3.38E−6 nd 4.31E−6
    Sens 2 86% nd nd 85% nd 89% 88% nd 85%
    Spec 2 66% nd nd 41% nd 39%  5% nd 16%
    Cutoff 3 4.31E−6 nd nd 4.31E−6 nd 4.31E−6 0 nd 3.38E−6
    Sens 3 100%  nd nd 90% nd 94% 100%  nd 92%
    Spec 3 16% nd nd 16% nd 16%  0% nd  5%
    Cutoff 4 0.00221 nd nd 0.00221 nd 0.00297 0.00221 nd 0.00297
    Sens 4 71% nd nd 60% nd 61% 56% nd 46%
    Spec 4 70% nd nd 70% nd 72% 70% nd 72%
    Cutoff 5 0.00423 nd nd 0.00423 nd 0.00486 0.00423 nd 0.00486
    Sens 5 43% nd nd 50% nd 44% 31% nd 31%
    Spec 5 80% nd nd 80% nd 80% 80% nd 80%
    Cutoff 6 0.00829 nd nd 0.00829 nd 0.00914 0.00829 nd 0.00914
    Sens 6 43% nd nd 35% nd 33% 19% nd 23%
    Spec 6 90% nd nd 90% nd 90% 90% nd 90%
    OR Quart 2 0 nd nd 1.4 nd 2.0 0 nd 0
    p Value na nd nd 0.70 nd 0.42 na nd na
    95% CI of na nd nd 0.29 nd 0.36 na nd na
    OR Quart 2 na nd nd 6.4 nd 12 na nd na
    OR Quart 3 2.0 nd nd 0.65 nd 1.5 0.64 nd 1.7
    p Value 0.57 nd nd 0.65 nd 0.67 0.51 nd 0.46
    95% CI of 0.18 nd nd 0.10 nd 0.24 0.17 nd 0.39
    OR Quart 3 23 nd nd 4.1 nd 9.4 2.4 nd 7.8
    OR Quart 4 4.3 nd nd 4.2 nd 5.2 0.98 nd 1.7
    p Value 0.20 nd nd 0.034 nd 0.042 0.97 nd 0.48
    95% CI of 0.46 nd nd 1.1 nd 1.1 0.29 nd 0.38
    OR Quart 4 39 nd nd 16 nd 25 3.3 nd 7.6
    Thyroxine-binding globulin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 36.9 34.2 36.9 29.8 36.9 30.0
    Average 37.8 35.8 37.8 33.3 37.8 35.1
    Stdev 10.8 10.4 10.8 12.0 10.8 12.8
    p (t-test) 0.36 0.026 0.31
    Min 12.8 15.2 12.8 14.2 12.8 16.3
    Max 75.8 57.7 75.8 63.7 75.8 62.0
    n (Samp) 437 26 437 32 437 17
    n (Patient) 174 26 174 32 174 17
    sCr only
    Median 36.2 28.7 36.2 30.3 36.2 33.2
    Average 37.0 31.4 37.0 33.8 37.0 34.0
    Stdev 11.1 12.8 11.1 14.8 11.1 14.2
    p (t-test) 0.22 0.42 0.47
    Min 12.8 18.0 12.8 15.9 11.8 15.2
    Max 75.8 56.0 75.8 63.7 75.8 62.0
    n (Samp) 535 6 535 8 535 7
    n (Patient) 207 6 207 8 207 7
    UO only
    Median 35.6 32.5 35.6 28.5 35.6 30.0
    Average 36.9 34.7 36.9 31.9 36.9 34.0
    Stdev 10.6 9.63 10.6 10.5 10.6 12.5
    p (t-test) 0.30 0.011 0.26
    Min 12.8 15.2 12.8 14.2 12.8 16.3
    Max 75.8 57.7 75.8 57.0 75.8 56.0
    n (Samp) 363 26 363 31 363 17
    n (Patient) 141 26 141 31 141 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.44 0.32 0.43 0.36 0.39 0.34 0.42 0.40 0.42
    SE 0.060 0.12 0.060 0.054 0.11 0.055 0.074 0.11 0.074
    p 0.28 0.15 0.24 0.013 0.29 0.0049 0.31 0.36 0.26
    nCohort 1 437 535 363 437 535 363 437 535 363
    nCohort 2 26 6 26 32 8 31 17 7 17
    Cutoff 1 28.4 26.8 28.4 25.7 28.4 26.4 28.2 29.8 27.4
    Sens 1 73% 83% 73% 72% 75% 71% 71% 71% 71%
    Spec 1 19% 18% 21% 12% 24% 15% 19% 28% 16%
    Cutoff 2 27.6 26.8 27.6 23.9 22.2 24.7 23.8 26.9 22.2
    Sens 2 85% 83% 81% 81% 88% 81% 82% 86% 82%
    Spec 2 17% 18% 18%  8%  8% 11%  8% 18%  6%
    Cutoff 3 26.5 17.9 26.5 20.5 15.8 20.5 19.6 15.0 19.6
    Sens 3 92% 100%  92% 91% 100%  90% 94% 100%  94%
    Spec 3 14%  4% 15%  5%  3%  6%  4%  1%  4%
    Cutoff 4 43.6 42.9 42.2 43.6 42.9 42.2 43.6 42.9 42.2
    Sens 4 19% 17% 23% 19% 25% 16% 29% 14% 35%
    Spec 4 70% 71% 71% 70% 71% 71% 70% 71% 71%
    Cutoff 5 46.7 46.3 46.0 46.7 46.3 46.0 46.7 46.3 46.0
    Sens 5 15% 17% 15% 12% 12% 10% 18% 14% 18%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 50.4 50.1 49.7 50.4 50.1 49.7 50.4 50.1 49.7
    Sens 6 12% 17%  8%  9% 12%  6% 12% 14% 18%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 0.79 0 1.3 1.0 0 1.5 0.75 1.0 0.39
    p Value 0.73 na 0.72 0.99 na 0.51 0.71 1.00 0.26
    95% CI of 0.21 na 0.33 0.32 na 0.42 0.16 0.062 0.073
    OR Quart 2 3.0 na 4.9 3.2 na 5.7 3.4 16 2.0
    OR Quart 3 1.6 2.0 2.1 0.66 1.0 1.3 1.0 3.0 0.39
    p Value 0.40 0.57 0.24 0.53 1.0 0.73 1.0 0.34 0.26
    95% CI of 0.52 0.18 0.61 0.18 0.14 0.33 0.24 0.31 0.073
    OR Quart 3 5.2 23 7.3 2.4 7.2 4.9 4.1 30 2.0
    OR Quart 4 1.9 3.1 2.4 3.0 2.0 4.6 1.5 2.0 1.7
    p Value 0.27 0.33 0.16 0.029 0.41 0.0081 0.51 0.57 0.39
    95% CI of 0.61 0.32 0.71 1.1 0.37 1.5 0.42 0.18 0.52
    OR Quart 4 5.8 30 8.1 7.8 11 14 5.6 23 5.3
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 101 105 101 98.7 101 69.9
    Average 201 193 201 156 201 244
    Stdev 415 178 415 144 415 637
    p (t-test) 0.94 0.57 0.69
    Min 12.8 53.7 12.8 12.8 12.8 4.06
    Max 3360 611 3360 595 3360 2700
    n (Samp) 217 16 217 28 217 17
    n (Patient) 133 16 133 28 133 17
    UO only
    Median 101 105 101 104 101 67.7
    Average 205 201 205 148 205 250
    Stdev 431 189 431 137 431 680
    p (t-test) 0.98 0.48 0.71
    Min 12.8 53.7 12.8 12.8 12.8 4.06
    Max 3360 611 3360 595 3360 2700
    n (Samp) 199 13 199 29 199 15
    n (Patient) 118 13 118 29 118 15
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.57 nd 0.58 0.49 nd 0.49 0.38 nd 0.34
    SE 0.077 nd 0.085 0.058 nd 0.058 0.075 nd 0.079
    p 0.39 nd 0.32 0.85 nd 0.89 0.12 nd 0.042
    nCohort 1 217 nd 199 217 nd 199 217 nd 199
    nCohort 2 16 nd 13 28 nd 29 17 nd 15
    Cutoff 1 75.4 nd 75.4 65.4 nd 68.4 47.2 nd 47.2
    Sens 1 75% nd 77% 71% nd 72% 71% nd 73%
    Spec 1 29% nd 30% 24% nd 26% 13% nd 13%
    Cutoff 2 74.6 nd 74.6 54.3 nd 54.3 37.8 nd 37.8
    Sens 2 81% nd 85% 86% nd 86% 82% nd 80%
    Spec 2 29% nd 29% 15% nd 15%  9% nd 10%
    Cutoff 3 53.7 nd 64.9 36.7 nd 36.7 36.7 nd 36.7
    Sens 3 94% nd 92% 93% nd 93% 94% nd 93%
    Spec 3 15% nd 23%  8% nd  9%  8% nd  9%
    Cutoff 4 148 nd 148 148 nd 148 148 nd 148
    Sens 4 38% nd 38% 29% nd 24% 24% nd 20%
    Spec 4 70% nd 70% 70% nd 70% 70% nd 70%
    Cutoff 5 192 nd 192 192 nd 192 192 nd 192
    Sens 5 31% nd 31% 29% nd 24% 12% nd  7%
    Spec 5 80% nd 80% 80% nd 80% 80% nd 80%
    Cutoff 6 285 nd 285 285 nd 285 285 nd 285
    Sens 6 19% nd 15% 18% nd 14% 12% nd  7%
    Spec 6 90% nd 90% 90% nd 90% 90% nd 90%
    OR Quart 2 1.4 nd 1.5 0.74 nd 1.2 1.0 nd 0.67
    p Value 0.70 nd 0.65 0.59 nd 0.78 0.98 nd 0.66
    95% CI of 0.29 nd 0.25 0.24 nd 0.39 0.20 nd 0.11
    OR Quart 2 6.4 nd 9.5 2.3 nd 3.5 5.3 nd 4.2
    OR Quart 3 1.4 nd 2.1 0.74 nd 0.84 1.4 nd 1.0
    p Value 0.70 nd 0.41 0.59 nd 0.77 0.70 nd 1.0
    95% CI of 0.29 nd 0.36 0.24 nd 0.26 0.29 nd 0.19
    OR Quart 3 6.4 nd 12 2.3 nd 2.7 6.3 nd 5.2
    OR Quart 4 1.7 nd 2.1 1.0 nd 1.2 2.6 nd 2.6
    p Value 0.48 nd 0.41 0.97 nd 0.78 0.19 nd 0.19
    95% CI of 0.39 nd 0.36 0.36 nd 0.39 0.63 nd 0.63
    OR Quart 4 7.5 nd 12 2.9 nd 3.5 10 nd 11
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.321 0.00880 0.321 0.410 0.321 0.441
    Average 0.350 0.327 0.350 0.470 0.350 0.497
    Stdev 0.333 0.467 0.333 0.436 0.333 0.351
    p (t-test) 0.79 0.078 0.058
    Min 0.00580 0.00580 0.00580 0.00580 0.00580 0.00580
    Max 1.81 1.63 1.81 1.53 1.81 1.19
    n (Samp) 282 16 282 28 282 20
    n (Patient) 160 16 160 28 160 20
    sCr only
    Median nd nd nd nd 0.327 0.484
    Average nd nd nd nd 0.355 0.487
    Stdev nd nd nd nd 0.348 0.303
    p (t-test) nd nd nd nd 0.35
    Min nd nd nd nd 0.00580 0.00580
    Max nd nd nd nd 1.81 0.924
    n (Samp) nd nd nd nd 353 6
    n (Patient) nd nd nd nd 193 6
    UO only
    Median 0.321 0.00880 0.321 0.376 0.321 0.445
    Average 0.342 0.279 0.342 0.438 0.342 0.527
    Stdev 0.333 0.504 0.333 0.420 0.333 0.418
    p (t-test) 0.52 0.18 0.030
    Min 0.00580 0.00580 0.00580 0.00580 0.00580 0.00580
    Max 1.81 1.63 1.81 1.53 1.81 1.31
    n (Samp) 258 13 258 26 258 17
    n (Patient) 140 13 140 26 140 17
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.43 nd 0.38 0.58 nd 0.56 0.64 0.64 0.65
    SE 0.076 nd 0.085 0.059 nd 0.061 0.069 0.12 0.074
    p 0.38 nd 0.15 0.19 nd 0.31 0.035 0.26 0.050
    nCohort 1 282 nd 258 282 nd 258 282 353 258
    nCohort 2 16 nd 13 28 nd 26 20 6 17
    Cutoff 1 0.00580 nd 0 0.0947 nd 0.00580 0.392 0.392 0.381
    Sens 1 75% nd 100%  71% nd 85% 70% 83% 71%
    Spec 1 16% nd  0% 32% nd 17% 62% 61% 59%
    Cutoff 2 0 nd 0 0.00580 nd 0.00580 0.221 0.392 0.00580
    Sens 2 100%  nd 100%  86% nd 85% 80% 83% 94%
    Spec 2  0% nd  0% 16% nd 17% 41% 61% 17%
    Cutoff 3 0 nd 0 0 nd 0 0.00580 0 0.00580
    Sens 3 100%  nd 100%  100%  nd 100%  95% 100%  94%
    Spec 3  0% nd  0%  0% nd  0% 16%  0% 17%
    Cutoff 4 0.496 nd 0.502 0.496 nd 0.502 0.496 0.509 0.502
    Sens 4 31% nd 23% 43% nd 42% 45% 50% 47%
    Spec 4 70% nd 70% 70% nd 70% 70% 70% 70%
    Cutoff 5 0.581 nd 0.581 0.581 nd 0.581 0.581 0.607 0.581
    Sens 5 25% nd 23% 36% nd 35% 35% 33% 41%
    Spec 5 80% nd 80% 80% nd 80% 80% 80% 80%
    Cutoff 6 0.767 nd 0.767 0.767 nd 0.767 0.767 0.803 0.767
    Sens 6 12% nd 15% 21% nd 19% 20% 17% 24%
    Spec 6 90% nd 90% 90% nd 90% 90% 90% 90%
    OR Quart 2 0.75 nd 0.32 0.54 nd 1.8 4.1 0 4.1
    p Value 0.71 nd 0.33 0.34 nd 0.35 0.21 na 0.21
    95% CI of 0.16 nd 0.033 0.15 nd 0.51 0.45 na 0.45
    OR Quart 2 3.5 nd 3.2 1.9 nd 6.6 38 na 38
    OR Quart 3 0.74 nd 1.7 0.85 nd 1.5 7.6 3.0 5.2
    p Value 0.70 nd 0.47 0.77 nd 0.51 0.061 0.34 0.14
    95% CI of 0.16 nd 0.39 0.27 nd 0.42 0.91 0.31 0.60
    OR Quart 3 3.4 nd 7.5 2.6 nd 5.7 64 30 46
    OR Quart 4 1.6 nd 1.4 1.6 nd 2.4 8.7 2.0 7.6
    p Value 0.50 nd 0.68 0.33 nd 0.16 0.044 0.57 0.062
    95% CI of 0.42 nd 0.30 0.60 nd 0.71 1.1 0.18 0.90
    OR Quart 4 5.8 nd 6.4 4.5 nd 8.3 71 22 63
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 51700 43400 51700 47500 51700 32700
    Average 63800 54300 63800 55300 63800 37200
    Stdev 46700 35100 46700 43000 46700 23500
    p (t-test) 0.30 0.31 0.014
    Min 4980 14500 4980 10500 4980 1940
    Max 260000 141000 260000 232000 260000 98400
    n (Samp) 325 27 325 34 325 19
    n (Patient) 192 27 192 34 192 19
    sCr only
    Median nd nd 51000 50300 nd nd
    Average nd nd 61200 86900 nd nd
    Stdev nd nd 44000 79800 nd nd
    p (t-test) nd nd 0.16 nd nd
    Min nd nd 1940 27200 nd nd
    Max nd nd 260000 232000 nd nd
    n (Samp) nd nd 417 6 nd nd
    n (Patient) nd nd 228 6 nd nd
    UO only
    Median 51100 46800 51100 41600 51100 30200
    Average 62700 55800 62700 46200 62700 34900
    Stdev 45100 34800 45100 26700 45100 22900
    p (t-test) 0.44 0.037 0.0100
    Min 4980 14500 4980 10500 4980 1940
    Max 244000 141000 244000 129000 244000 98400
    n (Samp) 295 27 295 34 295 18
    n (Patient) 167 27 167 34 167 18
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.45 nd 0.47 0.44 0.57 0.40 0.32 nd 0.29
    SE 0.059 nd 0.059 0.053 0.12 0.054 0.069 nd 0.070
    p 0.37 nd 0.62 0.29 0.59 0.076 0.0077 nd 0.0033
    nCohort 1 325 nd 295 325 417 295 325 nd 295
    nCohort 2 27 nd 27 34 6 34 19 nd 18
    Cutoff 1 29100 nd 30700 31300 33900 29100 25600 nd 25600
    Sens 1 70% nd 70% 71% 83% 71% 74% nd 72%
    Spec 1 22% nd 25% 26% 29% 22% 17% nd 17%
    Cutoff 2 25700 nd 25600 24700 33900 20900 16700 nd 16700
    Sens 2 81% nd 81% 82% 83% 82% 84% nd 83%
    Spec 2 17% nd 17% 16% 29% 14%  9% nd  9%
    Cutoff 3 20700 nd 20700 16700 27000 16700 4980 nd 4980
    Sens 3 93% nd 93% 91% 100%  91% 95% nd 94%
    Spec 3 13% nd 14%  9% 19%  9%  0% nd  0%
    Cutoff 4 75000 nd 75700 75000 68400 75700 75000 nd 75700
    Sens 4 19% nd 19% 18% 33% 12%  5% nd  6%
    Spec 4 70% nd 70% 70% 70% 70% 70% nd 70%
    Cutoff 5 90400 nd 90900 90400 87000 90900 90400 nd 90900
    Sens 5 11% nd 11% 12% 33%  6%  5% nd  6%
    Spec 5 80% nd 80% 80% 80% 80% 80% nd 80%
    Cutoff 6 124000 nd 121000 124000 120000 121000 124000 nd 121000
    Sens 6  7% nd 11%  9% 33%  3%  0% nd  0%
    Spec 6 90% nd 90% 90% 90% 90% 90% nd 90%
    OR Quart 2 1.4 nd 1.7 1.9 2.0 4.1 3.1 nd 2.1
    p Value 0.55 nd 0.38 0.27 0.57 0.035 0.34 nd 0.56
    95% CI of 0.44 nd 0.53 0.61 0.18 1.1 0.31 nd 0.18
    OR Quart 2 4.7 nd 5.4 5.9 22 15 30 nd 23
    OR Quart 3 1.2 nd 1.2 2.1 0.99 2.9 7.5 nd 6.5
    p Value 0.76 nd 0.76 0.19 0.99 0.13 0.062 nd 0.087
    95% CI of 0.36 nd 0.36 0.70 0.061 0.74 0.91 nd 0.76
    OR Quart 3 4.1 nd 4.2 6.5 16 11 63 nd 55
    OR Quart 4 1.9 nd 1.7 2.2 2.0 4.6 8.7 nd 10
    p Value 0.27 nd 0.38 0.18 0.57 0.022 0.043 nd 0.030
    95% CI of 0.61 nd 0.53 0.70 0.18 1.2 1.1 nd 1.3
    OR Quart 4 5.9 nd 5.4 6.6 22 17 71 nd 82
    Apolipoprotein(a)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 52400 30100 52400 41200 52400 15800
    Average 89500 61200 89500 73100 89500 42400
    Stdev 110000 72000 110000 95100 110000 58500
    p (t-test) 0.19 0.41 0.066
    Min 7.99 380 7.99 1030 7.99 1300
    Max 722000 234000 722000 423000 722000 187000
    n (Samp) 325 27 325 34 325 19
    n (Patient) 192 27 192 34 192 19
    sCr only
    Median nd nd 45000 30300 nd nd
    Average nd nd 84100 68400 nd nd
    Stdev nd nd 106000 83400 nd nd
    p (t-test) nd nd 0.72 nd nd
    Min nd nd 7.99 968 nd nd
    Max nd nd 722000 200000 nd nd
    n (Samp) nd nd 417 6 nd nd
    n (Patient) nd nd 228 6 nd nd
    UO only
    Median 47600 30100 47600 31200 47600 13500
    Average 82800 61400 82800 68900 82800 41800
    Stdev 102000 71900 102000 95000 102000 60300
    p (t-test) 0.28 0.45 0.092
    Min 7.99 380 7.99 1030 7.99 1300
    Max 631000 234000 631000 423000 631000 187000
    n (Samp) 295 27 295 34 295 18
    n (Patient) 167 27 167 34 167 18
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.41 nd 0.42 0.44 0.44 0.44 0.32 nd 0.32
    SE 0.060 nd 0.060 0.053 0.12 0.054 0.069 nd 0.071
    p 0.12 nd 0.20 0.29 0.60 0.23 0.0084 nd 0.010
    nCohort 1 325 nd 295 325 417 295 325 nd 295
    nCohort 2 27 nd 27 34 6 34 19 nd 18
    Cutoff 1 9720 nd 9720 14100 4320 10500 3140 nd 3010
    Sens 1 70% nd 70% 71% 83% 71% 74% nd 72%
    Spec 1 16% nd 17% 24%  9% 19%  5% nd  6%
    Cutoff 2 4320 nd 4320 6200 4320 6120 2260 nd 2260
    Sens 2 81% nd 81% 82% 83% 88% 84% nd 83%
    Spec 2  6% nd  7% 10%  9% 11%  4% nd  4%
    Cutoff 3 2710 nd 3010 5110 887 5110 1680 nd 1680
    Sens 3 93% nd 93% 91% 100%  91% 95% nd 94%
    Spec 3  4% nd  6%  7%  2%  7%  4% nd  4%
    Cutoff 4 99500 nd 92000 99500 95700 92000 99500 nd 92000
    Sens 4 22% nd 26% 26% 33% 26% 16% nd 22%
    Spec 4 70% nd 70% 70% 70% 70% 70% nd 70%
    Cutoff 5 142000 nd 128000 142000 135000 128000 142000 nd 128000
    Sens 5 15% nd 15% 18% 33% 15% 16% nd 17%
    Spec 5 80% nd 80% 80% 80% 80% 80% nd 80%
    Cutoff 6 235000 nd 219000 235000 225000 219000 235000 nd 219000
    Sens 6  0% nd  7%  6%  0%  6%  0% nd  0%
    Spec 6 90% nd 90% 90% 90% 90% 90% nd 90%
    OR Quart 2 0.82 nd 0.83 0.42 0 0.74 0.66 nd 0.33
    p Value 0.76 nd 0.77 0.16 na 0.59 0.65 nd 0.34
    95% CI of 0.24 nd 0.24 0.12 na 0.25 0.11 nd 0.033
    OR Quart 2 2.8 nd 2.8 1.4 na 2.2 4.0 nd 3.2
    OR Quart 3 1.0 nd 1.0 1.3 1.0 1.2 1.7 nd 1.7
    p Value 1.0 nd 1.0 0.64 1.0 0.78 0.47 nd 0.46
    95% CI of 0.31 nd 0.31 0.49 0.14 0.42 0.40 nd 0.40
    OR Quart 3 3.2 nd 3.2 3.2 7.2 3.2 7.4 nd 7.5
    OR Quart 4 1.8 nd 1.8 1.1 1.0 1.5 3.2 nd 3.3
    p Value 0.30 nd 0.29 0.79 0.99 0.45 0.087 nd 0.082
    95% CI of 0.61 nd 0.62 0.44 0.14 0.55 0.84 nd 0.86
    OR Quart 4 5.0 nd 5.2 3.0 7.3 3.8 12 nd 13
  • FIG. 7: Comparison of marker levels in EDTA samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F).
  •
    C-C motif chemokine 7
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.620 0.512 nd nd 0.620 0.512
    Average 10.9 11.4 nd nd 11.2 12.4
    Stdev 28.1 22.4 nd nd 30.3 24.3
    p (t-test) 0.94 nd nd 0.90
    Min 0.193 0.193 nd nd 0.193 0.193
    Max 166 79.4 nd nd 166 79.4
    n (Samp) 41 19 nd nd 31 15
    n (Patient) 41 19 nd nd 31 15
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.51 nd 0.49
    SE 0.081 nd 0.092
    p 0.95 nd 0.93
    nCohort 1 41 nd 31
    nCohort 2 19 nd 15
    Cutoff 1 0.193 nd 0.193
    Sens 1 95% nd 93%
    Spec 1 20% nd 19%
    Cutoff 2 0.193 nd 0.193
    Sens 2 95% nd 93%
    Spec 2 20% nd 19%
    Cutoff 3 0.193 nd 0.193
    Sens 3 95% nd 93%
    Spec 3 20% nd 19%
    Cutoff 4 9.43 nd 9.43
    Sens 4 32% nd 33%
    Spec 4 71% nd 71%
    Cutoff 5 13.9 nd 13.9
    Sens 5 21% nd 20%
    Spec 5 80% nd 81%
    Cutoff 6 19.6 nd 19.6
    Sens 6 16% nd 13%
    Spec 6 90% nd 90%
    OR Quart 2 1.0 nd 0.75
    p Value 1.0 nd 0.75
    95% CI of 0.22 nd 0.13
    OR Quart 2 4.6 nd 4.5
    OR Quart 3 0.73 nd 1.0
    p Value 0.69 nd 1.0
    95% CI of 0.15 nd 0.18
    OR Quart 3 3.5 nd 5.5
    OR Quart 4 1.0 nd 1.1
    p Value 1.0 nd 0.88
    95% CI of 0.22 nd 0.21
    OR Quart 4 4.6 nd 6.4
    Interleukin-33
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.0981 0.0981 nd nd 0.0981 0.0543
    Average 67.7 946 nd nd 3.24 1200
    Stdev 275 3200 nd nd 8.39 3590
    p (t-test) 0.084 nd nd 0.067
    Min 0.0445 0.0445 nd nd 0.0445 0.0445
    Max 1270 13500 nd nd 42.0 13500
    n (Samp) 41 19 nd nd 31 15
    n (Patient) 41 19 nd nd 31 15
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.48 nd 0.48
    SE 0.081 nd 0.092
    p 0.82 nd 0.84
    nCohort 1 41 nd 31
    nCohort 2 19 nd 15
    Cutoff 1 0.0445 nd 0.0445
    Sens 1 84% nd 87%
    Spec 1  7% nd 10%
    Cutoff 2 0.0445 nd 0.0445
    Sens 2 84% nd 87%
    Spec 2  7% nd 10%
    Cutoff 3 0 nd 0
    Sens 3 100%  nd 100% 
    Spec 3  0% nd  0%
    Cutoff 4 0.101 nd 0.101
    Sens 4 37% nd 33%
    Spec 4 76% nd 81%
    Cutoff 5 9.78 nd 0.101
    Sens 5 21% nd 33%
    Spec 5 80% nd 81%
    Cutoff 6 17.9 nd 9.90
    Sens 6 16% nd 27%
    Spec 6 90% nd 90%
    OR Quart 2 1.0 nd 0.14
    p Value 1.0 nd 0.10
    95% CI of 0.22 nd 0.013
    OR Quart 2 4.6 nd 1.5
    OR Quart 3 0.31 nd 0.47
    p Value 0.21 nd 0.39
    95% CI of 0.049 nd 0.082
    OR Quart 3 1.9 nd 2.7
    OR Quart 4 1.8 nd 1.7
    p Value 0.46 nd 0.54
    95% CI of 0.40 nd 0.32
    OR Quart 4 7.7 nd 8.8
    Interleukin-4 receptor alpha chain
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 208 186 nd nd 193 193
    Average 301 235 nd nd 289 254
    Stdev 242 256 nd nd 245 278
    p (t-test) 0.34 nd nd 0.67
    Min 49.7 3.27 nd nd 49.7 41.2
    Max 1040 1210 nd nd 1040 1210
    n (Samp) 41 19 nd nd 31 15
    n (Patient) 41 19 nd nd 31 15
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.39 nd 0.45
    SE 0.081 nd 0.092
    p 0.19 nd 0.59
    nCohort 1 41 nd 31
    nCohort 2 19 nd 15
    Cutoff 1 104 nd 108
    Sens 1 79% nd 73%
    Spec 1  7% nd  6%
    Cutoff 2 84.5 nd 104
    Sens 2 84% nd 87%
    Spec 2  5% nd  6%
    Cutoff 3 3.27 nd 49.7
    Sens 3 95% nd 93%
    Spec 3  0% nd  3%
    Cutoff 4 296 nd 234
    Sens 4 21% nd 33%
    Spec 4 71% nd 71%
    Cutoff 5 431 nd 336
    Sens 5  5% nd 13%
    Spec 5 80% nd 81%
    Cutoff 6 621 nd 621
    Sens 6  5% nd  7%
    Spec 6 90% nd 90%
    OR Quart 2 2.0 nd 1.1
    p Value 0.41 nd 0.88
    95% CI of 0.38 nd 0.21
    OR Quart 2 11 nd 6.4
    OR Quart 3 1.5 nd 0.40
    p Value 0.67 nd 0.35
    95% CI of 0.26 nd 0.058
    OR Quart 3 8.0 nd 2.8
    OR Quart 4 3.5 nd 1.7
    p Value 0.13 nd 0.55
    95% CI of 0.69 nd 0.31
    OR Quart 4 18 nd 9.0
    Lutropin subunit beta
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 3.69 1.32 nd nd nd nd
    Average 7.27 1.57 nd nd nd nd
    Stdev 10.3 1.24 nd nd nd nd
    p (t-test) 0.16 nd nd nd nd
    Min 0.0399 0.0768 nd nd nd nd
    Max 50.0 3.61 nd nd nd nd
    n (Samp) 30 7 nd nd nd nd
    n (Patient) 30 7 nd nd nd nd
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.28 nd nd
    SE 0.12 nd nd
    p 0.057 nd nd
    nCohort 1 30 nd nd
    nCohort 2 7 nd nd
    Cutoff 1 0.565 nd nd
    Sens 1 71% nd nd
    Spec 1 23% nd nd
    Cutoff 2 0.429 nd nd
    Sens 2 86% nd nd
    Spec 2 17% nd nd
    Cutoff 3 0.0621 nd nd
    Sens 3 100%  nd nd
    Spec 3  7% nd nd
    Cutoff 4 5.73 nd nd
    Sens 4  0% nd nd
    Spec 4 70% nd nd
    Cutoff 5 14.5 nd nd
    Sens 5  0% nd nd
    Spec 5 80% nd nd
    Cutoff 6 17.8 nd nd
    Sens 6  0% nd nd
    Spec 6 90% nd nd
    OR Quart 2 >1.2 nd nd
    p Value <0.88 nd nd
    95% CI of >0.067 nd nd
    OR Quart 2 na nd nd
    OR Quart 3 >8.0 nd nd
    p Value <0.095 nd nd
    95% CI of >0.70 nd nd
    OR Quart 3 na nd nd
    OR Quart 4 >2.9 nd nd
    p Value <0.43 nd nd
    95% CI of >0.21 nd nd
    OR Quart 4 na nd nd
    Platelet-derived growth factor subunit B (dimer)
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 347 370 nd nd 356 390
    Average 415 392 nd nd 425 404
    Stdev 228 193 nd nd 228 215
    p (t-test) 0.72 nd nd 0.78
    Min 65.1 152 nd nd 65.1 152
    Max 960 766 nd nd 960 766
    n (Samp) 57 15 nd nd 43 12
    n (Patient) 57 15 nd nd 43 12
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.47 nd 0.46
    SE 0.085 nd 0.096
    p 0.77 nd 0.70
    nCohort 1 57 nd 43
    nCohort 2 15 nd 12
    Cutoff 1 235 nd 220
    Sens 1 73% nd 75%
    Spec 1 23% nd 16%
    Cutoff 2 220 nd 212
    Sens 2 80% nd 83%
    Spec 2 19% nd 16%
    Cutoff 3 195 nd 192
    Sens 3 93% nd 92%
    Spec 3 19% nd 16%
    Cutoff 4 515 nd 567
    Sens 4 20% nd 25%
    Spec 4 70% nd 72%
    Cutoff 5 609 nd 629
    Sens 5 20% nd 17%
    Spec 5 81% nd 81%
    Cutoff 6 782 nd 779
    Sens 6  0% nd  0%
    Spec 6 91% nd 91%
    OR Quart 2 1.9 nd 1.0
    p Value 0.43 nd 1.0
    95% CI of 0.38 nd 0.16
    OR Quart 2 9.6 nd 6.1
    OR Quart 3 0.62 nd 0.28
    p Value 0.63 nd 0.30
    95% CI of 0.091 nd 0.026
    OR Quart 3 4.3 nd 3.1
    OR Quart 4 1.9 nd 2.3
    p Value 0.43 nd 0.34
    95% CI of 0.38 nd 0.42
    OR Quart 4 9.6 nd 13
    Corticotropin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.000624 0.00327 nd nd 0.000539 0.00321
    Average 0.00399 0.00614 nd nd 0.00371 0.00648
    Stdev 0.00894 0.00786 nd nd 0.00924 0.00821
    p (t-test) 0.44 nd nd 0.42
    Min 3.38E−6 4.31E−6 nd nd 3.38E−6 0.000293
    Max 0.0483 0.0251 nd nd 0.0483 0.0251
    n (Samp) 42 13 nd nd 33 9
    n (Patient) 42 13 nd nd 33 9
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.66 nd 0.74
    SE 0.091 nd 0.10
    p 0.078 nd 0.021
    nCohort 1 42 nd 33
    nCohort 2 13 nd 9
    Cutoff 1 0.000466 nd 0.00122
    Sens 1 77% nd 78%
    Spec 1 45% nd 61%
    Cutoff 2 0.000261 nd 0.000293
    Sens 2 85% nd 89%
    Spec 2 40% nd 45%
    Cutoff 3 4.31E−6 nd 0.000261
    Sens 3 92% nd 100% 
    Spec 3 24% nd 42%
    Cutoff 4 0.00201 nd 0.00183
    Sens 4 62% nd 67%
    Spec 4 71% nd 73%
    Cutoff 5 0.00486 nd 0.00329
    Sens 5 31% nd 33%
    Spec 5 81% nd 82%
    Cutoff 6 0.00761 nd 0.00658
    Sens 6 31% nd 33%
    Spec 6 90% nd 91%
    OR Quart 2 0.92 nd >2.2
    p Value 0.94 nd <0.54
    95% CI of 0.11 nd >0.17
    OR Quart 2 7.7 nd na
    OR Quart 3 2.2 nd >4.3
    p Value 0.42 nd <0.25
    95% CI of 0.33 nd >0.37
    OR Quart 3 15 nd na
    OR Quart 4 3.1 nd >5.7
    p Value 0.24 nd <0.15
    95% CI of 0.47 nd >0.52
    OR Quart 4 20 nd na
    Thyroxine-binding globulin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 36.1 28.0 nd nd 34.1 30.0
    Average 36.5 30.9 nd nd 36.1 31.3
    Stdev 10.8 10.6 nd nd 11.3 10.6
    p (t-test) 0.044 nd nd 0.14
    Min 12.8 14.2 nd nd 12.8 14.2
    Max 56.7 48.3 nd nd 56.7 46.0
    n (Samp) 55 22 nd nd 46 16
    n (Patient) 55 22 nd nd 46 16
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.35 nd 0.36
    SE 0.072 nd 0.084
    p 0.043 nd 0.10
    nCohort 1 55 nd 46
    nCohort 2 22 nd 16
    Cutoff 1 24.7 nd 25.2
    Sens 1 73% nd 75%
    Spec 1 15% nd 20%
    Cutoff 2 19.7 nd 22.8
    Sens 2 82% nd 81%
    Spec 2  7% nd 13%
    Cutoff 3 15.8 nd 15.4
    Sens 3 91% nd 94%
    Spec 3  5% nd  7%
    Cutoff 4 43.0 nd 42.3
    Sens 4 18% nd 25%
    Spec 4 71% nd 72%
    Cutoff 5 46.9 nd 47.1
    Sens 5  5% nd  0%
    Spec 5 80% nd 80%
    Cutoff 6 51.0 nd 51.0
    Sens 6  0% nd  0%
    Spec 6 91% nd 91%
    OR Quart 2 1.1 nd 1.1
    p Value 0.94 nd 0.93
    95% CI of 0.23 nd 0.18
    OR Quart 2 5.0 nd 6.4
    OR Quart 3 1.8 nd 2.0
    p Value 0.41 nd 0.42
    95% CI of 0.43 nd 0.38
    OR Quart 3 8.0 nd 10
    OR Quart 4 2.9 nd 2.2
    p Value 0.14 nd 0.36
    95% CI of 0.70 nd 0.42
    OR Quart 4 12 nd 11
    Alpha-fetoprotein
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.331 0.458 nd nd 0.302 0.452
    Average 0.318 0.516 nd nd 0.298 0.452
    Stdev 0.265 0.415 nd nd 0.238 0.396
    p (t-test) 0.023 nd nd 0.095
    Min 0.00580 0.00580 nd nd 0.00580 0.00580
    Max 1.11 1.31 nd nd 0.997 1.31
    n (Samp) 58 16 nd nd 44 12
    n (Patient) 58 16 nd nd 44 12
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.65 nd 0.62
    SE 0.082 nd 0.096
    p 0.076 nd 0.20
    nCohort 1 58 nd 44
    nCohort 2 16 nd 12
    Cutoff 1 0.225 nd 0.221
    Sens 1 75% nd 75%
    Spec 1 40% nd 39%
    Cutoff 2 0.221 nd 0.00580
    Sens 2 81% nd 92%
    Spec 2 38% nd 14%
    Cutoff 3 0.00580 nd 0.00580
    Sens 3 94% nd 92%
    Spec 3 14% nd 14%
    Cutoff 4 0.446 nd 0.415
    Sens 4 50% nd 50%
    Spec 4 71% nd 70%
    Cutoff 5 0.530 nd 0.513
    Sens 5 44% nd 50%
    Spec 5 81% nd 82%
    Cutoff 6 0.598 nd 0.570
    Sens 6 38% nd 33%
    Spec 6 91% nd 91%
    OR Quart 2 0.94 nd 0.61
    p Value 0.94 nd 0.62
    95% CI of 0.16 nd 0.085
    OR Quart 2 5.4 nd 4.4
    OR Quart 3 1.0 nd 0.28
    p Value 1.0 nd 0.30
    95% CI of 0.17 nd 0.026
    OR Quart 3 5.8 nd 3.1
    OR Quart 4 2.9 nd 2.8
    p Value 0.18 nd 0.23
    95% CI of 0.62 nd 0.52
    OR Quart 4 14 nd 14
    Apolipoprotein E
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 59000 43100 nd nd 59600 50600
    Average 74200 47600 nd nd 78300 50500
    Stdev 52400 31200 nd nd 54800 34500
    p (t-test) 0.027 nd nd 0.054
    Min 12600 1940 nd nd 13000 1940
    Max 244000 120000 nd nd 244000 120000
    n (Samp) 68 22 nd nd 53 17
    n (Patient) 68 22 nd nd 53 17
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.35 nd 0.36
    SE 0.071 nd 0.081
    p 0.029 nd 0.080
    nCohort 1 68 nd 53
    nCohort 2 22 nd 17
    Cutoff 1 23900 nd 27300
    Sens 1 73% nd 71%
    Spec 1 13% nd 11%
    Cutoff 2 17400 nd 14200
    Sens 2 82% nd 82%
    Spec 2  6% nd  4%
    Cutoff 3 14100 nd 1940
    Sens 3 91% nd 94%
    Spec 3  4% nd  0%
    Cutoff 4 85700 nd 91600
    Sens 4 14% nd 18%
    Spec 4 71% nd 72%
    Cutoff 5 98600 nd 98600
    Sens 5  9% nd 12%
    Spec 5 81% nd 81%
    Cutoff 6 164000 nd 164000
    Sens 6  0% nd  0%
    Spec 6 91% nd 91%
    OR Quart 2 1.5 nd 1.1
    p Value 0.64 nd 0.94
    95% CI of 0.29 nd 0.18
    OR Quart 2 7.5 nd 6.2
    OR Quart 3 3.6 nd 1.4
    p Value 0.094 nd 0.67
    95% CI of 0.80 nd 0.27
    OR Quart 3 16 nd 7.5
    OR Quart 4 3.1 nd 3.5
    p Value 0.14 nd 0.12
    95% CI of 0.69 nd 0.73
    OR Quart 4 14 nd 17
  • FIG. 8: Comparison of the maximum marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in EDTA samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2.
  •
    Complement C4-B
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 65500 61600 65500 61600 nd nd
    Average 73300 68700 73300 68700 nd nd
    Stdev 40400 39200 40400 39200 nd nd
    p (t-test) 0.76 0.76 nd nd
    Min 641 13500 641 13500 nd nd
    Max 203000 125000 203000 125000 nd nd
    n (Samp) 87 8 87 8 nd nd
    n (Patient) 87 8 87 8 nd nd
    UO only
    Median 65700 61600 65700 61600 nd nd
    Average 71600 68700 71600 68700 nd nd
    Stdev 35600 45800 35600 45800 nd nd
    p (t-test) 0.85 0.85 nd nd
    Min 641 13500 641 13500 nd nd
    Max 160000 125000 160000 125000 nd nd
    n (Samp) 80 6 80 6 nd nd
    n (Patient) 80 6 80 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.48 nd 0.46 0.48 nd 0.46 nd nd nd
    SE 0.11 nd 0.13 0.11 nd 0.13 nd nd nd
    p 0.84 nd 0.76 0.84 nd 0.76 nd nd nd
    nCohort 1 87 nd 80 87 nd 80 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 57800 nd 29600 57800 nd 29600 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 41% nd 10% 41% nd 10% nd nd nd
    Cutoff 2 29600 nd 29600 29600 nd 29600 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2 10% nd 10% 10% nd 10% nd nd nd
    Cutoff 3 5890 nd 5890 5890 nd 5890 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  2% nd  2%  2% nd  2% nd nd nd
    Cutoff 4 86300 nd 87900 86300 nd 87900 nd nd nd
    Sens 4 25% nd 33% 25% nd 33% nd nd nd
    Spec 4 70% nd 70% 70% nd 70% nd nd nd
    Cutoff 5 104000 nd 100000 104000 nd 100000 nd nd nd
    Sens 5 25% nd 33% 25% nd 33% nd nd nd
    Spec 5 80% nd 80% 80% nd 80% nd nd nd
    Cutoff 6 129000 nd 124000 129000 nd 124000 nd nd nd
    Sens 6  0% nd 17%  0% nd 17% nd nd nd
    Spec 6 91% nd 90% 91% nd 90% nd nd nd
    OR Quart 2 0.48 nd 0 0.48 nd 0 nd nd nd
    p Value 0.56 nd na 0.56 nd na nd nd nd
    95% CI of 0.040 nd na 0.040 nd na nd nd nd
    OR Quart 2 5.7 nd na 5.7 nd na nd nd nd
    OR Quart 3 1.6 nd 1.0 1.6 nd 1.0 nd nd nd
    p Value 0.64 nd 1.0 0.64 nd 1.0 nd nd nd
    95% CI of 0.24 nd 0.13 0.24 nd 0.13 nd nd nd
    OR Quart 3 10 nd 7.8 10 nd 7.8 nd nd nd
    OR Quart 4 1.0 nd 1.1 1.0 nd 1.1 nd nd nd
    p Value 0.96 nd 0.96 0.96 nd 0.96 nd nd nd
    95% CI of 0.13 nd 0.13 0.13 nd 0.13 nd nd nd
    OR Quart 4 8.1 nd 8.2 8.1 nd 8.2 nd nd nd
    C-C motif chemokine 26
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1.25 4.43 1.25 4.43 1.25 6.99
    Average 18.1 7.55 18.1 7.36 18.1 6.64
    Stdev 79.1 9.61 79.1 9.74 79.1 6.53
    p (t-test) 0.65 0.64 0.71
    Min 0.0121 0.0232 0.0121 0.0232 0.0121 0.652
    Max 468 33.0 468 33.0 468 18.3
    n (Samp) 64 12 64 12 64 7
    n (Patient) 64 12 64 12 64 7
    sCr only
    Median 1.76 1.73 1.76 0.937 nd nd
    Average 11.9 2.36 11.9 1.99 nd nd
    Stdev 55.9 2.51 55.9 2.69 nd nd
    p (t-test) 0.68 0.67 nd nd
    Min 0.0121 0.0232 0.0121 0.0232 nd nd
    Max 468 6.99 468 6.99 nd nd
    n (Samp) 131 6 131 6 nd nd
    n (Patient) 131 6 131 6 nd nd
    UO only
    Median 1.25 7.45 1.25 7.45 1.25 7.45
    Average 18.5 10.5 18.5 10.5 18.5 7.54
    Stdev 79.7 10.7 79.7 10.7 79.7 6.66
    p (t-test) 0.78 0.78 0.74
    Min 0.0121 0.652 0.0121 0.652 0.0121 0.652
    Max 468 33.0 468 33.0 468 18.3
    n (Samp) 63 8 63 8 63 6
    n (Patient) 63 8 63 8 63 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.63 0.46 0.73 0.59 0.38 0.73 0.65 nd 0.69
    SE 0.093 0.12 0.11 0.093 0.13 0.11 0.12 nd 0.12
    p 0.15 0.74 0.029 0.33 0.36 0.029 0.19 nd 0.12
    nCohort 1 64 131 63 64 131 63 64 nd 63
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 0.949 0.355 5.00 0.0587 0.0325 5.00 0.949 nd 0.0587
    Sens 1 75% 83% 75% 83% 83% 75% 71% nd 100% 
    Spec 1 44% 33% 78% 31%  7% 78% 44% nd 35%
    Cutoff 2 0.0587 0.355 0.0587 0.0587 0.0325 0.0587 0.0587 nd 0.0587
    Sens 2 92% 83% 100%  83% 83% 100%  100%  nd 100% 
    Spec 2 31% 33% 35% 31%  7% 35% 31% nd 35%
    Cutoff 3 0.0587 0.0121 0.0587 0.0232 0.0121 0.0587 0.0587 nd 0.0587
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 31%  2% 35%  8%  2% 35% 31% nd 35%
    Cutoff 4 3.61 5.00 3.57 3.61 5.00 3.57 3.61 nd 3.57
    Sens 4 50% 17% 75% 50% 17% 75% 57% nd 67%
    Spec 4 70% 71% 71% 70% 71% 71% 70% nd 71%
    Cutoff 5 6.86 7.86 6.86 6.86 7.86 6.86 6.86 nd 6.86
    Sens 5 42%  0% 62% 42%  0% 62% 57% nd 67%
    Spec 5 81% 80% 81% 81% 80% 81% 81% nd 81%
    Cutoff 6 14.2 14.2 14.2 14.2 14.2 14.2 14.2 nd 14.2
    Sens 6 17%  0% 25% 17%  0% 25% 14% nd 17%
    Spec 6 91% 90% 90% 91% 90% 90% 91% nd 90%
    OR Quart 2 3.4 2.1 >2.1 1.6 1.0 >2.1 >3.4 nd >2.3
    p Value 0.31 0.55 <0.55 0.63 0.98 <0.55 <0.31 nd <0.52
    95% CI of 0.32 0.18 >0.18 0.23 0.062 >0.18 >0.32 nd >0.19
    OR Quart 2 36 25 na 11 17 na na nd na
    OR Quart 3 3.4 2.1 >1.0 1.0 2.1 >1.0 >0 nd >0
    p Value 0.31 0.55 <1.0 1.0 0.55 <1.0 <na nd <na
    95% CI of 0.32 0.18 >0.058 0.13 0.18 > >na nd >na
    OR Quart 3 36 25 na 7.9 25 na na nd na
    OR Quart 4 6.4 1.0 >6.5 3.0 2.1 >6.5 >4.9 nd >4.9
    p Value 0.11 0.98 <0.10 0.22 0.55 <0.10 <0.18 nd <0.18
    95% CI of 0.67 0.062 >0.68 0.51 0.18 >0.68 >0.49 nd >0.49
    OR Quart 4 61 17 na 18 25 na na nd na
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.804 5.45 0.804 5.45 0.804 10.4
    Average 11.6 36.3 11.6 36.3 11.6 12.6
    Stdev 26.0 65.4 26.0 65.4 26.0 13.3
    p (t-test) 0.026 0.026 0.92
    Min 0.193 0.308 0.193 0.308 0.193 0.308
    Max 128 219 128 219 128 30.8
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 0.804 5.45 0.804 5.45 nd nd
    Average 13.2 22.1 13.2 22.1 nd nd
    Stdev 29.3 40.6 29.3 40.6 nd nd
    p (t-test) 0.48 0.48 nd nd
    Min 0.193 0.308 0.193 0.308 nd nd
    Max 181 104 181 104 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 0.804 5.45 0.804 5.45 0.804 5.45
    Average 10.4 39.2 10.4 39.2 10.4 11.9
    Stdev 25.9 75.1 25.9 75.1 25.9 14.5
    p (t-test) 0.028 0.028 0.89
    Min 0.193 0.308 0.193 0.308 0.193 0.308
    Max 128 219 128 219 128 30.8
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.50 0.58 0.56 0.50 0.58 0.56 nd 0.55
    SE 0.093 0.12 0.11 0.093 0.12 0.11 0.12 nd 0.13
    p 0.52 1.00 0.47 0.52 1.00 0.47 0.59 nd 0.71
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 0.308 0.193 0.308 0.308 0.193 0.308 0.308 nd 0.193
    Sens 1 75% 100%  75% 75% 100%  75% 71% nd 100% 
    Spec 1 25%  3% 28% 25%  3% 28% 25% nd  3%
    Cutoff 2 0.193 0.193 0.193 0.193 0.193 0.193 0.193 nd 0.193
    Sens 2 100%  100%  100%  100%  100%  100%  100%  nd 100% 
    Spec 2  3%  3%  3%  3%  3%  3%  3% nd  3%
    Cutoff 3 0.193 0.193 0.193 0.193 0.193 0.193 0.193 nd 0.193
    Sens 3 100%  100%  100%  100%  100%  100%  100%  nd 100% 
    Spec 3  3%  3%  3%  3%  3%  3%  3% nd  3%
    Cutoff 4 8.40 8.42 4.51 8.40 8.42 4.51 8.40 nd 4.51
    Sens 4 50% 50% 50% 50% 50% 50% 57% nd 50%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 12.2 15.3 8.42 12.2 15.3 8.42 12.2 nd 8.42
    Sens 5 42% 33% 50% 42% 33% 50% 43% nd 50%
    Spec 5 80% 80% 81% 80% 80% 81% 80% nd 81%
    Cutoff 6 32.2 33.2 18.9 32.2 33.2 18.9 32.2 nd 18.9
    Sens 6 25% 17% 38% 25% 17% 38%  0% nd 33%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 1.0 0.50 1.0 1.0 0.50 1.0 0.47 nd 0.44
    p Value 1.0 0.58 1.0 1.0 0.58 1.0 0.55 nd 0.52
    95% CI of 0.17 0.043 0.13 0.17 0.043 0.13 0.039 nd 0.036
    OR Quart 2 5.7 5.8 8.0 5.7 5.8 8.0 5.7 nd 5.4
    OR Quart 3 0 0.49 0 0 0.49 0 0 nd 0
    p Value na 0.56 na na 0.56 na na nd na
    95% CI of na 0.042 na na 0.042 na na nd na
    OR Quart 3 na 5.6 na na 5.6 na na nd na
    OR Quart 4 2.3 1.0 2.3 2.3 1.0 2.3 2.3 nd 1.5
    p Value 0.30 0.98 0.38 0.30 0.98 0.38 0.38 nd 0.68
    95% CI of 0.48 0.14 0.36 0.48 0.14 0.36 0.36 nd 0.22
    OR Quart 4 11 7.8 14 11 7.8 14 14 nd 10
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 5220 5750 5220 5190 5220 4620
    Average 7140 7290 7140 7190 7140 6080
    Stdev 5790 4660 5790 4690 5790 2970
    p (t-test) 0.93 0.98 0.64
    Min 565 1740 565 1740 565 3160
    Max 29400 16600 29400 16600 29400 10400
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 6370 4450 6370 4280 nd nd
    Average 7630 5070 7630 4880 nd nd
    Stdev 5970 3070 5970 3030 nd nd
    p (t-test) 0.30 0.27 nd nd
    Min 565 1740 565 1740 nd nd
    Max 43200 10400 43200 10400 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 5340 5790 5340 5790 5340 4410
    Average 7390 7970 7390 7970 7390 5350
    Stdev 6200 5200 6200 5200 6200 2480
    p (t-test) 0.80 0.80 0.43
    Min 565 3160 565 3160 565 3160
    Max 32800 16600 32800 16600 32800 9630
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.54 0.36 0.53 0.53 0.34 0.53 0.49 nd 0.40
    SE 0.092 0.12 0.11 0.092 0.12 0.11 0.12 nd 0.13
    p 0.70 0.25 0.79 0.78 0.19 0.79 0.90 nd 0.41
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 3920 3140 3920 3920 3140 3920 3920 nd 3400
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 31% 16% 28% 31% 16% 28% 31% nd 20%
    Cutoff 2 3400 3140 3400 3400 3140 3400 3400 nd 3400
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 23% 16% 20% 23% 16% 20% 23% nd 20%
    Cutoff 3 3140 1720 3140 3140 1720 3140 3140 nd 3140
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 17%  5% 14% 17%  5% 14% 17% nd 14%
    Cutoff 4 7590 8540 7610 7590 8540 7610 7590 nd 7610
    Sens 4 33% 17% 38% 33% 17% 38% 29% nd 17%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 9000 10300 9000 9000 10300 9000 9000 nd 9000
    Sens 5 33% 17% 38% 33% 17% 38% 29% nd 17%
    Spec 5 80% 80% 81% 80% 80% 81% 80% nd 81%
    Cutoff 6 13800 13200 13800 13800 13200 13800 13800 nd 13800
    Sens 6 17%  0% 25% 17%  0% 25%  0% nd  0%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 0.63 0 1.0 1.0 0 1.0 0.47 nd 1.1
    p Value 0.63 na 1.0 1.0 na 1.0 0.55 nd 0.97
    95% CI of 0.092 na 0.13 0.17 na 0.13 0.039 nd 0.061
    OR Quart 2 4.3 na 8.0 5.7 na 8.0 5.7 nd 18
    OR Quart 3 1.0 2.1 0.47 0.63 2.1 0.47 1.0 nd 2.1
    p Value 1.0 0.56 0.55 0.63 0.56 0.55 1.0 nd 0.55
    95% CI of 0.17 0.18 0.039 0.092 0.18 0.039 0.13 nd 0.18
    OR Quart 3 5.7 24 5.7 4.3 24 5.7 8.0 nd 26
    OR Quart 4 1.3 3.3 1.6 1.3 3.3 1.6 1.0 nd 2.3
    p Value 0.73 0.31 0.63 0.73 0.31 0.63 1.0 nd 0.52
    95% CI of 0.26 0.32 0.23 0.26 0.32 0.23 0.13 nd 0.19
    OR Quart 4 6.9 33 11 6.9 33 11 8.0 nd 28
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 14.0 23.9 14.0 23.9 14.0 14.0
    Average 22.3 34.7 22.3 34.4 22.3 16.8
    Stdev 33.5 43.9 33.5 44.0 33.5 14.9
    p (t-test) 0.26 0.28 0.67
    Min 0.0320 0.209 0.0320 0.209 0.0320 0.209
    Max 223 163 223 163 223 43.4
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 19.5 23.7 19.5 23.7 nd nd
    Average 23.8 20.4 23.8 19.7 nd nd
    Stdev 28.3 15.7 28.3 15.2 nd nd
    p (t-test) 0.78 0.73 nd nd
    Min 0.0320 0.209 0.0320 0.209 nd nd
    Max 223 39.2 223 39.2 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 13.3 23.9 13.3 23.9 13.3 10.6
    Average 21.0 39.9 21.0 39.9 21.0 15.9
    Stdev 35.0 53.2 35.0 53.2 35.0 16.1
    p (t-test) 0.18 0.18 0.73
    Min 0.0320 0.209 0.0320 0.209 0.0320 0.209
    Max 223 163 223 163 223 43.4
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.61 0.52 0.63 0.61 0.50 0.63 0.48 nd 0.49
    SE 0.093 0.12 0.11 0.093 0.12 0.11 0.12 nd 0.13
    p 0.24 0.90 0.23 0.25 0.98 0.23 0.88 nd 0.91
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 6.46 2.04 6.46 6.46 2.04 6.46 6.46 nd 4.65
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 28% 14% 31% 28% 14% 31% 28% nd 25%
    Cutoff 2 4.65 2.04 4.65 4.65 2.04 4.65 4.65 nd 4.65
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 22% 14% 25% 22% 14% 25% 22% nd 25%
    Cutoff 3 2.04 0.0997 0.0997 2.04 0.0997 0.0997 0.0997 nd 0.0997
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 15% 11%  9% 15% 11%  9%  8% nd  9%
    Cutoff 4 23.8 28.0 19.0 23.8 28.0 19.0 23.8 nd 19.0
    Sens 4 50% 33% 62% 50% 33% 62% 29% nd 33%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 29.2 32.9 26.8 29.2 32.9 26.8 29.2 nd 26.8
    Sens 5 42% 17% 38% 33% 17% 38% 14% nd 17%
    Spec 5 80% 80% 81% 80% 80% 81% 80% nd 81%
    Cutoff 6 44.4 43.4 34.3 44.4 43.4 34.3 44.4 nd 34.3
    Sens 6 17%  0% 38% 17%  0% 38%  0% nd 17%
    Spec 6 92% 90% 91% 92% 90% 91% 92% nd 91%
    OR Quart 2 0.30 0 0.47 0.30 0 0.47 3.4 nd 0.50
    p Value 0.31 na 0.55 0.31 na 0.55 0.31 nd 0.59
    95% CI of 0.028 na 0.039 0.028 na 0.039 0.32 nd 0.041
    OR Quart 2 3.1 na 5.7 3.1 na 5.7 36 nd 6.1
    OR Quart 3 1.0 1.0 0.47 1.0 1.5 0.47 1.0 nd 1.0
    p Value 1.0 1.0 0.55 1.0 0.64 0.55 1.0 nd 1.0
    95% CI of 0.17 0.13 0.039 0.17 0.24 0.039 0.058 nd 0.13
    OR Quart 3 5.7 7.5 5.7 5.7 9.9 5.7 17 nd 8.0
    OR Quart 4 1.8 0.97 2.3 1.8 0.47 2.3 2.1 nd 0.50
    p Value 0.48 0.98 0.38 0.48 0.55 0.38 0.55 nd 0.59
    95% CI of 0.36 0.13 0.36 0.36 0.041 0.36 0.18 nd 0.041
    OR Quart 4 8.8 7.3 14 8.8 5.4 14 26 nd 6.1
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.43 14.3 2.43 14.3 nd nd
    Average 12.0 16.2 12.0 16.2 nd nd
    Stdev 24.2 15.1 24.2 15.1 nd nd
    p (t-test) 0.63 0.63 nd nd
    Min 0.572 0.572 0.572 0.572 nd nd
    Max 158 33.4 158 33.4 nd nd
    n (Samp) 87 8 87 8 nd nd
    n (Patient) 87 8 87 8 nd nd
    UO only
    Median 2.93 15.8 2.93 15.8 nd nd
    Average 13.3 16.8 13.3 16.8 nd nd
    Stdev 25.0 16.4 25.0 16.4 nd nd
    p (t-test) 0.74 0.74 nd nd
    Min 0.572 0.572 0.572 0.572 nd nd
    Max 158 33.4 158 33.4 nd nd
    n (Samp) 80 6 80 6 nd nd
    n (Patient) 80 6 80 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.66 nd 0.61 0.66 nd 0.61 nd nd nd
    SE 0.11 nd 0.13 0.11 nd 0.13 nd nd nd
    p 0.14 nd 0.37 0.14 nd 0.37 nd nd nd
    nCohort 1 87 nd 80 87 nd 80 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 2.43 nd 0.971 2.43 nd 0.971 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 55% nd 38% 55% nd 38% nd nd nd
    Cutoff 2 0.971 nd 0.971 0.971 nd 0.971 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2 43% nd 38% 43% nd 38% nd nd nd
    Cutoff 3 0 nd 0 0 nd 0 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  0% nd  0%  0% nd  0% nd nd nd
    Cutoff 4 6.75 nd 10.7 6.75 nd 10.7 nd nd nd
    Sens 4 50% nd 50% 50% nd 50% nd nd nd
    Spec 4 70% nd 70% 70% nd 70% nd nd nd
    Cutoff 5 19.0 nd 21.4 19.0 nd 21.4 nd nd nd
    Sens 5 50% nd 50% 50% nd 50% nd nd nd
    Spec 5 80% nd 80% 80% nd 80% nd nd nd
    Cutoff 6 31.3 nd 34.2 31.3 nd 34.2 nd nd nd
    Sens 6 25% nd  0% 25% nd  0% nd nd nd
    Spec 6 91% nd 90% 91% nd 90% nd nd nd
    OR Quart 2 0 nd 2.0 0 nd 2.0 nd nd nd
    p Value na nd 0.58 na nd 0.58 nd nd nd
    95% CI of na nd 0.17 na nd 0.17 nd nd nd
    OR Quart 2 na nd 24 na nd 24 nd nd nd
    OR Quart 3 3.1 nd 0 3.1 nd 0 nd nd nd
    p Value 0.34 nd na 0.34 nd na nd nd nd
    95% CI of 0.30 nd na 0.30 nd na nd nd nd
    OR Quart 3 33 nd na 33 nd na nd nd nd
    OR Quart 4 4.4 nd 3.2 4.4 nd 3.2 nd nd nd
    p Value 0.20 nd 0.34 0.20 nd 0.34 nd nd nd
    95% CI of 0.45 nd 0.30 0.45 nd 0.30 nd nd nd
    OR Quart 4 43 nd 33 43 nd 33 nd nd nd
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 34.6 48.0 34.6 48.0 nd nd
    Average 47.2 43.5 47.2 43.5 nd nd
    Stdev 52.3 42.3 52.3 42.3 nd nd
    p (t-test) 0.85 0.85 nd nd
    Min 0.204 0.204 0.204 0.204 nd nd
    Max 257 117 257 117 nd nd
    n (Samp) 87 8 87 8 nd nd
    n (Patient) 87 8 87 8 nd nd
    UO only
    Median 24.6 62.6 24.6 62.6 nd nd
    Average 41.6 52.3 41.6 52.3 nd nd
    Stdev 53.2 44.9 53.2 44.9 nd nd
    p (t-test) 0.63 0.63 nd nd
    Min 0.204 0.204 0.204 0.204 nd nd
    Max 257 117 257 117 nd nd
    n (Samp) 80 6 80 6 nd nd
    n (Patient) 80 6 80 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.49 nd 0.59 0.49 nd 0.59 nd nd nd
    SE 0.11 nd 0.13 0.11 nd 0.13 nd nd nd
    p 0.92 nd 0.47 0.92 nd 0.47 nd nd nd
    nCohort 1 87 nd 80 87 nd 80 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 0.488 nd 0.488 0.488 nd 0.488 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 18% nd 22% 18% nd 22% nd nd nd
    Cutoff 2 0.204 nd 0.488 0.204 nd 0.488 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2  6% nd 22%  6% nd 22% nd nd nd
    Cutoff 3 0 nd 0 0 nd 0 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  0% nd  0%  0% nd  0% nd nd nd
    Cutoff 4 59.8 nd 47.6 59.8 nd 47.6 nd nd nd
    Sens 4 50% nd 67% 50% nd 67% nd nd nd
    Spec 4 70% nd 70% 70% nd 70% nd nd nd
    Cutoff 5 76.0 nd 65.5 76.0 nd 65.5 nd nd nd
    Sens 5 12% nd 33% 12% nd 33% nd nd nd
    Spec 5 80% nd 80% 80% nd 80% nd nd nd
    Cutoff 6 124 nd 97.6 124 nd 97.6 nd nd nd
    Sens 6  0% nd 17%  0% nd 17% nd nd nd
    Spec 6 91% nd 90% 91% nd 90% nd nd nd
    OR Quart 2 1.0 nd 0.95 1.0 nd 0.95 nd nd nd
    p Value 1.0 nd 0.97 1.0 nd 0.97 nd nd nd
    95% CI of 0.13 nd 0.056 0.13 nd 0.056 nd nd nd
    OR Quart 2 7.7 nd 16 7.7 nd 16 nd nd nd
    OR Quart 3 1.0 nd 0 1.0 nd 0 nd nd nd
    p Value 1.0 nd na 1.0 nd na nd nd nd
    95% CI of 0.13 nd na 0.13 nd na nd nd nd
    OR Quart 3 7.7 nd na 7.7 nd na nd nd nd
    OR Quart 4 1.0 nd 4.4 1.0 nd 4.4 nd nd nd
    p Value 0.96 nd 0.20 0.96 nd 0.20 nd nd nd
    95% CI of 0.13 nd 0.45 0.13 nd 0.45 nd nd nd
    OR Quart 4 8.1 nd 44 8.1 nd 44 nd nd nd
    Interleukin-21
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.783 1.89 0.783 1.75 0.783 1.89
    Average 88.7 4.14 88.7 3.98 88.7 2.64
    Stdev 673 7.38 673 7.45 673 2.51
    p (t-test) 0.67 0.67 0.74
    Min 0.0102 0.0102 0.0102 0.0102 0.0102 0.829
    Max 5430 26.6 5430 26.6 5430 8.25
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 0.783 2.01 0.783 1.80 nd nd
    Average 45.5 2.67 45.5 2.35 nd nd
    Stdev 473 2.84 473 3.02 nd nd
    p (t-test) 0.83 0.82 nd nd
    Min 0.0102 0.0102 0.0102 0.0102 nd nd
    Max 5430 8.25 5430 8.25 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 1.02 1.89 1.02 1.89 1.02 1.89
    Average 90.5 4.71 90.5 4.71 90.5 1.71
    Stdev 678 8.88 678 8.88 678 0.455
    p (t-test) 0.72 0.72 0.75
    Min 0.0102 0.783 0.0102 0.783 0.0102 0.829
    Max 5430 26.6 5430 26.6 5430 2.03
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.69 0.66 0.66 0.65 0.59 0.66 0.74 nd 0.65
    SE 0.090 0.12 0.11 0.092 0.12 0.11 0.11 nd 0.13
    p 0.038 0.19 0.14 0.10 0.45 0.14 0.034 nd 0.23
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 1.53 1.53 1.53 0.783 0.0314 1.53 1.79 nd 1.53
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 71% 67% 64% 51% 33% 64% 74% nd 64%
    Cutoff 2 0.783 1.53 0.783 0.605 0.0314 0.783 1.53 nd 1.53
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 51% 67% 45% 49% 33% 45% 71% nd 64%
    Cutoff 3 0.605 0.0102 0.605 0.0314 0.0102 0.605 0.783 nd 0.783
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 49%  8% 44% 34%  8% 44% 51% nd 45%
    Cutoff 4 1.53 1.79 1.89 1.53 1.79 1.89 1.53 nd 1.89
    Sens 4 75% 67% 38% 67% 50% 38% 86% nd 33%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 2.03 2.60 3.18 2.03 2.60 3.18 2.03 nd 3.18
    Sens 5 25% 17% 12% 17% 17% 12% 14% nd  0%
    Spec 5 80% 81% 81% 80% 81% 81% 80% nd 81%
    Cutoff 6 10.6 5.72 11.4 10.6 5.72 11.4 10.6 nd 11.4
    Sens 6  8% 17% 12%  8% 17% 12%  0% nd  0%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 2.1 0 >2.2 3.4 0.97 >2.2 >1.1 nd >1.0
    p Value 0.55 na <0.52 0.31 0.98 <0.52 <0.97 nd <1.0
    95% CI of 0.18 na >0.19 0.32 0.058 >0.19 >0.061 nd >0.058
    OR Quart 2 26 na na 36 16 na na nd na
    OR Quart 3 4.8 2.1 >6.9 4.8 2.1 >6.9 >5.1 nd >7.1
    p Value 0.18 0.56 <0.094 0.18 0.56 <0.094 <0.16 nd <0.091
    95% CI of 0.48 0.18 >0.72 0.48 0.18 >0.72 >0.52 nd >0.73
    OR Quart 3 48 24 na 48 24 na na nd na
    OR Quart 4 6.0 3.1 >1.1 4.5 2.0 >1.1 >2.2 nd >0
    p Value 0.12 0.34 <0.97 0.20 0.58 <0.97 <0.52 nd <na
    95% CI of 0.63 0.31 >0.061 0.45 0.17 >0.061 >0.19 nd >na
    OR Quart 4 57 31 na 45 23 na na nd na
    Interleukin-23
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.995 256 0.995 216 0.995 22.3
    Average 2550 9620 2550 9610 2550 1110
    Stdev 13000 28600 13000 28600 13000 2390
    p (t-test) 0.17 0.17 0.77
    Min 0.257 0.257 0.257 0.257 0.257 0.257
    Max 100000 100000 100000 100000 100000 6480
    n (Samp) 64 12 64 12 64 7
    n (Patient) 64 12 64 12 64 7
    sCr only
    Median 1.10 89.5 1.10 50.3 nd nd
    Average 3050 435 3050 421 nd nd
    Stdev 15200 637 15200 644 nd nd
    p (t-test) 0.68 0.67 nd nd
    Min 0.257 0.257 0.257 0.257 nd nd
    Max 100000 1520 100000 1520 nd nd
    n (Samp) 131 6 131 6 nd nd
    n (Patient) 131 6 131 6 nd nd
    UO only
    Median 1.10 621 1.10 621 1.10 178
    Average 3240 14200 3240 14200 3240 1290
    Stdev 13600 34800 13600 34800 13600 2560
    p (t-test) 0.091 0.091 0.73
    Min 0.257 0.257 0.257 0.257 0.257 0.257
    Max 100000 100000 100000 100000 100000 6480
    n (Samp) 63 8 63 8 63 6
    n (Patient) 63 8 63 8 63 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.67 0.58 0.70 0.66 0.57 0.70 0.62 nd 0.61
    SE 0.092 0.12 0.11 0.092 0.12 0.11 0.12 nd 0.13
    p 0.070 0.54 0.072 0.072 0.58 0.072 0.32 nd 0.40
    nCohort 1 64 131 63 64 131 63 64 nd 63
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 0.886 0.770 11.0 0.886 0.770 11.0 0.886 nd 0.603
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 50% 32% 67% 50% 32% 67% 50% nd 35%
    Cutoff 2 0.770 0.770 0.603 0.770 0.770 0.603 0.770 nd 0.603
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 36% 32% 35% 36% 32% 35% 36% nd 35%
    Cutoff 3 0 0 0 0 0 0 0 nd 0
    Sens 3 100%  100%  100%  100%  100%  100%  100%  nd 100% 
    Spec 3  0%  0%  0%  0%  0%  0%  0% nd  0%
    Cutoff 4 55.0 138 405 55.0 138 405 55.0 nd 405
    Sens 4 58% 50% 50% 58% 33% 50% 43% nd 33%
    Spec 4 70% 70% 71% 70% 70% 71% 70% nd 71%
    Cutoff 5 861 637 861 861 637 861 861 nd 861
    Sens 5 42% 33% 50% 42% 33% 50% 29% nd 33%
    Spec 5 81% 80% 81% 81% 80% 81% 81% nd 81%
    Cutoff 6 2000 1540 2000 2000 1540 2000 2000 nd 2000
    Sens 6 25%  0% 38% 25%  0% 38% 14% nd 17%
    Spec 6 91% 90% 90% 91% 90% 90% 91% nd 90%
    OR Quart 2 0.47 1.0 >2.1 0.47 1.0 >2.1 0.94 nd >2.3
    p Value 0.55 1.0 <0.55 0.55 1.0 <0.55 0.97 nd <0.52
    95% CI of 0.039 0.060 >0.18 0.039 0.060 >0.18 0.054 nd >0.19
    OR Quart 2 5.7 17 na 5.7 17 na 16 nd na
    OR Quart 3 2.3 2.1 >2.1 2.3 7.1 >2.1 3.2 nd >2.3
    p Value 0.38 0.56 <0.55 0.38 0.56 <0.55 0.34 nd <0.52
    95% CI of 0.36 0.18 >0.18 0.36 0.18 >0.18 0.30 nd >0.19
    OR Quart 3 14 24 na 14 24 na 34 nd na
    OR Quart 4 3.0 2.0 >4.9 3.0 2.0 >4.9 2.0 nd >2.1
    p Value 0.22 0.58 <0.18 0.22 0.58 <0.18 0.59 nd <0.55
    95% CI of 0.51 0.17 >0.49 0.51 0.17 >0.49 0.16 nd >0.18
    OR Quart 4 18 23 na 18 23 na 24 nd na
    Interleukin-28A
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.265 12.0 0.265 12.0 0.265 7.61
    Average 87.3 181 87.3 181 87.3 14.1
    Stdev 465 574 465 574 465 15.5
    p (t-test) 0.54 0.54 0.68
    Min 0.120 0.148 0.120 0.148 0.120 0.148
    Max 3150 2000 3150 2000 3150 35.6
    n (Samp) 64 12 64 12 64 7
    n (Patient) 64 12 64 12 64 7
    sCr only
    Median 0.265 0.626 0.265 0.265 nd nd
    Average 47.7 10.8 47.7 10.7 nd nd
    Stdev 326 22.2 326 22.3 nd nd
    p (t-test) 0.78 0.78 nd nd
    Min 0.0727 0.148 0.0727 0.148 nd nd
    Max 3150 55.8 3150 55.8 nd nd
    n (Samp) 131 6 131 6 nd nd
    n (Patient) 131 6 131 6 nd nd
    UO only
    Median 0.265 21.0 0.265 21.0 0.265 16.6
    Average 90.5 265 90.5 265 90.5 16.4
    Stdev 468 703 468 703 468 15.6
    p (t-test) 0.35 0.35 0.70
    Min 0.120 0.265 0.120 0.265 0.120 0.265
    Max 3150 2000 3150 2000 3150 35.6
    n (Samp) 63 8 63 8 63 6
    n (Patient) 63 8 63 8 63 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.73 0.57 0.82 0.70 0.52 0.82 0.68 nd 0.78
    SE 0.088 0.12 0.095 0.090 0.12 0.095 0.12 nd 0.11
    p 0.0095 0.59 8.5E−4 0.025 0.86 8.5E−4 0.13 nd 0.015
    nCohort 1 64 131 63 64 131 63 64 nd 63
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 0.195 0.195 3.03 0.195 0.168 3.03 0.195 nd 0.195
    Sens 1 92% 83% 75% 83% 83% 75% 86% nd 100% 
    Spec 1 41% 40% 78% 41% 31% 78% 41% nd 43%
    Cutoff 2 0.195 0.195 0.195 0.195 0.168 0.195 0.195 nd 0.195
    Sens 2 92% 83% 100%  83% 83% 100%  86% nd 100% 
    Spec 2 41% 40% 43% 41% 31% 43% 41% nd 43%
    Cutoff 3 0.195 0.120 0.195 0.168 0.120 0.195 0.120 nd 0.195
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 41%  2% 43% 34%  2% 43%  2% nd 43%
    Cutoff 4 0.265 10.2 0.265 0.265 10.2 0.265 0.265 nd 0.265
    Sens 4 67% 17% 75% 58% 17% 75% 57% nd 67%
    Spec 4 70% 71% 76% 70% 71% 76% 70% nd 76%
    Cutoff 5 12.3 14.3 10.8 12.3 14.3 10.8 12.3 nd 10.8
    Sens 5 50% 17% 62% 50% 17% 62% 43% nd 50%
    Spec 5 81% 80% 81% 81% 80% 81% 81% nd 81%
    Cutoff 6 21.6 25.6 21.6 21.6 25.6 21.6 21.6 nd 21.6
    Sens 6 42% 17% 50% 42% 17% 50% 43% nd 50%
    Spec 6 91% 91% 90% 91% 91% 90% 91% nd 90%
    OR Quart 2 3.4 0 >2.1 4.8 2.1 >2.1 2.0 nd >2.3
    p Value 0.31 na <0.55 0.18 0.56 <0.55 0.59 nd <0.52
    95% CI of 0.32 na >0.18 0.48 0.18 >0.18 0.16 nd >0.19
    OR Quart 2 36 na na 48 24 na 24 nd na
    OR Quart 3 2.1 4.4 >1.0 1.0 2.1 >1.0 0.94 nd >0
    p Value 0.55 0.20 <1.0 1.0 0.56 <1.0 0.97 nd <na
    95% CI of 0.18 0.47 >0.058 0.058 0.18 >0.058 0.054 nd >na
    OR Quart 3 26 42 na 17 24 na 16 nd na
    OR Quart 4 8.3 0.97 >6.5 8.3 0.97 >6.5 3.2 nd >4.9
    p Value 0.063 0.98 <0.10 0.063 0.98 <0.10 0.34 nd <0.18
    95% CI of 0.89 0.058 >0.68 0.89 0.058 >0.68 0.30 nd >0.49
    OR Quart 4 78 16 na 78 16 na 34 nd na
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.101 15.5 0.101 15.5 0.101 9.09
    Average 687 1070 687 1070 687 34.8
    Stdev 4960 3520 4960 3520 4960 54.3
    p (t-test) 0.80 0.80 0.73
    Min 0.0445 0.0455 0.0445 0.0455 0.0445 0.0455
    Max 40000 12300 40000 12300 40000 149
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 0.101 6.17 0.101 6.17 nd nd
    Average 489 24.6 489 24.6 nd nd
    Stdev 3680 44.2 3680 44.2 nd nd
    p (t-test) 0.76 0.76 nd nd
    Min 0.0445 0.0455 0.0445 0.0455 nd nd
    Max 40000 113 40000 113 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 0.0981 39.7 0.0981 39.7 0.0981 12.6
    Average 749 1600 749 1600 749 39.1
    Stdev 5000 4310 5000 4310 5000 58.2
    p (t-test) 0.65 0.65 0.73
    Min 0.0445 0.0455 0.0445 0.0455 0.0445 0.0455
    Max 40000 12300 40000 12300 40000 149
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.70 0.62 0.75 0.70 0.62 0.75 0.70 nd 0.68
    SE 0.090 0.12 0.10 0.090 0.12 0.10 0.12 nd 0.13
    p 0.023 0.33 0.018 0.023 0.33 0.018 0.086 nd 0.15
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 2.20 0.0981 2.65 2.20 0.0981 2.65 2.65 nd 2.20
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 68% 42% 67% 68% 42% 67% 68% nd 67%
    Cutoff 2 0.0981 0.0981 2.20 0.0981 0.0981 2.20 2.20 nd 2.20
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 46% 42% 67% 46% 42% 67% 68% nd 67%
    Cutoff 3 0.0445 0.0445 0.0445 0.0445 0.0445 0.0445 0.0445 nd 0.0445
    Sens 3 100%  100%  100%  100%  100%  100%  100%  nd 100% 
    Spec 3 11%  8%  8% 11%  8%  8% 11% nd  8%
    Cutoff 4 4.56 7.37 4.56 4.56 7.37 4.56 4.56 nd 4.56
    Sens 4 58% 50% 62% 58% 50% 62% 57% nd 50%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 20.5 27.4 31.5 20.5 27.4 31.5 20.5 nd 31.5
    Sens 5 50% 17% 50% 50% 17% 50% 43% nd 33%
    Spec 5 80% 80% 81% 80% 80% 81% 80% nd 81%
    Cutoff 6 89.5 89.5 99.5 89.5 89.5 99.5 89.5 nd 99.5
    Sens 6 33% 17% 38% 33% 17% 38% 14% nd 17%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 2.1 0 >1.1 2.1 0 >1.1 0 nd >1.0
    p Value 0.55 na <0.97 0.55 na <0.97 na nd <1.0
    95% CI of 0.18 na >0.061 0.18 na >0.061 na nd >0.058
    OR Quart 2 26 na na 26 na na na nd na
    OR Quart 3 3.4 3.2 >3.6 3.4 3.2 >3.6 3.4 nd >2.3
    p Value 0.31 0.33 <0.29 0.31 0.33 <0.29 0.31 nd <0.52
    95% CI of 0.32 0.32 >0.34 0.32 0.32 >0.34 0.32 nd >0.19
    OR Quart 3 36 32 na 36 32 na 36 nd na
    OR Quart 4 7.7 2.0 >5.1 7.7 2.0 >5.1 3.4 nd >3.4
    p Value 0.072 0.58 <0.16 0.072 0.58 <0.16 0.31 nd <0.31
    95% CI of 0.83 0.17 >0.52 0.83 0.17 >0.52 0.32 nd >0.32
    OR Quart 4 72 23 na 72 23 na 36 nd na
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 8020 7370 8020 7130 8020 7560
    Average 11300 25200 11300 25100 11300 7430
    Stdev 18600 60300 18600 60300 18600 1750
    p (t-test) 0.13 0.13 0.59
    Min 3720 5310 3720 5310 3720 5310
    Max 153000 216000 153000 216000 153000 10600
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 8020 6320 8020 5950 nd nd
    Average 11200 7000 11200 6800 nd nd
    Stdev 19000 1860 19000 1900 nd nd
    p (t-test) 0.59 0.57 nd nd
    Min 3720 5750 3720 5750 nd nd
    Max 166000 10600 166000 10600 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 8010 7860 8010 7860 8010 7130
    Average 11900 34100 11900 34100 11900 6900
    Stdev 19000 73700 19000 73700 19000 1150
    p (t-test) 0.049 0.049 0.53
    Min 3900 5310 3900 5310 3900 5310
    Max 153000 216000 153000 216000 153000 8150
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 0.31 0.52 0.44 0.28 0.52 0.39 nd 0.34
    SE 0.093 0.12 0.11 0.093 0.12 0.11 0.12 nd 0.13
    p 0.65 0.13 0.86 0.51 0.069 0.86 0.36 nd 0.21
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 5920 5830 6660 5920 5830 6660 6660 nd 5700
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 12% 15% 33% 12% 15% 33% 31% nd 12%
    Cutoff 2 5750 5830 5700 5750 5830 5700 5310 nd 5700
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 11% 15% 12% 11% 15% 12% 11% nd 12%
    Cutoff 3 5310 5720 5230 5310 5720 5230 5230 nd 5230
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 11% 14%  9% 11% 14%  9% 11% nd  9%
    Cutoff 4 9430 9520 9430 9430 9520 9430 9430 nd 9430
    Sens 4 33% 17% 38% 33% 17% 38% 14% nd  0%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 10800 10800 11100 10800 10800 11100 10800 nd 11100
    Sens 5 17%  0% 25% 17%  0% 25%  0% nd  0%
    Spec 5 80% 80% 81% 80% 80% 81% 80% nd 81%
    Cutoff 6 13800 14200 16000 13800 14200 16000 13800 nd 16000
    Sens 6  8%  0% 12%  8%  0% 12%  0% nd  0%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 0.67 0 1.0 0.67 0 1.0 1.0 nd >1.1
    p Value 0.68 na 1.0 0.68 na 1.0 1.0 nd <0.94
    95% CI of 0.099 na 0.13 0.099 na 0.13 0.058 nd >0.065
    OR Quart 2 4.5 na 8.0 4.5 na 8.0 17 nd na
    OR Quart 3 1.1 2.1 1.0 0.67 1.0 1.0 3.4 nd >3.6
    p Value 0.95 0.56 1.0 0.68 1.0 1.0 0.31 nd <0.29
    95% CI of 0.19 0.18 0.13 0.099 0.060 0.13 0.32 nd >0.34
    OR Quart 3 6.1 24 8.0 4.5 17 8.0 36 nd na
    OR Quart 4 1.5 3.3 1.0 2.0 4.5 1.0 2.1 nd >2.4
    p Value 0.62 0.31 1.0 0.39 0.19 1.0 0.55 nd <0.49
    95% CI of 0.29 0.32 0.13 0.41 0.48 0.13 0.18 nd >0.20
    OR Quart 4 7.9 33 8.0 10.0 43 8.0 26 nd na
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 189000 172000 189000 172000 nd nd
    Average 192000 180000 192000 177000 nd nd
    Stdev 74500 49600 74500 44400 nd nd
    p (t-test) 0.65 0.56 nd nd
    Min 73000 111000 73000 111000 nd nd
    Max 520000 256000 520000 245000 nd nd
    n (Samp) 86 8 86 8 nd nd
    n (Patient) 86 8 86 8 nd nd
    UO only
    Median 186000 162000 186000 162000 nd nd
    Average 193000 166000 193000 166000 nd nd
    Stdev 78400 45100 78400 45100 nd nd
    p (t-test) 0.41 0.41 nd nd
    Min 73000 111000 73000 111000 nd nd
    Max 520000 245000 520000 245000 nd nd
    n (Samp) 79 6 79 6 nd nd
    n (Patient) 79 6 79 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.46 nd 0.39 0.45 nd 0.39 nd nd nd
    SE 0.11 nd 0.13 0.11 nd 0.13 nd nd nd
    p 0.72 nd 0.40 0.67 nd 0.40 nd nd nd
    nCohort 1 86 nd 79 86 nd 79 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 158000 nd 139000 158000 nd 139000 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 35% nd 23% 35% nd 23% nd nd nd
    Cutoff 2 139000 nd 139000 139000 nd 139000 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2 22% nd 23% 22% nd 23% nd nd nd
    Cutoff 3 107000 nd 107000 107000 nd 107000 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  9% nd  9%  9% nd  9% nd nd nd
    Cutoff 4 217000 nd 217000 217000 nd 217000 nd nd nd
    Sens 4 25% nd 17% 25% nd 17% nd nd nd
    Spec 4 71% nd 71% 71% nd 71% nd nd nd
    Cutoff 5 227000 nd 228000 227000 nd 228000 nd nd nd
    Sens 5 25% nd 17% 25% nd 17% nd nd nd
    Spec 5 80% nd 81% 80% nd 81% nd nd nd
    Cutoff 6 272000 nd 262000 272000 nd 262000 nd nd nd
    Sens 6  0% nd  0%  0% nd  0% nd nd nd
    Spec 6 91% nd 91% 91% nd 91% nd nd nd
    OR Quart 2 0.50 nd 0 0.50 nd 0 nd nd nd
    p Value 0.58 nd na 0.58 nd na nd nd nd
    95% CI of 0.042 nd na 0.042 nd na nd nd nd
    OR Quart 2 5.9 nd na 5.9 nd na nd nd nd
    OR Quart 3 1.6 nd 3.5 1.6 nd 3.5 nd nd nd
    p Value 0.64 nd 0.30 0.64 nd 0.30 nd nd nd
    95% CI of 0.24 nd 0.33 0.24 nd 0.33 nd nd nd
    OR Quart 3 10 nd 37 10 nd 37 nd nd nd
    OR Quart 4 1.0 nd 2.2 1.0 nd 2.2 nd nd nd
    p Value 0.96 nd 0.53 0.96 nd 0.53 nd nd nd
    95% CI of 0.13 nd 0.19 0.13 nd 0.19 nd nd nd
    OR Quart 4 8.1 nd 26 8.1 nd 26 nd nd nd
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 468 535 468 535 nd nd
    Average 494 734 494 734 nd nd
    Stdev 267 833 267 833 nd nd
    p (t-test) 0.064 0.064 nd nd
    Min 113 91.9 113 91.9 nd nd
    Max 1540 2720 1540 2720 nd nd
    n (Samp) 85 8 85 8 nd nd
    n (Patient) 85 8 85 8 nd nd
    UO only
    Median 438 535 438 535 nd nd
    Average 463 485 463 485 nd nd
    Stdev 254 247 254 247 nd nd
    p (t-test) 0.83 0.83 nd nd
    Min 113 91.9 113 91.9 nd nd
    Max 1540 721 1540 721 nd nd
    n (Samp) 78 6 78 6 nd nd
    n (Patient) 78 6 78 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.55 nd 0.58 0.55 nd 0.58 nd nd nd
    SE 0.11 nd 0.13 0.11 nd 0.13 nd nd nd
    p 0.65 nd 0.52 0.65 nd 0.52 nd nd nd
    nCohort 1 85 nd 78 85 nd 78 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 326 nd 326 326 nd 326 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 34% nd 41% 34% nd 41% nd nd nd
    Cutoff 2 238 nd 326 238 nd 326 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2 12% nd 41% 12% nd 41% nd nd nd
    Cutoff 3 0 nd 0 0 nd 0 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  0% nd  0%  0% nd  0% nd nd nd
    Cutoff 4 595 nd 543 595 nd 543 nd nd nd
    Sens 4 50% nd 50% 50% nd 50% nd nd nd
    Spec 4 71% nd 71% 71% nd 71% nd nd nd
    Cutoff 5 660 nd 618 660 nd 618 nd nd nd
    Sens 5 38% nd 50% 38% nd 50% nd nd nd
    Spec 5 80% nd 81% 80% nd 81% nd nd nd
    Cutoff 6 763 nd 747 763 nd 747 nd nd nd
    Sens 6 12% nd  0% 12% nd  0% nd nd nd
    Spec 6 91% nd 91% 91% nd 91% nd nd nd
    OR Quart 2 1.0 nd 2.1 1.0 nd 2.1 nd nd nd
    p Value 1.0 nd 0.56 1.0 nd 0.56 nd nd nd
    95% CI of 0.13 nd 0.18 0.13 nd 0.18 nd nd nd
    OR Quart 2 7.8 nd 25 7.8 nd 25 nd nd nd
    OR Quart 3 0.48 nd 0 0.48 nd 0 nd nd nd
    p Value 0.56 nd na 0.56 nd na nd nd nd
    95% CI of 0.040 nd na 0.040 nd na nd nd nd
    OR Quart 3 5.7 nd na 5.7 nd na nd nd nd
    OR Quart 4 1.5 nd 3.3 1.5 nd 3.3 nd nd nd
    p Value 0.67 nd 0.32 0.67 nd 0.32 nd nd nd
    95% CI of 0.23 nd 0.32 0.23 nd 0.32 nd nd nd
    OR Quart 4 9.9 nd 35 9.9 nd 35 nd nd nd
    Corticotropin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00105 0.00369 0.00105 0.00369 nd nd
    Average 0.00913 0.00636 0.00913 0.00636 nd nd
    Stdev 0.0411 0.00856 0.0411 0.00856 nd nd
    p (t-test) 0.86 0.86 nd nd
    Min 3.38E−6 3.38E−6 3.38E−6 3.38E−6 nd nd
    Max 0.292 0.0245 0.292 0.0245 nd nd
    n (Samp) 75 7 75 7 nd nd
    n (Patient) 75 7 75 7 nd nd
    UO only
    Median 0.00140 0.00367 0.00140 0.00367 nd nd
    Average 0.0109 0.00681 0.0109 0.00681 nd nd
    Stdev 0.0444 0.00929 0.0444 0.00929 nd nd
    p (t-test) 0.82 0.82 nd nd
    Min 4.31E−6 3.38E−6 4.31E−6 3.38E−6 nd nd
    Max 0.292 0.0245 0.292 0.0245 nd nd
    n (Samp) 64 6 64 6 nd nd
    n (Patient) 64 6 64 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.65 nd 0.59 0.65 nd 0.59 nd nd nd
    SE 0.12 nd 0.13 0.12 nd 0.13 nd nd nd
    p 0.21 nd 0.49 0.21 nd 0.49 nd nd nd
    nCohort 1 75 nd 64 75 nd 64 nd nd nd
    nCohort 2 7 nd 6 7 nd 6 nd nd nd
    Cutoff 1 0.00170 nd 0.000278 0.00170 nd 0.000278 nd nd nd
    Sens 1 71% nd 83% 71% nd 83% nd nd nd
    Spec 1 64% nd 30% 64% nd 30% nd nd nd
    Cutoff 2 0.000278 nd 0.000278 0.000278 nd 0.000278 nd nd nd
    Sens 2 86% nd 83% 86% nd 83% nd nd nd
    Spec 2 36% nd 30% 36% nd 30% nd nd nd
    Cutoff 3 0 nd 0 0 nd 0 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  0% nd  0%  0% nd  0% nd nd nd
    Cutoff 4 0.00297 nd 0.00345 0.00297 nd 0.00345 nd nd nd
    Sens 4 57% nd 50% 57% nd 50% nd nd nd
    Spec 4 71% nd 70% 71% nd 70% nd nd nd
    Cutoff 5 0.00423 nd 0.00550 0.00423 nd 0.00550 nd nd nd
    Sens 5 43% nd 33% 43% nd 33% nd nd nd
    Spec 5 81% nd 81% 81% nd 81% nd nd nd
    Cutoff 6 0.00767 nd 0.00859 0.00767 nd 0.00859 nd nd nd
    Sens 6 29% nd 33% 29% nd 33% nd nd nd
    Spec 6 91% nd 91% 91% nd 91% nd nd nd
    OR Quart 2 0.95 nd 0.94 0.95 nd 0.94 nd nd nd
    p Value 0.97 nd 0.97 0.97 nd 0.97 nd nd nd
    95% CI of 0.055 nd 0.054 0.055 nd 0.054 nd nd nd
    OR Quart 2 16 nd 16 16 nd 16 nd nd nd
    OR Quart 3 2.1 nd 1.0 2.1 nd 1.0 nd nd nd
    p Value 0.56 nd 1.0 0.56 nd 1.0 nd nd nd
    95% CI of 0.18 nd 0.057 0.18 nd 0.057 nd nd nd
    OR Quart 3 25 nd 17 25 nd 17 nd nd nd
    OR Quart 4 3.2 nd 3.2 3.2 nd 3.2 nd nd nd
    p Value 0.34 nd 0.34 0.34 nd 0.34 nd nd nd
    95% CI of 0.30 nd 0.30 0.30 nd 0.30 nd nd nd
    OR Quart 4 33 nd 34 33 nd 34 nd nd nd
    Thyroxine-binding globulin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 43.7 29.2 43.7 28.6 43.7 42.5
    Average 42.7 35.2 42.7 34.5 42.7 42.1
    Stdev 12.2 13.1 12.2 13.5 12.2 14.0
    p (t-test) 0.029 0.017 0.89
    Min 15.5 21.0 15.5 21.0 15.5 24.8
    Max 75.8 63.7 75.8 63.7 75.8 62.0
    n (Samp) 110 15 110 15 110 8
    n (Patient) 110 15 110 15 110 8
    sCr only
    Median 39.3 30.1 39.3 28.6 nd nd
    Average 41.1 40.0 41.1 38.9 nd nd
    Stdev 12.1 16.1 12.1 17.1 nd nd
    p (t-test) 0.82 0.65 nd nd
    Min 14.2 23.4 14.2 22.3 nd nd
    Max 75.8 63.7 75.8 63.7 nd nd
    n (Samp) 180 7 180 7 nd nd
    n (Patient) 180 7 180 7 nd nd
    UO only
    Median 43.5 28.8 43.5 28.8 43.5 32.6
    Average 41.9 33.2 41.9 33.0 41.9 37.5
    Stdev 11.8 11.2 11.8 11.3 11.8 12.6
    p (t-test) 0.030 0.026 0.39
    Min 20.4 21.0 20.4 21.0 20.4 24.8
    Max 75.8 56.1 75.8 56.1 75.8 56.1
    n (Samp) 91 10 91 10 91 6
    n (Patient) 91 10 91 10 91 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.31 0.45 0.29 0.30 0.43 0.28 0.50 nd 0.41
    SE 0.080 0.11 0.095 0.079 0.11 0.095 0.11 nd 0.13
    p 0.018 0.66 0.024 0.011 0.54 0.021 1.00 nd 0.45
    nCohort 1 110 180 91 110 180 91 110 nd 91
    nCohort 2 15 7 10 15 7 10 8 nd 6
    Cutoff 1 27.9 28.5 27.9 26.5 28.2 27.4 29.2 nd 29.1
    Sens 1 73% 71% 70% 73% 71% 70% 75% nd 83%
    Spec 1 11% 14% 13%  8% 13% 11% 15% nd 18%
    Cutoff 2 27.4 28.2 27.4 23.7 23.3 26.8 29.1 nd 29.1
    Sens 2 80% 86% 80% 80% 86% 80% 88% nd 83%
    Spec 2  9% 13% 11%  5%  7% 10% 15% nd 18%
    Cutoff 3 23.3 23.3 24.6 21.0 21.0 24.6 23.7 nd 24.6
    Sens 3 93% 100%  90% 93% 100%  90% 100%  nd 100% 
    Spec 3  5%  7%  7%  2% 4%  7%  5% nd  7%
    Cutoff 4 48.0 47.1 47.2 48.0 47.1 47.2 48.0 nd 47.2
    Sens 4 27% 43% 20% 27% 43% 20% 50% nd 33%
    Spec 4 70% 70% 70% 70% 70% 70% 70% nd 70%
    Cutoff 5 52.3 50.1 50.4 52.3 50.1 50.4 52.3 nd 50.4
    Sens 5 13% 29% 10% 13% 29% 10% 25% nd 17%
    Spec 5 80% 80% 80% 80% 80% 80% 80% nd 80%
    Cutoff 6 57.6 56.1 55.2 57.6 56.1 55.2 57.6 nd 55.2
    Sens 6  7% 14% 10%  7% 14% 10% 12% nd 17%
    Spec 6 90% 90% 90% 90% 90% 90% 90% nd 90%
    OR Quart 2 0 0 0 0 0 0 0.32 nd 0
    p Value na na na na na na 0.34 nd na
    95% CI of na na na na na na 0.031 nd na
    OR Quart 2 na na na na na na 3.3 nd na
    OR Quart 3 0.23 0 0.50 0.23 0 0.50 0.31 nd 0.50
    p Value 0.21 na 0.58 0.21 na 0.58 0.32 nd 0.58
    95% CI of 0.025 na 0.042 0.025 na 0.042 0.030 nd 0.042
    OR Quart 3 2.2 na 5.9 2.2 na 5.9 3.2 nd 5.9
    OR Quart 4 3.3 1.4 4.7 3.3 1.4 4.7 1.0 nd 1.6
    p Value 0.067 0.67 0.073 0.067 0.67 0.073 0.97 nd 0.61
    95% CI of 0.92 0.29 0.86 0.92 0.29 0.86 0.19 nd 0.25
    OR Quart 4 12 6.6 25 12 6.6 25 5.6 nd 11
    Pigment epithelium-derived factor
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1670 1590 1670 1590 nd nd
    Average 1710 1630 1710 1590 nd nd
    Stdev 774 749 774 788 nd nd
    p (t-test) 0.78 0.67 nd nd
    Min 445 339 445 339 nd nd
    Max 4240 2850 4240 2850 nd nd
    n (Samp) 87 8 87 8 nd nd
    n (Patient) 87 8 87 8 nd nd
    UO only
    Median 1620 1850 1620 1850 nd nd
    Average 1760 1720 1760 1720 nd nd
    Stdev 841 855 841 855 nd nd
    p (t-test) 0.93 0.93 nd nd
    Min 445 339 445 339 nd nd
    Max 4510 2850 4510 2850 nd nd
    n (Samp) 80 6 80 6 nd nd
    n (Patient) 80 6 80 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.50 nd 0.53 0.48 nd 0.53 nd nd nd
    SE 0.11 nd 0.12 0.11 nd 0.12 nd nd nd
    p 0.99 nd 0.82 0.82 nd 0.82 nd nd nd
    nCohort 1 87 nd 80 87 nd 80 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 1280 nd 1280 1280 nd 1280 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 37% nd 34% 37% nd 34% nd nd nd
    Cutoff 2 1170 nd 1280 756 nd 1280 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2 30% nd 34%  9% nd 34% nd nd nd
    Cutoff 3 0 nd 0 0 nd 0 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  0% nd  0%  0% nd  0% nd nd nd
    Cutoff 4 2020 nd 2030 2020 nd 2030 nd nd nd
    Sens 4 38% nd 50% 38% nd 50% nd nd nd
    Spec 4 70% nd 70% 70% nd 70% nd nd nd
    Cutoff 5 2350 nd 2350 2350 nd 2350 nd nd nd
    Sens 5 12% nd 17% 12% nd 17% nd nd nd
    Spec 5 80% nd 80% 80% nd 80% nd nd nd
    Cutoff 6 2830 nd 2880 2830 nd 2880 nd nd nd
    Sens 6 12% nd  0% 12% nd  0% nd nd nd
    Spec 6 91% nd 91% 91% nd 91% nd nd nd
    OR Quart 2 3.1 nd 0.95 3.3 nd 0.95 nd nd nd
    p Value 0.34 nd 0.97 0.32 nd 0.97 nd nd nd
    95% CI of 0.30 nd 0.056 0.32 nd 0.056 nd nd nd
    OR Quart 2 33 nd 16 34 nd 16 nd nd nd
    OR Quart 3 3.1 nd 3.3 2.1 nd 3.3 nd nd nd
    p Value 0.34 nd 0.32 0.56 nd 0.32 nd nd nd
    95% CI of 0.30 nd 0.32 0.18 nd 0.32 nd nd nd
    OR Quart 3 33 nd 35 25 nd 35 nd nd nd
    OR Quart 4 0.96 nd 0.95 2.2 nd 0.95 nd nd nd
    p Value 0.98 nd 0.97 0.53 nd 0.97 nd nd nd
    95% CI of 0.056 nd 0.056 0.18 nd 0.056 nd nd nd
    OR Quart 4 16 nd 16 26 nd 16 nd nd nd
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 104 107 104 107 104 93.1
    Average 226 271 226 268 226 166
    Stdev 549 403 549 404 549 192
    p (t-test) 0.78 0.80 0.78
    Min 26.3 50.0 26.3 50.0 26.3 50.0
    Max 3360 1460 3360 1460 3360 595
    n (Samp) 65 12 65 12 65 7
    n (Patient) 65 12 65 12 65 7
    sCr only
    Median 117 100 117 94.1 nd nd
    Average 236 107 36 101 nd nd
    Stdev 507 26.7 507 33.0 nd nd
    p (t-test) 0.54 0.52 nd nd
    Min 26.3 82.5 26.3 60.0 nd nd
    Max 3360 152 3360 152 nd nd
    n (Samp) 132 6 132 6 nd nd
    n (Patient) 132 6 132 6 nd nd
    UO only
    Median 115 107 115 107 115 98.7
    Average 260 350 260 350 260 180
    Stdev 575 483 575 483 575 206
    p (t-test) 0.67 0.67 0.74
    Min 30.2 50.0 30.2 50.0 30.2 50.0
    Max 3360 1460 3360 1460 3360 595
    n (Samp) 64 8 64 8 64 6
    n (Patient) 64 8 64 8 64 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.42 0.56 0.54 0.38 0.56 0.48 nd 0.46
    SE 0.093 0.12 0.11 0.093 0.12 0.11 0.12 nd 0.13
    p 0.49 0.54 0.62 0.66 0.34 0.62 0.86 nd 0.78
    nCohort 1 65 132 64 65 132 64 65 nd 64
    nCohort 2 12 6 8 12 6 8 7 nd 6
    Cutoff 1 89.9 83.2 89.9 83.2 75.6 89.9 83.2 nd 83.2
    Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83%
    Spec 1 40% 28% 34% 34% 27% 34% 34% nd 28%
    Cutoff 2 83.2 83.2 83.2 75.6 75.6 83.2 75.6 nd 83.2
    Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83%
    Spec 2 34% 28% 28% 32% 27% 28% 32% nd 28%
    Cutoff 3 75.6 75.6 43.9 56.2 56.6 43.9 47.2 nd 43.9
    Sens 3 92% 100%  100%  92% 100%  100%  100%  nd 100% 
    Spec 3 32% 27%  9% 14% 11%  9% 12% nd  9%
    Cutoff 4 165 167 167 165 167 167 165 nd 167
    Sens 4 25%  0% 38% 25%  0% 38% 14% nd 17%
    Spec 4 71% 70% 70% 71% 70% 70% 71% nd 70%
    Cutoff 5 205 217 217 205 217 217 205 nd 217
    Sens 5 25%  0% 38% 25%  0% 38% 14% nd 17%
    Spec 5 82% 80% 81% 82% 80% 81% 82% nd 81%
    Cutoff 6 292 310 323 292 310 323 292 nd 323
    Sens 6 25%  0% 25% 25%  0% 25% 14% nd 17%
    Spec 6 91% 90% 91% 91% 90% 91% 91% nd 91%
    OR Quart 2 4.8 >2.2 4.9 1.6 >2.2 4.9 2.1 nd 1.1
    p Value 0.18 <0.53 0.18 0.63 <0.53 0.18 0.55 nd 0.97
    95% CI of 0.48 >0.19 0.49 0.23 >0.19 0.49 0.18 nd 0.061
    OR Quart 2 48 na 49 11 na 49 26 nd 18
    OR Quart 3 4.8 >4.5 0 2.3 >3.3 0 3.4 nd 3.4
    p Value 0.18 <0.19 na 0.38 <0.31 na 0.31 nd 0.31
    95% CI of 0.48 >0.48 na 0.36 >0.32 na 0.32 nd 0.32
    OR Quart 3 48 na na 14 na na 36 nd 36
    OR Quart 4 3.2 >0 3.4 1.5 >1.1 3.4 1.0 nd 1.1
    p Value 0.34 <na 0.31 0.68 <0.97 0.31 1.0 nd 0.97
    95% CI of 0.30 >na 0.32 0.22 >0.064 0.32 0.058 nd 0.061
    OR Quart 4 34 na 36 10 na 36 17 nd 18
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.381 0.719 0.381 0.719 nd nd
    Average 0.450 0.803 0.450 0.803 nd nd
    Stdev 0.361 0.466 0.361 0.466 nd nd
    p (t-test) 0.011 0.011 nd nd
    Min 0.00580 0.00880 0.00580 0.00880 nd nd
    Max 1.81 1.53 1.81 1.53 nd nd
    n (Samp) 87 8 87 8 nd nd
    n (Patient) 87 8 87 8 nd nd
    UO only
    Median 0.382 0.719 0.382 0.719 nd nd
    Average 0.449 0.851 0.449 0.851 nd nd
    Stdev 0.372 0.351 0.372 0.351 nd nd
    p (t-test) 0.012 0.012 nd nd
    Min 0.00580 0.583 0.00580 0.583 nd nd
    Max 1.81 1.53 1.81 1.53 nd nd
    n (Samp) 80 6 80 6 nd nd
    n (Patient) 80 6 80 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.76 nd 0.82 0.76 nd 0.82 nd nd nd
    SE 0.10 nd 0.11 0.10 nd 0.11 nd nd nd
    p 0.011 nd 0.0024 0.011 nd 0.0024 nd nd nd
    nCohort 1 87 nd 80 87 nd 80 nd nd nd
    nCohort 2 8 nd 6 8 nd 6 nd nd nd
    Cutoff 1 0.620 nd 0.620 0.620 nd 0.620 nd nd nd
    Sens 1 75% nd 83% 75% nd 83% nd nd nd
    Spec 1 78% nd 76% 78% nd 76% nd nd nd
    Cutoff 2 0.558 nd 0.620 0.558 nd 0.620 nd nd nd
    Sens 2 88% nd 83% 88% nd 83% nd nd nd
    Spec 2 74% nd 76% 74% nd 76% nd nd nd
    Cutoff 3 0.00580 nd 0.558 0.00580 nd 0.558 nd nd nd
    Sens 3 100%  nd 100%  100%  nd 100%  nd nd nd
    Spec 3  2% nd 71%  2% nd 71% nd nd nd
    Cutoff 4 0.541 nd 0.558 0.541 nd 0.558 nd nd nd
    Sens 4 88% nd 100%  88% nd 100%  nd nd nd
    Spec 4 70% nd 71% 70% nd 71% nd nd nd
    Cutoff 5 0.705 nd 0.741 0.705 nd 0.741 nd nd nd
    Sens 5 50% nd 33% 50% nd 33% nd nd nd
    Spec 5 80% nd 80% 80% nd 80% nd nd nd
    Cutoff 6 0.891 nd 0.891 0.891 nd 0.891 nd nd nd
    Sens 6 38% nd 33% 38% nd 33% nd nd nd
    Spec 6 91% nd 90% 91% nd 90% nd nd nd
    OR Quart 2 0 nd >0 0 nd >0 nd nd nd
    p Value na nd <na na nd <na nd nd nd
    95% CI of na nd >na na nd >na nd nd nd
    OR Quart 2 na nd na na nd na nd nd nd
    OR Quart 3 2.0 nd >2.2 2.0 nd >2.2 nd nd nd
    p Value 0.58 nd <0.53 0.58 nd <0.53 nd nd nd
    95% CI of 0.17 nd >0.19 0.17 nd >0.19 nd nd nd
    OR Quart 3 24 nd na 24 nd na nd nd nd
    OR Quart 4 5.8 nd >4.7 5.8 nd >4.7 nd nd nd
    p Value 0.12 nd <0.19 0.12 nd <0.19 nd nd nd
    95% CI of 0.62 nd >0.48 0.62 nd >0.48 nd nd nd
    OR Quart 4 54 nd na 54 nd na nd nd nd
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 55900 45300 55900 44900 55900 42800
    Average 67400 45200 67400 44600 67400 40300
    Stdev 48000 9980 48000 11000 48000 10100
    p (t-test) 0.11 0.12 0.14
    Min 8630 29200 8630 25800 8630 22400
    Max 260000 59600 260000 59600 260000 52300
    n (Samp) 111 12 111 11 111 7
    n (Patient) 111 12 111 11 111 7
    sCr only
    Median 56700 46700 nd nd nd nd
    Average 69900 47000 nd nd nd nd
    Stdev 49700 10900 nd nd nd nd
    p (t-test) 0.26 nd nd nd nd
    Min 8630 29200 nd nd nd nd
    Max 260000 59600 nd nd nd nd
    n (Samp) 193 6 nd nd nd nd
    n (Patient) 193 6 nd nd nd nd
    UO only
    Median 56300 43900 56300 42800 56300 42800
    Average 67500 43800 67500 41100 67500 39400
    Stdev 43600 8230 43600 10200 43600 10700
    p (t-test) 0.13 0.091 0.12
    Min 8630 31000 8630 25800 8630 22400
    Max 218000 54900 218000 54900 218000 52300
    n (Samp) 103 8 103 8 103 6
    n (Patient) 103 8 103 8 103 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.38 0.38 0.34 0.36 nd 0.30 0.32 nd 0.28
    SE 0.090 0.12 0.11 0.094 nd 0.11 0.11 nd 0.12
    p 0.17 0.34 0.14 0.15 nd 0.066 0.11 nd 0.074
    nCohort 1 111 193 103 111 nd 103 111 nd 103
    nCohort 2 12 6 8 11 nd 8 7 nd 6
    Cutoff 1 41000 41900 41000 41000 nd 33100 41000 nd 30600
    Sens 1 75% 83% 75% 73% nd 75% 71% nd 83%
    Spec 1 34% 32% 33% 34% nd 22% 34% nd 17%
    Cutoff 2 33100 41900 33100 33100 nd 30600 30600 nd 30600
    Sens 2 83% 83% 88% 82% nd 88% 86% nd 83%
    Spec 2 23% 32% 22% 23% nd 17% 19% nd 17%
    Cutoff 3 30600 28800 30600 30600 nd 25400 19800 nd 19800
    Sens 3 92% 100%  100%  91% nd 100%  100%  nd 100% 
    Spec 3 19% 17% 17% 19% nd 11%  7% nd  8%
    Cutoff 4 76700 79500 79500 76700 nd 79500 76700 nd 79500
    Sens 4  0%  0%  0%  0% nd  0%  0% nd  0%
    Spec 4 71% 70% 72% 71% nd 72% 71% nd 72%
    Cutoff 5 89800 93400 94900 89800 nd 94900 89800 nd 94900
    Sens 5  0%  0%  0%  0% nd  0%  0% nd  0%
    Spec 5 80% 80% 81% 80% nd 81% 80% nd 81%
    Cutoff 6 131000 139000 120000 131000 nd 120000 131000 nd 120000
    Sens 6  0%  0%  0%  0% nd  0%  0% nd  0%
    Spec 6 90% 90% 90% 90% nd 90% 90% nd 90%
    OR Quart 2 >3.3 >2.1 >1.0 >3.4 nd >1.0 >0 nd >0
    p Value <0.31 <0.55 <0.98 <0.30 nd <0.98 <na nd <na
    95% CI of >0.33 >0.18 >0.062 >0.34 nd >0.062 >na nd >na
    OR Quart 2 na na na na nd na na nd na
    OR Quart 3 >7.4 >3.2 >6.1 >6.0 nd >4.7 >6.0 nd >4.9
    p Value <0.071 <0.32 <0.11 <0.11 nd <0.18 <0.11 nd <0.17
    95% CI of >0.84 >0.32 >0.66 >0.65 nd >0.49 >0.66 nd >0.51
    OR Quart 3 na na na na nd na na nd na
    OR Quart 4 >3.4 >1.0 >2.2 >3.4 nd >3.5 >2.2 nd >2.2
    p Value <0.30 <0.98 <0.52 <0.30 nd <0.29 <0.52 nd <0.52
    95% CI of >0.34 >0.063 >0.19 >0.34 nd >0.34 >0.19 nd >0.19
    OR Quart 4 na na na na nd na na nd na
    Apolipoprotein(a)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 51300 43600 51300 44500 51300 94400
    Average 81000 62200 81000 65900 81000 78300
    Stdev 104000 61300 104000 62900 104000 47500
    p (t-test) 0.54 0.64 0.95
    Min 7.99 968 7.99 968 7.99 2260
    Max 631000 200000 631000 200000 631000 125000
    n (Samp) 111 12 111 11 111 7
    n (Patient) 111 12 111 11 111 7
    sCr only
    Median 47400 43600 nd nd nd nd
    Average 84900 45900 nd nd nd nd
    Stdev 109000 33900 nd nd nd nd
    p (t-test) 0.38 nd nd nd nd
    Min 7.99 968 nd nd nd nd
    Max 631000 94400 nd nd nd nd
    n (Samp) 193 6 nd nd nd nd
    n (Patient) 193 6 nd nd nd nd
    UO only
    Median 54000 68600 54000 68600 54000 104000
    Average 81600 76000 81600 75900 81600 79300
    Stdev 103000 69600 103000 69700 103000 52000
    p (t-test) 0.88 0.88 0.96
    Min 7.99 2260 7.99 2260 7.99 2260
    Max 631000 200000 631000 200000 631000 125000
    n (Samp) 103 8 103 8 103 6
    n (Patient) 103 8 103 8 103 6
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.47 0.45 0.52 0.49 nd 0.51 0.60 nd 0.59
    SE 0.089 0.12 0.11 0.092 nd 0.11 0.12 nd 0.13
    p 0.76 0.68 0.88 0.88 nd 0.89 0.38 nd 0.49
    nCohort 1 111 193 103 111 nd 103 111 nd 103
    nCohort 2 12 6 8 11 nd 8 7 nd 6
    Cutoff 1 18200 18800 26200 25100 nd 25100 69900 nd 25100
    Sens 1 75% 83% 75% 73% nd 75% 71% nd 83%
    Spec 1 31% 33% 37% 37% nd 36% 66% nd 36%
    Cutoff 2 2260 18800 2260 2260 nd 2260 25100 nd 25100
    Sens 2 83% 83% 88% 82% nd 88% 86% nd 83%
    Spec 2  7% 33%  5%  7% nd  5% 37% nd 36%
    Cutoff 3 1680 814 1680 1680 nd 1680 1680 nd 1680
    Sens 3 92% 100%  100%  91% nd 100%  100%  nd 100% 
    Spec 3  7%  3%  5%  7% nd  5%  7% nd  5%
    Cutoff 4 80900 85400 85400 80900 nd 85400 80900 nd 85400
    Sens 4 33% 17% 50% 36% nd 50% 57% nd 67%
    Spec 4 70% 70% 71% 70% nd 71% 70% nd 71%
    Cutoff 5 128000 129000 128000 128000 nd 128000 128000 nd 128000
    Sens 5  8%  0% 12%  9% nd 12%  0% nd  0%
    Spec 5 80% 80% 81% 80% nd 81% 80% nd 81%
    Cutoff 6 210000 221000 198000 210000 nd 198000 210000 nd 198000
    Sens 6  0%  0% 12%  0% nd 12%  0% nd  0%
    Spec 6 90% 90% 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.64 >2.1 0.96 0.67 nd 0.96 0.97 nd 1.0
    p Value 0.64 <0.55 0.97 0.67 nd 0.97 0.98 nd 1.0
    95% CI of 0.100 >0.18 0.13 0.10 nd 0.13 0.058 nd 0.059
    OR Quart 2 4.1 na 7.4 4.3 nd 7.4 16 nd 17
    OR Quart 3 1.4 >3.2 0.46 1.0 nd 0.46 2.1 nd 1.0
    p Value 0.69 <0.32 0.54 1.0 nd 0.54 0.56 nd 1.0
    95% CI of 0.28 >0.32 0.039 0.19 nd 0.039 0.18 nd 0.059
    OR Quart 3 6.8 na 5.4 5.4 nd 5.4 24 nd 17
    OR Quart 4 1.0 >1.0 1.5 1.0 nd 1.5 3.1 nd 3.1
    p Value 0.97 <0.98 0.67 0.97 nd 0.67 0.34 nd 0.34
    95% CI of 0.19 >0.063 0.23 0.19 nd 0.23 0.30 nd 0.30
    OR Quart 4 5.6 na 9.8 5.6 nd 9.8 32 nd 32
  • FIG. 9: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in urine samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.
  •
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.584 1.22 0.584 0.618 0.584 0.623
    Average 1.77 17.2 1.77 4.33 1.77 8.93
    Stdev 8.21 24.8 8.21 11.0 8.21 14.1
    p (t-test) 5.0E−16 0.17 0.0064
    Min 0.146 0.188 0.146 0.319 0.146 0.319
    Max 163 82.4 163 45.7 163 33.9
    n (Samp) 1277 22 1277 20 1277 10
    n (Patient) 452 22 452 20 452 10
    sCr only
    Median 0.584 1.22 nd nd nd nd
    Average 2.34 15.5 nd nd nd nd
    Stdev 12.1 24.5 nd nd nd nd
    p (t-test) 0.0024 nd nd nd nd
    Min 0.146 0.188 nd nd nd nd
    Max 291 69.7 nd nd nd nd
    n (Samp) 1341 8 nd nd nd nd
    n (Patient) 467 8 nd nd nd nd
    UO only
    Median 0.584 11.6 0.584 0.625 0.584 0.584
    Average 1.81 30.2 1.81 11.2 1.81 5.17
    Stdev 8.60 45.3 8.60 27.6 8.60 12.3
    p (t-test) 1.1E−25 1.2E−5 0.30
    Min 0.146 0.515 0.146 0.319 0.146 0.341
    Max 163 166 163 114 163 33.0
    n (Samp) 1124 14 1124 19 1124 7
    n (Patient) 362 14 362 19 362 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.75 0.70 0.78 0.54 nd 0.54 0.60 nd 0.53
    SE 0.061 0.10 0.074 0.067 nd 0.068 0.095 nd 0.11
    p 3.5E−5 0.054 1.6E−4 0.53 nd 0.58 0.28 nd 0.76
    nCohort 1 1277 1341 1124 1277 nd 1124 1277 nd 1124
    nCohort 2 22 8 14 20 nd 19 10 nd 7
    Cutoff 1 0.584 0.582 0.612 0.336 nd 0.319 0.451 nd 0.451
    Sens 1 77% 75% 86% 70% nd 89% 70% nd 71%
    Spec 1 52% 48% 51% 34% nd 25% 43% nd 41%
    Cutoff 2 0.582 0.386 0.612 0.319 nd 0.319 0.336 nd 0.336
    Sens 2 86% 88% 86% 90% nd 89% 90% nd 100% 
    Spec 2 49% 38% 51% 26% nd 25% 34% nd 33%
    Cutoff 3 0.512 0.146 0.582 0.319 nd 0.301 0.336 nd 0.336
    Sens 3 91% 100%  93% 90% nd 100%  90% nd 100% 
    Spec 3 44%  4% 47% 26% nd 17% 34% nd 33%
    Cutoff 4 1.04 1.04 1.04 1.04 nd 1.04 1.04 nd 1.04
    Sens 4 59% 62% 57% 20% nd 21% 30% nd 14%
    Spec 4 73% 72% 71% 73% nd 71% 73% nd 71%
    Cutoff 5 1.12 1.12 1.12 1.12 nd 1.12 1.12 nd 1.12
    Sens 5 59% 62% 57% 20% nd 21% 30% nd 14%
    Spec 5 81% 81% 80% 81% nd 80% 81% nd 80%
    Cutoff 6 1.59 1.59 1.59 1.59 nd 1.59 1.59 nd 1.59
    Sens 6 41% 38% 50% 15% nd 21% 30% nd 14%
    Spec 6 94% 93% 94% 94% nd 94% 94% nd 94%
    OR Quart 2 4.0 2.0 >1.0 3.6 nd 1.2 3.0 nd >4.0
    p Value 0.21 0.57 <1.0 0.12 nd 0.74 0.34 nd <0.21
    95% CI of 0.45 0.18 >0.062 0.73 nd 0.33 0.31 nd >0.45
    OR Quart 2 36 22 na 17 nd 4.7 29 nd na
    OR Quart 3 4.0 0 >5.1 3.6 nd 1.5 3.0 nd >2.0
    p Value 0.21 na <0.14 0.12 nd 0.53 0.34 nd <0.57
    95% CI of 0.45 na >0.59 0.73 nd 0.42 0.31 nd >0.18
    OR Quart 3 36 na na 17 nd 5.4 29 nd na
    OR Quart 4 13 5.0 >8.2 2.0 nd 1.00 3.0 nd >1.0
    p Value 0.012 0.14 <0.048 0.42 nd 1.00 0.34 nd <1.0
    95% CI of 1.8 0.59 >1.0 0.36 nd 0.25 0.31 nd >0.062
    OR Quart 4 100 43 na 11 nd 4.0 29 nd na
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 317 401 317 318 317 247
    Average 334 402 334 351 334 350
    Stdev 240 181 240 211 240 334
    p (t-test) 0.29 0.79 0.87
    Min 1.37 81.1 1.37 1.37 1.37 3.04
    Max 2750 711 2750 798 2750 913
    n (Samp) 655 14 655 15 655 7
    n (Patient) 299 14 299 15 299 7
    UO only
    Median 318 521 318 328 nd nd
    Average 341 475 341 359 nd nd
    Stdev 245 178 245 237 nd nd
    p (t-test) 0.10 0.81 nd nd
    Min 1.37 166 1.37 1.37 nd nd
    Max 2750 711 2750 798 nd nd
    n (Samp) 597 9 597 12 nd nd
    n (Patient) 262 9 262 12 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.63 nd 0.73 0.55 nd 0.55 0.46 nd nd
    SE 0.081 nd 0.096 0.077 nd 0.086 0.11 nd nd
    p 0.11 nd 0.016 0.54 nd 0.58 0.73 nd nd
    nCohort 1 655 nd 597 655 nd 597 655 nd nd
    nCohort 2 14 nd 9 15 nd 12 7 nd nd
    Cutoff 1 315 nd 364 273 nd 273 163 nd nd
    Sens 1 71% nd 78% 73% nd 75% 71% nd nd
    Spec 1 50% nd 62% 43% nd 41% 19% nd nd
    Cutoff 2 247 nd 249 264 nd 171 74.3 nd nd
    Sens 2 86% nd 89% 80% nd 83% 86% nd nd
    Spec 2 35% nd 36% 40% nd 20%  9% nd nd
    Cutoff 3 164 nd 164 0 nd 0 2.36 nd nd
    Sens 3 93% nd 100%  100%  nd 100%  100%  nd nd
    Spec 3 20% nd 19%  0% nd  0%  4% nd nd
    Cutoff 4 414 nd 414 414 nd 414 414 nd nd
    Sens 4 36% nd 67% 33% nd 42% 29% nd nd
    Spec 4 72% nd 72% 72% nd 72% 72% nd nd
    Cutoff 5 452 nd 455 452 nd 455 452 nd nd
    Sens 5 36% nd 67% 33% nd 42% 29% nd nd
    Spec 5 80% nd 80% 80% nd 80% 80% nd nd
    Cutoff 6 542 nd 542 542 nd 542 542 nd nd
    Sens 6 29% nd 44% 13% nd 17% 29% nd nd
    Spec 6 90% nd 90% 90% nd 90% 90% nd nd
    OR Quart 2 1.5 nd 0.99 1.3 nd 0.66 0.50 nd nd
    p Value 0.65 nd 1.00 0.71 nd 0.65 0.57 nd nd
    95% CI of 0.25 nd 0.062 0.29 nd 0.11 0.045 nd nd
    OR Quart 2 9.2 nd 16 6.1 nd 4.0 5.6 nd nd
    OR Quart 3 2.0 nd 1.0 1.0 nd 0.66 0.50 nd nd
    p Value 0.42 nd 1.0 1.0 nd 0.65 0.57 nd nd
    95% CI of 0.37 nd 0.062 0.20 nd 0.11 0.045 nd nd
    OR Quart 3 11 nd 16 5.0 nd 4.0 5.5 nd nd
    OR Quart 4 2.5 nd 6.2 1.7 nd 1.7 1.5 nd nd
    p Value 0.27 nd 0.094 0.48 nd 0.48 0.65 nd nd
    95% CI of 0.48 nd 0.73 0.39 nd 0.39 0.25 nd nd
    OR Quart 4 13 nd 52 7.1 nd 7.1 9.2 nd nd
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0967 0.0970 0.0967 0.0974 0.0967 1.20
    Average 7.83 6.68 7.83 2.57 7.83 8.13
    Stdev 18.2 10.4 18.2 6.54 18.2 13.0
    p (t-test) 0.77 0.20 0.96
    Min 0.0238 0.0348 0.0238 0.0348 0.0238 0.0418
    Max 126 31.4 126 24.7 126 34.2
    n (Samp) 1277 22 1277 20 1277 10
    n (Patient) 452 22 452 20 452 10
    sCr only
    Median 0.0967 1.14 nd nd nd nd
    Average 7.67 5.56 nd nd nd nd
    Stdev 17.9 8.77 nd nd nd nd
    p (t-test) 0.74 nd nd nd nd
    Min 0.0238 0.0656 nd nd nd nd
    Max 126 24.9 nd nd nd nd
    n (Samp) 1341 8 nd nd nd nd
    n (Patient) 467 8 nd nd nd nd
    UO only
    Median 0.0967 0.0739 0.0967 0.0974 0.0967 2.39
    Average 7.65 7.02 7.65 3.41 7.65 11.5
    Stdev 17.8 11.6 17.8 7.11 17.8 14.5
    p (t-test) 0.89 0.30 0.57
    Min 0.0238 0.0348 0.0238 0.0348 0.0238 0.104
    Max 126 31.4 126 24.7 126 34.2
    n (Samp) 1124 14 1124 19 1124 7
    n (Patient) 362 14 362 19 362 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.56 0.58 0.49 0.50 nd 0.49 0.69 nd 0.76
    SE 0.064 0.11 0.078 0.065 nd 0.067 0.094 nd 0.11
    p 0.34 0.48 0.94 0.94 nd 0.89 0.045 nd 0.017
    nCohort 1 1277 1341 1124 1277 nd 1124 1277 nd 1124
    nCohort 2 22 8 14 20 nd 19 10 nd 7
    Cutoff 1 0.0722 0.0672 0.0656 0.0802 nd 0.0722 0.114 nd 1.81
    Sens 1 73% 75% 79% 70% nd 74% 70% nd 71%
    Spec 1 37% 33% 29% 49% nd 36% 65% nd 75%
    Cutoff 2 0.0656 0.0656 0.0435 0.0722 nd 0.0398 0.0974 nd 0.0974
    Sens 2 91% 88% 86% 80% nd 89% 90% nd 100% 
    Spec 2 30% 30% 18% 37% nd 14% 57% nd 56%
    Cutoff 3 0.0656 0.0606 0.0238 0.0398 nd 0.0369 0.0974 nd 0.0974
    Sens 3 91% 100%  100%  90% nd 95% 90% nd 100% 
    Spec 3 30% 26%  3% 15% nd 11% 57% nd 56%
    Cutoff 4 0.311 0.191 0.311 0.311 nd 0.311 0.311 nd 0.311
    Sens 4 41% 50% 36% 15% nd 21% 60% nd 71%
    Spec 4 74% 70% 74% 74% nd 74% 74% nd 74%
    Cutoff 5 10.8 10.4 10.9 10.8 nd 10.9 10.8 nd 10.9
    Sens 5 27% 25% 29% 10% nd 16% 30% nd 43%
    Spec 5 80% 80% 80% 80% nd 80% 80% nd 80%
    Cutoff 6 30.7 30.0 29.7 30.7 nd 29.7 30.7 nd 29.7
    Sens 6  5%  0%  7%  0% nd  0% 10% nd 14%
    Spec 6 90% 90% 90% 90% nd 90% 90% nd 90%
    OR Quart 2 4.1 >4.0 0.50 0.75 nd 1.8 0 nd >0
    p Value 0.078 <0.21 0.42 0.70 nd 0.37 na nd <na
    95% CI of 0.86 >0.45 0.091 0.17 nd 0.51 na nd >na
    OR Quart 2 19 na 2.7 3.4 nd 6.1 na nd na
    OR Quart 3 1.5 >0 1.3 2.5 nd 1.0 5.0 nd >3.0
    p Value 0.66 <na 0.74 0.12 nd 1.0 0.14 nd <0.34
    95% CI of 0.25 >na 0.33 0.79 nd 0.25 0.59 nd >0.31
    OR Quart 3 9.0 na 4.7 8.2 nd 4.0 43 nd na
    OR Quart 4 4.6 >4.0 0.75 0.75 nd 1.0 4.0 nd >4.0
    p Value 0.053 <0.21 0.71 0.70 nd 1.00 0.21 nd <0.21
    95% CI of 0.98 >0.45 0.17 0.17 nd 0.25 0.45 nd >0.45
    OR Quart 4 21 na 3.4 3.4 nd 4.1 36 nd na
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.733 0.968 0.733 2.01 nd nd
    Average 1.72 1.38 1.72 4.03 nd nd
    Stdev 6.16 1.15 6.16 3.96 nd nd
    p (t-test) 0.88 0.22 nd nd
    Min 0.0319 0.0558 0.0319 0.0612 nd nd
    Max 85.6 2.84 85.6 11.4 nd nd
    n (Samp) 438 8 438 11 nd nd
    n (Patient) 226 8 226 11 nd nd
    UO only
    Median nd nd 0.733 3.77 nd nd
    Average nd nd 1.77 4.23 nd nd
    Stdev nd nd 6.43 3.74 nd nd
    p (t-test) nd nd 0.28 nd nd
    Min nd nd 0.0319 0.870 nd nd
    Max nd nd 85.6 11.4 nd nd
    n (Samp) nd nd 399 8 nd nd
    n (Patient) nd nd 196 8 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.64 nd nd 0.75 nd 0.82 nd nd nd
    SE 0.11 nd nd 0.086 nd 0.092 nd nd nd
    p 0.18 nd nd 0.0036 nd 4.8E−4 nd nd nd
    nCohort 1 438 nd nd 438 nd 399 nd nd nd
    nCohort 2 8 nd nd 11 nd 8 nd nd nd
    Cutoff 1 0.918 nd nd 0.918 nd 0.870 nd nd nd
    Sens 1 75% nd nd 73% nd 88% nd nd nd
    Spec 1 57% nd nd 57% nd 58% nd nd nd
    Cutoff 2 0.0585 nd nd 0.845 nd 0.870 nd nd nd
    Sens 2 88% nd nd 82% nd 88% nd nd nd
    Spec 2 18% nd nd 56% nd 58% nd nd nd
    Cutoff 3 0.0439 nd nd 0.670 nd 0.845 nd nd nd
    Sens 3 100%  nd nd 91% nd 100%  nd nd nd
    Spec 3 12% nd nd 47% nd 58% nd nd nd
    Cutoff 4 0.957 nd nd 0.957 nd 0.957 nd nd nd
    Sens 4 50% nd nd 55% nd 62% nd nd nd
    Spec 4 75% nd nd 75% nd 75% nd nd nd
    Cutoff 5 1.46 nd nd 1.46 nd 1.46 nd nd nd
    Sens 5 38% nd nd 55% nd 62% nd nd nd
    Spec 5 80% nd nd 80% nd 80% nd nd nd
    Cutoff 6 3.30 nd nd 3.30 nd 3.30 nd nd nd
    Sens 6  0% nd nd 45% nd 50% nd nd nd
    Spec 6 90% nd nd 90% nd 90% nd nd nd
    OR Quart 2 0 nd nd >1.0 nd >0 nd nd nd
    p Value na nd nd <0.99 nd <na nd nd nd
    95% CI of na nd nd >0.062 nd >na nd nd nd
    OR Quart 2 na nd nd na nd na nd nd nd
    OR Quart 3 1.0 nd nd >4.1 nd >3.1 nd nd nd
    p Value 1.0 nd nd <0.21 nd <0.34 nd nd nd
    95% CI of 0.14 nd nd >0.46 nd >0.31 nd nd nd
    OR Quart 3 7.2 nd nd na nd na nd nd nd
    OR Quart 4 2.0 nd nd >6.3 nd >5.2 nd nd nd
    p Value 0.42 nd nd <0.091 nd <0.14 nd nd nd
    95% CI of 0.36 nd nd >0.74 nd >0.60 nd nd nd
    OR Quart 4 11 nd nd na nd na nd nd nd
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.0682 0.811 0.0682 0.0682 nd nd
    Average 0.658 1.44 0.658 1.33 nd nd
    Stdev 1.43 1.85 1.43 1.59 nd nd
    p (t-test) 0.13 0.12 nd nd
    Min 0.0116 0.0210 0.0116 0.0210 nd nd
    Max 10.3 5.59 10.3 3.92 nd nd
    n (Samp) 439 8 439 11 nd nd
    n (Patient) 227 8 227 11 nd nd
    UO only
    Median nd nd 0.0682 0.808 nd nd
    Average nd nd 0.652 1.45 nd nd
    Stdev nd nd 1.46 1.66 nd nd
    p (t-test) nd nd 0.13 nd nd
    Min nd nd 0.0116 0.0210 nd nd
    Max nd nd 10.3 3.92 nd nd
    n (Samp) nd nd 400 8 nd nd
    n (Patient) nd nd 197 8 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.72 nd nd 0.57 nd 0.57 nd nd nd
    SE 0.10 nd nd 0.091 nd 0.11 nd nd nd
    p 0.038 nd nd 0.43 nd 0.50 nd nd nd
    nCohort 1 439 nd nd 439 nd 400 nd nd nd
    nCohort 2 8 nd nd 11 nd 8 nd nd nd
    Cutoff 1 0.369 nd nd 0.0262 nd 0.0116 nd nd nd
    Sens 1 75% nd nd 73% nd 100%  nd nd nd
    Spec 1 67% nd nd 23% nd 14% nd nd nd
    Cutoff 2 0.0544 nd nd 0.0116 nd 0.0116 nd nd nd
    Sens 2 88% nd nd 100%  nd 100%  nd nd nd
    Spec 2 46% nd nd 13% nd 14% nd nd nd
    Cutoff 3 0.0116 nd nd 0.0116 nd 0.0116 nd nd nd
    Sens 3 100%  nd nd 100%  nd 100%  nd nd nd
    Spec 3 13% nd nd 13% nd 14% nd nd nd
    Cutoff 4 0.397 nd nd 0.397 nd 0.397 nd nd nd
    Sens 4 50% nd nd 45% nd 50% nd nd nd
    Spec 4 77% nd nd 77% nd 78% nd nd nd
    Cutoff 5 0.762 nd nd 0.762 nd 0.558 nd nd nd
    Sens 5 50% nd nd 45% nd 50% nd nd nd
    Spec 5 80% nd nd 80% nd 80% nd nd nd
    Cutoff 6 2.38 nd nd 2.38 nd 2.38 nd nd nd
    Sens 6 12% nd nd 36% nd 38% nd nd nd
    Spec 6 90% nd nd 90% nd 90% nd nd nd
    OR Quart 2 0 nd nd 0.65 nd 0.33 nd nd nd
    p Value na nd nd 0.65 nd 0.34 nd nd nd
    95% CI of na nd nd 0.11 nd 0.033 nd nd nd
    OR Quart 2 na nd nd 4.0 nd 3.2 nd nd nd
    OR Quart 3 3.0 nd nd 0.33 nd 0 nd nd nd
    p Value 0.34 nd nd 0.34 nd na nd nd nd
    95% CI of 0.31 nd nd 0.034 nd na nd nd nd
    OR Quart 3 30 nd nd 3.2 nd na nd nd nd
    OR Quart 4 4.1 nd nd 1.7 nd 1.3 nd nd nd
    p Value 0.21 nd nd 0.48 nd 0.70 nd nd nd
    95% CI of 0.45 nd nd 0.39 nd 0.29 nd nd nd
    OR Quart 4 37 nd nd 7.2 nd 6.2 nd nd nd
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 40.9 22.9 40.9 35.9 40.9 21.0
    Average 56.0 37.6 56.0 37.0 56.0 34.9
    Stdev 60.8 43.3 60.8 24.9 60.8 42.2
    p (t-test) 0.16 0.16 0.27
    Min 0.0232 0.0523 0.0232 0.0232 0.0232 0.0688
    Max 958 170 958 84.1 958 136
    n (Samp) 1275 12 1275 20 1275 10
    n (Patient) 452 22 452 20 452 10
    sCr only
    Median 40.2 28.8 nd nd nd nd
    Average 55.1 51.4 nd nd nd nd
    Stdev 59.8 57.8 nd nd nd nd
    p (t-test) 0.86 nd nd nd nd
    Min 0.0232 1.78 nd nd nd nd
    Max 958 170 nd nd nd nd
    n (Samp) 1339 8 nd nd nd nd
    n (Patient) 467 8 nd nd nd nd
    UO only
    Median 41.0 19.8 41.0 27.1 41.0 41.9
    Average 56.3 30.4 56.3 32.8 56.3 42.8
    Stdev 62.1 31.4 62.1 27.2 62.1 49.0
    p (t-test) 0.12 0.10 0.57
    Min 0.0232 0.0436 0.0232 0.0232 0.0232 0.0688
    Max 958 105 958 84.1 958 136
    n (Samp) 1122 14 1122 19 1122 7
    n (Patient) 362 14 362 19 362 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.40 0.48 0.36 0.43 nd 0.39 0.39 nd 0.43
    SE 0.064 0.10 0.080 0.067 nd 0.069 0.095 nd 0.11
    p 0.13 0.84 0.080 0.33 nd 0.12 0.23 nd 0.52
    nCohort 1 1275 1339 1122 1275 nd 1122 1275 nd 1122
    nCohort 2 22 8 14 20 nd 19 10 nd 7
    Cutoff 1 12.9 20.9 12.9 23.2 nd 14.3 7.14 nd 6.03
    Sens 1 73% 75% 71% 70% nd 74% 70% nd 71%
    Spec 1 25% 33% 25% 34% nd 26% 19% nd 17%
    Cutoff 2 4.04 14.5 0.0558 14.9 nd 4.04 6.03 nd 0.0768
    Sens 2 82% 88% 86% 80% nd 84% 80% nd 86%
    Spec 2 16% 27%  5% 26% nd 16% 18% nd 10%
    Cutoff 3 0.106 1.78 0.0518 7.14 nd 0.0360 0.0768 nd 0.0686
    Sens 3 91% 100%  93% 90% nd 95% 90% nd 100% 
    Spec 3 12% 14%  3% 19% nd  2% 10% nd  6%
    Cutoff 4 73.1 71.8 72.6 73.1 nd 72.6 73.1 nd 72.6
    Sens 4 18% 25% 14%  5% nd  5% 10% nd 14%
    Spec 4 70% 70% 70% 70% nd 70% 70% nd 70%
    Cutoff 5 93.1 92.2 93.9 93.1 nd 93.9 93.1 nd 93.9
    Sens 5 14% 25%  7%  0% nd  0% 10% nd 14%
    Spec 5 80% 80% 80% 80% nd 80% 80% nd 80%
    Cutoff 6 127 126 127 127 nd 127 127 nd 127
    Sens 6  5% 12%  0%  0% nd  0% 10% nd 14%
    Spec 6 90% 90% 90% 90% nd 90% 90% nd 90%
    OR Quart 2 1.3 0 3.0 7.1 nd 6.1 3.0 nd 3.0
    p Value 0.70 na 0.34 0.067 nd 0.094 0.34 nd 0.34
    95% CI of 0.30 na 0.31 0.87 nd 0.73 0.31 nd 0.31
    OR Quart 2 6.0 na 29 58 nd 51 29 nd 29
    OR Quart 3 3.1 2.5 5.1 9.2 nd 7.2 2.0 nd 0
    p Value 0.095 0.27 0.14 0.036 nd 0.066 0.57 nd na
    95% CI of 0.82 0.49 0.59 1.2 nd 0.88 0.18 nd na
    OR Quart 3 11 13 44 73 nd 59 22 nd na
    OR Quart 4 2.0 0.50 5.1 3.0 nd 5.1 4.1 nd 3.0
    p Value 0.32 0.57 0.14 0.34 nd 0.14 0.21 nd 0.34
    95% CI of 0.50 0.045 0.59 0.31 nd 0.59 0.45 nd 0.31
    OR Quart 4 8.2 5.5 44 29 nd 44 36 nd 29
    Interleukin-4 receptor alpha chain
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 46.2 65.5 46.2 87.3 46.2 66.6
    Average 56.4 62.9 56.4 81.4 56.4 75.3
    Stdev 51.8 42.9 51.8 55.4 51.8 24.6
    p (t-test) 0.63 0.066 0.33
    Min 0.839 7.12 0.839 7.12 0.839 47.8
    Max 299 156 299 230 299 119
    n (Samp) 642 15 642 15 642 7
    n (Patient) 293 15 293 15 293 7
    UO only
    Median 46.2 66.5 46.2 77.9 nd nd
    Average 56.9 73.2 56.9 85.4 nd nd
    Stdev 52.8 49.1 52.8 58.9 nd nd
    p (t-test) 0.36 0.065 nd nd
    Min 0.839 7.12 0.839 7.12 nd nd
    Max 299 156 299 230 nd nd
    n (Samp) 587 9 587 12 nd nd
    n (Patient) 258 9 258 12 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.57 nd 0.61 0.66 nd 0.67 0.69 nd nd
    SE 0.078 nd 0.10 0.078 nd 0.087 0.11 nd nd
    p 0.37 nd 0.29 0.042 nd 0.057 0.089 nd nd
    nCohort 1 642 nd 587 642 nd 587 642 nd nd
    nCohort 2 15 nd 9 15 nd 12 7 nd nd
    Cutoff 1 50.2 nd 59.3 59.2 nd 59.2 60.1 nd nd
    Sens 1 73% nd 78% 73% nd 75% 71% nd nd
    Spec 1 56% nd 62% 61% nd 61% 63% nd nd
    Cutoff 2 11.8 nd 6.56 50.2 nd 50.2 59.3 nd nd
    Sens 2 80% nd 100%  80% nd 83% 86% nd nd
    Spec 2 25% nd  6% 56% nd 56% 62% nd nd
    Cutoff 3 6.56 nd 6.56 11.3 nd 11.3 46.5 nd nd
    Sens 3 100%  nd 100%  93% nd 92% 100%  nd nd
    Spec 3  6% nd  6% 20% nd 19% 51% nd nd
    Cutoff 4 75.2 nd 74.6 75.2 nd 74.6 75.2 nd nd
    Sens 4 27% nd 33% 53% nd 50% 43% nd nd
    Spec 4 71% nd 70% 71% nd 70% 71% nd nd
    Cutoff 5 94.3 nd 94.3 94.3 nd 94.3 94.3 nd nd
    Sens 5 20% nd 33% 33% nd 42% 29% nd nd
    Spec 5 81% nd 80% 81% nd 80% 81% nd nd
    Cutoff 6 122 nd 122 122 nd 122 122 nd nd
    Sens 6 13% nd 11% 13% nd 17%  0% nd nd
    Spec 6 90% nd 90% 90% nd 90% 90% nd nd
    OR Quart 2 0.33 nd 0 0.50 nd 0 >0 nd nd
    p Value 0.34 nd na 0.57 nd na <na nd nd
    95% CI of 0.034 nd na 0.045 nd na >na nd nd
    OR Quart 2 3.2 nd na 5.5 nd na na nd nd
    OR Quart 3 2.8 nd 2.0 2.0 nd 2.0 >5.2 nd nd
    p Value 0.14 nd 0.42 0.42 nd 0.42 <0.14 nd nd
    95% CI of 0.72 nd 0.37 0.37 nd 0.36 >0.60 nd nd
    OR Quart 3 11 nd 11 11 nd 11 na nd nd
    OR Quart 4 0.99 nd 1.5 4.1 nd 3.1 >2.0 nd nd
    p Value 0.99 nd 0.65 0.076 nd 0.17 <0.57 nd nd
    95% CI of 0.20 nd 0.25 0.86 nd 0.61 >0.18 nd nd
    OR Quart 4 5.0 nd 9.2 20 nd 15 na nd nd
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 605 866 605 825 605 561
    Average 804 1120 804 888 804 829
    Stdev 870 1050 870 798 870 1040
    p (t-test) 0.18 0.71 0.94
    Min 0.218 106 0.218 27.3 0.218 1.48
    Max 7140 4230 7140 2600 7140 2820
    n (Samp) 644 14 644 15 644 6
    n (Patient) 294 14 294 15 294 6
    UO only
    Median 626 1390 626 828 nd nd
    Average 824 1400 824 915 nd nd
    Stdev 875 1190 875 879 nd nd
    p (t-test) 0.051 0.72 nd nd
    Min 0.218 106 0.218 27.3 nd nd
    Max 7140 4230 7140 2600 nd nd
    n (Samp) 589 9 589 12 nd nd
    n (Patient) 259 9 259 12 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.62 nd 0.69 0.55 nd 0.53 0.48 nd nd
    SE 0.081 nd 0.099 0.077 nd 0.086 0.12 nd nd
    p 0.15 nd 0.058 0.52 nd 0.73 0.86 nd nd
    nCohort 1 644 nd 589 644 nd 589 644 nd nd
    nCohort 2 14 nd 9 15 nd 12 6 nd nd
    Cutoff 1 626 nd 747 224 nd 182 65.6 nd nd
    Sens 1 71% nd 78% 73% nd 75% 83% nd nd
    Spec 1 51% nd 58% 26% nd 21% 16% nd nd
    Cutoff 2 152 nd 581 182 nd 140 65.6 nd nd
    Sens 2 86% nd 89% 80% nd 83% 83% nd nd
    Spec 2 21% nd 47% 23% nd 18% 16% nd nd
    Cutoff 3 119 nd 106 119 nd 119 1.48 nd nd
    Sens 3 93% nd 100%  93% nd 92% 100%  nd nd
    Spec 3 19% nd 16% 19% nd 17%  8% nd nd
    Cutoff 4 981 nd 1020 981 nd 1020 981 nd nd
    Sens 4 43% nd 56% 40% nd 42% 17% nd nd
    Spec 4 70% nd 70% 70% nd 70% 70% nd nd
    Cutoff 5 1330 nd 1340 1330 nd 1340 1330 nd nd
    Sens 5 36% nd 56% 20% nd 25% 17% nd nd
    Spec 5 80% nd 80% 80% nd 80% 80% nd nd
    Cutoff 6 1740 nd 1770 1740 nd 1770 1740 nd nd
    Sens 6 14% nd 22% 13% nd 17% 17% nd nd
    Spec 6 90% nd 90% 90% nd 90% 90% nd nd
    OR Quart 2 0.33 nd 0.99 0.49 nd 0 2.0 nd nd
    p Value 0.34 nd 1.00 0.42 nd na 0.57 nd nd
    95% CI of 0.034 nd 0.062 0.089 nd na 0.18 nd nd
    OR Quart 2 3.2 nd 16 2.7 nd na 23 nd nd
    OR Quart 3 1.7 nd 2.0 1.2 nd 0.79 1.0 nd nd
    p Value 0.48 nd 0.57 0.74 nd 0.74 1.0 nd nd
    95% CI of 0.40 nd 0.18 0.33 nd 0.21 0.062 nd nd
    OR Quart 3 7.2 nd 22 4.7 nd 3.0 16 nd nd
    OR Quart 4 1.7 nd 5.1 0.99 nd 0.59 2.0 nd nd
    p Value 0.48 nd 0.14 0.99 nd 0.47 0.57 nd nd
    95% CI of 0.39 nd 0.59 0.24 nd 0.14 0.18 nd nd
    OR Quart 4 7.1 nd 44 4.0 nd 2.5 23 nd nd
    Lutropin subunit beta
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median nd nd 19.4 9.51 nd nd
    Average nd nd 56.4 42.0 nd nd
    Stdev nd nd 86.6 90.9 nd nd
    p (t-test) nd nd 0.57 nd nd
    Min nd nd 0.0297 0.341 nd nd
    Max nd nd 400 325 nd nd
    n (Samp) nd nd 353 12 nd nd
    n (Patient) nd nd 165 12 nd nd
    UO only
    Median nd nd 21.0 4.44 nd nd
    Average nd nd 60.2 7.20 nd nd
    Stdev nd nd 90.0 8.59 nd nd
    p (t-test) nd nd 0.12 nd nd
    Min nd nd 0.0297 0.505 nd nd
    Max nd nd 400 24.5 nd nd
    n (Samp) nd nd 352 7 nd nd
    n (Patient) nd nd 156 7 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.41 nd 0.25 nd nd nd
    SE nd nd nd 0.088 nd 0.11 nd nd nd
    p nd nd nd 0.28 nd 0.018 nd nd nd
    nCohort 1 nd nd nd 353 nd 352 nd nd nd
    nCohort 2 nd nd nd 12 nd 7 nd nd nd
    Cutoff 1 nd nd nd 1.09 nd 1.09 nd nd nd
    Sens 1 nd nd nd 75% nd 71% nd nd nd
    Spec 1 nd nd nd 12% nd 11% nd nd nd
    Cutoff 2 nd nd nd 0.840 nd 0.840 nd nd nd
    Sens 2 nd nd nd 83% nd 86% nd nd nd
    Spec 2 nd nd nd 10% nd 10% nd nd nd
    Cutoff 3 nd nd nd 0.463 nd 0.463 nd nd nd
    Sens 3 nd nd nd 92% nd 100%  nd nd nd
    Spec 3 nd nd nd  9% nd  9% nd nd nd
    Cutoff 4 nd nd nd 45.5 nd 49.1 nd nd nd
    Sens 4 nd nd nd 17% nd  0% nd nd nd
    Spec 4 nd nd nd 70% nd 70% nd nd nd
    Cutoff 5 nd nd nd 84.1 nd 92.0 nd nd nd
    Sens 5 nd nd nd  8% nd  0% nd nd nd
    Spec 5 nd nd nd 80% nd 80% nd nd nd
    Cutoff 6 nd nd nd 179 nd 207 nd nd nd
    Sens 6 nd nd nd  8% nd  0% nd nd nd
    Spec 6 nd nd nd 90% nd 90% nd nd nd
    OR Quart 2 nd nd nd 1.5 nd >1.0 nd nd nd
    p Value nd nd nd 0.64 nd <0.99 nd nd nd
    95% CI of nd nd nd 0.25 nd >0.062 nd nd nd
    OR Quart 2 nd nd nd 9.4 nd na nd nd nd
    OR Quart 3 nd nd nd 1.0 nd >2.0 nd nd nd
    p Value nd nd nd 0.99 nd <0.56 nd nd nd
    95% CI of nd nd nd 0.14 nd >0.18 nd nd nd
    OR Quart 3 nd nd nd 7.3 nd na nd nd nd
    OR Quart 4 nd nd nd 2.6 nd >4.2 nd nd nd
    p Value nd nd nd 0.26 nd <0.20 nd nd nd
    95% CI of nd nd nd 0.49 nd >0.46 nd nd nd
    OR Quart 4 nd nd nd 14 nd na nd nd nd
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2720 3990 2720 2660 2720 2100
    Average 3320 4390 3320 6260 3320 2840
    Stdev 2860 3520 2860 11900 2860 2900
    p (t-test) 0.085 4.5E−5 0.60
    Min 0.234 142 0.234 375 0.234 138
    Max 48400 15000 48400 55700 48400 9700
    n (Samp) 1272 27 1272 20 1272 10
    n (Patient) 450 22 450 20 450 10
    sCr only
    Median 2740 2260 nd nd nd nd
    Average 3430 2670 nd nd nd nd
    Stdev 3250 2170 nd nd nd nd
    p (t-test) 0.51 nd nd nd nd
    Min 0.234 142 nd nd nd nd
    Max 55700 6800 nd nd nd nd
    n (Samp) 1336 8 nd nd nd nd
    n (Patient) 465 8 nd nd nd nd
    UO only
    Median 2820 4560 2820 4560 2820 3060
    Average 3380 6830 3380 8190 3380 3540
    Stdev 2830 6750 2830 12900 2830 3190
    p (t-test) 1.1E−5 2.2E−10 0.88
    Min 0.234 416 0.234 375 0.234 346
    Max 48400 26600 48400 55700 48400 9700
    n (Samp) 1118 14 1118 19 1118 7
    n (Patient) 360 14 360 19 360 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.59 0.42 0.71 0.55 nd 0.62 0.40 nd 0.48
    SE 0.064 0.11 0.079 0.067 nd 0.069 0.095 nd 0.11
    p 0.15 0.46 0.0090 0.44 nd 0.079 0.31 nd 0.86
    nCohort 1 1272 1336 1118 1272 nd 1118 1272 nd 1118
    nCohort 2 22 8 14 20 nd 19 10 nd 7
    Cutoff 1 2200 1340 3860 2030 nd 2080 1180 nd 1650
    Sens 1 73% 75% 71% 70% nd 74% 70% nd 71%
    Spec 1 40% 19% 68% 35% nd 34% 16% nd 24%
    Cutoff 2 1340 623 2310 1740 nd 1740 962 nd 1180
    Sens 2 82% 88% 86% 80% nd 84% 80% nd 86%
    Spec 2 20%  5% 40% 29% nd 26% 11% nd 14%
    Cutoff 3 623 85.5 1490 1110 nd 1110 341 nd 337
    Sens 3 91% 100%  93% 90% nd 95% 90% nd 100% 
    Spec 3  5%  0% 21% 15% nd 14%  1% nd  1%
    Cutoff 4 3930 3980 3980 3930 nd 3980 3930 nd 3980
    Sens 4 55% 12% 64% 45% nd 58% 20% nd 29%
    Spec 4 70% 70% 70% 70% nd 70% 70% nd 70%
    Cutoff 5 4840 4910 4890 4840 nd 4890 4840 nd 4890
    Sens 5 41% 12% 43% 35% nd 42% 20% nd 29%
    Spec 5 80% 80% 80% 80% nd 80% 80% nd 80%
    Cutoff 6 6370 6470 6410 6370 nd 6410 6370 nd 6410
    Sens 6 23% 12% 36% 20% nd 32% 10% nd 14%
    Spec 6 90% 90% 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.33 2.0 0.50 1.5 nd 1.7 1.0 nd 1.0
    p Value 0.17 0.57 0.57 0.53 nd 0.48 1.00 nd 1.00
    95% CI of 0.066 0.18 0.045 0.42 nd 0.40 0.14 nd 0.14
    OR Quart 2 1.6 22 5.5 5.4 nd 7.1 7.2 nd 7.2
    OR Quart 3 0.83 2.0 2.0 0.50 nd 0.33 1.0 nd 0
    p Value 0.76 0.57 0.42 0.42 nd 0.34 1.0 nd na
    95% CI of 0.25 0.18 0.37 0.090 nd 0.034 0.14 nd na
    OR Quart 3 2.7 22 11 2.7 nd 3.2 7.1 nd na
    OR Quart 4 1.5 3.0 3.6 2.0 nd 3.4 2.0 nd 1.5
    p Value 0.44 0.34 0.12 0.25 nd 0.065 0.42 nd 0.65
    95% CI of 0.53 0.31 0.73 0.60 nd 0.93 0.37 nd 0.25
    OR Quart 4 4.3 29 17 6.8 nd 13 11 nd 9.1
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 1.19 3.23 1.19 1.55 1.19 2.47
    Average 3.27 6.13 3.27 68.5 3.27 1.87
    Stdev 12.5 8.36 12.5 249 12.5 1.44
    p (t-test) 0.41 6.0E−14 0.77
    Min 0.00246 1.15 0.00246 0.0144 0.00246 0.371
    Max 270 30.4 270 935 270 3.71
    n (Samp) 933 13 933 14 933 7
    n (Patient) 344 13 344 14 344 7
    sCr only
    Median 1.23 2.28 nd nd nd nd
    Average 4.24 2.60 nd nd nd nd
    Stdev 32.3 1.38 nd nd nd nd
    p (t-test) 0.90 nd nd nd nd
    Min 0.00246 1.15 nd nd nd nd
    Max 935 4.52 nd nd nd nd
    n (Samp) 970 6 nd nd nd nd
    n (Patient) 354 6 nd nd nd nd
    UO only
    Median 1.24 3.58 1.24 2.37 nd nd
    Average 3.30 10.3 3.30 72.4 nd nd
    Stdev 13.0 19.8 13.0 248 nd nd
    p (t-test) 0.13 1.2E−13 nd nd
    Min 0.00246 1.22 0.00246 0.0144 nd nd
    Max 270 59.1 270 935 nd nd
    n (Samp) 800 8 800 14 nd nd
    n (Patient) 263 8 263 14 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.77 0.69 0.80 0.57 nd 0.62 0.56 nd nd
    SE 0.077 0.12 0.095 0.080 nd 0.081 0.11 nd nd
    p 4.6E−4 0.11 0.0018 0.40 nd 0.14 0.59 nd nd
    nCohort 1 933 970 800 933 nd 800 933 nd nd
    nCohort 2 13 6 8 14 nd 14 7 nd nd
    Cutoff 1 2.03 1.39 2.84 0.943 nd 0.938 0.393 nd nd
    Sens 1 77% 83% 75% 71% nd 71% 71% nd nd
    Spec 1 67% 54% 76% 44% nd 43% 27% nd nd
    Cutoff 2 1.39 1.39 2.03 0.162 nd 0.162 0.392 nd nd
    Sens 2 85% 83% 88% 86% nd 86% 86% nd nd
    Spec 2 55% 54% 66% 20% nd 21% 27% nd nd
    Cutoff 3 1.20 1.14 1.20 0.0140 nd 0.0140 0.365 nd nd
    Sens 3 92% 100%  100%  100%  nd 100%  100%  nd nd
    Spec 3 50% 48% 49% 11% nd 12% 26% nd nd
    Cutoff 4 2.18 2.23 2.22 2.18 nd 2.22 2.18 nd nd
    Sens 4 69% 50% 75% 43% nd 50% 57% nd nd
    Spec 4 70% 70% 70% 70% nd 70% 70% nd nd
    Cutoff 5 3.13 3.16 3.15 3.13 nd 3.15 3.13 nd nd
    Sens 5 54% 33% 62% 29% nd 43% 14% nd nd
    Spec 5 80% 80% 80% 80% nd 80% 80% nd nd
    Cutoff 6 5.13 5.13 5.05 5.13 nd 5.05 5.13 nd nd
    Sens 6 23%  0% 25% 14% nd 29%  0% nd nd
    Spec 6 90% 90% 90% 90% nd 90% 90% nd nd
    OR Quart 2 >2.0 >1.0 >1.0 1.00 nd 0.66 >3.0 nd nd
    p Value <0.57 <1.00 <1.00 1.00 nd 0.65 <0.34 nd nd
    95% CI of >0.18 >0.062 >0.062 0.20 nd 0.11 >0.31 nd nd
    OR Quart 2 na na na 5.0 nd 4.0 na nd nd
    OR Quart 3 >3.0 >3.0 >1.0 1.00 nd 0.66 >1.0 nd nd
    p Value <0.34 <0.34 <1.00 1.00 nd 0.65 <1.00 nd nd
    95% CI of >0.31 >0.31 >0.062 0.20 nd 0.11 >0.062 nd nd
    OR Quart 3 na na na 5.0 nd 4.0 na nd nd
    OR Quart 4 >8.2 >2.0 >6.2 1.7 nd 2.4 >3.0 nd nd
    p Value <0.048 <0.57 <0.093 0.48 nd 0.22 <0.34 nd nd
    95% CI of >1.0 >0.18 >0.74 0.40 nd 0.60 >0.31 nd nd
    OR Quart 4 na na na 7.1 nd 9.3 na nd nd
    Corticotropin
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00162 0.00162 0.00162 0.00425 nd nd
    Average 0.00219 0.00196 0.00219 0.00914 nd nd
    Stdev 0.00354 0.00112 0.00354 0.0119 nd nd
    p (t-test) 0.87 1.1E−7 nd nd
    Min 3.92E−6 0.00109 3.92E−6 0.000794 nd nd
    Max 0.0489 0.00427 0.0489 0.0377 nd nd
    n (Samp) 332 7 332 10 nd nd
    n (Patient) 193 7 193 10 nd nd
    UO only
    Median nd nd 0.00163 0.00380 nd nd
    Average nd nd 0.00233 0.00797 nd nd
    Stdev nd nd 0.00396 0.0123 nd nd
    p (t-test) nd nd 3.4E−4 nd nd
    Min nd nd 0.000273 0.000794 nd nd
    Max nd nd 0.0489 0.0377 nd nd
    n (Samp) nd nd 290 8 nd nd
    n (Patient) nd nd 162 8 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.50 nd nd 0.78 nd 0.72 nd nd nd
    SE 0.11 nd nd 0.087 nd 0.10 nd nd nd
    p 1.00 nd nd 0.0013 nd 0.032 nd nd nd
    nCohort 1 332 nd nd 332 nd 290 nd nd nd
    nCohort 2 7 nd nd 10 nd 8 nd nd nd
    Cutoff 1 0.00134 nd nd 0.00375 nd 0.00229 nd nd nd
    Sens 1 71% nd nd 70% nd 75% nd nd nd
    Spec 1 32% nd nd 92% nd 72% nd nd nd
    Cutoff 2 0.00106 nd nd 0.00229 nd 0.00106 nd nd nd
    Sens 2 100%  nd nd 80% nd 88% nd nd nd
    Spec 2 19% nd nd 73% nd 20% nd nd nd
    Cutoff 3 0.00106 nd nd 0.00106 nd 0.000687 nd nd nd
    Sens 3 100%  nd nd 90% nd 100%  nd nd nd
    Spec 3 19% nd nd 19% nd  9% nd nd nd
    Cutoff 4 0.00212 nd nd 0.00212 nd 0.00218 nd nd nd
    Sens 4 29% nd nd 80% nd 75% nd nd nd
    Spec 4 70% nd nd 70% nd 70% nd nd nd
    Cutoff 5 0.00274 nd nd 0.00274 nd 0.00275 nd nd nd
    Sens 5 14% nd nd 70% nd 62% nd nd nd
    Spec 5 80% nd nd 80% nd 80% nd nd nd
    Cutoff 6 0.00352 nd nd 0.00352 nd 0.00362 nd nd nd
    Sens 6 14% nd nd 70% nd 62% nd nd nd
    Spec 6 90% nd nd 90% nd 90% nd nd nd
    OR Quart 2 0.49 nd nd 0 nd 0 nd nd nd
    p Value 0.57 nd nd na nd na nd nd nd
    95% CI of 0.044 nd nd na nd na nd nd nd
    OR Quart 2 5.6 nd nd na nd na nd nd nd
    OR Quart 3 1.0 nd nd 0.49 nd 0.49 nd nd nd
    p Value 1.0 nd nd 0.57 nd 0.57 nd nd nd
    95% CI of 0.14 nd nd 0.044 nd 0.044 nd nd nd
    OR Quart 3 73 nd nd 5.6 nd 5.6 nd nd nd
    OR Quart 4 1.0 nd nd 3.7 nd 2.6 nd nd nd
    p Value 0.99 nd nd 0.11 nd 0.27 nd nd nd
    95% CI of 0.14 nd nd 0.74 nd 0.48 nd nd nd
    OR Quart 4 7.4 nd nd 18 nd 14 nd nd nd
    Pigment epithelium-derived factor
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 3.21 8.76 3.21 11.6 3.21 4.86
    Average 20.2 39.5 20.2 41.2 20.2 21.3
    Stdev 47.4 63.3 47.4 54.0 47.4 36.7
    p (t-test) 0.060 0.050 0.94
    Min 0.000401 0.0312 0.000401 0.117 0.000401 0.00102
    Max 400 204 400 168 400 115
    n (Samp) 1273 22 1273 20 1273 10
    n (Patient) 451 22 451 20 451 10
    sCr only
    Median 3.33 12.0 nd nd nd nd
    Average 20.9 37.0 nd nd nd nd
    Stdev 47.9 57.0 nd nd nd nd
    p (t-test) 0.34 nd nd nd nd
    Min 0.000401 0.0312 nd nd nd nd
    Max 400 168 nd nd nd nd
    n (Samp) 1337 8 nd nd nd nd
    n (Patient) 466 8 nd nd nd nd
    UO only
    Median 3.46 19.8 3.46 14.9 3.46 2.22
    Average 22.0 53.2 22.0 55.6 22.0 26.7
    Stdev 50.6 75.1 50.6 71.6 50.6 43.3
    p (t-test) 0.023 0.0045 0.81
    Min 0.000401 0.106 0.000401 0.190 0.000401 0.644
    Max 400 204 400 250 400 115
    n (Samp) 1119 14 1119 19 1119 7
    n (Patient) 361 14 361 19 361 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.62 0.64 0.66 0.64 nd 0.68 0.52 nd 0.53
    SE 0.064 0.11 0.080 0.067 nd 0.069 0.093 nd 0.11
    p 0.069 0.19 0.048 0.033 nd 0.0099 0.81 nd 0.81
    nCohort 1 1273 1337 1119 1273 nd 1119 1273 nd 1119
    nCohort 2 22 8 14 20 nd 19 10 nd 7
    Cutoff 1 2.66 4.16 3.30 2.20 nd 2.20 1.56 nd 1.56
    Sens 1 73% 75% 71% 70% nd 74% 70% nd 71%
    Spec 1 46% 55% 49% 43% nd 41% 36% nd 34%
    Cutoff 2 2.01 2.29 2.01 1.99 nd 1.99 0.682 nd 0.682
    Sens 2 82% 88% 86% 80% nd 84% 80% nd 86%
    Spec 2 41% 43% 39% 41% nd 39% 21% nd 19%
    Cutoff 3 0.351 0.0292 0.511 1.24 nd 1.24 0.643 nd 0.640
    Sens 3 91% 100%  93% 90% nd 95% 90% nd 100% 
    Spec 3 12%  1% 14% 31% nd 29% 20% nd 19%
    Cutoff 4 10.1 10.5 11.0 10.1 nd 11.0 10.1 nd 11.0
    Sens 4 50% 50% 57% 50% nd 53% 40% nd 43%
    Spec 4 70% 70% 70% 70% nd 70% 70% nd 70%
    Cutoff 5 21.8 23.1 23.9 21.8 nd 23.9 21.8 nd 23.9
    Sens 5 41% 38% 43% 40% nd 47% 20% nd 29%
    Spec 5 80% 80% 80% 80% nd 80% 80% nd 80%
    Cutoff 6 52.9 58.1 60.9 52.9 nd 60.9 52.9 nd 60.9
    Sens 6 23% 25% 29% 30% nd 32% 20% nd 14%
    Spec 6 90% 90% 90% 90% nd 90% 90% nd 90%
    OR Quart 2 0.75 1.0 1.5 2.5 nd 5.1 0.66 nd 1.00
    p Value 0.70 1.0 0.66 0.27 nd 0.14 0.65 nd 1.00
    95% CI of 0.17 0.062 0.25 0.49 nd 0.59 0.11 nd 0.14
    OR Quart 2 3.4 16 9.1 13 nd 44 4.0 nd 7.1
    OR Quart 3 1.2 2.0 0.50 2.0 nd 4.0 0.66 nd 0.50
    p Value 0.74 0.57 0.57 0.42 nd 0.21 0.65 nd 0.57
    95% CI of 0.33 0.18 0.045 0.37 nd 0.45 0.11 nd 0.045
    OR Quart 3 4.7 22 5.5 11 nd 36 4.0 nd 5.5
    OR Quart 4 2.5 4.0 4.1 4.6 nd 9.2 1.00 nd 1.00
    p Value 0.12 0.21 0.077 0.053 nd 0.036 1.00 nd 1.00
    95% CI of 0.79 0.45 0.86 0.98 nd 1.2 0.20 nd 0.14
    OR Quart 4 8.2 36 19 21 nd 73 5.0 nd 7.1
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 19.5 38.9 19.5 19.6 19.5 13.2
    Average 29.9 57.9 29.9 29.5 29.9 23.3
    Stdev 44.8 86.8 44.8 30.1 44.8 23.1
    p (t-test) 0.020 0.97 0.70
    Min 0.0493 0.121 0.0493 0.0561 0.0493 0.196
    Max 554 353 554 102 554 50.0
    n (Samp) 658 15 658 16 658 7
    n (Patient) 300 15 300 16 300 7
    UO only
    Median 19.5 38.9 19.5 19.8 nd nd
    Average 29.9 44.8 29.9 31.2 nd nd
    Stdev 46.4 32.5 46.4 33.2 nd nd
    p (t-test) 0.34 0.92 nd nd
    Min 0.0493 6.52 0.0493 0.0561 nd nd
    Max 554 117 554 102 nd nd
    n (Samp) 600 9 600 13 nd nd
    n (Patient) 263 9 263 13 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.65 nd 0.72 0.51 nd 0.51 0.48 nd nd
    SE 0.078 nd 0.098 0.074 nd 0.082 0.11 nd nd
    p 0.053 nd 0.027 0.84 nd 0.86 0.85 nd nd
    nCohort 1 658 nd 600 658 nd 600 658 nd nd
    nCohort 2 15 nd 9 16 nd 13 7 nd nd
    Cutoff 1 25.6 nd 30.2 5.76 nd 4.22 6.53 nd nd
    Sens 1 73% nd 78% 75% nd 77% 71% nd nd
    Spec 1 60% nd 68% 23% nd 17% 25% nd nd
    Cutoff 2 15.4 nd 15.4 4.22 nd 3.98 0.196 nd nd
    Sens 2 80% nd 89% 81% nd 85% 86% nd nd
    Spec 2 44% nd 45% 16% nd 16%  8% nd nd
    Cutoff 3 1.18 nd 5.76 1.80 nd 1.80 0.121 nd nd
    Sens 3 93% nd 100%  94% nd 92% 100%  nd nd
    Spec 3 12% nd 25% 15% nd 16%  6% nd nd
    Cutoff 4 32.7 nd 31.4 32.7 nd 31.4 32.7 nd nd
    Sens 4 60% nd 67% 38% nd 46% 43% nd nd
    Spec 4 70% nd 70% 70% nd 70% 70% nd nd
    Cutoff 5 41.7 nd 41.1 41.7 nd 41.1 41.7 nd nd
    Sens 5 40% nd 33% 19% nd 23% 43% nd nd
    Spec 5 80% nd 80% 80% nd 80% 80% nd nd
    Cutoff 6 62.5 nd 62.5 62.5 nd 62.5 62.5 nd nd
    Sens 6 20% nd 22% 12% nd 15%  0% nd nd
    Spec 6 90% nd 90% 90% nd 90% 90% nd nd
    OR Quart 2 0.33 nd >2.0 0.39 nd 0.49 0 nd nd
    p Value 0.34 nd <0.57 0.27 nd 0.42 na nd nd
    95% CI of 0.034 nd >0.18 0.075 nd 0.089 na nd nd
    OR Quart 2 3.2 nd na 2.0 nd 2.7 na nd nd
    OR Quart 3 1.0 nd >2.0 0.80 nd 0.49 0.67 nd nd
    p Value 1.0 nd <0.57 0.74 nd 0.42 0.66 nd nd
    95% CI of 0.20 nd >0.18 0.21 nd 0.089 0.11 nd nd
    OR Quart 3 5.0 nd na 3.0 nd 2.7 4.0 nd nd
    OR Quart 4 2.7 nd >5.1 0.99 nd 1.2 0.67 nd nd
    p Value 0.14 nd <0.14 0.99 nd 0.74 0.66 nd nd
    95% CI of 0.71 nd >0.59 0.28 nd 0.33 0.11 nd nd
    OR Quart 4 10 nd na 3.5 nd 4.7 4.0 nd nd
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 0.00505 0.00508 0.00505 0.0385 0.00505 0.00446
    Average 0.0526 0.0780 0.0526 0.263 0.0526 0.0371
    Stdev 0.146 0.123 0.146 0.722 0.146 0.0669
    p (t-test) 0.59 1.4E−5 0.77
    Min 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463
    Max 1.74 0.296 1.74 2.85 1.74 0.185
    n (Samp) 558 10 558 15 558 8
    n (Patient) 262 10 262 15 262 8
    sCr only
    Median nd nd nd nd 0.00505 0.00286
    Average nd nd nd nd 0.0577 0.0473
    Stdev nd nd nd nd 0.187 0.0760
    p (t-test) nd nd nd nd 0.89
    Min nd nd nd nd 0.000463 0.000463
    Max nd nd nd nd 2.85 0.185
    n (Samp) nd nd nd nd 575 6
    n (Patient) nd nd nd nd 269 6
    UO only
    Median nd nd 0.00505 0.0604 nd nd
    Average nd nd 0.0546 0.339 nd nd
    Stdev nd nd 0.151 0.885 nd nd
    p (t-test) nd nd 3.0E−6 nd nd
    Min nd nd 0.000463 0.000463 nd nd
    Max nd nd 1.74 2.85 nd nd
    n (Samp) nd nd 533 10 nd nd
    n (Patient) nd nd 235 10 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.50 nd nd 0.60 nd 0.58 0.46 0.40 nd
    SE 0.092 nd nd 0.078 nd 0.095 0.10 0.12 nd
    p 0.97 nd nd 0.22 nd 0.39 0.74 0.40 nd
    nCohort 1 558 nd nd 558 nd 533 558 575 nd
    nCohort 2 10 nd nd 15 nd 10 8 6 nd
    Cutoff 1 0.00132 nd nd 0.00296 nd 0.00296 0.00132 0.00132 nd
    Sens 1 90% nd nd 73% nd 70% 88% 83% nd
    Spec 1 15% nd nd 22% nd 23% 15% 14% nd
    Cutoff 2 0.00132 nd nd 0.00132 nd 0.00132 0.00132 0.00132 nd
    Sens 2 90% nd nd 80% nd 80% 88% 83% nd
    Spec 2 15% nd nd 15% nd 17% 15% 14% nd
    Cutoff 3 0.00132 nd nd 0 nd 0 0 0 nd
    Sens 3 90% nd nd 100%  nd 100%  100%  100%  nd
    Spec 3 15% nd nd  0% nd  0%  0%  0% nd
    Cutoff 4 0.00660 nd nd 0.00660 nd 0.00660 0.00660 0.00660 nd
    Sens 4 30% nd nd 60% nd 60% 25% 33% nd
    Spec 4 72% nd nd 72% nd 73% 72% 72% nd
    Cutoff 5 0.0499 nd nd 0.0499 nd 0.0499 0.0499 0.0499 nd
    Sens 5 30% nd nd 47% nd 50% 25% 33% nd
    Spec 5 80% nd nd 80% nd 80% 80% 80% nd
    Cutoff 6 0.141 nd nd 0.141 nd 0.154 0.141 0.141 nd
    Sens 6 30% nd nd 27% nd 20% 12% 17% nd
    Spec 6 90% nd nd 90% nd 90% 90% 90% nd
    OR Quart 2 0.66 nd nd 0.49 nd 0.33 1.0 0 nd
    p Value 0.65 nd nd 0.42 nd 0.33 0.99 na nd
    95% CI of 0.11 nd nd 0.089 nd 0.033 0.14 na nd
    OR Quart 2 4.0 nd nd 2.7 nd 3.2 7.3 na nd
    OR Quart 3 0.33 nd nd 0.24 nd 0.33 0.50 0 nd
    p Value 0.34 nd nd 0.21 nd 0.33 0.57 na nd
    95% CI of 0.034 nd nd 0.027 nd 0.033 0.045 na nd
    OR Quart 3 3.2 nd nd 2.2 nd 3.2 5.5 na nd
    OR Quart 4 1.3 nd nd 2.0 nd 1.7 1.5 2.0 nd
    p Value 0.70 nd nd 0.25 nd 0.48 0.65 0.41 nd
    95% CI of 0.30 nd nd 0.60 nd 0.39 0.25 0.37 nd
    OR Quart 4 6.1 nd nd 6.9 nd 7.2 9.2 11 nd
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 2.46 1.66 2.46 1.59 2.46 1.96
    Average 18.0 33.9 18.0 99.3 18.0 3.18
    Stdev 114 122 114 435 114 3.65
    p (t-test) 0.50 0.0018 0.64
    Min 0.000147 0.00122 0.000147 0.000147 0.000147 0.00328
    Max 2160 594 2160 2140 2160 12.3
    n (Samp) 1388 24 1388 24 1388 13
    n (Patient) 484 24 484 24 484 13
    sCr only
    Median 2.41 0.351 2.41 0.985 2.41 0.907
    Average 19.4 75.3 19.4 3.39 19.4 1.85
    Stdev 125 210 125 5.64 125 2.68
    p (t-test) 0.21 0.75 0.71
    Min 0.000147 0.0847 0.000147 0.000147 0.000147 0.0263
    Max 2160 594 2160 14.6 2160 7.68
    n (Samp) 1455 8 1455 6 1455 7
    n (Patient) 500 8 500 6 500 7
    UO only
    Median 2.40 1.08 2.40 3.49 2.40 3.25
    Average 17.1 17.0 17.1 116 17.1 4.27
    Stdev 105 37.4 105 464 105 4.05
    p (t-test) 1.00 1.7E−4 0.75
    Min 0.000147 0.00122 0.000147 0.00247 0.000147 0.211
    Max 2140 135 2140 2140 2140 12.3
    n (Samp) 1246 15 1246 21 1246 7
    n (Patient) 397 15 397 21 397 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.44 0.35 0.41 0.46 0.36 0.52 0.42 0.32 0.52
    SE 0.061 0.11 0.078 0.061 0.12 0.064 0.083 0.11 0.11
    p 0.32 0.16 0.24 0.48 0.26 0.73 0.32 0.12 0.84
    nCohort 1 1388 1455 1246 1388 1455 1246 1388 1455 1246
    nCohort 2 24 8 15 24 6 21 13 7 7
    Cutoff 1 0.404 0.201 0.172 0.309 0.260 0.422 0.207 0.624 2.00
    Sens 1 71% 75% 73% 71% 83% 71% 77% 71% 71%
    Spec 1 18% 12% 11% 15% 13% 18% 13% 24% 45%
    Cutoff 2 0.172 0.130 0.130 0.0258 0.260 0.130 0.0537 0.0258 1.36
    Sens 2 83% 88% 80% 83% 83% 81% 85% 100%  86%
    Spec 2 11% 10% 10%  7% 13% 10%  8%  7% 38%
    Cutoff 3 0.00154 0.0782 0.00129 0.00238 0 0.0258 0.0258 0.0258 0.207
    Sens 3 92% 100%  93% 92% 100%  90% 92% 100%  100% 
    Spec 3  3%  9%  2%  4%  0%  7%  7%  7% 12%
    Cutoff 4 6.82 6.82 6.52 6.82 6.82 6.52 6.82 6.82 6.52
    Sens 4 25% 12% 33% 33% 17% 43% 15% 14% 14%
    Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70%
    Cutoff 5 11.8 12.1 11.3 11.8 12.1 11.3 11.8 12.1 11.3
    Sens 5 17% 12% 20% 29% 17% 38%  8%  0% 14%
    Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80%
    Cutoff 6 25.4 26.2 24.2 25.4 26.2 24.2 25.4 26.2 24.2
    Sens 6 12% 12% 20% 17%  0% 24%  0%  0%  0%
    Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90%
    OR Quart 2 1.2 2.0 0.25 0.57 1.0 0.11 4.0 >1.0 2.0
    p Value 0.76 0.57 0.21 0.37 1.00 0.035 0.21 <1.00 0.57
    95% CI of 0.36 0.18 0.028 0.16 0.062 0.014 0.45 >0.063 0.18
    OR Quart 2 4.0 22 2.2 2.0 16 0.86 36 na 22
    OR Quart 3 0.80 0 0.75 0.28 1.0 0.33 4.0 >3.0 3.0
    p Value 0.74 na 0.71 0.12 1.00 0.095 0.21 <0.34 0.34
    95% CI of 0.21 na 0.17 0.058 0.062 0.087 0.45 >0.31 0.31
    OR Quart 3 3.0 na 3.4 1.4 16 1.2 36 na 29
    OR Quart 4 1.8 5.1 1.8 1.6 3.0 0.88 4.0 >3.0 1.00
    p Value 0.29 0.14 0.36 0.34 0.34 0.80 0.21 <0.34 1.00
    95% CI of 0.60 0.59 0.51 0.61 0.31 0.34 0.45 >0.31 0.062
    OR Quart 4 5.5 44 6.1 4.1 29 2.3 36 na 16
  • FIG. 10: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in EDTA samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I.
  •
    C-C motif chemokine 7
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 0.758 0.410 nd nd
    Average nd nd 8.98 14.0 nd nd
    Stdev nd nd 22.1 22.1 nd nd
    p (t-test) nd nd 0.59 nd nd
    Min nd nd 0.193 0.193 nd nd
    Max nd nd 181 51.7 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.47 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.78 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 0.193 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 17% nd nd nd nd nd
    Cutoff 2 nd nd nd 0.193 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 17% nd nd nd nd nd
    Cutoff 3 nd nd nd 0 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  0% nd nd nd nd nd
    Cutoff 4 nd nd nd 2.71 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 13.1 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 26.6 nd nd nd nd nd
    Sens 6 nd nd nd 33% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd 0.49 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.044 nd nd nd nd nd
    OR Quart 3 nd nd nd 5.6 nd nd nd nd nd
    OR Quart 4 nd nd nd 1.5 nd nd nd nd nd
    p Value nd nd nd 0.65 nd nd nd nd nd
    95% CI of nd nd nd 0.25 nd nd nd nd nd
    OR Quart 4 nd nd nd 9.4 nd nd nd nd nd
    Vascular endothelial growth factor receptor 3
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 6150 5990 nd nd
    Average nd nd 7130 7240 nd nd
    Stdev nd nd 5340 4850 nd nd
    p (t-test) nd nd 0.96 nd nd
    Min nd nd 219 3540 nd nd
    Max nd nd 43200 16600 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.50 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.98 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 3920 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 28% nd nd nd nd nd
    Cutoff 2 nd nd nd 3920 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 28% nd nd nd nd nd
    Cutoff 3 nd nd nd 3530 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd 22% nd nd nd nd nd
    Cutoff 4 nd nd nd 8160 nd nd nd nd nd
    Sens 4 nd nd nd 17% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 9630 nd nd nd nd nd
    Sens 5 nd nd nd 17% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 12100 nd nd nd nd nd
    Sens 6 nd nd nd 17% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 2 nd nd nd 23 nd nd nd nd nd
    OR Quart 3 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 3 nd nd nd 23 nd nd nd nd nd
    OR Quart 4 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.061 nd nd nd nd nd
    OR Quart 4 nd nd nd 16 nd nd nd nd nd
    Interferon alpha-2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 12.3 6.12 nd nd
    Average nd nd 17.0 10.5 nd nd
    Stdev nd nd 23.1 12.0 nd nd
    p (t-test) nd nd 0.50 nd nd
    Min nd nd 0.0320 0.0627 nd nd
    Max nd nd 223 28.5 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.44 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.61 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 0.0997 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 25% nd nd nd nd nd
    Cutoff 2 nd nd nd 0.0997 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 25% nd nd nd nd nd
    Cutoff 3 nd nd nd 0.0324 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  2% nd nd nd nd nd
    Cutoff 4 nd nd nd 21.2 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 27.4 nd nd nd nd nd
    Sens 5 nd nd nd 17% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 36.4 nd nd nd nd nd
    Sens 6 nd nd nd  0% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.061 nd nd nd nd nd
    OR Quart 2 nd nd nd 16 nd nd nd nd nd
    OR Quart 3 nd nd nd 3.1 nd nd nd nd nd
    p Value nd nd nd 0.33 nd nd nd nd nd
    95% CI of nd nd nd 0.31 nd nd nd nd nd
    OR Quart 3 nd nd nd 30 nd nd nd nd nd
    OR Quart 4 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.061 nd nd nd nd nd
    OR Quart 4 nd nd nd 16 nd nd nd nd nd
    Insulin-like growth factor-binding protein 4
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 2.93 4.81 nd nd
    Average nd nd 12.8 12.6 nd nd
    Stdev nd nd 18.4 14.7 nd nd
    p (t-test) nd nd 0.98 nd nd
    Min nd nd 0.0728 0.572 nd nd
    Max nd nd 158 33.4 nd nd
    n (Samp) nd nd 361 6 nd nd
    n (Patient) nd nd 197 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.55 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.66 nd nd nd nd nd
    nCohort 1 nd nd nd 361 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 2.43 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 38% nd nd nd nd nd
    Cutoff 2 nd nd nd 2.43 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 38% nd nd nd nd nd
    Cutoff 3 nd nd nd 0.0862 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  1% nd nd nd nd nd
    Cutoff 4 nd nd nd 17.1 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 23.5 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 30.5 nd nd nd nd nd
    Sens 6 nd nd nd 17% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 2 nd nd nd 22 nd nd nd nd nd
    OR Quart 3 nd nd nd 0.99 nd nd nd nd nd
    p Value nd nd nd 0.99 nd nd nd nd nd
    95% CI of nd nd nd 0.061 nd nd nd nd nd
    OR Quart 3 nd nd nd 16 nd nd nd nd nd
    OR Quart 4 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 4 nd nd nd 22 nd nd nd nd nd
    Insulin-like growth factor-binding protein 5
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 11.5 0.763 nd nd
    Average nd nd 34.9 22.5 nd nd
    Stdev nd nd 49.9 34.1 nd nd
    p (t-test) nd nd 0.54 nd nd
    Min nd nd 0.204 0.204 nd nd
    Max nd nd 257 69.8 nd nd
    n (Samp) nd nd 361 6 nd nd
    n (Patient) nd nd 197 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.44 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.61 nd nd nd nd nd
    nCohort 1 nd nd nd 361 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 0.222 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 18% nd nd nd nd nd
    Cutoff 2 nd nd nd 0.222 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 18% nd nd nd nd nd
    Cutoff 3 nd nd nd 0 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  0% nd nd nd nd nd
    Cutoff 4 nd nd nd 40.2 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 62.1 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 119 nd nd nd nd nd
    Sens 6 nd nd nd  0% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.14 nd nd nd nd nd
    OR Quart 3 nd nd nd 7.3 nd nd nd nd nd
    OR Quart 4 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 0.99 nd nd nd nd nd
    95% CI of nd nd nd 0.14 nd nd nd nd nd
    OR Quart 4 nd nd nd 7.3 nd nd nd nd nd
    Interleukin-33
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 0.0981 5.87 nd nd
    Average nd nd 278 36.4 nd nd
    Stdev nd nd 2480 73.0 nd nd
    p (t-test) nd nd 0.81 nd nd
    Min nd nd 0.0445 0.0455 nd nd
    Max nd nd 40000 184 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.67 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.16 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 0.0996 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 56% nd nd nd nd nd
    Cutoff 2 nd nd nd 0.0996 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 56% nd nd nd nd nd
    Cutoff 3 nd nd nd 0.0445 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd 10% nd nd nd nd nd
    Cutoff 4 nd nd nd 1.13 nd nd nd nd nd
    Sens 4 nd nd nd 67% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 13.1 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 76.8 nd nd nd nd nd
    Sens 6 nd nd nd 17% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 3 nd nd nd 23 nd nd nd nd nd
    OR Quart 4 nd nd nd 3.1 nd nd nd nd nd
    p Value nd nd nd 0.33 nd nd nd nd nd
    95% CI of nd nd nd 0.31 nd nd nd nd nd
    OR Quart 4 nd nd nd 30 nd nd nd nd nd
    Interleukin-4 receptor alpha chain
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 219 275 nd nd
    Average nd nd 294 314 nd nd
    Stdev nd nd 230 226 nd nd
    p (t-test) nd nd 0.83 nd nd
    Min nd nd 3.27 84.5 nd nd
    Max nd nd 1210 646 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.52 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.86 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 104 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd  7% nd nd nd nd nd
    Cutoff 2 nd nd nd 104 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd  7% nd nd nd nd nd
    Cutoff 3 nd nd nd 83.5 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  4% nd nd nd nd nd
    Cutoff 4 nd nd nd 304 nd nd nd nd nd
    Sens 4 nd nd nd 50% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 376 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 554 nd nd nd nd nd
    Sens 6 nd nd nd 17% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0.49 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.044 nd nd nd nd nd
    OR Quart 2 nd nd nd 5.6 nd nd nd nd nd
    OR Quart 3 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd na nd nd nd nd nd
    OR Quart 4 nd nd nd 1.5 nd nd nd nd nd
    p Value nd nd nd 0.65 nd nd nd nd nd
    95% CI of nd nd nd 0.25 nd nd nd nd nd
    OR Quart 4 nd nd nd 9.4 nd nd nd nd nd
    Vascular endothelial growth factor receptor 2
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 7870 7420 nd nd
    Average nd nd 9920 7340 nd nd
    Stdev nd nd 13200 1600 nd nd
    p (t-test) nd nd 0.63 nd nd
    Min nd nd 3020 5310 nd nd
    Max nd nd 166000 9440 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.42 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.54 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 5920 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 20% nd nd nd nd nd
    Cutoff 2 nd nd nd 5920 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 20% nd nd nd nd nd
    Cutoff 3 nd nd nd 5300 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd 11% nd nd nd nd nd
    Cutoff 4 nd nd nd 9430 nd nd nd nd nd
    Sens 4 nd nd nd 17% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 10600 nd nd nd nd nd
    Sens 5 nd nd nd  0% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 14300 nd nd nd nd nd
    Sens 6 nd nd nd  0% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd >3.1 nd nd nd nd nd
    p Value nd nd nd <0.33 nd nd nd nd nd
    95% CI of nd nd nd >0.32 nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd >1.0 nd nd nd nd nd
    p Value nd nd nd <0.99 nd nd nd nd nd
    95% CI of nd nd nd >0.062 nd nd nd nd nd
    OR Quart 3 nd nd nd na nd nd nd nd nd
    OR Quart 4 nd nd nd >2.1 nd nd nd nd nd
    p Value nd nd nd <0.56 nd nd nd nd nd
    95% CI of nd nd nd >0.18 nd nd nd nd nd
    OR Quart 4 nd nd nd na nd nd nd nd nd
    Neural cell adhesion molecule 1
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 182000 166000 nd nd
    Average nd nd 189000 177000 nd nd
    Stdev nd nd 70000 50000 nd nd
    p (t-test) nd nd 0.68 nd nd
    Min nd nd 49200 125000 nd nd
    Max nd nd 520000 245000 nd nd
    n (Samp) nd nd 366 6 nd nd
    n (Patient) nd nd 196 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.46 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.75 nd nd nd nd nd
    nCohort 1 nd nd nd 366 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 131000 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 19% nd nd nd nd nd
    Cutoff 2 nd nd nd 131000 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 19% nd nd nd nd nd
    Cutoff 3 nd nd nd 125000 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd 15% nd nd nd nd nd
    Cutoff 4 nd nd nd 209000 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 230000 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 268000 nd nd nd nd nd
    Sens 6 nd nd nd  0% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.14 nd nd nd nd nd
    OR Quart 3 nd nd nd 7.3 nd nd nd nd nd
    OR Quart 4 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.14 nd nd nd nd nd
    OR Quart 4 nd nd nd 7.3 nd nd nd nd nd
    Platelet-derived growth factor subunit B (dimer)
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 337 403 nd nd
    Average nd nd 394 748 nd nd
    Stdev nd nd 270 983 nd nd
    p (t-test) nd nd 0.0034 nd nd
    Min nd nd 0.189 91.9 nd nd
    Max nd nd 2690 2720 nd nd
    n (Samp) nd nd 355 6 nd nd
    n (Patient) nd nd 192 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.57 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.59 nd nd nd nd nd
    nCohort 1 nd nd nd 355 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 242 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 31% nd nd nd nd nd
    Cutoff 2 nd nd nd 242 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 31% nd nd nd nd nd
    Cutoff 3 nd nd nd 91.4 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  7% nd nd nd nd nd
    Cutoff 4 nd nd nd 495 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 581 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 699 nd nd nd nd nd
    Sens 6 nd nd nd 17% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.062 nd nd nd nd nd
    OR Quart 2 nd nd nd 16 nd nd nd nd nd
    OR Quart 3 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 3 nd nd nd 23 nd nd nd nd nd
    OR Quart 4 nd nd nd 2.0 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.18 nd nd nd nd nd
    OR Quart 4 nd nd nd 22 nd nd nd nd nd
    Pigment epithelium-derived factor
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 1670 1350 nd nd
    Average nd nd 1920 1180 nd nd
    Stdev nd nd 1130 498 nd nd
    p (t-test) nd nd 0.11 nd nd
    Min nd nd 84.2 339 nd nd
    Max nd nd 7450 1650 nd nd
    n (Samp) nd nd 367 6 nd nd
    n (Patient) nd nd 197 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.29 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.086 nd nd nd nd nd
    nCohort 1 nd nd nd 367 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 823 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 10% nd nd nd nd nd
    Cutoff 2 nd nd nd 823 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 10% nd nd nd nd nd
    Cutoff 3 nd nd nd 328 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  1% nd nd nd nd nd
    Cutoff 4 nd nd nd 2120 nd nd nd nd nd
    Sens 4 nd nd nd  0% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 2510 nd nd nd nd nd
    Sens 5 nd nd nd  0% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 3550 nd nd nd nd nd
    Sens 6 nd nd nd  0% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd >0 nd nd nd nd nd
    p Value nd nd nd <na nd nd nd nd nd
    95% CI of nd nd nd >na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd >4.2 nd nd nd nd nd
    p Value nd nd nd <0.20 nd nd nd nd nd
    95% CI of nd nd nd >0.46 nd nd nd nd nd
    OR Quart 3 nd nd nd na nd nd nd nd nd
    OR Quart 4 nd nd nd >2.1 nd nd nd nd nd
    p Value nd nd nd <0.56 nd nd nd nd nd
    95% CI of nd nd nd >0.18 nd nd nd nd nd
    OR Quart 4 nd nd nd na nd nd nd nd nd
    Tumor necrosis factor receptor superfamily member 8
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 102 71.9 nd nd
    Average nd nd 195 189 nd nd
    Stdev nd nd 388 223 nd nd
    p (t-test) nd nd 0.97 nd nd
    Min nd nd 4.06 30.8 nd nd
    Max nd nd 3360 595 nd nd
    n (Samp) nd nd 298 6 nd nd
    n (Patient) nd nd 167 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.43 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.58 nd nd nd nd nd
    nCohort 1 nd nd nd 298 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 54.3 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 14% nd nd nd nd nd
    Cutoff 2 nd nd nd 54.3 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 14% nd nd nd nd nd
    Cutoff 3 nd nd nd 30.2 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  4% nd nd nd nd nd
    Cutoff 4 nd nd nd 149 nd nd nd nd nd
    Sens 4 nd nd nd 33% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 205 nd nd nd nd nd
    Sens 5 nd nd nd 33% nd nd nd nd nd
    Spec 5 nd nd nd 81% nd nd nd nd nd
    Cutoff 6 nd nd nd 305 nd nd nd nd nd
    Sens 6 nd nd nd 33% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd 0.49 nd nd nd nd nd
    p Value nd nd nd 0.57 nd nd nd nd nd
    95% CI of nd nd nd 0.044 nd nd nd nd nd
    OR Quart 3 nd nd nd 5.6 nd nd nd nd nd
    OR Quart 4 nd nd nd 1.5 nd nd nd nd nd
    p Value nd nd nd 0.65 nd nd nd nd nd
    95% CI of nd nd nd 0.25 nd nd nd nd nd
    OR Quart 4 nd nd nd 9.4 nd nd nd nd nd
    Alpha-fetoprotein
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median nd nd 0.328 0.608 nd nd
    Average nd nd 0.351 0.738 nd nd
    Stdev nd nd 0.339 0.576 nd nd
    p (t-test) nd nd 0.0065 nd nd
    Min nd nd 0.00580 0.00580 nd nd
    Max nd nd 1.81 1.53 nd nd
    n (Samp) nd nd 367 6 nd nd
    n (Patient) nd nd 197 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC nd nd nd 0.71 nd nd nd nd nd
    SE nd nd nd 0.12 nd nd nd nd nd
    p nd nd nd 0.087 nd nd nd nd nd
    nCohort 1 nd nd nd 367 nd nd nd nd nd
    nCohort 2 nd nd nd 6 nd nd nd nd nd
    Cutoff 1 nd nd nd 0.369 nd nd nd nd nd
    Sens 1 nd nd nd 83% nd nd nd nd nd
    Spec 1 nd nd nd 57% nd nd nd nd nd
    Cutoff 2 nd nd nd 0.369 nd nd nd nd nd
    Sens 2 nd nd nd 83% nd nd nd nd nd
    Spec 2 nd nd nd 57% nd nd nd nd nd
    Cutoff 3 nd nd nd 0 nd nd nd nd nd
    Sens 3 nd nd nd 100%  nd nd nd nd nd
    Spec 3 nd nd nd  0% nd nd nd nd nd
    Cutoff 4 nd nd nd 0.509 nd nd nd nd nd
    Sens 4 nd nd nd 67% nd nd nd nd nd
    Spec 4 nd nd nd 70% nd nd nd nd nd
    Cutoff 5 nd nd nd 0.598 nd nd nd nd nd
    Sens 5 nd nd nd 50% nd nd nd nd nd
    Spec 5 nd nd nd 80% nd nd nd nd nd
    Cutoff 6 nd nd nd 0.784 nd nd nd nd nd
    Sens 6 nd nd nd 33% nd nd nd nd nd
    Spec 6 nd nd nd 90% nd nd nd nd nd
    OR Quart 2 nd nd nd 0 nd nd nd nd nd
    p Value nd nd nd na nd nd nd nd nd
    95% CI of nd nd nd na nd nd nd nd nd
    OR Quart 2 nd nd nd na nd nd nd nd nd
    OR Quart 3 nd nd nd 1.0 nd nd nd nd nd
    p Value nd nd nd 1.0 nd nd nd nd nd
    95% CI of nd nd nd 0.062 nd nd nd nd nd
    OR Quart 3 nd nd nd 16 nd nd nd nd nd
    OR Quart 4 nd nd nd 4.1 nd nd nd nd nd
    p Value nd nd nd 0.21 nd nd nd nd nd
    95% CI of nd nd nd 0.45 nd nd nd nd nd
    OR Quart 4 nd nd nd 37 nd nd nd nd nd
    Apolipoprotein E
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    sCr or UO
    Median 51000 28200 51000 42800 nd nd
    Average 61600 35600 61600 39400 nd nd
    Stdev 44300 15000 44300 11700 nd nd
    p (t-test) 0.098 0.19 nd nd
    Min 1940 22400 1940 25800 nd nd
    Max 260000 59600 260000 54900 nd nd
    n (Samp) 434 8 434 7 nd nd
    n (Patient) 233 8 233 7 nd nd
    UO only
    Median nd nd 48700 37100 nd nd
    Average nd nd 59500 38400 nd nd
    Stdev nd nd 42000 12400 nd nd
    p (t-test) nd nd 0.22 nd nd
    Min nd nd 1940 25800 nd nd
    Max nd nd 244000 54900 nd nd
    n (Samp) nd nd 400 6 nd nd
    n (Patient) nd nd 205 6 nd nd
    0 hr prior to AKI stage 24 hr prior to AKI stage 48 hr prior to AKI stage
    sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only
    AUC 0.30 nd nd 0.36 nd 0.36 nd nd nd
    SE 0.10 nd nd 0.11 nd 0.12 nd nd nd
    p 0.058 nd nd 0.21 nd 0.25 nd nd nd
    nCohort 1 434 nd nd 434 nd 400 nd nd nd
    nCohort 2 8 nd nd 7 nd 6 nd nd nd
    Cutoff 1 25600 nd nd 31300 nd 25800 nd nd nd
    Sens 1 75% nd nd 71% nd 83% nd nd nd
    Spec 1 17% nd nd 26% nd 19% nd nd nd
    Cutoff 2 23900 nd nd 25800 nd 25800 nd nd nd
    Sens 2 88% nd nd 86% nd 83% nd nd nd
    Spec 2 15% nd nd 18% nd 19% nd nd nd
    Cutoff 3 20900 nd nd 25800 nd 25800 nd nd nd
    Sens 3 100%  nd nd 100%  nd 100%  nd nd nd
    Spec 3 13% nd nd 18% nd 19% nd nd nd
    Cutoff 4 69500 nd nd 69500 nd 67600 nd nd nd
    Sens 4  0% nd nd  0% nd  0% nd nd nd
    Spec 4 70% nd nd 70% nd 70% nd nd nd
    Cutoff 5 87400 nd nd 87400 nd 86400 nd nd nd
    Sens 5  0% nd nd  0% nd  0% nd nd nd
    Spec 5 80% nd nd 80% nd 80% nd nd nd
    Cutoff 6 120000 nd nd 120000 nd 110000 nd nd nd
    Sens 6  0% nd nd  0% nd  0% nd nd nd
    Spec 6 90% nd nd 90% nd 90% nd nd nd
    OR Quart 2 >2.1 nd nd >1.0 nd >2.1 nd nd nd
    p Value <0.56 nd nd <0.99 nd <0.56 nd nd nd
    95% CI of >0.18 nd nd >0.063 nd >0.18 nd nd nd
    OR Quart 2 na nd nd na nd na nd nd nd
    OR Quart 3 >1.0 nd nd >4.2 nd >2.0 nd nd nd
    p Value <0.99 nd nd <0.20 nd <0.56 nd nd nd
    95% CI of >0.062 nd nd >0.46 nd >0.18 nd nd nd
    OR Quart 3 na nd nd na nd na nd nd nd
    OR Quart 4 >5.3 nd nd >2.1 nd >2.1 nd nd nd
    p Value <0.13 nd nd <0.56 nd <0.56 nd nd nd
    95% CI of >0.61 nd nd >0.18 nd >0.18 nd nd nd
    OR Quart 4 na nd nd na nd na nd nd nd
  • FIG. 11: Comparison of marker levels in enroll urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48 hrs) and in enroll urine samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48 hrs). Enroll samples from patients already at RIFLE stage I or F were included in Cohort 2.
  •
    Complement C4-B
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 16.6 33.8 18.1 31.8 18.9 43.7
    Average 59.8 80.1 63.5 70.6 59.4 84.2
    Stdev 150 154 154 83.8 152 163
    p (t-test) 0.25 0.84 0.21
    Min 0.00329 0.00263 0.00263 0.448 0.00329 0.00263
    Max 1950 1150 1950 245 1950 1150
    n (Samp) 383 92 451 20 296 79
    n (Patient) 383 92 451 20 296 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.59 0.57 0.60
    SE 0.034 0.068 0.037
    p 0.0090 0.33 0.0092
    nCohort 1 383 451 296
    nCohort 2 92 20 79
    Cutoff 1 8.26 9.33 8.97
    Sens 1 71% 70% 71%
    Spec 1 38% 41% 38%
    Cutoff 2 4.30 4.27 5.44
    Sens 2 80% 80% 81%
    Spec 2 25% 24% 28%
    Cutoff 3 1.74 1.07 1.77
    Sens 3 90% 90% 91%
    Spec 3 15%  9% 14%
    Cutoff 4 36.7 44.0 38.7
    Sens 4 49% 50% 51%
    Spec 4 70% 70% 70%
    Cutoff 5 62.0 65.8 62.0
    Sens 5 34% 40% 34%
    Spec 5 80% 80% 80%
    Cutoff 6 147 150 129
    Sens 6 15% 20% 18%
    Spec 6 90% 90% 90%
    OR Quart 2 0.93 0.58 1.1
    p Value 0.84 0.47 0.72
    95% CI of 0.46 0.14 0.54
    OR Quart 2 1.9 2.5 2.5
    OR Quart 3 1.1 0.58 1.1
    p Value 0.75 0.47 0.72
    95% CI of 0.57 0.14 0.54
    OR Quart 3 2.2 2.5 2.5
    OR Quart 4 2.1 1.8 2.4
    p Value 0.023 0.28 0.013
    95% CI of 1.1 0.60 1.2
    OR Quart 4 3.9 5.7 4.9
    C-C motif chemokine 26
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.0311 0.0405 0.0320 0.0436 0.0311 0.0402
    Average 0.0737 0.647 0.162 0.728 0.0500 0.737
    Stdev 0.497 4.50 2.04 2.03 0.177 4.85
    p (t-test) 0.015 0.23 0.015
    Min 0.00872 0.00872 0.00872 0.00872 0.00872 0.00872
    Max 9.14 42.3 42.3 7.53 2.75 42.3
    n (Samp) 383 92 451 20 297 79
    n (Patient) 383 92 451 20 297 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.60 0.66 0.57
    SE 0.034 0.068 0.037
    p 0.0030 0.020 0.056
    nCohort 1 383 451 297
    nCohort 2 92 20 79
    Cutoff 1 0.0297 0.0311 0.0291
    Sens 1 71% 70% 76%
    Spec 1 49% 49% 45%
    Cutoff 2 0.0236 0.0262 0.0232
    Sens 2 80% 80% 82%
    Spec 2 45% 44% 35%
    Cutoff 3 0.0195 0.0232 0.0195
    Sens 3 95% 90% 94%
    Spec 3 18% 35% 18%
    Cutoff 4 0.0443 0.0443 0.0443
    Sens 4 28% 40% 25%
    Spec 4 75% 75% 72%
    Cutoff 5 0.0486 0.0486 0.0504
    Sens 5 24% 40% 20%
    Spec 5 80% 80% 86%
    Cutoff 6 0.0525 0.0525 0.0525
    Sens 6 21% 30% 19%
    Spec 6 91% 90% 90%
    OR Quart 2 2.3 2.0 2.6
    p Value 0.031 0.42 0.017
    95% CI of 1.1 0.36 1.2
    OR Quart 2 5.0 11 5.7
    OR Quart 3 3.9 3.1 3.0
    p Value 3.0E−4 0.17 0.0047
    95% CI of 1.9 0.61 1.4
    OR Quart 3 8.1 16 6.6
    OR Quart 4 2.5 4.2 1.7
    p Value 0.021 0.074 0.22
    95% CI of 1.1 0.87 0.73
    OR Quart 4 5.3 20 3.8
    C-C motif chemokine 7
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.515 0.812 0.515 1.29 0.584 0.625
    Average 2.03 14.0 2.82 39.3 2.36 14.4
    Stdev 8.31 60.4 15.9 110 9.29 64.5
    p (t-test) 2.0E−4 6.4E−9 0.0020
    Min 0.146 0.146 0.146 0.188 0.146 0.146
    Max 125 488 291 488 125 488
    n (Sump) 385 92 453 20 298 79
    n (Patient) 385 92 453 20 298 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.62 0.76 0.56
    SE 0.034 0.064 0.037
    p 6.5E−4 5.6E−5 0.11
    nCohort 1 385 453 298
    nCohort 2 92 20 79
    Cutoff 1 0.386 0.812 0.336
    Sens 1 71% 70% 73%
    Spec 1 47% 65% 33%
    Cutoff 2 0.320 0.584 0.319
    Sens 2 83% 80% 84%
    Spec 2 34% 54% 26%
    Cutoff 3 0.264 0.386 0.264
    Sens 3 92% 90% 91%
    Spec 3 15% 45% 13%
    Cutoff 4 0.816 0.816 1.04
    Sens 4 45% 60% 38%
    Spec 4 73% 70% 76%
    Cutoff 5 1.07 1.11 1.15
    Sens 5 40% 60% 24%
    Spec 5 80% 80% 82%
    Cutoff 6 1.59 1.59 1.59
    Sens 6 20% 40% 19%
    Spec 6 93% 92% 92%
    OR Quart 2 2.1 3.1 2.0
    p Value 0.052 0.34 0.072
    95% CI of 0.99 0.31 0.94
    OR Quart 2 4.3 30 4.1
    OR Quart 3 1.5 4.1 1.0
    p Value 0.34 0.21 1.0
    95% CI of 0.68 0.45 0.45
    OR Quart 3 3.1 37 2.2
    OR Quart 4 3.6 13 2.3
    p Value 2.7E−4 0.014 0.026
    95% CI of 1.8 1.7 1.1
    OR Quart 4 7.3 100 4.7
    Vascular endothelial growth factor receptor 3
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 308 354 315 403 308 348
    Average 297 431 322 403 295 437
    Stdev 170 381 241 87.3 168 412
    p (t-test) 2.1E−4 0.32 5.1E−4
    Min 1.37 1.37 1.37 308 1.37 1.37
    Max 942 2750 2750 601 942 2750
    n (Samp) 196 53 238 9 171 45
    n (Patient) 196 53 238 9 171 45
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.63 0.68 0.63
    SE 0.045 0.10 0.049
    p 0.0029 0.081 0.010
    nCohort 1 196 238 171
    nCohort 2 53 9 45
    Cutoff 1 282 332 273
    Sens 1 72% 78% 71%
    Spec 1 48% 55% 46%
    Cutoff 2 229 315 219
    Sens 2 81% 89% 82%
    Spec 2 37% 52% 34%
    Cutoff 3 163 295 66.4
    Sens 3 91% 100%  96%
    Spec 3 22% 47% 11%
    Cutoff 4 397 414 381
    Sens 4 49% 33% 47%
    Spec 4 72% 73% 70%
    Cutoff 5 440 445 425
    Sens 5 36% 11% 40%
    Spec 5 81% 81% 81%
    Cutoff 6 496 537 486
    Sens 6 28% 11% 33%
    Spec 6 90% 90% 90%
    OR Quart 2 1.6 >1.0 1.3
    p Value 0.33 <1.0 0.61
    95% CI of 0.61 >0.061 0.47
    OR Quart 2 4.3 na 3.6
    OR Quart 3 1.6 >6.5 1.0
    p Value 0.33 <0.087 1.0
    95% CI of 0.61 >0.76 0.35
    OR Quart 3 4.3 na 2.9
    OR Quart 4 3.4 >2.0 3.1
    p Value 0.0087 <0.57 0.017
    95% CI of 1.4 >0.18 1.2
    OR Quart 4 8.4 na 8.0
    Insulin-like growth factor-binding protein 5
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.0682 0.0682 nd nd 0.0682 0.0682
    Average 0.801 0.752 nd nd 0.788 0.760
    Stdev 1.63 1.13 nd nd 1.66 1.16
    p (t-test) 0.87 nd nd 0.93
    Min 0.0116 0.0116 nd nd 0.0116 0.0116
    Max 10.3 3.92 nd nd 10.3 3.92
    n (Samp) 138 32 nd nd 119 30
    n (Patient) 138 32 nd nd 119 30
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.49 nd 0.49
    SE 0.057 nd 0.059
    p 0.86 nd 0.86
    nCohort 1 138 nd 119
    nCohort 2 32 nd 30
    Cutoff 1 0.0116 nd 0.0116
    Sens 1 88% nd 87%
    Spec 1  8% nd  9%
    Cutoff 2 0.0116 nd 0.0116
    Sens 2 88% nd 87%
    Spec 2  8% nd  9%
    Cutoff 3 0 nd 0
    Sens 3 100%  nd 100% 
    Spec 3  0% nd  0%
    Cutoff 4 0.397 nd 0.397
    Sens 4 34% nd 33%
    Spec 4 73% nd 75%
    Cutoff 5 1.43 nd 1.40
    Sens 5 19% nd 23%
    Spec 5 81% nd 81%
    Cutoff 6 3.00 nd 3.00
    Sens 6  6% nd  7%
    Spec 6 91% nd 92%
    OR Quart 2 0.31 nd 0.54
    p Value 0.061 nd 0.29
    95% CI of 0.089 nd 0.17
    OR Quart 2 1.1 nd 1.7
    OR Quart 3 0.57 nd 0.34
    p Value 0.29 nd 0.094
    95% CI of 0.20 nd 0.096
    OR Quart 3 1.6 nd 1.2
    OR Quart 4 0.91 nd 1.0
    p Value 0.85 nd 0.94
    95% CI of 0.34 nd 0.37
    OR Quart 4 2.4 nd 2.9
    Immunoglogulin G4
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 180 384 203 460 203 405
    Average 452 829 508 894 476 853
    Stdev 664 921 717 977 671 928
    p (t-test) 8.8E−6 0.021 6.1E−5
    Min 0.00862 0.00996 0.00862 4.20 0.410 0.00996
    Max 2400 2400 2400 2400 2400 2400
    n (Samp) 379 92 447 20 292 79
    n (Patient) 379 92 447 20 292 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.62 0.60 0.62
    SE 0.034 0.068 0.037
    p 4.7E−4 0.15 0.0011
    nCohort 1 379 447 292
    nCohort 2 92 20 79
    Cutoff 1 132 241 134
    Sens 1 71% 70% 71%
    Spec 1 42% 54% 40%
    Cutoff 2 76.0 32.8 95.9
    Sens 2 80% 80% 81%
    Spec 2 29% 15% 33%
    Cutoff 3 21.3 20.5 41.4
    Sens 3 90% 90% 91%
    Spec 3 13% 12% 18%
    Cutoff 4 383 431 402
    Sens 4 50% 50% 51%
    Spec 4 70% 70% 70%
    Cutoff 5 597 676 663
    Sens 5 38% 40% 35%
    Spec 5 80% 80% 80%
    Cutoff 6 1470 2150 1510
    Sens 6 26% 25% 25%
    Spec 6 90% 90% 90%
    OR Quart 2 0.99 0 1.2
    p Value 0.98 na 0.70
    95% CI of 0.47 na 0.52
    OR Quart 2 2.1 na 2.6
    OR Quart 3 1.5 0.82 1.9
    p Value 0.23 0.75 0.10
    95% CI of 0.76 0.24 0.88
    OR Quart 3 3.1 2.8 4.0
    OR Quart 4 2.9 1.5 2.8
    p Value 0.0015 0.44 0.0067
    95% CI of 1.5 0.53 1.3
    OR Quart 4 5.6 4.4 5.7
    Interleukin-21
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 8.33 5.94 7.99 5.73 7.44 5.97
    Average 11.0 8.67 10.7 7.27 10.1 8.75
    Stdev 10.9 8.64 10.7 6.70 10.1 8.81
    p (t-test) 0.055 0.16 0.28
    Min 0.0122 0.00404 0.00404 0.0219 0.0122 0.00404
    Max 67.7 42.1 67.7 22.6 66.5 42.1
    n (Samp) 383 92 451 20 297 79
    n (Patient) 383 92 451 20 297 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.43 0.42 0.46
    SE 0.034 0.068 0.037
    p 0.051 0.22 0.24
    nCohort 1 383 451 297
    nCohort 2 92 20 79
    Cutoff 1 2.65 2.61 3.08
    Sens 1 71% 70% 71%
    Spec 1 26% 26% 29%
    Cutoff 2 0.596 1.78 0.586
    Sens 2 80% 80% 81%
    Spec 2  9% 20% 10%
    Cutoff 3 0.0247 0.0528 0.0247
    Sens 3 92% 90% 92%
    Spec 3  3%  5%  3%
    Cutoff 4 14.5 13.9 12.8
    Sens 4 23% 20% 24%
    Spec 4 70% 70% 70%
    Cutoff 5 18.0 17.5 16.9
    Sens 5 13% 10% 15%
    Spec 5 80% 80% 80%
    Cutoff 6 24.7 24.2 22.6
    Sens 6  5%  0%  6%
    Spec 6 90% 90% 90%
    OR Quart 2 1.1 0.74 1.0
    p Value 0.86 0.70 1.0
    95% CI of 0.53 0.16 0.48
    OR Quart 2 2.2 3.4 2.1
    OR Quart 3 1.8 1.8 1.6
    p Value 0.076 0.36 0.22
    95% CI of 0.94 0.51 0.77
    OR Quart 3 3.5 6.3 3.1
    OR Quart 4 1.6 1.5 1.3
    p Value 0.17 0.51 0.47
    95% CI of 0.82 0.42 0.64
    OR Quart 4 3.1 5.6 2.7
    Interleukin-23
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 302 96.7 268 3.63 302 102
    Average 492 329 466 280 487 327
    Stdev 691 526 671 497 700 520
    p (t-test) 0.035 0.22 0.059
    Min 0.491 0.491 0.491 0.552 0.491 0.491
    Max 8520 3250 8520 1820 8520 3250
    n (Samp) 383 92 451 20 297 79
    n (Patient) 383 92 451 20 297 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.40 0.35 0.41
    SE 0.034 0.068 0.037
    p 0.0044 0.028 0.011
    nCohort 1 383 451 297
    nCohort 2 92 20 79
    Cutoff 1 1.09 0.747 1.30
    Sens 1 71% 70% 71%
    Spec 1 20% 12% 23%
    Cutoff 2 0.844 0.708 1.01
    Sens 2 80% 80% 81%
    Spec 2 14% 10% 17%
    Cutoff 3 0.708 0.552 0.708
    Sens 3 90% 95% 94%
    Spec 3 10%  1%  9%
    Cutoff 4 603 553 608
    Sens 4 21% 20% 20%
    Spec 4 70% 70% 70%
    Cutoff 5 844 794 813
    Sens 5 12% 10% 13%
    Spec 5 80% 80% 80%
    Cutoff 6 1350 1180 1200
    Sens 6  5% 10%  5%
    Spec 6 90% 90% 90%
    OR Quart 2 1.0 1.0 1.2
    p Value 1.0 1.0 0.68
    95% CI of 0.47 0.20 0.53
    OR Quart 2 2.1 5.1 2.6
    OR Quart 3 2.3 1.3 2.3
    p Value 0.016 0.70 0.032
    95% CI of 1.2 0.29 1.1
    OR Quart 3 4.4 6.1 4.7
    OR Quart 4 2.1 3.6 2.4
    p Value 0.031 0.058 0.021
    95% CI of 1.1 0.96 1.1
    OR Quart 4 4.1 13 5.0
    Interleukin-28A
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 17.6 13.7 17.6 3.22 20.5 12.2
    Average 32.5 29.4 32.3 20.4 32.6 29.5
    Stdev 39.0 38.5 39.2 28.4 38.8 39.7
    p (t-test) 0.49 0.18 0.54
    Min 0.0254 0.0254 0.0254 0.0495 0.0254 0.0254
    Max 197 164 197 91.1 197 164
    n (Samp) 383 92 451 20 297 79
    n (Patient) 383 92 451 20 297 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.47 0.38 0.47
    SE 0.034 0.068 0.037
    p 0.43 0.076 0.38
    nCohort 1 383 451 297
    nCohort 2 92 20 79
    Cutoff 1 0.194 0.0860 0.184
    Sens 1 71% 70% 71%
    Spec 1 25% 13% 22%
    Cutoff 2 0.137 0.0784 0.0928
    Sens 2 80% 80% 84%
    Spec 2 19%  9% 15%
    Cutoff 3 0.0860 0.0775 0.0860
    Sens 3 90% 90% 91%
    Spec 3 14%  6% 14%
    Cutoff 4 45.8 44.0 45.8
    Sens 4 24% 15% 24%
    Spec 4 70% 70% 70%
    Cutoff 5 59.9 59.5 59.5
    Sens 5 17% 10% 18%
    Spec 5 80% 80% 80%
    Cutoff 6 84.4 84.9 84.4
    Sens 6 10%  5% 10%
    Spec 6 90% 90% 90%
    OR Quart 2 1.3 1.7 1.3
    p Value 0.41 0.48 0.47
    95% CI of 0.69 0.40 0.64
    OR Quart 2 2.5 7.3 2.7
    OR Quart 3 1.0 1.0 1.0
    p Value 1.0 1.0 1.0
    95% CI of 0.51 0.20 0.48
    OR Quart 3 2.0 5.1 2.1
    OR Quart 4 1.5 3.2 1.6
    p Value 0.24 0.088 0.22
    95% CI of 0.77 0.84 0.77
    OR Quart 4 2.8 12 3.1
    Interleukin-33
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 42.8 33.3 41.5 23.7 42.8 36.0
    Average 55.8 41.2 53.4 33.2 55.5 42.7
    Stdev 66.2 42.0 62.6 45.0 69.4 42.9
    p (t-test) 0.045 0.15 0.12
    Min 0.0232 0.0232 0.0232 0.0372 0.0232 0.0232
    Max 958 227 958 170 958 227
    n (Samp) 383 92 451 20 297 79
    n (Patient) 383 92 451 20 297 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.42 0.35 0.43
    SE 0.034 0.068 0.037
    p 0.015 0.025 0.049
    nCohort 1 383 451 297
    nCohort 2 92 20 79
    Cutoff 1 13.7 1.57 14.3
    Sens 1 71% 70% 71%
    Spec 1 22% 14% 21%
    Cutoff 2 0.0879 0.0645 0.0879
    Sens 2 80% 80% 81%
    Spec 2 11%  8%  9%
    Cutoff 3 0.0538 0.0518 0.0518
    Sens 3 90% 90% 92%
    Spec 3  4%  4%  3%
    Cutoff 4 69.3 67.1 68.2
    Sens 4 20% 15% 20%
    Spec 4 70% 70% 70%
    Cutoff 5 92.2 85.1 88.8
    Sens 5  9% 10%  9%
    Spec 5 80% 80% 80%
    Cutoff 6 120 118 119
    Sens 6  7% 10%  6%
    Spec 6 90% 90% 90%
    OR Quart 2 1.5 0.66 1.4
    p Value 0.29 0.65 0.35
    95% CI of 0.72 0.11 0.68
    OR Quart 2 2.9 4.0 3.0
    OR Quart 3 1.6 2.1 1.3
    p Value 0.17 0.32 0.45
    95% CI of 0.81 0.50 0.63
    OR Quart 3 3.2 8.4 2.8
    OR Quart 4 2.2 3.2 1.9
    p Value 0.022 0.088 0.077
    95% CI of 1.1 0.84 0.93
    OR Quart 4 4.3 12 3.9
    Vascular endothelial growth factor receptor 2
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 488 849 578 751 488 868
    Average 702 1100 767 1250 698 1070
    Stdev 724 865 754 1110 722 806
    p (t-test) 8.8E−4 0.064 0.0036
    Min 0.218 67.0 0.218 122 0.218 67.0
    Max 4860 3610 4860 3610 4860 3460
    n (Samp) 193 52 235 9 169 44
    n (Patient) 193 52 235 9 169 44
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.67 0.67 0.66
    SE 0.045 0.10 0.049
    p 1.9E−4 0.083 7.9E−4
    nCohort 1 193 235 169
    nCohort 2 52 9 44
    Cutoff 1 598 709 578
    Sens 1 71% 78% 70%
    Spec 1 58% 63% 55%
    Cutoff 2 414 626 370
    Sens 2 81% 89% 82%
    Spec 2 45% 55% 41%
    Cutoff 3 219 106 219
    Sens 3 90% 100%  91%
    Spec 3 27% 17% 27%
    Cutoff 4 809 898 801
    Sens 4 52% 44% 55%
    Spec 4 70% 71% 70%
    Cutoff 5 1310 1370 1250
    Sens 5 33% 22% 34%
    Spec 5 80% 80% 80%
    Cutoff 6 1680 1770 1710
    Sens 6 17% 22% 16%
    Spec 6 90% 90% 91%
    OR Quart 2 1.6 0 1.7
    p Value 0.41 na 0.38
    95% CI of 0.53 na 0.52
    OR Quart 2 4.8 na 5.6
    OR Quart 3 4.1 6.5 3.8
    p Value 0.0054 0.087 0.017
    95% CI of 1.5 0.76 1.3
    OR Quart 3 11 56 11
    OR Quart 4 3.8 2.0 4.0
    p Value 0.0100 0.57 0.012
    95% CI of 1.4 0.18 1.4
    OR Quart 4 10 23 12
    Neural cell adhesion molecule 1
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 2390 3490 2600 4140 2460 3690
    Average 3020 5420 3300 7660 3060 5620
    Stdev 2320 7250 3470 8830 2110 7570
    p (t-test) 8.6E−8 9.1E−7 5.2E−7
    Min 6.83 138 6.83 142 173 138
    Max 22000 55700 55700 31700 15500 55700
    n (Samp) 382 92 450 20 295 79
    n (Patient) 382 92 450 20 295 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.64 0.66 0.64
    SE 0.034 0.068 0.037
    p 3.9E−5 0.019 1.5E−4
    nCohort 1 382 450 295
    nCohort 2 92 20 79
    Cutoff 1 2490 2810 2670
    Sens 1 71% 70% 71%
    Spec 1 52% 54% 53%
    Cutoff 2 1880 2200 2060
    Sens 2 80% 80% 81%
    Spec 2 36% 42% 40%
    Cutoff 3 1210 1420 1110
    Sens 3 90% 90% 91%
    Spec 3 19% 23% 16%
    Cutoff 4 3670 3830 3790
    Sens 4 48% 50% 47%
    Spec 4 70% 70% 70%
    Cutoff 5 4530 4660 4720
    Sens 5 33% 50% 33%
    Spec 5 80% 80% 80%
    Cutoff 6 5740 6110 5940
    Sens 6 23% 30% 24%
    Spec 6 90% 90% 90%
    OR Quart 2 1.3 0.99 1.7
    p Value 0.57 0.99 0.22
    95% CI of 0.57 0.20 0.73
    OR Quart 2 2.7 5.0 4.0
    OR Quart 3 2.6 1.3 3.1
    p Value 0.0078 0.70 0.0063
    95% CI of 1.3 0.29 1.4
    OR Quart 3 5.4 6.1 6.8
    OR Quart 4 3.2 3.5 3.5
    p Value 0.0010 0.061 0.0018
    95% CI of 1.6 0.94 1.6
    OR Quart 4 6.5 13 7.8
    Platelet-derived growth factor subunit B (dimer)
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 1.13 1.32 1.13 2.52 1.17 1.32
    Average 2.50 21.1 5.21 20.7 2.59 23.2
    Stdev 6.41 120 50.9 47.9 6.55 126
    p (t-test) 0.0085 0.28 0.018
    Min 0.00246 0.00705 0.00246 0.436 0.00246 0.00705
    Max 67.2 935 935 176 67.2 935
    n (Samp) 294 62 340 13 215 56
    n (Patient) 294 62 340 13 215 56
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.57 0.73 0.56
    SE 0.041 0.081 0.044
    p 0.11 0.0038 0.18
    nCohort 1 294 340 215
    nCohort 2 62 13 56
    Cutoff 1 0.708 1.39 0.648
    Sens 1 71% 77% 71%
    Spec 1 35% 57% 34%
    Cutoff 2 0.429 0.928 0.392
    Sens 2 81% 85% 80%
    Spec 2 27% 44% 27%
    Cutoff 3 0.0488 0.850 0.0144
    Sens 3 90% 92% 91%
    Spec 3 16% 41% 11%
    Cutoff 4 2.00 2.07 2.13
    Sens 4 42% 69% 38%
    Spec 4 70% 70% 70%
    Cutoff 5 2.99 3.02 3.00
    Sens 5 29% 46% 32%
    Spec 5 80% 80% 80%
    Cutoff 6 4.46 4.75 4.49
    Sens 6 19% 31% 21%
    Spec 6 90% 90% 90%
    OR Quart 2 1.7 >3.1 1.3
    p Value 0.22 <0.33 0.53
    95% CI of 0.73 >0.32 0.55
    OR Quart 2 3.8 na 3.2
    OR Quart 3 1.4 >4.2 1.1
    p Value 0.40 <0.20 0.85
    95% CI of 0.62 >0.46 0.44
    OR Quart 3 3.3 na 2.7
    OR Quart 4 1.9 >6.4 2.0
    p Value 0.11 <0.090 0.11
    95% CI of 0.86 >0.75 0.86
    OR Quart 4 4.3 na 4.6
    Corticotropin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.00174 0.00208 nd nd 0.00174 0.00208
    Average 0.00227 0.00468 nd nd 0.00252 0.00404
    Stdev 0.00351 0.00835 nd nd 0.00436 0.00776
    p (t-test) 0.025 nd nd 0.22
    Min 0.000355 0.000388 nd nd 0.000355 0.000388
    Max 0.0373 0.0377 nd nd 0.0373 0.0377
    n (Samp) 111 24 nd nd 92 22
    n (Patient) 111 24 nd nd 92 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.57 nd 0.58
    SE 0.066 nd 0.070
    p 0.29 nd 0.28
    nCohort 1 111 nd 92
    nCohort 2 24 nd 22
    Cutoff 1 0.00136 nd 0.00136
    Sens 1 71% nd 73%
    Spec 1 28% nd 28%
    Cutoff 2 0.00106 nd 0.00109
    Sens 2 92% nd 82%
    Spec 2 17% nd 18%
    Cutoff 3 0.00106 nd 0.00106
    Sens 3 92% nd 91%
    Spec 3 17% nd 18%
    Cutoff 4 0.00227 nd 0.00212
    Sens 4 42% nd 50%
    Spec 4 70% nd 71%
    Cutoff 5 0.00282 nd 0.00282
    Sens 5 29% nd 27%
    Spec 5 82% nd 82%
    Cutoff 6 0.00356 nd 0.00362
    Sens 6 25% nd 23%
    Spec 6 90% nd 90%
    OR Quart 2 0.36 nd 0.42
    p Value 0.17 nd 0.26
    95% CI of 0.084 nd 0.095
    OR Quart 2 1.5 nd 1.9
    OR Quart 3 0.64 nd 0.80
    p Value 0.49 nd 0.74
    95% CI of 0.18 nd 0.21
    OR Quart 3 2.3 nd 3.0
    OR Quart 4 1.3 nd 1.4
    p Value 0.61 nd 0.59
    95% CI of 0.43 nd 0.41
    OR Quart 4 4.1 nd 4.7
    Thyroxine-binding globulin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.0625 0.225 0.0709 0.432 0.0629 0.240
    Average 0.165 0.369 0.192 0.489 0.168 0.380
    Stdev 0.254 0.639 0.363 0.493 0.261 0.679
    p (t-test) 0.0035 0.027 0.0084
    Min 0.000478 0.00343 0.000478 0.00635 0.000478 0.00343
    Max 1.59 3.60 3.60 1.47 1.59 3.60
    n (Samp) 139 35 165 8 112 30
    n (Patient) 139 35 165 8 112 30
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.63 0.69 0.64
    SE 0.055 0.11 0.060
    p 0.016 0.080 0.019
    nCohort 1 139 165 112
    nCohort 2 35 8 30
    Cutoff 1 0.0777 0.136 0.109
    Sens 1 71% 75% 70%
    Spec 1 56% 67% 62%
    Cutoff 2 0.0164 0.0115 0.0179
    Sens 2 80% 88% 80%
    Spec 2 24% 17% 26%
    Cutoff 3 0.00635 0.00620 0.00767
    Sens 3 91% 100%  90%
    Spec 3 11% 10% 11%
    Cutoff 4 0.135 0.163 0.142
    Sens 4 60% 62% 60%
    Spec 4 71% 70% 71%
    Cutoff 5 0.259 0.296 0.248
    Sens 5 43% 50% 50%
    Spec 5 81% 81% 80%
    Cutoff 6 0.466 0.486 0.466
    Sens 6 23% 50% 20%
    Spec 6 91% 90% 90%
    OR Quart 2 0.21 0 0.44
    p Value 0.057 na 0.27
    95% CI of 0.042 na 0.10
    OR Quart 2 1.0 na 1.9
    OR Quart 3 1.2 0.49 1.2
    p Value 0.79 0.56 0.76
    95% CI of 0.40 0.043 0.36
    OR Quart 3 3.4 5.6 4.0
    OR Quart 4 2.5 2.6 3.1
    p Value 0.068 0.26 0.046
    95% CI of 0.94 0.48 1.0
    OR Quart 4 6.7 14 9.3
    Pigment epithelium-derived factor
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 2.47 3.75 2.62 19.9 2.76 3.80
    Average 18.9 28.6 19.2 51.2 21.1 29.4
    Stdev 44.7 51.4 44.0 72.0 48.8 51.8
    p (t-test) 0.071 0.0021 0.19
    Min 0.000401 0.00102 0.000401 0.0292 0.000401 0.00102
    Max 391 250 391 250 391 250
    n (Samp) 383 92 451 20 296 79
    n (Patient) 383 92 451 20 296 79
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.57 0.64 0.57
    SE 0.034 0.068 0.037
    p 0.030 0.040 0.046
    nCohort 1 383 451 296
    nCohort 2 92 20 79
    Cutoff 1 1.71 3.61 1.78
    Sens 1 71% 70% 71%
    Spec 1 42% 57% 41%
    Cutoff 2 0.935 0.613 1.16
    Sens 2 80% 80% 81%
    Spec 2 32% 22% 32%
    Cutoff 3 0.293 0.155 0.346
    Sens 3 90% 90% 91%
    Spec 3 12%  5% 11%
    Cutoff 4 8.12 8.68 8.83
    Sens 4 37% 50% 39%
    Spec 4 70% 70% 70%
    Cutoff 5 21.8 21.9 23.7
    Sens 5 30% 50% 30%
    Spec 5 80% 80% 80%
    Cutoff 6 51.3 52.3 60.9
    Sens 6 15% 25% 13%
    Spec 6 90% 90% 90%
    OR Quart 2 1.5 0.19 2.0
    p Value 0.23 0.13 0.072
    95% CI of 0.76 0.022 0.94
    OR Quart 2 3.1 1.7 4.2
    OR Quart 3 1.6 0.79 1.5
    p Value 0.18 0.72 0.34
    95% CI of 0.81 0.21 0.67
    OR Quart 3 3.2 3.0 3.2
    OR Quart 4 2.1 2.1 2.2
    p Value 0.036 0.20 0.035
    95% CI of 1.0 0.69 1.1
    OR Quart 4 4.0 6.3 4.7
    Tumor necrosis factor receptor superfamily member 8
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 16.9 32.3 18.6 29.0 13.2 32.9
    Average 22.1 65.9 30.7 56.7 20.5 73.1
    Stdev 27.0 110 56.8 105 26.9 117
    p (t-test) 6.9E−7 0.18 1.7E−7
    Min 0.0493 0.0688 0.0493 0.0688 0.0493 0.196
    Max 265 554 554 353 265 554
    n (Samp) 197 55 240 10 172 47
    n (Patient) 197 55 240 10 172 47
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.63 0.60 0.66
    SE 0.044 0.097 0.047
    p 0.0023 0.28 7.0E−4
    nCohort 1 197 240 172
    nCohort 2 55 10 47
    Cutoff 1 11.4 24.9 11.4
    Sens 1 71% 70% 70%
    Spec 1 39% 63% 41%
    Cutoff 2 5.14 11.4 5.09
    Sens 2 80% 80% 81%
    Spec 2 24% 37% 26%
    Cutoff 3 1.18 7.30 1.18
    Sens 3 91% 90% 91%
    Spec 3 15% 31% 17%
    Cutoff 4 26.3 27.4 25.7
    Sens 4 51% 50% 53%
    Spec 4 71% 71% 70%
    Cutoff 5 32.6 38.9 31.4
    Sens 5 49% 20% 51%
    Spec 5 80% 80% 80%
    Cutoff 6 46.6 62.5 42.2
    Sens 6 31% 10% 36%
    Spec 6 90% 90% 90%
    OR Quart 2 0.80 2.0 0.98
    p Value 0.64 0.58 0.97
    95% CI of 0.32 0.18 0.36
    OR Quart 2 2.0 23 2.7
    OR Quart 3 0.53 4.2 0.50
    p Value 0.22 0.20 0.24
    95% CI of 0.19 0.46 0.16
    OR Quart 3 1.5 39 1.6
    OR Quart 4 3.0 3.0 3.9
    p Value 0.0077 0.34 0.0029
    95% CI of 1.3 0.31 1.6
    OR Quart 4 6.7 30 9.4
    Alpha-fetoprotein
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.00520 0.00660 nd nd 0.00554 0.00660
    Average 0.0545 0.137 nd nd 0.0561 0.135
    Stdev 0.125 0.473 nd nd 0.131 0.486
    p (t-test) 0.049 nd nd 0.083
    Min 0.000463 0.000463 nd nd 0.000463 0.000463
    Max 0.889 2.85 nd nd 0.889 2.85
    n (Samp) 169 36 nd nd 150 34
    n (Patient) 169 36 nd nd 150 34
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.57 nd 0.55
    SE 0.054 nd 0.056
    p 0.21 nd 0.33
    nCohort 1 169 nd 150
    nCohort 2 36 nd 34
    Cutoff 1 0.00483 nd 0.00483
    Sens 1 72% nd 71%
    Spec 1 41% nd 41%
    Cutoff 2 0.000523 nd 0.000523
    Sens 2 92% nd 91%
    Spec 2 12% nd 13%
    Cutoff 3 0.000523 nd 0.000523
    Sens 3 92% nd 91%
    Spec 3 12% nd 13%
    Cutoff 4 0.0444 nd 0.0385
    Sens 4 33% nd 32%
    Spec 4 75% nd 70%
    Cutoff 5 0.0728 nd 0.0671
    Sens 5 33% nd 32%
    Spec 5 83% nd 80%
    Cutoff 6 0.162 nd 0.162
    Sens 6 17% nd 15%
    Spec 6 91% nd 90%
    OR Quart 2 0.72 nd 0.62
    p Value 0.57 nd 0.40
    95% CI of 0.23 nd 0.20
    OR Quart 2 2.2 nd 1.9
    OR Quart 3 1.3 nd 0.87
    p Value 0.60 nd 0.79
    95% CI of 0.47 nd 0.30
    OR Quart 3 3.6 nd 2.5
    OR Quart 4 1.6 nd 1.3
    p Value 0.35 nd 0.61
    95% CI of 0.60 nd 0.48
    OR Quart 4 4.4 nd 3.5
    Apolipoprotein(a)
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 1.94 3.52 2.13 4.72 2.13 3.58
    Average 21.6 26.4 22.1 35.5 14.0 29.9
    Stdev 106 108 106 137 76.5 116
    p (t-test) 0.69 0.58 0.14
    Min 0.00646 0.00838 0.00646 0.00838 0.00646 0.0122
    Max 1110 802 1110 631 1000 802
    n (Samp) 400 95 469 21 313 82
    n (Patient) 400 95 469 21 313 82
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.60 0.61 0.61
    SE 0.033 0.067 0.036
    p 0.0022 0.085 0.0025
    nCohort 1 400 469 313
    nCohort 2 95 21 82
    Cutoff 1 1.44 1.84 1.39
    Sens 1 71% 71% 71%
    Spec 1 40% 48% 38%
    Cutoff 2 0.995 1.39 0.977
    Sens 2 80% 81% 80%
    Spec 2 31% 39% 29%
    Cutoff 3 0.479 0.911 0.479
    Sens 3 92% 90% 93%
    Spec 3 18% 28% 17%
    Cutoff 4 3.74 4.16 3.78
    Sens 4 48% 52% 49%
    Spec 4 70% 70% 70%
    Cutoff 5 5.82 6.54 5.56
    Sens 5 32% 29% 35%
    Spec 5 80% 80% 80%
    Cutoff 6 13.5 16.9 10.1
    Sens 6 16% 14% 21%
    Spec 6 90% 90% 90%
    OR Quart 2 1.6 3.1 1.5
    p Value 0.17 0.17 0.27
    95% CI of 0.81 0.61 0.72
    OR Quart 2 3.3 16 3.2
    OR Quart 3 1.5 2.0 1.2
    p Value 0.29 0.42 0.71
    95% CI of 0.72 0.37 0.53
    OR Quart 3 3.0 11 2.5
    OR Quart 4 2.9 4.7 2.9
    p Value 0.0014 0.050 0.0034
    95% CI of 1.5 1.0 1.4
    OR Quart 4 5.7 22 5.8
  • FIG. 12: Comparison of marker levels in enroll EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48 hrs) and in enroll EDTA samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48 hrs). Enroll samples from patients already at stage I or F were included in Cohort 2.
  •
    Complement C4-B
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 66700 61400 nd nd 66100 60500
    Average 74900 70900 nd nd 73000 70800
    Stdev 39100 44300 nd nd 37800 46800
    p (t-test) 0.65 nd nd 0.80
    Min 5220 9860 nd nd 5220 9860
    Max 203000 214000 nd nd 170000 214000
    n (Samp) 109 28 nd nd 98 25
    n (Patient) 109 28 nd nd 98 25
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.47 nd 0.47
    SE 0.062 nd 0.066
    p 0.62 nd 0.63
    nCohort 1 109 nd 98
    nCohort 2 28 nd 25
    Cutoff 1 48500 nd 45900
    Sens 1 71% nd 72%
    Spec 1 26% nd 26%
    Cutoff 2 40100 nd 40100
    Sens 2 82% nd 80%
    Spec 2 20% nd 21%
    Cutoff 3 10700 nd 10700
    Sens 3 93% nd 92%
    Spec 3  2% nd  2%
    Cutoff 4 90300 nd 86600
    Sens 4 29% nd 32%
    Spec 4 71% nd 70%
    Cutoff 5 114000 nd 112000
    Sens 5 14% nd 16%
    Spec 5 81% nd 81%
    Cutoff 6 132000 nd 132000
    Sens 6  4% nd  4%
    Spec 6 91% nd 91%
    OR Quart 2 1.3 nd 0.51
    p Value 0.71 nd 0.32
    95% CI of 0.37 nd 0.13
    OR Quart 2 4.2 nd 2.0
    OR Quart 3 1.3 nd 1.2
    p Value 0.71 nd 0.77
    95% CI of 0.37 nd 0.37
    OR Quart 3 4.2 nd 3.8
    OR Quart 4 1.5 nd 0.86
    p Value 0.51 nd 0.81
    95% CI of 0.46 nd 0.25
    OR Quart 4 4.9 nd 2.9
    C-C motif chemokine 26
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.725 1.27 0.689 4.30 0.652 1.27
    Average 5.53 5.61 5.23 10.5 5.47 4.12
    Stdev 12.0 10.6 11.2 18.1 12.4 5.47
    p (t-test) 0.98 0.25 0.62
    Min 0.0121 0.0121 0.0121 0.0232 0.0121 0.0121
    Max 62.5 50.9 62.5 50.9 62.5 18.3
    n (Samp) 89 26 108 7 81 22
    n (Patient) 89 26 108 7 81 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.52 0.61 0.54
    SE 0.065 0.12 0.071
    p 0.75 0.35 0.54
    nCohort 1 89 108 81
    nCohort 2 26 7 22
    Cutoff 1 0.0325 2.74 0.0339
    Sens 1 77% 71% 73%
    Spec 1 18% 67% 23%
    Cutoff 2 0.0232 0.0325 0.0232
    Sens 2 92% 86% 95%
    Spec 2  8% 19%  7%
    Cutoff 3 0.0232 0.0121 0.0232
    Sens 3 92% 100%  95%
    Spec 3  8%  3%  7%
    Cutoff 4 3.61 4.10 3.03
    Sens 4 42% 57% 41%
    Spec 4 71% 70% 70%
    Cutoff 5 6.86 6.86 6.58
    Sens 5 27% 29% 27%
    Spec 5 83% 81% 80%
    Cutoff 6 11.9 11.9 11.6
    Sens 6 12% 14%  9%
    Spec 6 91% 91% 90%
    OR Quart 2 0.40 0 0.58
    p Value 0.18 na 0.44
    95% CI of 0.11 na 0.14
    OR Quart 2 1.5 na 2.3
    OR Quart 3 0.65 0.96 0.75
    p Value 0.49 0.97 0.68
    95% CI of 0.19 0.13 0.20
    OR Quart 3 2.2 7.4 2.9
    OR Quart 4 0.95 1.5 1.2
    p Value 0.93 0.67 0.81
    95% CI of 0.30 0.23 0.33
    OR Quart 4 3.0 9.7 4.1
    C-C motif chemokine 7
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.512 0.804 0.620 4.45 0.512 0.804
    Average 7.45 31.8 8.43 82.9 7.42 36.4
    Stdev 20.8 88.6 20.4 166 21.5 95.8
    p (t-test) 0.017 2.0E−5 0.012
    Min 0.193 0.193 0.193 0.308 0.193 0.193
    Max 166 449 166 449 166 449
    n (Samp) 90 26 109 7 82 22
    n (Patient) 90 26 109 7 82 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.65 0.67 0.67
    SE 0.064 0.12 0.069
    p 0.020 0.15 0.014
    nCohort 1 90 109 82
    nCohort 2 26 7 22
    Cutoff 1 0.308 0.308 0.308
    Sens 1 81% 86% 82%
    Spec 1 38% 35% 39%
    Cutoff 2 0.308 0.308 0.308
    Sens 2 81% 86% 82%
    Spec 2 38% 35% 39%
    Cutoff 3 0.193 0.193 0.193
    Sens 3 92% 100%  91%
    Spec 3 19% 17% 21%
    Cutoff 4 0.804 2.71 0.804
    Sens 4 46% 57% 45%
    Spec 4 71% 71% 73%
    Cutoff 5 8.42 14.1 8.42
    Sens 5 42% 43% 45%
    Spec 5 80% 81% 80%
    Cutoff 6 18.4 28.9 17.1
    Sens 6 31% 29% 32%
    Spec 6 90% 91% 90%
    OR Quart 2 1.6 >3.3 0.72
    p Value 0.49 <0.31 0.69
    95% CI of 0.41 >0.33 0.14
    OR Quart 2 6.5 na 3.6
    OR Quart 3 1.3 >1.0 1.3
    p Value 0.72 <0.98 0.71
    95% CI of 0.31 >0.062 0.31
    OR Quart 3 5.4 na 5.6
    OR Quart 4 3.8 >3.3 3.4
    p Value 0.043 <0.31 0.068
    95% CI of 1.0 >0.33 0.91
    OR Quart 4 14 na 13
    Vascular endothelial growth factor receptor 3
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 5840 5630 5900 5010 5670 6100
    Average 6920 6190 6810 5980 6780 6570
    Stdev 4850 3230 4560 4390 4900 3350
    p (t-test) 0.47 0.64 0.85
    Min 529 1720 529 1740 529 1720
    Max 32400 14200 32400 14200 32400 14200
    n (Samp) 90 26 109 7 82 22
    n (Patient) 90 26 109 7 82 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.48 0.43 0.52
    SE 0.065 0.12 0.070
    p 0.74 0.52 0.74
    nCohort 1 90 109 82
    nCohort 2 26 7 22
    Cutoff 1 3700 3700 4200
    Sens 1 73% 71% 73%
    Spec 1 26% 26% 33%
    Cutoff 2 2640 2240 2640
    Sens 2 85% 86% 86%
    Spec 2 10%  9% 10%
    Cutoff 3 2240 1720 2240
    Sens 3 92% 100%  91%
    Spec 3 10%  6% 10%
    Cutoff 4 7860 8040 7770
    Sens 4 35% 29% 41%
    Spec 4 70% 71% 71%
    Cutoff 5 9450 9630 9320
    Sens 5 23% 14% 32%
    Spec 5 80% 81% 80%
    Cutoff 6 12600 11600 11600
    Sens 6  4% 14%  5%
    Spec 6 90% 91% 90%
    OR Quart 2 0.82 0 0.43
    p Value 0.75 na 0.28
    95% CI of 0.24 na 0.096
    OR Quart 2 2.8 na 2.0
    OR Quart 3 0.82 1.6 1.0
    p Value 0.75 0.64 1.0
    95% CI of 0.24 0.24 0.28
    OR Quart 3 2.8 10 3.6
    OR Quart 4 1.0 1.0 1.2
    p Value 1.0 1.0 0.75
    95% CI of 0.30 0.13 0.35
    OR Quart 4 3.3 7.6 4.3
    Insulin-like growth factor-binding protein 5
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 13.1 0.422 nd nd 2.58 0.488
    Average 36.2 16.6 nd nd 32.4 17.8
    Stdev 47.9 29.9 nd nd 46.8 31.3
    p (t-test) 0.041 nd nd 0.14
    Min 0.204 0.204 nd nd 0.204 0.204
    Max 200 117 nd nd 200 117
    n (Samp) 108 28 nd nd 97 25
    n (Patient) 108 28 nd nd 97 25
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.36 nd 0.40
    SE 0.062 nd 0.066
    p 0.026 nd 0.12
    nCohort 1 108 nd 97
    nCohort 2 28 nd 25
    Cutoff 1 0.222 nd 0.222
    Sens 1 75% nd 72%
    Spec 1 17% nd 19%
    Cutoff 2 0.204 nd 0.204
    Sens 2 93% nd 92%
    Spec 2  6% nd  6%
    Cutoff 3 0.204 nd 0.204
    Sens 3 93% nd 92%
    Spec 3  6% nd  6%
    Cutoff 4 45.3 nd 40.1
    Sens 4 14% nd 16%
    Spec 4 70% nd 70%
    Cutoff 5 72.4 nd 65.5
    Sens 5  7% nd  8%
    Spec 5 81% nd 80%
    Cutoff 6 122 nd 98.6
    Sens 6  0% nd  4%
    Spec 6 91% nd 91%
    OR Quart 2 1.9 nd 2.1
    p Value 0.33 nd 0.30
    95% CI of 0.51 nd 0.53
    OR Quart 2 7.4 nd 7.9
    OR Quart 3 1.6 nd 1.6
    p Value 0.50 nd 0.49
    95% CI of 0.41 nd 0.41
    OR Quart 3 6.3 nd 6.4
    OR Quart 4 3.6 nd 2.5
    p Value 0.048 nd 0.18
    95% CI of 1.0 nd 0.65
    OR Quart 4 13 nd 9.2
    Immunoglogulin G4
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 410000 219000 nd nd 407000 219000
    Average 703000 405000 nd nd 637000 405000
    Stdev 888000 472000 nd nd 737000 472000
    p (t-test) 0.18 nd nd 0.22
    Min 16100 15700 nd nd 16100 15700
    Max 5190000 1390000 nd nd 3700000 1390000
    n (Samp) 81 17 nd nd 74 17
    n (Patient) 81 17 nd nd 74 17
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.37 nd 0.38
    SE 0.078 nd 0.079
    p 0.092 nd 0.12
    nCohort 1 81 nd 74
    nCohort 2 17 nd 17
    Cutoff 1 162000 nd 162000
    Sens 1 71% nd 71%
    Spec 1 25% nd 26%
    Cutoff 2 61100 nd 61100
    Sens 2 82% nd 82%
    Spec 2 11% nd 11%
    Cutoff 3 38600 nd 38600
    Sens 3 94% nd 94%
    Spec 3  9% nd  8%
    Cutoff 4 767000 nd 766000
    Sens 4 18% nd 18%
    Spec 4 70% nd 70%
    Cutoff 5 1020000 nd 995000
    Sens 5 18% nd 18%
    Spec 5 80% nd 81%
    Cutoff 6 1480000 nd 1280000
    Sens 6  0% nd 12%
    Spec 6 90% nd 91%
    OR Quart 2 0.67 nd 0.63
    p Value 0.67 nd 0.64
    95% CI of 0.10 nd 0.096
    OR Quart 2 4.4 nd 4.2
    OR Quart 3 2.9 nd 2.9
    p Value 0.17 nd 0.16
    95% CI of 0.64 nd 0.65
    OR Quart 3 13 nd 13
    OR Quart 4 1.9 nd 2.0
    p Value 0.41 nd 0.40
    95% CI of 0.41 nd 0.41
    OR Quart 4 9.2 nd 9.4
    Interleukin-21
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.531 1.03 0.783 1.24 0.806 1.11
    Average 4.02 2.04 3.61 3.11 4.36 1.69
    Stdev 14.5 3.20 13.2 5.09 15.2 2.12
    p (t-test) 0.49 0.92 0.41
    Min 0.0102 0.0102 0.0102 0.0102 0.0102 0.0102
    Max 132 14.3 132 14.3 132 8.25
    n (Samp) 90 26 109 7 82 22
    n (Patient) 90 26 109 7 82 21
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.50 0.56 0.48
    SE 0.065 0.12 0.070
    p 0.97 0.59 0.79
    nCohort 1 90 109 82
    nCohort 2 26 7 22
    Cutoff 1 0.0182 0.632 0.0182
    Sens 1 73% 71% 73%
    Spec 1 23% 50% 23%
    Cutoff 2 0.0154 0.0922 0.0154
    Sens 2 81% 86% 82%
    Spec 2 18% 37% 17%
    Cutoff 3 0.0102 0.0102 0.0102
    Sens 3 92% 100%  91%
    Spec 3  4%  6%  4%
    Cutoff 4 2.38 2.03 2.46
    Sens 4 23% 29% 23%
    Spec 4 70% 71% 72%
    Cutoff 5 4.32 3.40 5.00
    Sens 5 12% 29%  9%
    Spec 5 80% 81% 80%
    Cutoff 6 7.58 7.58 8.25
    Sens 6  8% 14%  0%
    Spec 6 90% 91% 90%
    OR Quart 2 1.5 2.1 2.0
    p Value 0.54 0.56 0.31
    95% CI of 0.43 0.18 0.51
    OR Quart 2 4.9 24 8.0
    OR Quart 3 0.80 2.1 1.3
    p Value 0.74 0.56 0.71
    95% CI of 0.21 0.18 0.31
    OR Quart 3 3.0 24 5.6
    OR Quart 4 1.2 2.1 1.6
    p Value 0.75 0.56 0.48
    95% CI of 0.35 0.18 0.41
    OR Quart 4 4.2 24 6.7
    Interleukin-23
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.886 86.1 1.05 633 1.10 51.4
    Average 2790 1790 2470 4040 3040 1150
    Stdev 15200 4450 13800 7510 15900 2500
    p (t-test) 0.74 0.77 0.58
    Min 0.257 0.257 0.257 0.257 0.257 0.603
    Max 100000 20500 100000 20500 100000 9140
    n (Samp) 89 26 108 7 81 22
    n (Patient) 89 26 108 7 81 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.65 0.73 0.64
    SE 0.064 0.11 0.070
    p 0.021 0.036 0.049
    nCohort 1 89 108 81
    nCohort 2 26 7 22
    Cutoff 1 0.603 72.6 0.603
    Sens 1 88% 71% 91%
    Spec 1 30% 69% 28%
    Cutoff 2 0.603 22.3 0.603
    Sens 2 88% 86% 91%
    Spec 2 30% 66% 28%
    Cutoff 3 0.257 0 0.603
    Sens 3 96% 100%  91%
    Spec 3 21%  0% 28%
    Cutoff 4 44.5 99.6 44.5
    Sens 4 54% 57% 50%
    Spec 4 71% 70% 70%
    Cutoff 5 306 306 306
    Sens 5 31% 57% 27%
    Spec 5 81% 81% 80%
    Cutoff 6 1230 1230 1040
    Sens 6 19% 43% 18%
    Spec 6 91% 91% 90%
    OR Quart 2 4.1 0 3.4
    p Value 0.096 na 0.16
    95% CI of 0.78 na 0.62
    OR Quart 2 22 na 19
    OR Quart 3 3.4 2.0 2.7
    p Value 0.16 0.58 0.26
    95% CI of 0.62 0.17 0.48
    OR Quart 3 18 23 16
    OR Quart 4 7.9 4.3 6.1
    p Value 0.012 0.20 0.032
    95% CI of 1.6 0.45 1.2
    OR Quart 4 40 41 32
    Interleukin-28A
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.265 0.230 0.195 2.92 0.195 0.195
    Average 4.80 18.3 5.48 44.4 4.31 10.8
    Stdev 11.6 47.5 12.7 86.6 11.2 18.5
    p (t-test) 0.015 4.2E−5 0.042
    Min 0.0727 0.0727 0.0727 0.168 0.0727 0.0727
    Max 71.6 235 71.6 235 71.6 62.9
    n (Samp) 89 26 108 7 81 22
    n (Patient) 89 26 108 7 81 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.54 0.73 0.52
    SE 0.065 0.11 0.070
    p 0.56 0.039 0.77
    nCohort 1 89 108 81
    nCohort 2 26 7 22
    Cutoff 1 0.0727 0.195 0.0727
    Sens 1 77% 71% 73%
    Spec 1 13% 51% 15%
    Cutoff 2 0 0.168 0
    Sens 2 100%  86% 100% 
    Spec 2  0% 43%  0%
    Cutoff 3 0 0.148 0
    Sens 3 100%  100%  100% 
    Spec 3  0% 35%  0%
    Cutoff 4 0.265 0.265 0.265
    Sens 4 38% 57% 36%
    Spec 4 76% 75% 78%
    Cutoff 5 6.95 9.20 3.84
    Sens 5 35% 43% 36%
    Spec 5 82% 81% 80%
    Cutoff 6 16.5 18.2 14.3
    Sens 6 19% 29% 23%
    Spec 6 91% 91% 90%
    OR Quart 2 0.78 >2.1 0.75
    p Value 0.70 <0.56 0.68
    95% CI of 0.23 >0.18 0.20
    OR Quart 2 2.7 na 2.9
    OR Quart 3 0.48 >2.1 0.41
    p Value 0.29 <0.56 0.25
    95% CI of 0.12 >0.18 0.091
    OR Quart 3 1.9 na 1.9
    OR Quart 4 1.3 >3.2 1.4
    p Value 0.61 <0.32 0.59
    95% CI of 0.42 >0.32 0.41
    OR Quart 4 4.3 na 4.9
    Interleukin-33
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.0981 2.43 0.0981 12.5 0.0981 2.43
    Average 233 89.3 202 181 255 64.5
    Stdev 1490 222 1360 326 1560 162
    p (t-test) 0.63 0.97 0.57
    Min 0.0445 0.0455 0.0445 0.0455 0.0445 0.0543
    Max 13500 892 13500 892 13500 730
    n (Samp) 90 26 109 7 82 22
    n (Patient) 90 26 109 7 82 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.67 0.71 0.68
    SE 0.064 0.11 0.069
    p 0.0084 0.057 0.0097
    nCohort 1 90 109 82
    nCohort 2 26 7 22
    Cutoff 1 0.0981 2.03 0.0981
    Sens 1 73% 71% 73%
    Spec 1 56% 65% 57%
    Cutoff 2 0.0713 0.0981 0.0713
    Sens 2 81% 86% 82%
    Spec 2 39% 51% 39%
    Cutoff 3 0.0494 0.0445 0.0494
    Sens 3 96% 100%  100% 
    Spec 3 26%  5% 24%
    Cutoff 4 2.20 7.15 2.20
    Sens 4 50% 57% 50%
    Spec 4 70% 72% 71%
    Cutoff 5 11.1 14.9 11.1
    Sens 5 35% 43% 32%
    Spec 5 80% 81% 80%
    Cutoff 6 41.6 65.9 41.6
    Sens 6 23% 43% 23%
    Spec 6 90% 91% 90%
    OR Quart 2 7.3 0 6.0
    p Value 0.075 na 0.12
    95% CI of 0.82 na 0.64
    OR Quart 2 65 na 55
    OR Quart 3 15 2.1 13
    p Value 0.014 0.56 0.019
    95% CI of 1.7 0.18 1.5
    OR Quart 3 120 24 110
    OR Quart 4 13 4.5 9.2
    p Value 0.021 0.19 0.046
    95% CI of 1.5 0.47 1.0
    OR Quart 4 110 43 81
    Vascular endothelial growth factor receptor 2
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 7610 7540 7630 5950 7750 7990
    Average 10700 8210 10300 8400 11000 8290
    Stdev 17500 3210 16000 3790 18300 3100
    p (t-test) 0.47 0.76 0.49
    Min 3730 3880 3730 5120 3730 3880
    Max 166000 14800 166000 14300 166000 14800
    n (Samp) 90 26 109 7 82 22
    n (Patient) 90 26 109 7 82 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.47 0.46 0.48
    SE 0.065 0.12 0.070
    p 0.66 0.71 0.81
    nCohort 1 90 109 82
    nCohort 2 26 7 22
    Cutoff 1 5750 5920 5750
    Sens 1 73% 71% 73%
    Spec 1 18% 21% 16%
    Cutoff 2 5180 5700 5180
    Sens 2 81% 86% 82%
    Spec 2 10% 19%  9%
    Cutoff 3 4850 5110 4850
    Sens 3 92% 100%  91%
    Spec 3  8% 11%  6%
    Cutoff 4 9390 9460 9430
    Sens 4 35% 29% 36%
    Spec 4 70% 71% 71%
    Cutoff 5 10600 10600 10600
    Sens 5 23% 29% 23%
    Spec 5 80% 81% 80%
    Cutoff 6 11300 11800 11800
    Sens 6 15% 29% 14%
    Spec 6 90% 91% 90%
    OR Quart 2 0.82 0.48 1.0
    p Value 0.75 0.56 1.0
    95% CI of 0.24 0.041 0.28
    OR Quart 2 2.8 5.6 3.6
    OR Quart 3 0.23 0 0.28
    p Value 0.087 na 0.14
    95% CI of 0.044 na 0.050
    OR Quart 3 1.2 na 1.5
    OR Quart 4 1.9 2.2 1.5
    p Value 0.26 0.40 0.53
    95% CI of 0.62 0.36 0.43
    OR Quart 4 6.0 13 5.1
    Neural cell adhesion molecule 1
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 187000 166000 nd nd 182000 165000
    Average 190000 163000 nd nd 188000 158000
    Stdev 69400 60900 nd nd 64200 58500
    p (t-test) 0.069 nd nd 0.040
    Min 69000 77400 nd nd 69000 77400
    Max 494000 331000 nd nd 461000 331000
    n (Samp) 109 28 nd nd 98 25
    n (Patient) 109 28 nd nd 98 25
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.38 nd 0.35
    SE 0.062 nd 0.065
    p 0.044 nd 0.021
    nCohort 1 109 nd 98
    nCohort 2 28 nd 25
    Cutoff 1 114000 nd 111000
    Sens 1 71% nd 72%
    Spec 1 13% nd 11%
    Cutoff 2 101000 nd 101000
    Sens 2 82% nd 80%
    Spec 2  9% nd  9%
    Cutoff 3 82600 nd 82600
    Sens 3 93% nd 92%
    Spec 3  6% nd  5%
    Cutoff 4 216000 nd 220000
    Sens 4 18% nd 12%
    Spec 4 71% nd 70%
    Cutoff 5 229000 nd 230000
    Sens 5 14% nd  8%
    Spec 5 81% nd 81%
    Cutoff 6 272000 nd 268000
    Sens 6  4% nd  4%
    Spec 6 91% nd 91%
    OR Quart 2 1.0 nd 1.8
    p Value 0.96 nd 0.45
    95% CI of 0.27 nd 0.39
    OR Quart 2 4.0 nd 8.3
    OR Quart 3 1.8 nd 3.2
    p Value 0.33 nd 0.11
    95% CI of 0.54 nd 0.77
    OR Quart 3 6.3 nd 14
    OR Quart 4 2.5 nd 4.0
    p Value 0.13 nd 0.056
    95% CI of 0.75 nd 0.96
    OR Quart 4 8.3 nd 17
    Platelet-derived growth factor subunit B (dimer)
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 378 332 nd nd 337 360
    Average 404 362 nd nd 380 379
    Stdev 251 213 nd nd 237 221
    p (t-test) 0.43 nd nd 0.99
    Min 0.189 35.4 nd nd 0.189 35.4
    Max 1310 766 nd nd 969 766
    n (Samp) 104 26 nd nd 93 23
    n (Patient) 104 26 nd nd 93 23
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.46 nd 0.51
    SE 0.064 nd 0.068
    p 0.54 nd 0.89
    nCohort 1 104 nd 93
    nCohort 2 26 nd 23
    Cutoff 1 202 nd 202
    Sens 1 73% nd 74%
    Spec 1 26% nd 29%
    Cutoff 2 177 nd 155
    Sens 2 81% nd 83%
    Spec 2 22% nd 20%
    Cutoff 3 113 nd 113
    Sens 3 92% nd 91%
    Spec 3 12% nd 14%
    Cutoff 4 527 nd 504
    Sens 4 23% nd 30%
    Spec 4 70% nd 71%
    Cutoff 5 613 nd 575
    Sens 5 15% nd 22%
    Spec 5 81% nd 81%
    Cutoff 6 732 nd 716
    Sens 6  8% nd  9%
    Spec 6 90% nd 90%
    OR Quart 2 0.83 nd 0.80
    p Value 0.78 nd 0.74
    95% CI of 0.23 nd 0.21
    OR Quart 2 3.1 nd 3.0
    OR Quart 3 1.7 nd 1.0
    p Value 0.38 nd 1.0
    95% CI of 0.52 nd 0.28
    OR Quart 3 5.4 nd 3.6
    OR Quart 4 1.0 nd 1.0
    p Value 0.95 nd 1.0
    95% CI of 0.30 nd 0.28
    OR Quart 4 3.6 nd 3.6
    Corticotropin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.000700 0.00350 nd nd 0.000709 0.00277
    Average 0.00668 0.00992 nd nd 0.00765 0.0108
    Stdev 0.0334 0.0200 nd nd 0.0360 0.0217
    p (t-test) 0.68 nd nd 0.73
    Min 3.38E−6 3.38E−6 nd nd 3.38E−6 3.38E−6
    Max 0.292 0.0908 nd nd 0.292 0.0908
    n (Samp) 78 20 nd nd 67 17
    n (Patient) 78 20 nd nd 67 17
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.70 nd 0.67
    SE 0.071 nd 0.078
    p 0.0042 nd 0.035
    nCohort 1 78 nd 67
    nCohort 2 20 nd 17
    Cutoff 1 0.00208 nd 0.000539
    Sens 1 70% nd 71%
    Spec 1 71% nd 46%
    Cutoff 2 0.000278 nd 0.000278
    Sens 2 90% nd 88%
    Spec 2 40% nd 39%
    Cutoff 3 0.000278 nd 3.38E−6
    Sens 3 90% nd 94%
    Spec 3 40% nd  6%
    Cutoff 4 0.00208 nd 0.00229
    Sens 4 70% nd 59%
    Spec 4 71% nd 70%
    Cutoff 5 0.00381 nd 0.00423
    Sens 5 45% nd 47%
    Spec 5 81% nd 81%
    Cutoff 6 0.00772 nd 0.00914
    Sens 6 40% nd 29%
    Spec 6 91% nd 91%
    OR Quart 2 2.1 nd 2.2
    p Value 0.42 nd 0.39
    95% CI of 0.35 nd 0.36
    OR Quart 2 13 nd 14
    OR Quart 3 2.9 nd 1.6
    p Value 0.23 nd 0.64
    95% CI of 0.50 nd 0.24
    OR Quart 3 17 nd 11
    OR Quart 4 6.2 nd 5.8
    p Value 0.032 nd 0.042
    95% CI of 1.2 nd 1.1
    OR Quart 4 33 nd 32
    Thyroxine-binding globulin
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 34.2 30.0 33.7 28.5 33.6 30.0
    Average 36.0 31.7 35.4 29.6 34.9 31.6
    Stdev 10.5 11.5 10.9 7.07 10.0 11.9
    p (t-test) 0.032 0.12 0.13
    Min 13.5 14.2 13.5 22.3 13.5 14.2
    Max 74.3 59.5 74.3 42.5 74.3 59.5
    n (Samp) 140 36 166 9 112 31
    n (Patient) 140 36 166 9 112 31
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.37 0.32 0.39
    SE 0.054 0.10 0.059
    p 0.016 0.072 0.056
    nCohort 1 140 166 112
    nCohort 2 36 9 31
    Cutoff 1 23.9 23.3 25.7
    Sens 1 72% 78% 71%
    Spec 1 11% 11% 14%
    Cutoff 2 21.4 22.3 19.8
    Sens 2 81% 89% 81%
    Spec 2  6% 10%  6%
    Cutoff 3 16.3 21.4 16.3
    Sens 3 92% 100%  90%
    Spec 3  4% 10%  4%
    Cutoff 4 41.5 40.9 40.0
    Sens 4 17% 11% 23%
    Spec 4 71% 70% 71%
    Cutoff 5 44.9 44.9 43.4
    Sens 5 14%  0% 16%
    Spec 5 80% 80% 80%
    Cutoff 6 49.5 50.0 48.3
    Sens 6 11%  0% 16%
    Spec 6 90% 90% 90%
    OR Quart 2 1.0 1.0 1.0
    p Value 1.0 1.0 1.0
    95% CI of 0.30 0.061 0.26
    OR Quart 2 3.4 17 3.8
    OR Quart 3 1.6 4.3 2.4
    p Value 0.40 0.20 0.15
    95% CI of 0.53 0.46 0.72
    OR Quart 3 5.0 40 7.9
    OR Quart 4 3.3 3.2 2.8
    p Value 0.029 0.32 0.084
    95% CI of 1.1 0.32 0.87
    OR Quart 4 9.5 32 9.3
    Pigment epithelium-derived factor
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 1500 1260 nd nd 1490 1250
    Average 1690 1790 nd nd 1680 1760
    Stdev 869 1370 nd nd 896 1420
    p (t-test) 0.64 nd nd 0.74
    Min 84.2 339 nd nd 84.2 339
    Max 4510 6200 nd nd 4510 6200
    n (Samp) 109 28 nd nd 98 25
    n (Patient) 109 28 nd nd 98 25
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.45 nd 0.44
    SE 0.062 nd 0.066
    p 0.41 nd 0.33
    nCohort 1 109 nd 98
    nCohort 2 28 nd 25
    Cutoff 1 1030 nd 1030
    Sens 1 71% nd 72%
    Spec 1 19% nd 21%
    Cutoff 2 813 nd 950
    Sens 2 82% nd 80%
    Spec 2 10% nd 17%
    Cutoff 3 460 nd 460
    Sens 3 93% nd 92%
    Spec 3  3% nd  3%
    Cutoff 4 1800 nd 1770
    Sens 4 36% nd 32%
    Spec 4 71% nd 70%
    Cutoff 5 2350 nd 2350
    Sens 5 25% nd 20%
    Spec 5 81% nd 81%
    Cutoff 6 2870 nd 3150
    Sens 6 14% nd 16%
    Spec 6 91% nd 91%
    OR Quart 2 0.21 nd 0.29
    p Value 0.062 nd 0.15
    95% CI of 0.041 nd 0.053
    OR Quart 2 1.1 nd 1.6
    OR Quart 3 1.2 nd 1.7
    p Value 0.73 nd 0.38
    95% CI of 0.41 nd 0.52
    OR Quart 3 3.6 nd 5.6
    OR Quart 4 1.2 nd 1.5
    p Value 0.73 nd 0.50
    95% CI of 0.41 nd 0.45
    OR Quart 4 3.6 nd 5.0
    Tumor necrosis factor receptor superfamily member 8
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 100.0 95.1 96.5 110 100.0 95.1
    Average 199 149 192 126 204 152
    Stdev 378 136 349 79.2 393 143
    p (t-test) 0.51 0.62 0.55
    Min 12.8 36.8 12.8 54.3 12.8 36.8
    Max 2700 595 2700 288 2700 595
    n (Samp) 90 26 109 7 82 22
    n (Patient) 90 26 109 7 82 22
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.51 0.53 0.51
    SE 0.065 0.11 0.070
    p 0.87 0.81 0.86
    nCohort 1 90 109 82
    nCohort 2 26 7 22
    Cutoff 1 56.6 96.5 56.6
    Sens 1 73% 71% 73%
    Spec 1 23% 50% 23%
    Cutoff 2 54.3 59.2 53.7
    Sens 2 85% 86% 86%
    Spec 2 21% 26% 21%
    Cutoff 3 37.8 53.7 37.8
    Sens 3 92% 100%  91%
    Spec 3 14% 20% 13%
    Cutoff 4 149 156 150
    Sens 4 38% 14% 41%
    Spec 4 70% 71% 71%
    Cutoff 5 203 205 203
    Sens 5 19% 14% 18%
    Spec 5 80% 82% 80%
    Cutoff 6 277 305 277
    Sens 6 15%  0% 14%
    Spec 6 90% 91% 90%
    OR Quart 2 0.68 2.1 0.65
    p Value 0.54 0.56 0.51
    95% CI of 0.20 0.18 0.18
    OR Quart 2 2.3 24 2.4
    OR Quart 3 0.68 3.2 0.65
    p Value 0.54 0.32 0.51
    95% CI of 0.20 0.32 0.18
    OR Quart 3 2.3 33 2.4
    OR Quart 4 0.68 1.0 0.65
    p Value 0.54 1.0 0.51
    95% CI of 0.20 0.060 0.18
    OR Quart 4 2.3 17 2.4
    Alpha-fetoprotein
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 0.316 0.438 nd nd 0.317 0.438
    Average 0.321 0.467 nd nd 0.326 0.430
    Stdev 0.281 0.409 nd nd 0.306 0.396
    p (t-test) 0.028 nd nd 0.16
    Min 0.00580 0.00580 nd nd 0.00580 0.00580
    Max 1.39 1.53 nd nd 1.39 1.53
    n (Samp) 109 28 nd nd 98 25
    n (Patient) 109 28 nd nd 98 25
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.62 nd 0.60
    SE 0.062 nd 0.066
    p 0.046 nd 0.14
    nCohort 1 109 nd 98
    nCohort 2 28 nd 25
    Cutoff 1 0.225 nd 0.00580
    Sens 1 71% nd 92%
    Spec 1 39% nd 19%
    Cutoff 2 0.00580 nd 0.00580
    Sens 2 93% nd 92%
    Spec 2 17% nd 19%
    Cutoff 3 0.00580 nd 0.00580
    Sens 3 93% nd 92%
    Spec 3 17% nd 19%
    Cutoff 4 0.438 nd 0.438
    Sens 4 46% nd 44%
    Spec 4 71% nd 70%
    Cutoff 5 0.544 nd 0.550
    Sens 5 39% nd 32%
    Spec 5 81% nd 81%
    Cutoff 6 0.663 nd 0.687
    Sens 6 25% nd 24%
    Spec 6 91% nd 91%
    OR Quart 2 0.62 nd 2.6
    p Value 0.50 nd 0.20
    95% CI of 0.16 nd 0.61
    OR Quart 2 2.4 nd 11
    OR Quart 3 1.2 nd 2.2
    p Value 0.76 nd 0.31
    95% CI of 0.36 nd 0.49
    OR Quart 3 4.1 nd 9.6
    OR Quart 4 2.1 nd 3.7
    p Value 0.19 nd 0.073
    95% CI of 0.69 nd 0.89
    OR Quart 4 6.7 nd 15
    Apolipoprotein(a)
    sCr or UO sCr only UO only
    Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
    Median 55700 18600 nd nd 54000 17200
    Average 77500 43100 nd nd 77800 43100
    Stdev 85500 62700 nd nd 87900 63800
    p (t-test) 0.037 nd nd 0.044
    Min 58.7 968 nd nd 128 968
    Max 411000 314000 nd nd 411000 314000
    n (Samp) 132 31 nd nd 117 30
    n (Patient) 132 31 nd nd 117 30
    At Enrollment
    sCr or UO sCr only UO only
    AUC 0.35 nd 0.35
    SE 0.058 nd 0.059
    p 0.011 nd 0.010
    nCohort 1 132 nd 117
    nCohort 2 31 nd 30
    Cutoff 1 5630 nd 5630
    Sens 1 71% nd 70%
    Spec 1 15% nd 15%
    Cutoff 2 4320 nd 4320
    Sens 2 81% nd 80%
    Spec 2 11% nd 10%
    Cutoff 3 2710 nd 2710
    Sens 3 90% nd 90%
    Spec 3  7% nd  5%
    Cutoff 4 92400 nd 91700
    Sens 4 16% nd 17%
    Spec 4 70% nd 70%
    Cutoff 5 112000 nd 109000
    Sens 5 13% nd 13%
    Spec 5 80% nd 80%
    Cutoff 6 210000 nd 227000
    Sens 6  3% nd  3%
    Spec 6 90% nd 91%
    OR Quart 2 0.78 nd 0.78
    p Value 0.72 nd 0.72
    95% CI of 0.19 nd 0.19
    OR Quart 2 3.1 nd 3.2
    OR Quart 3 2.3 nd 2.1
    p Value 0.16 nd 0.24
    95% CI of 0.72 nd 0.62
    OR Quart 3 7.5 nd 6.9
    OR Quart 4 3.1 nd 3.2
    p Value 0.056 nd 0.051
    95% CI of 0.97 nd 0.99
    OR Quart 4 9.8 nd 10
  • While the invention has been described and exemplified in sufficient detail for those skilled in this art to make and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.
  • It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
  • All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
  • The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
  • Other embodiments are set forth within the following claims.

Claims (27)

We claim:
1. A method for evaluating renal status in a subject, comprising:
obtaining a urine sample from a subject selected for evaluation based on a determination that the subject is at risk of a future or current acute renal injury;
performing one or more assays configured to detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor-binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase-1, Neural cell adhesion molecule 1, Pigment epithelium-derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 by introducing the urine sample obtained from the subject into an assay instrument which (i) for each analyte binding assay performed, contacts all or a portion of the urine sample with a binding reagent which specifically binds for detection the kidney injury marker which is assayed, and (ii) generates one or more assay results indicative of binding of each biomarker which is assayed to its respective binding reagent and displays the assay results generated in human readable form; and
correlating the assay result(s) generated by the assay instrument to the renal status of the subject.
2. A method according to claim 1, wherein said correlation step comprises correlating the assay results to one or more of risk stratification, diagnosis, staging, prognosis, classifying and monitoring of the renal status of the subject.
3. A method according to claim 1, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future acute renal injury.
4. A method according to claim 3, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).
5. A method according to claim 1, wherein said assay results comprise at least 2, 3, 4, or 5 of:
a measured concentration of Tumor necrosis factor receptor superfamily member 8,
a measured concentration of Alpha-Fetoprotein,
a measured concentration of Thyroxine-binding globulin,
a measured concentration of Prostate-specific antigen (free form),
a measured concentration of Apolipoprotein A,
a measured concentration of Apolipoprotein E,
a measured concentration of Thyrotropin subunit beta,
a measured concentration of Platelet-derived growth factor B/B dimer,
a measured concentration of C-C motif chemokine 7,
a measured concentration of C-C motif chemokine 26,
a measured concentration of Complement C4-B,
a measured concentration of Corticotropin,
a measured concentration of Interferon alpha-2,
a measured concentration of Interleukin-4 receptor alpha chain,
a measured concentration of Insulin-like growth factor-binding protein 4,
a measured concentration of Insulin-like growth factor-binding protein 5,
a measured concentration of Interleukin 21,
a measured concentration of Interleukin 23 alpha subunit,
a measured concentration of Interleukin-28A,
a measured concentration of Interleukin-33,
a measured concentration of Lutropin subunit beta,
a measured concentration of Matrix Metalloproteinase-1,
a measured concentration of Neural cell adhesion molecule 1,
a measured concentration of Pigment epithelium-derived factor,
a measured concentration of Vascular endothelial growth factor receptor 2,
a measured concentration of Vascular endothelial growth factor receptor 3, and
a measured concentration of IgG4.
6. A method according to claim 5, wherein a plurality of assay results are combined using a function that converts the plurality of assay results into a single composite result.
7. (canceled)
8. A method according to claim 3, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future acute renal injury within 30 days of the time at which the urine sample is obtained from the subject.
9. A method according to claim 8, wherein the subject is selected for evaluation based on a determination that the subject is at risk of a future acute renal injury within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.
10. A method according to claim 1, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.
11. A method according to claim 1, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.
12. A method according to claim 1, wherein each assay is an immunoassay performed by (i) introducing the urine sample into an assay device comprising at least one of which binds to a biomarker which is assayed, and (ii) generating an assay result indicative of binding of each biomarker to its respective antibody.
13. A method according to claim 1, wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result(s).
14-23. (canceled)
24. A method according to claim 1, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 72 hours of the time at which the body fluid sample is obtained.
25. A method according to claim 1, wherein said correlating step comprises correlating the assay results to a likelihood of one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 48 hours of the time at which the body fluid sample is obtained.
26. A method according to claim 1, wherein correlating step comprises correlating the assay results to a likelihood of one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.
27. A method according to claim 1, wherein the subject is in RIFLE stage 0 or R.
28. A method according to claim 27, wherein the subject is in RIFLE stage 0.
29-32. (canceled)
33. A method according to claim 27, wherein the subject is in RIFLE stage R.
34. (canceled)
35. A method according to claim 1, wherein the subject is in RIFLE stage 0, R, or I.
36. A method according to claim 35, wherein the subject is in RIFLE stage I.
37-54. (canceled)
55. A method according to claim 1, wherein the subject is not in acute renal failure.
56-108. (canceled)
US13/806,761 2010-06-23 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure Abandoned US20130203074A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/806,761 US20130203074A1 (en) 2010-06-23 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35796510P 2010-06-23 2010-06-23
US35796610P 2010-06-23 2010-06-23
US35795610P 2010-06-23 2010-06-23
US36429610P 2010-07-14 2010-07-14
US36430510P 2010-07-14 2010-07-14
US13/806,761 US20130203074A1 (en) 2010-06-23 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PCT/US2011/001125 WO2011162819A1 (en) 2010-06-23 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/001125 A-371-Of-International WO2011162819A1 (en) 2010-02-26 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/602,031 Continuation US20170261519A1 (en) 2010-06-23 2017-05-22 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
US20130203074A1 true US20130203074A1 (en) 2013-08-08

Family

ID=45371737

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/806,761 Abandoned US20130203074A1 (en) 2010-06-23 2011-06-23 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US15/602,031 Abandoned US20170261519A1 (en) 2010-06-23 2017-05-22 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US16/237,479 Active US10928403B2 (en) 2010-06-23 2018-12-31 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US17/153,200 Abandoned US20210148937A1 (en) 2010-06-23 2021-01-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/602,031 Abandoned US20170261519A1 (en) 2010-06-23 2017-05-22 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US16/237,479 Active US10928403B2 (en) 2010-06-23 2018-12-31 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US17/153,200 Abandoned US20210148937A1 (en) 2010-06-23 2021-01-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Country Status (7)

Country Link
US (4) US20130203074A1 (en)
EP (2) EP3339859A1 (en)
AU (1) AU2011269847A1 (en)
CA (1) CA2803498A1 (en)
IN (1) IN2012MN02812A (en)
NZ (2) NZ605561A (en)
WO (1) WO2011162819A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201214440D0 (en) * 2012-08-13 2012-09-26 Randox Lab Ltd Kidney disease biomarker
JP6792553B2 (en) * 2014-10-20 2020-11-25 アスチュート メディカル，インコーポレイテッド Methods and compositions for the diagnosis and prognosis of renal damage and failure
US11143658B2 (en) 2015-05-12 2021-10-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2019008260A (en) 2017-01-12 2020-01-27 Astute Medical Inc Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246485A1 (en) * 2005-03-14 2006-11-02 Sarwal Minnie S Methods and compositions for evaluating graft survival in a solid organ transplant recipient

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (en) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Method of differential analysis of glomerolonephritis and pyelonephritis
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (en) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド Antibodies against ligand receptors and ligand complexes and their use in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (en) 1991-04-10 1999-04-15 Biosite Diagnostics Inc CROSSTALK OR CROSSTALK INHIBITORS AND THEIR USE
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
NZ336467A (en) 1996-05-24 2000-10-27 Gen Hospital Corp Modulators of tissue regeneration using DNA enclding a kidney injury molecule KIM
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0984984A2 (en) 1997-06-03 2000-03-15 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
MXPA01006404A (en) 1998-12-21 2003-06-06 Univ Monash Kidney disease detection and treatment.
RU2180965C1 (en) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Method of differentiated prediction of renal diseases
EP1405072A2 (en) 2000-12-29 2004-04-07 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
JP2006508014A (en) 2001-07-24 2006-03-09 イエール・ユニバーシテイ Chitinases and chitinase-like molecules and methods, compositions and kits for inflammatory diseases
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) 2001-12-20 2002-02-06 Serono Internat S A Proteins
CA2478288A1 (en) 2002-03-07 2003-09-12 Adrian Woolfson Scd fingerprints
WO2003081201A2 (en) 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
WO2004053074A2 (en) 2002-12-06 2004-06-24 Science And Technology Corporation @ Unm Outcome prediction and risk classification in childhood leukemia
US20040219603A1 (en) 2003-03-27 2004-11-04 Prasad Devarajan Method and kit for detecting the early onset of renal tubular cell injury
CN1791797A (en) 2003-03-27 2006-06-21 儿童医院医疗中心 A method and kit for detecting the early onset of renal tubular cell injury
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
WO2005002416A2 (en) 2003-06-04 2005-01-13 Joslin Diabetes Center, Inc. Predictors of renal disease
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
CA2560200A1 (en) 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
EP1743031A4 (en) 2004-04-26 2008-05-28 Childrens Medical Center Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
WO2006008661A2 (en) 2004-07-19 2006-01-26 Neurochem (International) Limited Diagnostic methods of multiple organ amyloidosis
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
US20060134708A1 (en) 2004-10-14 2006-06-22 Northwestern University Detection and treatment of renal cancer
WO2006083986A2 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
CA2792443A1 (en) 2005-04-18 2006-10-26 Ryan Parr Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
CA2624569A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090298073A1 (en) 2006-06-30 2009-12-03 Gerhold David L Kidney Toxicity Biomarkers
EP2049713A4 (en) 2006-07-21 2010-06-16 Univ Alberta Tissue rejection
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
WO2008073899A2 (en) 2006-12-08 2008-06-19 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2125899B1 (en) 2007-03-26 2012-11-14 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
WO2008122670A2 (en) 2007-04-10 2008-10-16 Integragen Human diabetes susceptibility tnfrsf10b gene
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
US9091695B2 (en) 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
WO2008154238A1 (en) 2007-06-06 2008-12-18 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
WO2009038742A2 (en) 2007-09-20 2009-03-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
EP2203743A4 (en) 2007-09-20 2011-03-02 Univ Louisville Res Found Peptide biomarkers predictive of renal function decline and kidney disease
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
JP4423375B2 (en) 2008-02-29 2010-03-03 国立大学法人名古屋大学 Biomarker for estimating acute kidney injury and prognosis and its use
CN101358976A (en) 2008-04-28 2009-02-04 北京华大吉比爱生物技术有限公司 Micro array-ELISA detecting kit for detecting six tumor markers
WO2009146450A2 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for monitoring immunosuppressant drug levels, renal function, and hepatic function using small volume samples
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2149613A1 (en) 2008-07-28 2010-02-03 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
WO2010022210A2 (en) 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
NZ610356A (en) 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2813848A3 (en) 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
CA2740923A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106370857A (en) 2008-10-21 2017-02-01 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2742113A1 (en) 2008-11-10 2010-05-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20110097850A (en) 2008-11-22 2011-08-31 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594771A (en) 2009-02-06 2013-06-28 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and failure
JP2012522491A (en) 2009-04-03 2012-09-27 ベジニクス ピーティーワイ リミテッド Anti-VEGF-D antibody
US20120183543A1 (en) 2009-05-08 2012-07-19 Novartis Ag Diagnostic biomarkers for fibrotic disorders
WO2011017679A1 (en) 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting glomerulonephritis and associated disorders
EP3151005A1 (en) 2009-08-28 2017-04-05 Astute Medical, Inc. Methods for diagnosis of renal injury and renal failure
US20120190044A1 (en) 2009-09-21 2012-07-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (en) 2009-12-20 2016-10-19 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
KR20140051754A (en) 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102539745B (en) 2010-12-31 2013-03-06 中国人民解放军第三〇九医院 Early diagnosis and early warning kit for transplanted kidney rejection reaction and detection method
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246485A1 (en) * 2005-03-14 2006-11-02 Sarwal Minnie S Methods and compositions for evaluating graft survival in a solid organ transplant recipient

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Coca et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney International. 2008; 73: 1008-1016. *
Coca et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney International. 2008; 73:1008-1016. *
Coca et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney International.2008; 73:1008-1016. *
Furuichi et al. Chemokine/chemokine receptor-mediated inflammation regulates pathologc changes from acute kidney injury to chronic kidney disease. Clinical Experimental Nephrology. 2009; 13: 9-14. *
Furuichi et al. Chemokine/chemokine receptor-mediated inflammation regulates pathologc changes from acute kidney injury tochronic kidney disease. Clinical Experimental Nephrology. 2009; 13: 9-14. *
Waiker et al. Imperfect gold standards for kidney injury biomarker evaluation. Journal of the American Society of Nephrology. 2012 January; 23(1): 13-21. *
Waiker et al. Imperfect gold standards for kidney injury biomarker evaluation. Journal of the American Society of Nephrology.2012 January; 23(1): 13-21. *

Also Published As

Publication number Publication date
US20210148937A1 (en) 2021-05-20
US10928403B2 (en) 2021-02-23
EP3339859A1 (en) 2018-06-27
US20170261519A1 (en) 2017-09-14
AU2011269847A1 (en) 2013-01-31
NZ703055A (en) 2016-07-29
NZ605561A (en) 2015-03-27
EP2585825A4 (en) 2013-12-11
WO2011162819A1 (en) 2011-12-29
EP2585825A1 (en) 2013-05-01
EP2585825B1 (en) 2018-01-10
IN2012MN02812A (en) 2015-05-22
CA2803498A1 (en) 2011-12-29
US20190265253A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
US9784750B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10823742B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9360488B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20230038581A1 (en) Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
EP2899545B1 (en) Methods for diagnosis and prognosis of renal injury and renal failure
US20200292560A1 (en) Methods for diagnosis and prognosis of renal injury and renal failure
US10928403B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20160097779A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130210043A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2531622B1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20190353667A1 (en) Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
US20130005601A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20170315134A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20190120858A1 (en) Methods for evaluating renal injury and renal failure using urine levels of chitinase-3-like protein 1
US20150010929A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20150241419A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130157297A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20150093448A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20140363834A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20150168422A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTUTE MEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERBERG, JOSEPH;GRAY, JEFF;MCPHERSON, PAUL;AND OTHERS;SIGNING DATES FROM 20130116 TO 20130117;REEL/FRAME:029771/0110

AS Assignment

Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P., TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:032459/0246

Effective date: 20140317

Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P., TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:032459/0246

Effective date: 20140317

Owner name: CAPITAL ROYALTY PARTNERS II L.P., TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:032459/0246

Effective date: 20140317

Owner name: CAPITAL ROYALTY PARTNERS II ? PARALLEL FUND ?A? L.

Free format text: SECURITY INTEREST;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:032459/0246

Effective date: 20140317

Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.

Free format text: SECURITY INTEREST;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:032459/0246

Effective date: 20140317

Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.

Free format text: SECURITY INTEREST;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:032459/0246

Effective date: 20140317

AS Assignment

Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P., TEXAS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 61831594 PREVIOUSLY RECORDED AT REEL: 032459 FRAME: 0246. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:037207/0287

Effective date: 20140317

Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P., TEXAS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 61831594 PREVIOUSLY RECORDED AT REEL: 032459 FRAME: 0246. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:037207/0287

Effective date: 20140317

Owner name: CAPITAL ROYALTY PARTNERS II L.P., TEXAS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 61831594 PREVIOUSLY RECORDED AT REEL: 032459 FRAME: 0246. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:037207/0287

Effective date: 20140317

Owner name: PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 61831594 PREVIOUSLY RECORDED AT REEL: 032459 FRAME: 0246. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:037207/0287

Effective date: 20140317

Owner name: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 61831594 PREVIOUSLY RECORDED AT REEL: 032459 FRAME: 0246. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT;ASSIGNOR:ASTUTE MEDICAL, INC.;REEL/FRAME:037207/0287

Effective date: 20140317

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ASTUTE MEDICAL, INC., CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:CAPITAL ROYALTY PARTNERS II L.P.;CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.;PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.;REEL/FRAME:046077/0084

Effective date: 20180404

AS Assignment

Owner name: ASTUTE MEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERBERG, JOSEPH;MCPHERSON, PAUL;NAKAMURA, KEVIN;AND OTHERS;SIGNING DATES FROM 20200310 TO 20200505;REEL/FRAME:052819/0391

Owner name: ASTUTE MEDICAL, INC., CALIFORNIA

Free format text: EMPLOYEE PROPRIETARY INFORMATION AND INVENTION AGREEMENT;ASSIGNOR:GRAY, JEFF;REEL/FRAME:052822/0697

Effective date: 20080502